https://www.guideline.gov/summaries/summary/10019/environmental-management-of-pediatric-asthma-guidelines-for-health-care-providers	ARCHIVED	3 mementos	[{'datetime': '2018-06-09T20:12:14Z', 'uri': 'http://web.archive.org/web/20180609201214/https://www.guideline.gov/summaries/summary/10019/environmental-management-of-pediatric-asthma-guidelines-for-health-care-providers'}, {'datetime': '2018-07-13T07:22:08Z', 'uri': 'http://web.archive.org/web/20180713072208/https://www.guideline.gov/summaries/summary/10019/environmental-management-of-pediatric-asthma-guidelines-for-health-care-providers'}, {'datetime': '2018-07-13T07:32:28Z', 'uri': 'http://archive.is/20180713073228/https://www.guideline.gov/summaries/summary/10019/environmental-management-of-pediatric-asthma-guidelines-for-health-care-providers'}]
https://www.guideline.gov/summaries/summary/10922/postpartum-hemorrhage	ARCHIVED	3 mementos	[{'datetime': '2018-06-09T23:13:41Z', 'uri': 'http://web.archive.org/web/20180609231341/https://www.guideline.gov/summaries/summary/10922/postpartum-hemorrhage'}, {'datetime': '2018-07-13T07:22:22Z', 'uri': 'http://web.archive.org/web/20180713072222/https://www.guideline.gov/summaries/summary/10922/postpartum-hemorrhage'}, {'datetime': '2018-07-13T07:32:59Z', 'uri': 'http://archive.is/20180713073259/https://www.guideline.gov/summaries/summary/10922/postpartum-hemorrhage'}]
https://www.guideline.gov/summaries/summary/12379/delirium-and-acute-problematic-behavior-in-the-longterm-care-setting	ARCHIVED	4 mementos	[{'datetime': '2018-06-09T12:11:46Z', 'uri': 'http://web.archive.org/web/20180609121146/https://www.guideline.gov/summaries/summary/12379/delirium-and-acute-problematic-behavior-in-the-longterm-care-setting'}, {'datetime': '2018-06-15T15:03:49Z', 'uri': 'http://web.archive.org/web/20180615150349/https://guideline.gov/summaries/summary/12379/delirium-and-acute-problematic-behavior-in-the-longterm-care-setting'}, {'datetime': '2018-07-13T07:22:35Z', 'uri': 'http://web.archive.org/web/20180713072235/https://www.guideline.gov/summaries/summary/12379/delirium-and-acute-problematic-behavior-in-the-longterm-care-setting'}, {'datetime': '2018-07-13T07:33:45Z', 'uri': 'http://archive.is/20180713073345/https://www.guideline.gov/summaries/summary/12379/delirium-and-acute-problematic-behavior-in-the-longterm-care-setting'}]
https://www.guideline.gov/summaries/summary/12381/pressure-ulcers-in-the-longterm-care-setting	ARCHIVED	4 mementos	[{'datetime': '2018-06-09T15:18:24Z', 'uri': 'http://web.archive.org/web/20180609151824/https://www.guideline.gov/summaries/summary/12381/pressure-ulcers-in-the-longterm-care-setting'}, {'datetime': '2018-06-15T15:04:03Z', 'uri': 'http://web.archive.org/web/20180615150403/https://guideline.gov/summaries/summary/12381/pressure-ulcers-in-the-longterm-care-setting'}, {'datetime': '2018-07-13T07:22:48Z', 'uri': 'http://web.archive.org/web/20180713072248/https://www.guideline.gov/summaries/summary/12381/pressure-ulcers-in-the-longterm-care-setting'}, {'datetime': '2018-07-13T07:31:29Z', 'uri': 'http://archive.is/20180713073129/https://www.guideline.gov/summaries/summary/12381/pressure-ulcers-in-the-longterm-care-setting'}]
https://www.guideline.gov/summaries/summary/12626/diagnosis-and-management-of-vulvar-skin-disorders	ARCHIVED	3 mementos	[{'datetime': '2018-06-09T23:13:47Z', 'uri': 'http://web.archive.org/web/20180609231347/https://www.guideline.gov/summaries/summary/12626/diagnosis-and-management-of-vulvar-skin-disorders'}, {'datetime': '2018-07-13T07:23:01Z', 'uri': 'http://web.archive.org/web/20180713072301/https://www.guideline.gov/summaries/summary/12626/diagnosis-and-management-of-vulvar-skin-disorders'}, {'datetime': '2018-07-13T07:30:09Z', 'uri': 'http://archive.is/20180713073009/https://www.guideline.gov/summaries/summary/12626/diagnosis-and-management-of-vulvar-skin-disorders'}]
https://www.guideline.gov/summaries/summary/13320/anemia-in-pregnancy	ARCHIVED	4 mementos	[{'datetime': '2018-06-09T21:59:05Z', 'uri': 'http://web.archive.org/web/20180609215905/https://www.guideline.gov/summaries/summary/13320/anemia-in-pregnancy'}, {'datetime': '2018-06-15T15:37:03Z', 'uri': 'http://web.archive.org/web/20180615153703/https://guideline.gov/summaries/summary/13320/anemia-in-pregnancy'}, {'datetime': '2018-07-13T07:23:14Z', 'uri': 'http://web.archive.org/web/20180713072314/https://www.guideline.gov/summaries/summary/13320/anemia-in-pregnancy'}, {'datetime': '2018-07-13T07:33:49Z', 'uri': 'http://archive.is/20180713073349/https://www.guideline.gov/summaries/summary/13320/anemia-in-pregnancy'}]
https://www.guideline.gov/summaries/summary/13416/surgical-site-infection-prevention-and-treatment-of-surgical-site-infection	ARCHIVED	4 mementos	[{'datetime': '2018-06-10T11:10:36Z', 'uri': 'http://web.archive.org/web/20180610111036/https://www.guideline.gov/summaries/summary/13416/surgical-site-infection-prevention-and-treatment-of-surgical-site-infection'}, {'datetime': '2018-06-15T15:05:13Z', 'uri': 'http://web.archive.org/web/20180615150513/https://guideline.gov/summaries/summary/13416/surgical-site-infection-prevention-and-treatment-of-surgical-site-infection'}, {'datetime': '2018-07-13T07:23:28Z', 'uri': 'http://web.archive.org/web/20180713072328/https://www.guideline.gov/summaries/summary/13416/surgical-site-infection-prevention-and-treatment-of-surgical-site-infection'}, {'datetime': '2018-07-13T07:34:21Z', 'uri': 'http://archive.is/20180713073421/https://www.guideline.gov/summaries/summary/13416/surgical-site-infection-prevention-and-treatment-of-surgical-site-infection'}]
https://www.guideline.gov/summaries/summary/13564/efns-guideline-on-the-management-of-communityacquired-bacterial-meningitis-report-of-an-efns-task-force-on-acute-bacterial-meningitis-in-older-children-and-adults	ARCHIVED	4 mementos	[{'datetime': '2018-06-09T23:43:01Z', 'uri': 'http://web.archive.org/web/20180609234301/https://www.guideline.gov/summaries/summary/13564/efns-guideline-on-the-management-of-communityacquired-bacterial-meningitis-report-of-an-efns-task-force-on-acute-bacterial-meningitis-in-older-children-and-adults'}, {'datetime': '2018-06-15T15:04:22Z', 'uri': 'http://web.archive.org/web/20180615150422/https://guideline.gov/summaries/summary/13564/efns-guideline-on-the-management-of-communityacquired-bacterial-meningitis-report-of-an-efns-task-force-on-acute-bacterial-meningitis-in-older-children-and-adults'}, {'datetime': '2018-07-13T07:23:42Z', 'uri': 'http://web.archive.org/web/20180713072342/https://www.guideline.gov/summaries/summary/13564/efns-guideline-on-the-management-of-communityacquired-bacterial-meningitis-report-of-an-efns-task-force-on-acute-bacterial-meningitis-in-older-children-and-adults'}, {'datetime': '2018-07-13T07:27:55Z', 'uri': 'http://archive.is/20180713072755/https://www.guideline.gov/summaries/summary/13564/efns-guideline-on-the-management-of-communityacquired-bacterial-meningitis-report-of-an-efns-task-force-on-acute-bacterial-meningitis-in-older-children-and-adults'}]
https://www.guideline.gov/summaries/summary/13616/practice-parameter-evaluation-of-distal-symmetric-polyneuropathy-role-of-laboratory-and-genetic-testing-an-evidencebased-review	ARCHIVED	3 mementos	[{'datetime': '2018-06-09T20:47:19Z', 'uri': 'http://web.archive.org/web/20180609204719/https://www.guideline.gov/summaries/summary/13616/practice-parameter-evaluation-of-distal-symmetric-polyneuropathy-role-of-laboratory-and-genetic-testing-an-evidencebased-review'}, {'datetime': '2018-07-13T07:23:56Z', 'uri': 'http://web.archive.org/web/20180713072356/https://www.guideline.gov/summaries/summary/13616/practice-parameter-evaluation-of-distal-symmetric-polyneuropathy-role-of-laboratory-and-genetic-testing-an-evidencebased-review'}, {'datetime': '2018-07-13T07:34:33Z', 'uri': 'http://archive.is/20180713073433/https://www.guideline.gov/summaries/summary/13616/practice-parameter-evaluation-of-distal-symmetric-polyneuropathy-role-of-laboratory-and-genetic-testing-an-evidencebased-review'}]
https://www.guideline.gov/summaries/summary/14308/induction-of-labour	ARCHIVED	3 mementos	[{'datetime': '2018-06-10T16:12:11Z', 'uri': 'http://web.archive.org/web/20180610161211/https://www.guideline.gov/summaries/summary/14308/induction-of-labour'}, {'datetime': '2018-07-13T07:24:11Z', 'uri': 'http://web.archive.org/web/20180713072411/https://www.guideline.gov/summaries/summary/14308/induction-of-labour'}, {'datetime': '2018-07-13T07:34:54Z', 'uri': 'http://archive.is/20180713073454/https://www.guideline.gov/summaries/summary/14308/induction-of-labour'}]
https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt	ARCHIVED	7 mementos	[{'datetime': '2017-10-02T20:06:10Z', 'uri': 'http://wayback.archive-it.org/all/20171002200610/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}, {'datetime': '2017-10-02T20:06:10Z', 'uri': 'http://web.archive.org/web/20171002200610/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}, {'datetime': '2018-05-18T19:31:37Z', 'uri': 'http://wayback.archive-it.org/all/20180518193137/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}, {'datetime': '2018-05-18T19:31:37Z', 'uri': 'http://web.archive.org/web/20180518193137/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}, {'datetime': '2018-06-09T10:41:07Z', 'uri': 'http://web.archive.org/web/20180609104107/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}, {'datetime': '2018-07-12T21:37:23Z', 'uri': 'http://web.archive.org/web/20180712213723/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}, {'datetime': '2018-07-12T21:37:23Z', 'uri': 'http://web.archive.org/web/20180712213723/https://www.guideline.gov/summaries/summary/14679/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-vitamin-k-folic-acid-blood-levels-and-breastfeeding-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-assessment-subcommitt'}]
https://www.guideline.gov/summaries/summary/14680/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-teratogenesis-and-perinatal-outcomes-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-subcommittee-of-the-american-academy	ARCHIVED	1 mementos	[{'datetime': '2018-06-09T22:56:45Z', 'uri': 'http://web.archive.org/web/20180609225645/https://www.guideline.gov/summaries/summary/14680/practice-parameter-update-management-issues-for-women-with-epilepsyfocus-on-pregnancy-an-evidencebased-review-teratogenesis-and-perinatal-outcomes-report-of-the-quality-standards-subcommittee-and-therapeutics-and-technology-subcommittee-of-the-american-academy'}]
https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:29Z', 'uri': 'http://wayback.archive-it.org/all/20161001003229/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2016-10-01T00:32:29Z', 'uri': 'http://web.archive.org/web/20161001003229/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2017-10-03T06:10:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003061054/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2017-10-03T06:10:54Z', 'uri': 'http://web.archive.org/web/20171003061054/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2018-04-14T05:20:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414052047/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2018-04-14T05:20:47Z', 'uri': 'http://web.archive.org/web/20180414052047/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2018-05-19T12:11:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519121105/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2018-05-19T12:11:05Z', 'uri': 'http://web.archive.org/web/20180519121105/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}, {'datetime': '2018-06-09T20:20:12Z', 'uri': 'http://web.archive.org/web/20180609202012/https://www.guideline.gov/summaries/summary/15487/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-diagnosis-and-treatment-of-acute-achilles-tendon-rupture'}]
https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:32Z', 'uri': 'http://wayback.archive-it.org/all/20161001003232/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2016-10-01T00:32:32Z', 'uri': 'http://web.archive.org/web/20161001003232/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2017-10-03T06:11:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003061101/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2017-10-03T06:11:01Z', 'uri': 'http://web.archive.org/web/20171003061101/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2018-04-14T05:20:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414052057/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2018-04-14T05:20:57Z', 'uri': 'http://web.archive.org/web/20180414052057/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2018-05-19T12:11:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519121114/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2018-05-19T12:11:14Z', 'uri': 'http://web.archive.org/web/20180519121114/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}, {'datetime': '2018-06-10T01:16:02Z', 'uri': 'http://web.archive.org/web/20180610011602/https://www.guideline.gov/summaries/summary/15488/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-glenohumeral-joint-osteoarthritis'}]
https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:39Z', 'uri': 'http://wayback.archive-it.org/all/20161001003239/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2016-10-01T00:32:39Z', 'uri': 'http://web.archive.org/web/20161001003239/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2017-10-03T06:11:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003061138/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2017-10-03T06:11:38Z', 'uri': 'http://web.archive.org/web/20171003061138/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2018-04-14T05:21:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414052146/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2018-04-14T05:21:46Z', 'uri': 'http://web.archive.org/web/20180414052146/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2018-05-19T12:12:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519121209/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2018-05-19T12:12:09Z', 'uri': 'http://web.archive.org/web/20180519121209/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}, {'datetime': '2018-06-09T18:58:08Z', 'uri': 'http://web.archive.org/web/20180609185808/https://www.guideline.gov/summaries/summary/15632/practice-parameter-pharmacologic-treatment-of-spasticity-in-children-and-adolescents-with-cerebral-palsy-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology'}]
https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:38Z', 'uri': 'http://wayback.archive-it.org/all/20161001003238/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:32:38Z', 'uri': 'http://web.archive.org/web/20161001003238/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:11:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003061133/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:11:33Z', 'uri': 'http://web.archive.org/web/20171003061133/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:21:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414052138/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:21:38Z', 'uri': 'http://web.archive.org/web/20180414052138/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:12:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519121201/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:12:01Z', 'uri': 'http://web.archive.org/web/20180519121201/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T21:19:15Z', 'uri': 'http://web.archive.org/web/20180609211915/https://www.guideline.gov/summaries/summary/15633/assessment-efficacy-of-transcutaneous-electric-nerve-stimulation-in-the-treatment-of-pain-in-neurologic-disorders-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:31:47Z', 'uri': 'http://wayback.archive-it.org/all/20161001003147/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2016-10-01T00:31:47Z', 'uri': 'http://web.archive.org/web/20161001003147/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2017-10-03T06:07:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003060725/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2017-10-03T06:07:25Z', 'uri': 'http://web.archive.org/web/20171003060725/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2018-04-14T05:16:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414051617/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2018-04-14T05:16:17Z', 'uri': 'http://web.archive.org/web/20180414051617/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2018-05-19T12:06:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519120616/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2018-05-19T12:06:16Z', 'uri': 'http://web.archive.org/web/20180519120616/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}, {'datetime': '2018-06-10T01:35:46Z', 'uri': 'http://web.archive.org/web/20180610013546/https://www.guideline.gov/summaries/summary/15711/clinical-practice-guideline-on-the-management-of-lipids-as-a-cardiovascular-risk-factor'}]
https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:31:59Z', 'uri': 'http://wayback.archive-it.org/all/20161001003159/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2016-10-01T00:31:59Z', 'uri': 'http://web.archive.org/web/20161001003159/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2017-10-03T06:08:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003060810/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2017-10-03T06:08:10Z', 'uri': 'http://web.archive.org/web/20171003060810/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2018-04-14T05:17:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414051718/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2018-04-14T05:17:18Z', 'uri': 'http://web.archive.org/web/20180414051718/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2018-05-19T12:07:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519120727/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2018-05-19T12:07:27Z', 'uri': 'http://web.archive.org/web/20180519120727/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}, {'datetime': '2018-06-10T01:35:30Z', 'uri': 'http://web.archive.org/web/20180610013530/https://www.guideline.gov/summaries/summary/15712/clinical-practice-guidelines-on-arterial-hypertension-2007-update'}]
https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:12Z', 'uri': 'http://wayback.archive-it.org/all/20161001003212/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:32:12Z', 'uri': 'http://web.archive.org/web/20161001003212/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:09:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003060920/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:09:20Z', 'uri': 'http://web.archive.org/web/20171003060920/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:19:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414051909/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:19:09Z', 'uri': 'http://web.archive.org/web/20180414051909/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:09:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519120920/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:09:20Z', 'uri': 'http://web.archive.org/web/20180519120920/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T15:29:44Z', 'uri': 'http://web.archive.org/web/20180609152944/https://www.guideline.gov/summaries/summary/15851/assessment-symptomatic-treatment-for-muscle-cramps-an-evidencebased-review-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:13Z', 'uri': 'http://wayback.archive-it.org/all/20161001003213/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:32:13Z', 'uri': 'http://web.archive.org/web/20161001003213/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:09:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003060926/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:09:26Z', 'uri': 'http://web.archive.org/web/20171003060926/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:19:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414051916/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:19:16Z', 'uri': 'http://web.archive.org/web/20180414051916/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:09:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519120928/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:09:28Z', 'uri': 'http://web.archive.org/web/20180519120928/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T10:35:16Z', 'uri': 'http://web.archive.org/web/20180609103516/https://www.guideline.gov/summaries/summary/15853/practice-parameter-update-evaluation-and-management-of-driving-risk-in-dementia-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:07Z', 'uri': 'http://wayback.archive-it.org/all/20161001003207/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:32:07Z', 'uri': 'http://web.archive.org/web/20161001003207/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:08:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003060846/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:08:46Z', 'uri': 'http://web.archive.org/web/20171003060846/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:18:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414051810/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:18:10Z', 'uri': 'http://web.archive.org/web/20180414051810/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:08:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519120825/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T12:08:25Z', 'uri': 'http://web.archive.org/web/20180519120825/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T20:52:49Z', 'uri': 'http://web.archive.org/web/20180609205249/https://www.guideline.gov/summaries/summary/15953/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-drug-nutritional-and-respiratory-therapies-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:08Z', 'uri': 'http://wayback.archive-it.org/all/20161001003208/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2016-10-01T00:32:08Z', 'uri': 'http://web.archive.org/web/20161001003208/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2017-10-03T06:08:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003060853/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2017-10-03T06:08:53Z', 'uri': 'http://web.archive.org/web/20171003060853/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2018-04-14T05:18:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414051820/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2018-04-14T05:18:20Z', 'uri': 'http://web.archive.org/web/20180414051820/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2018-05-19T12:08:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519120834/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2018-05-19T12:08:34Z', 'uri': 'http://web.archive.org/web/20180519120834/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}, {'datetime': '2018-06-09T12:15:22Z', 'uri': 'http://web.archive.org/web/20180609121522/https://www.guideline.gov/summaries/summary/15954/practice-parameter-update-the-care-of-the-patient-with-amyotrophic-lateral-sclerosis-multidisciplinary-care-symptom-management-and-cognitivebehavioral-impairment-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-ne'}]
https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:32:09Z', 'uri': 'http://wayback.archive-it.org/all/20161001003209/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2016-10-01T00:32:09Z', 'uri': 'http://web.archive.org/web/20161001003209/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2017-10-03T06:08:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003060859/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2017-10-03T06:08:59Z', 'uri': 'http://web.archive.org/web/20171003060859/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-04-14T05:18:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414051829/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-04-14T05:18:29Z', 'uri': 'http://web.archive.org/web/20180414051829/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-05-19T12:08:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519120844/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-05-19T12:08:44Z', 'uri': 'http://web.archive.org/web/20180519120844/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-06-09T22:56:46Z', 'uri': 'http://web.archive.org/web/20180609225646/https://www.guideline.gov/summaries/summary/15955/practice-parameter-evaluation-of-the-child-with-microcephaly-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}]
https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:31:03Z', 'uri': 'http://wayback.archive-it.org/all/20161001003103/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2016-10-01T00:31:03Z', 'uri': 'http://web.archive.org/web/20161001003103/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2017-10-03T06:04:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003060454/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2017-10-03T06:04:54Z', 'uri': 'http://web.archive.org/web/20171003060454/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2018-04-14T05:13:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414051300/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2018-04-14T05:13:00Z', 'uri': 'http://web.archive.org/web/20180414051300/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2018-05-19T12:02:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519120244/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2018-05-19T12:02:44Z', 'uri': 'http://web.archive.org/web/20180519120244/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}, {'datetime': '2018-06-09T12:21:11Z', 'uri': 'http://web.archive.org/web/20180609122111/https://www.guideline.gov/summaries/summary/24127/aafp-guideline-for-the-detection-and-management-of-postmyocardial-infarction-depression'}]
https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition	ARCHIVED	24 mementos	[{'datetime': '2016-09-30T14:29:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930142911/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2016-09-30T14:29:11Z', 'uri': 'http://web.archive.org/web/20160930142911/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2016-11-15T12:44:53Z', 'uri': 'http://web.archive.org/web/20161115124453/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2016-11-18T03:11:01Z', 'uri': 'http://web.archive.org/web/20161118031101/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-01-25T06:13:22Z', 'uri': 'http://web.archive.org/web/20170125061322/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-01-30T13:16:01Z', 'uri': 'http://web.archive.org/web/20170130131601/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-02-04T04:34:03Z', 'uri': 'http://web.archive.org/web/20170204043403/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-02-05T12:23:06Z', 'uri': 'http://web.archive.org/web/20170205122306/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-02-26T21:33:00Z', 'uri': 'http://web.archive.org/web/20170226213300/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-07-13T02:58:54Z', 'uri': 'http://web.archive.org/web/20170713025854/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-09-02T02:34:09Z', 'uri': 'http://web.archive.org/web/20170902023409/https://guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-10-03T06:07:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003060716/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2017-10-03T06:07:16Z', 'uri': 'http://web.archive.org/web/20171003060716/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-04-14T05:16:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414051607/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-04-14T05:16:07Z', 'uri': 'http://web.archive.org/web/20180414051607/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-05-19T12:06:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519120606/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-05-19T12:06:06Z', 'uri': 'http://web.archive.org/web/20180519120606/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-02T20:42:42Z', 'uri': 'http://web.archive.org/web/20180602204242/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-09T10:32:11Z', 'uri': 'http://web.archive.org/web/20180609103211/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-09T10:36:28Z', 'uri': 'http://web.archive.org/web/20180609103628/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-09T12:21:16Z', 'uri': 'http://web.archive.org/web/20180609122116/https://www.guideline.gov/summaries/summary/24158/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-20T17:39:43Z', 'uri': 'http://web.archive.org/web/20180620173943/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-21T00:04:21Z', 'uri': 'http://web.archive.org/web/20180621000421/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}, {'datetime': '2018-06-23T02:56:25Z', 'uri': 'http://web.archive.org/web/20180623025625/https://www.guideline.gov/summaries/summary/24158/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition'}]
https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:30:18Z', 'uri': 'http://wayback.archive-it.org/all/20161001003018/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:30:18Z', 'uri': 'http://web.archive.org/web/20161001003018/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:02:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003060217/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:02:17Z', 'uri': 'http://web.archive.org/web/20171003060217/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:09:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414050912/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:09:12Z', 'uri': 'http://web.archive.org/web/20180414050912/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:58:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519115856/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:58:56Z', 'uri': 'http://web.archive.org/web/20180519115856/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T21:59:06Z', 'uri': 'http://web.archive.org/web/20180610215906/https://www.guideline.gov/summaries/summary/24167/evidencebased-guideline-the-role-of-diffusion-and-perfusion-mri-for-the-diagnosis-of-acute-ischemic-stroke-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition	ARCHIVED	14 mementos	[{'datetime': '2016-10-01T00:31:01Z', 'uri': 'http://wayback.archive-it.org/all/20161001003101/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2016-10-01T00:31:01Z', 'uri': 'http://web.archive.org/web/20161001003101/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2017-07-13T03:40:32Z', 'uri': 'http://web.archive.org/web/20170713034032/https://www.guideline.gov/summaries/summary/24176/Guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-In-Shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2017-10-03T06:04:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003060441/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2017-10-03T06:04:41Z', 'uri': 'http://web.archive.org/web/20171003060441/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-04-14T05:12:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414051242/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-04-14T05:12:42Z', 'uri': 'http://web.archive.org/web/20180414051242/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-05-19T12:02:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519120224/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-05-19T12:02:24Z', 'uri': 'http://web.archive.org/web/20180519120224/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-06-09T10:35:39Z', 'uri': 'http://web.archive.org/web/20180609103539/https://www.guideline.gov/summaries/summary/24176/Guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-In-Shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-06-10T01:28:20Z', 'uri': 'http://web.archive.org/web/20180610012820/https://www.guideline.gov/summaries/summary/24176/guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-06-20T17:39:41Z', 'uri': 'http://web.archive.org/web/20180620173941/https://www.guideline.gov/summaries/summary/24176/Guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-In-Shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-06-21T00:19:14Z', 'uri': 'http://web.archive.org/web/20180621001914/https://www.guideline.gov/summaries/summary/24176/Guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-In-Shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-06-23T03:58:55Z', 'uri': 'http://web.archive.org/web/20180623035855/https://www.guideline.gov/summaries/summary/24176/Guideline-recommendations-and-their-rationales-for-the-treatment-of-adult-patients-In-Shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}]
https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:31:02Z', 'uri': 'http://wayback.archive-it.org/all/20161001003102/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2016-10-01T00:31:02Z', 'uri': 'http://web.archive.org/web/20161001003102/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2017-10-03T06:04:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003060448/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2017-10-03T06:04:48Z', 'uri': 'http://web.archive.org/web/20171003060448/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-04-14T05:12:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414051253/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-04-14T05:12:53Z', 'uri': 'http://web.archive.org/web/20180414051253/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-05-19T12:02:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519120235/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-05-19T12:02:35Z', 'uri': 'http://web.archive.org/web/20180519120235/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}, {'datetime': '2018-06-09T19:39:12Z', 'uri': 'http://web.archive.org/web/20180609193912/https://www.guideline.gov/summaries/summary/24177/guideline-recommendations-and-their-rationales-for-the-treatment-of-neonates-infants-children-and-adolescents-in-shared-decisionmaking-in-the-appropriate-initiation-of-and-withdrawal-from-dialysis-2nd-edition'}]
https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:30:15Z', 'uri': 'http://wayback.archive-it.org/all/20161001003015/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:30:15Z', 'uri': 'http://web.archive.org/web/20161001003015/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-02T20:06:17Z', 'uri': 'http://wayback.archive-it.org/all/20171002200617/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-02T20:06:17Z', 'uri': 'http://web.archive.org/web/20171002200617/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:08:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414050857/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:08:57Z', 'uri': 'http://web.archive.org/web/20180414050857/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-18T19:31:52Z', 'uri': 'http://wayback.archive-it.org/all/20180518193152/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-18T19:31:52Z', 'uri': 'http://web.archive.org/web/20180518193152/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T10:39:56Z', 'uri': 'http://web.archive.org/web/20180609103956/https://www.guideline.gov/summaries/summary/24497/evidence-report-the-efficacy-and-safety-of-mitoxantrone-novantrone-in-the-treatment-of-multiple-sclerosis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:30:01Z', 'uri': 'http://wayback.archive-it.org/all/20161001003001/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:30:01Z', 'uri': 'http://web.archive.org/web/20161001003001/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:01:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003060141/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T06:01:41Z', 'uri': 'http://web.archive.org/web/20171003060141/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:08:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414050812/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T05:08:12Z', 'uri': 'http://web.archive.org/web/20180414050812/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:58:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519115804/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:58:04Z', 'uri': 'http://web.archive.org/web/20180519115804/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T15:19:56Z', 'uri': 'http://web.archive.org/web/20180610151956/https://www.guideline.gov/summaries/summary/25656/evidencebased-guideline-update-plasmapheresis-in-neurologic-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/2826/practice-parameter-thymectomy-for-autoimmune-myasthenia-gravis-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	1 mementos	[{'datetime': '2018-06-09T22:01:25Z', 'uri': 'http://web.archive.org/web/20180609220125/https://www.guideline.gov/summaries/summary/2826/practice-parameter-thymectomy-for-autoimmune-myasthenia-gravis-an-evidencebased-review-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:26:56Z', 'uri': 'http://wayback.archive-it.org/all/20161001002656/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2016-10-01T00:26:56Z', 'uri': 'http://web.archive.org/web/20161001002656/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2017-10-03T05:55:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003055532/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2017-10-03T05:55:32Z', 'uri': 'http://web.archive.org/web/20171003055532/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2018-04-14T04:59:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414045924/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2018-04-14T04:59:24Z', 'uri': 'http://web.archive.org/web/20180414045924/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2018-05-19T11:49:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519114914/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2018-05-19T11:49:14Z', 'uri': 'http://web.archive.org/web/20180519114914/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}, {'datetime': '2018-06-09T21:40:07Z', 'uri': 'http://web.archive.org/web/20180609214007/https://www.guideline.gov/summaries/summary/33038/evidencebased-guideline-treatment-of-painful-diabetic-neuropathy-report-of-the-american-academy-of-neurology-the-american-association-of-neuromuscular-and-electrodiagnostic-medicine-and-the-american-academy-of-physical-medicine-and-rehabilitation'}]
https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:21:05Z', 'uri': 'http://wayback.archive-it.org/all/20161001002105/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2016-10-01T00:21:05Z', 'uri': 'http://web.archive.org/web/20161001002105/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2017-10-03T05:53:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003055316/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2017-10-03T05:53:16Z', 'uri': 'http://web.archive.org/web/20171003055316/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-04-14T04:56:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414045600/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-04-14T04:56:00Z', 'uri': 'http://web.archive.org/web/20180414045600/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-05-19T11:45:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519114555/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-05-19T11:45:55Z', 'uri': 'http://web.archive.org/web/20180519114555/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-06-09T10:33:08Z', 'uri': 'http://web.archive.org/web/20180609103308/https://www.guideline.gov/summaries/summary/34822/autism-recognition-referral-and-diagnosis-of-children-and-young-people-on-the-autism-spectrum'}]
https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass	ARCHIVED	12 mementos	[{'datetime': '2016-10-01T00:14:23Z', 'uri': 'http://wayback.archive-it.org/all/20161001001423/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2016-10-01T00:14:23Z', 'uri': 'http://web.archive.org/web/20161001001423/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2017-07-14T09:53:29Z', 'uri': 'http://web.archive.org/web/20170714095329/https://guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2017-10-03T05:26:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003052622/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2017-10-03T05:26:22Z', 'uri': 'http://web.archive.org/web/20171003052622/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-04-14T04:45:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414044514/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-04-14T04:45:14Z', 'uri': 'http://web.archive.org/web/20180414044514/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-05-19T11:35:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519113528/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-05-19T11:35:28Z', 'uri': 'http://web.archive.org/web/20180519113528/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-06-09T11:04:26Z', 'uri': 'http://web.archive.org/web/20180609110426/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-07-12T21:46:17Z', 'uri': 'http://web.archive.org/web/20180712214617/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}, {'datetime': '2018-07-12T21:46:17Z', 'uri': 'http://web.archive.org/web/20180712214617/https://www.guideline.gov/summaries/summary/35094/management-of-a-suspicious-adnexal-mass'}]
https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:17:59Z', 'uri': 'http://wayback.archive-it.org/all/20161001001759/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:17:59Z', 'uri': 'http://web.archive.org/web/20161001001759/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:44:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003054406/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:44:06Z', 'uri': 'http://web.archive.org/web/20171003054406/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:49:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414044945/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:49:45Z', 'uri': 'http://web.archive.org/web/20180414044945/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:40:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519114000/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:40:00Z', 'uri': 'http://web.archive.org/web/20180519114000/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T15:20:10Z', 'uri': 'http://web.archive.org/web/20180610152010/https://www.guideline.gov/summaries/summary/35116/evidencebased-guideline-clinical-evaluation-and-treatment-of-transverse-myelitis-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/36817/caesarean-section	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:17:44Z', 'uri': 'http://wayback.archive-it.org/all/20161001001744/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2016-10-01T00:17:44Z', 'uri': 'http://web.archive.org/web/20161001001744/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2017-10-03T05:43:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003054332/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2017-10-03T05:43:32Z', 'uri': 'http://web.archive.org/web/20171003054332/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2018-04-14T04:49:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414044930/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2018-04-14T04:49:30Z', 'uri': 'http://web.archive.org/web/20180414044930/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2018-05-19T11:39:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519113945/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2018-05-19T11:39:45Z', 'uri': 'http://web.archive.org/web/20180519113945/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}, {'datetime': '2018-06-09T20:19:47Z', 'uri': 'http://web.archive.org/web/20180609201947/https://www.guideline.gov/summaries/summary/36817/caesarean-section'}]
https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:17:03Z', 'uri': 'http://wayback.archive-it.org/all/20161001001703/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2016-10-01T00:17:03Z', 'uri': 'http://web.archive.org/web/20161001001703/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2017-10-03T05:40:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003054055/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2017-10-03T05:40:55Z', 'uri': 'http://web.archive.org/web/20171003054055/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2018-04-14T04:48:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414044805/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2018-04-14T04:48:05Z', 'uri': 'http://web.archive.org/web/20180414044805/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2018-05-19T11:38:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519113824/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2018-05-19T11:38:24Z', 'uri': 'http://web.archive.org/web/20180519113824/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}, {'datetime': '2018-06-09T23:38:22Z', 'uri': 'http://web.archive.org/web/20180609233822/https://www.guideline.gov/summaries/summary/36879/evidencebased-guideline-antiepileptic-drug-selection-for-people-with-hivaids-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-ad-hoc-task-force-of-the-commission-on-therapeutic-strategies-of-the-international-league-aga'}]
https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	10 mementos	[{'datetime': '2016-10-01T00:15:57Z', 'uri': 'http://wayback.archive-it.org/all/20161001001557/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:15:57Z', 'uri': 'http://web.archive.org/web/20161001001557/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-01-07T13:18:23Z', 'uri': 'http://web.archive.org/web/20170107131823/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:36:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003053600/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:36:00Z', 'uri': 'http://web.archive.org/web/20171003053600/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:46:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414044658/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:46:58Z', 'uri': 'http://web.archive.org/web/20180414044658/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:37:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519113723/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:37:23Z', 'uri': 'http://web.archive.org/web/20180519113723/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T22:01:20Z', 'uri': 'http://web.archive.org/web/20180609220120/https://www.guideline.gov/summaries/summary/36895/evidencebased-guideline-intravenous-immunoglobulin-in-the-treatment-of-neuromuscular-disorders-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:15:55Z', 'uri': 'http://wayback.archive-it.org/all/20161001001555/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2016-10-01T00:15:55Z', 'uri': 'http://web.archive.org/web/20161001001555/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2017-10-03T05:35:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003053546/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2017-10-03T05:35:46Z', 'uri': 'http://web.archive.org/web/20171003053546/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2018-04-14T04:46:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414044647/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2018-04-14T04:46:47Z', 'uri': 'http://web.archive.org/web/20180414044647/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2018-05-19T11:37:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519113715/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2018-05-19T11:37:15Z', 'uri': 'http://web.archive.org/web/20180519113715/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}, {'datetime': '2018-06-09T21:24:42Z', 'uri': 'http://web.archive.org/web/20180609212442/https://www.guideline.gov/summaries/summary/36896/evidencebased-guideline-update-intraoperative-spinal-monitoring-with-somatosensory-and-transcranial-electrical-motor-evoked-potentials-report-of-the-therapeutics-and-technology-assessment-subcommittee-of-the-american-academy-of-neurology-and-the-american-clini'}]
https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:16:58Z', 'uri': 'http://wayback.archive-it.org/all/20161001001658/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2016-10-01T00:16:58Z', 'uri': 'http://web.archive.org/web/20161001001658/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2017-10-03T05:40:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003054047/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2017-10-03T05:40:47Z', 'uri': 'http://web.archive.org/web/20171003054047/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2018-04-14T04:47:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414044754/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2018-04-14T04:47:54Z', 'uri': 'http://web.archive.org/web/20180414044754/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2018-05-19T11:38:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519113813/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2018-05-19T11:38:13Z', 'uri': 'http://web.archive.org/web/20180519113813/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}, {'datetime': '2018-06-10T11:29:28Z', 'uri': 'http://web.archive.org/web/20180610112928/https://www.guideline.gov/summaries/summary/37563/acute-upper-gastrointestinal-bleeding-management'}]
https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:15:03Z', 'uri': 'http://wayback.archive-it.org/all/20161001001503/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2016-10-01T00:15:03Z', 'uri': 'http://web.archive.org/web/20161001001503/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2017-10-03T05:31:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003053148/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2017-10-03T05:31:48Z', 'uri': 'http://web.archive.org/web/20171003053148/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-04-14T04:46:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414044608/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-04-14T04:46:08Z', 'uri': 'http://web.archive.org/web/20180414044608/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-05-19T11:36:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519113634/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-05-19T11:36:34Z', 'uri': 'http://web.archive.org/web/20180519113634/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}, {'datetime': '2018-06-10T01:39:32Z', 'uri': 'http://web.archive.org/web/20180610013932/https://www.guideline.gov/summaries/summary/37692/evidencebased-guideline-update-medical-treatment-of-infantile-spasms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society'}]
https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:14:50Z', 'uri': 'http://wayback.archive-it.org/all/20161001001450/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2016-10-01T00:14:50Z', 'uri': 'http://web.archive.org/web/20161001001450/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2017-10-03T05:30:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003053034/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2017-10-03T05:30:34Z', 'uri': 'http://web.archive.org/web/20171003053034/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T04:45:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414044537/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T04:45:37Z', 'uri': 'http://web.archive.org/web/20180414044537/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T11:36:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519113604/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T11:36:04Z', 'uri': 'http://web.archive.org/web/20180519113604/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}, {'datetime': '2018-06-09T11:04:41Z', 'uri': 'http://web.archive.org/web/20180609110441/https://www.guideline.gov/summaries/summary/38022/evidencebased-guideline-neuromuscular-ultrasound-for-the-diagnosis-of-carpal-tunnel-syndrome'}]
https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline	ARCHIVED	10 mementos	[{'datetime': '2016-10-01T00:13:43Z', 'uri': 'http://wayback.archive-it.org/all/20161001001343/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2016-10-01T00:13:43Z', 'uri': 'http://web.archive.org/web/20161001001343/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2017-10-03T05:22:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003052251/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2017-10-03T05:22:51Z', 'uri': 'http://web.archive.org/web/20171003052251/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2017-11-17T06:56:11Z', 'uri': 'http://web.archive.org/web/20171117065611/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:44:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414044432/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:44:32Z', 'uri': 'http://web.archive.org/web/20180414044432/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:34:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519113445/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:34:45Z', 'uri': 'http://web.archive.org/web/20180519113445/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}, {'datetime': '2018-06-09T21:17:20Z', 'uri': 'http://web.archive.org/web/20180609211720/https://www.guideline.gov/summaries/summary/38367/antithrombotics-indications-and-management-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:11:13Z', 'uri': 'http://wayback.archive-it.org/all/20161001001113/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:11:13Z', 'uri': 'http://web.archive.org/web/20161001001113/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:18:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003051831/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:18:31Z', 'uri': 'http://web.archive.org/web/20171003051831/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:42:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414044255/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:42:55Z', 'uri': 'http://web.archive.org/web/20180414044255/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:33:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519113307/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:33:07Z', 'uri': 'http://web.archive.org/web/20180519113307/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T15:20:25Z', 'uri': 'http://web.archive.org/web/20180610152025/https://www.guideline.gov/summaries/summary/38442/evidencebased-guideline-pharmacologic-treatment-of-chorea-in-huntington-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:10:47Z', 'uri': 'http://wayback.archive-it.org/all/20161001001047/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2016-10-01T00:10:47Z', 'uri': 'http://web.archive.org/web/20161001001047/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2017-10-03T05:16:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003051638/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2017-10-03T05:16:38Z', 'uri': 'http://web.archive.org/web/20171003051638/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2018-04-14T04:42:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414044234/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2018-04-14T04:42:34Z', 'uri': 'http://web.archive.org/web/20180414044234/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2018-05-19T11:32:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519113246/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2018-05-19T11:32:46Z', 'uri': 'http://web.archive.org/web/20180519113246/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}, {'datetime': '2018-06-09T15:21:54Z', 'uri': 'http://web.archive.org/web/20180609152154/https://www.guideline.gov/summaries/summary/38490/aspen-clinical-guidelines-nutrition-support-of-adult-patients-with-hyperglycemia'}]
https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:09:12Z', 'uri': 'http://wayback.archive-it.org/all/20161001000912/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:09:12Z', 'uri': 'http://web.archive.org/web/20161001000912/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:10:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003051054/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:10:54Z', 'uri': 'http://web.archive.org/web/20171003051054/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:40:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414044008/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:40:08Z', 'uri': 'http://web.archive.org/web/20180414044008/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:30:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519113020/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:30:20Z', 'uri': 'http://web.archive.org/web/20180519113020/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T22:17:02Z', 'uri': 'http://web.archive.org/web/20180610221702/https://www.guideline.gov/summaries/summary/38657/evidencebased-guideline-diagnostic-accuracy-of-csf-1433-protein-in-sporadic-creutzfeldtjakob-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:56Z', 'uri': 'http://wayback.archive-it.org/all/20161001000856/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:08:56Z', 'uri': 'http://web.archive.org/web/20161001000856/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:09:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003050939/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T05:09:39Z', 'uri': 'http://web.archive.org/web/20171003050939/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:39:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414043929/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:39:29Z', 'uri': 'http://web.archive.org/web/20180414043929/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:29:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519112937/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:29:37Z', 'uri': 'http://web.archive.org/web/20180519112937/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-11T00:16:25Z', 'uri': 'http://web.archive.org/web/20180611001625/https://www.guideline.gov/summaries/summary/38700/evidencebased-guideline-update-steroids-and-antivirals-for-bell-palsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:09:13Z', 'uri': 'http://wayback.archive-it.org/all/20161001000913/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2016-10-01T00:09:13Z', 'uri': 'http://web.archive.org/web/20161001000913/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T05:11:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003051100/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T05:11:00Z', 'uri': 'http://web.archive.org/web/20171003051100/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T04:40:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414044016/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T04:40:16Z', 'uri': 'http://web.archive.org/web/20180414044016/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T11:30:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519113027/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T11:30:27Z', 'uri': 'http://web.archive.org/web/20180519113027/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T00:21:55Z', 'uri': 'http://web.archive.org/web/20180610002155/https://www.guideline.gov/summaries/summary/38701/breast-cancer-followup-and-management-after-primary-treatment-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:09:15Z', 'uri': 'http://wayback.archive-it.org/all/20161001000915/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2016-10-01T00:09:15Z', 'uri': 'http://web.archive.org/web/20161001000915/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2017-10-03T05:11:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003051129/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2017-10-03T05:11:29Z', 'uri': 'http://web.archive.org/web/20171003051129/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2018-04-14T04:40:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414044026/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2018-04-14T04:40:26Z', 'uri': 'http://web.archive.org/web/20180414044026/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2018-05-19T11:30:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519113036/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2018-05-19T11:30:36Z', 'uri': 'http://web.archive.org/web/20180519113036/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}, {'datetime': '2018-06-09T18:41:37Z', 'uri': 'http://web.archive.org/web/20180609184137/https://www.guideline.gov/summaries/summary/38947/guideline-on-the-management-of-bleeding-in-patients-on-antithrombotic-agents'}]
https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:46Z', 'uri': 'http://wayback.archive-it.org/all/20161001000846/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2016-10-01T00:08:46Z', 'uri': 'http://web.archive.org/web/20161001000846/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2017-10-03T05:09:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003050912/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2017-10-03T05:09:12Z', 'uri': 'http://web.archive.org/web/20171003050912/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-04-14T04:39:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414043921/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-04-14T04:39:21Z', 'uri': 'http://web.archive.org/web/20180414043921/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-05-19T11:29:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519112928/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-05-19T11:29:28Z', 'uri': 'http://web.archive.org/web/20180519112928/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-06-09T20:51:35Z', 'uri': 'http://web.archive.org/web/20180609205135/https://www.guideline.gov/summaries/summary/39266/consensus-statement-on-effective-communication-of-urgent-diagnoses-and-significant-unexpected-diagnoses-in-surgical-pathology-and-cytopathology-from-the-college-of-american-pathologists-and-association-of-directors-of-anatomic-and-surgical-pathology'}]
https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:09:04Z', 'uri': 'http://wayback.archive-it.org/all/20161001000904/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2016-10-01T00:09:04Z', 'uri': 'http://web.archive.org/web/20161001000904/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2017-10-03T05:09:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003050959/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2017-10-03T05:09:59Z', 'uri': 'http://web.archive.org/web/20171003050959/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2018-04-14T04:39:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414043942/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2018-04-14T04:39:42Z', 'uri': 'http://web.archive.org/web/20180414043942/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2018-05-19T11:29:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519112953/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2018-05-19T11:29:53Z', 'uri': 'http://web.archive.org/web/20180519112953/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}, {'datetime': '2018-06-09T19:21:25Z', 'uri': 'http://web.archive.org/web/20180609192125/https://www.guideline.gov/summaries/summary/39267/diagnosis-and-management-of-prosthetic-joint-infection-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america'}]
https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:45Z', 'uri': 'http://wayback.archive-it.org/all/20161001000845/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-10-01T00:08:45Z', 'uri': 'http://web.archive.org/web/20161001000845/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T05:09:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003050906/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T05:09:06Z', 'uri': 'http://web.archive.org/web/20171003050906/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:39:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414043912/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:39:12Z', 'uri': 'http://web.archive.org/web/20180414043912/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:29:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519112918/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:29:18Z', 'uri': 'http://web.archive.org/web/20180519112918/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T15:14:05Z', 'uri': 'http://web.archive.org/web/20180609151405/https://www.guideline.gov/summaries/summary/39425/screening-for-intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:03Z', 'uri': 'http://wayback.archive-it.org/all/20161001000803/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2016-10-01T00:08:03Z', 'uri': 'http://web.archive.org/web/20161001000803/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T05:06:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003050604/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T05:06:04Z', 'uri': 'http://web.archive.org/web/20171003050604/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T04:37:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414043726/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T04:37:26Z', 'uri': 'http://web.archive.org/web/20180414043726/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T11:27:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519112729/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T11:27:29Z', 'uri': 'http://web.archive.org/web/20180519112729/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-06-09T21:11:56Z', 'uri': 'http://web.archive.org/web/20180609211156/https://www.guideline.gov/summaries/summary/39429/2013-accfaha-guideline-for-the-management-of-stelevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization	ARCHIVED	10 mementos	[{'datetime': '2016-10-01T00:09:08Z', 'uri': 'http://wayback.archive-it.org/all/20161001000908/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2016-10-01T00:09:08Z', 'uri': 'http://web.archive.org/web/20161001000908/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2017-02-03T16:28:01Z', 'uri': 'http://web.archive.org/web/20170203162801/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2017-10-03T05:10:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003051038/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2017-10-03T05:10:38Z', 'uri': 'http://web.archive.org/web/20171003051038/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2018-04-14T04:39:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414043952/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2018-04-14T04:39:52Z', 'uri': 'http://web.archive.org/web/20180414043952/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2018-05-19T11:30:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519113006/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2018-05-19T11:30:06Z', 'uri': 'http://web.archive.org/web/20180519113006/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}, {'datetime': '2018-06-09T23:13:45Z', 'uri': 'http://web.archive.org/web/20180609231345/https://www.guideline.gov/summaries/summary/39431/benefits-and-risks-of-sterilization'}]
https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:14Z', 'uri': 'http://wayback.archive-it.org/all/20161001000814/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2016-10-01T00:08:14Z', 'uri': 'http://web.archive.org/web/20161001000814/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2017-10-03T05:07:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003050710/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2017-10-03T05:07:10Z', 'uri': 'http://web.archive.org/web/20171003050710/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2018-04-14T04:38:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414043815/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2018-04-14T04:38:15Z', 'uri': 'http://web.archive.org/web/20180414043815/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2018-05-19T11:28:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519112814/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2018-05-19T11:28:14Z', 'uri': 'http://web.archive.org/web/20180519112814/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}, {'datetime': '2018-06-10T00:27:27Z', 'uri': 'http://web.archive.org/web/20180610002727/https://www.guideline.gov/summaries/summary/39437/recommendations-on-screening-for-cervical-cancer'}]
https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:06:43Z', 'uri': 'http://wayback.archive-it.org/all/20161001000643/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2016-10-01T00:06:43Z', 'uri': 'http://web.archive.org/web/20161001000643/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2017-10-03T05:04:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003050420/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2017-10-03T05:04:20Z', 'uri': 'http://web.archive.org/web/20171003050420/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2018-04-14T04:36:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414043634/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2018-04-14T04:36:34Z', 'uri': 'http://web.archive.org/web/20180414043634/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2018-05-19T11:26:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519112638/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2018-05-19T11:26:38Z', 'uri': 'http://web.archive.org/web/20180519112638/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}, {'datetime': '2018-06-09T20:50:23Z', 'uri': 'http://web.archive.org/web/20180609205023/https://www.guideline.gov/summaries/summary/39440/best-evidence-statement-best-reducing-pain-for-children-and-adolescents-receiving-injections'}]
https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:06:45Z', 'uri': 'http://wayback.archive-it.org/all/20161001000645/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2016-10-01T00:06:45Z', 'uri': 'http://web.archive.org/web/20161001000645/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2017-10-03T05:04:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003050426/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2017-10-03T05:04:26Z', 'uri': 'http://web.archive.org/web/20171003050426/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2018-04-14T04:36:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414043643/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2018-04-14T04:36:43Z', 'uri': 'http://web.archive.org/web/20180414043643/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2018-05-19T11:26:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519112646/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2018-05-19T11:26:46Z', 'uri': 'http://web.archive.org/web/20180519112646/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}, {'datetime': '2018-06-10T11:00:37Z', 'uri': 'http://web.archive.org/web/20180610110037/https://www.guideline.gov/summaries/summary/39444/evidencebased-care-guideline-for-postoperative-management-of-leggcalveperthes-disease-in-children-aged-3-to-12-years'}]
https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:31:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930163131/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2016-09-30T16:31:31Z', 'uri': 'http://web.archive.org/web/20160930163131/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2017-10-02T20:11:14Z', 'uri': 'http://wayback.archive-it.org/all/20171002201114/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2017-10-02T20:11:14Z', 'uri': 'http://web.archive.org/web/20171002201114/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2018-04-14T00:47:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414004721/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2018-04-14T00:47:21Z', 'uri': 'http://web.archive.org/web/20180414004721/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2018-05-18T22:04:46Z', 'uri': 'http://wayback.archive-it.org/all/20180518220446/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2018-05-18T22:04:46Z', 'uri': 'http://web.archive.org/web/20180518220446/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}, {'datetime': '2018-06-09T19:21:22Z', 'uri': 'http://web.archive.org/web/20180609192122/https://www.guideline.gov/summaries/summary/39533/clinical-practice-guidelines-for-antimicrobial-prophylaxis-in-surgery'}]
https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:53Z', 'uri': 'http://wayback.archive-it.org/all/20161001000353/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2016-10-01T00:03:53Z', 'uri': 'http://web.archive.org/web/20161001000353/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2017-10-03T04:57:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003045705/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2017-10-03T04:57:05Z', 'uri': 'http://web.archive.org/web/20171003045705/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2018-04-14T04:32:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414043208/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2018-04-14T04:32:08Z', 'uri': 'http://web.archive.org/web/20180414043208/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2018-05-19T11:22:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519112214/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2018-05-19T11:22:14Z', 'uri': 'http://web.archive.org/web/20180519112214/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}, {'datetime': '2018-06-09T20:11:19Z', 'uri': 'http://web.archive.org/web/20180609201119/https://www.guideline.gov/summaries/summary/39535/clinical-pharmacogenetics-implementation-consortium-guidelines-for-hlab-genotype-and-abacavir-dosing'}]
https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:54Z', 'uri': 'http://wayback.archive-it.org/all/20161001000354/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2016-10-01T00:03:54Z', 'uri': 'http://web.archive.org/web/20161001000354/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2017-10-03T04:57:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003045711/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2017-10-03T04:57:11Z', 'uri': 'http://web.archive.org/web/20171003045711/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2018-04-14T04:32:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414043216/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2018-04-14T04:32:16Z', 'uri': 'http://web.archive.org/web/20180414043216/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2018-05-19T11:22:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519112223/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2018-05-19T11:22:23Z', 'uri': 'http://web.archive.org/web/20180519112223/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}, {'datetime': '2018-06-09T20:11:36Z', 'uri': 'http://web.archive.org/web/20180609201136/https://www.guideline.gov/summaries/summary/39536/clinical-pharmacogenetics-implementation-consortium-guidelines-for-human-leukocyte-antigenb-genotype-and-allopurinol-dosing'}]
https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:00Z', 'uri': 'http://wayback.archive-it.org/all/20161001000800/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2016-10-01T00:08:00Z', 'uri': 'http://web.archive.org/web/20161001000800/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2017-10-03T05:05:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003050551/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2017-10-03T05:05:51Z', 'uri': 'http://web.archive.org/web/20171003050551/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2018-04-14T04:37:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414043707/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2018-04-14T04:37:07Z', 'uri': 'http://web.archive.org/web/20180414043707/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2018-05-19T11:27:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519112710/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2018-05-19T11:27:10Z', 'uri': 'http://web.archive.org/web/20180519112710/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}, {'datetime': '2018-06-09T21:39:43Z', 'uri': 'http://web.archive.org/web/20180609213943/https://www.guideline.gov/summaries/summary/39539/management-of-newly-diagnosed-type-2-diabetes-mellitus-t2dm-in-children-and-adolescents'}]
https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:05:31Z', 'uri': 'http://wayback.archive-it.org/all/20161001000531/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2016-10-01T00:05:31Z', 'uri': 'http://web.archive.org/web/20161001000531/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2017-10-03T05:02:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003050226/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2017-10-03T05:02:26Z', 'uri': 'http://web.archive.org/web/20171003050226/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2018-04-14T04:36:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414043611/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2018-04-14T04:36:11Z', 'uri': 'http://web.archive.org/web/20180414043611/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2018-05-19T11:26:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519112609/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2018-05-19T11:26:09Z', 'uri': 'http://web.archive.org/web/20180519112609/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}, {'datetime': '2018-06-09T21:45:09Z', 'uri': 'http://web.archive.org/web/20180609214509/https://www.guideline.gov/summaries/summary/43610/american-gastroenterological-association-medical-position-statement-on-constipation'}]
https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:05:25Z', 'uri': 'http://wayback.archive-it.org/all/20161001000525/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2016-10-01T00:05:25Z', 'uri': 'http://web.archive.org/web/20161001000525/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2017-10-03T05:02:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003050215/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2017-10-03T05:02:15Z', 'uri': 'http://web.archive.org/web/20171003050215/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2018-04-14T04:35:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414043551/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2018-04-14T04:35:51Z', 'uri': 'http://web.archive.org/web/20180414043551/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2018-05-19T11:25:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519112553/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2018-05-19T11:25:53Z', 'uri': 'http://web.archive.org/web/20180519112553/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}, {'datetime': '2018-06-09T18:53:27Z', 'uri': 'http://web.archive.org/web/20180609185327/https://www.guideline.gov/summaries/summary/43612/clinical-guideline-management-of-gastroparesis'}]
https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:28Z', 'uri': 'http://wayback.archive-it.org/all/20161001000828/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2016-10-01T00:08:28Z', 'uri': 'http://web.archive.org/web/20161001000828/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2017-10-03T05:08:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003050817/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2017-10-03T05:08:17Z', 'uri': 'http://web.archive.org/web/20171003050817/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2018-04-14T04:38:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414043848/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2018-04-14T04:38:48Z', 'uri': 'http://web.archive.org/web/20180414043848/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2018-05-19T11:28:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519112855/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2018-05-19T11:28:55Z', 'uri': 'http://web.archive.org/web/20180519112855/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}, {'datetime': '2018-06-09T19:32:07Z', 'uri': 'http://web.archive.org/web/20180609193207/https://www.guideline.gov/summaries/summary/43745/guideline-for-prescribing-opioids-to-treat-pain-in-injured-workers'}]
https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:17Z', 'uri': 'http://wayback.archive-it.org/all/20161001000817/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2016-10-01T00:08:17Z', 'uri': 'http://web.archive.org/web/20161001000817/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2017-10-03T05:07:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003050730/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2017-10-03T05:07:30Z', 'uri': 'http://web.archive.org/web/20171003050730/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2018-04-14T04:38:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414043831/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2018-04-14T04:38:31Z', 'uri': 'http://web.archive.org/web/20180414043831/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2018-05-19T11:28:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519112832/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2018-05-19T11:28:32Z', 'uri': 'http://web.archive.org/web/20180519112832/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}, {'datetime': '2018-06-09T21:44:28Z', 'uri': 'http://web.archive.org/web/20180609214428/https://www.guideline.gov/summaries/summary/43768/child-passenger-safety-an-evidencebased-review'}]
https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:16Z', 'uri': 'http://wayback.archive-it.org/all/20161001000816/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2016-10-01T00:08:16Z', 'uri': 'http://web.archive.org/web/20161001000816/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2017-10-03T05:07:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003050725/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2017-10-03T05:07:25Z', 'uri': 'http://web.archive.org/web/20171003050725/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2018-04-14T04:38:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414043823/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2018-04-14T04:38:23Z', 'uri': 'http://web.archive.org/web/20180414043823/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2018-05-19T11:28:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519112823/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2018-05-19T11:28:23Z', 'uri': 'http://web.archive.org/web/20180519112823/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}, {'datetime': '2018-06-09T21:44:08Z', 'uri': 'http://web.archive.org/web/20180609214408/https://www.guideline.gov/summaries/summary/43769/an-evidence-based-review-efficacy-of-safety-helmets-in-reduction-of-head-injuries-in-recreational-skiers-and-snowboarders'}]
https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:47Z', 'uri': 'http://wayback.archive-it.org/all/20161001000347/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2016-10-01T00:03:47Z', 'uri': 'http://web.archive.org/web/20161001000347/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:56:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003045638/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:56:38Z', 'uri': 'http://web.archive.org/web/20171003045638/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:31:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414043139/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:31:39Z', 'uri': 'http://web.archive.org/web/20180414043139/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:21:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519112141/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:21:41Z', 'uri': 'http://web.archive.org/web/20180519112141/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-06-10T12:54:52Z', 'uri': 'http://web.archive.org/web/20180610125452/https://www.guideline.gov/summaries/summary/43772/evaluation-and-management-of-penetrating-lower-extremity-arterial-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}]
https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:48Z', 'uri': 'http://wayback.archive-it.org/all/20161001000348/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2016-10-01T00:03:48Z', 'uri': 'http://web.archive.org/web/20161001000348/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:56:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003045644/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:56:44Z', 'uri': 'http://web.archive.org/web/20171003045644/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:31:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414043148/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:31:48Z', 'uri': 'http://web.archive.org/web/20180414043148/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:21:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519112149/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:21:49Z', 'uri': 'http://web.archive.org/web/20180519112149/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-06-09T21:44:11Z', 'uri': 'http://web.archive.org/web/20180609214411/https://www.guideline.gov/summaries/summary/43773/evaluation-and-management-of-smallbowel-obstruction-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}]
https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:22Z', 'uri': 'http://wayback.archive-it.org/all/20161001000322/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2016-10-01T00:03:22Z', 'uri': 'http://web.archive.org/web/20161001000322/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2017-10-03T04:56:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003045622/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2017-10-03T04:56:22Z', 'uri': 'http://web.archive.org/web/20171003045622/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2018-04-14T04:31:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414043122/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2018-04-14T04:31:22Z', 'uri': 'http://web.archive.org/web/20180414043122/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2018-05-19T11:21:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519112124/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2018-05-19T11:21:24Z', 'uri': 'http://web.archive.org/web/20180519112124/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}, {'datetime': '2018-06-09T21:44:20Z', 'uri': 'http://web.archive.org/web/20180609214420/https://www.guideline.gov/summaries/summary/43774/an-evidencebased-review-helmet-efficacy-to-reduce-head-injury-and-mortality-in-motorcycle-crashes-east-practice-management-guidelines'}]
https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:33Z', 'uri': 'http://wayback.archive-it.org/all/20161001000333/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2016-10-01T00:03:33Z', 'uri': 'http://web.archive.org/web/20161001000333/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2017-10-03T04:56:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003045627/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2017-10-03T04:56:27Z', 'uri': 'http://web.archive.org/web/20171003045627/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2018-04-14T04:31:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414043130/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2018-04-14T04:31:30Z', 'uri': 'http://web.archive.org/web/20180414043130/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2018-05-19T11:21:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519112134/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2018-05-19T11:21:34Z', 'uri': 'http://web.archive.org/web/20180519112134/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}, {'datetime': '2018-06-09T21:44:36Z', 'uri': 'http://web.archive.org/web/20180609214436/https://www.guideline.gov/summaries/summary/43776/eastern-association-for-the-surgery-of-trauma-practice-management-guidelines-for-hemorrhage-in-pelvic-fracture-update-and-systematic-review'}]
https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:07:57Z', 'uri': 'http://wayback.archive-it.org/all/20161001000757/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2016-10-01T00:07:57Z', 'uri': 'http://web.archive.org/web/20161001000757/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T05:05:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003050539/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T05:05:39Z', 'uri': 'http://web.archive.org/web/20171003050539/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:36:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414043659/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:36:59Z', 'uri': 'http://web.archive.org/web/20180414043659/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:27:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519112703/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:27:03Z', 'uri': 'http://web.archive.org/web/20180519112703/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-06-10T11:48:55Z', 'uri': 'http://web.archive.org/web/20180610114855/https://www.guideline.gov/summaries/summary/43778/prophylactic-antibiotic-use-in-penetrating-abdominal-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}]
https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:02Z', 'uri': 'http://wayback.archive-it.org/all/20161001000402/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2016-10-01T00:04:02Z', 'uri': 'http://web.archive.org/web/20161001000402/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:57:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003045727/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:57:27Z', 'uri': 'http://web.archive.org/web/20171003045727/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:32:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414043240/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:32:40Z', 'uri': 'http://web.archive.org/web/20180414043240/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:22:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519112246/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:22:46Z', 'uri': 'http://web.archive.org/web/20180519112246/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-06-09T21:44:19Z', 'uri': 'http://web.archive.org/web/20180609214419/https://www.guideline.gov/summaries/summary/43780/screening-for-blunt-cardiac-injury-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}]
https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:03Z', 'uri': 'http://wayback.archive-it.org/all/20161001000403/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2016-10-01T00:04:03Z', 'uri': 'http://web.archive.org/web/20161001000403/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:57:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003045732/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T04:57:32Z', 'uri': 'http://web.archive.org/web/20171003045732/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:32:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414043248/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T04:32:48Z', 'uri': 'http://web.archive.org/web/20180414043248/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:22:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519112255/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T11:22:55Z', 'uri': 'http://web.archive.org/web/20180519112255/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-06-10T21:59:35Z', 'uri': 'http://web.archive.org/web/20180610215935/https://www.guideline.gov/summaries/summary/43781/screening-for-thoracolumbar-spinal-injuries-in-blunt-trauma-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}]
https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache	ARCHIVED	15 mementos	[{'datetime': '2016-09-30T16:19:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930161927/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2016-09-30T16:19:27Z', 'uri': 'http://web.archive.org/web/20160930161927/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2016-12-16T22:41:03Z', 'uri': 'http://web.archive.org/web/20161216224103/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2017-07-13T03:11:47Z', 'uri': 'http://web.archive.org/web/20170713031147/https://www.guideline.gov/summaries/summary/43791/Diagnosis-and-treatment-of-headache'}, {'datetime': '2017-10-02T20:02:42Z', 'uri': 'http://wayback.archive-it.org/all/20171002200242/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2017-10-02T20:02:42Z', 'uri': 'http://web.archive.org/web/20171002200242/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2018-04-13T18:52:29Z', 'uri': 'http://wayback.archive-it.org/all/20180413185229/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2018-04-13T18:52:29Z', 'uri': 'http://web.archive.org/web/20180413185229/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2018-05-18T21:47:36Z', 'uri': 'http://wayback.archive-it.org/all/20180518214736/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2018-05-18T21:47:36Z', 'uri': 'http://web.archive.org/web/20180518214736/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2018-06-09T10:36:39Z', 'uri': 'http://web.archive.org/web/20180609103639/https://www.guideline.gov/summaries/summary/43791/Diagnosis-and-treatment-of-headache'}, {'datetime': '2018-06-09T11:35:05Z', 'uri': 'http://web.archive.org/web/20180609113505/https://www.guideline.gov/summaries/summary/43791/diagnosis-and-treatment-of-headache'}, {'datetime': '2018-06-11T16:19:10Z', 'uri': 'http://web.archive.org/web/20180611161910/https://www.guideline.gov/summaries/summary/43791/Diagnosis-and-treatment-of-headache'}, {'datetime': '2018-06-20T17:39:26Z', 'uri': 'http://web.archive.org/web/20180620173926/https://www.guideline.gov/summaries/summary/43791/Diagnosis-and-treatment-of-headache'}, {'datetime': '2018-06-21T00:06:30Z', 'uri': 'http://web.archive.org/web/20180621000630/https://www.guideline.gov/summaries/summary/43791/Diagnosis-and-treatment-of-headache'}]
https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	11 mementos	[{'datetime': '2016-10-01T00:06:11Z', 'uri': 'http://wayback.archive-it.org/all/20161001000611/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-10-01T00:06:11Z', 'uri': 'http://web.archive.org/web/20161001000611/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T05:02:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003050258/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T05:02:58Z', 'uri': 'http://web.archive.org/web/20171003050258/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:36:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414043625/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:36:25Z', 'uri': 'http://web.archive.org/web/20180414043625/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:26:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519112629/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:26:29Z', 'uri': 'http://web.archive.org/web/20180519112629/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T10:37:03Z', 'uri': 'http://web.archive.org/web/20180609103703/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-07-12T21:44:44Z', 'uri': 'http://web.archive.org/web/20180712214444/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-07-12T21:44:44Z', 'uri': 'http://web.archive.org/web/20180712214444/https://www.guideline.gov/summaries/summary/43793/vitamin-d-and-calcium-supplementation-to-prevent-fractures-in-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:21Z', 'uri': 'http://wayback.archive-it.org/all/20161001000421/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2016-10-01T00:04:21Z', 'uri': 'http://web.archive.org/web/20161001000421/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2017-10-03T04:58:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003045841/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2017-10-03T04:58:41Z', 'uri': 'http://web.archive.org/web/20171003045841/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2018-04-14T04:33:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414043350/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2018-04-14T04:33:50Z', 'uri': 'http://web.archive.org/web/20180414043350/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2018-05-19T11:23:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519112355/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2018-05-19T11:23:55Z', 'uri': 'http://web.archive.org/web/20180519112355/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}, {'datetime': '2018-06-09T15:28:34Z', 'uri': 'http://web.archive.org/web/20180609152834/https://www.guideline.gov/summaries/summary/43837/apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation'}]
https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:25Z', 'uri': 'http://wayback.archive-it.org/all/20161001000425/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2016-10-01T00:04:25Z', 'uri': 'http://web.archive.org/web/20161001000425/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2017-10-03T04:58:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003045847/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2017-10-03T04:58:47Z', 'uri': 'http://web.archive.org/web/20171003045847/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2018-04-14T04:33:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414043359/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2018-04-14T04:33:59Z', 'uri': 'http://web.archive.org/web/20180414043359/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2018-05-19T11:24:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519112404/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2018-05-19T11:24:04Z', 'uri': 'http://web.archive.org/web/20180519112404/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}, {'datetime': '2018-06-09T15:20:57Z', 'uri': 'http://web.archive.org/web/20180609152057/https://www.guideline.gov/summaries/summary/43838/ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237'}]
https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:27Z', 'uri': 'http://wayback.archive-it.org/all/20161001000427/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2016-10-01T00:04:27Z', 'uri': 'http://web.archive.org/web/20161001000427/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2017-10-03T04:58:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003045852/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2017-10-03T04:58:52Z', 'uri': 'http://web.archive.org/web/20171003045852/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2018-04-14T04:34:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414043408/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2018-04-14T04:34:08Z', 'uri': 'http://web.archive.org/web/20180414043408/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2018-05-19T11:24:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519112412/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2018-05-19T11:24:12Z', 'uri': 'http://web.archive.org/web/20180519112412/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}, {'datetime': '2018-06-10T23:04:36Z', 'uri': 'http://web.archive.org/web/20180610230436/https://www.guideline.gov/summaries/summary/43840/vinflunine-for-the-treatment-of-advanced-or-metastatic-transitional-cell-carcinoma-of-the-urothelial-tract'}]
https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:35Z', 'uri': 'http://wayback.archive-it.org/all/20161001000835/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2016-10-01T00:08:35Z', 'uri': 'http://web.archive.org/web/20161001000835/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2017-10-03T05:08:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003050844/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2017-10-03T05:08:44Z', 'uri': 'http://web.archive.org/web/20171003050844/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2018-04-14T04:38:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414043858/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2018-04-14T04:38:58Z', 'uri': 'http://web.archive.org/web/20180414043858/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2018-05-19T11:29:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519112905/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2018-05-19T11:29:05Z', 'uri': 'http://web.archive.org/web/20180519112905/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}, {'datetime': '2018-06-10T11:10:29Z', 'uri': 'http://web.archive.org/web/20180610111029/https://www.guideline.gov/summaries/summary/43841/fertility-assessment-and-treatment-for-people-with-fertility-problems'}]
https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:09Z', 'uri': 'http://wayback.archive-it.org/all/20161001000809/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2016-10-01T00:08:09Z', 'uri': 'http://web.archive.org/web/20161001000809/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2017-10-03T05:06:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003050640/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2017-10-03T05:06:40Z', 'uri': 'http://web.archive.org/web/20171003050640/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2018-04-14T04:38:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414043801/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2018-04-14T04:38:01Z', 'uri': 'http://web.archive.org/web/20180414043801/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2018-05-19T11:27:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519112758/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2018-05-19T11:27:58Z', 'uri': 'http://web.archive.org/web/20180519112758/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}, {'datetime': '2018-06-09T22:22:04Z', 'uri': 'http://web.archive.org/web/20180609222204/https://www.guideline.gov/summaries/summary/43842/surgical-safety-checklist-in-obstetrics-and-gynaecology'}]
https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:10Z', 'uri': 'http://wayback.archive-it.org/all/20161001000810/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2016-10-01T00:08:10Z', 'uri': 'http://web.archive.org/web/20161001000810/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2017-10-03T05:06:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003050645/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2017-10-03T05:06:45Z', 'uri': 'http://web.archive.org/web/20171003050645/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2018-04-14T04:38:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414043807/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2018-04-14T04:38:07Z', 'uri': 'http://web.archive.org/web/20180414043807/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2018-05-19T11:28:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519112805/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2018-05-19T11:28:05Z', 'uri': 'http://web.archive.org/web/20180519112805/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}, {'datetime': '2018-06-09T22:21:53Z', 'uri': 'http://web.archive.org/web/20180609222153/https://www.guideline.gov/summaries/summary/43843/toxoplasmosis-in-pregnancy-prevention-screening-and-treatment'}]
https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:01Z', 'uri': 'http://wayback.archive-it.org/all/20161001000301/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2016-10-01T00:03:01Z', 'uri': 'http://web.archive.org/web/20161001000301/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2017-10-03T04:55:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003045547/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2017-10-03T04:55:47Z', 'uri': 'http://web.archive.org/web/20171003045547/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2018-04-14T04:30:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414043052/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2018-04-14T04:30:52Z', 'uri': 'http://web.archive.org/web/20180414043052/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2018-05-19T11:20:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519112055/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2018-05-19T11:20:55Z', 'uri': 'http://web.archive.org/web/20180519112055/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}, {'datetime': '2018-06-09T21:24:49Z', 'uri': 'http://web.archive.org/web/20180609212449/https://www.guideline.gov/summaries/summary/43845/efnsmdses-recommendations-for-the-diagnosis-of-parkinsons-disease'}]
https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:05:27Z', 'uri': 'http://wayback.archive-it.org/all/20161001000527/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2016-10-01T00:05:27Z', 'uri': 'http://web.archive.org/web/20161001000527/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2017-10-03T05:02:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003050221/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2017-10-03T05:02:21Z', 'uri': 'http://web.archive.org/web/20171003050221/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2018-04-14T04:36:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414043601/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2018-04-14T04:36:01Z', 'uri': 'http://web.archive.org/web/20180414043601/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2018-05-19T11:26:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519112601/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2018-05-19T11:26:01Z', 'uri': 'http://web.archive.org/web/20180519112601/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}, {'datetime': '2018-06-09T18:53:19Z', 'uri': 'http://web.archive.org/web/20180609185319/https://www.guideline.gov/summaries/summary/43847/guidelines-for-the-diagnosis-and-management-of-gastroesophageal-reflux-disease'}]
https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:02Z', 'uri': 'http://wayback.archive-it.org/all/20161001000802/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2016-10-01T00:08:02Z', 'uri': 'http://web.archive.org/web/20161001000802/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2017-10-03T05:05:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003050557/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2017-10-03T05:05:57Z', 'uri': 'http://web.archive.org/web/20171003050557/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2018-04-14T04:37:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414043717/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2018-04-14T04:37:17Z', 'uri': 'http://web.archive.org/web/20180414043717/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2018-05-19T11:27:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519112720/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2018-05-19T11:27:20Z', 'uri': 'http://web.archive.org/web/20180519112720/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}, {'datetime': '2018-06-09T21:39:37Z', 'uri': 'http://web.archive.org/web/20180609213937/https://www.guideline.gov/summaries/summary/43892/the-diagnosis-and-management-of-acute-otitis-media'}]
https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:04Z', 'uri': 'http://wayback.archive-it.org/all/20161001000404/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2016-10-01T00:04:04Z', 'uri': 'http://web.archive.org/web/20161001000404/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2017-10-03T04:57:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003045739/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2017-10-03T04:57:39Z', 'uri': 'http://web.archive.org/web/20171003045739/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2018-04-14T04:32:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414043258/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2018-04-14T04:32:58Z', 'uri': 'http://web.archive.org/web/20180414043258/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2018-05-19T11:23:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519112306/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2018-05-19T11:23:06Z', 'uri': 'http://web.archive.org/web/20180519112306/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}, {'datetime': '2018-06-09T23:04:51Z', 'uri': 'http://web.archive.org/web/20180609230451/https://www.guideline.gov/summaries/summary/43894/american-cancer-society-lung-cancer-screening-guidelines'}]
https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:02:32Z', 'uri': 'http://wayback.archive-it.org/all/20161001000232/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2016-10-01T00:02:32Z', 'uri': 'http://web.archive.org/web/20161001000232/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2017-10-03T04:55:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003045517/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2017-10-03T04:55:17Z', 'uri': 'http://web.archive.org/web/20171003045517/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2018-04-14T04:30:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414043013/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2018-04-14T04:30:13Z', 'uri': 'http://web.archive.org/web/20180414043013/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2018-05-19T11:20:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519112018/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2018-05-19T11:20:18Z', 'uri': 'http://web.archive.org/web/20180519112018/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}, {'datetime': '2018-06-09T19:21:07Z', 'uri': 'http://web.archive.org/web/20180609192107/https://www.guideline.gov/summaries/summary/43895/practice-advisory-for-the-prevention-and-management-of-operating-room-fires-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-operating-room-fires'}]
https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:02:38Z', 'uri': 'http://wayback.archive-it.org/all/20161001000238/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2016-10-01T00:02:38Z', 'uri': 'http://web.archive.org/web/20161001000238/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2017-10-03T04:55:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003045528/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2017-10-03T04:55:28Z', 'uri': 'http://web.archive.org/web/20171003045528/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2018-04-14T04:30:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414043033/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2018-04-14T04:30:33Z', 'uri': 'http://web.archive.org/web/20180414043033/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2018-05-19T11:20:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519112037/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2018-05-19T11:20:37Z', 'uri': 'http://web.archive.org/web/20180519112037/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}, {'datetime': '2018-06-09T19:23:15Z', 'uri': 'http://web.archive.org/web/20180609192315/https://www.guideline.gov/summaries/summary/43896/practice-guidelines-for-postanesthetic-care-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-postanesthetic-care'}]
https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:02:36Z', 'uri': 'http://wayback.archive-it.org/all/20161001000236/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2016-10-01T00:02:36Z', 'uri': 'http://web.archive.org/web/20161001000236/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2017-10-03T04:55:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003045522/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2017-10-03T04:55:22Z', 'uri': 'http://web.archive.org/web/20171003045522/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2018-04-14T04:30:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414043023/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2018-04-14T04:30:23Z', 'uri': 'http://web.archive.org/web/20180414043023/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2018-05-19T11:20:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519112028/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2018-05-19T11:20:28Z', 'uri': 'http://web.archive.org/web/20180519112028/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}, {'datetime': '2018-06-09T20:56:33Z', 'uri': 'http://web.archive.org/web/20180609205633/https://www.guideline.gov/summaries/summary/43897/practice-guidelines-for-management-of-the-difficult-airway-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-management-of-the-difficult-airway'}]
https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:30:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930163042/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T16:30:42Z', 'uri': 'http://web.archive.org/web/20160930163042/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:10:53Z', 'uri': 'http://wayback.archive-it.org/all/20171002201053/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:10:53Z', 'uri': 'http://web.archive.org/web/20171002201053/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:47:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414004701/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:47:01Z', 'uri': 'http://web.archive.org/web/20180414004701/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:04:28Z', 'uri': 'http://wayback.archive-it.org/all/20180518220428/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:04:28Z', 'uri': 'http://web.archive.org/web/20180518220428/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T05:33:01Z', 'uri': 'http://web.archive.org/web/20180610053301/https://www.guideline.gov/summaries/summary/43898/central-venous-catheter-care-for-the-patient-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:05:22Z', 'uri': 'http://wayback.archive-it.org/all/20161001000522/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2016-10-01T00:05:22Z', 'uri': 'http://web.archive.org/web/20161001000522/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2017-10-03T05:01:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003050153/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2017-10-03T05:01:53Z', 'uri': 'http://web.archive.org/web/20171003050153/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2018-04-14T04:35:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414043540/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2018-04-14T04:35:40Z', 'uri': 'http://web.archive.org/web/20180414043540/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2018-05-19T11:25:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519112543/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2018-05-19T11:25:43Z', 'uri': 'http://web.archive.org/web/20180519112543/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}, {'datetime': '2018-06-09T21:05:37Z', 'uri': 'http://web.archive.org/web/20180609210537/https://www.guideline.gov/summaries/summary/43903/clinical-practice-guidelines-for-the-management-of-pain-agitation-and-delirium-in-adult-patients-in-the-intensive-care-unit'}]
https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:05Z', 'uri': 'http://wayback.archive-it.org/all/20161001000805/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2016-10-01T00:08:05Z', 'uri': 'http://web.archive.org/web/20161001000805/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2017-10-03T05:06:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003050619/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2017-10-03T05:06:19Z', 'uri': 'http://web.archive.org/web/20171003050619/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2018-04-14T04:37:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414043751/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2018-04-14T04:37:51Z', 'uri': 'http://web.archive.org/web/20180414043751/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2018-05-19T11:27:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519112751/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2018-05-19T11:27:51Z', 'uri': 'http://web.archive.org/web/20180519112751/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}, {'datetime': '2018-06-09T22:21:47Z', 'uri': 'http://web.archive.org/web/20180609222147/https://www.guideline.gov/summaries/summary/43907/cancer-chemotherapy-and-pregnancy'}]
https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:08:27Z', 'uri': 'http://wayback.archive-it.org/all/20161001000827/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2016-10-01T00:08:27Z', 'uri': 'http://web.archive.org/web/20161001000827/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2017-10-03T05:08:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003050811/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2017-10-03T05:08:11Z', 'uri': 'http://web.archive.org/web/20171003050811/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:38:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414043840/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:38:40Z', 'uri': 'http://web.archive.org/web/20180414043840/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:28:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519112845/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:28:45Z', 'uri': 'http://web.archive.org/web/20180519112845/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-06-09T12:10:35Z', 'uri': 'http://web.archive.org/web/20180609121035/https://www.guideline.gov/summaries/summary/43914/brain-injury-rehabilitation-in-adults-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:30:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930163016/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2016-09-30T16:30:16Z', 'uri': 'http://web.archive.org/web/20160930163016/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2017-10-02T20:10:40Z', 'uri': 'http://wayback.archive-it.org/all/20171002201040/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2017-10-02T20:10:40Z', 'uri': 'http://web.archive.org/web/20171002201040/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2018-04-14T00:46:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414004648/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2018-04-14T00:46:48Z', 'uri': 'http://web.archive.org/web/20180414004648/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2018-05-18T22:04:19Z', 'uri': 'http://wayback.archive-it.org/all/20180518220419/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2018-05-18T22:04:19Z', 'uri': 'http://web.archive.org/web/20180518220419/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}, {'datetime': '2018-06-10T00:16:09Z', 'uri': 'http://web.archive.org/web/20180610001609/https://www.guideline.gov/summaries/summary/43945/catheterisation-urethral-intermittent-in-adults-dilatation-urethral-intermittent-in-adults'}]
https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:34Z', 'uri': 'http://wayback.archive-it.org/all/20161001000434/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-10-01T00:04:34Z', 'uri': 'http://web.archive.org/web/20161001000434/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:59:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003045903/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:59:03Z', 'uri': 'http://web.archive.org/web/20171003045903/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:34:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414043425/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:34:25Z', 'uri': 'http://web.archive.org/web/20180414043425/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:24:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519112430/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:24:30Z', 'uri': 'http://web.archive.org/web/20180519112430/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T15:20:19Z', 'uri': 'http://web.archive.org/web/20180610152019/https://www.guideline.gov/summaries/summary/43947/summary-of-evidencebased-guideline-update-evaluation-and-management-of-concussion-in-sports-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:31Z', 'uri': 'http://wayback.archive-it.org/all/20161001000431/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2016-10-01T00:04:31Z', 'uri': 'http://web.archive.org/web/20161001000431/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2017-10-03T04:58:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003045858/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2017-10-03T04:58:58Z', 'uri': 'http://web.archive.org/web/20171003045858/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2018-04-14T04:34:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414043416/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2018-04-14T04:34:16Z', 'uri': 'http://web.archive.org/web/20180414043416/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2018-05-19T11:24:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519112422/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2018-05-19T11:24:22Z', 'uri': 'http://web.archive.org/web/20180519112422/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}, {'datetime': '2018-06-09T21:53:28Z', 'uri': 'http://web.archive.org/web/20180609215328/https://www.guideline.gov/summaries/summary/43948/nsgc-practice-guideline-risk-assessment-and-genetic-counseling-for-hereditary-breast-and-ovarian-cancer'}]
https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:15Z', 'uri': 'http://wayback.archive-it.org/all/20161001000415/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2016-10-01T00:04:15Z', 'uri': 'http://web.archive.org/web/20161001000415/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2017-10-03T04:58:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003045825/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2017-10-03T04:58:25Z', 'uri': 'http://web.archive.org/web/20171003045825/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2018-04-14T04:33:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414043341/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2018-04-14T04:33:41Z', 'uri': 'http://web.archive.org/web/20180414043341/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2018-05-19T11:23:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519112347/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2018-05-19T11:23:47Z', 'uri': 'http://web.archive.org/web/20180519112347/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}, {'datetime': '2018-06-09T20:18:43Z', 'uri': 'http://web.archive.org/web/20180609201843/https://www.guideline.gov/summaries/summary/43950/nsgc-practice-guideline-prenatal-screening-and-diagnostic-testing-options-for-chromosome-aneuploidy'}]
https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235937/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2016-09-30T23:59:37Z', 'uri': 'http://web.archive.org/web/20160930235937/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2017-10-03T04:48:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003044859/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2017-10-03T04:48:59Z', 'uri': 'http://web.archive.org/web/20171003044859/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2018-04-14T04:27:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414042721/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2018-04-14T04:27:21Z', 'uri': 'http://web.archive.org/web/20180414042721/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2018-05-19T11:17:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519111749/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2018-05-19T11:17:49Z', 'uri': 'http://web.archive.org/web/20180519111749/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}, {'datetime': '2018-06-09T20:35:45Z', 'uri': 'http://web.archive.org/web/20180609203545/https://www.guideline.gov/summaries/summary/43951/guidelines-for-the-minimally-invasive-treatment-of-adrenal-pathology'}]
https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:59Z', 'uri': 'http://wayback.archive-it.org/all/20161001000359/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2016-10-01T00:03:59Z', 'uri': 'http://web.archive.org/web/20161001000359/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2017-10-03T04:57:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003045717/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2017-10-03T04:57:17Z', 'uri': 'http://web.archive.org/web/20171003045717/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2018-04-14T04:32:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414043225/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2018-04-14T04:32:25Z', 'uri': 'http://web.archive.org/web/20180414043225/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2018-05-19T11:22:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519112231/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2018-05-19T11:22:31Z', 'uri': 'http://web.archive.org/web/20180519112231/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}, {'datetime': '2018-06-09T20:11:38Z', 'uri': 'http://web.archive.org/web/20180609201138/https://www.guideline.gov/summaries/summary/43955/clinical-pharmacogenetics-implementation-consortium-guidelines-for-thiopurine-methyltransferase-genotype-and-thiopurine-dosing'}]
https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235935/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:59:35Z', 'uri': 'http://web.archive.org/web/20160930235935/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:48:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003044829/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:48:29Z', 'uri': 'http://web.archive.org/web/20171003044829/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:27:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414042712/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:27:12Z', 'uri': 'http://web.archive.org/web/20180414042712/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:17:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519111738/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:17:38Z', 'uri': 'http://web.archive.org/web/20180519111738/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}, {'datetime': '2018-06-09T10:34:22Z', 'uri': 'http://web.archive.org/web/20180609103422/https://www.guideline.gov/summaries/summary/43956/management-of-schizophrenia-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:05:13Z', 'uri': 'http://wayback.archive-it.org/all/20161001000513/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2016-10-01T00:05:13Z', 'uri': 'http://web.archive.org/web/20161001000513/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2017-10-03T05:00:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003050049/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2017-10-03T05:00:49Z', 'uri': 'http://web.archive.org/web/20171003050049/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2018-04-14T04:35:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414043510/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2018-04-14T04:35:10Z', 'uri': 'http://web.archive.org/web/20180414043510/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2018-05-19T11:25:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519112512/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2018-05-19T11:25:12Z', 'uri': 'http://web.archive.org/web/20180519112512/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}, {'datetime': '2018-06-10T09:19:45Z', 'uri': 'http://web.archive.org/web/20180610091945/https://www.guideline.gov/summaries/summary/44058/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-infection-in-cystic-fibrosis'}]
https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235944/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2016-09-30T23:59:44Z', 'uri': 'http://web.archive.org/web/20160930235944/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2017-10-03T04:49:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003044941/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2017-10-03T04:49:41Z', 'uri': 'http://web.archive.org/web/20171003044941/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2018-04-14T04:28:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414042809/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2018-04-14T04:28:09Z', 'uri': 'http://web.archive.org/web/20180414042809/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2018-05-19T11:18:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519111832/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2018-05-19T11:18:32Z', 'uri': 'http://web.archive.org/web/20180519111832/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}, {'datetime': '2018-06-09T11:58:36Z', 'uri': 'http://web.archive.org/web/20180609115836/https://www.guideline.gov/summaries/summary/44087/antisocial-behaviour-and-conduct-disorders-in-children-and-young-people-recognition-intervention-and-management'}]
https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930235945/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2016-09-30T23:59:45Z', 'uri': 'http://web.archive.org/web/20160930235945/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2017-10-03T04:49:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003044950/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2017-10-03T04:49:50Z', 'uri': 'http://web.archive.org/web/20171003044950/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2018-04-14T04:28:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414042824/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2018-04-14T04:28:24Z', 'uri': 'http://web.archive.org/web/20180414042824/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2018-05-19T11:18:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519111845/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2018-05-19T11:18:45Z', 'uri': 'http://web.archive.org/web/20180519111845/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}, {'datetime': '2018-06-10T11:28:17Z', 'uri': 'http://web.archive.org/web/20180610112817/https://www.guideline.gov/summaries/summary/44088/hyperphosphataemia-in-chronic-kidney-disease-management-of-hyperphosphataemia-in-patients-with-stage-4-or-5-chronic-kidney-disease'}]
https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930235924/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2016-09-30T23:59:24Z', 'uri': 'http://web.archive.org/web/20160930235924/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2017-10-03T04:47:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003044715/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2017-10-03T04:47:15Z', 'uri': 'http://web.archive.org/web/20171003044715/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2018-04-14T04:26:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414042611/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2018-04-14T04:26:11Z', 'uri': 'http://web.archive.org/web/20180414042611/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2018-05-19T11:16:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519111619/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2018-05-19T11:16:19Z', 'uri': 'http://web.archive.org/web/20180519111619/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}, {'datetime': '2018-06-09T18:37:56Z', 'uri': 'http://web.archive.org/web/20180609183756/https://www.guideline.gov/summaries/summary/44118/the-role-of-endoscopy-in-the-evaluation-and-treatment-of-patients-with-biliary-neoplasia'}]
https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930235923/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2016-09-30T23:59:23Z', 'uri': 'http://web.archive.org/web/20160930235923/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2017-10-03T04:47:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003044709/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2017-10-03T04:47:09Z', 'uri': 'http://web.archive.org/web/20171003044709/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2018-04-14T04:26:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414042603/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2018-04-14T04:26:03Z', 'uri': 'http://web.archive.org/web/20180414042603/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2018-05-19T11:16:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519111611/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2018-05-19T11:16:11Z', 'uri': 'http://web.archive.org/web/20180519111611/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}, {'datetime': '2018-06-09T18:37:59Z', 'uri': 'http://web.archive.org/web/20180609183759/https://www.guideline.gov/summaries/summary/44119/the-role-of-endoscopy-in-the-assessment-and-treatment-of-esophageal-cancer'}]
https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930235812/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:12Z', 'uri': 'http://web.archive.org/web/20160930235812/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003043948/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:48Z', 'uri': 'http://web.archive.org/web/20171003043948/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414041518/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:18Z', 'uri': 'http://web.archive.org/web/20180414041518/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519110717/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:17Z', 'uri': 'http://web.archive.org/web/20180519110717/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T19:48:37Z', 'uri': 'http://web.archive.org/web/20180609194837/https://www.guideline.gov/summaries/summary/44234/prehospital-cervical-spinal-immobilization-after-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235818/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:18Z', 'uri': 'http://web.archive.org/web/20160930235818/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003044025/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:25Z', 'uri': 'http://web.archive.org/web/20171003044025/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:16:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414041613/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:16:13Z', 'uri': 'http://web.archive.org/web/20180414041613/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:08:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519110811/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:08:11Z', 'uri': 'http://web.archive.org/web/20180519110811/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T11:23:59Z', 'uri': 'http://web.archive.org/web/20180609112359/https://www.guideline.gov/summaries/summary/44237/transportation-of-patients-with-acute-traumatic-cervical-spine-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930235759/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:57:59Z', 'uri': 'http://web.archive.org/web/20160930235759/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003043807/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:07Z', 'uri': 'http://web.archive.org/web/20171003043807/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414041321/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:21Z', 'uri': 'http://web.archive.org/web/20180414041321/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519110509/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:09Z', 'uri': 'http://web.archive.org/web/20180519110509/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:14:19Z', 'uri': 'http://web.archive.org/web/20180610221419/https://www.guideline.gov/summaries/summary/44250/clinical-assessment-following-acute-cervical-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235813/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:13Z', 'uri': 'http://web.archive.org/web/20160930235813/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003043954/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:54Z', 'uri': 'http://web.archive.org/web/20171003043954/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414041526/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:26Z', 'uri': 'http://web.archive.org/web/20180414041526/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519110726/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:26Z', 'uri': 'http://web.archive.org/web/20180519110726/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T21:59:16Z', 'uri': 'http://web.archive.org/web/20180610215916/https://www.guideline.gov/summaries/summary/44264/radiographic-assessment-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235801/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:01Z', 'uri': 'http://web.archive.org/web/20160930235801/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003043838/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:38Z', 'uri': 'http://web.archive.org/web/20171003043838/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414041340/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:40Z', 'uri': 'http://web.archive.org/web/20180414041340/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519110527/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:27Z', 'uri': 'http://web.archive.org/web/20180519110527/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T00:47:25Z', 'uri': 'http://web.archive.org/web/20180610004725/https://www.guideline.gov/summaries/summary/44272/initial-closed-reduction-of-cervical-spinal-fracturedislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235816/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:16Z', 'uri': 'http://web.archive.org/web/20160930235816/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003044013/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:13Z', 'uri': 'http://web.archive.org/web/20171003044013/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414041553/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:53Z', 'uri': 'http://web.archive.org/web/20180414041553/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519110753/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:53Z', 'uri': 'http://web.archive.org/web/20180519110753/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T11:23:53Z', 'uri': 'http://web.archive.org/web/20180609112353/https://www.guideline.gov/summaries/summary/44280/the-acute-cardiopulmonary-management-of-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235811/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:11Z', 'uri': 'http://web.archive.org/web/20160930235811/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003043942/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:42Z', 'uri': 'http://web.archive.org/web/20171003043942/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414041508/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:08Z', 'uri': 'http://web.archive.org/web/20180414041508/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519110707/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:07Z', 'uri': 'http://web.archive.org/web/20180519110707/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T11:25:15Z', 'uri': 'http://web.archive.org/web/20180609112515/https://www.guideline.gov/summaries/summary/44291/pharmacological-therapy-for-acute-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930235809/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:09Z', 'uri': 'http://web.archive.org/web/20160930235809/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003043929/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:29Z', 'uri': 'http://web.archive.org/web/20171003043929/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414041451/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:51Z', 'uri': 'http://web.archive.org/web/20180414041451/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519110643/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:43Z', 'uri': 'http://web.archive.org/web/20180519110643/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:13:52Z', 'uri': 'http://web.archive.org/web/20180610221352/https://www.guideline.gov/summaries/summary/44298/occipital-condyle-fractures-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235817/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:17Z', 'uri': 'http://web.archive.org/web/20160930235817/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003044019/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:19Z', 'uri': 'http://web.archive.org/web/20171003044019/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:16:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414041604/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:16:04Z', 'uri': 'http://web.archive.org/web/20180414041604/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:08:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519110802/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:08:02Z', 'uri': 'http://web.archive.org/web/20180519110802/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T21:59:16Z', 'uri': 'http://web.archive.org/web/20180610215916/https://www.guideline.gov/summaries/summary/44301/the-diagnosis-and-management-of-traumatic-atlantooccipital-dislocation-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235804/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:04Z', 'uri': 'http://web.archive.org/web/20160930235804/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003043857/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:57Z', 'uri': 'http://web.archive.org/web/20171003043857/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414041410/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:10Z', 'uri': 'http://web.archive.org/web/20180414041410/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519110556/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:56Z', 'uri': 'http://web.archive.org/web/20180519110556/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T19:48:11Z', 'uri': 'http://web.archive.org/web/20180609194811/https://www.guideline.gov/summaries/summary/44312/management-of-isolated-fractures-of-the-atlas-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235805/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:05Z', 'uri': 'http://web.archive.org/web/20160930235805/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003043903/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:03Z', 'uri': 'http://web.archive.org/web/20171003043903/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414041418/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:18Z', 'uri': 'http://web.archive.org/web/20180414041418/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519110605/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:05Z', 'uri': 'http://web.archive.org/web/20180519110605/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T19:48:39Z', 'uri': 'http://web.archive.org/web/20180609194839/https://www.guideline.gov/summaries/summary/44317/management-of-isolated-fractures-of-the-axis-in-adults-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235802/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:02Z', 'uri': 'http://web.archive.org/web/20160930235802/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003043845/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:45Z', 'uri': 'http://web.archive.org/web/20171003043845/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414041349/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:49Z', 'uri': 'http://web.archive.org/web/20180414041349/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519110537/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:37Z', 'uri': 'http://web.archive.org/web/20180519110537/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:08:24Z', 'uri': 'http://web.archive.org/web/20180610220824/https://www.guideline.gov/summaries/summary/44322/management-of-acute-combination-fractures-of-the-atlas-and-axis-in-adult-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235810/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:10Z', 'uri': 'http://web.archive.org/web/20160930235810/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003043935/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:35Z', 'uri': 'http://web.archive.org/web/20171003043935/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414041500/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:00Z', 'uri': 'http://web.archive.org/web/20180414041500/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519110651/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:51Z', 'uri': 'http://web.archive.org/web/20180519110651/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T19:48:28Z', 'uri': 'http://web.archive.org/web/20180609194828/https://www.guideline.gov/summaries/summary/44323/os-odontoideum-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235815/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:15Z', 'uri': 'http://web.archive.org/web/20160930235815/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003044007/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:07Z', 'uri': 'http://web.archive.org/web/20171003044007/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414041544/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:44Z', 'uri': 'http://web.archive.org/web/20180414041544/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519110744/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:44Z', 'uri': 'http://web.archive.org/web/20180519110744/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:13:53Z', 'uri': 'http://web.archive.org/web/20180610221353/https://www.guideline.gov/summaries/summary/44336/subaxial-cervical-spine-injury-classification-systems-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235819/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:19Z', 'uri': 'http://web.archive.org/web/20160930235819/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003044031/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:31Z', 'uri': 'http://web.archive.org/web/20171003044031/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:16:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414041623/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:16:23Z', 'uri': 'http://web.archive.org/web/20180414041623/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:08:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519110818/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:08:18Z', 'uri': 'http://web.archive.org/web/20180519110818/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T19:48:34Z', 'uri': 'http://web.archive.org/web/20180609194834/https://www.guideline.gov/summaries/summary/44337/treatment-of-subaxial-cervical-spinal-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235803/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:03Z', 'uri': 'http://web.archive.org/web/20160930235803/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003043851/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:51Z', 'uri': 'http://web.archive.org/web/20171003043851/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414041359/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:59Z', 'uri': 'http://web.archive.org/web/20180414041359/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519110546/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:46Z', 'uri': 'http://web.archive.org/web/20180519110546/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:13:44Z', 'uri': 'http://web.archive.org/web/20180610221344/https://www.guideline.gov/summaries/summary/44338/management-of-acute-traumatic-central-cord-syndrome-atccs-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235806/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:06Z', 'uri': 'http://web.archive.org/web/20160930235806/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003043909/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:09Z', 'uri': 'http://web.archive.org/web/20171003043909/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414041426/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:26Z', 'uri': 'http://web.archive.org/web/20180414041426/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519110614/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:14Z', 'uri': 'http://web.archive.org/web/20180519110614/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:08:22Z', 'uri': 'http://web.archive.org/web/20180610220822/https://www.guideline.gov/summaries/summary/44339/management-of-pediatric-cervical-spine-and-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235814/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:14Z', 'uri': 'http://web.archive.org/web/20160930235814/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003044001/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:40:01Z', 'uri': 'http://web.archive.org/web/20171003044001/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414041535/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:15:35Z', 'uri': 'http://web.archive.org/web/20180414041535/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519110735/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:07:35Z', 'uri': 'http://web.archive.org/web/20180519110735/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T11:24:16Z', 'uri': 'http://web.archive.org/web/20180609112416/https://www.guideline.gov/summaries/summary/44340/spinal-cord-injury-without-radiographic-abnormality-sciwora-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235807/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:07Z', 'uri': 'http://web.archive.org/web/20160930235807/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003043916/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:16Z', 'uri': 'http://web.archive.org/web/20171003043916/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414041436/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:36Z', 'uri': 'http://web.archive.org/web/20180414041436/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519110624/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:24Z', 'uri': 'http://web.archive.org/web/20180519110624/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:13:53Z', 'uri': 'http://web.archive.org/web/20180610221353/https://www.guideline.gov/summaries/summary/44341/management-of-vertebral-artery-injuries-following-nonpenetrating-cervical-trauma-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235800/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:00Z', 'uri': 'http://web.archive.org/web/20160930235800/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003043832/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:38:32Z', 'uri': 'http://web.archive.org/web/20171003043832/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414041331/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:13:31Z', 'uri': 'http://web.archive.org/web/20180414041331/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519110518/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:05:18Z', 'uri': 'http://web.archive.org/web/20180519110518/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-10T22:08:23Z', 'uri': 'http://web.archive.org/web/20180610220823/https://www.guideline.gov/summaries/summary/44342/deep-venous-thrombosis-and-thromboembolism-in-patients-with-cervical-spinal-cord-injuries-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930235808/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2016-09-30T23:58:08Z', 'uri': 'http://web.archive.org/web/20160930235808/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003043924/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2017-10-03T04:39:24Z', 'uri': 'http://web.archive.org/web/20171003043924/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414041443/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-04-14T04:14:43Z', 'uri': 'http://web.archive.org/web/20180414041443/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519110634/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-05-19T11:06:34Z', 'uri': 'http://web.archive.org/web/20180519110634/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}, {'datetime': '2018-06-09T19:48:11Z', 'uri': 'http://web.archive.org/web/20180609194811/https://www.guideline.gov/summaries/summary/44343/nutritional-support-after-spinal-cord-injury-in-guidelines-for-the-management-of-acute-cervical-spine-and-spinal-cord-injuries'}]
https://www.guideline.gov/summaries/summary/44346/management-of-labor	ARCHIVED	15 mementos	[{'datetime': '2016-09-30T16:19:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930161954/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2016-09-30T16:19:54Z', 'uri': 'http://web.archive.org/web/20160930161954/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2016-12-19T17:29:23Z', 'uri': 'http://web.archive.org/web/20161219172923/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2017-07-13T03:16:57Z', 'uri': 'http://web.archive.org/web/20170713031657/https://www.guideline.gov/summaries/summary/44346/Management-of-labor'}, {'datetime': '2017-10-02T20:03:05Z', 'uri': 'http://wayback.archive-it.org/all/20171002200305/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2017-10-02T20:03:05Z', 'uri': 'http://web.archive.org/web/20171002200305/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2018-04-13T18:53:02Z', 'uri': 'http://wayback.archive-it.org/all/20180413185302/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2018-04-13T18:53:02Z', 'uri': 'http://web.archive.org/web/20180413185302/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2018-05-18T21:47:50Z', 'uri': 'http://wayback.archive-it.org/all/20180518214750/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2018-05-18T21:47:50Z', 'uri': 'http://web.archive.org/web/20180518214750/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2018-06-09T10:35:37Z', 'uri': 'http://web.archive.org/web/20180609103537/https://www.guideline.gov/summaries/summary/44346/Management-of-labor'}, {'datetime': '2018-06-09T11:34:44Z', 'uri': 'http://web.archive.org/web/20180609113444/https://www.guideline.gov/summaries/summary/44346/management-of-labor'}, {'datetime': '2018-06-11T16:44:08Z', 'uri': 'http://web.archive.org/web/20180611164408/https://www.guideline.gov/summaries/summary/44346/Management-of-labor'}, {'datetime': '2018-06-20T17:39:36Z', 'uri': 'http://web.archive.org/web/20180620173936/https://www.guideline.gov/summaries/summary/44346/Management-of-labor'}, {'datetime': '2018-06-21T00:09:11Z', 'uri': 'http://web.archive.org/web/20180621000911/https://www.guideline.gov/summaries/summary/44346/Management-of-labor'}]
https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:01:20Z', 'uri': 'http://wayback.archive-it.org/all/20161001000120/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2016-10-01T00:01:20Z', 'uri': 'http://web.archive.org/web/20161001000120/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2017-10-03T04:53:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003045356/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2017-10-03T04:53:56Z', 'uri': 'http://web.archive.org/web/20171003045356/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2018-04-14T04:29:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414042955/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2018-04-14T04:29:55Z', 'uri': 'http://web.archive.org/web/20180414042955/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2018-05-19T11:20:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519112000/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2018-05-19T11:20:00Z', 'uri': 'http://web.archive.org/web/20180519112000/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}, {'datetime': '2018-06-09T19:41:01Z', 'uri': 'http://web.archive.org/web/20180609194101/https://www.guideline.gov/summaries/summary/44347/the-investigation-and-management-of-the-smallforgestationalage-fetus'}]
https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:00:49Z', 'uri': 'http://wayback.archive-it.org/all/20161001000049/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2016-10-01T00:00:49Z', 'uri': 'http://web.archive.org/web/20161001000049/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2017-10-02T20:06:35Z', 'uri': 'http://wayback.archive-it.org/all/20171002200635/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2017-10-02T20:06:35Z', 'uri': 'http://web.archive.org/web/20171002200635/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2018-04-14T04:28:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414042851/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2018-04-14T04:28:51Z', 'uri': 'http://web.archive.org/web/20180414042851/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2018-05-18T19:32:13Z', 'uri': 'http://wayback.archive-it.org/all/20180518193213/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2018-05-18T19:32:13Z', 'uri': 'http://web.archive.org/web/20180518193213/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}, {'datetime': '2018-06-09T10:39:37Z', 'uri': 'http://web.archive.org/web/20180609103937/https://www.guideline.gov/summaries/summary/44348/best-evidence-statement-best-adding-home-based-services-to-complement-center-based-intervention-for-children-with-autism'}]
https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:00:50Z', 'uri': 'http://wayback.archive-it.org/all/20161001000050/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2016-10-01T00:00:50Z', 'uri': 'http://web.archive.org/web/20161001000050/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2017-10-03T04:53:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003045314/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2017-10-03T04:53:14Z', 'uri': 'http://web.archive.org/web/20171003045314/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2018-04-14T04:29:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414042900/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2018-04-14T04:29:00Z', 'uri': 'http://web.archive.org/web/20180414042900/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2018-05-19T11:19:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519111911/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2018-05-19T11:19:11Z', 'uri': 'http://web.archive.org/web/20180519111911/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}, {'datetime': '2018-06-09T11:59:35Z', 'uri': 'http://web.archive.org/web/20180609115935/https://www.guideline.gov/summaries/summary/44349/best-evidence-statement-best-horticultural-therapy-for-children-and-adolescents-in-residential-treatment-for-mental-health'}]
https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:00:59Z', 'uri': 'http://wayback.archive-it.org/all/20161001000059/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2016-10-01T00:00:59Z', 'uri': 'http://web.archive.org/web/20161001000059/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2017-10-03T04:53:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003045331/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2017-10-03T04:53:31Z', 'uri': 'http://web.archive.org/web/20171003045331/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2018-04-14T04:29:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414042927/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2018-04-14T04:29:27Z', 'uri': 'http://web.archive.org/web/20180414042927/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2018-05-19T11:19:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519111936/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2018-05-19T11:19:36Z', 'uri': 'http://web.archive.org/web/20180519111936/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}, {'datetime': '2018-06-10T17:22:10Z', 'uri': 'http://web.archive.org/web/20180610172210/https://www.guideline.gov/summaries/summary/44350/best-evidence-statement-best-vital-sign-monitoring-in-children-and-adolescents-who-are-overweight-or-obese-in-the-outpatient-physical-therapy-clinic'}]
https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:00:49Z', 'uri': 'http://wayback.archive-it.org/all/20161001000049/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2016-10-01T00:00:49Z', 'uri': 'http://web.archive.org/web/20161001000049/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2017-10-03T04:53:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003045309/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2017-10-03T04:53:09Z', 'uri': 'http://web.archive.org/web/20171003045309/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2018-04-14T04:28:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414042843/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2018-04-14T04:28:43Z', 'uri': 'http://web.archive.org/web/20180414042843/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2018-05-19T11:19:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519111904/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2018-05-19T11:19:04Z', 'uri': 'http://web.archive.org/web/20180519111904/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}, {'datetime': '2018-06-09T11:20:59Z', 'uri': 'http://web.archive.org/web/20180609112059/https://www.guideline.gov/summaries/summary/44351/best-evidence-statement-best-a-formal-followup-process-in-the-safety-reporting-system'}]
https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:00:57Z', 'uri': 'http://wayback.archive-it.org/all/20161001000057/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2016-10-01T00:00:57Z', 'uri': 'http://web.archive.org/web/20161001000057/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2017-10-03T04:53:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003045325/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2017-10-03T04:53:25Z', 'uri': 'http://web.archive.org/web/20171003045325/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2018-04-14T04:29:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414042918/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2018-04-14T04:29:18Z', 'uri': 'http://web.archive.org/web/20180414042918/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2018-05-19T11:19:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519111927/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2018-05-19T11:19:27Z', 'uri': 'http://web.archive.org/web/20180519111927/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}, {'datetime': '2018-06-09T20:50:18Z', 'uri': 'http://web.archive.org/web/20180609205018/https://www.guideline.gov/summaries/summary/44352/best-evidence-statement-best-tracheal-cuff-pressure-management'}]
https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:00:54Z', 'uri': 'http://wayback.archive-it.org/all/20161001000054/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2016-10-01T00:00:54Z', 'uri': 'http://web.archive.org/web/20161001000054/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2017-10-03T04:53:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003045320/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2017-10-03T04:53:20Z', 'uri': 'http://web.archive.org/web/20171003045320/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2018-04-14T04:29:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414042908/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2018-04-14T04:29:08Z', 'uri': 'http://web.archive.org/web/20180414042908/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2018-05-19T11:19:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519111919/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2018-05-19T11:19:19Z', 'uri': 'http://web.archive.org/web/20180519111919/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}, {'datetime': '2018-06-09T20:50:35Z', 'uri': 'http://web.archive.org/web/20180609205035/https://www.guideline.gov/summaries/summary/44353/best-evidence-statement-best-team-building-and-mentoring-for-increased-satisfaction-and-retention'}]
https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:59:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235934/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:59:34Z', 'uri': 'http://web.archive.org/web/20160930235934/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:48:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003044808/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:48:08Z', 'uri': 'http://web.archive.org/web/20171003044808/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2017-11-17T07:17:31Z', 'uri': 'http://web.archive.org/web/20171117071731/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:27:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414042702/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:27:02Z', 'uri': 'http://web.archive.org/web/20180414042702/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:17:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519111729/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T11:17:29Z', 'uri': 'http://web.archive.org/web/20180519111729/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}, {'datetime': '2018-06-09T21:16:56Z', 'uri': 'http://web.archive.org/web/20180609211656/https://www.guideline.gov/summaries/summary/44532/long-term-follow-up-of-survivors-of-childhood-cancer-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:04:11Z', 'uri': 'http://wayback.archive-it.org/all/20161001000411/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2016-10-01T00:04:11Z', 'uri': 'http://web.archive.org/web/20161001000411/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2017-10-03T04:58:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003045813/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2017-10-03T04:58:13Z', 'uri': 'http://web.archive.org/web/20171003045813/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2018-04-14T04:33:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414043329/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2018-04-14T04:33:29Z', 'uri': 'http://web.archive.org/web/20180414043329/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2018-05-19T11:23:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519112338/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2018-05-19T11:23:38Z', 'uri': 'http://web.archive.org/web/20180519112338/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}, {'datetime': '2018-06-09T19:22:29Z', 'uri': 'http://web.archive.org/web/20180609192229/https://www.guideline.gov/summaries/summary/44533/molecular-testing-guideline-for-selection-of-lung-cancer-patients-for-egfr-and-alk-tyrosine-kinase-inhibitors-guideline-from-the-college-of-american-pathologists-international-association-for-the-study-of-lung-cancer-and-association-for-molecular-pathology'}]
https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235930/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:59:30Z', 'uri': 'http://web.archive.org/web/20160930235930/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:47:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003044746/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:47:46Z', 'uri': 'http://web.archive.org/web/20171003044746/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:26:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414042653/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:26:53Z', 'uri': 'http://web.archive.org/web/20180414042653/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:17:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519111720/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:17:20Z', 'uri': 'http://web.archive.org/web/20180519111720/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T08:14:28Z', 'uri': 'http://web.archive.org/web/20180610081428/https://www.guideline.gov/summaries/summary/44534/evidencebased-guideline-treatment-of-parenchymal-neurocysticercosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235938/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2016-09-30T23:59:38Z', 'uri': 'http://web.archive.org/web/20160930235938/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2017-10-03T04:49:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003044906/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2017-10-03T04:49:06Z', 'uri': 'http://web.archive.org/web/20171003044906/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2018-04-14T04:27:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414042730/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2018-04-14T04:27:30Z', 'uri': 'http://web.archive.org/web/20180414042730/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2018-05-19T11:17:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519111756/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2018-05-19T11:17:56Z', 'uri': 'http://web.archive.org/web/20180519111756/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}, {'datetime': '2018-06-09T12:21:59Z', 'uri': 'http://web.archive.org/web/20180609122159/https://www.guideline.gov/summaries/summary/44984/bathing-persons-with-dementia'}]
https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235920/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2016-09-30T23:59:20Z', 'uri': 'http://web.archive.org/web/20160930235920/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2017-10-03T04:46:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003044649/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2017-10-03T04:46:49Z', 'uri': 'http://web.archive.org/web/20171003044649/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2018-04-14T04:25:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414042545/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2018-04-14T04:25:45Z', 'uri': 'http://web.archive.org/web/20180414042545/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2018-05-19T11:15:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519111553/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2018-05-19T11:15:53Z', 'uri': 'http://web.archive.org/web/20180519111553/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}, {'datetime': '2018-06-09T19:46:15Z', 'uri': 'http://web.archive.org/web/20180609194615/https://www.guideline.gov/summaries/summary/45103/management-of-adult-patients-with-ascites-due-to-cirrhosis-update-2012'}]
https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:01:02Z', 'uri': 'http://wayback.archive-it.org/all/20161001000102/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2016-10-01T00:01:02Z', 'uri': 'http://web.archive.org/web/20161001000102/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2017-10-03T04:53:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003045337/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2017-10-03T04:53:37Z', 'uri': 'http://web.archive.org/web/20171003045337/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2018-04-14T04:29:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414042936/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2018-04-14T04:29:36Z', 'uri': 'http://web.archive.org/web/20180414042936/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2018-05-19T11:19:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519111944/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2018-05-19T11:19:44Z', 'uri': 'http://web.archive.org/web/20180519111944/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}, {'datetime': '2018-06-09T23:13:26Z', 'uri': 'http://web.archive.org/web/20180609231326/https://www.guideline.gov/summaries/summary/45107/fetal-growth-restriction'}]
https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:59:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930235926/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2016-09-30T23:59:26Z', 'uri': 'http://web.archive.org/web/20160930235926/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2017-10-03T04:47:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003044726/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2017-10-03T04:47:26Z', 'uri': 'http://web.archive.org/web/20171003044726/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2018-04-14T04:26:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414042624/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2018-04-14T04:26:24Z', 'uri': 'http://web.archive.org/web/20180414042624/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2018-05-19T11:16:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519111634/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2018-05-19T11:16:34Z', 'uri': 'http://web.archive.org/web/20180519111634/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2018-06-09T20:12:59Z', 'uri': 'http://web.archive.org/web/20180609201259/https://www.guideline.gov/summaries/summary/45128/omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}, {'datetime': '2018-06-11T15:28:17Z', 'uri': 'http://web.archive.org/web/20180611152817/https://www.guideline.gov/summaries/summary/45128/Omalizumab-for-treating-severe-persistent-allergic-asthma-review-of-technology-appraisal-guidance-133-and-201'}]
https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930235927/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2016-09-30T23:59:27Z', 'uri': 'http://web.archive.org/web/20160930235927/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2017-10-03T04:47:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003044732/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2017-10-03T04:47:32Z', 'uri': 'http://web.archive.org/web/20171003044732/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2018-04-14T04:26:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414042634/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2018-04-14T04:26:34Z', 'uri': 'http://web.archive.org/web/20180414042634/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2018-05-19T11:16:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519111644/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2018-05-19T11:16:44Z', 'uri': 'http://web.archive.org/web/20180519111644/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}, {'datetime': '2018-06-09T15:20:13Z', 'uri': 'http://web.archive.org/web/20180609152013/https://www.guideline.gov/summaries/summary/45130/percutaneous-vertebroplasty-and-percutaneous-balloon-kyphoplasty-for-treating-osteoporotic-vertebral-compression-fractures'}]
https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235928/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2016-09-30T23:59:28Z', 'uri': 'http://web.archive.org/web/20160930235928/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2017-10-03T04:47:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003044738/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2017-10-03T04:47:38Z', 'uri': 'http://web.archive.org/web/20171003044738/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-04-14T04:26:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414042643/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-04-14T04:26:43Z', 'uri': 'http://web.archive.org/web/20180414042643/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-05-19T11:16:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519111653/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-05-19T11:16:53Z', 'uri': 'http://web.archive.org/web/20180519111653/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-06-09T22:07:01Z', 'uri': 'http://web.archive.org/web/20180609220701/https://www.guideline.gov/summaries/summary/45133/pirfenidone-for-treating-idiopathic-pulmonary-fibrosis'}]
https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235941/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2016-09-30T23:59:41Z', 'uri': 'http://web.archive.org/web/20160930235941/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2017-10-03T04:49:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003044928/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2017-10-03T04:49:28Z', 'uri': 'http://web.archive.org/web/20171003044928/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2018-04-14T04:27:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414042750/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2018-04-14T04:27:50Z', 'uri': 'http://web.archive.org/web/20180414042750/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2018-05-19T11:18:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519111814/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2018-05-19T11:18:14Z', 'uri': 'http://web.archive.org/web/20180519111814/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}, {'datetime': '2018-06-09T15:22:40Z', 'uri': 'http://web.archive.org/web/20180609152240/https://www.guideline.gov/summaries/summary/45138/recommendations-for-antithrombotic-agents-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation'}]
https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:59:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235921/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2016-09-30T23:59:21Z', 'uri': 'http://web.archive.org/web/20160930235921/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2016-12-16T13:34:49Z', 'uri': 'http://web.archive.org/web/20161216133449/https://guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2017-10-03T04:46:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003044656/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2017-10-03T04:46:56Z', 'uri': 'http://web.archive.org/web/20171003044656/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2018-04-14T04:25:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414042555/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2018-04-14T04:25:55Z', 'uri': 'http://web.archive.org/web/20180414042555/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2018-05-19T11:16:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519111603/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2018-05-19T11:16:03Z', 'uri': 'http://web.archive.org/web/20180519111603/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}, {'datetime': '2018-06-09T18:53:13Z', 'uri': 'http://web.archive.org/web/20180609185313/https://www.guideline.gov/summaries/summary/45139/guidelines-for-diagnosis-treatment-and-prevention-of-clostridium-difficile-infections'}]
https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235918/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2016-09-30T23:59:18Z', 'uri': 'http://web.archive.org/web/20160930235918/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2017-10-03T04:46:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003044634/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2017-10-03T04:46:34Z', 'uri': 'http://web.archive.org/web/20171003044634/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2018-04-14T04:25:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414042525/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2018-04-14T04:25:25Z', 'uri': 'http://web.archive.org/web/20180414042525/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2018-05-19T11:15:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519111535/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2018-05-19T11:15:35Z', 'uri': 'http://web.archive.org/web/20180519111535/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}, {'datetime': '2018-06-10T01:16:21Z', 'uri': 'http://web.archive.org/web/20180610011621/https://www.guideline.gov/summaries/summary/45147/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-distal-radius-fractures'}]
https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235947/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:59:47Z', 'uri': 'http://web.archive.org/web/20160930235947/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:50:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003045022/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:50:22Z', 'uri': 'http://web.archive.org/web/20171003045022/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:28:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414042834/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:28:34Z', 'uri': 'http://web.archive.org/web/20180414042834/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:18:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519111854/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:18:54Z', 'uri': 'http://web.archive.org/web/20180519111854/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T08:21:32Z', 'uri': 'http://web.archive.org/web/20180610082132/https://www.guideline.gov/summaries/summary/45148/screening-for-hiv-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health	ARCHIVED	10 mementos	[{'datetime': '2016-10-01T00:02:56Z', 'uri': 'http://wayback.archive-it.org/all/20161001000256/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2016-10-01T00:02:56Z', 'uri': 'http://web.archive.org/web/20161001000256/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2017-07-10T16:05:24Z', 'uri': 'http://web.archive.org/web/20170710160524/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2017-10-03T04:55:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003045535/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2017-10-03T04:55:35Z', 'uri': 'http://web.archive.org/web/20171003045535/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2018-04-14T04:30:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414043042/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2018-04-14T04:30:42Z', 'uri': 'http://web.archive.org/web/20180414043042/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2018-05-19T11:20:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519112046/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2018-05-19T11:20:46Z', 'uri': 'http://web.archive.org/web/20180519112046/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}, {'datetime': '2018-06-09T11:01:40Z', 'uri': 'http://web.archive.org/web/20180609110140/https://www.guideline.gov/summaries/summary/45307/cystic-fibrosis-pulmonary-guidelines-chronic-medications-for-maintenance-of-lung-health'}]
https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:01:14Z', 'uri': 'http://wayback.archive-it.org/all/20161001000114/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2016-10-01T00:01:14Z', 'uri': 'http://web.archive.org/web/20161001000114/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:53:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003045343/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:53:43Z', 'uri': 'http://web.archive.org/web/20171003045343/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-04-14T04:29:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414042945/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-04-14T04:29:45Z', 'uri': 'http://web.archive.org/web/20180414042945/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-05-19T11:19:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519111952/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-05-19T11:19:52Z', 'uri': 'http://web.archive.org/web/20180519111952/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:20Z', 'uri': 'http://web.archive.org/web/20180609192220/https://www.guideline.gov/summaries/summary/45309/screening-for-prostate-cancer-a-guidance-statement-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235907/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2016-09-30T23:59:07Z', 'uri': 'http://web.archive.org/web/20160930235907/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2017-10-03T04:45:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003044520/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2017-10-03T04:45:20Z', 'uri': 'http://web.archive.org/web/20171003044520/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-04-14T04:24:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414042430/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-04-14T04:24:30Z', 'uri': 'http://web.archive.org/web/20180414042430/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-05-19T11:14:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519111442/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-05-19T11:14:42Z', 'uri': 'http://web.archive.org/web/20180519111442/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-06-09T21:08:40Z', 'uri': 'http://web.archive.org/web/20180609210840/https://www.guideline.gov/summaries/summary/45326/validating-whole-slide-imaging-for-diagnostic-purposes-in-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}]
https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235902/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2016-09-30T23:59:02Z', 'uri': 'http://web.archive.org/web/20160930235902/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2017-10-03T04:44:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003044446/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2017-10-03T04:44:46Z', 'uri': 'http://web.archive.org/web/20171003044446/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2018-04-14T04:23:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414042340/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2018-04-14T04:23:40Z', 'uri': 'http://web.archive.org/web/20180414042340/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2018-05-19T11:13:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519111353/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2018-05-19T11:13:53Z', 'uri': 'http://web.archive.org/web/20180519111353/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}, {'datetime': '2018-06-09T11:25:50Z', 'uri': 'http://web.archive.org/web/20180609112550/https://www.guideline.gov/summaries/summary/45327/acg-clinical-guidelines-diagnosis-and-management-of-celiac-disease'}]
https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235901/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2016-09-30T23:59:01Z', 'uri': 'http://web.archive.org/web/20160930235901/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2017-10-03T04:44:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003044440/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2017-10-03T04:44:40Z', 'uri': 'http://web.archive.org/web/20171003044440/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2018-04-14T04:23:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414042330/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2018-04-14T04:23:30Z', 'uri': 'http://web.archive.org/web/20180414042330/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2018-05-19T11:13:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519111345/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2018-05-19T11:13:45Z', 'uri': 'http://web.archive.org/web/20180519111345/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}, {'datetime': '2018-06-09T18:53:36Z', 'uri': 'http://web.archive.org/web/20180609185336/https://www.guideline.gov/summaries/summary/45348/acg-clinical-guideline-evidenced-based-approach-to-the-diagnosis-and-management-of-esophageal-eosinophilia-and-eosinophilic-esophagitis-eoe'}]
https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235916/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2016-09-30T23:59:16Z', 'uri': 'http://web.archive.org/web/20160930235916/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2017-10-03T04:46:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003044616/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2017-10-03T04:46:16Z', 'uri': 'http://web.archive.org/web/20171003044616/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2018-04-14T04:24:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414042458/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2018-04-14T04:24:58Z', 'uri': 'http://web.archive.org/web/20180414042458/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2018-05-19T11:15:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519111510/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2018-05-19T11:15:10Z', 'uri': 'http://web.archive.org/web/20180519111510/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}, {'datetime': '2018-06-09T20:55:07Z', 'uri': 'http://web.archive.org/web/20180609205507/https://www.guideline.gov/summaries/summary/45375/proton-beam-radiation-therapy'}]
https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930235909/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2016-09-30T23:59:09Z', 'uri': 'http://web.archive.org/web/20160930235909/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2017-10-03T04:45:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003044533/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2017-10-03T04:45:33Z', 'uri': 'http://web.archive.org/web/20171003044533/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2018-04-14T04:24:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414042439/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2018-04-14T04:24:39Z', 'uri': 'http://web.archive.org/web/20180414042439/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2018-05-19T11:14:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519111451/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2018-05-19T11:14:51Z', 'uri': 'http://web.archive.org/web/20180519111451/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}, {'datetime': '2018-06-09T23:01:27Z', 'uri': 'http://web.archive.org/web/20180609230127/https://www.guideline.gov/summaries/summary/45377/aarc-clinical-practice-guideline-surfactant-replacement-therapy-2013'}]
https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235906/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2016-09-30T23:59:06Z', 'uri': 'http://web.archive.org/web/20160930235906/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2017-10-03T04:45:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003044513/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2017-10-03T04:45:13Z', 'uri': 'http://web.archive.org/web/20171003044513/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2018-04-14T04:24:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414042420/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2018-04-14T04:24:20Z', 'uri': 'http://web.archive.org/web/20180414042420/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2018-05-19T11:14:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519111435/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2018-05-19T11:14:35Z', 'uri': 'http://web.archive.org/web/20180519111435/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}, {'datetime': '2018-06-10T01:48:51Z', 'uri': 'http://web.archive.org/web/20180610014851/https://www.guideline.gov/summaries/summary/45378/guideline-for-the-laboratory-diagnosis-of-functional-iron-deficiency'}]
https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235903/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2016-09-30T23:59:03Z', 'uri': 'http://web.archive.org/web/20160930235903/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2017-10-03T04:44:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003044452/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2017-10-03T04:44:52Z', 'uri': 'http://web.archive.org/web/20171003044452/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2018-04-14T04:23:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414042350/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2018-04-14T04:23:50Z', 'uri': 'http://web.archive.org/web/20180414042350/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2018-05-19T11:14:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519111404/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2018-05-19T11:14:04Z', 'uri': 'http://web.archive.org/web/20180519111404/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}, {'datetime': '2018-06-09T20:49:57Z', 'uri': 'http://web.archive.org/web/20180609204957/https://www.guideline.gov/summaries/summary/45379/an-update-of-comprehensive-evidencebased-guidelines-for-interventional-techniques-in-chronic-spinal-pain-part-ii-guidance-and-recommendations'}]
https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement	ARCHIVED	14 mementos	[{'datetime': '2016-09-30T23:58:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235829/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:58:29Z', 'uri': 'http://web.archive.org/web/20160930235829/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-07-13T03:31:25Z', 'uri': 'http://web.archive.org/web/20170713033125/https://www.guideline.gov/summaries/summary/45519/Screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-US-Preventive-Services-Task-Force-recommendation-statement'}, {'datetime': '2017-10-03T04:41:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003044108/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:41:08Z', 'uri': 'http://web.archive.org/web/20171003044108/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:18:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414041828/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:18:28Z', 'uri': 'http://web.archive.org/web/20180414041828/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:08:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519110857/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:08:57Z', 'uri': 'http://web.archive.org/web/20180519110857/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T10:35:55Z', 'uri': 'http://web.archive.org/web/20180609103555/https://www.guideline.gov/summaries/summary/45519/Screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-US-Preventive-Services-Task-Force-recommendation-statement'}, {'datetime': '2018-06-09T18:39:00Z', 'uri': 'http://web.archive.org/web/20180609183900/https://www.guideline.gov/summaries/summary/45519/screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-20T17:39:45Z', 'uri': 'http://web.archive.org/web/20180620173945/https://www.guideline.gov/summaries/summary/45519/Screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-US-Preventive-Services-Task-Force-recommendation-statement'}, {'datetime': '2018-06-21T00:13:28Z', 'uri': 'http://web.archive.org/web/20180621001328/https://www.guideline.gov/summaries/summary/45519/Screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-US-Preventive-Services-Task-Force-recommendation-statement'}, {'datetime': '2018-06-23T03:05:36Z', 'uri': 'http://web.archive.org/web/20180623030536/https://www.guideline.gov/summaries/summary/45519/Screening-and-behavioral-counseling-interventions-in-primary-care-to-reduce-alcohol-misuse-US-Preventive-Services-Task-Force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	9 mementos	[{'datetime': '2016-10-01T00:03:19Z', 'uri': 'http://wayback.archive-it.org/all/20161001000319/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2016-10-01T00:03:19Z', 'uri': 'http://web.archive.org/web/20161001000319/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T04:56:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003045616/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T04:56:16Z', 'uri': 'http://web.archive.org/web/20171003045616/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T04:31:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414043114/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T04:31:14Z', 'uri': 'http://web.archive.org/web/20180414043114/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T11:21:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519112115/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T11:21:15Z', 'uri': 'http://web.archive.org/web/20180519112115/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T11:12:55Z', 'uri': 'http://web.archive.org/web/20180610111255/https://www.guideline.gov/summaries/summary/45520/venous-thromboembolism-prophylaxis-and-treatment-in-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235905/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2016-09-30T23:59:05Z', 'uri': 'http://web.archive.org/web/20160930235905/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2017-10-03T04:45:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003044507/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2017-10-03T04:45:07Z', 'uri': 'http://web.archive.org/web/20171003044507/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2018-04-14T04:24:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414042411/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2018-04-14T04:24:11Z', 'uri': 'http://web.archive.org/web/20180414042411/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2018-05-19T11:14:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519111425/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2018-05-19T11:14:25Z', 'uri': 'http://web.archive.org/web/20180519111425/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}, {'datetime': '2018-06-10T01:48:54Z', 'uri': 'http://web.archive.org/web/20180610014854/https://www.guideline.gov/summaries/summary/45673/diagnosis-and-treatment-of-factor-viii-and-ix-inhibitors-in-congenital-haemophilia-4th-edition'}]
https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235942/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2016-09-30T23:59:42Z', 'uri': 'http://web.archive.org/web/20160930235942/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2017-10-03T04:49:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003044934/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2017-10-03T04:49:34Z', 'uri': 'http://web.archive.org/web/20171003044934/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2018-04-14T04:27:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414042759/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2018-04-14T04:27:59Z', 'uri': 'http://web.archive.org/web/20180414042759/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2018-05-19T11:18:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519111823/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2018-05-19T11:18:23Z', 'uri': 'http://web.archive.org/web/20180519111823/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}, {'datetime': '2018-06-09T10:34:10Z', 'uri': 'http://web.archive.org/web/20180609103410/https://www.guideline.gov/summaries/summary/45688/recommendations-on-screening-for-depression-in-adults'}]
https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235904/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2016-09-30T23:59:04Z', 'uri': 'http://web.archive.org/web/20160930235904/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2017-10-03T04:45:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003044500/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2017-10-03T04:45:00Z', 'uri': 'http://web.archive.org/web/20171003044500/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2018-04-14T04:24:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414042401/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2018-04-14T04:24:01Z', 'uri': 'http://web.archive.org/web/20180414042401/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2018-05-19T11:14:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519111415/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2018-05-19T11:14:15Z', 'uri': 'http://web.archive.org/web/20180519111415/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}, {'datetime': '2018-06-09T19:20:25Z', 'uri': 'http://web.archive.org/web/20180609192025/https://www.guideline.gov/summaries/summary/46086/evidencebased-clinical-practice-guideline-breast-reconstruction-with-expanders-and-implants'}]
https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235842/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:42Z', 'uri': 'http://web.archive.org/web/20160930235842/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003044226/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:26Z', 'uri': 'http://web.archive.org/web/20171003044226/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414042024/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:24Z', 'uri': 'http://web.archive.org/web/20180414042024/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:10:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519111037/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:10:37Z', 'uri': 'http://web.archive.org/web/20180519111037/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-10T17:50:37Z', 'uri': 'http://web.archive.org/web/20180610175037/https://www.guideline.gov/summaries/summary/46162/chemoprevention-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235900/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:59:00Z', 'uri': 'http://web.archive.org/web/20160930235900/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003044434/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:34Z', 'uri': 'http://web.archive.org/web/20171003044434/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:23:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414042322/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:23:22Z', 'uri': 'http://web.archive.org/web/20180414042322/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519111336/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:36Z', 'uri': 'http://web.archive.org/web/20180519111336/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T19:32:30Z', 'uri': 'http://web.archive.org/web/20180609193230/https://www.guideline.gov/summaries/summary/46163/treatment-of-tobacco-use-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235848/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:48Z', 'uri': 'http://web.archive.org/web/20160930235848/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003044307/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:07Z', 'uri': 'http://web.archive.org/web/20171003044307/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414042117/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:17Z', 'uri': 'http://web.archive.org/web/20180414042117/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519111133/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:33Z', 'uri': 'http://web.archive.org/web/20180519111133/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-10T17:02:56Z', 'uri': 'http://web.archive.org/web/20180610170256/https://www.guideline.gov/summaries/summary/46165/evaluation-of-individuals-with-pulmonary-nodules-when-is-it-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235843/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:43Z', 'uri': 'http://web.archive.org/web/20160930235843/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003044233/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:33Z', 'uri': 'http://web.archive.org/web/20171003044233/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414042032/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:32Z', 'uri': 'http://web.archive.org/web/20180414042032/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:10:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519111047/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:10:47Z', 'uri': 'http://web.archive.org/web/20180519111047/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:04Z', 'uri': 'http://web.archive.org/web/20180609205104/https://www.guideline.gov/summaries/summary/46166/clinical-and-organizational-factors-in-the-initial-evaluation-of-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235847/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:47Z', 'uri': 'http://web.archive.org/web/20160930235847/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003044300/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:00Z', 'uri': 'http://web.archive.org/web/20171003044300/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414042108/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:08Z', 'uri': 'http://web.archive.org/web/20180414042108/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519111124/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:24Z', 'uri': 'http://web.archive.org/web/20180519111124/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:50:58Z', 'uri': 'http://web.archive.org/web/20180609205058/https://www.guideline.gov/summaries/summary/46167/establishing-the-diagnosis-of-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235852/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:52Z', 'uri': 'http://web.archive.org/web/20160930235852/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003044337/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:37Z', 'uri': 'http://web.archive.org/web/20171003044337/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414042156/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:56Z', 'uri': 'http://web.archive.org/web/20180414042156/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519111217/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:17Z', 'uri': 'http://web.archive.org/web/20180519111217/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-10T22:44:59Z', 'uri': 'http://web.archive.org/web/20180610224459/https://www.guideline.gov/summaries/summary/46168/physiologic-evaluation-of-the-patient-with-lung-cancer-being-considered-for-resectional-surgery-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235850/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:50Z', 'uri': 'http://web.archive.org/web/20160930235850/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003044323/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:23Z', 'uri': 'http://web.archive.org/web/20171003044323/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414042137/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:37Z', 'uri': 'http://web.archive.org/web/20180414042137/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519111152/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:52Z', 'uri': 'http://web.archive.org/web/20180519111152/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:50:51Z', 'uri': 'http://web.archive.org/web/20180609205051/https://www.guideline.gov/summaries/summary/46169/methods-for-staging-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235846/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:46Z', 'uri': 'http://web.archive.org/web/20160930235846/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003044252/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:52Z', 'uri': 'http://web.archive.org/web/20171003044252/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414042059/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:59Z', 'uri': 'http://web.archive.org/web/20180414042059/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519111115/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:15Z', 'uri': 'http://web.archive.org/web/20180519111115/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:12Z', 'uri': 'http://web.archive.org/web/20180609205112/https://www.guideline.gov/summaries/summary/46170/diagnostic-surgical-pathology-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930235845/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:45Z', 'uri': 'http://web.archive.org/web/20160930235845/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003044245/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:45Z', 'uri': 'http://web.archive.org/web/20171003044245/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414042049/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:49Z', 'uri': 'http://web.archive.org/web/20180414042049/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519111106/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:06Z', 'uri': 'http://web.archive.org/web/20180519111106/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-10T23:03:51Z', 'uri': 'http://web.archive.org/web/20180610230351/https://www.guideline.gov/summaries/summary/46171/diagnosis-and-treatment-of-bronchial-intraepithelial-neoplasia-and-early-lung-cancer-of-the-central-airways-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235857/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:57Z', 'uri': 'http://web.archive.org/web/20160930235857/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003044414/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:14Z', 'uri': 'http://web.archive.org/web/20171003044414/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414042252/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:52Z', 'uri': 'http://web.archive.org/web/20180414042252/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519111308/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:08Z', 'uri': 'http://web.archive.org/web/20180519111308/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:28Z', 'uri': 'http://web.archive.org/web/20180609205128/https://www.guideline.gov/summaries/summary/46172/treatment-of-stage-i-and-ii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930235858/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:58Z', 'uri': 'http://web.archive.org/web/20160930235858/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003044420/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:20Z', 'uri': 'http://web.archive.org/web/20171003044420/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:23:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414042302/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:23:02Z', 'uri': 'http://web.archive.org/web/20180414042302/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519111317/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:17Z', 'uri': 'http://web.archive.org/web/20180519111317/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:09Z', 'uri': 'http://web.archive.org/web/20180609205109/https://www.guideline.gov/summaries/summary/46173/treatment-of-stage-iii-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930235859/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:59Z', 'uri': 'http://web.archive.org/web/20160930235859/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003044427/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:27Z', 'uri': 'http://web.archive.org/web/20171003044427/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:23:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414042312/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:23:12Z', 'uri': 'http://web.archive.org/web/20180414042312/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519111326/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:13:26Z', 'uri': 'http://web.archive.org/web/20180519111326/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-10T19:09:13Z', 'uri': 'http://web.archive.org/web/20180610190913/https://www.guideline.gov/summaries/summary/46174/treatment-of-stage-iv-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235854/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:54Z', 'uri': 'http://web.archive.org/web/20160930235854/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003044350/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:50Z', 'uri': 'http://web.archive.org/web/20171003044350/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414042216/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:16Z', 'uri': 'http://web.archive.org/web/20180414042216/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519111236/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:36Z', 'uri': 'http://web.archive.org/web/20180519111236/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:17Z', 'uri': 'http://web.archive.org/web/20180609205117/https://www.guideline.gov/summaries/summary/46175/special-treatment-issues-in-nonsmall-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235856/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:56Z', 'uri': 'http://web.archive.org/web/20160930235856/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003044407/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:44:07Z', 'uri': 'http://web.archive.org/web/20171003044407/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414042242/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:42Z', 'uri': 'http://web.archive.org/web/20180414042242/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519111259/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:59Z', 'uri': 'http://web.archive.org/web/20180519111259/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:27Z', 'uri': 'http://web.archive.org/web/20180609205127/https://www.guideline.gov/summaries/summary/46176/treatment-of-small-cell-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235844/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:44Z', 'uri': 'http://web.archive.org/web/20160930235844/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003044239/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:42:39Z', 'uri': 'http://web.archive.org/web/20171003044239/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414042040/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:20:40Z', 'uri': 'http://web.archive.org/web/20180414042040/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:10:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519111057/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:10:57Z', 'uri': 'http://web.archive.org/web/20180519111057/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-10T00:05:16Z', 'uri': 'http://web.archive.org/web/20180610000516/https://www.guideline.gov/summaries/summary/46177/complementary-therapies-and-integrative-medicine-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930235849/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:49Z', 'uri': 'http://web.archive.org/web/20160930235849/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003044316/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:16Z', 'uri': 'http://web.archive.org/web/20171003044316/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414042127/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:27Z', 'uri': 'http://web.archive.org/web/20180414042127/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519111142/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:11:42Z', 'uri': 'http://web.archive.org/web/20180519111142/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:08Z', 'uri': 'http://web.archive.org/web/20180609205108/https://www.guideline.gov/summaries/summary/46178/followup-and-surveillance-of-the-patient-with-lung-cancer-after-curativeintent-therapy-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235855/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:55Z', 'uri': 'http://web.archive.org/web/20160930235855/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003044358/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:58Z', 'uri': 'http://web.archive.org/web/20171003044358/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414042227/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:22:27Z', 'uri': 'http://web.archive.org/web/20180414042227/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519111246/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:46Z', 'uri': 'http://web.archive.org/web/20180519111246/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T20:51:05Z', 'uri': 'http://web.archive.org/web/20180609205105/https://www.guideline.gov/summaries/summary/46179/symptom-management-in-patients-with-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:58:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930235851/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2016-09-30T23:58:51Z', 'uri': 'http://web.archive.org/web/20160930235851/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-07-14T10:31:35Z', 'uri': 'http://web.archive.org/web/20170714103135/https://guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003044330/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2017-10-03T04:43:30Z', 'uri': 'http://web.archive.org/web/20171003044330/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414042147/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-04-14T04:21:47Z', 'uri': 'http://web.archive.org/web/20180414042147/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519111208/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-05-19T11:12:08Z', 'uri': 'http://web.archive.org/web/20180519111208/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}, {'datetime': '2018-06-09T11:40:56Z', 'uri': 'http://web.archive.org/web/20180609114056/https://www.guideline.gov/summaries/summary/46180/palliative-and-endoflife-care-in-lung-cancer-diagnosis-and-management-of-lung-cancer-3rd-ed-american-college-of-chest-physicians-evidencebased-clinical-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235910/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2016-09-30T23:59:10Z', 'uri': 'http://web.archive.org/web/20160930235910/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2017-10-03T04:45:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003044539/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2017-10-03T04:45:39Z', 'uri': 'http://web.archive.org/web/20171003044539/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-04-14T04:24:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414042448/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-04-14T04:24:48Z', 'uri': 'http://web.archive.org/web/20180414042448/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-05-19T11:15:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519111500/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-05-19T11:15:00Z', 'uri': 'http://web.archive.org/web/20180519111500/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-06-09T19:46:05Z', 'uri': 'http://web.archive.org/web/20180609194605/https://www.guideline.gov/summaries/summary/46232/longterm-management-of-the-successful-adult-liver-transplant-2012-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}]
https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235917/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2016-09-30T23:59:17Z', 'uri': 'http://web.archive.org/web/20160930235917/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2017-10-03T04:46:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003044622/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2017-10-03T04:46:22Z', 'uri': 'http://web.archive.org/web/20171003044622/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2018-04-14T04:25:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414042508/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2018-04-14T04:25:08Z', 'uri': 'http://web.archive.org/web/20180414042508/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2018-05-19T11:15:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519111519/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2018-05-19T11:15:19Z', 'uri': 'http://web.archive.org/web/20180519111519/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}, {'datetime': '2018-06-09T22:28:00Z', 'uri': 'http://web.archive.org/web/20180609222800/https://www.guideline.gov/summaries/summary/46233/feverish-illness-in-children-assessment-and-initial-management-in-children-younger-than-5-years'}]
https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235916/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2016-09-30T23:59:16Z', 'uri': 'http://web.archive.org/web/20160930235916/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2017-10-03T04:46:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003044625/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2017-10-03T04:46:25Z', 'uri': 'http://web.archive.org/web/20171003044625/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2018-04-14T04:25:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414042512/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2018-04-14T04:25:12Z', 'uri': 'http://web.archive.org/web/20180414042512/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2018-05-19T11:15:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519111523/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2018-05-19T11:15:23Z', 'uri': 'http://web.archive.org/web/20180519111523/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}, {'datetime': '2018-06-09T13:00:28Z', 'uri': 'http://web.archive.org/web/20180609130028/https://www.guideline.gov/summaries/summary/46234/social-anxiety-disorder-recognition-assessment-and-treatment'}]
https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235820/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2016-09-30T23:58:20Z', 'uri': 'http://web.archive.org/web/20160930235820/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2017-10-03T04:40:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003044037/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2017-10-03T04:40:37Z', 'uri': 'http://web.archive.org/web/20171003044037/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2018-04-14T04:16:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414041632/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2018-04-14T04:16:32Z', 'uri': 'http://web.archive.org/web/20180414041632/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2018-05-19T11:08:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519110826/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2018-05-19T11:08:26Z', 'uri': 'http://web.archive.org/web/20180519110826/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}, {'datetime': '2018-06-10T22:26:54Z', 'uri': 'http://web.archive.org/web/20180610222654/https://www.guideline.gov/summaries/summary/46235/bevacizumab-in-combination-with-gemcitabine-and-carboplatin-for-treating-the-first-recurrence-of-platinumsensitive-advanced-ovarian-cancer'}]
https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235821/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2016-09-30T23:58:21Z', 'uri': 'http://web.archive.org/web/20160930235821/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2017-10-03T04:40:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003044044/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2017-10-03T04:40:44Z', 'uri': 'http://web.archive.org/web/20171003044044/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2018-04-14T04:16:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414041641/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2018-04-14T04:16:41Z', 'uri': 'http://web.archive.org/web/20180414041641/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2018-05-19T11:08:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519110834/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2018-05-19T11:08:34Z', 'uri': 'http://web.archive.org/web/20180519110834/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}, {'datetime': '2018-06-10T23:04:39Z', 'uri': 'http://web.archive.org/web/20180610230439/https://www.guideline.gov/summaries/summary/46236/bevacizumab-in-combination-with-paclitaxel-and-carboplatin-for-firstline-treatment-of-advanced-ovarian-cancer'}]
https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235822/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2016-09-30T23:58:22Z', 'uri': 'http://web.archive.org/web/20160930235822/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2017-10-03T04:40:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003044050/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2017-10-03T04:40:50Z', 'uri': 'http://web.archive.org/web/20171003044050/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2018-04-14T04:16:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414041650/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2018-04-14T04:16:50Z', 'uri': 'http://web.archive.org/web/20180414041650/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2018-05-19T11:08:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519110843/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2018-05-19T11:08:43Z', 'uri': 'http://web.archive.org/web/20180519110843/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}, {'datetime': '2018-06-09T15:45:24Z', 'uri': 'http://web.archive.org/web/20180609154524/https://www.guideline.gov/summaries/summary/46237/ranibizumab-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-retinal-vein-occlusion'}]
https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235834/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2016-09-30T23:58:34Z', 'uri': 'http://web.archive.org/web/20160930235834/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2017-10-03T04:41:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003044137/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2017-10-03T04:41:37Z', 'uri': 'http://web.archive.org/web/20171003044137/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2018-04-14T04:19:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414041908/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2018-04-14T04:19:08Z', 'uri': 'http://web.archive.org/web/20180414041908/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2018-05-19T11:09:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519110934/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2018-05-19T11:09:34Z', 'uri': 'http://web.archive.org/web/20180519110934/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}, {'datetime': '2018-06-09T19:17:03Z', 'uri': 'http://web.archive.org/web/20180609191703/https://www.guideline.gov/summaries/summary/46238/practice-parameters-for-the-management-of-rectal-cancer-revised'}]
https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults	ARCHIVED	14 mementos	[{'datetime': '2016-09-30T16:20:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930162002/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2016-09-30T16:20:02Z', 'uri': 'http://web.archive.org/web/20160930162002/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2017-07-13T03:18:30Z', 'uri': 'http://web.archive.org/web/20170713031830/https://www.guideline.gov/summaries/summary/46240/Prevention-and-management-of-obesity-for-adults'}, {'datetime': '2017-10-02T20:03:15Z', 'uri': 'http://wayback.archive-it.org/all/20171002200315/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2017-10-02T20:03:15Z', 'uri': 'http://web.archive.org/web/20171002200315/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-04-13T18:53:15Z', 'uri': 'http://wayback.archive-it.org/all/20180413185315/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-04-13T18:53:15Z', 'uri': 'http://web.archive.org/web/20180413185315/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-05-18T21:48:03Z', 'uri': 'http://wayback.archive-it.org/all/20180518214803/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-05-18T21:48:03Z', 'uri': 'http://web.archive.org/web/20180518214803/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-06-09T10:36:03Z', 'uri': 'http://web.archive.org/web/20180609103603/https://www.guideline.gov/summaries/summary/46240/Prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-06-09T11:35:13Z', 'uri': 'http://web.archive.org/web/20180609113513/https://www.guideline.gov/summaries/summary/46240/prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-06-11T17:48:44Z', 'uri': 'http://web.archive.org/web/20180611174844/https://www.guideline.gov/summaries/summary/46240/Prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-06-20T17:39:55Z', 'uri': 'http://web.archive.org/web/20180620173955/https://www.guideline.gov/summaries/summary/46240/Prevention-and-management-of-obesity-for-adults'}, {'datetime': '2018-06-21T00:05:09Z', 'uri': 'http://web.archive.org/web/20180621000509/https://www.guideline.gov/summaries/summary/46240/Prevention-and-management-of-obesity-for-adults'}]
https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease	ARCHIVED	15 mementos	[{'datetime': '2016-09-30T16:20:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930162010/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2016-09-30T16:20:10Z', 'uri': 'http://web.archive.org/web/20160930162010/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2016-12-19T21:41:35Z', 'uri': 'http://web.archive.org/web/20161219214135/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2017-07-13T03:18:02Z', 'uri': 'http://web.archive.org/web/20170713031802/https://www.guideline.gov/summaries/summary/46241/Stable-coronary-artery-disease'}, {'datetime': '2017-10-02T20:03:24Z', 'uri': 'http://wayback.archive-it.org/all/20171002200324/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2017-10-02T20:03:24Z', 'uri': 'http://web.archive.org/web/20171002200324/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2018-04-13T18:53:28Z', 'uri': 'http://wayback.archive-it.org/all/20180413185328/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2018-04-13T18:53:28Z', 'uri': 'http://web.archive.org/web/20180413185328/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2018-05-18T21:48:16Z', 'uri': 'http://wayback.archive-it.org/all/20180518214816/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2018-05-18T21:48:16Z', 'uri': 'http://web.archive.org/web/20180518214816/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2018-06-09T10:36:11Z', 'uri': 'http://web.archive.org/web/20180609103611/https://www.guideline.gov/summaries/summary/46241/Stable-coronary-artery-disease'}, {'datetime': '2018-06-09T11:35:00Z', 'uri': 'http://web.archive.org/web/20180609113500/https://www.guideline.gov/summaries/summary/46241/stable-coronary-artery-disease'}, {'datetime': '2018-06-11T16:08:39Z', 'uri': 'http://web.archive.org/web/20180611160839/https://www.guideline.gov/summaries/summary/46241/Stable-coronary-artery-disease'}, {'datetime': '2018-06-20T17:38:21Z', 'uri': 'http://web.archive.org/web/20180620173821/https://www.guideline.gov/summaries/summary/46241/Stable-coronary-artery-disease'}, {'datetime': '2018-06-21T00:05:53Z', 'uri': 'http://web.archive.org/web/20180621000553/https://www.guideline.gov/summaries/summary/46241/Stable-coronary-artery-disease'}]
https://www.guideline.gov/summaries/summary/46411/secondtrimester-abortion	ARCHIVED	4 mementos	[{'datetime': '2016-10-01T00:01:09Z', 'uri': 'http://wayback.archive-it.org/all/20161001000109/https://www.guideline.gov/summaries/summary/46411/secondtrimester-abortion'}, {'datetime': '2016-10-01T00:01:09Z', 'uri': 'http://web.archive.org/web/20161001000109/https://www.guideline.gov/summaries/summary/46411/secondtrimester-abortion'}, {'datetime': '2018-06-09T23:13:37Z', 'uri': 'http://web.archive.org/web/20180609231337/https://www.guideline.gov/summaries/summary/46411/secondtrimester-abortion'}, {'datetime': '2018-06-15T15:13:32Z', 'uri': 'http://web.archive.org/web/20180615151332/https://guideline.gov/summaries/summary/46411/secondtrimester-abortion'}]
https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235832/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:58:32Z', 'uri': 'http://web.archive.org/web/20160930235832/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:41:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003044123/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:41:23Z', 'uri': 'http://web.archive.org/web/20171003044123/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:18:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414041848/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:18:48Z', 'uri': 'http://web.archive.org/web/20180414041848/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:09:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519110916/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T11:09:16Z', 'uri': 'http://web.archive.org/web/20180519110916/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T18:59:55Z', 'uri': 'http://web.archive.org/web/20180609185955/https://www.guideline.gov/summaries/summary/46412/summary-of-evidencebased-guideline-periprocedural-management-of-antithrombotic-medications-in-patients-with-ischemic-cerebrovascular-disease-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930235731/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2016-09-30T23:57:31Z', 'uri': 'http://web.archive.org/web/20160930235731/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2017-10-03T04:35:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003043541/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2017-10-03T04:35:41Z', 'uri': 'http://web.archive.org/web/20171003043541/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2018-04-14T04:10:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414041017/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2018-04-14T04:10:17Z', 'uri': 'http://web.archive.org/web/20180414041017/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2018-05-19T11:02:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519110221/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2018-05-19T11:02:21Z', 'uri': 'http://web.archive.org/web/20180519110221/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}, {'datetime': '2018-06-09T15:30:01Z', 'uri': 'http://web.archive.org/web/20180609153001/https://www.guideline.gov/summaries/summary/46413/2012-accfahahrs-focused-update-incorporated-into-the-accfahahrs-2008-guidelines-for-devicebased-therapy-of-cardiac-rhythm-abnormalities-a-report-of-the-american-college-of-cardiology-foundationamerican-heart-association-task-force-on-practice-guidelines-and-th'}]
https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:57:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930225756/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2016-09-30T22:57:56Z', 'uri': 'http://web.archive.org/web/20160930225756/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2017-10-03T02:13:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003021325/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2017-10-03T02:13:25Z', 'uri': 'http://web.archive.org/web/20171003021325/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2018-04-14T01:02:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414010206/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2018-04-14T01:02:06Z', 'uri': 'http://web.archive.org/web/20180414010206/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2018-05-19T07:42:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519074237/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2018-05-19T07:42:37Z', 'uri': 'http://web.archive.org/web/20180519074237/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}, {'datetime': '2018-06-09T11:11:24Z', 'uri': 'http://web.archive.org/web/20180609111124/https://www.guideline.gov/summaries/summary/46415/attentiondeficit-hyperactivity-disorder'}]
https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235739/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2016-09-30T23:57:39Z', 'uri': 'http://web.archive.org/web/20160930235739/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2017-10-03T04:36:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003043636/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2017-10-03T04:36:36Z', 'uri': 'http://web.archive.org/web/20171003043636/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2018-04-14T04:11:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414041124/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2018-04-14T04:11:24Z', 'uri': 'http://web.archive.org/web/20180414041124/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2018-05-19T11:03:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519110319/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2018-05-19T11:03:19Z', 'uri': 'http://web.archive.org/web/20180519110319/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}, {'datetime': '2018-06-09T22:22:07Z', 'uri': 'http://web.archive.org/web/20180609222207/https://www.guideline.gov/summaries/summary/46416/abnormal-uterine-bleeding-in-premenopausal-women'}]
https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:57:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930225710/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2016-09-30T22:57:10Z', 'uri': 'http://web.archive.org/web/20160930225710/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2017-10-03T02:12:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003021234/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2017-10-03T02:12:34Z', 'uri': 'http://web.archive.org/web/20171003021234/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2018-04-14T01:01:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414010149/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2018-04-14T01:01:49Z', 'uri': 'http://web.archive.org/web/20180414010149/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2018-05-19T07:42:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519074218/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2018-05-19T07:42:18Z', 'uri': 'http://web.archive.org/web/20180519074218/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}, {'datetime': '2018-06-09T21:18:30Z', 'uri': 'http://web.archive.org/web/20180609211830/https://www.guideline.gov/summaries/summary/46417/mature-oocyte-cryopreservation-a-guideline'}]
https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:57:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930225704/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2016-09-30T22:57:04Z', 'uri': 'http://web.archive.org/web/20160930225704/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2017-10-03T02:12:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003021227/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2017-10-03T02:12:27Z', 'uri': 'http://web.archive.org/web/20171003021227/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2018-04-14T01:01:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414010142/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2018-04-14T01:01:42Z', 'uri': 'http://web.archive.org/web/20180414010142/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2018-05-19T07:42:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519074209/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2018-05-19T07:42:09Z', 'uri': 'http://web.archive.org/web/20180519074209/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}, {'datetime': '2018-06-09T22:23:56Z', 'uri': 'http://web.archive.org/web/20180609222356/https://www.guideline.gov/summaries/summary/46418/adjuvant-and-salvage-radiotherapy-after-prostatectomy-astroaua-guideline'}]
https://www.guideline.gov/summaries/summary/46420/otitis-media	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235742/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2016-09-30T23:57:42Z', 'uri': 'http://web.archive.org/web/20160930235742/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2017-10-03T04:36:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003043654/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2017-10-03T04:36:54Z', 'uri': 'http://web.archive.org/web/20171003043654/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2018-04-14T04:11:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414041151/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2018-04-14T04:11:51Z', 'uri': 'http://web.archive.org/web/20180414041151/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2018-05-19T11:03:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519110345/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2018-05-19T11:03:45Z', 'uri': 'http://web.archive.org/web/20180519110345/https://www.guideline.gov/summaries/summary/46420/otitis-media'}, {'datetime': '2018-06-09T21:34:19Z', 'uri': 'http://web.archive.org/web/20180609213419/https://www.guideline.gov/summaries/summary/46420/otitis-media'}]
https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235919/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2016-09-30T23:59:19Z', 'uri': 'http://web.archive.org/web/20160930235919/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2017-10-03T04:46:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003044642/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2017-10-03T04:46:42Z', 'uri': 'http://web.archive.org/web/20171003044642/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2018-04-14T04:25:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414042534/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2018-04-14T04:25:34Z', 'uri': 'http://web.archive.org/web/20180414042534/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2018-05-19T11:15:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519111544/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2018-05-19T11:15:44Z', 'uri': 'http://web.archive.org/web/20180519111544/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}, {'datetime': '2018-06-10T01:16:24Z', 'uri': 'http://web.archive.org/web/20180610011624/https://www.guideline.gov/summaries/summary/46422/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-osteoarthritis-of-the-knee-2nd-edition'}]
https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235838/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2016-09-30T23:58:38Z', 'uri': 'http://web.archive.org/web/20160930235838/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2017-10-03T04:42:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003044205/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2017-10-03T04:42:05Z', 'uri': 'http://web.archive.org/web/20171003044205/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2018-04-14T04:19:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414041955/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2018-04-14T04:19:55Z', 'uri': 'http://web.archive.org/web/20180414041955/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2018-05-19T11:10:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519111011/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2018-05-19T11:10:11Z', 'uri': 'http://web.archive.org/web/20180519111011/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}, {'datetime': '2018-06-09T22:23:50Z', 'uri': 'http://web.archive.org/web/20180609222350/https://www.guideline.gov/summaries/summary/46426/early-detection-of-prostate-cancer-aua-guideline'}]
https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235839/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2016-09-30T23:58:39Z', 'uri': 'http://web.archive.org/web/20160930235839/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2017-10-03T04:42:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003044211/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2017-10-03T04:42:11Z', 'uri': 'http://web.archive.org/web/20171003044211/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2018-04-14T04:20:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414042003/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2018-04-14T04:20:03Z', 'uri': 'http://web.archive.org/web/20180414042003/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2018-05-19T11:10:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519111019/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2018-05-19T11:10:19Z', 'uri': 'http://web.archive.org/web/20180519111019/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}, {'datetime': '2018-06-09T19:38:27Z', 'uri': 'http://web.archive.org/web/20180609193827/https://www.guideline.gov/summaries/summary/46430/followup-for-clinically-localized-renal-neoplasms-aua-guideline'}]
https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:57:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235734/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2016-09-30T23:57:34Z', 'uri': 'http://web.archive.org/web/20160930235734/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2017-10-03T04:36:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003043606/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2017-10-03T04:36:06Z', 'uri': 'http://web.archive.org/web/20171003043606/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-04-14T04:10:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414041051/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-04-14T04:10:51Z', 'uri': 'http://web.archive.org/web/20180414041051/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-05-19T11:02:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519110249/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-05-19T11:02:49Z', 'uri': 'http://web.archive.org/web/20180519110249/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-06-09T11:22:13Z', 'uri': 'http://web.archive.org/web/20180609112213/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-07-12T21:45:39Z', 'uri': 'http://web.archive.org/web/20180712214539/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}, {'datetime': '2018-07-12T21:45:39Z', 'uri': 'http://web.archive.org/web/20180712214539/https://www.guideline.gov/summaries/summary/46455/best-evidence-statement-best-postpartum-mother-accompaniment-during-neonatal-transport'}]
https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235736/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2016-09-30T23:57:36Z', 'uri': 'http://web.archive.org/web/20160930235736/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2017-10-03T04:36:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003043619/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2017-10-03T04:36:19Z', 'uri': 'http://web.archive.org/web/20171003043619/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2018-04-14T04:11:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414041108/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2018-04-14T04:11:08Z', 'uri': 'http://web.archive.org/web/20180414041108/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2018-05-19T11:03:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519110304/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2018-05-19T11:03:04Z', 'uri': 'http://web.archive.org/web/20180519110304/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}, {'datetime': '2018-06-09T20:50:24Z', 'uri': 'http://web.archive.org/web/20180609205024/https://www.guideline.gov/summaries/summary/46459/best-evidence-statement-best-support-from-bedside-nurses-for-caregivers-of-children-newly-diagnosed-with-type-1-diabetes-mellitus'}]
https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235735/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2016-09-30T23:57:35Z', 'uri': 'http://web.archive.org/web/20160930235735/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2017-10-03T04:36:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003043612/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2017-10-03T04:36:12Z', 'uri': 'http://web.archive.org/web/20171003043612/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2018-04-14T04:11:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414041100/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2018-04-14T04:11:00Z', 'uri': 'http://web.archive.org/web/20180414041100/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2018-05-19T11:02:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519110257/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2018-05-19T11:02:57Z', 'uri': 'http://web.archive.org/web/20180519110257/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}, {'datetime': '2018-06-10T17:21:58Z', 'uri': 'http://web.archive.org/web/20180610172158/https://www.guideline.gov/summaries/summary/46460/best-evidence-statement-best-skin-to-skin-care-in-a-level-iiiiv-nicu'}]
https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235732/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2016-09-30T23:57:32Z', 'uri': 'http://web.archive.org/web/20160930235732/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2017-10-03T04:35:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003043552/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2017-10-03T04:35:52Z', 'uri': 'http://web.archive.org/web/20171003043552/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2018-04-14T04:10:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414041033/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2018-04-14T04:10:33Z', 'uri': 'http://web.archive.org/web/20180414041033/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2018-05-19T11:02:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519110234/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2018-05-19T11:02:34Z', 'uri': 'http://web.archive.org/web/20180519110234/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}, {'datetime': '2018-06-09T20:12:51Z', 'uri': 'http://web.archive.org/web/20180609201251/https://www.guideline.gov/summaries/summary/46461/best-evidence-statement-best-allergy-testing-and-immunotherapy-administration'}]
https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235733/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2016-09-30T23:57:33Z', 'uri': 'http://web.archive.org/web/20160930235733/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2017-10-03T04:35:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003043558/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2017-10-03T04:35:58Z', 'uri': 'http://web.archive.org/web/20171003043558/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2018-04-14T04:10:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414041042/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2018-04-14T04:10:42Z', 'uri': 'http://web.archive.org/web/20180414041042/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2018-05-19T11:02:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519110242/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2018-05-19T11:02:42Z', 'uri': 'http://web.archive.org/web/20180519110242/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}, {'datetime': '2018-06-09T20:50:49Z', 'uri': 'http://web.archive.org/web/20180609205049/https://www.guideline.gov/summaries/summary/46462/best-evidence-statement-best-culturally-sensitive-asthma-education'}]
https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:57:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235737/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2016-09-30T23:57:37Z', 'uri': 'http://web.archive.org/web/20160930235737/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2017-10-03T04:36:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003043624/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2017-10-03T04:36:24Z', 'uri': 'http://web.archive.org/web/20171003043624/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2018-01-10T12:16:19Z', 'uri': 'http://web.archive.org/web/20180110121619/https://guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2018-04-14T04:11:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414041116/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2018-04-14T04:11:16Z', 'uri': 'http://web.archive.org/web/20180414041116/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2018-05-19T11:03:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519110311/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2018-05-19T11:03:11Z', 'uri': 'http://web.archive.org/web/20180519110311/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}, {'datetime': '2018-06-10T21:54:54Z', 'uri': 'http://web.archive.org/web/20180610215454/https://www.guideline.gov/summaries/summary/46463/best-evidence-statement-best-the-effect-of-communication-skills-training-on-nurses-confidence-and-competence-in-providing-psychosocial-support-to-patients-and-families'}]
https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:57:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930225715/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2016-09-30T22:57:15Z', 'uri': 'http://web.archive.org/web/20160930225715/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2017-10-03T02:12:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003021239/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2017-10-03T02:12:39Z', 'uri': 'http://web.archive.org/web/20171003021239/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2018-04-14T01:01:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414010155/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2018-04-14T01:01:55Z', 'uri': 'http://web.archive.org/web/20180414010155/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2018-05-19T07:42:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519074225/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2018-05-19T07:42:25Z', 'uri': 'http://web.archive.org/web/20180519074225/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}, {'datetime': '2018-06-09T15:17:14Z', 'uri': 'http://web.archive.org/web/20180609151714/https://www.guideline.gov/summaries/summary/46510/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease'}]
https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:58:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235828/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:58:28Z', 'uri': 'http://web.archive.org/web/20160930235828/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:41:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003044103/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:41:03Z', 'uri': 'http://web.archive.org/web/20171003044103/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:17:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414041731/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:17:31Z', 'uri': 'http://web.archive.org/web/20180414041731/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:08:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519110851/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:08:51Z', 'uri': 'http://web.archive.org/web/20180519110851/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T23:17:32Z', 'uri': 'http://web.archive.org/web/20180610231732/https://www.guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-15T14:47:56Z', 'uri': 'http://web.archive.org/web/20180615144756/https://guideline.gov/summaries/summary/46511/primary-care-interventions-to-prevent-child-maltreatment-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235744/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2016-09-30T23:57:44Z', 'uri': 'http://web.archive.org/web/20160930235744/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2017-10-03T04:37:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003043708/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2017-10-03T04:37:08Z', 'uri': 'http://web.archive.org/web/20171003043708/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2018-04-14T04:12:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414041200/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2018-04-14T04:12:00Z', 'uri': 'http://web.archive.org/web/20180414041200/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2018-05-19T11:03:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519110354/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2018-05-19T11:03:54Z', 'uri': 'http://web.archive.org/web/20180519110354/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}, {'datetime': '2018-06-09T19:40:55Z', 'uri': 'http://web.archive.org/web/20180609194055/https://www.guideline.gov/summaries/summary/46659/care-of-the-patient-with-myasthenia-gravis'}]
https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930235831/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:58:31Z', 'uri': 'http://web.archive.org/web/20160930235831/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:41:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003044115/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:41:15Z', 'uri': 'http://web.archive.org/web/20171003044115/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:18:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414041839/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:18:39Z', 'uri': 'http://web.archive.org/web/20180414041839/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:09:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519110907/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:09:07Z', 'uri': 'http://web.archive.org/web/20180519110907/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T08:21:13Z', 'uri': 'http://web.archive.org/web/20180610082113/https://www.guideline.gov/summaries/summary/46769/screening-for-hepatitis-c-virus-infection-in-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235729/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2016-09-30T23:57:29Z', 'uri': 'http://web.archive.org/web/20160930235729/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2017-10-03T04:35:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003043526/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2017-10-03T04:35:26Z', 'uri': 'http://web.archive.org/web/20171003043526/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2018-04-14T04:09:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414040956/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2018-04-14T04:09:56Z', 'uri': 'http://web.archive.org/web/20180414040956/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2018-05-19T11:01:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519110143/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2018-05-19T11:01:43Z', 'uri': 'http://web.archive.org/web/20180519110143/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}, {'datetime': '2018-06-09T21:23:57Z', 'uri': 'http://web.archive.org/web/20180609212357/https://www.guideline.gov/summaries/summary/46770/clinical-practice-guideline-improving-voice-outcomes-after-thyroid-surgery'}]
https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235716/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2016-09-30T23:57:16Z', 'uri': 'http://web.archive.org/web/20160930235716/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2017-10-03T04:34:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003043410/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2017-10-03T04:34:10Z', 'uri': 'http://web.archive.org/web/20171003043410/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2018-04-14T04:08:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414040825/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2018-04-14T04:08:25Z', 'uri': 'http://web.archive.org/web/20180414040825/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2018-05-19T11:00:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519110003/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2018-05-19T11:00:03Z', 'uri': 'http://web.archive.org/web/20180519110003/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}, {'datetime': '2018-06-10T01:36:05Z', 'uri': 'http://web.archive.org/web/20180610013605/https://www.guideline.gov/summaries/summary/46908/breastfeedingfriendly-physicians-office-optimizing-care-for-infants-and-children-revised-2013'}]
https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235730/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2016-09-30T23:57:30Z', 'uri': 'http://web.archive.org/web/20160930235730/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2017-10-03T04:35:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003043534/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2017-10-03T04:35:34Z', 'uri': 'http://web.archive.org/web/20171003043534/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2018-04-14T04:10:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414041006/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2018-04-14T04:10:06Z', 'uri': 'http://web.archive.org/web/20180414041006/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2018-05-19T11:01:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519110152/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2018-05-19T11:01:52Z', 'uri': 'http://web.archive.org/web/20180519110152/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}, {'datetime': '2018-06-09T21:31:40Z', 'uri': 'http://web.archive.org/web/20180609213140/https://www.guideline.gov/summaries/summary/46909/clinical-practice-guideline-tympanostomy-tubes-in-children'}]
https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235836/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2016-09-30T23:58:36Z', 'uri': 'http://web.archive.org/web/20160930235836/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2017-10-03T04:41:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003044155/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2017-10-03T04:41:55Z', 'uri': 'http://web.archive.org/web/20171003044155/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2018-04-14T04:19:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414041940/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2018-04-14T04:19:40Z', 'uri': 'http://web.archive.org/web/20180414041940/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2018-05-19T11:09:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519110956/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2018-05-19T11:09:56Z', 'uri': 'http://web.archive.org/web/20180519110956/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}, {'datetime': '2018-06-09T19:17:24Z', 'uri': 'http://web.archive.org/web/20180609191724/https://www.guideline.gov/summaries/summary/46911/followup-of-colorectal-polyps-or-cancer'}]
https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235752/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2016-09-30T23:57:52Z', 'uri': 'http://web.archive.org/web/20160930235752/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2017-10-03T04:37:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003043721/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2017-10-03T04:37:21Z', 'uri': 'http://web.archive.org/web/20171003043721/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2018-04-14T04:12:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414041216/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2018-04-14T04:12:16Z', 'uri': 'http://web.archive.org/web/20180414041216/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2018-05-19T11:04:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519110409/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2018-05-19T11:04:09Z', 'uri': 'http://web.archive.org/web/20180519110409/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}, {'datetime': '2018-06-09T22:27:44Z', 'uri': 'http://web.archive.org/web/20180609222744/https://www.guideline.gov/summaries/summary/46921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-in-the-emergency-department-with-asymptomatic-elevated-blood-pressure'}]
https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235757/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:57:57Z', 'uri': 'http://web.archive.org/web/20160930235757/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:37:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003043752/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:37:52Z', 'uri': 'http://web.archive.org/web/20171003043752/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:13:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414041300/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:13:00Z', 'uri': 'http://web.archive.org/web/20180414041300/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:04:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519110450/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:04:50Z', 'uri': 'http://web.archive.org/web/20180519110450/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T15:29:05Z', 'uri': 'http://web.archive.org/web/20180609152905/https://www.guideline.gov/summaries/summary/46922/screening-for-glaucoma-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235841/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2016-09-30T23:58:41Z', 'uri': 'http://web.archive.org/web/20160930235841/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2017-10-03T04:42:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003044218/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2017-10-03T04:42:18Z', 'uri': 'http://web.archive.org/web/20171003044218/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2018-04-14T04:20:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414042013/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2018-04-14T04:20:13Z', 'uri': 'http://web.archive.org/web/20180414042013/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2018-05-19T11:10:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519111027/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2018-05-19T11:10:27Z', 'uri': 'http://web.archive.org/web/20180519111027/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}, {'datetime': '2018-06-09T21:14:45Z', 'uri': 'http://web.archive.org/web/20180609211445/https://www.guideline.gov/summaries/summary/46923/clinical-practice-guidelines-for-the-management-of-rotator-cuff-syndrome-in-the-workplace'}]
https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235713/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2016-09-30T23:57:13Z', 'uri': 'http://web.archive.org/web/20160930235713/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2017-10-03T04:33:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003043351/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2017-10-03T04:33:51Z', 'uri': 'http://web.archive.org/web/20171003043351/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2018-04-14T04:07:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414040757/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2018-04-14T04:07:57Z', 'uri': 'http://web.archive.org/web/20180414040757/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2018-05-19T10:59:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519105935/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2018-05-19T10:59:35Z', 'uri': 'http://web.archive.org/web/20180519105935/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}, {'datetime': '2018-06-11T03:39:31Z', 'uri': 'http://web.archive.org/web/20180611033931/https://www.guideline.gov/summaries/summary/46927/mirabegron-for-treating-symptoms-of-overactive-bladder'}]
https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235714/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2016-09-30T23:57:14Z', 'uri': 'http://web.archive.org/web/20160930235714/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2017-10-03T04:33:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003043357/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2017-10-03T04:33:57Z', 'uri': 'http://web.archive.org/web/20171003043357/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2018-04-14T04:08:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414040806/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2018-04-14T04:08:06Z', 'uri': 'http://web.archive.org/web/20180414040806/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2018-05-19T10:59:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519105944/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2018-05-19T10:59:44Z', 'uri': 'http://web.archive.org/web/20180519105944/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}, {'datetime': '2018-06-09T19:25:59Z', 'uri': 'http://web.archive.org/web/20180609192559/https://www.guideline.gov/summaries/summary/46928/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout'}]
https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235715/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2016-09-30T23:57:15Z', 'uri': 'http://web.archive.org/web/20160930235715/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2017-10-03T04:34:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003043403/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2017-10-03T04:34:03Z', 'uri': 'http://web.archive.org/web/20171003043403/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2018-04-14T04:08:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414040815/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2018-04-14T04:08:15Z', 'uri': 'http://web.archive.org/web/20180414040815/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2018-05-19T10:59:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519105953/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2018-05-19T10:59:53Z', 'uri': 'http://web.archive.org/web/20180519105953/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}, {'datetime': '2018-06-10T21:59:02Z', 'uri': 'http://web.archive.org/web/20180610215902/https://www.guideline.gov/summaries/summary/46929/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism'}]
https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:29:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930162914/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2016-09-30T16:29:14Z', 'uri': 'http://web.archive.org/web/20160930162914/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2017-10-02T20:09:45Z', 'uri': 'http://wayback.archive-it.org/all/20171002200945/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2017-10-02T20:09:45Z', 'uri': 'http://web.archive.org/web/20171002200945/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2018-04-13T23:28:28Z', 'uri': 'http://wayback.archive-it.org/all/20180413232828/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2018-04-13T23:28:28Z', 'uri': 'http://web.archive.org/web/20180413232828/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2018-05-18T22:04:01Z', 'uri': 'http://wayback.archive-it.org/all/20180518220401/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2018-05-18T22:04:01Z', 'uri': 'http://web.archive.org/web/20180518220401/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}, {'datetime': '2018-06-09T15:28:57Z', 'uri': 'http://web.archive.org/web/20180609152857/https://www.guideline.gov/summaries/summary/46931/falls-assessment-and-prevention-of-falls-in-older-people'}]
https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235722/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2016-09-30T23:57:22Z', 'uri': 'http://web.archive.org/web/20160930235722/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2017-10-03T04:34:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003043447/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2017-10-03T04:34:47Z', 'uri': 'http://web.archive.org/web/20171003043447/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2018-04-14T04:09:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414040911/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2018-04-14T04:09:11Z', 'uri': 'http://web.archive.org/web/20180414040911/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2018-05-19T11:00:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519110052/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2018-05-19T11:00:52Z', 'uri': 'http://web.archive.org/web/20180519110052/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}, {'datetime': '2018-06-10T22:19:42Z', 'uri': 'http://web.archive.org/web/20180610221942/https://www.guideline.gov/summaries/summary/46932/familial-breast-cancer-classification-and-care-of-people-at-risk-of-familial-breast-cancer-and-management-of-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer'}]
https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:57:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235700/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2016-09-30T23:57:00Z', 'uri': 'http://web.archive.org/web/20160930235700/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2017-10-03T04:32:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003043233/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2017-10-03T04:32:33Z', 'uri': 'http://web.archive.org/web/20171003043233/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-04-14T04:06:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414040623/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-04-14T04:06:23Z', 'uri': 'http://web.archive.org/web/20180414040623/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-05-19T10:58:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519105808/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-05-19T10:58:08Z', 'uri': 'http://web.archive.org/web/20180519105808/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-06-09T11:02:06Z', 'uri': 'http://web.archive.org/web/20180609110206/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-07-12T21:40:31Z', 'uri': 'http://web.archive.org/web/20180712214031/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}, {'datetime': '2018-07-12T21:40:31Z', 'uri': 'http://web.archive.org/web/20180712214031/https://www.guideline.gov/summaries/summary/46933/hepatitis-b-chronic-diagnosis-and-management-of-chronic-hepatitis-b-in-children-young-people-and-adults'}]
https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235701/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2016-09-30T23:57:01Z', 'uri': 'http://web.archive.org/web/20160930235701/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2017-10-03T04:32:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003043236/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2017-10-03T04:32:36Z', 'uri': 'http://web.archive.org/web/20171003043236/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-04-14T04:06:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414040627/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-04-14T04:06:27Z', 'uri': 'http://web.archive.org/web/20180414040627/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-05-19T10:58:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519105811/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-05-19T10:58:11Z', 'uri': 'http://web.archive.org/web/20180519105811/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}, {'datetime': '2018-06-09T20:12:06Z', 'uri': 'http://web.archive.org/web/20180609201206/https://www.guideline.gov/summaries/summary/46934/idiopathic-pulmonary-fibrosis-the-diagnosis-and-management-of-suspected-idiopathic-pulmonary-fibrosis'}]
https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235647/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2016-09-30T23:56:47Z', 'uri': 'http://web.archive.org/web/20160930235647/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2017-10-03T04:30:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003043054/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2017-10-03T04:30:54Z', 'uri': 'http://web.archive.org/web/20171003043054/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2018-04-14T04:04:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414040432/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2018-04-14T04:04:32Z', 'uri': 'http://web.archive.org/web/20180414040432/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2018-05-19T10:56:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519105615/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2018-05-19T10:56:15Z', 'uri': 'http://web.archive.org/web/20180519105615/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}, {'datetime': '2018-06-09T12:12:51Z', 'uri': 'http://web.archive.org/web/20180609121251/https://www.guideline.gov/summaries/summary/46935/stroke-rehabilitation-longterm-rehabilitation-after-stroke'}]
https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:56:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235648/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2016-09-30T23:56:48Z', 'uri': 'http://web.archive.org/web/20160930235648/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2017-10-03T04:31:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003043104/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2017-10-03T04:31:04Z', 'uri': 'http://web.archive.org/web/20171003043104/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2018-01-10T13:03:26Z', 'uri': 'http://web.archive.org/web/20180110130326/https://guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2018-04-14T04:04:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414040445/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2018-04-14T04:04:45Z', 'uri': 'http://web.archive.org/web/20180414040445/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2018-05-19T10:56:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519105627/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2018-05-19T10:56:27Z', 'uri': 'http://web.archive.org/web/20180519105627/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}, {'datetime': '2018-06-09T19:16:34Z', 'uri': 'http://web.archive.org/web/20180609191634/https://www.guideline.gov/summaries/summary/46936/ulcerative-colitis-management-in-adults-children-and-young-people'}]
https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235721/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2016-09-30T23:57:21Z', 'uri': 'http://web.archive.org/web/20160930235721/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2017-10-03T04:34:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003043441/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2017-10-03T04:34:41Z', 'uri': 'http://web.archive.org/web/20171003043441/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2018-04-14T04:09:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414040904/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2018-04-14T04:09:04Z', 'uri': 'http://web.archive.org/web/20180414040904/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2018-05-19T11:00:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519110045/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2018-05-19T11:00:45Z', 'uri': 'http://web.archive.org/web/20180519110045/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}, {'datetime': '2018-06-09T18:42:28Z', 'uri': 'http://web.archive.org/web/20180609184228/https://www.guideline.gov/summaries/summary/46937/risk-of-acute-hyponatremia-in-hospitalized-children-and-youth-receiving-maintenance-intravenous-fluids'}]
https://www.guideline.gov/summaries/summary/46938/common-breast-problems	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930235725/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2016-09-30T23:57:25Z', 'uri': 'http://web.archive.org/web/20160930235725/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2017-10-03T04:35:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003043509/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2017-10-03T04:35:09Z', 'uri': 'http://web.archive.org/web/20171003043509/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2018-04-14T04:09:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414040931/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2018-04-14T04:09:31Z', 'uri': 'http://web.archive.org/web/20180414040931/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2018-05-19T11:01:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519110114/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2018-05-19T11:01:14Z', 'uri': 'http://web.archive.org/web/20180519110114/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}, {'datetime': '2018-06-09T21:34:25Z', 'uri': 'http://web.archive.org/web/20180609213425/https://www.guideline.gov/summaries/summary/46938/common-breast-problems'}]
https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235833/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2016-09-30T23:58:33Z', 'uri': 'http://web.archive.org/web/20160930235833/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2017-10-03T04:41:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003044130/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2017-10-03T04:41:30Z', 'uri': 'http://web.archive.org/web/20171003044130/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2018-04-14T04:18:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414041858/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2018-04-14T04:18:58Z', 'uri': 'http://web.archive.org/web/20180414041858/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2018-05-19T11:09:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519110925/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2018-05-19T11:09:25Z', 'uri': 'http://web.archive.org/web/20180519110925/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}, {'datetime': '2018-06-09T11:01:11Z', 'uri': 'http://web.archive.org/web/20180609110111/https://www.guideline.gov/summaries/summary/46939/clinical-practice-guideline-for-the-diagnosis-and-management-of-acute-bacterial-sinusitis-in-children-aged-1-to-18-years'}]
https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235740/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2016-09-30T23:57:40Z', 'uri': 'http://web.archive.org/web/20160930235740/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2017-10-03T04:36:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003043643/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2017-10-03T04:36:43Z', 'uri': 'http://web.archive.org/web/20171003043643/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2018-04-14T04:11:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414041134/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2018-04-14T04:11:34Z', 'uri': 'http://web.archive.org/web/20180414041134/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2018-05-19T11:03:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519110328/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2018-05-19T11:03:28Z', 'uri': 'http://web.archive.org/web/20180519110328/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}, {'datetime': '2018-06-09T22:21:51Z', 'uri': 'http://web.archive.org/web/20180609222151/https://www.guideline.gov/summaries/summary/46940/health-professionals-working-with-first-nations-inuit-and-m-tis-consensus-guideline'}]
https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930235724/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2016-09-30T23:57:24Z', 'uri': 'http://web.archive.org/web/20160930235724/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2017-10-03T04:35:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003043503/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2017-10-03T04:35:03Z', 'uri': 'http://web.archive.org/web/20171003043503/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2018-04-14T04:09:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414040924/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2018-04-14T04:09:24Z', 'uri': 'http://web.archive.org/web/20180414040924/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2018-05-19T11:01:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519110106/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2018-05-19T11:01:06Z', 'uri': 'http://web.archive.org/web/20180519110106/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}, {'datetime': '2018-06-09T23:21:05Z', 'uri': 'http://web.archive.org/web/20180609232105/https://www.guideline.gov/summaries/summary/46941/the-society-of-thoracic-surgeons-guidelines-on-the-diagnosis-and-staging-of-patients-with-esophageal-cancer'}]
https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235717/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2016-09-30T23:57:17Z', 'uri': 'http://web.archive.org/web/20160930235717/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2017-10-03T04:34:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003043416/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2017-10-03T04:34:16Z', 'uri': 'http://web.archive.org/web/20171003043416/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2018-04-14T04:08:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414040834/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2018-04-14T04:08:34Z', 'uri': 'http://web.archive.org/web/20180414040834/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2018-05-19T11:00:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519110012/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2018-05-19T11:00:12Z', 'uri': 'http://web.archive.org/web/20180519110012/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}, {'datetime': '2018-06-09T18:37:54Z', 'uri': 'http://web.archive.org/web/20180609183754/https://www.guideline.gov/summaries/summary/46942/adverse-events-associated-with-eus-and-eus-with-fna'}]
https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235718/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2016-09-30T23:57:18Z', 'uri': 'http://web.archive.org/web/20160930235718/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2017-10-03T04:34:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003043423/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2017-10-03T04:34:23Z', 'uri': 'http://web.archive.org/web/20171003043423/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2018-04-14T04:08:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414040841/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2018-04-14T04:08:41Z', 'uri': 'http://web.archive.org/web/20180414040841/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2018-05-19T11:00:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519110019/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2018-05-19T11:00:19Z', 'uri': 'http://web.archive.org/web/20180519110019/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}, {'datetime': '2018-06-09T15:30:23Z', 'uri': 'http://web.archive.org/web/20180609153023/https://www.guideline.gov/summaries/summary/46943/modifications-in-endoscopic-practice-for-the-elderly'}]
https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235719/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2016-09-30T23:57:19Z', 'uri': 'http://web.archive.org/web/20160930235719/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2017-10-03T04:34:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003043429/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2017-10-03T04:34:29Z', 'uri': 'http://web.archive.org/web/20171003043429/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2018-04-14T04:08:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414040848/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2018-04-14T04:08:48Z', 'uri': 'http://web.archive.org/web/20180414040848/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2018-05-19T11:00:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519110028/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2018-05-19T11:00:28Z', 'uri': 'http://web.archive.org/web/20180519110028/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}, {'datetime': '2018-06-09T18:38:03Z', 'uri': 'http://web.archive.org/web/20180609183803/https://www.guideline.gov/summaries/summary/46944/role-of-endoscopy-in-the-staging-and-management-of-colorectal-cancer'}]
https://www.guideline.gov/summaries/summary/46947/pharyngitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930235727/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2016-09-30T23:57:27Z', 'uri': 'http://web.archive.org/web/20160930235727/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2017-10-03T04:35:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003043521/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2017-10-03T04:35:21Z', 'uri': 'http://web.archive.org/web/20171003043521/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2018-04-14T04:09:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414040948/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2018-04-14T04:09:48Z', 'uri': 'http://web.archive.org/web/20180414040948/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2018-05-19T11:01:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519110134/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2018-05-19T11:01:34Z', 'uri': 'http://web.archive.org/web/20180519110134/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}, {'datetime': '2018-06-09T22:12:01Z', 'uri': 'http://web.archive.org/web/20180609221201/https://www.guideline.gov/summaries/summary/46947/pharyngitis'}]
https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235720/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2016-09-30T23:57:20Z', 'uri': 'http://web.archive.org/web/20160930235720/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2017-10-03T04:34:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003043435/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2017-10-03T04:34:35Z', 'uri': 'http://web.archive.org/web/20171003043435/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2018-04-14T04:08:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414040856/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2018-04-14T04:08:56Z', 'uri': 'http://web.archive.org/web/20180414040856/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2018-05-19T11:00:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519110036/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2018-05-19T11:00:36Z', 'uri': 'http://web.archive.org/web/20180519110036/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}, {'datetime': '2018-06-09T11:43:29Z', 'uri': 'http://web.archive.org/web/20180609114329/https://www.guideline.gov/summaries/summary/47013/canadian-cardiovascular-societycanadian-heart-rhythm-society-joint-position-statement-on-the-use-of-remote-monitoring-for-cardiovascular-implantable-electronic-device-followup'}]
https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235741/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2016-09-30T23:57:41Z', 'uri': 'http://web.archive.org/web/20160930235741/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2017-10-03T04:36:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003043649/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2017-10-03T04:36:49Z', 'uri': 'http://web.archive.org/web/20171003043649/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2018-04-14T04:11:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414041143/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2018-04-14T04:11:43Z', 'uri': 'http://web.archive.org/web/20180414041143/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2018-05-19T11:03:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519110338/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2018-05-19T11:03:38Z', 'uri': 'http://web.archive.org/web/20180519110338/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}, {'datetime': '2018-06-09T22:22:00Z', 'uri': 'http://web.archive.org/web/20180609222200/https://www.guideline.gov/summaries/summary/47015/technical-update-on-pessary-use'}]
https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235702/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2016-09-30T23:57:02Z', 'uri': 'http://web.archive.org/web/20160930235702/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2017-10-03T04:32:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003043245/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2017-10-03T04:32:45Z', 'uri': 'http://web.archive.org/web/20171003043245/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2018-04-14T04:06:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414040639/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2018-04-14T04:06:39Z', 'uri': 'http://web.archive.org/web/20180414040639/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2018-05-19T10:58:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519105823/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2018-05-19T10:58:23Z', 'uri': 'http://web.archive.org/web/20180519105823/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}, {'datetime': '2018-06-09T20:45:54Z', 'uri': 'http://web.archive.org/web/20180609204554/https://www.guideline.gov/summaries/summary/47016/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration'}]
https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235703/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2016-09-30T23:57:03Z', 'uri': 'http://web.archive.org/web/20160930235703/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2017-10-03T04:32:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003043251/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2017-10-03T04:32:51Z', 'uri': 'http://web.archive.org/web/20171003043251/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2018-04-14T04:06:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414040648/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2018-04-14T04:06:48Z', 'uri': 'http://web.archive.org/web/20180414040648/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2018-05-19T10:58:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519105832/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2018-05-19T10:58:32Z', 'uri': 'http://web.archive.org/web/20180519105832/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}, {'datetime': '2018-06-09T12:12:11Z', 'uri': 'http://web.archive.org/web/20180609121211/https://www.guideline.gov/summaries/summary/47017/aripiprazole-for-treating-moderate-to-severe-manic-episodes-in-adolescents-with-bipolar-i-disorder'}]
https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235704/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2016-09-30T23:57:04Z', 'uri': 'http://web.archive.org/web/20160930235704/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2017-10-03T04:32:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003043258/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2017-10-03T04:32:58Z', 'uri': 'http://web.archive.org/web/20171003043258/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2018-04-14T04:06:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414040658/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2018-04-14T04:06:58Z', 'uri': 'http://web.archive.org/web/20180414040658/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2018-05-19T10:58:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519105841/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2018-05-19T10:58:41Z', 'uri': 'http://web.archive.org/web/20180519105841/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}, {'datetime': '2018-06-11T08:02:11Z', 'uri': 'http://web.archive.org/web/20180611080211/https://www.guideline.gov/summaries/summary/47018/eltrombopag-for-treating-chronic-immune-idiopathic-thrombocytopenic-purpura-review-of-technology-appraisal-205'}]
https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235646/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2016-09-30T23:56:46Z', 'uri': 'http://web.archive.org/web/20160930235646/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2017-10-03T04:30:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003043047/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2017-10-03T04:30:47Z', 'uri': 'http://web.archive.org/web/20171003043047/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2018-04-14T04:04:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414040421/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2018-04-14T04:04:21Z', 'uri': 'http://web.archive.org/web/20180414040421/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2018-05-19T10:56:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519105604/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2018-05-19T10:56:04Z', 'uri': 'http://web.archive.org/web/20180519105604/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}, {'datetime': '2018-06-09T23:36:09Z', 'uri': 'http://web.archive.org/web/20180609233609/https://www.guideline.gov/summaries/summary/47019/myocardial-infarction-with-stsegment-elevation-the-acute-management-of-myocardial-infarction-with-stsegment-elevation'}]
https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930235649/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2016-09-30T23:56:49Z', 'uri': 'http://web.archive.org/web/20160930235649/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2017-10-03T04:31:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003043113/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2017-10-03T04:31:13Z', 'uri': 'http://web.archive.org/web/20171003043113/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2018-04-14T04:04:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414040458/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2018-04-14T04:04:58Z', 'uri': 'http://web.archive.org/web/20180414040458/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2018-05-19T10:56:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519105639/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2018-05-19T10:56:39Z', 'uri': 'http://web.archive.org/web/20180519105639/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}, {'datetime': '2018-06-10T11:23:23Z', 'uri': 'http://web.archive.org/web/20180610112323/https://www.guideline.gov/summaries/summary/47020/varicose-veins-in-the-legs-the-diagnosis-and-management-of-varicose-veins'}]
https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235638/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:56:38Z', 'uri': 'http://web.archive.org/web/20160930235638/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:30:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003043005/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:30:05Z', 'uri': 'http://web.archive.org/web/20171003043005/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:03:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414040315/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:03:15Z', 'uri': 'http://web.archive.org/web/20180414040315/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:55:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519105505/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:55:05Z', 'uri': 'http://web.archive.org/web/20180519105505/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T21:28:22Z', 'uri': 'http://web.archive.org/web/20180610212822/https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235705/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2016-09-30T23:57:05Z', 'uri': 'http://web.archive.org/web/20160930235705/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2017-10-03T04:33:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003043305/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2017-10-03T04:33:05Z', 'uri': 'http://web.archive.org/web/20171003043305/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2018-04-14T04:07:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414040707/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2018-04-14T04:07:07Z', 'uri': 'http://web.archive.org/web/20180414040707/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2018-05-19T10:58:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519105850/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2018-05-19T10:58:50Z', 'uri': 'http://web.archive.org/web/20180519105850/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}, {'datetime': '2018-06-09T12:01:15Z', 'uri': 'http://web.archive.org/web/20180609120115/https://www.guideline.gov/summaries/summary/47022/alzheimers-association-recommendations-for-operationalizing-the-detection-of-cognitive-impairment-during-the-medicare-annual-wellness-visit-in-a-primary-care-setting'}]
https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:58:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235835/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2016-09-30T23:58:35Z', 'uri': 'http://web.archive.org/web/20160930235835/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2017-10-03T04:41:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003044144/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2017-10-03T04:41:44Z', 'uri': 'http://web.archive.org/web/20171003044144/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2018-04-14T04:19:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414041923/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2018-04-14T04:19:23Z', 'uri': 'http://web.archive.org/web/20180414041923/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2018-05-19T11:09:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519110944/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2018-05-19T11:09:44Z', 'uri': 'http://web.archive.org/web/20180519110944/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}, {'datetime': '2018-06-09T11:57:51Z', 'uri': 'http://web.archive.org/web/20180609115751/https://www.guideline.gov/summaries/summary/47023/vadod-clinical-practice-guideline-for-assessment-and-management-of-patients-at-risk-for-suicide'}]
https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930235726/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2016-09-30T23:57:26Z', 'uri': 'http://web.archive.org/web/20160930235726/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2017-10-03T04:35:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003043515/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2017-10-03T04:35:15Z', 'uri': 'http://web.archive.org/web/20171003043515/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2018-04-14T04:09:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414040940/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2018-04-14T04:09:40Z', 'uri': 'http://web.archive.org/web/20180414040940/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2018-05-19T11:01:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519110125/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2018-05-19T11:01:25Z', 'uri': 'http://web.archive.org/web/20180519110125/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}, {'datetime': '2018-06-09T21:34:57Z', 'uri': 'http://web.archive.org/web/20180609213457/https://www.guideline.gov/summaries/summary/47027/obesity-prevention-and-management'}]
https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235755/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:57:55Z', 'uri': 'http://web.archive.org/web/20160930235755/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T04:37:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003043734/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T04:37:34Z', 'uri': 'http://web.archive.org/web/20171003043734/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T04:12:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414041235/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T04:12:35Z', 'uri': 'http://web.archive.org/web/20180414041235/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T11:04:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519110427/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T11:04:27Z', 'uri': 'http://web.archive.org/web/20180519110427/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-09T21:19:23Z', 'uri': 'http://web.archive.org/web/20180609211923/https://www.guideline.gov/summaries/summary/47028/use-of-pharmacologic-interventions-for-breast-cancer-risk-reduction-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235652/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:56:52Z', 'uri': 'http://web.archive.org/web/20160930235652/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:31:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003043134/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:31:34Z', 'uri': 'http://web.archive.org/web/20171003043134/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:05:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414040527/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2018-04-14T04:05:27Z', 'uri': 'http://web.archive.org/web/20180414040527/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:57:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519105714/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:57:14Z', 'uri': 'http://web.archive.org/web/20180519105714/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}, {'datetime': '2018-06-09T21:16:38Z', 'uri': 'http://web.archive.org/web/20180609211638/https://www.guideline.gov/summaries/summary/47029/management-of-hepatitis-c-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults	ARCHIVED	14 mementos	[{'datetime': '2016-09-30T16:20:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930162018/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2016-09-30T16:20:18Z', 'uri': 'http://web.archive.org/web/20160930162018/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2017-07-13T03:20:39Z', 'uri': 'http://web.archive.org/web/20170713032039/https://www.guideline.gov/summaries/summary/47030/Heart-failure-in-adults'}, {'datetime': '2017-10-02T20:03:34Z', 'uri': 'http://wayback.archive-it.org/all/20171002200334/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2017-10-02T20:03:34Z', 'uri': 'http://web.archive.org/web/20171002200334/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2018-04-13T18:53:41Z', 'uri': 'http://wayback.archive-it.org/all/20180413185341/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2018-04-13T18:53:41Z', 'uri': 'http://web.archive.org/web/20180413185341/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2018-05-18T21:48:28Z', 'uri': 'http://wayback.archive-it.org/all/20180518214828/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2018-05-18T21:48:28Z', 'uri': 'http://web.archive.org/web/20180518214828/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2018-06-09T10:36:27Z', 'uri': 'http://web.archive.org/web/20180609103627/https://www.guideline.gov/summaries/summary/47030/Heart-failure-in-adults'}, {'datetime': '2018-06-09T11:34:49Z', 'uri': 'http://web.archive.org/web/20180609113449/https://www.guideline.gov/summaries/summary/47030/heart-failure-in-adults'}, {'datetime': '2018-06-11T18:10:28Z', 'uri': 'http://web.archive.org/web/20180611181028/https://www.guideline.gov/summaries/summary/47030/Heart-failure-in-adults'}, {'datetime': '2018-06-20T17:39:57Z', 'uri': 'http://web.archive.org/web/20180620173957/https://www.guideline.gov/summaries/summary/47030/Heart-failure-in-adults'}, {'datetime': '2018-06-20T22:50:36Z', 'uri': 'http://web.archive.org/web/20180620225036/https://www.guideline.gov/summaries/summary/47030/Heart-failure-in-adults'}]
https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235639/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2016-09-30T23:56:39Z', 'uri': 'http://web.archive.org/web/20160930235639/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2017-10-03T04:30:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003043012/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2017-10-03T04:30:12Z', 'uri': 'http://web.archive.org/web/20171003043012/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2018-04-14T04:03:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414040323/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2018-04-14T04:03:23Z', 'uri': 'http://web.archive.org/web/20180414040323/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2018-05-19T10:55:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519105514/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2018-05-19T10:55:14Z', 'uri': 'http://web.archive.org/web/20180519105514/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}, {'datetime': '2018-06-09T20:14:03Z', 'uri': 'http://web.archive.org/web/20180609201403/https://www.guideline.gov/summaries/summary/47031/2013-uk-national-guideline-for-consultations-requiring-sexual-history-taking'}]
https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults	ARCHIVED	14 mementos	[{'datetime': '2016-09-30T23:56:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235656/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2016-09-30T23:56:56Z', 'uri': 'http://web.archive.org/web/20160930235656/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2017-07-13T03:01:43Z', 'uri': 'http://web.archive.org/web/20170713030143/https://www.guideline.gov/summaries/summary/47036/British-Thoracic-Society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2017-10-03T04:32:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003043200/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2017-10-03T04:32:00Z', 'uri': 'http://web.archive.org/web/20171003043200/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-04-14T04:06:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414040603/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-04-14T04:06:03Z', 'uri': 'http://web.archive.org/web/20180414040603/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-05-19T10:57:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519105749/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-05-19T10:57:49Z', 'uri': 'http://web.archive.org/web/20180519105749/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-06-09T10:35:37Z', 'uri': 'http://web.archive.org/web/20180609103537/https://www.guideline.gov/summaries/summary/47036/British-Thoracic-Society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-06-09T11:21:56Z', 'uri': 'http://web.archive.org/web/20180609112156/https://www.guideline.gov/summaries/summary/47036/british-thoracic-society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-06-20T17:39:32Z', 'uri': 'http://web.archive.org/web/20180620173932/https://www.guideline.gov/summaries/summary/47036/British-Thoracic-Society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-06-20T18:07:05Z', 'uri': 'http://web.archive.org/web/20180620180705/https://www.guideline.gov/summaries/summary/47036/British-Thoracic-Society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}, {'datetime': '2018-06-23T02:30:53Z', 'uri': 'http://web.archive.org/web/20180623023053/https://www.guideline.gov/summaries/summary/47036/British-Thoracic-Society-guideline-for-diagnostic-flexible-bronchoscopy-in-adults'}]
https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:56:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235657/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2016-09-30T23:56:57Z', 'uri': 'http://web.archive.org/web/20160930235657/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2017-02-03T11:11:23Z', 'uri': 'http://web.archive.org/web/20170203111123/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2017-10-03T04:32:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003043208/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2017-10-03T04:32:08Z', 'uri': 'http://web.archive.org/web/20171003043208/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2018-04-14T04:06:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414040612/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2018-04-14T04:06:12Z', 'uri': 'http://web.archive.org/web/20180414040612/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2018-05-19T10:57:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519105758/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2018-05-19T10:57:58Z', 'uri': 'http://web.archive.org/web/20180519105758/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}, {'datetime': '2018-06-09T22:51:36Z', 'uri': 'http://web.archive.org/web/20180609225136/https://www.guideline.gov/summaries/summary/47037/british-thoracic-society-guideline-on-pulmonary-rehabilitation-in-adults'}]
https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:59:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235939/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2016-09-30T23:59:39Z', 'uri': 'http://web.archive.org/web/20160930235939/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2017-10-03T04:49:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003044912/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2017-10-03T04:49:12Z', 'uri': 'http://web.archive.org/web/20171003044912/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2018-04-14T04:27:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414042740/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2018-04-14T04:27:40Z', 'uri': 'http://web.archive.org/web/20180414042740/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2018-05-19T11:18:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519111805/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2018-05-19T11:18:05Z', 'uri': 'http://web.archive.org/web/20180519111805/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}, {'datetime': '2018-06-09T22:39:46Z', 'uri': 'http://web.archive.org/web/20180609223946/https://www.guideline.gov/summaries/summary/47038/phs-guideline-for-reducing-human-immunodeficiency-virus-hepatitis-b-virus-and-hepatitis-c-virus-transmission-through-organ-transplantation'}]
https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235653/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2016-09-30T23:56:53Z', 'uri': 'http://web.archive.org/web/20160930235653/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2017-10-03T04:31:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003043142/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2017-10-03T04:31:42Z', 'uri': 'http://web.archive.org/web/20171003043142/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2018-04-14T04:05:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414040538/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2018-04-14T04:05:38Z', 'uri': 'http://web.archive.org/web/20180414040538/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2018-05-19T10:57:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519105725/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2018-05-19T10:57:25Z', 'uri': 'http://web.archive.org/web/20180519105725/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}, {'datetime': '2018-06-09T11:04:32Z', 'uri': 'http://web.archive.org/web/20180609110432/https://www.guideline.gov/summaries/summary/47039/acg-clinical-guideline-diagnosis-and-management-of-achalasia'}]
https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235706/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2016-09-30T23:57:06Z', 'uri': 'http://web.archive.org/web/20160930235706/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2017-10-03T04:33:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003043311/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2017-10-03T04:33:11Z', 'uri': 'http://web.archive.org/web/20171003043311/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2018-04-14T04:07:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414040716/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2018-04-14T04:07:16Z', 'uri': 'http://web.archive.org/web/20180414040716/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2018-05-19T10:58:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519105857/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2018-05-19T10:58:57Z', 'uri': 'http://web.archive.org/web/20180519105857/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}, {'datetime': '2018-06-09T18:38:08Z', 'uri': 'http://web.archive.org/web/20180609183808/https://www.guideline.gov/summaries/summary/47051/endoscopic-mucosal-tissue-sampling'}]
https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235754/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2016-09-30T23:57:54Z', 'uri': 'http://web.archive.org/web/20160930235754/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2017-10-03T04:37:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003043728/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2017-10-03T04:37:28Z', 'uri': 'http://web.archive.org/web/20171003043728/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2018-04-14T04:12:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414041225/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2018-04-14T04:12:25Z', 'uri': 'http://web.archive.org/web/20180414041225/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2018-05-19T11:04:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519110417/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2018-05-19T11:04:17Z', 'uri': 'http://web.archive.org/web/20180519110417/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}, {'datetime': '2018-06-09T23:13:44Z', 'uri': 'http://web.archive.org/web/20180609231344/https://www.guideline.gov/summaries/summary/47061/inherited-thrombophilias-in-pregnancy'}]
https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235640/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2016-09-30T23:56:40Z', 'uri': 'http://web.archive.org/web/20160930235640/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2017-10-03T04:30:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003043019/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2017-10-03T04:30:19Z', 'uri': 'http://web.archive.org/web/20171003043019/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2018-04-14T04:03:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414040332/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2018-04-14T04:03:32Z', 'uri': 'http://web.archive.org/web/20180414040332/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2018-05-19T10:55:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519105523/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2018-05-19T10:55:23Z', 'uri': 'http://web.archive.org/web/20180519105523/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}, {'datetime': '2018-06-09T10:34:58Z', 'uri': 'http://web.archive.org/web/20180609103458/https://www.guideline.gov/summaries/summary/47062/best-evidence-statement-best-behavioral-and-oral-motor-interventions-for-feeding-problems-in-children'}]
https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235643/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2016-09-30T23:56:43Z', 'uri': 'http://web.archive.org/web/20160930235643/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2017-10-03T04:30:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003043035/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2017-10-03T04:30:35Z', 'uri': 'http://web.archive.org/web/20171003043035/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2018-04-14T04:04:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414040404/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2018-04-14T04:04:04Z', 'uri': 'http://web.archive.org/web/20180414040404/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2018-05-19T10:55:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519105549/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2018-05-19T10:55:49Z', 'uri': 'http://web.archive.org/web/20180519105549/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}, {'datetime': '2018-06-09T20:50:34Z', 'uri': 'http://web.archive.org/web/20180609205034/https://www.guideline.gov/summaries/summary/47063/best-evidence-statement-best-promoting-family-satisfaction-during-care-level-transition'}]
https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930235645/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2016-09-30T23:56:45Z', 'uri': 'http://web.archive.org/web/20160930235645/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2017-10-03T04:30:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003043041/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2017-10-03T04:30:41Z', 'uri': 'http://web.archive.org/web/20171003043041/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2018-04-14T04:04:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414040412/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2018-04-14T04:04:12Z', 'uri': 'http://web.archive.org/web/20180414040412/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2018-05-19T10:55:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519105556/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2018-05-19T10:55:56Z', 'uri': 'http://web.archive.org/web/20180519105556/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}, {'datetime': '2018-06-09T20:50:46Z', 'uri': 'http://web.archive.org/web/20180609205046/https://www.guideline.gov/summaries/summary/47064/best-evidence-statement-best-using-oral-cryotherapy-to-prevent-oral-mucositis-in-patients-receiving-chemotherapy'}]
https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235642/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2016-09-30T23:56:42Z', 'uri': 'http://web.archive.org/web/20160930235642/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2017-10-03T04:30:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003043030/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2017-10-03T04:30:30Z', 'uri': 'http://web.archive.org/web/20171003043030/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2018-04-14T04:03:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414040355/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2018-04-14T04:03:55Z', 'uri': 'http://web.archive.org/web/20180414040355/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2018-05-19T10:55:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519105541/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2018-05-19T10:55:41Z', 'uri': 'http://web.archive.org/web/20180519105541/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}, {'datetime': '2018-06-09T20:50:35Z', 'uri': 'http://web.archive.org/web/20180609205035/https://www.guideline.gov/summaries/summary/47065/best-evidence-statement-best-decreasing-compassion-fatigue-among-pediatric-intensive-care-nurses-using-selfcare-skills-and-compassion-fatigue-training'}]
https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235641/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2016-09-30T23:56:41Z', 'uri': 'http://web.archive.org/web/20160930235641/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2017-10-03T04:30:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003043025/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2017-10-03T04:30:25Z', 'uri': 'http://web.archive.org/web/20171003043025/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2018-04-14T04:03:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414040341/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2018-04-14T04:03:41Z', 'uri': 'http://web.archive.org/web/20180414040341/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2018-05-19T10:55:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519105533/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2018-05-19T10:55:33Z', 'uri': 'http://web.archive.org/web/20180519105533/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}, {'datetime': '2018-06-09T20:50:29Z', 'uri': 'http://web.archive.org/web/20180609205029/https://www.guideline.gov/summaries/summary/47066/best-evidence-statement-best-daily-bathing-of-children-in-critical-care-settings-with-chlorhexidine-gluconate'}]
https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:57:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235756/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:57:56Z', 'uri': 'http://web.archive.org/web/20160930235756/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:37:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003043745/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:37:45Z', 'uri': 'http://web.archive.org/web/20171003043745/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:12:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414041250/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:12:50Z', 'uri': 'http://web.archive.org/web/20180414041250/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:04:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519110441/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:04:41Z', 'uri': 'http://web.archive.org/web/20180519110441/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T00:05:16Z', 'uri': 'http://web.archive.org/web/20180610000516/https://www.guideline.gov/summaries/summary/47067/primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-11T15:28:17Z', 'uri': 'http://web.archive.org/web/20180611152817/https://www.guideline.gov/summaries/summary/47067/Primary-care-interventions-to-prevent-tobacco-use-in-children-and-adolescents-US-Preventive-Services-Task-Force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235707/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2016-09-30T23:57:07Z', 'uri': 'http://web.archive.org/web/20160930235707/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2017-10-03T04:33:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003043318/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2017-10-03T04:33:18Z', 'uri': 'http://web.archive.org/web/20171003043318/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-04-14T04:07:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414040725/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-04-14T04:07:25Z', 'uri': 'http://web.archive.org/web/20180414040725/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-05-19T10:59:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519105906/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-05-19T10:59:06Z', 'uri': 'http://web.archive.org/web/20180519105906/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-06-09T22:21:34Z', 'uri': 'http://web.archive.org/web/20180609222134/https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation'}]
https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235710/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2016-09-30T23:57:10Z', 'uri': 'http://web.archive.org/web/20160930235710/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2017-10-03T04:33:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003043338/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2017-10-03T04:33:38Z', 'uri': 'http://web.archive.org/web/20171003043338/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2018-04-14T04:07:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414040736/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2018-04-14T04:07:36Z', 'uri': 'http://web.archive.org/web/20180414040736/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2018-05-19T10:59:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519105918/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2018-05-19T10:59:18Z', 'uri': 'http://web.archive.org/web/20180519105918/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}, {'datetime': '2018-06-09T21:36:10Z', 'uri': 'http://web.archive.org/web/20180609213610/https://www.guideline.gov/summaries/summary/47071/guidelines-for-the-management-of-mature-tcell-and-nkcell-neoplasms-excluding-cutaneous-tcell-lymphoma'}]
https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235711/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2016-09-30T23:57:11Z', 'uri': 'http://web.archive.org/web/20160930235711/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2017-10-03T04:33:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003043345/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2017-10-03T04:33:45Z', 'uri': 'http://web.archive.org/web/20171003043345/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2018-04-14T04:07:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414040747/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2018-04-14T04:07:47Z', 'uri': 'http://web.archive.org/web/20180414040747/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2018-05-19T10:59:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519105927/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2018-05-19T10:59:27Z', 'uri': 'http://web.archive.org/web/20180519105927/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}, {'datetime': '2018-06-10T01:49:01Z', 'uri': 'http://web.archive.org/web/20180610014901/https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation'}]
https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235650/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2016-09-30T23:56:50Z', 'uri': 'http://web.archive.org/web/20160930235650/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2017-10-03T04:31:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003043122/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2017-10-03T04:31:22Z', 'uri': 'http://web.archive.org/web/20171003043122/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2018-04-14T04:05:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414040508/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2018-04-14T04:05:08Z', 'uri': 'http://web.archive.org/web/20180414040508/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2018-05-19T10:56:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519105648/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2018-05-19T10:56:48Z', 'uri': 'http://web.archive.org/web/20180519105648/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}, {'datetime': '2018-06-09T21:16:18Z', 'uri': 'http://web.archive.org/web/20180609211618/https://www.guideline.gov/summaries/summary/47074/bortezomib-in-multiple-myeloma-and-lymphoma'}]
https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930235651/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2016-09-30T23:56:51Z', 'uri': 'http://web.archive.org/web/20160930235651/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2017-10-03T04:31:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003043128/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2017-10-03T04:31:28Z', 'uri': 'http://web.archive.org/web/20171003043128/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2018-04-14T04:05:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414040517/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2018-04-14T04:05:17Z', 'uri': 'http://web.archive.org/web/20180414040517/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2018-05-19T10:57:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519105705/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2018-05-19T10:57:05Z', 'uri': 'http://web.archive.org/web/20180519105705/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}, {'datetime': '2018-06-10T22:18:20Z', 'uri': 'http://web.archive.org/web/20180610221820/https://www.guideline.gov/summaries/summary/47075/routine-hpv-testing-in-head-and-neck-squamous-cell-carcinoma'}]
https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235630/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2016-09-30T23:56:30Z', 'uri': 'http://web.archive.org/web/20160930235630/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2017-10-03T04:29:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003042924/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2017-10-03T04:29:24Z', 'uri': 'http://web.archive.org/web/20171003042924/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2018-04-14T04:02:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414040226/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2018-04-14T04:02:26Z', 'uri': 'http://web.archive.org/web/20180414040226/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2018-05-19T10:54:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519105413/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2018-05-19T10:54:13Z', 'uri': 'http://web.archive.org/web/20180519105413/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}, {'datetime': '2018-06-09T19:10:39Z', 'uri': 'http://web.archive.org/web/20180609191039/https://www.guideline.gov/summaries/summary/47077/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c19-genotype-and-clopidogrel-therapy-2013-update'}]
https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:57:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930235758/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:57:58Z', 'uri': 'http://web.archive.org/web/20160930235758/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:38:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003043800/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:38:00Z', 'uri': 'http://web.archive.org/web/20171003043800/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:13:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414041310/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T04:13:10Z', 'uri': 'http://web.archive.org/web/20180414041310/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:04:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519110459/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T11:04:59Z', 'uri': 'http://web.archive.org/web/20180519110459/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T10:37:07Z', 'uri': 'http://web.archive.org/web/20180609103707/https://www.guideline.gov/summaries/summary/47079/screening-for-peripheral-artery-disease-and-cardiovascular-disease-risk-assessment-with-the-ankle-brachial-index-in-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235632/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2016-09-30T23:56:32Z', 'uri': 'http://web.archive.org/web/20160930235632/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2017-10-03T04:29:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003042945/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2017-10-03T04:29:45Z', 'uri': 'http://web.archive.org/web/20171003042945/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2018-04-14T04:02:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414040253/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2018-04-14T04:02:53Z', 'uri': 'http://web.archive.org/web/20180414040253/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2018-05-19T10:54:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519105442/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2018-05-19T10:54:42Z', 'uri': 'http://web.archive.org/web/20180519105442/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}, {'datetime': '2018-06-09T15:16:36Z', 'uri': 'http://web.archive.org/web/20180609151636/https://www.guideline.gov/summaries/summary/47080/acute-kidney-injury-prevention-detection-and-management-of-acute-kidney-injury-up-to-the-point-of-renal-replacement-therapy'}]
https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235634/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2016-09-30T23:56:34Z', 'uri': 'http://web.archive.org/web/20160930235634/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2017-10-03T04:29:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003042936/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2017-10-03T04:29:36Z', 'uri': 'http://web.archive.org/web/20171003042936/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-04-14T04:02:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414040241/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-04-14T04:02:41Z', 'uri': 'http://web.archive.org/web/20180414040241/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-05-19T10:54:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519105431/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-05-19T10:54:31Z', 'uri': 'http://web.archive.org/web/20180519105431/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}, {'datetime': '2018-06-09T12:12:51Z', 'uri': 'http://web.archive.org/web/20180609121251/https://www.guideline.gov/summaries/summary/47081/autism-the-management-and-support-of-children-and-young-people-on-the-autism-spectrum'}]
https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:34:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930143456/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2016-09-30T14:34:56Z', 'uri': 'http://web.archive.org/web/20160930143456/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2017-10-03T04:28:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003042812/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2017-10-03T04:28:12Z', 'uri': 'http://web.archive.org/web/20171003042812/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2018-04-14T04:01:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414040103/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2018-04-14T04:01:03Z', 'uri': 'http://web.archive.org/web/20180414040103/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2018-05-19T10:52:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519105257/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2018-05-19T10:52:57Z', 'uri': 'http://web.archive.org/web/20180519105257/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}, {'datetime': '2018-06-09T22:06:59Z', 'uri': 'http://web.archive.org/web/20180609220659/https://www.guideline.gov/summaries/summary/47082/everolimus-in-combination-with-exemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy'}]
https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235636/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2016-09-30T23:56:36Z', 'uri': 'http://web.archive.org/web/20160930235636/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2017-10-03T04:29:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003042954/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2017-10-03T04:29:54Z', 'uri': 'http://web.archive.org/web/20171003042954/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2018-04-14T04:02:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414040257/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2018-04-14T04:02:57Z', 'uri': 'http://web.archive.org/web/20180414040257/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2018-05-19T10:54:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519105447/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2018-05-19T10:54:47Z', 'uri': 'http://web.archive.org/web/20180519105447/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}, {'datetime': '2018-06-09T22:21:45Z', 'uri': 'http://web.archive.org/web/20180609222145/https://www.guideline.gov/summaries/summary/47083/intrauterine-growth-restriction-screening-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930235624/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2016-09-30T23:56:24Z', 'uri': 'http://web.archive.org/web/20160930235624/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2017-10-03T04:28:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003042837/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2017-10-03T04:28:37Z', 'uri': 'http://web.archive.org/web/20171003042837/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2018-04-14T04:01:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414040132/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2018-04-14T04:01:32Z', 'uri': 'http://web.archive.org/web/20180414040132/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2018-05-19T10:53:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519105328/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2018-05-19T10:53:28Z', 'uri': 'http://web.archive.org/web/20180519105328/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}, {'datetime': '2018-06-09T15:39:00Z', 'uri': 'http://web.archive.org/web/20180609153900/https://www.guideline.gov/summaries/summary/47084/heart-failure--systolic-dysfunction'}]
https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235629/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2016-09-30T23:56:29Z', 'uri': 'http://web.archive.org/web/20160930235629/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2017-10-03T04:29:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003042917/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2017-10-03T04:29:17Z', 'uri': 'http://web.archive.org/web/20171003042917/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2018-04-14T04:02:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414040217/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2018-04-14T04:02:17Z', 'uri': 'http://web.archive.org/web/20180414040217/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2018-05-19T10:54:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519105404/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2018-05-19T10:54:04Z', 'uri': 'http://web.archive.org/web/20180519105404/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}, {'datetime': '2018-06-09T19:16:30Z', 'uri': 'http://web.archive.org/web/20180609191630/https://www.guideline.gov/summaries/summary/47086/practice-parameters-for-the-management-of-pilonidal-disease'}]
https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women	ARCHIVED	19 mementos	[{'datetime': '2016-09-30T23:56:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235620/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2016-09-30T23:56:20Z', 'uri': 'http://web.archive.org/web/20160930235620/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2017-10-03T04:27:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003042749/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2017-10-03T04:27:49Z', 'uri': 'http://web.archive.org/web/20171003042749/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-04-14T04:00:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414040039/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-04-14T04:00:39Z', 'uri': 'http://web.archive.org/web/20180414040039/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-05-19T10:52:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519105237/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-05-19T10:52:37Z', 'uri': 'http://web.archive.org/web/20180519105237/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-06-09T10:36:33Z', 'uri': 'http://web.archive.org/web/20180609103633/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:29Z', 'uri': 'http://web.archive.org/web/20180712220229/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:29Z', 'uri': 'http://web.archive.org/web/20180712220229/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:32Z', 'uri': 'http://web.archive.org/web/20180712220232/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:32Z', 'uri': 'http://web.archive.org/web/20180712220232/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:43Z', 'uri': 'http://web.archive.org/web/20180712220243/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:43Z', 'uri': 'http://web.archive.org/web/20180712220243/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:47Z', 'uri': 'http://web.archive.org/web/20180712220247/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:47Z', 'uri': 'http://web.archive.org/web/20180712220247/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:55Z', 'uri': 'http://web.archive.org/web/20180712220255/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}, {'datetime': '2018-07-12T22:02:55Z', 'uri': 'http://web.archive.org/web/20180712220255/https://www.guideline.gov/summaries/summary/47099/urinary-incontinence-the-management-of-urinary-incontinence-in-women'}]
https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235628/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2016-09-30T23:56:28Z', 'uri': 'http://web.archive.org/web/20160930235628/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2017-10-03T04:29:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003042912/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2017-10-03T04:29:12Z', 'uri': 'http://web.archive.org/web/20171003042912/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2018-04-14T04:02:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414040208/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2018-04-14T04:02:08Z', 'uri': 'http://web.archive.org/web/20180414040208/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2018-05-19T10:53:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519105354/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2018-05-19T10:53:54Z', 'uri': 'http://web.archive.org/web/20180519105354/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}, {'datetime': '2018-06-09T19:47:37Z', 'uri': 'http://web.archive.org/web/20180609194737/https://www.guideline.gov/summaries/summary/47100/aspen-clinical-guidelines-nutrition-support-of-neonatal-patients-at-risk-for-metabolic-bone-disease'}]
https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235541/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2016-09-30T23:55:41Z', 'uri': 'http://web.archive.org/web/20160930235541/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2017-10-03T04:24:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003042424/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2017-10-03T04:24:24Z', 'uri': 'http://web.archive.org/web/20171003042424/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2018-04-14T03:56:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414035607/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2018-04-14T03:56:07Z', 'uri': 'http://web.archive.org/web/20180414035607/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2018-05-19T10:48:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519104820/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2018-05-19T10:48:20Z', 'uri': 'http://web.archive.org/web/20180519104820/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}, {'datetime': '2018-06-09T20:35:30Z', 'uri': 'http://web.archive.org/web/20180609203530/https://www.guideline.gov/summaries/summary/47101/guidelines-for-the-management-of-hiatal-hernia'}]
https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents	ARCHIVED	15 mementos	[{'datetime': '2016-09-30T16:20:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930162027/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2016-09-30T16:20:27Z', 'uri': 'http://web.archive.org/web/20160930162027/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2016-12-20T08:36:22Z', 'uri': 'http://web.archive.org/web/20161220083622/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2017-07-13T03:21:11Z', 'uri': 'http://web.archive.org/web/20170713032111/https://www.guideline.gov/summaries/summary/47102/Prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2017-10-02T20:03:45Z', 'uri': 'http://wayback.archive-it.org/all/20171002200345/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2017-10-02T20:03:45Z', 'uri': 'http://web.archive.org/web/20171002200345/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-04-13T18:53:55Z', 'uri': 'http://wayback.archive-it.org/all/20180413185355/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-04-13T18:53:55Z', 'uri': 'http://web.archive.org/web/20180413185355/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-05-18T19:33:57Z', 'uri': 'http://wayback.archive-it.org/all/20180518193357/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-05-18T19:33:57Z', 'uri': 'http://web.archive.org/web/20180518193357/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-06-09T10:33:02Z', 'uri': 'http://web.archive.org/web/20180609103302/https://www.guideline.gov/summaries/summary/47102/prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-06-09T10:36:17Z', 'uri': 'http://web.archive.org/web/20180609103617/https://www.guideline.gov/summaries/summary/47102/Prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-06-11T00:04:18Z', 'uri': 'http://web.archive.org/web/20180611000418/https://www.guideline.gov/summaries/summary/47102/Prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-06-20T17:38:25Z', 'uri': 'http://web.archive.org/web/20180620173825/https://www.guideline.gov/summaries/summary/47102/Prevention-and-management-of-obesity-for-children-and-adolescents'}, {'datetime': '2018-06-21T00:06:17Z', 'uri': 'http://web.archive.org/web/20180621000617/https://www.guideline.gov/summaries/summary/47102/Prevention-and-management-of-obesity-for-children-and-adolescents'}]
https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235621/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2016-09-30T23:56:21Z', 'uri': 'http://web.archive.org/web/20160930235621/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2017-10-03T04:28:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003042805/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2017-10-03T04:28:05Z', 'uri': 'http://web.archive.org/web/20171003042805/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2018-04-14T04:00:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414040054/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2018-04-14T04:00:54Z', 'uri': 'http://web.archive.org/web/20180414040054/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2018-05-19T10:52:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519105249/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2018-05-19T10:52:49Z', 'uri': 'http://web.archive.org/web/20180519105249/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}, {'datetime': '2018-06-10T20:39:10Z', 'uri': 'http://web.archive.org/web/20180610203910/https://www.guideline.gov/summaries/summary/47104/crizotinib-for-previously-treated-nonsmallcell-lung-cancer-associated-with-an-anaplastic-lymphoma-kinase-fusion-gene'}]
https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235603/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:56:03Z', 'uri': 'http://web.archive.org/web/20160930235603/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:26:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003042618/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:26:18Z', 'uri': 'http://web.archive.org/web/20171003042618/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:58:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414035822/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:58:22Z', 'uri': 'http://web.archive.org/web/20180414035822/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:50:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519105029/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:50:29Z', 'uri': 'http://web.archive.org/web/20180519105029/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}, {'datetime': '2018-06-09T18:41:41Z', 'uri': 'http://web.archive.org/web/20180609184141/https://www.guideline.gov/summaries/summary/47105/treatment-of-primary-breast-cancer-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:56:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235610/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2016-09-30T23:56:10Z', 'uri': 'http://web.archive.org/web/20160930235610/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T04:26:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003042654/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T04:26:54Z', 'uri': 'http://web.archive.org/web/20171003042654/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T03:59:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414035911/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T03:59:11Z', 'uri': 'http://web.archive.org/web/20180414035911/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T10:51:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519105115/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T10:51:15Z', 'uri': 'http://web.archive.org/web/20180519105115/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-09T11:05:17Z', 'uri': 'http://web.archive.org/web/20180609110517/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-07-12T21:56:55Z', 'uri': 'http://web.archive.org/web/20180712215655/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-07-12T21:56:55Z', 'uri': 'http://web.archive.org/web/20180712215655/https://www.guideline.gov/summaries/summary/47119/fertility-preservation-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235655/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:56:55Z', 'uri': 'http://web.archive.org/web/20160930235655/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:31:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003043154/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:31:54Z', 'uri': 'http://web.archive.org/web/20171003043154/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T04:05:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414040554/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T04:05:54Z', 'uri': 'http://web.archive.org/web/20180414040554/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:57:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519105741/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:57:41Z', 'uri': 'http://web.archive.org/web/20180519105741/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:14Z', 'uri': 'http://web.archive.org/web/20180609192214/https://www.guideline.gov/summaries/summary/47136/management-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235619/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2016-09-30T23:56:19Z', 'uri': 'http://web.archive.org/web/20160930235619/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2017-10-03T04:27:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003042744/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2017-10-03T04:27:44Z', 'uri': 'http://web.archive.org/web/20171003042744/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2018-04-14T04:00:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414040028/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2018-04-14T04:00:28Z', 'uri': 'http://web.archive.org/web/20180414040028/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2018-05-19T10:52:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519105230/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2018-05-19T10:52:30Z', 'uri': 'http://web.archive.org/web/20180519105230/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}, {'datetime': '2018-06-09T20:11:45Z', 'uri': 'http://web.archive.org/web/20180609201145/https://www.guideline.gov/summaries/summary/47137/clinical-genetics-evaluation-in-identifying-the-etiology-of-autism-spectrum-disorders-2013-guideline-revisions'}]
https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235618/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2016-09-30T23:56:18Z', 'uri': 'http://web.archive.org/web/20160930235618/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2017-10-03T04:27:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003042738/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2017-10-03T04:27:38Z', 'uri': 'http://web.archive.org/web/20171003042738/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2018-04-14T04:00:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414040019/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2018-04-14T04:00:19Z', 'uri': 'http://web.archive.org/web/20180414040019/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2018-05-19T10:52:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519105223/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2018-05-19T10:52:23Z', 'uri': 'http://web.archive.org/web/20180519105223/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}, {'datetime': '2018-06-09T21:54:07Z', 'uri': 'http://web.archive.org/web/20180609215407/https://www.guideline.gov/summaries/summary/47146/acmg-practice-guideline-lack-of-evidence-for-mthfr-polymorphism-testing'}]
https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235617/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2016-09-30T23:56:17Z', 'uri': 'http://web.archive.org/web/20160930235617/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2017-10-03T04:27:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003042732/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2017-10-03T04:27:32Z', 'uri': 'http://web.archive.org/web/20171003042732/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-04-14T04:00:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414040010/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-04-14T04:00:10Z', 'uri': 'http://web.archive.org/web/20180414040010/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-05-19T10:52:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519105214/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-05-19T10:52:14Z', 'uri': 'http://web.archive.org/web/20180519105214/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}, {'datetime': '2018-06-09T19:45:59Z', 'uri': 'http://web.archive.org/web/20180609194559/https://www.guideline.gov/summaries/summary/47151/longterm-medical-management-of-the-pediatric-patient-after-liver-transplantation-2013-practice-guideline-by-the-american-association-for-the-study-of-liver-diseases-and-the-american-society-of-transplantation'}]
https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235654/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2016-09-30T23:56:54Z', 'uri': 'http://web.archive.org/web/20160930235654/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2017-10-03T04:31:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003043147/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2017-10-03T04:31:47Z', 'uri': 'http://web.archive.org/web/20171003043147/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2018-04-14T04:05:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414040545/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2018-04-14T04:05:45Z', 'uri': 'http://web.archive.org/web/20180414040545/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2018-05-19T10:57:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519105733/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2018-05-19T10:57:33Z', 'uri': 'http://web.archive.org/web/20180519105733/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}, {'datetime': '2018-06-09T18:53:22Z', 'uri': 'http://web.archive.org/web/20180609185322/https://www.guideline.gov/summaries/summary/47155/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis'}]
https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235600/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2016-09-30T23:56:00Z', 'uri': 'http://web.archive.org/web/20160930235600/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2017-10-03T04:26:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003042600/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2017-10-03T04:26:00Z', 'uri': 'http://web.archive.org/web/20171003042600/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2018-04-14T03:57:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414035754/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2018-04-14T03:57:54Z', 'uri': 'http://web.archive.org/web/20180414035754/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2018-05-19T10:50:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519105002/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2018-05-19T10:50:02Z', 'uri': 'http://web.archive.org/web/20180519105002/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}, {'datetime': '2018-06-10T19:10:51Z', 'uri': 'http://web.archive.org/web/20180610191051/https://www.guideline.gov/summaries/summary/47272/extracorporeal-photopheresis-in-the-management-of-graftversushost-disease-in-patients-who-have-received-allogeneic-blood-or-bone-marrow-transplants-recommendations'}]
https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235601/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2016-09-30T23:56:01Z', 'uri': 'http://web.archive.org/web/20160930235601/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2017-10-03T04:26:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003042605/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2017-10-03T04:26:05Z', 'uri': 'http://web.archive.org/web/20171003042605/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2018-04-14T03:58:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414035803/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2018-04-14T03:58:03Z', 'uri': 'http://web.archive.org/web/20180414035803/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2018-05-19T10:50:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519105010/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2018-05-19T10:50:10Z', 'uri': 'http://web.archive.org/web/20180519105010/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}, {'datetime': '2018-06-09T21:16:01Z', 'uri': 'http://web.archive.org/web/20180609211601/https://www.guideline.gov/summaries/summary/47274/screening-highrisk-populations-for-lung-cancer'}]
https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235622/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2016-09-30T23:56:22Z', 'uri': 'http://web.archive.org/web/20160930235622/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2017-10-03T04:28:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003042818/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2017-10-03T04:28:18Z', 'uri': 'http://web.archive.org/web/20171003042818/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2018-04-14T04:01:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414040112/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2018-04-14T04:01:12Z', 'uri': 'http://web.archive.org/web/20180414040112/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2018-05-19T10:53:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519105306/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2018-05-19T10:53:06Z', 'uri': 'http://web.archive.org/web/20180519105306/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}, {'datetime': '2018-06-09T15:29:10Z', 'uri': 'http://web.archive.org/web/20180609152910/https://www.guideline.gov/summaries/summary/47278/aortic-valve-and-ascending-aorta-guidelines-for-management-and-quality-measures'}]
https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235605/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2016-09-30T23:56:05Z', 'uri': 'http://web.archive.org/web/20160930235605/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2017-10-03T04:26:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003042632/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2017-10-03T04:26:32Z', 'uri': 'http://web.archive.org/web/20171003042632/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2018-04-14T03:58:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414035842/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2018-04-14T03:58:42Z', 'uri': 'http://web.archive.org/web/20180414035842/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2018-05-19T10:50:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519105048/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2018-05-19T10:50:48Z', 'uri': 'http://web.archive.org/web/20180519105048/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}, {'datetime': '2018-06-09T22:50:19Z', 'uri': 'http://web.archive.org/web/20180609225019/https://www.guideline.gov/summaries/summary/47286/aarc-clinical-practice-guideline-blood-gas-analysis-and-hemoximetry-2013'}]
https://www.guideline.gov/summaries/summary/47317/preventive-services-for-children-and-adolescents	ARCHIVED	4 mementos	[{'datetime': '2016-09-30T16:20:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930162035/https://www.guideline.gov/summaries/summary/47317/preventive-services-for-children-and-adolescents'}, {'datetime': '2017-10-02T20:03:55Z', 'uri': 'http://wayback.archive-it.org/all/20171002200355/https://www.guideline.gov/summaries/summary/47317/preventive-services-for-children-and-adolescents'}, {'datetime': '2018-04-13T18:54:10Z', 'uri': 'http://wayback.archive-it.org/all/20180413185410/https://www.guideline.gov/summaries/summary/47317/preventive-services-for-children-and-adolescents'}, {'datetime': '2018-05-18T21:48:41Z', 'uri': 'http://wayback.archive-it.org/all/20180518214841/https://www.guideline.gov/summaries/summary/47317/preventive-services-for-children-and-adolescents'}]
https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235604/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2016-09-30T23:56:04Z', 'uri': 'http://web.archive.org/web/20160930235604/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2017-10-03T04:26:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003042625/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2017-10-03T04:26:25Z', 'uri': 'http://web.archive.org/web/20171003042625/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2018-04-14T03:58:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414035831/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2018-04-14T03:58:31Z', 'uri': 'http://web.archive.org/web/20180414035831/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2018-05-19T10:50:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519105038/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2018-05-19T10:50:38Z', 'uri': 'http://web.archive.org/web/20180519105038/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}, {'datetime': '2018-06-09T15:21:26Z', 'uri': 'http://web.archive.org/web/20180609152126/https://www.guideline.gov/summaries/summary/47335/management-of-symptomatic-vulvovaginal-atrophy-2013-position-statement-of-the-north-american-menopause-society'}]
https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235637/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:56:37Z', 'uri': 'http://web.archive.org/web/20160930235637/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:30:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003043000/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:30:00Z', 'uri': 'http://web.archive.org/web/20171003043000/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:03:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414040306/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T04:03:06Z', 'uri': 'http://web.archive.org/web/20180414040306/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:54:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519105455/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:54:55Z', 'uri': 'http://web.archive.org/web/20180519105455/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-10T21:23:26Z', 'uri': 'http://web.archive.org/web/20180610212326/https://www.guideline.gov/summaries/summary/47336/evidencebased-guideline-update-vagus-nerve-stimulation-for-the-treatment-of-epilepsy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235557/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2016-09-30T23:55:57Z', 'uri': 'http://web.archive.org/web/20160930235557/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2017-10-03T04:25:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003042543/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2017-10-03T04:25:43Z', 'uri': 'http://web.archive.org/web/20171003042543/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2018-04-14T03:57:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414035723/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2018-04-14T03:57:23Z', 'uri': 'http://web.archive.org/web/20180414035723/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2018-05-19T10:49:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519104934/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2018-05-19T10:49:34Z', 'uri': 'http://web.archive.org/web/20180519104934/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}, {'datetime': '2018-06-09T19:04:59Z', 'uri': 'http://web.archive.org/web/20180609190459/https://www.guideline.gov/summaries/summary/47342/subluxation-chiropractic-practice'}]
https://www.guideline.gov/summaries/summary/47344/surgical-abortion-prior-to-7-weeks-of-gestation	ARCHIVED	4 mementos	[{'datetime': '2016-09-30T23:55:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235548/https://www.guideline.gov/summaries/summary/47344/surgical-abortion-prior-to-7-weeks-of-gestation'}, {'datetime': '2016-09-30T23:55:48Z', 'uri': 'http://web.archive.org/web/20160930235548/https://www.guideline.gov/summaries/summary/47344/surgical-abortion-prior-to-7-weeks-of-gestation'}, {'datetime': '2018-06-09T21:12:25Z', 'uri': 'http://web.archive.org/web/20180609211225/https://www.guideline.gov/summaries/summary/47344/surgical-abortion-prior-to-7-weeks-of-gestation'}, {'datetime': '2018-06-15T14:48:14Z', 'uri': 'http://web.archive.org/web/20180615144814/https://guideline.gov/summaries/summary/47344/surgical-abortion-prior-to-7-weeks-of-gestation'}]
https://www.guideline.gov/summaries/summary/47345/management-of-postabortion-hemorrhage	ARCHIVED	3 mementos	[{'datetime': '2016-09-30T23:55:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235547/https://www.guideline.gov/summaries/summary/47345/management-of-postabortion-hemorrhage'}, {'datetime': '2016-09-30T23:55:47Z', 'uri': 'http://web.archive.org/web/20160930235547/https://www.guideline.gov/summaries/summary/47345/management-of-postabortion-hemorrhage'}, {'datetime': '2018-06-09T21:12:26Z', 'uri': 'http://web.archive.org/web/20180609211226/https://www.guideline.gov/summaries/summary/47345/management-of-postabortion-hemorrhage'}]
https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:56:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235611/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2016-09-30T23:56:11Z', 'uri': 'http://web.archive.org/web/20160930235611/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2017-07-14T10:59:35Z', 'uri': 'http://web.archive.org/web/20170714105935/https://guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T04:27:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003042700/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T04:27:00Z', 'uri': 'http://web.archive.org/web/20171003042700/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T03:59:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414035920/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T03:59:20Z', 'uri': 'http://web.archive.org/web/20180414035920/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T10:51:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519105124/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T10:51:24Z', 'uri': 'http://web.archive.org/web/20180519105124/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}, {'datetime': '2018-06-09T11:40:22Z', 'uri': 'http://web.archive.org/web/20180609114022/https://www.guideline.gov/summaries/summary/47348/recommendations-for-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-american-society-of-clinical-oncologycollege-of-american-pathologists-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:56:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930235625/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2016-09-30T23:56:25Z', 'uri': 'http://web.archive.org/web/20160930235625/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2017-10-03T04:28:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003042844/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2017-10-03T04:28:44Z', 'uri': 'http://web.archive.org/web/20171003042844/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2018-01-10T12:57:21Z', 'uri': 'http://web.archive.org/web/20180110125721/https://guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2018-04-14T04:01:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414040143/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2018-04-14T04:01:43Z', 'uri': 'http://web.archive.org/web/20180414040143/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2018-05-19T10:53:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519105337/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2018-05-19T10:53:37Z', 'uri': 'http://web.archive.org/web/20180519105337/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}, {'datetime': '2018-06-09T21:34:20Z', 'uri': 'http://web.archive.org/web/20180609213420/https://www.guideline.gov/summaries/summary/47349/vertebral-osteomyelitis-discitis-and-spinal-epidural-abscess-in-adults'}]
https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235553/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:55:53Z', 'uri': 'http://web.archive.org/web/20160930235553/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:25:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003042519/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:25:19Z', 'uri': 'http://web.archive.org/web/20171003042519/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:56:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414035656/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:56:56Z', 'uri': 'http://web.archive.org/web/20180414035656/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:49:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519104908/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:49:08Z', 'uri': 'http://web.archive.org/web/20180519104908/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T19:54:12Z', 'uri': 'http://web.archive.org/web/20180610195412/https://www.guideline.gov/summaries/summary/47350/medications-for-risk-reduction-of-primary-breast-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:55:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235555/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:55:55Z', 'uri': 'http://web.archive.org/web/20160930235555/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:25:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003042533/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:25:33Z', 'uri': 'http://web.archive.org/web/20171003042533/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:57:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414035716/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:57:16Z', 'uri': 'http://web.archive.org/web/20180414035716/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:49:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519104926/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:49:26Z', 'uri': 'http://web.archive.org/web/20180519104926/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T19:03:39Z', 'uri': 'http://web.archive.org/web/20180609190339/https://www.guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-15T14:47:31Z', 'uri': 'http://web.archive.org/web/20180615144731/https://guideline.gov/summaries/summary/47351/screening-for-primary-hypertension-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930235612/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2016-09-30T23:56:12Z', 'uri': 'http://web.archive.org/web/20160930235612/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2017-10-03T04:27:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003042706/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2017-10-03T04:27:06Z', 'uri': 'http://web.archive.org/web/20171003042706/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2018-04-14T03:59:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414035930/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2018-04-14T03:59:30Z', 'uri': 'http://web.archive.org/web/20180414035930/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2018-05-19T10:51:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519105134/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2018-05-19T10:51:34Z', 'uri': 'http://web.archive.org/web/20180519105134/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}, {'datetime': '2018-06-09T20:50:23Z', 'uri': 'http://web.archive.org/web/20180609205023/https://www.guideline.gov/summaries/summary/47378/best-evidence-statement-best-increasing-patient-satisfaction-by-moving-nursing-shift-report-to-the-bedside'}]
https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235613/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2016-09-30T23:56:13Z', 'uri': 'http://web.archive.org/web/20160930235613/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2017-10-03T04:27:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003042711/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2017-10-03T04:27:11Z', 'uri': 'http://web.archive.org/web/20171003042711/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2018-04-14T03:59:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414035938/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2018-04-14T03:59:38Z', 'uri': 'http://web.archive.org/web/20180414035938/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2018-05-19T10:51:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519105141/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2018-05-19T10:51:41Z', 'uri': 'http://web.archive.org/web/20180519105141/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}, {'datetime': '2018-06-09T20:18:51Z', 'uri': 'http://web.archive.org/web/20180609201851/https://www.guideline.gov/summaries/summary/47379/best-evidence-statement-best-providing-most-effective-child-life-care-for-patients-having-general-anesthesia'}]
https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235614/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2016-09-30T23:56:14Z', 'uri': 'http://web.archive.org/web/20160930235614/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2017-10-03T04:27:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003042717/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2017-10-03T04:27:17Z', 'uri': 'http://web.archive.org/web/20171003042717/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2018-04-14T03:59:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414035948/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2018-04-14T03:59:48Z', 'uri': 'http://web.archive.org/web/20180414035948/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2018-05-19T10:51:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519105149/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2018-05-19T10:51:49Z', 'uri': 'http://web.archive.org/web/20180519105149/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}, {'datetime': '2018-06-09T11:02:09Z', 'uri': 'http://web.archive.org/web/20180609110209/https://www.guideline.gov/summaries/summary/47380/evidencebased-care-guideline-for-cytomegalovirus-prevention-following-solid-organ-transplantation'}]
https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235552/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2016-09-30T23:55:52Z', 'uri': 'http://web.archive.org/web/20160930235552/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2017-10-03T04:25:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003042512/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2017-10-03T04:25:12Z', 'uri': 'http://web.archive.org/web/20171003042512/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2018-04-14T03:56:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414035647/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2018-04-14T03:56:47Z', 'uri': 'http://web.archive.org/web/20180414035647/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2018-05-19T10:48:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519104859/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2018-05-19T10:48:59Z', 'uri': 'http://web.archive.org/web/20180519104859/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}, {'datetime': '2018-06-09T20:13:55Z', 'uri': 'http://web.archive.org/web/20180609201355/https://www.guideline.gov/summaries/summary/47381/2013-uk-national-guideline-for-the-management-of-lymphogranuloma-venereum'}]
https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235542/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2016-09-30T23:55:42Z', 'uri': 'http://web.archive.org/web/20160930235542/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2017-10-03T04:24:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003042431/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2017-10-03T04:24:31Z', 'uri': 'http://web.archive.org/web/20171003042431/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2018-04-14T03:56:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414035616/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2018-04-14T03:56:16Z', 'uri': 'http://web.archive.org/web/20180414035616/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2018-05-19T10:48:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519104830/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2018-05-19T10:48:30Z', 'uri': 'http://web.archive.org/web/20180519104830/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}, {'datetime': '2018-06-10T01:59:45Z', 'uri': 'http://web.archive.org/web/20180610015945/https://www.guideline.gov/summaries/summary/47399/healthpartners-dental-group-and-clinics-third-molar-guideline'}]
https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930235559/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2016-09-30T23:55:59Z', 'uri': 'http://web.archive.org/web/20160930235559/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2017-10-03T04:25:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003042554/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2017-10-03T04:25:54Z', 'uri': 'http://web.archive.org/web/20171003042554/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-04-14T03:57:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414035746/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-04-14T03:57:46Z', 'uri': 'http://web.archive.org/web/20180414035746/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-05-19T10:49:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519104954/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-05-19T10:49:54Z', 'uri': 'http://web.archive.org/web/20180519104954/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-06-09T22:39:59Z', 'uri': 'http://web.archive.org/web/20180609223959/https://www.guideline.gov/summaries/summary/47400/molecular-testing-for-cystic-fibrosis-carrier-status-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}]
https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:56:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930235626/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2016-09-30T23:56:26Z', 'uri': 'http://web.archive.org/web/20160930235626/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2017-10-03T04:29:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003042901/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2017-10-03T04:29:01Z', 'uri': 'http://web.archive.org/web/20171003042901/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-04-14T04:01:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414040152/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-04-14T04:01:52Z', 'uri': 'http://web.archive.org/web/20180414040152/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-05-18T19:33:50Z', 'uri': 'http://wayback.archive-it.org/all/20180518193350/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-05-18T19:33:50Z', 'uri': 'http://web.archive.org/web/20180518193350/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-06-09T10:38:49Z', 'uri': 'http://web.archive.org/web/20180609103849/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-07-12T21:39:32Z', 'uri': 'http://web.archive.org/web/20180712213932/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}, {'datetime': '2018-07-12T21:39:32Z', 'uri': 'http://web.archive.org/web/20180712213932/https://www.guideline.gov/summaries/summary/47451/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction'}]
https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235615/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2016-09-30T23:56:15Z', 'uri': 'http://web.archive.org/web/20160930235615/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2017-10-03T04:27:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003042724/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2017-10-03T04:27:24Z', 'uri': 'http://web.archive.org/web/20171003042724/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2018-04-14T03:59:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414035957/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2018-04-14T03:59:57Z', 'uri': 'http://web.archive.org/web/20180414035957/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2018-05-19T10:52:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519105204/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2018-05-19T10:52:04Z', 'uri': 'http://web.archive.org/web/20180519105204/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}, {'datetime': '2018-06-10T01:07:36Z', 'uri': 'http://web.archive.org/web/20180610010736/https://www.guideline.gov/summaries/summary/47452/ocriplasmin-for-treating-vitreomacular-traction'}]
https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235607/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:56:07Z', 'uri': 'http://web.archive.org/web/20160930235607/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:26:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003042639/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:26:39Z', 'uri': 'http://web.archive.org/web/20171003042639/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:58:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414035851/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:58:51Z', 'uri': 'http://web.archive.org/web/20180414035851/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:50:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519105058/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:50:58Z', 'uri': 'http://web.archive.org/web/20180519105058/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:04Z', 'uri': 'http://web.archive.org/web/20180609192204/https://www.guideline.gov/summaries/summary/47453/screening-monitoring-and-treatment-of-stage-1-to-3-chronic-kidney-disease-a-clinical-practice-guideline-from-the-clinical-guidelines-committee-of-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235537/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2016-09-30T23:55:37Z', 'uri': 'http://web.archive.org/web/20160930235537/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2017-10-03T04:24:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003042400/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2017-10-03T04:24:00Z', 'uri': 'http://web.archive.org/web/20171003042400/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2018-04-14T03:55:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414035529/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2018-04-14T03:55:29Z', 'uri': 'http://web.archive.org/web/20180414035529/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2018-05-19T10:47:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519104744/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2018-05-19T10:47:44Z', 'uri': 'http://web.archive.org/web/20180519104744/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}, {'datetime': '2018-06-09T10:33:02Z', 'uri': 'http://web.archive.org/web/20180609103302/https://www.guideline.gov/summaries/summary/47480/occupational-therapy-practice-guidelines-for-early-childhood-birth-through-5-years'}]
https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235539/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2016-09-30T23:55:39Z', 'uri': 'http://web.archive.org/web/20160930235539/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2017-10-03T04:24:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003042412/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2017-10-03T04:24:12Z', 'uri': 'http://web.archive.org/web/20171003042412/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2018-04-14T03:55:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414035548/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2018-04-14T03:55:48Z', 'uri': 'http://web.archive.org/web/20180414035548/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2018-05-19T10:48:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519104803/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2018-05-19T10:48:03Z', 'uri': 'http://web.archive.org/web/20180519104803/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}, {'datetime': '2018-06-09T15:22:32Z', 'uri': 'http://web.archive.org/web/20180609152232/https://www.guideline.gov/summaries/summary/47481/occupational-therapy-practice-guidelines-for-older-adults-with-low-vision'}]
https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235538/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2016-09-30T23:55:38Z', 'uri': 'http://web.archive.org/web/20160930235538/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2017-10-03T04:24:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003042406/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2017-10-03T04:24:06Z', 'uri': 'http://web.archive.org/web/20171003042406/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2018-04-14T03:55:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414035539/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2018-04-14T03:55:39Z', 'uri': 'http://web.archive.org/web/20180414035539/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2018-05-19T10:47:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519104754/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2018-05-19T10:47:54Z', 'uri': 'http://web.archive.org/web/20180519104754/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}, {'datetime': '2018-06-09T12:11:07Z', 'uri': 'http://web.archive.org/web/20180609121107/https://www.guideline.gov/summaries/summary/47482/occupational-therapy-practice-guidelines-for-mental-health-promotion-prevention-and-intervention-for-children-and-youth'}]
https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235519/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2016-09-30T23:55:19Z', 'uri': 'http://web.archive.org/web/20160930235519/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2017-10-03T04:22:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003042201/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2017-10-03T04:22:01Z', 'uri': 'http://web.archive.org/web/20171003042201/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2018-04-14T03:52:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414035219/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2018-04-14T03:52:19Z', 'uri': 'http://web.archive.org/web/20180414035219/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2018-05-19T10:45:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519104512/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2018-05-19T10:45:12Z', 'uri': 'http://web.archive.org/web/20180519104512/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}, {'datetime': '2018-06-09T21:31:37Z', 'uri': 'http://web.archive.org/web/20180609213137/https://www.guideline.gov/summaries/summary/47483/clinical-practice-guideline-bells-palsy'}]
https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235514/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2016-09-30T23:55:14Z', 'uri': 'http://web.archive.org/web/20160930235514/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2017-10-03T04:21:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003042133/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2017-10-03T04:21:33Z', 'uri': 'http://web.archive.org/web/20171003042133/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2018-04-14T03:51:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414035133/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2018-04-14T03:51:33Z', 'uri': 'http://web.archive.org/web/20180414035133/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2018-05-19T10:44:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519104428/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2018-05-19T10:44:28Z', 'uri': 'http://web.archive.org/web/20180519104428/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}, {'datetime': '2018-06-09T15:26:27Z', 'uri': 'http://web.archive.org/web/20180609152627/https://www.guideline.gov/summaries/summary/47484/frailty-in-elderly-people'}]
https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:56:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930235627/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2016-09-30T23:56:27Z', 'uri': 'http://web.archive.org/web/20160930235627/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2017-02-03T11:10:00Z', 'uri': 'http://web.archive.org/web/20170203111000/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2017-10-03T04:29:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003042906/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2017-10-03T04:29:06Z', 'uri': 'http://web.archive.org/web/20171003042906/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2018-04-14T04:02:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414040200/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2018-04-14T04:02:00Z', 'uri': 'http://web.archive.org/web/20180414040200/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2018-05-19T10:53:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519105345/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2018-05-19T10:53:45Z', 'uri': 'http://web.archive.org/web/20180519105345/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}, {'datetime': '2018-06-09T19:47:27Z', 'uri': 'http://web.archive.org/web/20180609194727/https://www.guideline.gov/summaries/summary/47538/aspen-clinical-guidelines-nutrition-support-of-hospitalized-adult-patients-with-obesity'}]
https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235506/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2016-09-30T23:55:06Z', 'uri': 'http://web.archive.org/web/20160930235506/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2017-10-03T04:20:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003042055/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2017-10-03T04:20:55Z', 'uri': 'http://web.archive.org/web/20171003042055/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2018-04-14T03:50:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414035037/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2018-04-14T03:50:37Z', 'uri': 'http://web.archive.org/web/20180414035037/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2018-05-19T10:43:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519104335/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2018-05-19T10:43:35Z', 'uri': 'http://web.archive.org/web/20180519104335/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}, {'datetime': '2018-06-09T22:11:37Z', 'uri': 'http://web.archive.org/web/20180609221137/https://www.guideline.gov/summaries/summary/47540/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-optimizing-the-management-of-fullthickness-rotator-cuff-tears'}]
https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235602/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:56:02Z', 'uri': 'http://web.archive.org/web/20160930235602/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:26:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003042611/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:26:11Z', 'uri': 'http://web.archive.org/web/20171003042611/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:58:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414035811/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:58:11Z', 'uri': 'http://web.archive.org/web/20180414035811/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:50:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519105020/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:50:20Z', 'uri': 'http://web.archive.org/web/20180519105020/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}, {'datetime': '2018-06-09T18:41:18Z', 'uri': 'http://web.archive.org/web/20180609184118/https://www.guideline.gov/summaries/summary/47541/management-of-epithelial-ovarian-cancer-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930235623/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2016-09-30T23:56:23Z', 'uri': 'http://web.archive.org/web/20160930235623/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2017-10-03T04:28:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003042829/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2017-10-03T04:28:29Z', 'uri': 'http://web.archive.org/web/20171003042829/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2018-04-14T04:01:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414040125/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2018-04-14T04:01:25Z', 'uri': 'http://web.archive.org/web/20180414040125/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2018-05-19T10:53:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519105318/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2018-05-19T10:53:18Z', 'uri': 'http://web.archive.org/web/20180519105318/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}, {'datetime': '2018-06-09T15:38:47Z', 'uri': 'http://web.archive.org/web/20180609153847/https://www.guideline.gov/summaries/summary/47548/allergic-rhinitis'}]
https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930235449/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2016-09-30T23:54:49Z', 'uri': 'http://web.archive.org/web/20160930235449/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2017-10-03T04:19:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003041903/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2017-10-03T04:19:03Z', 'uri': 'http://web.archive.org/web/20171003041903/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-04-14T03:48:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414034827/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-04-14T03:48:27Z', 'uri': 'http://web.archive.org/web/20180414034827/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-05-19T10:41:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519104118/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-05-19T10:41:18Z', 'uri': 'http://web.archive.org/web/20180519104118/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-06-09T21:45:29Z', 'uri': 'http://web.archive.org/web/20180609214529/https://www.guideline.gov/summaries/summary/47551/ankle-stability-and-movement-coordination-impairments-ankle-ligament-sprains-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}]
https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235450/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2016-09-30T23:54:50Z', 'uri': 'http://web.archive.org/web/20160930235450/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2017-10-03T04:19:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003041910/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2017-10-03T04:19:10Z', 'uri': 'http://web.archive.org/web/20171003041910/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-04-14T03:48:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414034836/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-04-14T03:48:36Z', 'uri': 'http://web.archive.org/web/20180414034836/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-05-19T10:41:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519104127/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-05-19T10:41:27Z', 'uri': 'http://web.archive.org/web/20180519104127/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}, {'datetime': '2018-06-09T11:25:27Z', 'uri': 'http://web.archive.org/web/20180609112527/https://www.guideline.gov/summaries/summary/47552/shoulder-pain-and-mobility-deficits-adhesive-capsulitis-clinical-practice-guidelines-linked-to-the-international-classification-of-functioning-disability-and-health-from-the-orthopaedic-section-of-the-american-physical-therapy-association'}]
https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235535/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2016-09-30T23:55:35Z', 'uri': 'http://web.archive.org/web/20160930235535/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2017-10-03T04:23:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003042353/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2017-10-03T04:23:53Z', 'uri': 'http://web.archive.org/web/20171003042353/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2018-04-14T03:55:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414035518/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2018-04-14T03:55:18Z', 'uri': 'http://web.archive.org/web/20180414035518/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2018-05-19T10:47:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519104735/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2018-05-19T10:47:35Z', 'uri': 'http://web.archive.org/web/20180519104735/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}, {'datetime': '2018-06-09T20:54:49Z', 'uri': 'http://web.archive.org/web/20180609205449/https://www.guideline.gov/summaries/summary/47553/topical-fluoride-for-caries-prevention'}]
https://www.guideline.gov/summaries/summary/47555/induction-of-labour	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:55:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235516/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2016-09-30T23:55:16Z', 'uri': 'http://web.archive.org/web/20160930235516/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2017-10-03T04:21:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003042144/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2017-10-03T04:21:44Z', 'uri': 'http://web.archive.org/web/20171003042144/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2018-04-14T03:51:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414035152/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2018-04-14T03:51:52Z', 'uri': 'http://web.archive.org/web/20180414035152/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2018-05-19T10:44:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519104446/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2018-05-19T10:44:46Z', 'uri': 'http://web.archive.org/web/20180519104446/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2018-06-09T22:21:56Z', 'uri': 'http://web.archive.org/web/20180609222156/https://www.guideline.gov/summaries/summary/47555/induction-of-labour'}, {'datetime': '2018-06-11T15:28:16Z', 'uri': 'http://web.archive.org/web/20180611152816/https://www.guideline.gov/summaries/summary/47555/Induction-of-labour'}]
https://www.guideline.gov/summaries/summary/47556/female-genital-cutting	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235515/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2016-09-30T23:55:15Z', 'uri': 'http://web.archive.org/web/20160930235515/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2017-10-03T04:21:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003042139/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2017-10-03T04:21:39Z', 'uri': 'http://web.archive.org/web/20171003042139/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2018-04-14T03:51:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414035143/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2018-04-14T03:51:43Z', 'uri': 'http://web.archive.org/web/20180414035143/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2018-05-19T10:44:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519104437/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2018-05-19T10:44:37Z', 'uri': 'http://web.archive.org/web/20180519104437/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}, {'datetime': '2018-06-09T22:21:41Z', 'uri': 'http://web.archive.org/web/20180609222141/https://www.guideline.gov/summaries/summary/47556/female-genital-cutting'}]
https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235518/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2016-09-30T23:55:18Z', 'uri': 'http://web.archive.org/web/20160930235518/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2017-10-03T04:21:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003042155/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2017-10-03T04:21:55Z', 'uri': 'http://web.archive.org/web/20171003042155/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2018-04-14T03:52:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414035209/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2018-04-14T03:52:09Z', 'uri': 'http://web.archive.org/web/20180414035209/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2018-05-19T10:45:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519104503/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2018-05-19T10:45:03Z', 'uri': 'http://web.archive.org/web/20180519104503/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}, {'datetime': '2018-06-09T11:02:18Z', 'uri': 'http://web.archive.org/web/20180609110218/https://www.guideline.gov/summaries/summary/47557/the-prevention-of-earlyonset-neonatal-group-b-streptococcal-disease'}]
https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235517/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2016-09-30T23:55:17Z', 'uri': 'http://web.archive.org/web/20160930235517/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2017-10-03T04:21:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003042150/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2017-10-03T04:21:50Z', 'uri': 'http://web.archive.org/web/20171003042150/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2018-04-14T03:52:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414035201/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2018-04-14T03:52:01Z', 'uri': 'http://web.archive.org/web/20180414035201/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2018-05-19T10:44:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519104455/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2018-05-19T10:44:55Z', 'uri': 'http://web.archive.org/web/20180519104455/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}, {'datetime': '2018-06-09T22:21:49Z', 'uri': 'http://web.archive.org/web/20180609222149/https://www.guideline.gov/summaries/summary/47558/investigation-and-management-of-nonimmune-fetal-hydrops'}]
https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235430/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2016-09-30T23:54:30Z', 'uri': 'http://web.archive.org/web/20160930235430/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2017-10-03T04:17:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003041700/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2017-10-03T04:17:00Z', 'uri': 'http://web.archive.org/web/20171003041700/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2018-04-14T03:45:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414034520/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2018-04-14T03:45:20Z', 'uri': 'http://web.archive.org/web/20180414034520/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2018-05-19T10:38:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519103834/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2018-05-19T10:38:34Z', 'uri': 'http://web.archive.org/web/20180519103834/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}, {'datetime': '2018-06-09T12:06:22Z', 'uri': 'http://web.archive.org/web/20180609120622/https://www.guideline.gov/summaries/summary/47559/appropriate-use-criteria-for-amyloid-pet-a-report-of-the-amyloid-imaging-task-force-the-society-of-nuclear-medicine-and-molecular-imaging-and-the-alzheimers-association'}]
https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930235451/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2016-09-30T23:54:51Z', 'uri': 'http://web.archive.org/web/20160930235451/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2017-10-03T04:19:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003041916/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2017-10-03T04:19:16Z', 'uri': 'http://web.archive.org/web/20171003041916/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2018-04-14T03:48:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414034845/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2018-04-14T03:48:45Z', 'uri': 'http://web.archive.org/web/20180414034845/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2018-05-19T10:41:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519104137/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2018-05-19T10:41:37Z', 'uri': 'http://web.archive.org/web/20180519104137/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}, {'datetime': '2018-06-09T19:21:41Z', 'uri': 'http://web.archive.org/web/20180609192141/https://www.guideline.gov/summaries/summary/47560/guideline-on-the-management-of-primary-resistant-and-relapsed-classical-hodgkin-lymphoma'}]
https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235554/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:55:54Z', 'uri': 'http://web.archive.org/web/20160930235554/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:25:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003042526/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:25:26Z', 'uri': 'http://web.archive.org/web/20171003042526/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:57:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414035706/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:57:06Z', 'uri': 'http://web.archive.org/web/20180414035706/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:49:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519104917/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:49:17Z', 'uri': 'http://web.archive.org/web/20180519104917/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T18:01:48Z', 'uri': 'http://web.archive.org/web/20180610180148/https://www.guideline.gov/summaries/summary/47562/screening-for-oral-cancer-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235405/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2016-09-30T23:54:05Z', 'uri': 'http://web.archive.org/web/20160930235405/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2017-10-03T04:14:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003041458/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2017-10-03T04:14:58Z', 'uri': 'http://web.archive.org/web/20171003041458/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2018-04-14T03:43:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414034300/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2018-04-14T03:43:00Z', 'uri': 'http://web.archive.org/web/20180414034300/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2018-05-19T10:36:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519103605/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2018-05-19T10:36:05Z', 'uri': 'http://web.archive.org/web/20180519103605/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}, {'datetime': '2018-06-09T19:20:50Z', 'uri': 'http://web.archive.org/web/20180609192050/https://www.guideline.gov/summaries/summary/47566/assessment-and-management-of-foot-ulcers-for-people-with-diabetes'}]
https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:56:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930235608/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:56:08Z', 'uri': 'http://web.archive.org/web/20160930235608/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:26:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003042647/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T04:26:47Z', 'uri': 'http://web.archive.org/web/20171003042647/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:59:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414035900/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:59:00Z', 'uri': 'http://web.archive.org/web/20180414035900/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:51:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519105107/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:51:07Z', 'uri': 'http://web.archive.org/web/20180519105107/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T15:29:06Z', 'uri': 'http://web.archive.org/web/20180609152906/https://www.guideline.gov/summaries/summary/47570/treatment-of-anemia-in-patients-with-heart-disease-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235522/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2016-09-30T23:55:22Z', 'uri': 'http://web.archive.org/web/20160930235522/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2017-10-03T04:22:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003042219/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2017-10-03T04:22:19Z', 'uri': 'http://web.archive.org/web/20171003042219/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2018-04-14T03:52:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414035251/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2018-04-14T03:52:51Z', 'uri': 'http://web.archive.org/web/20180414035251/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2018-05-19T10:45:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519104537/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2018-05-19T10:45:37Z', 'uri': 'http://web.archive.org/web/20180519104537/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}, {'datetime': '2018-06-10T00:05:13Z', 'uri': 'http://web.archive.org/web/20180610000513/https://www.guideline.gov/summaries/summary/47628/screening-for-sudden-cardiac-death-before-participation-in-high-school-and-collegiate-sports'}]
https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults	ARCHIVED	15 mementos	[{'datetime': '2016-09-30T16:20:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930162051/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2016-09-30T16:20:51Z', 'uri': 'http://web.archive.org/web/20160930162051/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2016-12-20T22:41:47Z', 'uri': 'http://web.archive.org/web/20161220224147/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2017-07-13T03:28:55Z', 'uri': 'http://web.archive.org/web/20170713032855/https://www.guideline.gov/summaries/summary/47629/Palliative-care-for-adults'}, {'datetime': '2017-10-02T20:04:15Z', 'uri': 'http://wayback.archive-it.org/all/20171002200415/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2017-10-02T20:04:15Z', 'uri': 'http://web.archive.org/web/20171002200415/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2018-04-13T18:54:26Z', 'uri': 'http://wayback.archive-it.org/all/20180413185426/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2018-04-13T18:54:26Z', 'uri': 'http://web.archive.org/web/20180413185426/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2018-05-18T21:48:55Z', 'uri': 'http://wayback.archive-it.org/all/20180518214855/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2018-05-18T21:48:55Z', 'uri': 'http://web.archive.org/web/20180518214855/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2018-06-09T10:36:01Z', 'uri': 'http://web.archive.org/web/20180609103601/https://www.guideline.gov/summaries/summary/47629/Palliative-care-for-adults'}, {'datetime': '2018-06-09T11:35:15Z', 'uri': 'http://web.archive.org/web/20180609113515/https://www.guideline.gov/summaries/summary/47629/palliative-care-for-adults'}, {'datetime': '2018-06-11T18:19:34Z', 'uri': 'http://web.archive.org/web/20180611181934/https://www.guideline.gov/summaries/summary/47629/Palliative-care-for-adults'}, {'datetime': '2018-06-20T17:39:52Z', 'uri': 'http://web.archive.org/web/20180620173952/https://www.guideline.gov/summaries/summary/47629/Palliative-care-for-adults'}, {'datetime': '2018-06-20T22:21:38Z', 'uri': 'http://web.archive.org/web/20180620222138/https://www.guideline.gov/summaries/summary/47629/Palliative-care-for-adults'}]
https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235400/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2016-09-30T23:54:00Z', 'uri': 'http://web.archive.org/web/20160930235400/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2017-10-03T04:14:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003041443/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2017-10-03T04:14:43Z', 'uri': 'http://web.archive.org/web/20171003041443/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2018-04-14T03:42:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414034238/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2018-04-14T03:42:38Z', 'uri': 'http://web.archive.org/web/20180414034238/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2018-05-19T10:35:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519103545/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2018-05-19T10:35:45Z', 'uri': 'http://web.archive.org/web/20180519103545/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}, {'datetime': '2018-06-09T10:37:50Z', 'uri': 'http://web.archive.org/web/20180609103750/https://www.guideline.gov/summaries/summary/47637/best-practices---practice-guidelines'}]
https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930235526/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2016-09-30T23:55:26Z', 'uri': 'http://web.archive.org/web/20160930235526/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2017-10-03T04:22:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003042246/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2017-10-03T04:22:46Z', 'uri': 'http://web.archive.org/web/20171003042246/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2018-04-14T03:53:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414035318/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2018-04-14T03:53:18Z', 'uri': 'http://web.archive.org/web/20180414035318/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2018-05-19T10:46:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519104603/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2018-05-19T10:46:03Z', 'uri': 'http://web.archive.org/web/20180519104603/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}, {'datetime': '2018-06-10T03:51:24Z', 'uri': 'http://web.archive.org/web/20180610035124/https://www.guideline.gov/summaries/summary/47647/acr-appropriateness-criteria--asymptomatic-patient-at-risk-for-coronary-artery-disease'}]
https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235530/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2016-09-30T23:55:30Z', 'uri': 'http://web.archive.org/web/20160930235530/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2017-10-03T04:23:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003042314/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2017-10-03T04:23:14Z', 'uri': 'http://web.archive.org/web/20171003042314/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2018-04-14T03:53:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414035359/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2018-04-14T03:53:59Z', 'uri': 'http://web.archive.org/web/20180414035359/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2018-05-19T10:46:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519104640/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2018-05-19T10:46:40Z', 'uri': 'http://web.archive.org/web/20180519104640/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}, {'datetime': '2018-06-10T23:06:12Z', 'uri': 'http://web.archive.org/web/20180610230612/https://www.guideline.gov/summaries/summary/47648/acr-appropriateness-criteria--nonischemic-myocardial-disease-with-clinical-manifestations-ischemic-cardiomyopathy-already-excluded'}]
https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930235525/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2016-09-30T23:55:25Z', 'uri': 'http://web.archive.org/web/20160930235525/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2017-10-03T04:22:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003042239/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2017-10-03T04:22:39Z', 'uri': 'http://web.archive.org/web/20171003042239/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2018-04-14T03:53:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414035308/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2018-04-14T03:53:08Z', 'uri': 'http://web.archive.org/web/20180414035308/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2018-05-19T10:45:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519104553/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2018-05-19T10:45:53Z', 'uri': 'http://web.archive.org/web/20180519104553/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}, {'datetime': '2018-06-10T03:14:50Z', 'uri': 'http://web.archive.org/web/20180610031450/https://www.guideline.gov/summaries/summary/47649/acr-appropriateness-criteria--acute-pancreatitis'}]
https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930235527/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2016-09-30T23:55:27Z', 'uri': 'http://web.archive.org/web/20160930235527/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2017-10-03T04:22:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003042252/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2017-10-03T04:22:52Z', 'uri': 'http://web.archive.org/web/20171003042252/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2018-04-14T03:53:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414035329/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2018-04-14T03:53:29Z', 'uri': 'http://web.archive.org/web/20180414035329/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2018-05-19T10:46:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519104612/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2018-05-19T10:46:12Z', 'uri': 'http://web.archive.org/web/20180519104612/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}, {'datetime': '2018-06-10T22:39:19Z', 'uri': 'http://web.archive.org/web/20180610223919/https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening'}]
https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235528/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2016-09-30T23:55:28Z', 'uri': 'http://web.archive.org/web/20160930235528/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2017-10-03T04:22:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003042259/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2017-10-03T04:22:59Z', 'uri': 'http://web.archive.org/web/20171003042259/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2018-04-14T03:53:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414035338/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2018-04-14T03:53:38Z', 'uri': 'http://web.archive.org/web/20180414035338/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2018-05-19T10:46:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519104622/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2018-05-19T10:46:22Z', 'uri': 'http://web.archive.org/web/20180519104622/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}, {'datetime': '2018-06-09T20:18:53Z', 'uri': 'http://web.archive.org/web/20180609201853/https://www.guideline.gov/summaries/summary/47651/acr-appropriateness-criteria--dysphagia'}]
https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235532/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2016-09-30T23:55:32Z', 'uri': 'http://web.archive.org/web/20160930235532/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2017-10-03T04:23:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003042330/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2017-10-03T04:23:30Z', 'uri': 'http://web.archive.org/web/20171003042330/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2018-04-14T03:54:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414035447/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2018-04-14T03:54:47Z', 'uri': 'http://web.archive.org/web/20180414035447/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2018-05-19T10:47:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519104707/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2018-05-19T10:47:07Z', 'uri': 'http://web.archive.org/web/20180519104707/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}, {'datetime': '2018-06-10T01:23:26Z', 'uri': 'http://web.archive.org/web/20180610012326/https://www.guideline.gov/summaries/summary/47652/acr-appropriateness-criteria--right-lower-quadrant-pain---suspected-appendicitis'}]
https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235533/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2016-09-30T23:55:33Z', 'uri': 'http://web.archive.org/web/20160930235533/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2017-10-03T04:23:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003042338/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2017-10-03T04:23:38Z', 'uri': 'http://web.archive.org/web/20171003042338/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2018-04-14T03:54:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414035457/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2018-04-14T03:54:57Z', 'uri': 'http://web.archive.org/web/20180414035457/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2018-05-19T10:47:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519104717/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2018-05-19T10:47:17Z', 'uri': 'http://web.archive.org/web/20180519104717/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}, {'datetime': '2018-06-10T11:22:08Z', 'uri': 'http://web.archive.org/web/20180610112208/https://www.guideline.gov/summaries/summary/47653/acr-appropriateness-criteria--right-upper-quadrant-pain'}]
https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235534/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2016-09-30T23:55:34Z', 'uri': 'http://web.archive.org/web/20160930235534/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2017-10-03T04:23:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003042345/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2017-10-03T04:23:45Z', 'uri': 'http://web.archive.org/web/20171003042345/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2018-04-14T03:55:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414035507/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2018-04-14T03:55:07Z', 'uri': 'http://web.archive.org/web/20180414035507/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2018-05-19T10:47:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519104726/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2018-05-19T10:47:26Z', 'uri': 'http://web.archive.org/web/20180519104726/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}, {'datetime': '2018-06-10T11:22:26Z', 'uri': 'http://web.archive.org/web/20180610112226/https://www.guideline.gov/summaries/summary/47654/acr-appropriateness-criteria--suspected-smallbowel-obstruction'}]
https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235529/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2016-09-30T23:55:29Z', 'uri': 'http://web.archive.org/web/20160930235529/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2017-10-03T04:23:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003042306/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2017-10-03T04:23:06Z', 'uri': 'http://web.archive.org/web/20171003042306/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2018-04-14T03:53:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414035349/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2018-04-14T03:53:49Z', 'uri': 'http://web.archive.org/web/20180414035349/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2018-05-19T10:46:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519104631/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2018-05-19T10:46:31Z', 'uri': 'http://web.archive.org/web/20180519104631/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}, {'datetime': '2018-06-09T15:20:12Z', 'uri': 'http://web.archive.org/web/20180609152012/https://www.guideline.gov/summaries/summary/47655/acr-appropriateness-criteria--management-of-vertebral-compression-fractures'}]
https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930235531/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2016-09-30T23:55:31Z', 'uri': 'http://web.archive.org/web/20160930235531/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2017-10-03T04:23:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003042323/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2017-10-03T04:23:23Z', 'uri': 'http://web.archive.org/web/20171003042323/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2018-04-14T03:54:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414035410/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2018-04-14T03:54:10Z', 'uri': 'http://web.archive.org/web/20180414035410/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2018-05-19T10:46:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519104649/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2018-05-19T10:46:49Z', 'uri': 'http://web.archive.org/web/20180519104649/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}, {'datetime': '2018-06-10T22:28:08Z', 'uri': 'http://web.archive.org/web/20180610222808/https://www.guideline.gov/summaries/summary/47656/acr-appropriateness-criteria--radiologic-management-of-iliofemoral-venous-thrombosis'}]
https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235513/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2016-09-30T23:55:13Z', 'uri': 'http://web.archive.org/web/20160930235513/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2017-10-03T04:21:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003042126/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2017-10-03T04:21:26Z', 'uri': 'http://web.archive.org/web/20171003042126/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2018-04-14T03:51:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414035123/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2018-04-14T03:51:23Z', 'uri': 'http://web.archive.org/web/20180414035123/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2018-05-19T10:44:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519104418/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2018-05-19T10:44:18Z', 'uri': 'http://web.archive.org/web/20180519104418/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}, {'datetime': '2018-06-09T20:49:42Z', 'uri': 'http://web.archive.org/web/20180609204942/https://www.guideline.gov/summaries/summary/47657/acr-appropriateness-criteria--radiologic-management-of-urinary-tract-obstruction'}]
https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235507/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2016-09-30T23:55:07Z', 'uri': 'http://web.archive.org/web/20160930235507/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2017-10-03T04:21:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003042102/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2017-10-03T04:21:02Z', 'uri': 'http://web.archive.org/web/20171003042102/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2018-04-14T03:50:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414035047/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2018-04-14T03:50:47Z', 'uri': 'http://web.archive.org/web/20180414035047/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2018-05-19T10:43:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519104344/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2018-05-19T10:43:44Z', 'uri': 'http://web.archive.org/web/20180519104344/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}, {'datetime': '2018-06-10T21:59:58Z', 'uri': 'http://web.archive.org/web/20180610215958/https://www.guideline.gov/summaries/summary/47667/acr-appropriateness-criteria--acute-hand-and-wrist-trauma'}]
https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235510/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2016-09-30T23:55:10Z', 'uri': 'http://web.archive.org/web/20160930235510/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2017-10-03T04:21:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003042110/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2017-10-03T04:21:10Z', 'uri': 'http://web.archive.org/web/20171003042110/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2018-04-14T03:50:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414035058/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2018-04-14T03:50:58Z', 'uri': 'http://web.archive.org/web/20180414035058/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2018-05-19T10:43:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519104355/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2018-05-19T10:43:55Z', 'uri': 'http://web.archive.org/web/20180519104355/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}, {'datetime': '2018-06-09T15:22:08Z', 'uri': 'http://web.archive.org/web/20180609152208/https://www.guideline.gov/summaries/summary/47668/acr-appropriateness-criteria--acute-hip-pain-suspected-fracture'}]
https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235511/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2016-09-30T23:55:11Z', 'uri': 'http://web.archive.org/web/20160930235511/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2017-10-03T04:21:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003042116/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2017-10-03T04:21:16Z', 'uri': 'http://web.archive.org/web/20171003042116/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2018-04-14T03:51:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414035107/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2018-04-14T03:51:07Z', 'uri': 'http://web.archive.org/web/20180414035107/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2018-05-19T10:44:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519104405/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2018-05-19T10:44:05Z', 'uri': 'http://web.archive.org/web/20180519104405/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}, {'datetime': '2018-06-09T19:25:41Z', 'uri': 'http://web.archive.org/web/20180609192541/https://www.guideline.gov/summaries/summary/47669/acr-appropriateness-criteria--chronic-foot-pain'}]
https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930235512/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2016-09-30T23:55:12Z', 'uri': 'http://web.archive.org/web/20160930235512/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2017-10-03T04:21:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003042123/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2017-10-03T04:21:23Z', 'uri': 'http://web.archive.org/web/20171003042123/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2018-04-14T03:51:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414035118/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2018-04-14T03:51:18Z', 'uri': 'http://web.archive.org/web/20180414035118/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2018-05-19T10:44:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519104415/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2018-05-19T10:44:15Z', 'uri': 'http://web.archive.org/web/20180519104415/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}, {'datetime': '2018-06-10T15:50:25Z', 'uri': 'http://web.archive.org/web/20180610155025/https://www.guideline.gov/summaries/summary/47670/acr-appropriateness-criteria--chronic-neck-pain'}]
https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930235459/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2016-09-30T23:54:59Z', 'uri': 'http://web.archive.org/web/20160930235459/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2017-10-03T04:20:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003042013/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2017-10-03T04:20:13Z', 'uri': 'http://web.archive.org/web/20171003042013/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2018-04-14T03:50:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414035012/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2018-04-14T03:50:12Z', 'uri': 'http://web.archive.org/web/20180414035012/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2018-05-19T10:43:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519104312/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2018-05-19T10:43:12Z', 'uri': 'http://web.archive.org/web/20180519104312/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}, {'datetime': '2018-06-10T23:02:47Z', 'uri': 'http://web.archive.org/web/20180610230247/https://www.guideline.gov/summaries/summary/47672/acr-appropriateness-criteria--primary-bone-tumors'}]
https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235455/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2016-09-30T23:54:55Z', 'uri': 'http://web.archive.org/web/20160930235455/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2017-10-03T04:19:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003041941/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2017-10-03T04:19:41Z', 'uri': 'http://web.archive.org/web/20171003041941/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2018-04-14T03:49:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414034923/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2018-04-14T03:49:23Z', 'uri': 'http://web.archive.org/web/20180414034923/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2018-05-19T10:42:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519104229/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2018-05-19T10:42:29Z', 'uri': 'http://web.archive.org/web/20180519104229/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}, {'datetime': '2018-06-10T17:02:47Z', 'uri': 'http://web.archive.org/web/20180610170247/https://www.guideline.gov/summaries/summary/47673/acr-appropriateness-criteria--headache'}]
https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235456/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2016-09-30T23:54:56Z', 'uri': 'http://web.archive.org/web/20160930235456/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2017-10-03T04:19:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003041951/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2017-10-03T04:19:51Z', 'uri': 'http://web.archive.org/web/20171003041951/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2018-04-14T03:49:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414034940/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2018-04-14T03:49:40Z', 'uri': 'http://web.archive.org/web/20180414034940/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2018-05-19T10:42:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519104241/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2018-05-19T10:42:41Z', 'uri': 'http://web.archive.org/web/20180519104241/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}, {'datetime': '2018-06-10T23:02:54Z', 'uri': 'http://web.archive.org/web/20180610230254/https://www.guideline.gov/summaries/summary/47674/acr-appropriateness-criteria--hearing-loss-andor-vertigo'}]
https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235454/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2016-09-30T23:54:54Z', 'uri': 'http://web.archive.org/web/20160930235454/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2017-10-03T04:19:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003041935/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2017-10-03T04:19:35Z', 'uri': 'http://web.archive.org/web/20171003041935/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2018-04-14T03:49:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414034914/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2018-04-14T03:49:14Z', 'uri': 'http://web.archive.org/web/20180414034914/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2018-05-19T10:42:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519104221/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2018-05-19T10:42:21Z', 'uri': 'http://web.archive.org/web/20180519104221/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}, {'datetime': '2018-06-10T16:13:15Z', 'uri': 'http://web.archive.org/web/20180610161315/https://www.guideline.gov/summaries/summary/47675/acr-appropriateness-criteria--developmental-dysplasia-of-the-hip---child'}]
https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235452/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2016-09-30T23:54:52Z', 'uri': 'http://web.archive.org/web/20160930235452/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2017-10-03T04:19:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003041922/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2017-10-03T04:19:22Z', 'uri': 'http://web.archive.org/web/20171003041922/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2018-04-14T03:48:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414034855/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2018-04-14T03:48:55Z', 'uri': 'http://web.archive.org/web/20180414034855/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2018-05-19T10:41:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519104145/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2018-05-19T10:41:45Z', 'uri': 'http://web.archive.org/web/20180519104145/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}, {'datetime': '2018-06-11T03:34:41Z', 'uri': 'http://web.archive.org/web/20180611033441/https://www.guideline.gov/summaries/summary/47676/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompetent-patients'}]
https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235453/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2016-09-30T23:54:53Z', 'uri': 'http://web.archive.org/web/20160930235453/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2017-10-03T04:19:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003041928/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2017-10-03T04:19:28Z', 'uri': 'http://web.archive.org/web/20171003041928/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2018-04-14T03:49:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414034905/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2018-04-14T03:49:05Z', 'uri': 'http://web.archive.org/web/20180414034905/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2018-05-19T10:42:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519104211/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2018-05-19T10:42:11Z', 'uri': 'http://web.archive.org/web/20180519104211/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}, {'datetime': '2018-06-10T02:16:28Z', 'uri': 'http://web.archive.org/web/20180610021628/https://www.guideline.gov/summaries/summary/47677/acr-appropriateness-criteria--blunt-chest-trauma'}]
https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235457/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2016-09-30T23:54:57Z', 'uri': 'http://web.archive.org/web/20160930235457/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2017-10-03T04:19:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003041959/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2017-10-03T04:19:59Z', 'uri': 'http://web.archive.org/web/20171003041959/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2018-04-14T03:49:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414034951/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2018-04-14T03:49:51Z', 'uri': 'http://web.archive.org/web/20180414034951/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2018-05-19T10:42:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519104251/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2018-05-19T10:42:51Z', 'uri': 'http://web.archive.org/web/20180519104251/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}, {'datetime': '2018-06-09T21:30:59Z', 'uri': 'http://web.archive.org/web/20180609213059/https://www.guideline.gov/summaries/summary/47678/acr-appropriateness-criteria--noninvasive-clinical-staging-of-bronchogenic-carcinoma'}]
https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235501/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2016-09-30T23:55:01Z', 'uri': 'http://web.archive.org/web/20160930235501/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2017-10-03T04:20:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003042023/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2017-10-03T04:20:23Z', 'uri': 'http://web.archive.org/web/20171003042023/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2018-04-14T03:50:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414035027/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2018-04-14T03:50:27Z', 'uri': 'http://web.archive.org/web/20180414035027/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2018-05-19T10:43:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519104325/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2018-05-19T10:43:25Z', 'uri': 'http://web.archive.org/web/20180519104325/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}, {'datetime': '2018-06-10T23:03:44Z', 'uri': 'http://web.archive.org/web/20180610230344/https://www.guideline.gov/summaries/summary/47679/acr-appropriateness-criteria--screening-for-pulmonary-metastases'}]
https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:54:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930235458/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2016-09-30T23:54:58Z', 'uri': 'http://web.archive.org/web/20160930235458/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2017-07-14T11:21:28Z', 'uri': 'http://web.archive.org/web/20170714112128/https://guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2017-10-03T04:20:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003042006/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2017-10-03T04:20:06Z', 'uri': 'http://web.archive.org/web/20171003042006/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2018-04-14T03:50:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414035001/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2018-04-14T03:50:01Z', 'uri': 'http://web.archive.org/web/20180414035001/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2018-05-19T10:43:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519104303/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2018-05-19T10:43:03Z', 'uri': 'http://web.archive.org/web/20180519104303/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}, {'datetime': '2018-06-09T11:04:27Z', 'uri': 'http://web.archive.org/web/20180609110427/https://www.guideline.gov/summaries/summary/47680/acr-appropriateness-criteria--posttreatment-followup-of-renal-cell-carcinoma'}]
https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235500/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2016-09-30T23:55:00Z', 'uri': 'http://web.archive.org/web/20160930235500/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2017-10-03T04:20:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003042015/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2017-10-03T04:20:15Z', 'uri': 'http://web.archive.org/web/20171003042015/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2018-04-14T03:50:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414035016/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2018-04-14T03:50:16Z', 'uri': 'http://web.archive.org/web/20180414035016/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2018-05-19T10:43:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519104315/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2018-05-19T10:43:15Z', 'uri': 'http://web.archive.org/web/20180519104315/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}, {'datetime': '2018-06-09T19:38:36Z', 'uri': 'http://web.archive.org/web/20180609193836/https://www.guideline.gov/summaries/summary/47681/acr-appropriateness-criteria--renal-failure'}]
https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235447/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2016-09-30T23:54:47Z', 'uri': 'http://web.archive.org/web/20160930235447/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2017-10-03T04:18:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003041854/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2017-10-03T04:18:54Z', 'uri': 'http://web.archive.org/web/20171003041854/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2018-04-14T03:48:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414034808/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2018-04-14T03:48:08Z', 'uri': 'http://web.archive.org/web/20180414034808/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2018-05-19T10:41:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519104105/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2018-05-19T10:41:05Z', 'uri': 'http://web.archive.org/web/20180519104105/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}, {'datetime': '2018-06-10T22:06:31Z', 'uri': 'http://web.archive.org/web/20180610220631/https://www.guideline.gov/summaries/summary/47682/acr-appropriateness-criteria--suspected-lower-urinary-tract-trauma'}]
https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235444/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2016-09-30T23:54:44Z', 'uri': 'http://web.archive.org/web/20160930235444/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2017-10-03T04:18:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003041833/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2017-10-03T04:18:33Z', 'uri': 'http://web.archive.org/web/20171003041833/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2018-04-14T03:47:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414034738/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2018-04-14T03:47:38Z', 'uri': 'http://web.archive.org/web/20180414034738/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2018-05-19T10:40:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519104037/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2018-05-19T10:40:37Z', 'uri': 'http://web.archive.org/web/20180519104037/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}, {'datetime': '2018-06-09T11:03:55Z', 'uri': 'http://web.archive.org/web/20180609110355/https://www.guideline.gov/summaries/summary/47683/acr-appropriateness-criteria--followup-of-lowerextremity-arterial-bypass-surgery'}]
https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235446/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2016-09-30T23:54:46Z', 'uri': 'http://web.archive.org/web/20160930235446/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2017-10-03T04:18:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003041847/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2017-10-03T04:18:47Z', 'uri': 'http://web.archive.org/web/20171003041847/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2018-04-14T03:47:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414034758/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2018-04-14T03:47:58Z', 'uri': 'http://web.archive.org/web/20180414034758/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2018-05-19T10:40:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519104056/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2018-05-19T10:40:56Z', 'uri': 'http://web.archive.org/web/20180519104056/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}, {'datetime': '2018-06-10T23:06:39Z', 'uri': 'http://web.archive.org/web/20180610230639/https://www.guideline.gov/summaries/summary/47685/acr-appropriateness-criteria--nontraumatic-aortic-disease'}]
https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235448/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2016-09-30T23:54:48Z', 'uri': 'http://web.archive.org/web/20160930235448/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2017-10-03T04:19:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003041901/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2017-10-03T04:19:01Z', 'uri': 'http://web.archive.org/web/20171003041901/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2018-04-14T03:48:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414034819/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2018-04-14T03:48:19Z', 'uri': 'http://web.archive.org/web/20180414034819/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2018-05-19T10:41:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519104114/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2018-05-19T10:41:14Z', 'uri': 'http://web.archive.org/web/20180519104114/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}, {'datetime': '2018-06-10T19:13:33Z', 'uri': 'http://web.archive.org/web/20180610191333/https://www.guideline.gov/summaries/summary/47686/acr-appropriateness-criteria--suspected-lowerextremity-deep-vein-thrombosis'}]
https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235441/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2016-09-30T23:54:41Z', 'uri': 'http://web.archive.org/web/20160930235441/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2017-10-03T04:18:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003041809/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2017-10-03T04:18:09Z', 'uri': 'http://web.archive.org/web/20171003041809/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2018-04-14T03:47:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414034704/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2018-04-14T03:47:04Z', 'uri': 'http://web.archive.org/web/20180414034704/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2018-05-19T10:40:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519104008/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2018-05-19T10:40:08Z', 'uri': 'http://web.archive.org/web/20180519104008/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}, {'datetime': '2018-06-10T02:14:36Z', 'uri': 'http://web.archive.org/web/20180610021436/https://www.guideline.gov/summaries/summary/47687/acr-appropriateness-criteria--pretreatment-evaluation-and-followup-of-endometrial-cancer'}]
https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235442/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2016-09-30T23:54:42Z', 'uri': 'http://web.archive.org/web/20160930235442/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2017-10-03T04:18:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003041817/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2017-10-03T04:18:17Z', 'uri': 'http://web.archive.org/web/20171003041817/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2018-04-14T03:47:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414034715/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2018-04-14T03:47:15Z', 'uri': 'http://web.archive.org/web/20180414034715/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2018-05-19T10:40:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519104018/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2018-05-19T10:40:18Z', 'uri': 'http://web.archive.org/web/20180519104018/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}, {'datetime': '2018-06-11T06:01:47Z', 'uri': 'http://web.archive.org/web/20180611060147/https://www.guideline.gov/summaries/summary/47688/acr-appropriateness-criteria--second-and-third-trimester-bleeding'}]
https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235439/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2016-09-30T23:54:39Z', 'uri': 'http://web.archive.org/web/20160930235439/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2017-10-03T04:17:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003041754/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2017-10-03T04:17:54Z', 'uri': 'http://web.archive.org/web/20171003041754/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2018-04-14T03:46:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414034643/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2018-04-14T03:46:43Z', 'uri': 'http://web.archive.org/web/20180414034643/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2018-05-19T10:39:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519103950/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2018-05-19T10:39:50Z', 'uri': 'http://web.archive.org/web/20180519103950/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}, {'datetime': '2018-06-09T20:49:51Z', 'uri': 'http://web.archive.org/web/20180609204951/https://www.guideline.gov/summaries/summary/47689/acr-appropriateness-criteria--localregional-recurrence-lrr-and-salvage-surgery-breast-cancer'}]
https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235433/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2016-09-30T23:54:33Z', 'uri': 'http://web.archive.org/web/20160930235433/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2017-10-03T04:17:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003041712/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2017-10-03T04:17:12Z', 'uri': 'http://web.archive.org/web/20171003041712/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2018-04-14T03:45:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414034538/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2018-04-14T03:45:38Z', 'uri': 'http://web.archive.org/web/20180414034538/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2018-05-19T10:38:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519103853/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2018-05-19T10:38:53Z', 'uri': 'http://web.archive.org/web/20180519103853/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}, {'datetime': '2018-06-09T19:17:16Z', 'uri': 'http://web.archive.org/web/20180609191716/https://www.guideline.gov/summaries/summary/47690/acr-appropriateness-criteria--anal-cancer'}]
https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235440/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2016-09-30T23:54:40Z', 'uri': 'http://web.archive.org/web/20160930235440/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2017-10-03T04:18:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003041801/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2017-10-03T04:18:01Z', 'uri': 'http://web.archive.org/web/20171003041801/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2018-04-14T03:46:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414034654/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2018-04-14T03:46:54Z', 'uri': 'http://web.archive.org/web/20180414034654/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2018-05-19T10:39:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519103959/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2018-05-19T10:39:59Z', 'uri': 'http://web.archive.org/web/20180519103959/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}, {'datetime': '2018-06-10T23:43:23Z', 'uri': 'http://web.archive.org/web/20180610234323/https://www.guideline.gov/summaries/summary/47691/acr-appropriateness-criteria--management-of-vaginal-cancer'}]
https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235443/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2016-09-30T23:54:43Z', 'uri': 'http://web.archive.org/web/20160930235443/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2017-10-03T04:18:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003041825/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2017-10-03T04:18:25Z', 'uri': 'http://web.archive.org/web/20171003041825/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2018-04-14T03:47:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414034726/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2018-04-14T03:47:26Z', 'uri': 'http://web.archive.org/web/20180414034726/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2018-05-19T10:40:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519104027/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2018-05-19T10:40:27Z', 'uri': 'http://web.archive.org/web/20180519104027/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}, {'datetime': '2018-06-10T11:22:28Z', 'uri': 'http://web.archive.org/web/20180610112228/https://www.guideline.gov/summaries/summary/47692/acr-appropriateness-criteria--thyroid-carcinoma'}]
https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235435/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2016-09-30T23:54:35Z', 'uri': 'http://web.archive.org/web/20160930235435/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2017-10-03T04:17:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003041727/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2017-10-03T04:17:27Z', 'uri': 'http://web.archive.org/web/20171003041727/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2018-04-14T03:46:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414034601/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2018-04-14T03:46:01Z', 'uri': 'http://web.archive.org/web/20180414034601/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2018-05-19T10:39:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519103913/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2018-05-19T10:39:13Z', 'uri': 'http://web.archive.org/web/20180519103913/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}, {'datetime': '2018-06-10T23:03:43Z', 'uri': 'http://web.archive.org/web/20180610230343/https://www.guideline.gov/summaries/summary/47693/acr-appropriateness-criteria--earlystage-non-smallcell-lung-cancer'}]
https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235437/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2016-09-30T23:54:37Z', 'uri': 'http://web.archive.org/web/20160930235437/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2017-10-03T04:17:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003041740/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2017-10-03T04:17:40Z', 'uri': 'http://web.archive.org/web/20171003041740/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2018-04-14T03:46:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414034622/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2018-04-14T03:46:22Z', 'uri': 'http://web.archive.org/web/20180414034622/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2018-05-19T10:39:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519103931/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2018-05-19T10:39:31Z', 'uri': 'http://web.archive.org/web/20180519103931/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}, {'datetime': '2018-06-09T20:18:47Z', 'uri': 'http://web.archive.org/web/20180609201847/https://www.guideline.gov/summaries/summary/47694/acr-appropriateness-criteria--induction-and-adjuvant-therapy-for-n2-non-smallcell-lung-cancer'}]
https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235438/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2016-09-30T23:54:38Z', 'uri': 'http://web.archive.org/web/20160930235438/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2017-10-03T04:17:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003041747/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2017-10-03T04:17:47Z', 'uri': 'http://web.archive.org/web/20171003041747/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2018-04-14T03:46:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414034633/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2018-04-14T03:46:33Z', 'uri': 'http://web.archive.org/web/20180414034633/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2018-05-19T10:39:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519103941/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2018-05-19T10:39:41Z', 'uri': 'http://web.archive.org/web/20180519103941/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}, {'datetime': '2018-06-10T12:36:54Z', 'uri': 'http://web.archive.org/web/20180610123654/https://www.guideline.gov/summaries/summary/47695/acr-appropriateness-criteria--localized-nodal-indolent-lymphoma'}]
https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235434/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2016-09-30T23:54:34Z', 'uri': 'http://web.archive.org/web/20160930235434/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2017-10-03T04:17:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003041720/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2017-10-03T04:17:20Z', 'uri': 'http://web.archive.org/web/20171003041720/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2018-04-14T03:45:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414034550/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2018-04-14T03:45:50Z', 'uri': 'http://web.archive.org/web/20180414034550/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2018-05-19T10:39:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519103903/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2018-05-19T10:39:03Z', 'uri': 'http://web.archive.org/web/20180519103903/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}, {'datetime': '2018-06-11T00:48:18Z', 'uri': 'http://web.archive.org/web/20180611004818/https://www.guideline.gov/summaries/summary/47696/acr-appropriateness-criteria--definitive-externalbeam-irradiation-in-stage-t1-and-t2-prostate-cancer'}]
https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235436/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2016-09-30T23:54:36Z', 'uri': 'http://web.archive.org/web/20160930235436/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2017-10-03T04:17:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003041734/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2017-10-03T04:17:34Z', 'uri': 'http://web.archive.org/web/20171003041734/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2018-04-14T03:46:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414034613/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2018-04-14T03:46:13Z', 'uri': 'http://web.archive.org/web/20180414034613/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2018-05-19T10:39:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519103922/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2018-05-19T10:39:22Z', 'uri': 'http://web.archive.org/web/20180519103922/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}, {'datetime': '2018-06-10T12:44:05Z', 'uri': 'http://web.archive.org/web/20180610124405/https://www.guideline.gov/summaries/summary/47697/acr-appropriateness-criteria--highdoserate-brachytherapy-for-prostate-cancer'}]
https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235328/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2016-09-30T23:53:28Z', 'uri': 'http://web.archive.org/web/20160930235328/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2017-10-03T04:11:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003041115/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2017-10-03T04:11:15Z', 'uri': 'http://web.archive.org/web/20171003041115/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2018-04-14T03:38:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414033815/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2018-04-14T03:38:15Z', 'uri': 'http://web.archive.org/web/20180414033815/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2018-05-19T10:31:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519103128/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2018-05-19T10:31:28Z', 'uri': 'http://web.archive.org/web/20180519103128/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}, {'datetime': '2018-06-09T18:42:09Z', 'uri': 'http://web.archive.org/web/20180609184209/https://www.guideline.gov/summaries/summary/47699/kdigo-clinical-practice-guideline-for-lipid-management-in-chronic-kidney-disease'}]
https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235402/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2016-09-30T23:54:02Z', 'uri': 'http://web.archive.org/web/20160930235402/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2017-10-03T04:14:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003041453/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2017-10-03T04:14:53Z', 'uri': 'http://web.archive.org/web/20171003041453/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2018-04-14T03:42:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414034252/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2018-04-14T03:42:52Z', 'uri': 'http://web.archive.org/web/20180414034252/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2018-05-19T10:35:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519103558/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2018-05-19T10:35:58Z', 'uri': 'http://web.archive.org/web/20180519103558/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}, {'datetime': '2018-06-09T11:44:24Z', 'uri': 'http://web.archive.org/web/20180609114424/https://www.guideline.gov/summaries/summary/47700/mi--secondary-prevention-secondary-prevention-in-primary-and-secondary-care-for-patients-following-a-myocardial-infarction'}]
https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:54:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235403/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2016-09-30T23:54:03Z', 'uri': 'http://web.archive.org/web/20160930235403/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2017-02-03T11:12:26Z', 'uri': 'http://web.archive.org/web/20170203111226/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2017-10-03T04:14:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003041456/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2017-10-03T04:14:56Z', 'uri': 'http://web.archive.org/web/20171003041456/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2018-04-14T03:42:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414034256/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2018-04-14T03:42:56Z', 'uri': 'http://web.archive.org/web/20180414034256/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2018-05-19T10:36:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519103601/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2018-05-19T10:36:01Z', 'uri': 'http://web.archive.org/web/20180519103601/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}, {'datetime': '2018-06-09T12:10:14Z', 'uri': 'http://web.archive.org/web/20180609121014/https://www.guideline.gov/summaries/summary/47701/neuropathic-pain--pharmacological-management-the-pharmacological-management-of-neuropathic-pain-in-adults-in-nonspecialist-settings'}]
https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930235524/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:55:24Z', 'uri': 'http://web.archive.org/web/20160930235524/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:22:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003042232/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:22:32Z', 'uri': 'http://web.archive.org/web/20171003042232/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:52:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414035258/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:52:58Z', 'uri': 'http://web.archive.org/web/20180414035258/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:45:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519104544/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:45:44Z', 'uri': 'http://web.archive.org/web/20180519104544/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}, {'datetime': '2018-06-09T12:12:13Z', 'uri': 'http://web.archive.org/web/20180609121213/https://www.guideline.gov/summaries/summary/47707/management-of-chronic-pain-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235543/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2016-09-30T23:55:43Z', 'uri': 'http://web.archive.org/web/20160930235543/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2017-10-03T04:24:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003042440/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2017-10-03T04:24:40Z', 'uri': 'http://web.archive.org/web/20171003042440/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2018-04-14T03:56:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414035629/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2018-04-14T03:56:29Z', 'uri': 'http://web.archive.org/web/20180414035629/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2018-05-19T10:48:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519104843/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2018-05-19T10:48:43Z', 'uri': 'http://web.archive.org/web/20180519104843/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}, {'datetime': '2018-06-10T22:46:10Z', 'uri': 'http://web.archive.org/web/20180610224610/https://www.guideline.gov/summaries/summary/47708/bosutinib-for-previously-treated-chronic-myeloid-leukaemia'}]
https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235540/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2016-09-30T23:55:40Z', 'uri': 'http://web.archive.org/web/20160930235540/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2017-10-03T04:24:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003042418/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2017-10-03T04:24:18Z', 'uri': 'http://web.archive.org/web/20171003042418/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2018-04-14T03:55:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414035557/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2018-04-14T03:55:57Z', 'uri': 'http://web.archive.org/web/20180414035557/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2018-05-19T10:48:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519104811/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2018-05-19T10:48:11Z', 'uri': 'http://web.archive.org/web/20180519104811/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}, {'datetime': '2018-06-10T08:12:37Z', 'uri': 'http://web.archive.org/web/20180610081237/https://www.guideline.gov/summaries/summary/47709/1-peginterferon-alfa-and-ribavirin-for-the-treatment-of-mild-chronic-hepatitis-c-2-peginterferon-alfa-and-ribavirin-for-the-treatment-of-chronic-hepatitis-c-2010-addendum-3-peginterferon-alfa-and-ribavirin-for-treating-chronic-hepatitis-c-in-children-and-young'}]
https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235544/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2016-09-30T23:55:44Z', 'uri': 'http://web.archive.org/web/20160930235544/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2017-10-03T04:24:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003042446/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2017-10-03T04:24:46Z', 'uri': 'http://web.archive.org/web/20171003042446/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2018-04-14T03:56:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414035638/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2018-04-14T03:56:38Z', 'uri': 'http://web.archive.org/web/20180414035638/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2018-05-19T10:48:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519104851/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2018-05-19T10:48:51Z', 'uri': 'http://web.archive.org/web/20180519104851/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}, {'datetime': '2018-06-10T01:07:04Z', 'uri': 'http://web.archive.org/web/20180610010704/https://www.guideline.gov/summaries/summary/47710/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia'}]
https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235415/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:54:15Z', 'uri': 'http://web.archive.org/web/20160930235415/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:16:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003041602/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:16:02Z', 'uri': 'http://web.archive.org/web/20171003041602/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:44:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414034411/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:44:11Z', 'uri': 'http://web.archive.org/web/20180414034411/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:37:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519103724/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:37:24Z', 'uri': 'http://web.archive.org/web/20180519103724/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T21:28:35Z', 'uri': 'http://web.archive.org/web/20180609212835/https://www.guideline.gov/summaries/summary/47749/risk-assessment-genetic-counseling-and-genetic-testing-for-brcarelated-cancer-in-women-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235420/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:54:20Z', 'uri': 'http://web.archive.org/web/20160930235420/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:16:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003041610/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:16:10Z', 'uri': 'http://web.archive.org/web/20171003041610/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:44:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414034421/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:44:21Z', 'uri': 'http://web.archive.org/web/20180414034421/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:37:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519103733/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:37:33Z', 'uri': 'http://web.archive.org/web/20180519103733/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T02:39:22Z', 'uri': 'http://web.archive.org/web/20180610023922/https://www.guideline.gov/summaries/summary/47750/screening-for-lung-cancer-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235521/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2016-09-30T23:55:21Z', 'uri': 'http://web.archive.org/web/20160930235521/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2017-10-03T04:22:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003042214/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2017-10-03T04:22:14Z', 'uri': 'http://web.archive.org/web/20171003042214/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2018-04-14T03:52:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414035241/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2018-04-14T03:52:41Z', 'uri': 'http://web.archive.org/web/20180414035241/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2018-05-19T10:45:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519104529/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2018-05-19T10:45:29Z', 'uri': 'http://web.archive.org/web/20180519104529/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}, {'datetime': '2018-06-09T23:13:28Z', 'uri': 'http://web.archive.org/web/20180609231328/https://www.guideline.gov/summaries/summary/47751/management-of-menopausal-symptoms'}]
https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235401/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2016-09-30T23:54:01Z', 'uri': 'http://web.archive.org/web/20160930235401/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2017-10-03T04:14:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003041451/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2017-10-03T04:14:51Z', 'uri': 'http://web.archive.org/web/20171003041451/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2018-04-14T03:42:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414034248/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2018-04-14T03:42:48Z', 'uri': 'http://web.archive.org/web/20180414034248/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2018-05-19T10:35:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519103554/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2018-05-19T10:35:54Z', 'uri': 'http://web.archive.org/web/20180519103554/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}, {'datetime': '2018-06-09T15:45:26Z', 'uri': 'http://web.archive.org/web/20180609154526/https://www.guideline.gov/summaries/summary/47754/intravenous-fluid-therapy-in-adults-in-hospital'}]
https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:54:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235428/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2016-09-30T23:54:28Z', 'uri': 'http://web.archive.org/web/20160930235428/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2017-10-03T04:16:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003041646/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2017-10-03T04:16:46Z', 'uri': 'http://web.archive.org/web/20171003041646/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2017-11-17T10:19:59Z', 'uri': 'http://web.archive.org/web/20171117101959/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2018-04-14T03:44:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414034459/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2018-04-14T03:44:59Z', 'uri': 'http://web.archive.org/web/20180414034459/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2018-05-19T10:38:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519103815/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2018-05-19T10:38:15Z', 'uri': 'http://web.archive.org/web/20180519103815/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}, {'datetime': '2018-06-10T00:23:19Z', 'uri': 'http://web.archive.org/web/20180610002319/https://www.guideline.gov/summaries/summary/47755/healthpartners-dental-group-and-clinics-caries-guideline'}]
https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930235424/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2016-09-30T23:54:24Z', 'uri': 'http://web.archive.org/web/20160930235424/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2017-10-03T04:16:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003041628/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2017-10-03T04:16:28Z', 'uri': 'http://web.archive.org/web/20171003041628/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2018-04-14T03:44:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414034446/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2018-04-14T03:44:46Z', 'uri': 'http://web.archive.org/web/20180414034446/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2018-05-19T10:38:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519103800/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2018-05-19T10:38:00Z', 'uri': 'http://web.archive.org/web/20180519103800/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}, {'datetime': '2018-06-09T19:16:41Z', 'uri': 'http://web.archive.org/web/20180609191641/https://www.guideline.gov/summaries/summary/47756/practice-parameters-for-the-surgical-treatment-of-ulcerative-colitis'}]
https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930235409/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:54:09Z', 'uri': 'http://web.archive.org/web/20160930235409/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:15:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003041526/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:15:26Z', 'uri': 'http://web.archive.org/web/20171003041526/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:43:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414034321/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:43:21Z', 'uri': 'http://web.archive.org/web/20180414034321/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:36:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519103623/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:36:23Z', 'uri': 'http://web.archive.org/web/20180519103623/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T22:17:43Z', 'uri': 'http://web.archive.org/web/20180610221743/https://www.guideline.gov/summaries/summary/47757/screening-for-gestational-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235203/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2016-09-30T23:52:03Z', 'uri': 'http://web.archive.org/web/20160930235203/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2017-10-03T03:59:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003035935/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2017-10-03T03:59:35Z', 'uri': 'http://web.archive.org/web/20171003035935/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2018-04-14T03:28:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414032837/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2018-04-14T03:28:37Z', 'uri': 'http://web.archive.org/web/20180414032837/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2018-05-19T10:21:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519102130/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2018-05-19T10:21:30Z', 'uri': 'http://web.archive.org/web/20180519102130/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}, {'datetime': '2018-06-09T11:58:10Z', 'uri': 'http://web.archive.org/web/20180609115810/https://www.guideline.gov/summaries/summary/47758/british-hiv-association-guidelines-for-the-management-of-hepatitis-viruses-in-adults-infected-with-hiv-2013'}]
https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930235345/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:53:45Z', 'uri': 'http://web.archive.org/web/20160930235345/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:13:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003041317/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:13:17Z', 'uri': 'http://web.archive.org/web/20171003041317/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T03:40:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414034041/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T03:40:41Z', 'uri': 'http://web.archive.org/web/20180414034041/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:33:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519103355/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:33:55Z', 'uri': 'http://web.archive.org/web/20180519103355/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T12:20:49Z', 'uri': 'http://web.archive.org/web/20180609122049/https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235356/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2016-09-30T23:53:56Z', 'uri': 'http://web.archive.org/web/20160930235356/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2017-10-03T04:14:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003041423/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2017-10-03T04:14:23Z', 'uri': 'http://web.archive.org/web/20171003041423/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2018-04-14T03:42:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414034225/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2018-04-14T03:42:25Z', 'uri': 'http://web.archive.org/web/20180414034225/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2018-05-19T10:35:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519103530/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2018-05-19T10:35:30Z', 'uri': 'http://web.archive.org/web/20180519103530/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}, {'datetime': '2018-06-09T19:21:16Z', 'uri': 'http://web.archive.org/web/20180609192116/https://www.guideline.gov/summaries/summary/47760/female-genital-cosmetic-surgery'}]
https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235355/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2016-09-30T23:53:55Z', 'uri': 'http://web.archive.org/web/20160930235355/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2017-10-03T04:14:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003041417/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2017-10-03T04:14:17Z', 'uri': 'http://web.archive.org/web/20171003041417/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2018-04-14T03:42:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414034217/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2018-04-14T03:42:17Z', 'uri': 'http://web.archive.org/web/20180414034217/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2018-05-19T10:35:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519103522/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2018-05-19T10:35:22Z', 'uri': 'http://web.archive.org/web/20180519103522/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}, {'datetime': '2018-06-09T22:21:44Z', 'uri': 'http://web.archive.org/web/20180609222144/https://www.guideline.gov/summaries/summary/47761/cervical-insufficiency-and-cervical-cerclage'}]
https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235344/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2016-09-30T23:53:44Z', 'uri': 'http://web.archive.org/web/20160930235344/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2017-10-03T04:13:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003041309/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2017-10-03T04:13:09Z', 'uri': 'http://web.archive.org/web/20171003041309/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2018-04-14T03:40:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414034031/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2018-04-14T03:40:31Z', 'uri': 'http://web.archive.org/web/20180414034031/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2018-05-19T10:33:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519103346/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2018-05-19T10:33:46Z', 'uri': 'http://web.archive.org/web/20180519103346/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}, {'datetime': '2018-06-09T22:25:56Z', 'uri': 'http://web.archive.org/web/20180609222556/https://www.guideline.gov/summaries/summary/47762/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-1-diagnosis-and-assessment-of-atopic-dermatitis'}]
https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235340/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2016-09-30T23:53:40Z', 'uri': 'http://web.archive.org/web/20160930235340/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2017-10-03T04:12:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003041231/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2017-10-03T04:12:31Z', 'uri': 'http://web.archive.org/web/20171003041231/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2018-04-14T03:40:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414034005/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2018-04-14T03:40:05Z', 'uri': 'http://web.archive.org/web/20180414034005/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2018-05-19T10:33:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519103324/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2018-05-19T10:33:24Z', 'uri': 'http://web.archive.org/web/20180519103324/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}, {'datetime': '2018-06-09T11:19:12Z', 'uri': 'http://web.archive.org/web/20180609111912/https://www.guideline.gov/summaries/summary/47763/head-injury-triage-assessment-investigation-and-early-management-of-head-injury-in-children-young-people-and-adults'}]
https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235341/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2016-09-30T23:53:41Z', 'uri': 'http://web.archive.org/web/20160930235341/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2017-10-03T04:12:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003041222/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2017-10-03T04:12:22Z', 'uri': 'http://web.archive.org/web/20171003041222/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2018-04-14T03:39:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414033952/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2018-04-14T03:39:52Z', 'uri': 'http://web.archive.org/web/20180414033952/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2018-05-19T10:33:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519103313/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2018-05-19T10:33:13Z', 'uri': 'http://web.archive.org/web/20180519103313/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}, {'datetime': '2018-06-09T11:55:52Z', 'uri': 'http://web.archive.org/web/20180609115552/https://www.guideline.gov/summaries/summary/47764/prostate-cancer-diagnosis-and-treatment'}]
https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:53:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235354/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2016-09-30T23:53:54Z', 'uri': 'http://web.archive.org/web/20160930235354/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2017-10-03T04:14:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003041409/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2017-10-03T04:14:09Z', 'uri': 'http://web.archive.org/web/20171003041409/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-04-14T03:42:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414034205/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-04-14T03:42:05Z', 'uri': 'http://web.archive.org/web/20180414034205/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-05-19T10:35:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519103513/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-05-19T10:35:13Z', 'uri': 'http://web.archive.org/web/20180519103513/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-06-09T10:33:13Z', 'uri': 'http://web.archive.org/web/20180609103313/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-07-12T21:41:06Z', 'uri': 'http://web.archive.org/web/20180712214106/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}, {'datetime': '2018-07-12T21:41:06Z', 'uri': 'http://web.archive.org/web/20180712214106/https://www.guideline.gov/summaries/summary/47766/adapting-your-practice-treatment-and-recommendations-for-unstably-housed-patients-with-hivaids'}]
https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235353/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2016-09-30T23:53:53Z', 'uri': 'http://web.archive.org/web/20160930235353/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2017-10-03T04:14:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003041402/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2017-10-03T04:14:02Z', 'uri': 'http://web.archive.org/web/20171003041402/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2018-04-14T03:41:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414034155/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2018-04-14T03:41:55Z', 'uri': 'http://web.archive.org/web/20180414034155/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2018-05-19T10:35:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519103502/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2018-05-19T10:35:02Z', 'uri': 'http://web.archive.org/web/20180519103502/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}, {'datetime': '2018-06-09T19:32:24Z', 'uri': 'http://web.archive.org/web/20180609193224/https://www.guideline.gov/summaries/summary/47767/adapting-your-practice-treatment-and-recommendations-for-patients-who-are-homeless-with-diabetes-mellitus'}]
https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235235/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2016-09-30T23:52:35Z', 'uri': 'http://web.archive.org/web/20160930235235/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2017-10-03T04:01:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003040147/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2017-10-03T04:01:47Z', 'uri': 'http://web.archive.org/web/20171003040147/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2018-04-14T03:31:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414033155/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2018-04-14T03:31:55Z', 'uri': 'http://web.archive.org/web/20180414033155/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2018-05-19T10:25:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519102529/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2018-05-19T10:25:29Z', 'uri': 'http://web.archive.org/web/20180519102529/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}, {'datetime': '2018-06-09T20:12:57Z', 'uri': 'http://web.archive.org/web/20180609201257/https://www.guideline.gov/summaries/summary/47769/2013-idsa-clinical-practice-guideline-for-vaccination-of-the-immunocompromised-host'}]
https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:55:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235520/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2016-09-30T23:55:20Z', 'uri': 'http://web.archive.org/web/20160930235520/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2017-10-03T04:22:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003042209/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2017-10-03T04:22:09Z', 'uri': 'http://web.archive.org/web/20171003042209/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2018-04-14T03:52:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414035233/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2018-04-14T03:52:33Z', 'uri': 'http://web.archive.org/web/20180414035233/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2018-05-19T10:45:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519104521/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2018-05-19T10:45:21Z', 'uri': 'http://web.archive.org/web/20180519104521/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}, {'datetime': '2018-06-09T23:13:27Z', 'uri': 'http://web.archive.org/web/20180609231327/https://www.guideline.gov/summaries/summary/47771/cerclage-for-the-management-of-cervical-insufficiency'}]
https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235422/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2016-09-30T23:54:22Z', 'uri': 'http://web.archive.org/web/20160930235422/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2017-10-03T04:16:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003041616/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2017-10-03T04:16:16Z', 'uri': 'http://web.archive.org/web/20171003041616/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2018-04-14T03:44:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414034430/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2018-04-14T03:44:30Z', 'uri': 'http://web.archive.org/web/20180414034430/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2018-05-19T10:37:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519103742/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2018-05-19T10:37:42Z', 'uri': 'http://web.archive.org/web/20180519103742/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}, {'datetime': '2018-06-09T20:56:12Z', 'uri': 'http://web.archive.org/web/20180609205612/https://www.guideline.gov/summaries/summary/47772/clinical-policy-procedural-sedation-and-analgesia-in-the-emergency-department'}]
https://www.guideline.gov/summaries/summary/47781/esophageal-varices	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235342/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2016-09-30T23:53:42Z', 'uri': 'http://web.archive.org/web/20160930235342/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2017-10-03T04:13:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003041301/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2017-10-03T04:13:01Z', 'uri': 'http://web.archive.org/web/20171003041301/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2018-04-14T03:40:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414034018/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2018-04-14T03:40:18Z', 'uri': 'http://web.archive.org/web/20180414034018/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2018-05-19T10:33:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519103336/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2018-05-19T10:33:36Z', 'uri': 'http://web.archive.org/web/20180519103336/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}, {'datetime': '2018-06-09T11:30:49Z', 'uri': 'http://web.archive.org/web/20180609113049/https://www.guideline.gov/summaries/summary/47781/esophageal-varices'}]
https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235334/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2016-09-30T23:53:34Z', 'uri': 'http://web.archive.org/web/20160930235334/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2017-10-03T04:12:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003041202/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2017-10-03T04:12:02Z', 'uri': 'http://web.archive.org/web/20171003041202/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2018-04-14T03:39:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414033923/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2018-04-14T03:39:23Z', 'uri': 'http://web.archive.org/web/20180414033923/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2018-05-19T10:32:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519103247/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2018-05-19T10:32:47Z', 'uri': 'http://web.archive.org/web/20180519103247/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}, {'datetime': '2018-06-09T21:45:02Z', 'uri': 'http://web.archive.org/web/20180609214502/https://www.guideline.gov/summaries/summary/47784/american-gastroenterological-association-institute-guideline-on-the-use-of-thiopurines-methotrexate-and-anti-tnf--biologic-drugs-for-the-induction-and-maintenance-of-remission-in-inflammatory-crohns-disease'}]
https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235333/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2016-09-30T23:53:33Z', 'uri': 'http://web.archive.org/web/20160930235333/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2017-10-03T04:11:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003041152/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2017-10-03T04:11:52Z', 'uri': 'http://web.archive.org/web/20171003041152/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2018-04-14T03:39:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414033908/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2018-04-14T03:39:08Z', 'uri': 'http://web.archive.org/web/20180414033908/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2018-05-19T10:32:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519103237/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2018-05-19T10:32:37Z', 'uri': 'http://web.archive.org/web/20180519103237/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}, {'datetime': '2018-06-09T11:55:15Z', 'uri': 'http://web.archive.org/web/20180609115515/https://www.guideline.gov/summaries/summary/47785/clinical-practice-guidelines-for-the-perioperative-nutritional-metabolic-and-nonsurgical-support-of-the-bariatric-surgery-patient--2013-update-cosponsored-by-american-association-of-clinical-endocrinologists-the-obesity-society-and-american-society-for-metabol'}]
https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930235423/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2016-09-30T23:54:23Z', 'uri': 'http://web.archive.org/web/20160930235423/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2017-10-03T04:16:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003041623/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2017-10-03T04:16:23Z', 'uri': 'http://web.archive.org/web/20171003041623/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2018-04-14T03:44:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414034438/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2018-04-14T03:44:38Z', 'uri': 'http://web.archive.org/web/20180414034438/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2018-05-19T10:37:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519103752/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2018-05-19T10:37:52Z', 'uri': 'http://web.archive.org/web/20180519103752/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}, {'datetime': '2018-06-09T18:37:51Z', 'uri': 'http://web.archive.org/web/20180609183751/https://www.guideline.gov/summaries/summary/47786/the-role-of-endoscopy-in-the-evaluation-and-management-of-dysphagia'}]
https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235429/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:54:29Z', 'uri': 'http://web.archive.org/web/20160930235429/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:16:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003041652/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2017-10-03T04:16:52Z', 'uri': 'http://web.archive.org/web/20171003041652/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:45:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414034509/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:45:09Z', 'uri': 'http://web.archive.org/web/20180414034509/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:38:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519103824/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:38:24Z', 'uri': 'http://web.archive.org/web/20180519103824/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}, {'datetime': '2018-06-09T21:16:46Z', 'uri': 'http://web.archive.org/web/20180609211646/https://www.guideline.gov/summaries/summary/47788/management-of-lung-cancer-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235411/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2016-09-30T23:54:11Z', 'uri': 'http://web.archive.org/web/20160930235411/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2017-10-03T04:15:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003041540/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2017-10-03T04:15:40Z', 'uri': 'http://web.archive.org/web/20171003041540/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2018-04-14T03:43:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414034334/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2018-04-14T03:43:34Z', 'uri': 'http://web.archive.org/web/20180414034334/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2018-05-19T10:36:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519103633/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2018-05-19T10:36:33Z', 'uri': 'http://web.archive.org/web/20180519103633/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}, {'datetime': '2018-06-09T21:16:02Z', 'uri': 'http://web.archive.org/web/20180609211602/https://www.guideline.gov/summaries/summary/47790/comparison-of-oncotype-dx-with-multigene-profiling-assays-eg-mammaprint-pam50-and-other-tests-eg-adjuvant-online-ki67-and-ihc4-in-earlystage-breast-cancer'}]
https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:54:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235413/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2016-09-30T23:54:13Z', 'uri': 'http://web.archive.org/web/20160930235413/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2017-10-03T04:15:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003041549/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2017-10-03T04:15:49Z', 'uri': 'http://web.archive.org/web/20171003041549/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2018-04-14T03:43:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414034347/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2018-04-14T03:43:47Z', 'uri': 'http://web.archive.org/web/20180414034347/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2018-05-19T10:36:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519103646/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2018-05-19T10:36:46Z', 'uri': 'http://web.archive.org/web/20180519103646/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2018-06-09T19:10:57Z', 'uri': 'http://web.archive.org/web/20180609191057/https://www.guideline.gov/summaries/summary/47792/safe-handling-of-cytotoxics'}, {'datetime': '2018-06-11T15:28:15Z', 'uri': 'http://web.archive.org/web/20180611152815/https://www.guideline.gov/summaries/summary/47792/Safe-handling-of-cytotoxics'}]
https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235414/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2016-09-30T23:54:14Z', 'uri': 'http://web.archive.org/web/20160930235414/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2017-10-03T04:15:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003041557/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2017-10-03T04:15:57Z', 'uri': 'http://web.archive.org/web/20171003041557/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2018-04-14T03:43:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414034358/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2018-04-14T03:43:58Z', 'uri': 'http://web.archive.org/web/20180414034358/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2018-05-19T10:37:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519103717/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2018-05-19T10:37:17Z', 'uri': 'http://web.archive.org/web/20180519103717/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}, {'datetime': '2018-06-09T21:15:53Z', 'uri': 'http://web.archive.org/web/20180609211553/https://www.guideline.gov/summaries/summary/47793/the-prognostic-value-of-the-dnmt3a-biomarker-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia'}]
https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:32:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930143245/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2016-09-30T14:32:45Z', 'uri': 'http://web.archive.org/web/20160930143245/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2017-10-03T04:11:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003041146/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2017-10-03T04:11:46Z', 'uri': 'http://web.archive.org/web/20171003041146/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2018-04-14T03:38:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414033859/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2018-04-14T03:38:59Z', 'uri': 'http://web.archive.org/web/20180414033859/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2018-05-19T10:32:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519103227/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2018-05-19T10:32:27Z', 'uri': 'http://web.archive.org/web/20180519103227/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}, {'datetime': '2018-06-09T21:31:46Z', 'uri': 'http://web.archive.org/web/20180609213146/https://www.guideline.gov/summaries/summary/47795/clinical-practice-guideline-acute-otitis-externa'}]
https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235406/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2016-09-30T23:54:06Z', 'uri': 'http://web.archive.org/web/20160930235406/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2017-10-03T04:15:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003041505/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2017-10-03T04:15:05Z', 'uri': 'http://web.archive.org/web/20171003041505/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2018-04-14T03:43:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414034312/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2018-04-14T03:43:12Z', 'uri': 'http://web.archive.org/web/20180414034312/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2018-05-19T10:36:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519103614/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2018-05-19T10:36:14Z', 'uri': 'http://web.archive.org/web/20180519103614/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}, {'datetime': '2018-06-09T23:34:39Z', 'uri': 'http://web.archive.org/web/20180609233439/https://www.guideline.gov/summaries/summary/47796/assessment-and-management-of-pain'}]
https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235319/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2016-09-30T23:53:19Z', 'uri': 'http://web.archive.org/web/20160930235319/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2017-10-03T04:09:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003040959/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2017-10-03T04:09:59Z', 'uri': 'http://web.archive.org/web/20171003040959/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-04-14T03:37:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414033711/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-04-14T03:37:11Z', 'uri': 'http://web.archive.org/web/20180414033711/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-05-19T10:30:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519103030/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-05-19T10:30:30Z', 'uri': 'http://web.archive.org/web/20180519103030/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-06-09T15:45:24Z', 'uri': 'http://web.archive.org/web/20180609154524/https://www.guideline.gov/summaries/summary/47797/aarc-clinical-practice-guideline-effectiveness-of-nonpharmacologic-airway-clearance-therapies-in-hospitalized-patients'}]
https://www.guideline.gov/summaries/summary/47802/prenatal-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:54:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930235431/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2016-09-30T23:54:31Z', 'uri': 'http://web.archive.org/web/20160930235431/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2017-10-03T04:17:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003041706/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2017-10-03T04:17:06Z', 'uri': 'http://web.archive.org/web/20171003041706/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2018-04-14T03:45:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414034529/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2018-04-14T03:45:29Z', 'uri': 'http://web.archive.org/web/20180414034529/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2018-05-19T10:38:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519103844/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2018-05-19T10:38:44Z', 'uri': 'http://web.archive.org/web/20180519103844/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}, {'datetime': '2018-06-09T21:34:15Z', 'uri': 'http://web.archive.org/web/20180609213415/https://www.guideline.gov/summaries/summary/47802/prenatal-care'}]
https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235201/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2016-09-30T23:52:01Z', 'uri': 'http://web.archive.org/web/20160930235201/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2017-10-03T03:59:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003035920/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2017-10-03T03:59:20Z', 'uri': 'http://web.archive.org/web/20171003035920/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-04-14T03:28:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414032813/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-04-14T03:28:13Z', 'uri': 'http://web.archive.org/web/20180414032813/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-05-19T10:21:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519102110/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-05-19T10:21:10Z', 'uri': 'http://web.archive.org/web/20180519102110/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-06-09T15:29:31Z', 'uri': 'http://web.archive.org/web/20180609152931/https://www.guideline.gov/summaries/summary/47819/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-nonarthroplasty-treatment-of-osteoarthritis-of-the-knee'}]
https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235302/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2016-09-30T23:53:02Z', 'uri': 'http://web.archive.org/web/20160930235302/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2017-10-03T04:04:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003040436/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2017-10-03T04:04:36Z', 'uri': 'http://web.archive.org/web/20171003040436/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2018-04-14T03:36:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414033606/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2018-04-14T03:36:06Z', 'uri': 'http://web.archive.org/web/20180414033606/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2018-05-19T10:29:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519102931/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2018-05-19T10:29:31Z', 'uri': 'http://web.archive.org/web/20180519102931/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}, {'datetime': '2018-06-09T20:13:55Z', 'uri': 'http://web.archive.org/web/20180609201355/https://www.guideline.gov/summaries/summary/47820/2014-uk-national-guideline-on-the-management-of-vulval-conditions'}]
https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235301/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2016-09-30T23:53:01Z', 'uri': 'http://web.archive.org/web/20160930235301/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2017-10-03T04:04:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003040429/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2017-10-03T04:04:29Z', 'uri': 'http://web.archive.org/web/20171003040429/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2018-04-14T03:35:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414033556/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2018-04-14T03:35:56Z', 'uri': 'http://web.archive.org/web/20180414033556/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2018-05-19T10:29:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519102921/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2018-05-19T10:29:21Z', 'uri': 'http://web.archive.org/web/20180519102921/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}, {'datetime': '2018-06-09T22:16:15Z', 'uri': 'http://web.archive.org/web/20180609221615/https://www.guideline.gov/summaries/summary/47822/practice-parameters-for-the-treatment-of-sigmoid-diverticulitis'}]
https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235348/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2016-09-30T23:53:48Z', 'uri': 'http://web.archive.org/web/20160930235348/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2017-10-03T04:13:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003041335/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2017-10-03T04:13:35Z', 'uri': 'http://web.archive.org/web/20171003041335/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2018-04-14T03:41:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414034109/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2018-04-14T03:41:09Z', 'uri': 'http://web.archive.org/web/20180414034109/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2018-05-19T10:34:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519103423/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2018-05-19T10:34:23Z', 'uri': 'http://web.archive.org/web/20180519103423/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}, {'datetime': '2018-06-09T11:04:35Z', 'uri': 'http://web.archive.org/web/20180609110435/https://www.guideline.gov/summaries/summary/47823/guideline-for-environmental-cleaning'}]
https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:53:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930235349/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2016-09-30T23:53:49Z', 'uri': 'http://web.archive.org/web/20160930235349/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2017-10-03T04:13:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003041340/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2017-10-03T04:13:40Z', 'uri': 'http://web.archive.org/web/20171003041340/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2018-04-14T03:41:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414034119/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2018-04-14T03:41:19Z', 'uri': 'http://web.archive.org/web/20180414034119/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2018-05-19T10:34:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519103431/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2018-05-19T10:34:31Z', 'uri': 'http://web.archive.org/web/20180519103431/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2018-06-09T23:20:16Z', 'uri': 'http://web.archive.org/web/20180609232016/https://www.guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}, {'datetime': '2018-06-15T12:55:51Z', 'uri': 'http://web.archive.org/web/20180615125551/https://guideline.gov/summaries/summary/47824/guideline-for-selection-and-use-of-packaging-systems-for-sterilization'}]
https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235347/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2016-09-30T23:53:47Z', 'uri': 'http://web.archive.org/web/20160930235347/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2017-10-03T04:13:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003041329/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2017-10-03T04:13:29Z', 'uri': 'http://web.archive.org/web/20171003041329/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2018-04-14T03:40:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414034059/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2018-04-14T03:40:59Z', 'uri': 'http://web.archive.org/web/20180414034059/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2018-05-19T10:34:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519103415/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2018-05-19T10:34:15Z', 'uri': 'http://web.archive.org/web/20180519103415/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}, {'datetime': '2018-06-09T23:20:28Z', 'uri': 'http://web.archive.org/web/20180609232028/https://www.guideline.gov/summaries/summary/47825/guideline-for-care-of-patients-undergoing-pneumatic-tourniquetassisted-procedures'}]
https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235350/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2016-09-30T23:53:50Z', 'uri': 'http://web.archive.org/web/20160930235350/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2017-10-03T04:13:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003041345/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2017-10-03T04:13:45Z', 'uri': 'http://web.archive.org/web/20171003041345/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2018-04-14T03:41:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414034128/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2018-04-14T03:41:28Z', 'uri': 'http://web.archive.org/web/20180414034128/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2018-05-19T10:34:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519103440/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2018-05-19T10:34:40Z', 'uri': 'http://web.archive.org/web/20180519103440/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}, {'datetime': '2018-06-09T21:07:28Z', 'uri': 'http://web.archive.org/web/20180609210728/https://www.guideline.gov/summaries/summary/47826/guideline-for-sharps-safety'}]
https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235329/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2016-09-30T23:53:29Z', 'uri': 'http://web.archive.org/web/20160930235329/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2017-10-03T04:11:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003041122/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2017-10-03T04:11:22Z', 'uri': 'http://web.archive.org/web/20171003041122/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2018-04-14T03:38:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414033824/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2018-04-14T03:38:24Z', 'uri': 'http://web.archive.org/web/20180414033824/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2018-05-19T10:31:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519103136/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2018-05-19T10:31:36Z', 'uri': 'http://web.archive.org/web/20180519103136/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}, {'datetime': '2018-06-09T15:19:35Z', 'uri': 'http://web.archive.org/web/20180609151935/https://www.guideline.gov/summaries/summary/47827/shoulder-conditions-diagnosis-and-treatment-guideline'}]
https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235330/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2016-09-30T23:53:30Z', 'uri': 'http://web.archive.org/web/20160930235330/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2017-10-03T04:11:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003041128/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2017-10-03T04:11:28Z', 'uri': 'http://web.archive.org/web/20171003041128/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2018-04-14T03:38:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414033834/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2018-04-14T03:38:34Z', 'uri': 'http://web.archive.org/web/20180414033834/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2018-05-19T10:31:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519103145/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2018-05-19T10:31:45Z', 'uri': 'http://web.archive.org/web/20180519103145/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}, {'datetime': '2018-06-10T01:19:48Z', 'uri': 'http://web.archive.org/web/20180610011948/https://www.guideline.gov/summaries/summary/47828/workrelated-carpal-tunnel-syndrome-diagnosis-and-treatment-guideline'}]
https://www.guideline.gov/summaries/summary/47829/medical-management-of-firsttrimester-abortion	ARCHIVED	5 mementos	[{'datetime': '2016-09-30T23:53:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235346/https://www.guideline.gov/summaries/summary/47829/medical-management-of-firsttrimester-abortion'}, {'datetime': '2016-09-30T23:53:46Z', 'uri': 'http://web.archive.org/web/20160930235346/https://www.guideline.gov/summaries/summary/47829/medical-management-of-firsttrimester-abortion'}, {'datetime': '2018-06-09T11:21:43Z', 'uri': 'http://web.archive.org/web/20180609112143/https://www.guideline.gov/summaries/summary/47829/medical-management-of-firsttrimester-abortion'}, {'datetime': '2018-07-12T21:46:48Z', 'uri': 'http://web.archive.org/web/20180712214648/https://www.guideline.gov/summaries/summary/47829/medical-management-of-firsttrimester-abortion'}, {'datetime': '2018-07-12T21:46:48Z', 'uri': 'http://web.archive.org/web/20180712214648/https://www.guideline.gov/summaries/summary/47829/medical-management-of-firsttrimester-abortion'}]
https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930235323/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2016-09-30T23:53:23Z', 'uri': 'http://web.archive.org/web/20160930235323/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2017-10-03T04:10:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003041055/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2017-10-03T04:10:55Z', 'uri': 'http://web.archive.org/web/20171003041055/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2018-04-14T03:37:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414033748/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2018-04-14T03:37:48Z', 'uri': 'http://web.archive.org/web/20180414033748/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2018-05-19T10:31:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519103103/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2018-05-19T10:31:03Z', 'uri': 'http://web.archive.org/web/20180519103103/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}, {'datetime': '2018-06-09T20:55:35Z', 'uri': 'http://web.archive.org/web/20180609205535/https://www.guideline.gov/summaries/summary/47830/biopsy-of-a-suspicious-pigmented-lesion'}]
https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930235326/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2016-09-30T23:53:26Z', 'uri': 'http://web.archive.org/web/20160930235326/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2017-10-03T04:11:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003041101/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2017-10-03T04:11:01Z', 'uri': 'http://web.archive.org/web/20171003041101/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2018-04-14T03:37:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414033757/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2018-04-14T03:37:57Z', 'uri': 'http://web.archive.org/web/20180414033757/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2018-05-19T10:31:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519103110/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2018-05-19T10:31:10Z', 'uri': 'http://web.archive.org/web/20180519103110/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}, {'datetime': '2018-06-09T20:55:36Z', 'uri': 'http://web.archive.org/web/20180609205536/https://www.guideline.gov/summaries/summary/47831/muscle-invasive-and-locally-advancedmetastatic-bladder-cancer'}]
https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930235327/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2016-09-30T23:53:27Z', 'uri': 'http://web.archive.org/web/20160930235327/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2017-10-03T04:11:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003041108/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2017-10-03T04:11:08Z', 'uri': 'http://web.archive.org/web/20171003041108/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-04-14T03:38:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414033807/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-04-14T03:38:07Z', 'uri': 'http://web.archive.org/web/20180414033807/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-05-19T10:31:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519103119/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-05-19T10:31:19Z', 'uri': 'http://web.archive.org/web/20180519103119/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-06-09T20:55:18Z', 'uri': 'http://web.archive.org/web/20180609205518/https://www.guideline.gov/summaries/summary/47832/nonmuscle-invasive-bladder-cancer'}]
https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235304/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2016-09-30T23:53:04Z', 'uri': 'http://web.archive.org/web/20160930235304/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2017-10-03T04:04:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003040451/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2017-10-03T04:04:51Z', 'uri': 'http://web.archive.org/web/20171003040451/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2018-04-14T03:36:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414033617/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2018-04-14T03:36:17Z', 'uri': 'http://web.archive.org/web/20180414033617/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2018-05-19T10:29:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519102940/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2018-05-19T10:29:40Z', 'uri': 'http://web.archive.org/web/20180519102940/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}, {'datetime': '2018-06-09T20:55:28Z', 'uri': 'http://web.archive.org/web/20180609205528/https://www.guideline.gov/summaries/summary/47835/epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer'}]
https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930235249/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2016-09-30T23:52:49Z', 'uri': 'http://web.archive.org/web/20160930235249/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2017-10-03T04:03:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003040307/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2017-10-03T04:03:07Z', 'uri': 'http://web.archive.org/web/20171003040307/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2018-04-14T03:33:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414033352/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2018-04-14T03:33:52Z', 'uri': 'http://web.archive.org/web/20180414033352/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2018-05-19T10:27:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519102731/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2018-05-19T10:27:31Z', 'uri': 'http://web.archive.org/web/20180519102731/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}, {'datetime': '2018-06-09T20:18:47Z', 'uri': 'http://web.archive.org/web/20180609201847/https://www.guideline.gov/summaries/summary/47840/management-of-febrile-neutropenia-in-adult-cancer-patients'}]
https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235250/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2016-09-30T23:52:50Z', 'uri': 'http://web.archive.org/web/20160930235250/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2017-10-03T04:03:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003040313/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2017-10-03T04:03:13Z', 'uri': 'http://web.archive.org/web/20171003040313/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2018-04-14T03:34:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414033402/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2018-04-14T03:34:02Z', 'uri': 'http://web.archive.org/web/20180414033402/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2018-05-19T10:27:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519102739/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2018-05-19T10:27:39Z', 'uri': 'http://web.archive.org/web/20180519102739/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}, {'datetime': '2018-06-09T20:55:41Z', 'uri': 'http://web.archive.org/web/20180609205541/https://www.guideline.gov/summaries/summary/47841/management-of-intransit-disease-of-the-limbs'}]
https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930235251/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2016-09-30T23:52:51Z', 'uri': 'http://web.archive.org/web/20160930235251/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2017-10-03T04:03:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003040319/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2017-10-03T04:03:19Z', 'uri': 'http://web.archive.org/web/20171003040319/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2018-04-14T03:34:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414033412/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2018-04-14T03:34:12Z', 'uri': 'http://web.archive.org/web/20180414033412/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2018-05-19T10:27:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519102749/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2018-05-19T10:27:49Z', 'uri': 'http://web.archive.org/web/20180519102749/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}, {'datetime': '2018-06-10T11:37:23Z', 'uri': 'http://web.archive.org/web/20180610113723/https://www.guideline.gov/summaries/summary/47842/management-of-resectable-stage-iv-primary-cutaneous-melanoma-without-nodal-disease'}]
https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235252/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2016-09-30T23:52:52Z', 'uri': 'http://web.archive.org/web/20160930235252/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2017-10-03T04:03:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003040325/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2017-10-03T04:03:25Z', 'uri': 'http://web.archive.org/web/20171003040325/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2018-04-14T03:34:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414033421/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2018-04-14T03:34:21Z', 'uri': 'http://web.archive.org/web/20180414033421/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2018-05-19T10:27:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519102756/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2018-05-19T10:27:56Z', 'uri': 'http://web.archive.org/web/20180519102756/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}, {'datetime': '2018-06-10T23:04:13Z', 'uri': 'http://web.archive.org/web/20180610230413/https://www.guideline.gov/summaries/summary/47843/nonsmall-cell-lung-cancer-stage-iv'}]
https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235253/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2016-09-30T23:52:53Z', 'uri': 'http://web.archive.org/web/20160930235253/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2017-10-03T04:03:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003040331/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2017-10-03T04:03:31Z', 'uri': 'http://web.archive.org/web/20171003040331/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2018-04-14T03:34:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414033429/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2018-04-14T03:34:29Z', 'uri': 'http://web.archive.org/web/20180414033429/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2018-05-19T10:28:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519102804/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2018-05-19T10:28:04Z', 'uri': 'http://web.archive.org/web/20180519102804/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}, {'datetime': '2018-06-09T20:55:09Z', 'uri': 'http://web.archive.org/web/20180609205509/https://www.guideline.gov/summaries/summary/47844/optimal-excision-margins-for-primary-cutaneous-melanoma'}]
https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235237/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2016-09-30T23:52:37Z', 'uri': 'http://web.archive.org/web/20160930235237/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2017-10-03T04:02:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003040202/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2017-10-03T04:02:02Z', 'uri': 'http://web.archive.org/web/20171003040202/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2018-04-14T03:32:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414033215/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2018-04-14T03:32:15Z', 'uri': 'http://web.archive.org/web/20180414033215/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2018-05-19T10:25:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519102547/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2018-05-19T10:25:47Z', 'uri': 'http://web.archive.org/web/20180519102547/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}, {'datetime': '2018-06-10T11:37:43Z', 'uri': 'http://web.archive.org/web/20180610113743/https://www.guideline.gov/summaries/summary/47845/ovarian-germ-cell-tumours'}]
https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:52:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235238/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2016-09-30T23:52:38Z', 'uri': 'http://web.archive.org/web/20160930235238/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2017-07-14T11:27:43Z', 'uri': 'http://web.archive.org/web/20170714112743/https://guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2017-10-03T04:02:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003040210/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2017-10-03T04:02:10Z', 'uri': 'http://web.archive.org/web/20171003040210/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2018-04-14T03:32:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414033224/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2018-04-14T03:32:24Z', 'uri': 'http://web.archive.org/web/20180414033224/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2018-05-19T10:25:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519102557/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2018-05-19T10:25:57Z', 'uri': 'http://web.archive.org/web/20180519102557/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}, {'datetime': '2018-06-09T11:06:15Z', 'uri': 'http://web.archive.org/web/20180609110615/https://www.guideline.gov/summaries/summary/47846/preoperative-and-pretreatment-investigations-for-malignant-melanoma'}]
https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235240/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2016-09-30T23:52:40Z', 'uri': 'http://web.archive.org/web/20160930235240/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2017-10-03T04:02:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003040216/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2017-10-03T04:02:16Z', 'uri': 'http://web.archive.org/web/20171003040216/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2018-04-14T03:32:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414033233/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2018-04-14T03:32:33Z', 'uri': 'http://web.archive.org/web/20180414033233/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2018-05-19T10:26:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519102604/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2018-05-19T10:26:04Z', 'uri': 'http://web.archive.org/web/20180519102604/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}, {'datetime': '2018-06-10T02:11:49Z', 'uri': 'http://web.archive.org/web/20180610021149/https://www.guideline.gov/summaries/summary/47848/referral-and-followup-surveillance-of-cutaneous-melanoma'}]
https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235241/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2016-09-30T23:52:41Z', 'uri': 'http://web.archive.org/web/20160930235241/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2017-10-03T04:02:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003040221/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2017-10-03T04:02:21Z', 'uri': 'http://web.archive.org/web/20171003040221/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2018-04-14T03:32:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414033242/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2018-04-14T03:32:42Z', 'uri': 'http://web.archive.org/web/20180414033242/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2018-05-19T10:26:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519102613/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2018-05-19T10:26:13Z', 'uri': 'http://web.archive.org/web/20180519102613/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}, {'datetime': '2018-06-09T18:41:49Z', 'uri': 'http://web.archive.org/web/20180609184149/https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva'}]
https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:52:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235234/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2016-09-30T23:52:34Z', 'uri': 'http://web.archive.org/web/20160930235234/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2017-10-03T04:01:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003040141/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2017-10-03T04:01:41Z', 'uri': 'http://web.archive.org/web/20171003040141/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2018-01-10T12:28:54Z', 'uri': 'http://web.archive.org/web/20180110122854/https://guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2018-04-14T03:31:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414033136/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2018-04-14T03:31:36Z', 'uri': 'http://web.archive.org/web/20180414033136/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2018-05-19T10:25:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519102518/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2018-05-19T10:25:18Z', 'uri': 'http://web.archive.org/web/20180519102518/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}, {'datetime': '2018-06-10T11:37:24Z', 'uri': 'http://web.archive.org/web/20180610113724/https://www.guideline.gov/summaries/summary/47854/uterine-sarcoma'}]
https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235300/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:53:00Z', 'uri': 'http://web.archive.org/web/20160930235300/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:04:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003040421/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:04:21Z', 'uri': 'http://web.archive.org/web/20171003040421/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:35:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414033545/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:35:45Z', 'uri': 'http://web.archive.org/web/20180414033545/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:29:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519102912/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:29:12Z', 'uri': 'http://web.archive.org/web/20180519102912/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T17:21:03Z', 'uri': 'http://web.archive.org/web/20180610172103/https://www.guideline.gov/summaries/summary/47855/vitamin-mineral-and-multivitamin-supplements-for-the-primary-prevention-of-cardiovascular-disease-and-cancer-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235254/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2016-09-30T23:52:54Z', 'uri': 'http://web.archive.org/web/20160930235254/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2017-10-03T04:03:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003040337/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2017-10-03T04:03:37Z', 'uri': 'http://web.archive.org/web/20171003040337/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2018-04-14T03:34:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414033438/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2018-04-14T03:34:38Z', 'uri': 'http://web.archive.org/web/20180414033438/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2018-05-19T10:28:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519102812/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2018-05-19T10:28:12Z', 'uri': 'http://web.archive.org/web/20180519102812/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}, {'datetime': '2018-06-09T15:45:21Z', 'uri': 'http://web.archive.org/web/20180609154521/https://www.guideline.gov/summaries/summary/47857/solutions--wound-care-algorithm'}]
https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235202/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2016-09-30T23:52:02Z', 'uri': 'http://web.archive.org/web/20160930235202/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2017-10-03T03:59:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003035927/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2017-10-03T03:59:27Z', 'uri': 'http://web.archive.org/web/20171003035927/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2018-04-14T03:28:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414032825/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2018-04-14T03:28:25Z', 'uri': 'http://web.archive.org/web/20180414032825/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2018-05-19T10:21:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519102120/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2018-05-19T10:21:20Z', 'uri': 'http://web.archive.org/web/20180519102120/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}, {'datetime': '2018-06-09T11:01:49Z', 'uri': 'http://web.archive.org/web/20180609110149/https://www.guideline.gov/summaries/summary/47858/british-hiv-association-guidelines-for-hivassociated-malignancies-2014'}]
https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235155/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2016-09-30T23:51:55Z', 'uri': 'http://web.archive.org/web/20160930235155/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2017-10-03T03:58:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003035844/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2017-10-03T03:58:44Z', 'uri': 'http://web.archive.org/web/20171003035844/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2018-04-14T03:27:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414032723/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2018-04-14T03:27:23Z', 'uri': 'http://web.archive.org/web/20180414032723/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2018-05-19T10:20:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519102024/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2018-05-19T10:20:24Z', 'uri': 'http://web.archive.org/web/20180519102024/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}, {'datetime': '2018-06-09T20:41:18Z', 'uri': 'http://web.archive.org/web/20180609204118/https://www.guideline.gov/summaries/summary/47861/physical-therapy-management-of-congenital-muscular-torticollis-an-evidencebased-clinical-practice-guideline-from-the-section-on-pediatrics-of-the-american-physical-therapy-association'}]
https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235255/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2016-09-30T23:52:55Z', 'uri': 'http://web.archive.org/web/20160930235255/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2017-10-03T04:03:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003040353/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2017-10-03T04:03:53Z', 'uri': 'http://web.archive.org/web/20171003040353/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2018-04-14T03:35:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414033505/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2018-04-14T03:35:05Z', 'uri': 'http://web.archive.org/web/20180414033505/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2018-05-19T10:28:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519102835/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2018-05-19T10:28:35Z', 'uri': 'http://web.archive.org/web/20180519102835/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}, {'datetime': '2018-06-09T15:57:51Z', 'uri': 'http://web.archive.org/web/20180609155751/https://www.guideline.gov/summaries/summary/47862/osteoarthritis-care-and-management-in-adults'}]
https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235256/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2016-09-30T23:52:56Z', 'uri': 'http://web.archive.org/web/20160930235256/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2017-10-03T04:03:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003040344/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2017-10-03T04:03:44Z', 'uri': 'http://web.archive.org/web/20171003040344/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2018-04-14T03:34:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414033450/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2018-04-14T03:34:50Z', 'uri': 'http://web.archive.org/web/20180414033450/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2018-05-19T10:28:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519102822/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2018-05-19T10:28:22Z', 'uri': 'http://web.archive.org/web/20180519102822/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}, {'datetime': '2018-06-09T11:58:04Z', 'uri': 'http://web.archive.org/web/20180609115804/https://www.guideline.gov/summaries/summary/47863/psychosis-and-schizophrenia-in-adults-treatment-and-management'}]
https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:53:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930235331/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2016-09-30T23:53:31Z', 'uri': 'http://web.archive.org/web/20160930235331/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2017-01-08T03:46:51Z', 'uri': 'http://web.archive.org/web/20170108034651/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2017-10-03T04:11:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003041133/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2017-10-03T04:11:33Z', 'uri': 'http://web.archive.org/web/20171003041133/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2018-04-14T03:38:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414033843/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2018-04-14T03:38:43Z', 'uri': 'http://web.archive.org/web/20180414033843/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2018-05-19T10:31:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519103153/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2018-05-19T10:31:53Z', 'uri': 'http://web.archive.org/web/20180519103153/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}, {'datetime': '2018-06-10T00:04:02Z', 'uri': 'http://web.archive.org/web/20180610000402/https://www.guideline.gov/summaries/summary/47864/guideline-on-the-use-of-devices-for-adult-male-circumcision-for-hiv-prevention'}]
https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors	ARCHIVED	12 mementos	[{'datetime': '2016-09-30T14:33:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930143355/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2016-09-30T14:33:55Z', 'uri': 'http://web.archive.org/web/20160930143355/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2017-07-14T11:00:27Z', 'uri': 'http://web.archive.org/web/20170714110027/https://guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2017-10-03T04:13:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003041323/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2017-10-03T04:13:23Z', 'uri': 'http://web.archive.org/web/20171003041323/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-04-14T03:40:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414034050/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-04-14T03:40:50Z', 'uri': 'http://web.archive.org/web/20180414034050/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-05-19T10:34:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519103405/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-05-19T10:34:05Z', 'uri': 'http://web.archive.org/web/20180519103405/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-06-09T11:42:03Z', 'uri': 'http://web.archive.org/web/20180609114203/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-07-12T21:56:35Z', 'uri': 'http://web.archive.org/web/20180712215635/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}, {'datetime': '2018-07-12T21:56:35Z', 'uri': 'http://web.archive.org/web/20180712215635/https://www.guideline.gov/summaries/summary/47866/management-of-abnormal-cervical-cancer-screening-test-results-and-cervical-cancer-precursors'}]
https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235244/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2016-09-30T23:52:44Z', 'uri': 'http://web.archive.org/web/20160930235244/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2017-10-03T04:02:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003040239/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2017-10-03T04:02:39Z', 'uri': 'http://web.archive.org/web/20171003040239/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:33:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414033310/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:33:10Z', 'uri': 'http://web.archive.org/web/20180414033310/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:26:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519102640/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:26:40Z', 'uri': 'http://web.archive.org/web/20180519102640/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-06-09T21:13:47Z', 'uri': 'http://web.archive.org/web/20180609211347/https://www.guideline.gov/summaries/summary/47867/teriflunomide-for-treating-relapsing-remitting-multiple-sclerosis'}]
https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235242/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2016-09-30T23:52:42Z', 'uri': 'http://web.archive.org/web/20160930235242/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2017-10-03T04:02:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003040227/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2017-10-03T04:02:27Z', 'uri': 'http://web.archive.org/web/20171003040227/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2018-04-14T03:32:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414033252/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2018-04-14T03:32:52Z', 'uri': 'http://web.archive.org/web/20180414033252/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2018-05-19T10:26:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519102622/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2018-05-19T10:26:22Z', 'uri': 'http://web.archive.org/web/20180519102622/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}, {'datetime': '2018-06-11T07:03:23Z', 'uri': 'http://web.archive.org/web/20180611070323/https://www.guideline.gov/summaries/summary/47868/aflibercept-for-treating-visual-impairment-caused-by-macular-oedema-secondary-to-central-retinal-vein-occlusion'}]
https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235243/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2016-09-30T23:52:43Z', 'uri': 'http://web.archive.org/web/20160930235243/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2017-10-03T04:02:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003040233/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2017-10-03T04:02:33Z', 'uri': 'http://web.archive.org/web/20171003040233/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2018-04-14T03:33:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414033300/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2018-04-14T03:33:00Z', 'uri': 'http://web.archive.org/web/20180414033300/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2018-05-19T10:26:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519102630/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2018-05-19T10:26:30Z', 'uri': 'http://web.archive.org/web/20180519102630/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}, {'datetime': '2018-06-09T21:59:09Z', 'uri': 'http://web.archive.org/web/20180609215909/https://www.guideline.gov/summaries/summary/47869/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma'}]
https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930235245/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2016-09-30T23:52:45Z', 'uri': 'http://web.archive.org/web/20160930235245/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2017-10-03T04:02:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003040245/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2017-10-03T04:02:45Z', 'uri': 'http://web.archive.org/web/20171003040245/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2018-04-14T03:33:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414033318/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2018-04-14T03:33:18Z', 'uri': 'http://web.archive.org/web/20180414033318/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2018-05-19T10:26:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519102648/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2018-05-19T10:26:48Z', 'uri': 'http://web.archive.org/web/20180519102648/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}, {'datetime': '2018-06-09T15:20:37Z', 'uri': 'http://web.archive.org/web/20180609152037/https://www.guideline.gov/summaries/summary/47870/total-hip-replacement-and-resurfacing-arthroplasty-for-endstage-arthritis-of-the-hip-review-of-technology-appraisal-guidance-2-and-44'}]
https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235335/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2016-09-30T23:53:35Z', 'uri': 'http://web.archive.org/web/20160930235335/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2017-10-03T04:12:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003041208/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2017-10-03T04:12:08Z', 'uri': 'http://web.archive.org/web/20171003041208/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2018-04-14T03:39:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414033931/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2018-04-14T03:39:31Z', 'uri': 'http://web.archive.org/web/20180414033931/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2018-05-19T10:32:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519103255/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2018-05-19T10:32:55Z', 'uri': 'http://web.archive.org/web/20180519103255/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}, {'datetime': '2018-06-09T23:10:45Z', 'uri': 'http://web.archive.org/web/20180609231045/https://www.guideline.gov/summaries/summary/47871/guidelines-for-the-prevention-of-stroke-in-women-a-statement-for-healthcare-professionals-from-the-american-heart-associationamerican-stroke-association'}]
https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235220/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:52:20Z', 'uri': 'http://web.archive.org/web/20160930235220/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:01:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003040117/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T04:01:17Z', 'uri': 'http://web.archive.org/web/20171003040117/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T03:31:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414033109/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T03:31:09Z', 'uri': 'http://web.archive.org/web/20180414033109/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:24:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519102455/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:24:55Z', 'uri': 'http://web.archive.org/web/20180519102455/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T22:01:17Z', 'uri': 'http://web.archive.org/web/20180609220117/https://www.guideline.gov/summaries/summary/47873/summary-of-evidencebased-guideline-update-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235152/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2016-09-30T23:51:52Z', 'uri': 'http://web.archive.org/web/20160930235152/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2017-10-03T03:58:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003035824/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2017-10-03T03:58:24Z', 'uri': 'http://web.archive.org/web/20171003035824/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2018-04-14T03:26:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414032655/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2018-04-14T03:26:55Z', 'uri': 'http://web.archive.org/web/20180414032655/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2018-05-19T10:19:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519101956/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2018-05-19T10:19:56Z', 'uri': 'http://web.archive.org/web/20180519101956/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}, {'datetime': '2018-06-10T01:13:16Z', 'uri': 'http://web.archive.org/web/20180610011316/https://www.guideline.gov/summaries/summary/47874/presentation-diagnosis-and-medical-management-of-heart-failure-in-children-canadian-cardiovascular-society-guidelines'}]
https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235315/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2016-09-30T23:53:15Z', 'uri': 'http://web.archive.org/web/20160930235315/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2017-10-03T04:05:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003040528/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2017-10-03T04:05:28Z', 'uri': 'http://web.archive.org/web/20171003040528/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2018-04-14T03:36:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414033643/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2018-04-14T03:36:43Z', 'uri': 'http://web.archive.org/web/20180414033643/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2018-05-19T10:30:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519103005/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2018-05-19T10:30:05Z', 'uri': 'http://web.archive.org/web/20180519103005/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}, {'datetime': '2018-06-09T21:53:42Z', 'uri': 'http://web.archive.org/web/20180609215342/https://www.guideline.gov/summaries/summary/47875/pregnancy-outcomes-after-assisted-human-reproduction'}]
https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235314/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2016-09-30T23:53:14Z', 'uri': 'http://web.archive.org/web/20160930235314/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2017-10-03T04:05:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003040522/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2017-10-03T04:05:22Z', 'uri': 'http://web.archive.org/web/20171003040522/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2018-04-14T03:36:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414033635/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2018-04-14T03:36:35Z', 'uri': 'http://web.archive.org/web/20180414033635/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2018-05-19T10:29:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519102958/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2018-05-19T10:29:58Z', 'uri': 'http://web.archive.org/web/20180519102958/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}, {'datetime': '2018-06-09T22:21:54Z', 'uri': 'http://web.archive.org/web/20180609222154/https://www.guideline.gov/summaries/summary/47876/determination-of-gestational-age-by-ultrasound'}]
https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235313/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2016-09-30T23:53:13Z', 'uri': 'http://web.archive.org/web/20160930235313/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2017-10-03T04:05:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003040516/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2017-10-03T04:05:16Z', 'uri': 'http://web.archive.org/web/20171003040516/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2018-04-14T03:36:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414033627/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2018-04-14T03:36:27Z', 'uri': 'http://web.archive.org/web/20180414033627/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2018-05-19T10:29:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519102950/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2018-05-19T10:29:50Z', 'uri': 'http://web.archive.org/web/20180519102950/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}, {'datetime': '2018-06-09T22:22:01Z', 'uri': 'http://web.archive.org/web/20180609222201/https://www.guideline.gov/summaries/summary/47877/best-practices-to-minimize-risk-of-infection-with-intrauterine-device-insertion'}]
https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235213/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2016-09-30T23:52:13Z', 'uri': 'http://web.archive.org/web/20160930235213/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2017-10-03T04:00:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003040041/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2017-10-03T04:00:41Z', 'uri': 'http://web.archive.org/web/20171003040041/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2018-04-14T03:30:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414033011/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2018-04-14T03:30:11Z', 'uri': 'http://web.archive.org/web/20180414033011/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2018-05-19T10:23:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519102311/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2018-05-19T10:23:11Z', 'uri': 'http://web.archive.org/web/20180519102311/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}, {'datetime': '2018-06-10T01:48:47Z', 'uri': 'http://web.archive.org/web/20180610014847/https://www.guideline.gov/summaries/summary/47878/guidelines-for-the-first-line-management-of-classical-hodgkin-lymphoma'}]
https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235322/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2016-09-30T23:53:22Z', 'uri': 'http://web.archive.org/web/20160930235322/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2017-10-03T04:10:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003041048/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2017-10-03T04:10:48Z', 'uri': 'http://web.archive.org/web/20171003041048/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2018-04-14T03:37:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414033739/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2018-04-14T03:37:39Z', 'uri': 'http://web.archive.org/web/20180414033739/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2018-05-19T10:30:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519103053/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2018-05-19T10:30:53Z', 'uri': 'http://web.archive.org/web/20180519103053/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}, {'datetime': '2018-06-09T20:13:52Z', 'uri': 'http://web.archive.org/web/20180609201352/https://www.guideline.gov/summaries/summary/47881/united-kingdom-national-guideline-on-the-management-of-trichomonas-vaginalis-2014'}]
https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235210/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:52:10Z', 'uri': 'http://web.archive.org/web/20160930235210/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:00:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003040022/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:00:22Z', 'uri': 'http://web.archive.org/web/20171003040022/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:29:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414032945/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:29:45Z', 'uri': 'http://web.archive.org/web/20180414032945/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:22:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519102244/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:22:44Z', 'uri': 'http://web.archive.org/web/20180519102244/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T21:54:37Z', 'uri': 'http://web.archive.org/web/20180610215437/https://www.guideline.gov/summaries/summary/47882/primary-care-behavioral-interventions-to-reduce-illicit-drug-and-nonmedical-pharmaceutical-use-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235211/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2016-09-30T23:52:11Z', 'uri': 'http://web.archive.org/web/20160930235211/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2017-10-03T04:00:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003040028/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2017-10-03T04:00:28Z', 'uri': 'http://web.archive.org/web/20171003040028/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2018-04-14T03:29:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414032954/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2018-04-14T03:29:54Z', 'uri': 'http://web.archive.org/web/20180414032954/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2018-05-19T10:22:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519102254/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2018-05-19T10:22:54Z', 'uri': 'http://web.archive.org/web/20180519102254/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}, {'datetime': '2018-06-10T01:48:46Z', 'uri': 'http://web.archive.org/web/20180610014846/https://www.guideline.gov/summaries/summary/47890/bcsh-guideline-for-the-use-of-antid-immunoglobulin-for-the-prevention-of-haemolytic-disease-of-the-fetus-and-newborn'}]
https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930235212/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2016-09-30T23:52:12Z', 'uri': 'http://web.archive.org/web/20160930235212/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2017-10-03T04:00:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003040034/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2017-10-03T04:00:34Z', 'uri': 'http://web.archive.org/web/20171003040034/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2018-04-14T03:30:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414033002/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2018-04-14T03:30:02Z', 'uri': 'http://web.archive.org/web/20180414033002/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2018-05-19T10:23:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519102302/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2018-05-19T10:23:02Z', 'uri': 'http://web.archive.org/web/20180519102302/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}, {'datetime': '2018-06-10T01:48:57Z', 'uri': 'http://web.archive.org/web/20180610014857/https://www.guideline.gov/summaries/summary/47891/guidelines-for-the-diagnosis-and-management-of-adult-myelodysplastic-syndromes'}]
https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:53:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930235351/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2016-09-30T23:53:51Z', 'uri': 'http://web.archive.org/web/20160930235351/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2017-10-03T04:13:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003041351/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2017-10-03T04:13:51Z', 'uri': 'http://web.archive.org/web/20171003041351/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2017-11-17T09:31:46Z', 'uri': 'http://web.archive.org/web/20171117093146/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2018-04-14T03:41:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414034138/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2018-04-14T03:41:38Z', 'uri': 'http://web.archive.org/web/20180414034138/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2018-05-19T10:34:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519103447/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2018-05-19T10:34:47Z', 'uri': 'http://web.archive.org/web/20180519103447/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}, {'datetime': '2018-06-09T10:36:29Z', 'uri': 'http://web.archive.org/web/20180609103629/https://www.guideline.gov/summaries/summary/47892/cdc-guidance-for-evaluating-healthcare-personnel-for-hepatitis-b-virus-protection-and-for-administering-postexposure-management'}]
https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235336/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2016-09-30T23:53:36Z', 'uri': 'http://web.archive.org/web/20160930235336/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2017-10-03T04:12:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003041215/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2017-10-03T04:12:15Z', 'uri': 'http://web.archive.org/web/20171003041215/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2018-04-14T03:39:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414033941/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2018-04-14T03:39:41Z', 'uri': 'http://web.archive.org/web/20180414033941/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2018-05-19T10:33:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519103304/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2018-05-19T10:33:04Z', 'uri': 'http://web.archive.org/web/20180519103304/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}, {'datetime': '2018-06-09T20:56:33Z', 'uri': 'http://web.archive.org/web/20180609205633/https://www.guideline.gov/summaries/summary/47893/practice-guidelines-for-the-perioperative-management-of-patients-with-obstructive-sleep-apnea-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-management-of-patients-with-obstructive-sleep-apnea'}]
https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235221/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2016-09-30T23:52:21Z', 'uri': 'http://web.archive.org/web/20160930235221/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2017-10-03T04:01:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003040124/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2017-10-03T04:01:24Z', 'uri': 'http://web.archive.org/web/20171003040124/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2018-04-14T03:31:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414033120/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2018-04-14T03:31:20Z', 'uri': 'http://web.archive.org/web/20180414033120/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2018-05-19T10:25:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519102504/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2018-05-19T10:25:04Z', 'uri': 'http://web.archive.org/web/20180519102504/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}, {'datetime': '2018-06-09T19:39:55Z', 'uri': 'http://web.archive.org/web/20180609193955/https://www.guideline.gov/summaries/summary/47894/british-association-of-dermatologists-guidelines-for-the-management-of-squamous-cell-carcinoma-in-situ-bowens-disease-2014'}]
https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235146/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2016-09-30T23:51:46Z', 'uri': 'http://web.archive.org/web/20160930235146/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2017-10-03T03:57:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003035743/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2017-10-03T03:57:43Z', 'uri': 'http://web.archive.org/web/20171003035743/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2018-04-14T03:26:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414032614/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2018-04-14T03:26:14Z', 'uri': 'http://web.archive.org/web/20180414032614/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2018-05-19T10:19:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519101911/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2018-05-19T10:19:11Z', 'uri': 'http://web.archive.org/web/20180519101911/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}, {'datetime': '2018-06-09T11:50:29Z', 'uri': 'http://web.archive.org/web/20180609115029/https://www.guideline.gov/summaries/summary/47895/manual-medicine-guidelines-for-musculoskeletal-injuries'}]
https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235153/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2016-09-30T23:51:53Z', 'uri': 'http://web.archive.org/web/20160930235153/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2017-10-03T03:58:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003035831/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2017-10-03T03:58:31Z', 'uri': 'http://web.archive.org/web/20171003035831/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2018-04-14T03:27:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414032705/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2018-04-14T03:27:05Z', 'uri': 'http://web.archive.org/web/20180414032705/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2018-05-19T10:20:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519102005/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2018-05-19T10:20:05Z', 'uri': 'http://web.archive.org/web/20180519102005/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}, {'datetime': '2018-06-10T01:48:23Z', 'uri': 'http://web.archive.org/web/20180610014823/https://www.guideline.gov/summaries/summary/47897/clinical-practice-guidelines-for-management-of-gout'}]
https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235200/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:52:00Z', 'uri': 'http://web.archive.org/web/20160930235200/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:59:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003035913/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:59:13Z', 'uri': 'http://web.archive.org/web/20171003035913/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:28:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414032802/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:28:02Z', 'uri': 'http://web.archive.org/web/20180414032802/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:21:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519102100/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:21:00Z', 'uri': 'http://web.archive.org/web/20180519102100/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:08Z', 'uri': 'http://web.archive.org/web/20180610010608/https://www.guideline.gov/summaries/summary/47898/diabetes-and-pregnancy-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235140/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:51:40Z', 'uri': 'http://web.archive.org/web/20160930235140/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:57:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003035707/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:57:07Z', 'uri': 'http://web.archive.org/web/20171003035707/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:25:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414032515/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:25:15Z', 'uri': 'http://web.archive.org/web/20180414032515/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:18:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519101826/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:18:26Z', 'uri': 'http://web.archive.org/web/20180519101826/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:09Z', 'uri': 'http://web.archive.org/web/20180610010609/https://www.guideline.gov/summaries/summary/47899/diagnosis-and-treatment-of-polycystic-ovary-syndrome-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235332/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2016-09-30T23:53:32Z', 'uri': 'http://web.archive.org/web/20160930235332/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2017-10-03T04:11:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003041139/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2017-10-03T04:11:39Z', 'uri': 'http://web.archive.org/web/20171003041139/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2018-04-14T03:38:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414033850/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2018-04-14T03:38:50Z', 'uri': 'http://web.archive.org/web/20180414033850/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2018-05-19T10:32:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519103218/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2018-05-19T10:32:18Z', 'uri': 'http://web.archive.org/web/20180519103218/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}, {'datetime': '2018-06-10T16:46:33Z', 'uri': 'http://web.archive.org/web/20180610164633/https://www.guideline.gov/summaries/summary/47900/who-recommendations-on-postnatal-care-of-the-mother-and-newborn'}]
https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:51:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930235159/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:51:59Z', 'uri': 'http://web.archive.org/web/20160930235159/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:59:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003035907/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:59:07Z', 'uri': 'http://web.archive.org/web/20171003035907/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2017-11-17T08:23:06Z', 'uri': 'http://web.archive.org/web/20171117082306/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:27:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414032753/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2018-04-14T03:27:53Z', 'uri': 'http://web.archive.org/web/20180414032753/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:20:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519102050/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2018-05-19T10:20:50Z', 'uri': 'http://web.archive.org/web/20180519102050/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}, {'datetime': '2018-06-09T21:16:53Z', 'uri': 'http://web.archive.org/web/20180609211653/https://www.guideline.gov/summaries/summary/47901/dental-interventions-to-prevent-caries-in-children-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235205/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2016-09-30T23:52:05Z', 'uri': 'http://web.archive.org/web/20160930235205/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2017-10-03T03:59:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003035950/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2017-10-03T03:59:50Z', 'uri': 'http://web.archive.org/web/20171003035950/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2018-04-14T03:28:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414032856/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2018-04-14T03:28:56Z', 'uri': 'http://web.archive.org/web/20180414032856/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2018-05-19T10:21:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519102148/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2018-05-19T10:21:48Z', 'uri': 'http://web.archive.org/web/20180519102148/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}, {'datetime': '2018-06-09T19:20:37Z', 'uri': 'http://web.archive.org/web/20180609192037/https://www.guideline.gov/summaries/summary/47902/best-evidence-statement-best-use-of-pressure-therapy-for-management-of-hypertrophic-scarring'}]
https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235204/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2016-09-30T23:52:04Z', 'uri': 'http://web.archive.org/web/20160930235204/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2017-10-03T03:59:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003035944/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2017-10-03T03:59:44Z', 'uri': 'http://web.archive.org/web/20171003035944/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2018-04-14T03:28:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414032847/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2018-04-14T03:28:47Z', 'uri': 'http://web.archive.org/web/20180414032847/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2018-05-19T10:21:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519102140/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2018-05-19T10:21:40Z', 'uri': 'http://web.archive.org/web/20180519102140/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}, {'datetime': '2018-06-10T21:28:24Z', 'uri': 'http://web.archive.org/web/20180610212824/https://www.guideline.gov/summaries/summary/47903/best-evidence-statement-best-physical-therapy-during-the-hemopoietic-stem-cell-transplant-process-to-improve-quality-of-life'}]
https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235206/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2016-09-30T23:52:06Z', 'uri': 'http://web.archive.org/web/20160930235206/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2017-10-03T03:59:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003035955/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2017-10-03T03:59:55Z', 'uri': 'http://web.archive.org/web/20171003035955/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2018-04-14T03:29:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414032906/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2018-04-14T03:29:06Z', 'uri': 'http://web.archive.org/web/20180414032906/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2018-05-19T10:22:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519102208/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2018-05-19T10:22:08Z', 'uri': 'http://web.archive.org/web/20180519102208/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}, {'datetime': '2018-06-09T20:50:44Z', 'uri': 'http://web.archive.org/web/20180609205044/https://www.guideline.gov/summaries/summary/47904/best-evidence-statement-best-venous-thromboembolism-vte-prophylaxis-in-children-and-adolescents'}]
https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235207/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2016-09-30T23:52:07Z', 'uri': 'http://web.archive.org/web/20160930235207/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2017-10-03T04:00:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003040002/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2017-10-03T04:00:02Z', 'uri': 'http://web.archive.org/web/20171003040002/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2018-04-14T03:29:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414032915/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2018-04-14T03:29:15Z', 'uri': 'http://web.archive.org/web/20180414032915/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2018-05-19T10:22:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519102217/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2018-05-19T10:22:17Z', 'uri': 'http://web.archive.org/web/20180519102217/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}, {'datetime': '2018-06-10T17:22:02Z', 'uri': 'http://web.archive.org/web/20180610172202/https://www.guideline.gov/summaries/summary/47905/evidencebased-care-guideline-for-conservative-management-of-lateral-patellar-dislocations-and-instability-in-children-and-young-adults-aged-825-years'}]
https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235154/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:51:54Z', 'uri': 'http://web.archive.org/web/20160930235154/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T03:58:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003035838/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T03:58:38Z', 'uri': 'http://web.archive.org/web/20171003035838/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T03:27:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414032714/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T03:27:14Z', 'uri': 'http://web.archive.org/web/20180414032714/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:20:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519102014/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T10:20:14Z', 'uri': 'http://web.archive.org/web/20180519102014/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T18:59:12Z', 'uri': 'http://web.archive.org/web/20180609185912/https://www.guideline.gov/summaries/summary/47909/summary-of-evidencebased-guideline-complementary-and-alternative-medicine-in-multiple-sclerosis-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235321/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2016-09-30T23:53:21Z', 'uri': 'http://web.archive.org/web/20160930235321/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2017-10-03T04:10:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003041042/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2017-10-03T04:10:42Z', 'uri': 'http://web.archive.org/web/20171003041042/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2018-04-14T03:37:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414033729/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2018-04-14T03:37:29Z', 'uri': 'http://web.archive.org/web/20180414033729/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2018-05-19T10:30:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519103045/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2018-05-19T10:30:45Z', 'uri': 'http://web.archive.org/web/20180519103045/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}, {'datetime': '2018-06-09T18:37:47Z', 'uri': 'http://web.archive.org/web/20180609183747/https://www.guideline.gov/summaries/summary/47910/guidelines-for-safety-in-the-gastrointestinal-endoscopy-unit'}]
https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:34:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930143442/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2016-09-30T14:34:42Z', 'uri': 'http://web.archive.org/web/20160930143442/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2017-10-03T03:55:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003035559/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2017-10-03T03:55:59Z', 'uri': 'http://web.archive.org/web/20171003035559/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2018-04-14T03:24:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414032417/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2018-04-14T03:24:17Z', 'uri': 'http://web.archive.org/web/20180414032417/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2018-05-19T10:17:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519101734/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2018-05-19T10:17:34Z', 'uri': 'http://web.archive.org/web/20180519101734/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}, {'datetime': '2018-06-09T21:17:24Z', 'uri': 'http://web.archive.org/web/20180609211724/https://www.guideline.gov/summaries/summary/47915/evidencebased-clinical-practice-guideline-eye-care-of-the-patient-with-diabetes-mellitus'}]
https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235246/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2016-09-30T23:52:46Z', 'uri': 'http://web.archive.org/web/20160930235246/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2017-10-03T04:02:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003040252/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2017-10-03T04:02:52Z', 'uri': 'http://web.archive.org/web/20171003040252/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-04-14T03:33:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414033327/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-04-14T03:33:27Z', 'uri': 'http://web.archive.org/web/20180414033327/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-05-19T10:27:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519102710/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-05-19T10:27:10Z', 'uri': 'http://web.archive.org/web/20180519102710/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}, {'datetime': '2018-06-09T22:39:59Z', 'uri': 'http://web.archive.org/web/20180609223959/https://www.guideline.gov/summaries/summary/47917/fabry-disease-practice-guidelines-recommendations-of-the-national-society-of-genetic-counselors'}]
https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235236/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2016-09-30T23:52:36Z', 'uri': 'http://web.archive.org/web/20160930235236/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2017-10-03T04:01:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003040156/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2017-10-03T04:01:56Z', 'uri': 'http://web.archive.org/web/20171003040156/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2018-04-14T03:32:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414033206/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2018-04-14T03:32:06Z', 'uri': 'http://web.archive.org/web/20180414033206/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2018-05-19T10:25:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519102540/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2018-05-19T10:25:40Z', 'uri': 'http://web.archive.org/web/20180519102540/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}, {'datetime': '2018-06-09T19:41:03Z', 'uri': 'http://web.archive.org/web/20180609194103/https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy'}]
https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235317/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2016-09-30T23:53:17Z', 'uri': 'http://web.archive.org/web/20160930235317/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2017-10-03T04:09:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003040910/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2017-10-03T04:09:10Z', 'uri': 'http://web.archive.org/web/20171003040910/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2018-04-14T03:37:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414033701/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2018-04-14T03:37:01Z', 'uri': 'http://web.archive.org/web/20180414033701/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2018-05-19T10:30:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519103021/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2018-05-19T10:30:21Z', 'uri': 'http://web.archive.org/web/20180519103021/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}, {'datetime': '2018-06-09T22:12:15Z', 'uri': 'http://web.archive.org/web/20180609221215/https://www.guideline.gov/summaries/summary/47920/management-of-chronic-kidney-disease'}]
https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235247/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2016-09-30T23:52:47Z', 'uri': 'http://web.archive.org/web/20160930235247/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2017-10-03T04:02:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003040257/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2017-10-03T04:02:57Z', 'uri': 'http://web.archive.org/web/20171003040257/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2018-04-14T03:33:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414033335/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2018-04-14T03:33:35Z', 'uri': 'http://web.archive.org/web/20180414033335/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2018-05-19T10:27:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519102717/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2018-05-19T10:27:17Z', 'uri': 'http://web.archive.org/web/20180519102717/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}, {'datetime': '2018-06-09T22:27:39Z', 'uri': 'http://web.archive.org/web/20180609222739/https://www.guideline.gov/summaries/summary/47921/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-seizures'}]
https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235257/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2016-09-30T23:52:57Z', 'uri': 'http://web.archive.org/web/20160930235257/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2017-10-03T04:04:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003040402/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2017-10-03T04:04:02Z', 'uri': 'http://web.archive.org/web/20171003040402/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2018-04-14T03:35:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414033516/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2018-04-14T03:35:16Z', 'uri': 'http://web.archive.org/web/20180414033516/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2018-05-19T10:28:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519102846/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2018-05-19T10:28:46Z', 'uri': 'http://web.archive.org/web/20180519102846/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}, {'datetime': '2018-06-10T22:39:18Z', 'uri': 'http://web.archive.org/web/20180610223918/https://www.guideline.gov/summaries/summary/47922/aflibercept-in-combination-with-irinotecan-and-fluorouracilbased-therapy-for-treating-metastatic-colorectal-cancer-that-has-progressed-following-prior-oxaliplatinbased-chemotherapy'}]
https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930235258/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2016-09-30T23:52:58Z', 'uri': 'http://web.archive.org/web/20160930235258/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2017-10-03T04:04:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003040408/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2017-10-03T04:04:08Z', 'uri': 'http://web.archive.org/web/20171003040408/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2018-04-14T03:35:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414033526/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2018-04-14T03:35:26Z', 'uri': 'http://web.archive.org/web/20180414033526/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2018-05-19T10:28:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519102854/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2018-05-19T10:28:54Z', 'uri': 'http://web.archive.org/web/20180519102854/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}, {'datetime': '2018-06-11T06:38:00Z', 'uri': 'http://web.archive.org/web/20180611063800/https://www.guideline.gov/summaries/summary/47923/rituximab-in-combination-with-glucocorticoids-for-treating-antineutrophil-cytoplasmic-antibodyassociated-vasculitis'}]
https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:51:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235138/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2016-09-30T23:51:38Z', 'uri': 'http://web.archive.org/web/20160930235138/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2017-10-03T03:56:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003035636/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2017-10-03T03:56:36Z', 'uri': 'http://web.archive.org/web/20171003035636/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2018-01-10T13:22:47Z', 'uri': 'http://web.archive.org/web/20180110132247/https://guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2018-04-14T03:25:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414032502/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2018-04-14T03:25:02Z', 'uri': 'http://web.archive.org/web/20180414032502/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2018-05-19T10:18:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519101818/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2018-05-19T10:18:18Z', 'uri': 'http://web.archive.org/web/20180519101818/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}, {'datetime': '2018-06-09T20:14:02Z', 'uri': 'http://web.archive.org/web/20180609201402/https://www.guideline.gov/summaries/summary/47924/uk-national-guideline-for-the-management-of-chancroid-2014'}]
https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235316/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2016-09-30T23:53:16Z', 'uri': 'http://web.archive.org/web/20160930235316/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2017-10-03T04:05:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003040534/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2017-10-03T04:05:34Z', 'uri': 'http://web.archive.org/web/20171003040534/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2018-04-14T03:36:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414033653/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2018-04-14T03:36:53Z', 'uri': 'http://web.archive.org/web/20180414033653/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2018-05-19T10:30:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519103013/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2018-05-19T10:30:13Z', 'uri': 'http://web.archive.org/web/20180519103013/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}, {'datetime': '2018-06-09T22:21:39Z', 'uri': 'http://web.archive.org/web/20180609222139/https://www.guideline.gov/summaries/summary/47925/the-use-of-magnetic-resonance-imaging-in-the-obstetric-patient'}]
https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930235123/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2016-09-30T23:51:23Z', 'uri': 'http://web.archive.org/web/20160930235123/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2017-10-03T03:55:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003035511/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2017-10-03T03:55:11Z', 'uri': 'http://web.archive.org/web/20171003035511/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2018-04-14T03:23:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414032308/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2018-04-14T03:23:08Z', 'uri': 'http://web.archive.org/web/20180414032308/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2018-05-19T10:16:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519101625/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2018-05-19T10:16:25Z', 'uri': 'http://web.archive.org/web/20180519101625/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}, {'datetime': '2018-06-09T19:09:32Z', 'uri': 'http://web.archive.org/web/20180609190932/https://www.guideline.gov/summaries/summary/47993/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cytochrome-p450-2d6-genotype-and-codeine-therapy-2014-update'}]
https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930235122/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2016-09-30T23:51:22Z', 'uri': 'http://web.archive.org/web/20160930235122/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2017-10-03T03:55:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003035505/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2017-10-03T03:55:05Z', 'uri': 'http://web.archive.org/web/20171003035505/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2018-04-14T03:22:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414032259/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2018-04-14T03:22:59Z', 'uri': 'http://web.archive.org/web/20180414032259/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2018-05-19T10:16:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519101615/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2018-05-19T10:16:15Z', 'uri': 'http://web.archive.org/web/20180519101615/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}, {'datetime': '2018-06-09T11:02:53Z', 'uri': 'http://web.archive.org/web/20180609110253/https://www.guideline.gov/summaries/summary/47995/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ifnl3-il28b-genotype-and-peg-interferon--based-regimens'}]
https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930235259/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2016-09-30T23:52:59Z', 'uri': 'http://web.archive.org/web/20160930235259/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2017-10-03T04:04:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003040415/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2017-10-03T04:04:15Z', 'uri': 'http://web.archive.org/web/20171003040415/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2018-04-14T03:35:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414033536/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2018-04-14T03:35:36Z', 'uri': 'http://web.archive.org/web/20180414033536/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2018-05-19T10:29:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519102903/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2018-05-19T10:29:03Z', 'uri': 'http://web.archive.org/web/20180519102903/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}, {'datetime': '2018-06-09T21:16:27Z', 'uri': 'http://web.archive.org/web/20180609211627/https://www.guideline.gov/summaries/summary/48001/safe-administration-of-systemic-cancer-therapy-part-2-administration-of-chemotherapy-and-management-of-preventable-adverse-events'}]
https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235150/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2016-09-30T23:51:50Z', 'uri': 'http://web.archive.org/web/20160930235150/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2017-10-03T03:58:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003035807/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2017-10-03T03:58:07Z', 'uri': 'http://web.archive.org/web/20171003035807/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2018-04-14T03:26:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414032648/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2018-04-14T03:26:48Z', 'uri': 'http://web.archive.org/web/20180414032648/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2018-05-19T10:19:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519101948/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2018-05-19T10:19:48Z', 'uri': 'http://web.archive.org/web/20180519101948/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}, {'datetime': '2018-06-09T19:10:53Z', 'uri': 'http://web.archive.org/web/20180609191053/https://www.guideline.gov/summaries/summary/48024/aspen-clinical-guidelines-parenteral-nutrition-ordering-order-review-compounding-labeling-and-dispensing'}]
https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:53:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235320/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2016-09-30T23:53:20Z', 'uri': 'http://web.archive.org/web/20160930235320/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2017-10-03T04:10:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003041036/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2017-10-03T04:10:36Z', 'uri': 'http://web.archive.org/web/20171003041036/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2018-04-14T03:37:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414033720/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2018-04-14T03:37:20Z', 'uri': 'http://web.archive.org/web/20180414033720/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2018-05-19T10:30:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519103037/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2018-05-19T10:30:37Z', 'uri': 'http://web.archive.org/web/20180519103037/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}, {'datetime': '2018-06-09T23:13:29Z', 'uri': 'http://web.archive.org/web/20180609231329/https://www.guideline.gov/summaries/summary/48025/multifetal-gestations-twin-triplet-and-higherorder-multifetal-pregnancies'}]
https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:28:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930162801/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2016-09-30T16:28:01Z', 'uri': 'http://web.archive.org/web/20160930162801/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2017-10-02T20:09:00Z', 'uri': 'http://wayback.archive-it.org/all/20171002200900/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2017-10-02T20:09:00Z', 'uri': 'http://web.archive.org/web/20171002200900/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2018-04-14T00:45:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414004518/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2018-04-14T00:45:18Z', 'uri': 'http://web.archive.org/web/20180414004518/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2018-05-18T22:03:06Z', 'uri': 'http://wayback.archive-it.org/all/20180518220306/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2018-05-18T22:03:06Z', 'uri': 'http://web.archive.org/web/20180518220306/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}, {'datetime': '2018-06-09T15:45:26Z', 'uri': 'http://web.archive.org/web/20180609154526/https://www.guideline.gov/summaries/summary/48026/pressure-ulcers-prevention-and-management-of-pressure-ulcers'}]
https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235156/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2016-09-30T23:51:56Z', 'uri': 'http://web.archive.org/web/20160930235156/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2017-10-03T03:58:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003035853/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2017-10-03T03:58:53Z', 'uri': 'http://web.archive.org/web/20171003035853/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-04-14T03:27:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414032733/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-04-14T03:27:33Z', 'uri': 'http://web.archive.org/web/20180414032733/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-05-19T10:20:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519102034/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-05-19T10:20:34Z', 'uri': 'http://web.archive.org/web/20180519102034/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-06-10T01:43:32Z', 'uri': 'http://web.archive.org/web/20180610014332/https://www.guideline.gov/summaries/summary/48027/afatinib-for-treating-epidermal-growth-factor-receptor-mutationpositive-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}]
https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235157/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2016-09-30T23:51:57Z', 'uri': 'http://web.archive.org/web/20160930235157/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2017-10-03T03:59:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003035901/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2017-10-03T03:59:01Z', 'uri': 'http://web.archive.org/web/20171003035901/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2018-04-14T03:27:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414032742/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2018-04-14T03:27:42Z', 'uri': 'http://web.archive.org/web/20180414032742/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2018-05-19T10:20:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519102042/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2018-05-19T10:20:42Z', 'uri': 'http://web.archive.org/web/20180519102042/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}, {'datetime': '2018-06-11T08:42:41Z', 'uri': 'http://web.archive.org/web/20180611084241/https://www.guideline.gov/summaries/summary/48028/bortezomib-for-induction-therapy-in-multiple-myeloma-before-highdose-chemotherapy-and-autologous-stem-cell-transplantation'}]
https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930235121/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2016-09-30T23:51:21Z', 'uri': 'http://web.archive.org/web/20160930235121/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2017-10-03T03:54:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003035457/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2017-10-03T03:54:57Z', 'uri': 'http://web.archive.org/web/20171003035457/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2018-04-14T03:22:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414032249/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2018-04-14T03:22:49Z', 'uri': 'http://web.archive.org/web/20180414032249/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2018-05-19T10:16:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519101606/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2018-05-19T10:16:06Z', 'uri': 'http://web.archive.org/web/20180519101606/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}, {'datetime': '2018-06-09T23:31:07Z', 'uri': 'http://web.archive.org/web/20180609233107/https://www.guideline.gov/summaries/summary/48048/providing-quality-family-planning-services-recommendations-of-cdc-and-the-us-office-of-population-affairs'}]
https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia	ARCHIVED	13 mementos	[{'datetime': '2016-09-30T23:51:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930235106/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2016-09-30T23:51:06Z', 'uri': 'http://web.archive.org/web/20160930235106/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2017-10-03T03:53:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003035340/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2017-10-03T03:53:40Z', 'uri': 'http://web.archive.org/web/20171003035340/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-04-14T03:21:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414032100/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-04-14T03:21:00Z', 'uri': 'http://web.archive.org/web/20180414032100/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-05-19T10:14:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519101442/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-05-19T10:14:42Z', 'uri': 'http://web.archive.org/web/20180519101442/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-06-09T10:37:38Z', 'uri': 'http://web.archive.org/web/20180609103738/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-07-12T22:01:45Z', 'uri': 'http://web.archive.org/web/20180712220145/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-07-12T22:01:45Z', 'uri': 'http://web.archive.org/web/20180712220145/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-07-12T22:01:46Z', 'uri': 'http://web.archive.org/web/20180712220146/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}, {'datetime': '2018-07-12T22:01:46Z', 'uri': 'http://web.archive.org/web/20180712220146/https://www.guideline.gov/summaries/summary/48052/clinical-practice-guidelines-for-the-management-of-overweight-and-obesity-in-adults-adolescents-and-children-in-australia'}]
https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235135/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2016-09-30T23:51:35Z', 'uri': 'http://web.archive.org/web/20160930235135/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2017-10-03T03:56:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003035619/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2017-10-03T03:56:19Z', 'uri': 'http://web.archive.org/web/20171003035619/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2018-04-14T03:24:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414032445/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2018-04-14T03:24:45Z', 'uri': 'http://web.archive.org/web/20180414032445/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2018-05-19T10:18:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519101803/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2018-05-19T10:18:03Z', 'uri': 'http://web.archive.org/web/20180519101803/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}, {'datetime': '2018-06-09T21:18:41Z', 'uri': 'http://web.archive.org/web/20180609211841/https://www.guideline.gov/summaries/summary/48053/the-clinical-utility-of-sperm-dna-integrity-testing-a-guideline'}]
https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930235209/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:52:09Z', 'uri': 'http://web.archive.org/web/20160930235209/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:00:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003040016/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T04:00:16Z', 'uri': 'http://web.archive.org/web/20171003040016/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:29:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414032935/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:29:35Z', 'uri': 'http://web.archive.org/web/20180414032935/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:22:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519102235/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:22:35Z', 'uri': 'http://web.archive.org/web/20180519102235/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T16:56:46Z', 'uri': 'http://web.archive.org/web/20180610165646/https://www.guideline.gov/summaries/summary/48054/prevention-of-dental-caries-in-children-from-birth-through-age-5-years-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235214/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2016-09-30T23:52:14Z', 'uri': 'http://web.archive.org/web/20160930235214/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2017-10-03T04:00:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003040047/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2017-10-03T04:00:47Z', 'uri': 'http://web.archive.org/web/20171003040047/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-04-14T03:30:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414033021/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-04-14T03:30:21Z', 'uri': 'http://web.archive.org/web/20180414033021/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-05-19T10:23:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519102318/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-05-19T10:23:18Z', 'uri': 'http://web.archive.org/web/20180519102318/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-06-09T11:43:34Z', 'uri': 'http://web.archive.org/web/20180609114334/https://www.guideline.gov/summaries/summary/48055/diagnosis-of-hypertensive-disorders-of-pregnancy-and-classification-of-blood-pressure-measurements-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}]
https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235215/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2016-09-30T23:52:15Z', 'uri': 'http://web.archive.org/web/20160930235215/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2017-10-03T04:00:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003040053/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2017-10-03T04:00:53Z', 'uri': 'http://web.archive.org/web/20171003040053/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-04-14T03:30:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414033030/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-04-14T03:30:30Z', 'uri': 'http://web.archive.org/web/20180414033030/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-05-19T10:23:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519102326/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-05-19T10:23:26Z', 'uri': 'http://web.archive.org/web/20180519102326/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-06-09T22:21:57Z', 'uri': 'http://web.archive.org/web/20180609222157/https://www.guideline.gov/summaries/summary/48056/prediction-and-prevention-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}]
https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235217/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2016-09-30T23:52:17Z', 'uri': 'http://web.archive.org/web/20160930235217/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2017-10-03T04:00:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003040058/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2017-10-03T04:00:58Z', 'uri': 'http://web.archive.org/web/20171003040058/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-04-14T03:30:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414033039/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-04-14T03:30:39Z', 'uri': 'http://web.archive.org/web/20180414033039/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-05-19T10:23:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519102335/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-05-19T10:23:35Z', 'uri': 'http://web.archive.org/web/20180519102335/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}, {'datetime': '2018-06-09T22:21:51Z', 'uri': 'http://web.archive.org/web/20180609222151/https://www.guideline.gov/summaries/summary/48057/treatment-of-the-hypertensive-disorders-of-pregnancy-in-diagnosis-evaluation-and-management-of-the-hypertensive-disorders-of-pregnancy-executive-summary'}]
https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930234935/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2016-09-30T23:49:35Z', 'uri': 'http://web.archive.org/web/20160930234935/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2017-10-03T03:46:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003034607/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2017-10-03T03:46:07Z', 'uri': 'http://web.archive.org/web/20171003034607/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2018-04-14T03:11:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414031133/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2018-04-14T03:11:33Z', 'uri': 'http://web.archive.org/web/20180414031133/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2018-05-19T10:05:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519100551/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2018-05-19T10:05:51Z', 'uri': 'http://web.archive.org/web/20180519100551/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}, {'datetime': '2018-06-09T11:01:09Z', 'uri': 'http://web.archive.org/web/20180609110109/https://www.guideline.gov/summaries/summary/48058/2013-update-of-the-2011-american-college-of-rheumatology-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis-recommendations-for-the-medical-therapy-of-children-with-systemic-juvenile-idiopathic-arthritis-and-tuberculosis-screening-among-childre'}]
https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930235125/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:51:25Z', 'uri': 'http://web.archive.org/web/20160930235125/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:55:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003035524/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:55:24Z', 'uri': 'http://web.archive.org/web/20171003035524/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:23:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414032328/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:23:28Z', 'uri': 'http://web.archive.org/web/20180414032328/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:16:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519101640/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:16:40Z', 'uri': 'http://web.archive.org/web/20180519101640/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T15:29:23Z', 'uri': 'http://web.archive.org/web/20180609152923/https://www.guideline.gov/summaries/summary/48059/screening-for-cognitive-impairment-in-older-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235111/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2016-09-30T23:51:11Z', 'uri': 'http://web.archive.org/web/20160930235111/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2017-10-03T03:53:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003035354/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2017-10-03T03:53:54Z', 'uri': 'http://web.archive.org/web/20171003035354/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2018-04-14T03:21:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414032111/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2018-04-14T03:21:11Z', 'uri': 'http://web.archive.org/web/20180414032111/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2018-05-19T10:14:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519101451/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2018-05-19T10:14:51Z', 'uri': 'http://web.archive.org/web/20180519101451/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}, {'datetime': '2018-06-09T21:08:59Z', 'uri': 'http://web.archive.org/web/20180609210859/https://www.guideline.gov/summaries/summary/48097/guidelines-for-the-practice-and-performance-of-manipulation-under-anesthesia'}]
https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930235130/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2016-09-30T23:51:30Z', 'uri': 'http://web.archive.org/web/20160930235130/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2017-10-03T03:55:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003035539/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2017-10-03T03:55:39Z', 'uri': 'http://web.archive.org/web/20171003035539/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2018-04-14T03:23:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414032349/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2018-04-14T03:23:49Z', 'uri': 'http://web.archive.org/web/20180414032349/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2018-05-19T10:17:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519101717/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2018-05-19T10:17:17Z', 'uri': 'http://web.archive.org/web/20180519101717/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}, {'datetime': '2018-06-09T19:40:41Z', 'uri': 'http://web.archive.org/web/20180609194041/https://www.guideline.gov/summaries/summary/48105/care-of-the-adult-patient-with-a-brain-tumor'}]
https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235134/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2016-09-30T23:51:34Z', 'uri': 'http://web.archive.org/web/20160930235134/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2017-10-03T03:56:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003035612/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2017-10-03T03:56:12Z', 'uri': 'http://web.archive.org/web/20171003035612/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2018-04-14T03:24:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414032436/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2018-04-14T03:24:36Z', 'uri': 'http://web.archive.org/web/20180414032436/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2018-05-19T10:17:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519101756/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2018-05-19T10:17:56Z', 'uri': 'http://web.archive.org/web/20180519101756/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-10T01:14:31Z', 'uri': 'http://web.archive.org/web/20180610011431/https://www.guideline.gov/summaries/summary/48107/the-role-of-postoperative-radiation-therapy-for-endometrial-cancer-an-astro-evidencebased-guideline'}]
https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:51:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235132/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2016-09-30T23:51:32Z', 'uri': 'http://web.archive.org/web/20160930235132/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2017-10-03T03:55:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003035553/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2017-10-03T03:55:53Z', 'uri': 'http://web.archive.org/web/20171003035553/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2018-04-14T03:24:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414032408/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2018-04-14T03:24:08Z', 'uri': 'http://web.archive.org/web/20180414032408/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2018-05-18T19:33:43Z', 'uri': 'http://wayback.archive-it.org/all/20180518193343/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2018-05-18T19:33:43Z', 'uri': 'http://web.archive.org/web/20180518193343/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2018-06-09T10:43:26Z', 'uri': 'http://web.archive.org/web/20180609104326/https://www.guideline.gov/summaries/summary/48115/an-evidencebased-prehospital-guideline-for-external-hemorrhage-control-american-college-of-surgeons-committee-on-trauma'}, {'datetime': '2018-06-10T03:39:28Z', 'uri': 'http://web.archive.org/web/20180610033928/https://www.guideline.gov/summaries/summary/48115/An-evidencebased-prehospital-guideline-for-external-hemorrhage-control-American-College-of-Surgeons-Committee-on-Trauma'}]
https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc	ARCHIVED	12 mementos	[{'datetime': '2016-09-30T23:50:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930235027/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2016-09-30T23:50:27Z', 'uri': 'http://web.archive.org/web/20160930235027/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2017-07-14T10:07:26Z', 'uri': 'http://web.archive.org/web/20170714100726/https://guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2017-10-03T03:49:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003034946/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2017-10-03T03:49:46Z', 'uri': 'http://web.archive.org/web/20171003034946/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-04-14T03:15:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414031532/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-04-14T03:15:32Z', 'uri': 'http://web.archive.org/web/20180414031532/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-05-19T10:09:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519100937/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-05-19T10:09:37Z', 'uri': 'http://web.archive.org/web/20180519100937/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-06-09T11:41:27Z', 'uri': 'http://web.archive.org/web/20180609114127/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-07-12T21:45:12Z', 'uri': 'http://web.archive.org/web/20180712214512/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}, {'datetime': '2018-07-12T21:45:12Z', 'uri': 'http://web.archive.org/web/20180712214512/https://www.guideline.gov/summaries/summary/48121/optimal-use-of-taxanes-in-metastatic-breast-cancer-mbc'}]
https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930235029/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2016-09-30T23:50:29Z', 'uri': 'http://web.archive.org/web/20160930235029/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2017-10-03T03:49:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003034957/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2017-10-03T03:49:57Z', 'uri': 'http://web.archive.org/web/20171003034957/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2018-04-14T03:15:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414031547/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2018-04-14T03:15:47Z', 'uri': 'http://web.archive.org/web/20180414031547/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2018-05-19T10:09:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519100950/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2018-05-19T10:09:50Z', 'uri': 'http://web.archive.org/web/20180519100950/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}, {'datetime': '2018-06-09T20:55:21Z', 'uri': 'http://web.archive.org/web/20180609205521/https://www.guideline.gov/summaries/summary/48127/the-use-of-dexamethasone-in-patients-with-high-grade-gliomas'}]
https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235014/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2016-09-30T23:50:14Z', 'uri': 'http://web.archive.org/web/20160930235014/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2017-10-03T03:49:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003034914/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2017-10-03T03:49:14Z', 'uri': 'http://web.archive.org/web/20171003034914/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2018-04-14T03:15:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414031504/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2018-04-14T03:15:04Z', 'uri': 'http://web.archive.org/web/20180414031504/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2018-05-19T10:09:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519100910/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2018-05-19T10:09:10Z', 'uri': 'http://web.archive.org/web/20180519100910/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}, {'datetime': '2018-06-10T23:04:14Z', 'uri': 'http://web.archive.org/web/20180610230414/https://www.guideline.gov/summaries/summary/48129/adjuvant-interferon-for-malignant-melanoma'}]
https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930235028/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2016-09-30T23:50:28Z', 'uri': 'http://web.archive.org/web/20160930235028/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2017-10-03T03:49:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003034951/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2017-10-03T03:49:51Z', 'uri': 'http://web.archive.org/web/20171003034951/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2018-04-14T03:15:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414031539/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2018-04-14T03:15:39Z', 'uri': 'http://web.archive.org/web/20180414031539/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2018-05-19T10:09:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519100943/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2018-05-19T10:09:43Z', 'uri': 'http://web.archive.org/web/20180519100943/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}, {'datetime': '2018-06-09T20:55:35Z', 'uri': 'http://web.archive.org/web/20180609205535/https://www.guideline.gov/summaries/summary/48130/prevention-of-skin-cancer'}]
https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930235025/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2016-09-30T23:50:25Z', 'uri': 'http://web.archive.org/web/20160930235025/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2017-10-03T03:49:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003034936/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2017-10-03T03:49:36Z', 'uri': 'http://web.archive.org/web/20171003034936/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2018-04-14T03:15:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414031519/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2018-04-14T03:15:19Z', 'uri': 'http://web.archive.org/web/20180414031519/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2018-05-19T10:09:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519100925/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2018-05-19T10:09:25Z', 'uri': 'http://web.archive.org/web/20180519100925/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}, {'datetime': '2018-06-09T20:55:08Z', 'uri': 'http://web.archive.org/web/20180609205508/https://www.guideline.gov/summaries/summary/48131/mitotane-for-the-management-of-adrenocortical-carcinoma'}]
https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930234920/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2016-09-30T23:49:20Z', 'uri': 'http://web.archive.org/web/20160930234920/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2017-10-03T03:45:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003034525/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2017-10-03T03:45:25Z', 'uri': 'http://web.archive.org/web/20171003034525/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2018-04-14T03:10:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414031048/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2018-04-14T03:10:48Z', 'uri': 'http://web.archive.org/web/20180414031048/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2018-05-19T10:04:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519100459/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2018-05-19T10:04:59Z', 'uri': 'http://web.archive.org/web/20180519100459/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}, {'datetime': '2018-06-10T11:36:31Z', 'uri': 'http://web.archive.org/web/20180610113631/https://www.guideline.gov/summaries/summary/48137/management-of-patients-with-early-esophageal-cancer-dysplastic-and-nondysplastic-barretts-esophagus'}]
https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:49:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930234910/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2016-09-30T23:49:10Z', 'uri': 'http://web.archive.org/web/20160930234910/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2017-07-14T09:43:28Z', 'uri': 'http://web.archive.org/web/20170714094328/https://guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2017-10-03T03:45:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003034519/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2017-10-03T03:45:19Z', 'uri': 'http://web.archive.org/web/20171003034519/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2018-04-14T03:10:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414031039/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2018-04-14T03:10:39Z', 'uri': 'http://web.archive.org/web/20180414031039/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2018-05-19T10:04:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519100450/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2018-05-19T10:04:50Z', 'uri': 'http://web.archive.org/web/20180519100450/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}, {'datetime': '2018-06-09T11:05:32Z', 'uri': 'http://web.archive.org/web/20180609110532/https://www.guideline.gov/summaries/summary/48138/extragonadal-germ-cell-tumours'}]
https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930234934/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2016-09-30T23:49:34Z', 'uri': 'http://web.archive.org/web/20160930234934/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2017-10-03T03:46:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003034601/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2017-10-03T03:46:01Z', 'uri': 'http://web.archive.org/web/20171003034601/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2018-04-14T03:11:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414031124/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2018-04-14T03:11:24Z', 'uri': 'http://web.archive.org/web/20180414031124/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2018-05-19T10:05:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519100531/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2018-05-19T10:05:31Z', 'uri': 'http://web.archive.org/web/20180519100531/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}, {'datetime': '2018-06-09T20:55:06Z', 'uri': 'http://web.archive.org/web/20180609205506/https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours'}]
https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:49:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930234928/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2016-09-30T23:49:28Z', 'uri': 'http://web.archive.org/web/20160930234928/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2017-10-03T03:45:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003034532/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2017-10-03T03:45:32Z', 'uri': 'http://web.archive.org/web/20171003034532/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2018-01-10T13:22:16Z', 'uri': 'http://web.archive.org/web/20180110132216/https://guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2018-04-14T03:10:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414031058/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2018-04-14T03:10:58Z', 'uri': 'http://web.archive.org/web/20180414031058/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2018-05-19T10:05:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519100508/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2018-05-19T10:05:08Z', 'uri': 'http://web.archive.org/web/20180519100508/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}, {'datetime': '2018-06-09T21:23:21Z', 'uri': 'http://web.archive.org/web/20180609212321/https://www.guideline.gov/summaries/summary/48140/nasopharyngeal-cancer-treatment'}]
https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930234931/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2016-09-30T23:49:31Z', 'uri': 'http://web.archive.org/web/20160930234931/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2017-10-03T03:45:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003034545/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2017-10-03T03:45:45Z', 'uri': 'http://web.archive.org/web/20171003034545/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2018-04-14T03:11:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414031108/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2018-04-14T03:11:08Z', 'uri': 'http://web.archive.org/web/20180414031108/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2018-05-19T10:05:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519100517/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2018-05-19T10:05:17Z', 'uri': 'http://web.archive.org/web/20180519100517/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}, {'datetime': '2018-06-09T20:55:11Z', 'uri': 'http://web.archive.org/web/20180609205511/https://www.guideline.gov/summaries/summary/48145/prophylaxis-and-treatment-of-venous-thromboembolism-in-patients-undergoing-treatment-for-solid-tumours'}]
https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930235101/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2016-09-30T23:51:01Z', 'uri': 'http://web.archive.org/web/20160930235101/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2017-10-03T03:53:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003035306/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2017-10-03T03:53:06Z', 'uri': 'http://web.archive.org/web/20171003035306/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2018-04-14T03:20:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414032012/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2018-04-14T03:20:12Z', 'uri': 'http://web.archive.org/web/20180414032012/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2018-05-19T10:14:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519101401/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2018-05-19T10:14:01Z', 'uri': 'http://web.archive.org/web/20180519101401/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}, {'datetime': '2018-06-10T00:33:59Z', 'uri': 'http://web.archive.org/web/20180610003359/https://www.guideline.gov/summaries/summary/48186/american-college-of-medical-genetics-and-genomics-guideline-for-the-clinical-evaluation-and-etiologic-diagnosis-of-hearing-loss'}]
https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8	ARCHIVED	14 mementos	[{'datetime': '2016-09-30T23:52:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930235208/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2016-09-30T23:52:08Z', 'uri': 'http://web.archive.org/web/20160930235208/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2017-07-13T03:32:36Z', 'uri': 'http://web.archive.org/web/20170713033236/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-Report-from-the-panel-members-appointed-to-the-Eighth-Joint-National-Committee-JNC-8'}, {'datetime': '2017-10-03T04:00:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003040010/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2017-10-03T04:00:10Z', 'uri': 'http://web.archive.org/web/20171003040010/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2018-04-14T03:29:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414032926/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2018-04-14T03:29:26Z', 'uri': 'http://web.archive.org/web/20180414032926/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2018-05-19T10:22:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519102227/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2018-05-19T10:22:27Z', 'uri': 'http://web.archive.org/web/20180519102227/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2018-06-09T10:35:54Z', 'uri': 'http://web.archive.org/web/20180609103554/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-Report-from-the-panel-members-appointed-to-the-Eighth-Joint-National-Committee-JNC-8'}, {'datetime': '2018-06-09T15:17:15Z', 'uri': 'http://web.archive.org/web/20180609151715/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-report-from-the-panel-members-appointed-to-the-eighth-joint-national-committee-jnc-8'}, {'datetime': '2018-06-20T17:39:38Z', 'uri': 'http://web.archive.org/web/20180620173938/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-Report-from-the-panel-members-appointed-to-the-Eighth-Joint-National-Committee-JNC-8'}, {'datetime': '2018-06-21T00:15:19Z', 'uri': 'http://web.archive.org/web/20180621001519/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-Report-from-the-panel-members-appointed-to-the-Eighth-Joint-National-Committee-JNC-8'}, {'datetime': '2018-06-23T03:06:37Z', 'uri': 'http://web.archive.org/web/20180623030637/https://www.guideline.gov/summaries/summary/48192/2014-evidencebased-guideline-for-the-management-of-high-blood-pressure-in-adults-Report-from-the-panel-members-appointed-to-the-Eighth-Joint-National-Committee-JNC-8'}]
https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930235126/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:51:26Z', 'uri': 'http://web.archive.org/web/20160930235126/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:55:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003035532/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:55:32Z', 'uri': 'http://web.archive.org/web/20171003035532/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:23:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414032339/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:23:39Z', 'uri': 'http://web.archive.org/web/20180414032339/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:16:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519101649/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:16:49Z', 'uri': 'http://web.archive.org/web/20180519101649/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T15:15:12Z', 'uri': 'http://web.archive.org/web/20180609151512/https://www.guideline.gov/summaries/summary/48193/screening-for-suicide-risk-in-adolescents-adults-and-older-adults-in-primary-care-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235047/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2016-09-30T23:50:47Z', 'uri': 'http://web.archive.org/web/20160930235047/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2017-10-03T03:51:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003035134/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2017-10-03T03:51:34Z', 'uri': 'http://web.archive.org/web/20171003035134/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2018-04-14T03:17:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414031758/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2018-04-14T03:17:58Z', 'uri': 'http://web.archive.org/web/20180414031758/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2018-05-19T10:11:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519101146/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2018-05-19T10:11:46Z', 'uri': 'http://web.archive.org/web/20180519101146/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}, {'datetime': '2018-06-09T15:30:47Z', 'uri': 'http://web.archive.org/web/20180609153047/https://www.guideline.gov/summaries/summary/48194/screening-and-management-of-lipids'}]
https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930235049/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2016-09-30T23:50:49Z', 'uri': 'http://web.archive.org/web/20160930235049/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2017-10-03T03:51:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003035148/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2017-10-03T03:51:48Z', 'uri': 'http://web.archive.org/web/20171003035148/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2018-04-14T03:18:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414031818/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2018-04-14T03:18:18Z', 'uri': 'http://web.archive.org/web/20180414031818/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2018-05-19T10:12:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519101220/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2018-05-19T10:12:20Z', 'uri': 'http://web.archive.org/web/20180519101220/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}, {'datetime': '2018-06-09T22:12:28Z', 'uri': 'http://web.archive.org/web/20180609221228/https://www.guideline.gov/summaries/summary/48195/venous-thromboembolism-vte'}]
https://www.guideline.gov/summaries/summary/48196/essential-hypertension	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930235046/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2016-09-30T23:50:46Z', 'uri': 'http://web.archive.org/web/20160930235046/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2017-10-03T03:51:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003035128/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2017-10-03T03:51:28Z', 'uri': 'http://web.archive.org/web/20171003035128/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2018-04-14T03:17:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414031750/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2018-04-14T03:17:50Z', 'uri': 'http://web.archive.org/web/20180414031750/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2018-05-19T10:11:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519101136/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2018-05-19T10:11:36Z', 'uri': 'http://web.archive.org/web/20180519101136/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}, {'datetime': '2018-06-09T21:34:45Z', 'uri': 'http://web.archive.org/web/20180609213445/https://www.guideline.gov/summaries/summary/48196/essential-hypertension'}]
https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930235056/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2016-09-30T23:50:56Z', 'uri': 'http://web.archive.org/web/20160930235056/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2017-10-03T03:52:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003035239/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2017-10-03T03:52:39Z', 'uri': 'http://web.archive.org/web/20171003035239/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2018-04-14T03:19:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414031935/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2018-04-14T03:19:35Z', 'uri': 'http://web.archive.org/web/20180414031935/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2018-05-19T10:13:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519101329/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2018-05-19T10:13:29Z', 'uri': 'http://web.archive.org/web/20180519101329/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}, {'datetime': '2018-06-10T01:49:02Z', 'uri': 'http://web.archive.org/web/20180610014902/https://www.guideline.gov/summaries/summary/48197/guidelines-for-the-diagnosis-and-treatment-of-cobalamin-and-folate-disorders'}]
https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930235120/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2016-09-30T23:51:20Z', 'uri': 'http://web.archive.org/web/20160930235120/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2017-10-03T03:54:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003035451/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2017-10-03T03:54:51Z', 'uri': 'http://web.archive.org/web/20171003035451/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2018-04-14T03:22:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414032240/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2018-04-14T03:22:40Z', 'uri': 'http://web.archive.org/web/20180414032240/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2018-05-19T10:15:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519101559/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2018-05-19T10:15:59Z', 'uri': 'http://web.archive.org/web/20180519101559/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}, {'datetime': '2018-06-09T19:10:04Z', 'uri': 'http://web.archive.org/web/20180609191004/https://www.guideline.gov/summaries/summary/48199/preexposure-prophylaxis-for-the-prevention-of-hiv-infection-in-the-united-states--2014'}]
https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930234947/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2016-09-30T23:49:47Z', 'uri': 'http://web.archive.org/web/20160930234947/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2017-10-03T03:47:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003034733/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2017-10-03T03:47:33Z', 'uri': 'http://web.archive.org/web/20171003034733/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2018-04-14T03:12:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414031240/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2018-04-14T03:12:40Z', 'uri': 'http://web.archive.org/web/20180414031240/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2018-05-19T10:06:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519100650/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2018-05-19T10:06:50Z', 'uri': 'http://web.archive.org/web/20180519100650/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}, {'datetime': '2018-06-09T15:21:30Z', 'uri': 'http://web.archive.org/web/20180609152130/https://www.guideline.gov/summaries/summary/48208/the-official-positions-of-the-international-society-for-clinical-densitometry-body-composition-analysis-reporting'}]
https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930234946/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2016-09-30T23:49:46Z', 'uri': 'http://web.archive.org/web/20160930234946/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2017-10-03T03:47:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003034727/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2017-10-03T03:47:27Z', 'uri': 'http://web.archive.org/web/20171003034727/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2018-04-14T03:12:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414031230/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2018-04-14T03:12:30Z', 'uri': 'http://web.archive.org/web/20180414031230/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2018-05-19T10:06:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519100642/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2018-05-19T10:06:42Z', 'uri': 'http://web.archive.org/web/20180519100642/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}, {'datetime': '2018-06-09T15:21:19Z', 'uri': 'http://web.archive.org/web/20180609152119/https://www.guideline.gov/summaries/summary/48209/the-official-positions-of-the-international-society-for-clinical-densitometry-acquisition-of-dualenergy-xray-absorptiometry-body-composition-and-considerations-regarding-analysis-and-repeatability-of-measures'}]
https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930234948/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2016-09-30T23:49:48Z', 'uri': 'http://web.archive.org/web/20160930234948/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2017-10-03T03:47:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003034739/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2017-10-03T03:47:39Z', 'uri': 'http://web.archive.org/web/20171003034739/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2018-04-14T03:12:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414031250/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2018-04-14T03:12:50Z', 'uri': 'http://web.archive.org/web/20180414031250/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2018-05-19T10:07:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519100709/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2018-05-19T10:07:09Z', 'uri': 'http://web.archive.org/web/20180519100709/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}, {'datetime': '2018-06-09T15:19:38Z', 'uri': 'http://web.archive.org/web/20180609151938/https://www.guideline.gov/summaries/summary/48210/the-official-positions-of-the-international-society-for-clinical-densitometry-indications-of-use-and-reporting-of-dxa-for-body-composition'}]
https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930234945/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2016-09-30T23:49:45Z', 'uri': 'http://web.archive.org/web/20160930234945/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2017-10-03T03:47:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003034720/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2017-10-03T03:47:20Z', 'uri': 'http://web.archive.org/web/20171003034720/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2018-04-14T03:12:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414031221/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2018-04-14T03:12:21Z', 'uri': 'http://web.archive.org/web/20180414031221/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2018-05-19T10:06:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519100632/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2018-05-19T10:06:32Z', 'uri': 'http://web.archive.org/web/20180519100632/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}, {'datetime': '2018-06-09T15:20:55Z', 'uri': 'http://web.archive.org/web/20180609152055/https://www.guideline.gov/summaries/summary/48211/indications-of-dxa-in-women-younger-than-65-yr-and-men-younger-than-70-yr-the-2013-official-positions'}]
https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930234949/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2016-09-30T23:49:49Z', 'uri': 'http://web.archive.org/web/20160930234949/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2017-10-03T03:47:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003034745/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2017-10-03T03:47:45Z', 'uri': 'http://web.archive.org/web/20171003034745/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2018-04-14T03:12:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414031259/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2018-04-14T03:12:59Z', 'uri': 'http://web.archive.org/web/20180414031259/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2018-05-19T10:07:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519100718/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2018-05-19T10:07:18Z', 'uri': 'http://web.archive.org/web/20180519100718/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}, {'datetime': '2018-06-09T15:27:42Z', 'uri': 'http://web.archive.org/web/20180609152742/https://www.guideline.gov/summaries/summary/48212/the-official-positions-of-the-international-society-for-clinical-densitometry-vertebral-fracture-assessment'}]
https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930234945/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2016-09-30T23:49:45Z', 'uri': 'http://web.archive.org/web/20160930234945/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2017-10-03T03:46:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003034655/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2017-10-03T03:46:55Z', 'uri': 'http://web.archive.org/web/20171003034655/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2018-04-14T03:12:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414031212/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2018-04-14T03:12:12Z', 'uri': 'http://web.archive.org/web/20180414031212/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2018-05-19T10:06:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519100624/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2018-05-19T10:06:24Z', 'uri': 'http://web.archive.org/web/20180519100624/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}, {'datetime': '2018-06-09T15:19:51Z', 'uri': 'http://web.archive.org/web/20180609151951/https://www.guideline.gov/summaries/summary/48213/2013-international-society-for-clinical-densitometry-position-development-conference-task-force-on-normative-databases'}]
https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235141/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2016-09-30T23:51:41Z', 'uri': 'http://web.archive.org/web/20160930235141/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2017-10-03T03:57:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003035715/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2017-10-03T03:57:15Z', 'uri': 'http://web.archive.org/web/20171003035715/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T03:25:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414032525/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T03:25:25Z', 'uri': 'http://web.archive.org/web/20180414032525/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T10:18:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519101836/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T10:18:36Z', 'uri': 'http://web.archive.org/web/20180519101836/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}, {'datetime': '2018-06-09T21:14:57Z', 'uri': 'http://web.archive.org/web/20180609211457/https://www.guideline.gov/summaries/summary/48214/conservative-care-options-for-occupational-carpal-tunnel-syndrome'}]
https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930235144/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2016-09-30T23:51:44Z', 'uri': 'http://web.archive.org/web/20160930235144/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2017-10-03T03:57:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003035733/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2017-10-03T03:57:33Z', 'uri': 'http://web.archive.org/web/20171003035733/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2018-04-14T03:25:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414032553/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2018-04-14T03:25:53Z', 'uri': 'http://web.archive.org/web/20180414032553/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2018-05-19T10:18:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519101858/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2018-05-19T10:18:58Z', 'uri': 'http://web.archive.org/web/20180519101858/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}, {'datetime': '2018-06-10T00:20:27Z', 'uri': 'http://web.archive.org/web/20180610002027/https://www.guideline.gov/summaries/summary/48215/options-for-documenting-functional-improvement-in-conservative-care'}]
https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235142/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2016-09-30T23:51:42Z', 'uri': 'http://web.archive.org/web/20160930235142/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2017-10-03T03:57:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003035720/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2017-10-03T03:57:20Z', 'uri': 'http://web.archive.org/web/20171003035720/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2018-04-14T03:25:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414032534/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2018-04-14T03:25:34Z', 'uri': 'http://web.archive.org/web/20180414032534/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2018-05-19T10:18:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519101843/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2018-05-19T10:18:43Z', 'uri': 'http://web.archive.org/web/20180519101843/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}, {'datetime': '2018-06-09T11:24:05Z', 'uri': 'http://web.archive.org/web/20180609112405/https://www.guideline.gov/summaries/summary/48216/conservative-care-options-for-workrelated-epicondylosis'}]
https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235143/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2016-09-30T23:51:43Z', 'uri': 'http://web.archive.org/web/20160930235143/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2017-10-03T03:57:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003035727/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2017-10-03T03:57:27Z', 'uri': 'http://web.archive.org/web/20171003035727/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2018-04-14T03:25:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414032543/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2018-04-14T03:25:43Z', 'uri': 'http://web.archive.org/web/20180414032543/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2018-05-19T10:18:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519101850/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2018-05-19T10:18:50Z', 'uri': 'http://web.archive.org/web/20180519101850/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}, {'datetime': '2018-06-09T21:15:33Z', 'uri': 'http://web.archive.org/web/20180609211533/https://www.guideline.gov/summaries/summary/48217/conservative-care-options-for-workrelated-mechanical-shoulder-conditions'}]
https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235048/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2016-09-30T23:50:48Z', 'uri': 'http://web.archive.org/web/20160930235048/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2017-10-03T03:51:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003035140/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2017-10-03T03:51:40Z', 'uri': 'http://web.archive.org/web/20171003035140/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2018-04-14T03:18:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414031807/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2018-04-14T03:18:07Z', 'uri': 'http://web.archive.org/web/20180414031807/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2018-05-19T10:12:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519101211/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2018-05-19T10:12:11Z', 'uri': 'http://web.archive.org/web/20180519101211/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}, {'datetime': '2018-06-09T11:28:37Z', 'uri': 'http://web.archive.org/web/20180609112837/https://www.guideline.gov/summaries/summary/48221/secondary-prevention-of-ischemic-heart-disease-and-stroke-in-adults'}]
https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930235043/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2016-09-30T23:50:43Z', 'uri': 'http://web.archive.org/web/20160930235043/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2017-10-03T03:51:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003035113/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2017-10-03T03:51:13Z', 'uri': 'http://web.archive.org/web/20171003035113/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:17:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414031742/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:17:42Z', 'uri': 'http://web.archive.org/web/20180414031742/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:11:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519101128/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:11:28Z', 'uri': 'http://web.archive.org/web/20180519101128/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-06-10T00:14:03Z', 'uri': 'http://web.archive.org/web/20180610001403/https://www.guideline.gov/summaries/summary/48222/recommendations-for-drug-therapies-for-relapsingremitting-multiple-sclerosis'}]
https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930235136/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2016-09-30T23:51:36Z', 'uri': 'http://web.archive.org/web/20160930235136/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2017-10-03T03:56:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003035624/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2017-10-03T03:56:24Z', 'uri': 'http://web.archive.org/web/20171003035624/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2018-04-14T03:24:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414032452/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2018-04-14T03:24:52Z', 'uri': 'http://web.archive.org/web/20180414032452/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2018-05-19T10:18:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519101810/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2018-05-19T10:18:10Z', 'uri': 'http://web.archive.org/web/20180519101810/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}, {'datetime': '2018-06-09T19:41:07Z', 'uri': 'http://web.archive.org/web/20180609194107/https://www.guideline.gov/summaries/summary/48223/the-management-of-women-with-red-cell-antibodies-during-pregnancy'}]
https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235133/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2016-09-30T23:51:33Z', 'uri': 'http://web.archive.org/web/20160930235133/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2017-10-03T03:56:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003035606/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2017-10-03T03:56:06Z', 'uri': 'http://web.archive.org/web/20171003035606/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2018-04-14T03:24:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414032427/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2018-04-14T03:24:27Z', 'uri': 'http://web.archive.org/web/20180414032427/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2018-05-19T10:17:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519101745/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2018-05-19T10:17:45Z', 'uri': 'http://web.archive.org/web/20180519101745/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}, {'datetime': '2018-06-09T22:44:54Z', 'uri': 'http://web.archive.org/web/20180609224454/https://www.guideline.gov/summaries/summary/48224/society-of-surgical-oncology-american-society-for-radiation-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-stages-i-and-ii-invasive-breast-cancer'}]
https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930234936/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2016-09-30T23:49:36Z', 'uri': 'http://web.archive.org/web/20160930234936/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2017-10-03T03:46:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003034615/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2017-10-03T03:46:15Z', 'uri': 'http://web.archive.org/web/20171003034615/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2018-04-14T03:11:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414031143/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2018-04-14T03:11:43Z', 'uri': 'http://web.archive.org/web/20180414031143/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2018-05-19T10:06:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519100600/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2018-05-19T10:06:00Z', 'uri': 'http://web.archive.org/web/20180519100600/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}, {'datetime': '2018-06-09T20:48:50Z', 'uri': 'http://web.archive.org/web/20180609204850/https://www.guideline.gov/summaries/summary/48226/diagnosis-and-treatment-of-overactive-bladder-nonneurogenic-in-adults-auasufu-guideline'}]
https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930234939/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2016-09-30T23:49:39Z', 'uri': 'http://web.archive.org/web/20160930234939/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2017-10-03T03:46:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003034630/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2017-10-03T03:46:30Z', 'uri': 'http://web.archive.org/web/20171003034630/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2018-04-14T03:12:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414031202/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2018-04-14T03:12:02Z', 'uri': 'http://web.archive.org/web/20180414031202/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2018-05-19T10:06:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519100617/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2018-05-19T10:06:17Z', 'uri': 'http://web.archive.org/web/20180519100617/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}, {'datetime': '2018-06-09T22:23:32Z', 'uri': 'http://web.archive.org/web/20180609222332/https://www.guideline.gov/summaries/summary/48227/urotrauma-aua-guideline'}]
https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930234938/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2016-09-30T23:49:38Z', 'uri': 'http://web.archive.org/web/20160930234938/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2017-10-03T03:46:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003034624/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2017-10-03T03:46:24Z', 'uri': 'http://web.archive.org/web/20171003034624/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2018-04-14T03:11:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414031153/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2018-04-14T03:11:53Z', 'uri': 'http://web.archive.org/web/20180414031153/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2018-05-19T10:06:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519100609/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2018-05-19T10:06:09Z', 'uri': 'http://web.archive.org/web/20180519100609/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}, {'datetime': '2018-06-09T22:23:57Z', 'uri': 'http://web.archive.org/web/20180609222357/https://www.guideline.gov/summaries/summary/48228/evaluation-and-treatment-of-cryptorchidism-aua-guideline'}]
https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930235032/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2016-09-30T23:50:32Z', 'uri': 'http://web.archive.org/web/20160930235032/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2017-10-03T03:50:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003035008/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2017-10-03T03:50:08Z', 'uri': 'http://web.archive.org/web/20171003035008/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2018-04-14T03:16:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414031602/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2018-04-14T03:16:02Z', 'uri': 'http://web.archive.org/web/20180414031602/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2018-05-19T10:10:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519101002/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2018-05-19T10:10:02Z', 'uri': 'http://web.archive.org/web/20180519101002/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}, {'datetime': '2018-06-09T22:23:41Z', 'uri': 'http://web.archive.org/web/20180609222341/https://www.guideline.gov/summaries/summary/48229/medical-management-of-kidney-stones-aua-guideline'}]
https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930235057/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2016-09-30T23:50:57Z', 'uri': 'http://web.archive.org/web/20160930235057/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2017-10-03T03:52:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003035245/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2017-10-03T03:52:45Z', 'uri': 'http://web.archive.org/web/20171003035245/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2018-04-14T03:19:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414031945/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2018-04-14T03:19:45Z', 'uri': 'http://web.archive.org/web/20180414031945/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2018-05-19T10:13:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519101336/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2018-05-19T10:13:36Z', 'uri': 'http://web.archive.org/web/20180519101336/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}, {'datetime': '2018-06-09T21:58:55Z', 'uri': 'http://web.archive.org/web/20180609215855/https://www.guideline.gov/summaries/summary/48230/guidelines-on-the-diagnosis-and-management-of-waldenstr-m-macroglobulinaemia'}]
https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930235058/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2016-09-30T23:50:58Z', 'uri': 'http://web.archive.org/web/20160930235058/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2017-10-03T03:52:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003035252/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2017-10-03T03:52:52Z', 'uri': 'http://web.archive.org/web/20171003035252/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2018-04-14T03:19:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414031954/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2018-04-14T03:19:54Z', 'uri': 'http://web.archive.org/web/20180414031954/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2018-05-19T10:13:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519101344/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2018-05-19T10:13:44Z', 'uri': 'http://web.archive.org/web/20180519101344/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}, {'datetime': '2018-06-10T01:48:49Z', 'uri': 'http://web.archive.org/web/20180610014849/https://www.guideline.gov/summaries/summary/48260/guidelines-on-the-use-of-multicolour-flow-cytometry-in-the-diagnosis-of-haematological-neoplasms'}]
https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235218/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2016-09-30T23:52:18Z', 'uri': 'http://web.archive.org/web/20160930235218/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2017-10-03T04:01:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003040111/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2017-10-03T04:01:11Z', 'uri': 'http://web.archive.org/web/20171003040111/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2018-04-14T03:30:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414033058/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2018-04-14T03:30:58Z', 'uri': 'http://web.archive.org/web/20180414033058/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2018-05-19T10:23:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519102353/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2018-05-19T10:23:53Z', 'uri': 'http://web.archive.org/web/20180519102353/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}, {'datetime': '2018-06-09T10:37:24Z', 'uri': 'http://web.archive.org/web/20180609103724/https://www.guideline.gov/summaries/summary/48261/management-of-acute-atrial-fibrillation-and-atrial-flutter-in-nonpregnant-hospitalized-adults'}]
https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:52:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235217/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2016-09-30T23:52:17Z', 'uri': 'http://web.archive.org/web/20160930235217/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2017-10-03T04:01:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003040106/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2017-10-03T04:01:06Z', 'uri': 'http://web.archive.org/web/20171003040106/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2018-04-14T03:30:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414033050/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2018-04-14T03:30:50Z', 'uri': 'http://web.archive.org/web/20180414033050/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2018-05-19T10:23:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519102345/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2018-05-19T10:23:45Z', 'uri': 'http://web.archive.org/web/20180519102345/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}, {'datetime': '2018-06-09T21:35:04Z', 'uri': 'http://web.archive.org/web/20180609213504/https://www.guideline.gov/summaries/summary/48262/evaluation-and-management-of-gallstonerelated-diseases-in-nonpregnant-adults'}]
https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930235033/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2016-09-30T23:50:33Z', 'uri': 'http://web.archive.org/web/20160930235033/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2017-10-03T03:50:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003035015/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2017-10-03T03:50:15Z', 'uri': 'http://web.archive.org/web/20171003035015/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:16:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414031611/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:16:11Z', 'uri': 'http://web.archive.org/web/20180414031611/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:10:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519101010/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:10:10Z', 'uri': 'http://web.archive.org/web/20180519101010/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}, {'datetime': '2018-06-09T22:08:10Z', 'uri': 'http://web.archive.org/web/20180609220810/https://www.guideline.gov/summaries/summary/48264/alemtuzumab-for-treating-relapsing-remitting-multiple-sclerosis'}]
https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:50:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235003/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2016-09-30T23:50:03Z', 'uri': 'http://web.archive.org/web/20160930235003/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:48:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003034801/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:48:01Z', 'uri': 'http://web.archive.org/web/20171003034801/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:13:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414031320/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:13:20Z', 'uri': 'http://web.archive.org/web/20180414031320/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:07:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519100739/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:07:39Z', 'uri': 'http://web.archive.org/web/20180519100739/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-06-09T11:21:38Z', 'uri': 'http://web.archive.org/web/20180609112138/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-07-12T21:41:42Z', 'uri': 'http://web.archive.org/web/20180712214142/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-07-12T21:41:42Z', 'uri': 'http://web.archive.org/web/20180712214142/https://www.guideline.gov/summaries/summary/48267/2014-ahaacc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930234904/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2016-09-30T23:49:04Z', 'uri': 'http://web.archive.org/web/20160930234904/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2017-10-03T03:44:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003034442/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2017-10-03T03:44:42Z', 'uri': 'http://web.archive.org/web/20171003034442/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2018-04-14T03:09:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414030947/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2018-04-14T03:09:47Z', 'uri': 'http://web.archive.org/web/20180414030947/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2018-05-19T10:04:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519100404/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2018-05-19T10:04:04Z', 'uri': 'http://web.archive.org/web/20180519100404/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}, {'datetime': '2018-06-09T20:35:49Z', 'uri': 'http://web.archive.org/web/20180609203549/https://www.guideline.gov/summaries/summary/48268/multiple-sleep-latency-testing-mslt-and-maintenance-of-wakefulness-testing-mwt'}]
https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930235145/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2016-09-30T23:51:45Z', 'uri': 'http://web.archive.org/web/20160930235145/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2017-10-03T03:57:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003035738/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2017-10-03T03:57:38Z', 'uri': 'http://web.archive.org/web/20171003035738/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2018-04-14T03:26:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414032602/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2018-04-14T03:26:02Z', 'uri': 'http://web.archive.org/web/20180414032602/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2018-05-19T10:19:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519101904/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2018-05-19T10:19:04Z', 'uri': 'http://web.archive.org/web/20180519101904/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}, {'datetime': '2018-06-10T01:20:10Z', 'uri': 'http://web.archive.org/web/20180610012010/https://www.guideline.gov/summaries/summary/48277/workrelated-acute-cauda-equina-syndrome-ces-diagnosis-and-treatment'}]
https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930235147/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2016-09-30T23:51:47Z', 'uri': 'http://web.archive.org/web/20160930235147/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2017-10-03T03:57:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003035750/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2017-10-03T03:57:50Z', 'uri': 'http://web.archive.org/web/20171003035750/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2018-04-14T03:26:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414032624/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2018-04-14T03:26:24Z', 'uri': 'http://web.archive.org/web/20180414032624/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2018-05-19T10:19:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519101923/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2018-05-19T10:19:23Z', 'uri': 'http://web.archive.org/web/20180519101923/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}, {'datetime': '2018-06-10T02:15:06Z', 'uri': 'http://web.archive.org/web/20180610021506/https://www.guideline.gov/summaries/summary/48279/acr-appropriateness-criteria--acute-chest-pain---suspected-aortic-dissection'}]
https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930235148/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2016-09-30T23:51:48Z', 'uri': 'http://web.archive.org/web/20160930235148/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2017-10-03T03:57:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003035756/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2017-10-03T03:57:56Z', 'uri': 'http://web.archive.org/web/20171003035756/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2018-04-14T03:26:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414032633/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2018-04-14T03:26:33Z', 'uri': 'http://web.archive.org/web/20180414032633/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2018-05-19T10:19:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519101933/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2018-05-19T10:19:33Z', 'uri': 'http://web.archive.org/web/20180519101933/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}, {'datetime': '2018-06-10T22:06:48Z', 'uri': 'http://web.archive.org/web/20180610220648/https://www.guideline.gov/summaries/summary/48280/acr-appropriateness-criteria--chest-pain-suggestive-of-acute-coronary-syndrome'}]
https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930235118/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2016-09-30T23:51:18Z', 'uri': 'http://web.archive.org/web/20160930235118/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2017-10-03T03:54:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003035435/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2017-10-03T03:54:35Z', 'uri': 'http://web.archive.org/web/20171003035435/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2018-04-14T03:22:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414032218/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2018-04-14T03:22:18Z', 'uri': 'http://web.archive.org/web/20180414032218/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2018-05-19T10:15:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519101540/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2018-05-19T10:15:40Z', 'uri': 'http://web.archive.org/web/20180519101540/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}, {'datetime': '2018-06-09T11:43:34Z', 'uri': 'http://web.archive.org/web/20180609114334/https://www.guideline.gov/summaries/summary/48281/acr-appropriateness-criteria--suspected-infective-endocarditis'}]
https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930235115/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2016-09-30T23:51:15Z', 'uri': 'http://web.archive.org/web/20160930235115/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2017-10-03T03:54:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003035418/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2017-10-03T03:54:18Z', 'uri': 'http://web.archive.org/web/20171003035418/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2018-04-14T03:21:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414032154/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2018-04-14T03:21:54Z', 'uri': 'http://web.archive.org/web/20180414032154/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2018-05-19T10:15:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519101518/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2018-05-19T10:15:18Z', 'uri': 'http://web.archive.org/web/20180519101518/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}, {'datetime': '2018-06-10T13:14:11Z', 'uri': 'http://web.archive.org/web/20180610131411/https://www.guideline.gov/summaries/summary/48282/acr-appropriateness-criteria--left-lower-quadrant-pain---suspected-diverticulitis'}]
https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930235116/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2016-09-30T23:51:16Z', 'uri': 'http://web.archive.org/web/20160930235116/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2017-10-03T03:54:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003035424/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2017-10-03T03:54:24Z', 'uri': 'http://web.archive.org/web/20171003035424/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2018-04-14T03:22:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414032203/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2018-04-14T03:22:03Z', 'uri': 'http://web.archive.org/web/20180414032203/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2018-05-19T10:15:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519101526/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2018-05-19T10:15:26Z', 'uri': 'http://web.archive.org/web/20180519101526/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}, {'datetime': '2018-06-11T05:59:28Z', 'uri': 'http://web.archive.org/web/20180611055928/https://www.guideline.gov/summaries/summary/48283/acr-appropriateness-criteria--liver-lesion---initial-characterization'}]
https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930235112/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2016-09-30T23:51:12Z', 'uri': 'http://web.archive.org/web/20160930235112/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2017-10-02T20:06:03Z', 'uri': 'http://wayback.archive-it.org/all/20171002200603/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2017-10-02T20:06:03Z', 'uri': 'http://web.archive.org/web/20171002200603/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2018-04-14T03:21:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414032119/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2018-04-14T03:21:19Z', 'uri': 'http://web.archive.org/web/20180414032119/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2018-05-18T19:31:29Z', 'uri': 'http://wayback.archive-it.org/all/20180518193129/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2018-05-18T19:31:29Z', 'uri': 'http://web.archive.org/web/20180518193129/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}, {'datetime': '2018-06-09T10:41:50Z', 'uri': 'http://web.archive.org/web/20180609104150/https://www.guideline.gov/summaries/summary/48284/acr-appropriateness-criteria--acute-trauma-to-the-ankle'}]
https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235113/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2016-09-30T23:51:13Z', 'uri': 'http://web.archive.org/web/20160930235113/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2017-10-03T03:54:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003035400/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2017-10-03T03:54:00Z', 'uri': 'http://web.archive.org/web/20171003035400/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2018-04-14T03:21:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414032128/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2018-04-14T03:21:28Z', 'uri': 'http://web.archive.org/web/20180414032128/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2018-05-19T10:14:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519101458/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2018-05-19T10:14:58Z', 'uri': 'http://web.archive.org/web/20180519101458/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}, {'datetime': '2018-06-09T12:21:09Z', 'uri': 'http://web.archive.org/web/20180609122109/https://www.guideline.gov/summaries/summary/48285/acr-appropriateness-criteria--dementia-and-movement-disorders'}]
https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930235103/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2016-09-30T23:51:03Z', 'uri': 'http://web.archive.org/web/20160930235103/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2017-10-03T03:53:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003035319/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2017-10-03T03:53:19Z', 'uri': 'http://web.archive.org/web/20171003035319/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2018-04-14T03:20:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414032029/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2018-04-14T03:20:29Z', 'uri': 'http://web.archive.org/web/20180414032029/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2018-05-19T10:14:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519101416/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2018-05-19T10:14:16Z', 'uri': 'http://web.archive.org/web/20180519101416/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}, {'datetime': '2018-06-10T11:49:09Z', 'uri': 'http://web.archive.org/web/20180610114909/https://www.guideline.gov/summaries/summary/48286/acr-appropriateness-criteria--imaging-in-the-diagnosis-of-thoracic-outlet-syndrome'}]
https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930235117/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2016-09-30T23:51:17Z', 'uri': 'http://web.archive.org/web/20160930235117/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2017-10-03T03:54:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003035427/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2017-10-03T03:54:27Z', 'uri': 'http://web.archive.org/web/20171003035427/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2018-04-14T03:22:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414032207/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2018-04-14T03:22:07Z', 'uri': 'http://web.archive.org/web/20180414032207/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2018-05-19T10:15:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519101530/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2018-05-19T10:15:30Z', 'uri': 'http://web.archive.org/web/20180519101530/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}, {'datetime': '2018-06-09T11:23:22Z', 'uri': 'http://web.archive.org/web/20180609112322/https://www.guideline.gov/summaries/summary/48287/acr-appropriateness-criteria--seizures-and-epilepsy'}]
https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930235114/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2016-09-30T23:51:14Z', 'uri': 'http://web.archive.org/web/20160930235114/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2017-10-03T03:54:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003035409/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2017-10-03T03:54:09Z', 'uri': 'http://web.archive.org/web/20171003035409/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2018-04-14T03:21:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414032142/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2018-04-14T03:21:42Z', 'uri': 'http://web.archive.org/web/20180414032142/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2018-05-19T10:15:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519101509/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2018-05-19T10:15:09Z', 'uri': 'http://web.archive.org/web/20180519101509/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}, {'datetime': '2018-06-10T19:00:51Z', 'uri': 'http://web.archive.org/web/20180610190051/https://www.guideline.gov/summaries/summary/48288/acr-appropriateness-criteria--head-trauma---child'}]
https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235102/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2016-09-30T23:51:02Z', 'uri': 'http://web.archive.org/web/20160930235102/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2017-10-03T03:53:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003035312/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2017-10-03T03:53:12Z', 'uri': 'http://web.archive.org/web/20171003035312/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2018-04-14T03:20:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414032019/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2018-04-14T03:20:19Z', 'uri': 'http://web.archive.org/web/20180414032019/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2018-05-19T10:14:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519101408/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2018-05-19T10:14:08Z', 'uri': 'http://web.archive.org/web/20180519101408/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}, {'datetime': '2018-06-10T22:00:49Z', 'uri': 'http://web.archive.org/web/20180610220049/https://www.guideline.gov/summaries/summary/48289/acr-appropriateness-criteria--hemoptysis'}]
https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235105/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2016-09-30T23:51:05Z', 'uri': 'http://web.archive.org/web/20160930235105/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2017-10-03T03:53:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003035332/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2017-10-03T03:53:32Z', 'uri': 'http://web.archive.org/web/20171003035332/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2018-04-14T03:20:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414032051/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2018-04-14T03:20:51Z', 'uri': 'http://web.archive.org/web/20180414032051/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2018-05-19T10:14:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519101434/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2018-05-19T10:14:34Z', 'uri': 'http://web.archive.org/web/20180519101434/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}, {'datetime': '2018-06-09T15:19:50Z', 'uri': 'http://web.archive.org/web/20180609151950/https://www.guideline.gov/summaries/summary/48290/acr-appropriateness-criteria--rib-fractures'}]
https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235104/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2016-09-30T23:51:04Z', 'uri': 'http://web.archive.org/web/20160930235104/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2017-10-03T03:53:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003035325/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2017-10-03T03:53:25Z', 'uri': 'http://web.archive.org/web/20171003035325/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2018-04-14T03:20:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414032039/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2018-04-14T03:20:39Z', 'uri': 'http://web.archive.org/web/20180414032039/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2018-05-19T10:14:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519101424/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2018-05-19T10:14:24Z', 'uri': 'http://web.archive.org/web/20180519101424/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}, {'datetime': '2018-06-09T19:39:11Z', 'uri': 'http://web.archive.org/web/20180609193911/https://www.guideline.gov/summaries/summary/48291/acr-appropriateness-criteria--indeterminate-renal-mass'}]
https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235007/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2016-09-30T23:50:07Z', 'uri': 'http://web.archive.org/web/20160930235007/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2017-10-03T03:48:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003034839/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2017-10-03T03:48:39Z', 'uri': 'http://web.archive.org/web/20171003034839/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2018-04-14T03:14:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414031410/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2018-04-14T03:14:10Z', 'uri': 'http://web.archive.org/web/20180414031410/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2018-05-19T10:08:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519100823/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2018-05-19T10:08:23Z', 'uri': 'http://web.archive.org/web/20180519100823/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}, {'datetime': '2018-06-09T15:16:55Z', 'uri': 'http://web.archive.org/web/20180609151655/https://www.guideline.gov/summaries/summary/48292/acr-appropriateness-criteria--lower-urinary-tract-symptoms-suspicion-of-benign-prostatic-hyperplasia'}]
https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930235012/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2016-09-30T23:50:12Z', 'uri': 'http://web.archive.org/web/20160930235012/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2017-10-03T03:48:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003034859/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2017-10-03T03:48:59Z', 'uri': 'http://web.archive.org/web/20171003034859/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2018-04-14T03:14:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414031445/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2018-04-14T03:14:45Z', 'uri': 'http://web.archive.org/web/20180414031445/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2018-05-19T10:08:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519100852/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2018-05-19T10:08:52Z', 'uri': 'http://web.archive.org/web/20180519100852/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}, {'datetime': '2018-06-10T02:15:42Z', 'uri': 'http://web.archive.org/web/20180610021542/https://www.guideline.gov/summaries/summary/48293/acr-appropriateness-criteria--posttreatment-surveillance-of-bladder-cancer'}]
https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930235005/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2016-09-30T23:50:05Z', 'uri': 'http://web.archive.org/web/20160930235005/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2017-10-03T03:48:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003034823/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2017-10-03T03:48:23Z', 'uri': 'http://web.archive.org/web/20171003034823/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2018-04-14T03:13:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414031352/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2018-04-14T03:13:52Z', 'uri': 'http://web.archive.org/web/20180414031352/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2018-05-19T10:08:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519100805/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2018-05-19T10:08:05Z', 'uri': 'http://web.archive.org/web/20180519100805/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}, {'datetime': '2018-06-10T17:02:38Z', 'uri': 'http://web.archive.org/web/20180610170238/https://www.guideline.gov/summaries/summary/48294/acr-appropriateness-criteria--abnormal-vaginal-bleeding'}]
https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930235011/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2016-09-30T23:50:11Z', 'uri': 'http://web.archive.org/web/20160930235011/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2017-10-03T03:48:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003034851/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2017-10-03T03:48:51Z', 'uri': 'http://web.archive.org/web/20171003034851/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2018-04-14T03:14:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414031436/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2018-04-14T03:14:36Z', 'uri': 'http://web.archive.org/web/20180414031436/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2018-05-19T10:08:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519100841/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2018-05-19T10:08:41Z', 'uri': 'http://web.archive.org/web/20180519100841/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}, {'datetime': '2018-06-09T15:22:43Z', 'uri': 'http://web.archive.org/web/20180609152243/https://www.guideline.gov/summaries/summary/48295/acr-appropriateness-criteria--pelvic-floor-dysfunction'}]
https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930235010/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2016-09-30T23:50:10Z', 'uri': 'http://web.archive.org/web/20160930235010/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2017-10-03T03:48:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003034845/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2017-10-03T03:48:45Z', 'uri': 'http://web.archive.org/web/20171003034845/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2018-04-14T03:14:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414031429/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2018-04-14T03:14:29Z', 'uri': 'http://web.archive.org/web/20180414031429/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2018-05-19T10:08:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519100832/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2018-05-19T10:08:32Z', 'uri': 'http://web.archive.org/web/20180519100832/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}, {'datetime': '2018-06-10T21:28:37Z', 'uri': 'http://web.archive.org/web/20180610212837/https://www.guideline.gov/summaries/summary/48296/acr-appropriateness-criteria--multiple-brain-metastases'}]
https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930235013/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2016-09-30T23:50:13Z', 'uri': 'http://web.archive.org/web/20160930235013/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2017-10-03T03:49:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003034907/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2017-10-03T03:49:07Z', 'uri': 'http://web.archive.org/web/20171003034907/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2018-04-14T03:14:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414031455/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2018-04-14T03:14:55Z', 'uri': 'http://web.archive.org/web/20180414031455/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2018-05-19T10:09:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519100901/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2018-05-19T10:09:01Z', 'uri': 'http://web.archive.org/web/20180519100901/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}, {'datetime': '2018-06-10T23:02:38Z', 'uri': 'http://web.archive.org/web/20180610230238/https://www.guideline.gov/summaries/summary/48297/acr-appropriateness-criteria--preirradiation-evaluation-and-management-of-brain-metastases'}]
https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930235007/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2016-09-30T23:50:07Z', 'uri': 'http://web.archive.org/web/20160930235007/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2017-10-03T03:48:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003034831/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2017-10-03T03:48:31Z', 'uri': 'http://web.archive.org/web/20171003034831/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2018-04-14T03:14:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414031402/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2018-04-14T03:14:02Z', 'uri': 'http://web.archive.org/web/20180414031402/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2018-05-19T10:08:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519100814/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2018-05-19T10:08:14Z', 'uri': 'http://web.archive.org/web/20180519100814/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}, {'datetime': '2018-06-09T20:18:40Z', 'uri': 'http://web.archive.org/web/20180609201840/https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer'}]
https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930235040/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2016-09-30T23:50:40Z', 'uri': 'http://web.archive.org/web/20160930235040/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2017-10-03T03:50:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003035059/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2017-10-03T03:50:59Z', 'uri': 'http://web.archive.org/web/20171003035059/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2018-04-14T03:17:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414031712/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2018-04-14T03:17:12Z', 'uri': 'http://web.archive.org/web/20180414031712/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2018-05-19T10:11:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519101109/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2018-05-19T10:11:09Z', 'uri': 'http://web.archive.org/web/20180519101109/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}, {'datetime': '2018-06-09T19:16:40Z', 'uri': 'http://web.archive.org/web/20180609191640/https://www.guideline.gov/summaries/summary/48299/acr-appropriateness-criteria--rectal-cancermetastatic-disease-at-presentation'}]
https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930235039/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2016-09-30T23:50:39Z', 'uri': 'http://web.archive.org/web/20160930235039/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2017-10-03T03:50:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003035052/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2017-10-03T03:50:52Z', 'uri': 'http://web.archive.org/web/20171003035052/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2018-04-14T03:17:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414031702/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2018-04-14T03:17:02Z', 'uri': 'http://web.archive.org/web/20180414031702/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2018-05-19T10:11:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519101100/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2018-05-19T10:11:00Z', 'uri': 'http://web.archive.org/web/20180519101100/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}, {'datetime': '2018-06-10T22:39:37Z', 'uri': 'http://web.archive.org/web/20180610223937/https://www.guideline.gov/summaries/summary/48300/acr-appropriateness-criteria--advanced-stage-endometrial-cancer'}]
https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930235041/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2016-09-30T23:50:41Z', 'uri': 'http://web.archive.org/web/20160930235041/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2017-10-03T03:51:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003035106/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2017-10-03T03:51:06Z', 'uri': 'http://web.archive.org/web/20171003035106/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2018-04-14T03:17:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414031723/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2018-04-14T03:17:23Z', 'uri': 'http://web.archive.org/web/20180414031723/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2018-05-19T10:11:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519101118/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2018-05-19T10:11:18Z', 'uri': 'http://web.archive.org/web/20180519101118/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}, {'datetime': '2018-06-10T12:44:04Z', 'uri': 'http://web.archive.org/web/20180610124404/https://www.guideline.gov/summaries/summary/48301/acr-appropriateness-criteria--role-of-adjuvant-therapy-in-the-management-of-early-stage-cervical-cancer'}]
https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930235053/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2016-09-30T23:50:53Z', 'uri': 'http://web.archive.org/web/20160930235053/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2017-10-03T03:52:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003035216/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2017-10-03T03:52:16Z', 'uri': 'http://web.archive.org/web/20171003035216/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2018-04-14T03:18:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414031857/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2018-04-14T03:18:57Z', 'uri': 'http://web.archive.org/web/20180414031857/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2018-05-19T10:12:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519101257/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2018-05-19T10:12:57Z', 'uri': 'http://web.archive.org/web/20180519101257/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}, {'datetime': '2018-06-09T22:43:20Z', 'uri': 'http://web.archive.org/web/20180609224320/https://www.guideline.gov/summaries/summary/48302/acr-appropriateness-criteria--retreatment-of-recurrent-head-and-neck-cancer-after-prior-definitive-radiation'}]
https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930235051/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2016-09-30T23:50:51Z', 'uri': 'http://web.archive.org/web/20160930235051/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2017-10-03T03:52:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003035202/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2017-10-03T03:52:02Z', 'uri': 'http://web.archive.org/web/20171003035202/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2018-04-14T03:18:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414031838/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2018-04-14T03:18:38Z', 'uri': 'http://web.archive.org/web/20180414031838/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2018-05-19T10:12:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519101238/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2018-05-19T10:12:38Z', 'uri': 'http://web.archive.org/web/20180519101238/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}, {'datetime': '2018-06-11T05:58:22Z', 'uri': 'http://web.archive.org/web/20180611055822/https://www.guideline.gov/summaries/summary/48303/acr-appropriateness-criteria--nonsurgical-treatment-for-locally-advanced-nonsmallcell-lung-cancer-good-performance-statusdefinitive-intent'}]
https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930235050/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2016-09-30T23:50:50Z', 'uri': 'http://web.archive.org/web/20160930235050/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2017-10-03T03:51:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003035154/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2017-10-03T03:51:54Z', 'uri': 'http://web.archive.org/web/20171003035154/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2018-04-14T03:18:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414031827/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2018-04-14T03:18:27Z', 'uri': 'http://web.archive.org/web/20180414031827/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2018-05-19T10:12:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519101229/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2018-05-19T10:12:29Z', 'uri': 'http://web.archive.org/web/20180519101229/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}, {'datetime': '2018-06-09T20:49:55Z', 'uri': 'http://web.archive.org/web/20180609204955/https://www.guideline.gov/summaries/summary/48304/acr-appropriateness-criteria--followup-of-hodgkin-lymphoma'}]
https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930235052/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2016-09-30T23:50:52Z', 'uri': 'http://web.archive.org/web/20160930235052/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2017-10-03T03:52:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003035209/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2017-10-03T03:52:09Z', 'uri': 'http://web.archive.org/web/20171003035209/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2018-04-14T03:18:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414031848/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2018-04-14T03:18:48Z', 'uri': 'http://web.archive.org/web/20180414031848/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2018-05-19T10:12:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519101248/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2018-05-19T10:12:48Z', 'uri': 'http://web.archive.org/web/20180519101248/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}, {'datetime': '2018-06-10T00:15:47Z', 'uri': 'http://web.archive.org/web/20180610001547/https://www.guideline.gov/summaries/summary/48305/acr-appropriateness-criteria--postradical-prostatectomy-irradiation-in-prostate-cancer'}]
https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930235042/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2016-09-30T23:50:42Z', 'uri': 'http://web.archive.org/web/20160930235042/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2017-10-02T20:06:30Z', 'uri': 'http://wayback.archive-it.org/all/20171002200630/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2017-10-02T20:06:30Z', 'uri': 'http://web.archive.org/web/20171002200630/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2018-04-14T03:17:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414031733/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2018-04-14T03:17:33Z', 'uri': 'http://web.archive.org/web/20180414031733/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2018-05-18T19:32:06Z', 'uri': 'http://wayback.archive-it.org/all/20180518193206/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2018-05-18T19:32:06Z', 'uri': 'http://web.archive.org/web/20180518193206/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}, {'datetime': '2018-06-09T10:41:08Z', 'uri': 'http://web.archive.org/web/20180609104108/https://www.guideline.gov/summaries/summary/48330/aspen-clinical-guidelines-support-of-pediatric-patients-with-intestinal-failure-at-risk-of-parenteral-nutrition-associated-liver-disease'}]
https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930235100/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:51:00Z', 'uri': 'http://web.archive.org/web/20160930235100/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:52:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003035258/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:52:58Z', 'uri': 'http://web.archive.org/web/20171003035258/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:20:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414032002/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:20:02Z', 'uri': 'http://web.archive.org/web/20180414032002/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:13:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519101352/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:13:52Z', 'uri': 'http://web.archive.org/web/20180519101352/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T08:21:28Z', 'uri': 'http://web.archive.org/web/20180610082128/https://www.guideline.gov/summaries/summary/48331/screening-for-hepatitis-b-virus-infection-in-nonpregnant-adolescents-and-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930235119/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2016-09-30T23:51:19Z', 'uri': 'http://web.archive.org/web/20160930235119/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2017-10-03T03:54:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003035442/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2017-10-03T03:54:42Z', 'uri': 'http://web.archive.org/web/20171003035442/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2018-04-14T03:22:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414032227/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2018-04-14T03:22:27Z', 'uri': 'http://web.archive.org/web/20180414032227/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2018-05-19T10:15:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519101549/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2018-05-19T10:15:49Z', 'uri': 'http://web.archive.org/web/20180519101549/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}, {'datetime': '2018-06-09T15:29:51Z', 'uri': 'http://web.archive.org/web/20180609152951/https://www.guideline.gov/summaries/summary/48333/atrial-fibrillation-the-management-of-atrial-fibrillation'}]
https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:51:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930235131/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:51:31Z', 'uri': 'http://web.archive.org/web/20160930235131/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:55:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003035546/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:55:46Z', 'uri': 'http://web.archive.org/web/20171003035546/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:23:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414032359/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:23:59Z', 'uri': 'http://web.archive.org/web/20180414032359/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:17:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519101726/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:17:26Z', 'uri': 'http://web.archive.org/web/20180519101726/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:21:56Z', 'uri': 'http://web.archive.org/web/20180609192156/https://www.guideline.gov/summaries/summary/48334/screening-pelvic-examination-in-adult-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930235035/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2016-09-30T23:50:35Z', 'uri': 'http://web.archive.org/web/20160930235035/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2017-10-03T03:50:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003035027/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2017-10-03T03:50:27Z', 'uri': 'http://web.archive.org/web/20171003035027/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2018-04-14T03:16:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414031629/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2018-04-14T03:16:29Z', 'uri': 'http://web.archive.org/web/20180414031629/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2018-05-19T10:10:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519101027/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2018-05-19T10:10:27Z', 'uri': 'http://web.archive.org/web/20180519101027/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}, {'datetime': '2018-06-10T02:12:20Z', 'uri': 'http://web.archive.org/web/20180610021220/https://www.guideline.gov/summaries/summary/48335/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120'}]
https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930235002/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2016-09-30T23:50:02Z', 'uri': 'http://web.archive.org/web/20160930235002/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2017-10-03T03:47:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003034752/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2017-10-03T03:47:52Z', 'uri': 'http://web.archive.org/web/20171003034752/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2018-04-14T03:13:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414031309/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2018-04-14T03:13:09Z', 'uri': 'http://web.archive.org/web/20180414031309/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2018-05-19T10:07:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519100729/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2018-05-19T10:07:29Z', 'uri': 'http://web.archive.org/web/20180519100729/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}, {'datetime': '2018-06-09T15:11:11Z', 'uri': 'http://web.archive.org/web/20180609151111/https://www.guideline.gov/summaries/summary/48336/clinical-practice-guidelines-for-healthy-eating-for-the-prevention-and-treatment-of-metabolic-and-endocrine-diseases-in-adults-cosponsored-by-the-american-association-of-clinical-endocrinologiststhe-american-college-of-endocrinology-and-the-obesity-society'}]
https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930234831/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2016-09-30T23:48:31Z', 'uri': 'http://web.archive.org/web/20160930234831/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:42:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003034212/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:42:12Z', 'uri': 'http://web.archive.org/web/20171003034212/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:06:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414030642/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:06:42Z', 'uri': 'http://web.archive.org/web/20180414030642/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:00:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519100049/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:00:49Z', 'uri': 'http://web.archive.org/web/20180519100049/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-06-09T15:21:32Z', 'uri': 'http://web.archive.org/web/20180609152132/https://www.guideline.gov/summaries/summary/48337/2013-accaha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-atherosclerotic-cardiovascular-risk-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930234832/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2016-09-30T23:48:32Z', 'uri': 'http://web.archive.org/web/20160930234832/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:42:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003034222/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:42:22Z', 'uri': 'http://web.archive.org/web/20171003034222/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:06:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414030655/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:06:55Z', 'uri': 'http://web.archive.org/web/20180414030655/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:01:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519100101/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:01:01Z', 'uri': 'http://web.archive.org/web/20180519100101/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-06-09T21:11:36Z', 'uri': 'http://web.archive.org/web/20180609211136/https://www.guideline.gov/summaries/summary/48338/2013-ahaacc-guideline-on-lifestyle-management-to-reduce-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930234833/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2016-09-30T23:48:33Z', 'uri': 'http://web.archive.org/web/20160930234833/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2017-10-03T03:42:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003034232/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2017-10-03T03:42:32Z', 'uri': 'http://web.archive.org/web/20171003034232/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2018-04-14T03:07:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414030706/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2018-04-14T03:07:06Z', 'uri': 'http://web.archive.org/web/20180414030706/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2018-05-19T10:01:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519100111/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2018-05-19T10:01:11Z', 'uri': 'http://web.archive.org/web/20180519100111/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}, {'datetime': '2018-06-09T19:24:55Z', 'uri': 'http://web.archive.org/web/20180609192455/https://www.guideline.gov/summaries/summary/48339/2013-ahaacctos-guideline-for-the-management-of-overweight-and-obesity-in-adults-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines-and-the-obesity-society'}]
https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930234830/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2016-09-30T23:48:30Z', 'uri': 'http://web.archive.org/web/20160930234830/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:42:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003034204/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2017-10-03T03:42:04Z', 'uri': 'http://web.archive.org/web/20171003034204/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:06:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414030631/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-04-14T03:06:31Z', 'uri': 'http://web.archive.org/web/20180414030631/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:00:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519100038/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-05-19T10:00:38Z', 'uri': 'http://web.archive.org/web/20180519100038/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}, {'datetime': '2018-06-09T21:11:49Z', 'uri': 'http://web.archive.org/web/20180609211149/https://www.guideline.gov/summaries/summary/48340/2013-accaha-guideline-on-the-assessment-of-cardiovascular-risk-a-report-of-the-american-college-of-cardiologyamerican-heart-association-task-force-on-practice-guidelines'}]
https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930235054/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:50:54Z', 'uri': 'http://web.archive.org/web/20160930235054/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:52:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003035223/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:52:23Z', 'uri': 'http://web.archive.org/web/20171003035223/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:19:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414031909/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:19:09Z', 'uri': 'http://web.archive.org/web/20180414031909/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:13:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519101306/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:13:06Z', 'uri': 'http://web.archive.org/web/20180519101306/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T23:04:43Z', 'uri': 'http://web.archive.org/web/20180610230443/https://www.guideline.gov/summaries/summary/48366/prevention-and-management-of-chemotherapyinduced-peripheral-neuropathy-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930235055/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2016-09-30T23:50:55Z', 'uri': 'http://web.archive.org/web/20160930235055/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2017-10-03T03:52:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003035229/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2017-10-03T03:52:29Z', 'uri': 'http://web.archive.org/web/20171003035229/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2018-04-14T03:19:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414031920/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2018-04-14T03:19:20Z', 'uri': 'http://web.archive.org/web/20180414031920/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2018-05-19T10:13:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519101314/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2018-05-19T10:13:14Z', 'uri': 'http://web.archive.org/web/20180519101314/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}, {'datetime': '2018-06-09T22:46:17Z', 'uri': 'http://web.archive.org/web/20180609224617/https://www.guideline.gov/summaries/summary/48367/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation'}]
https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:48:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930234852/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2016-09-30T23:48:52Z', 'uri': 'http://web.archive.org/web/20160930234852/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2016-12-16T13:30:42Z', 'uri': 'http://web.archive.org/web/20161216133042/https://guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2017-10-03T03:43:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003034334/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2017-10-03T03:43:34Z', 'uri': 'http://web.archive.org/web/20171003034334/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2018-04-14T03:08:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414030828/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2018-04-14T03:08:28Z', 'uri': 'http://web.archive.org/web/20180414030828/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2018-05-19T10:02:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519100248/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2018-05-19T10:02:48Z', 'uri': 'http://web.archive.org/web/20180519100248/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}, {'datetime': '2018-06-09T19:38:00Z', 'uri': 'http://web.archive.org/web/20180609193800/https://www.guideline.gov/summaries/summary/48368/guidelines-for-laparoscopic-peritoneal-dialysis-access-surgery'}]
https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930234851/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:48:51Z', 'uri': 'http://web.archive.org/web/20160930234851/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:43:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003034328/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:43:28Z', 'uri': 'http://web.archive.org/web/20171003034328/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:08:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414030819/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:08:19Z', 'uri': 'http://web.archive.org/web/20180414030819/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:02:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519100240/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:02:40Z', 'uri': 'http://web.archive.org/web/20180519100240/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T23:02:44Z', 'uri': 'http://web.archive.org/web/20180610230244/https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930234841/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2016-09-30T23:48:41Z', 'uri': 'http://web.archive.org/web/20160930234841/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2017-10-03T03:42:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003034255/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2017-10-03T03:42:55Z', 'uri': 'http://web.archive.org/web/20171003034255/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2018-04-14T03:07:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414030734/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2018-04-14T03:07:34Z', 'uri': 'http://web.archive.org/web/20180414030734/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2018-05-19T10:01:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519100138/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2018-05-19T10:01:38Z', 'uri': 'http://web.archive.org/web/20180519100138/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}, {'datetime': '2018-06-09T12:01:53Z', 'uri': 'http://web.archive.org/web/20180609120153/https://www.guideline.gov/summaries/summary/48378/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-autism-spectrum-disorder'}]
https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930234840/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2016-09-30T23:48:40Z', 'uri': 'http://web.archive.org/web/20160930234840/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2017-10-03T03:42:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003034247/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2017-10-03T03:42:47Z', 'uri': 'http://web.archive.org/web/20171003034247/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2018-04-14T03:07:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414030725/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2018-04-14T03:07:25Z', 'uri': 'http://web.archive.org/web/20180414030725/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2018-05-19T10:01:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519100129/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2018-05-19T10:01:29Z', 'uri': 'http://web.archive.org/web/20180519100129/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}, {'datetime': '2018-06-09T12:02:08Z', 'uri': 'http://web.archive.org/web/20180609120208/https://www.guideline.gov/summaries/summary/48379/practice-parameter-for-cultural-competence-in-child-and-adolescent-psychiatric-practice'}]
https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:44Z', 'uri': 'http://wayback.archive-it.org/all/20160930234844/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2016-09-30T23:48:44Z', 'uri': 'http://web.archive.org/web/20160930234844/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2017-10-03T03:43:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003034315/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2017-10-03T03:43:15Z', 'uri': 'http://web.archive.org/web/20171003034315/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2018-04-14T03:08:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414030802/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2018-04-14T03:08:02Z', 'uri': 'http://web.archive.org/web/20180414030802/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2018-05-19T10:02:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519100222/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2018-05-19T10:02:22Z', 'uri': 'http://web.archive.org/web/20180519100222/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}, {'datetime': '2018-06-09T12:01:56Z', 'uri': 'http://web.archive.org/web/20180609120156/https://www.guideline.gov/summaries/summary/48380/practice-parameter-on-disaster-preparedness'}]
https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930234842/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2016-09-30T23:48:42Z', 'uri': 'http://web.archive.org/web/20160930234842/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2017-10-03T03:43:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003034302/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2017-10-03T03:43:02Z', 'uri': 'http://web.archive.org/web/20171003034302/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2018-04-14T03:07:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414030744/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2018-04-14T03:07:44Z', 'uri': 'http://web.archive.org/web/20180414030744/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2018-05-19T10:01:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519100146/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2018-05-19T10:01:46Z', 'uri': 'http://web.archive.org/web/20180519100146/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}, {'datetime': '2018-06-09T12:02:09Z', 'uri': 'http://web.archive.org/web/20180609120209/https://www.guideline.gov/summaries/summary/48381/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-schizophrenia'}]
https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930234843/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2016-09-30T23:48:43Z', 'uri': 'http://web.archive.org/web/20160930234843/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2017-10-03T03:43:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003034308/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2017-10-03T03:43:08Z', 'uri': 'http://web.archive.org/web/20171003034308/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2018-04-14T03:07:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414030753/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2018-04-14T03:07:53Z', 'uri': 'http://web.archive.org/web/20180414030753/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2018-05-19T10:02:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519100213/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2018-05-19T10:02:13Z', 'uri': 'http://web.archive.org/web/20180519100213/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}, {'datetime': '2018-06-09T12:01:38Z', 'uri': 'http://web.archive.org/web/20180609120138/https://www.guideline.gov/summaries/summary/48382/practice-parameter-for-the-assessment-and-treatment-of-children-and-adolescents-with-tic-disorders'}]
https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930234853/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:48:53Z', 'uri': 'http://web.archive.org/web/20160930234853/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:43:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003034340/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:43:40Z', 'uri': 'http://web.archive.org/web/20171003034340/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:08:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414030836/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:08:36Z', 'uri': 'http://web.archive.org/web/20180414030836/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:02:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519100257/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:02:57Z', 'uri': 'http://web.archive.org/web/20180519100257/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:27:09Z', 'uri': 'http://web.archive.org/web/20180609222709/https://www.guideline.gov/summaries/summary/48399/recommendations-on-disease-management-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-and-brain-metastases-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930234854/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:48:54Z', 'uri': 'http://web.archive.org/web/20160930234854/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:43:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003034348/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:43:48Z', 'uri': 'http://web.archive.org/web/20171003034348/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:08:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414030846/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:08:46Z', 'uri': 'http://web.archive.org/web/20180414030846/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:03:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519100307/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T10:03:07Z', 'uri': 'http://web.archive.org/web/20180519100307/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T00:26:42Z', 'uri': 'http://web.archive.org/web/20180610002642/https://www.guideline.gov/summaries/summary/48400/systemic-therapy-for-patients-with-advanced-human-epidermal-growth-factor-receptor-2positive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930235034/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2016-09-30T23:50:34Z', 'uri': 'http://web.archive.org/web/20160930235034/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2017-10-03T03:50:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003035021/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2017-10-03T03:50:21Z', 'uri': 'http://web.archive.org/web/20171003035021/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2018-04-14T03:16:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414031620/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2018-04-14T03:16:20Z', 'uri': 'http://web.archive.org/web/20180414031620/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2018-05-19T10:10:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519101018/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2018-05-19T10:10:18Z', 'uri': 'http://web.archive.org/web/20180519101018/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}, {'datetime': '2018-06-11T09:20:15Z', 'uri': 'http://web.archive.org/web/20180611092015/https://www.guideline.gov/summaries/summary/48401/enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen'}]
https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930235037/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2016-09-30T23:50:37Z', 'uri': 'http://web.archive.org/web/20160930235037/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2017-10-03T03:50:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003035033/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2017-10-03T03:50:33Z', 'uri': 'http://web.archive.org/web/20171003035033/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2018-04-14T03:16:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414031638/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2018-04-14T03:16:38Z', 'uri': 'http://web.archive.org/web/20180414031638/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2018-05-19T10:10:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519101036/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2018-05-19T10:10:36Z', 'uri': 'http://web.archive.org/web/20180519101036/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}, {'datetime': '2018-06-09T21:35:25Z', 'uri': 'http://web.archive.org/web/20180609213525/https://www.guideline.gov/summaries/summary/48402/ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma'}]
https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235038/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2016-09-30T23:50:38Z', 'uri': 'http://web.archive.org/web/20160930235038/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2017-10-03T03:50:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003035039/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2017-10-03T03:50:39Z', 'uri': 'http://web.archive.org/web/20171003035039/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2018-04-14T03:16:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414031646/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2018-04-14T03:16:46Z', 'uri': 'http://web.archive.org/web/20180414031646/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2018-05-19T10:10:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519101044/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2018-05-19T10:10:44Z', 'uri': 'http://web.archive.org/web/20180519101044/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}, {'datetime': '2018-06-11T08:31:24Z', 'uri': 'http://web.archive.org/web/20180611083124/https://www.guideline.gov/summaries/summary/48403/lubiprostone-for-treating-chronic-idiopathic-constipation'}]
https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930235038/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2016-09-30T23:50:38Z', 'uri': 'http://web.archive.org/web/20160930235038/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2017-10-03T03:50:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003035045/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2017-10-03T03:50:45Z', 'uri': 'http://web.archive.org/web/20171003035045/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2018-04-14T03:16:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414031654/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2018-04-14T03:16:54Z', 'uri': 'http://web.archive.org/web/20180414031654/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2018-05-19T10:10:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519101052/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2018-05-19T10:10:52Z', 'uri': 'http://web.archive.org/web/20180519101052/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}, {'datetime': '2018-06-10T22:25:53Z', 'uri': 'http://web.archive.org/web/20180610222553/https://www.guideline.gov/summaries/summary/48404/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-technology-appraisal-guidance-182'}]
https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930234834/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2016-09-30T23:48:34Z', 'uri': 'http://web.archive.org/web/20160930234834/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2017-10-03T03:42:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003034241/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2017-10-03T03:42:41Z', 'uri': 'http://web.archive.org/web/20171003034241/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2018-04-14T03:07:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414030717/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2018-04-14T03:07:17Z', 'uri': 'http://web.archive.org/web/20180414030717/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2018-05-19T10:01:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519100122/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2018-05-19T10:01:22Z', 'uri': 'http://web.archive.org/web/20180519100122/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}, {'datetime': '2018-06-09T15:16:53Z', 'uri': 'http://web.archive.org/web/20180609151653/https://www.guideline.gov/summaries/summary/48405/chronic-kidney-disease-early-identification-and-management-of-chronic-kidney-disease-in-adults-in-primary-and-secondary-care'}]
https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930234835/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2016-09-30T23:48:35Z', 'uri': 'http://web.archive.org/web/20160930234835/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2017-10-03T03:42:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003034244/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2017-10-03T03:42:44Z', 'uri': 'http://web.archive.org/web/20171003034244/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2018-04-14T03:07:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414030721/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2018-04-14T03:07:21Z', 'uri': 'http://web.archive.org/web/20180414030721/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2018-05-19T10:01:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519100126/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2018-05-19T10:01:26Z', 'uri': 'http://web.archive.org/web/20180519100126/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}, {'datetime': '2018-06-09T18:02:03Z', 'uri': 'http://web.archive.org/web/20180609180203/https://www.guideline.gov/summaries/summary/48406/lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease'}]
https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930234850/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2016-09-30T23:48:50Z', 'uri': 'http://web.archive.org/web/20160930234850/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2017-10-03T03:43:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003034322/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2017-10-03T03:43:22Z', 'uri': 'http://web.archive.org/web/20171003034322/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2018-04-14T03:08:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414030811/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2018-04-14T03:08:11Z', 'uri': 'http://web.archive.org/web/20180414030811/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2018-05-19T10:02:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519100231/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2018-05-19T10:02:31Z', 'uri': 'http://web.archive.org/web/20180519100231/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}, {'datetime': '2018-06-09T11:29:45Z', 'uri': 'http://web.archive.org/web/20180609112945/https://www.guideline.gov/summaries/summary/48407/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-ivacaftor-therapy-in-the-context-of-cftr-genotype'}]
https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol	ARCHIVED	15 mementos	[{'datetime': '2016-09-30T16:21:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930162116/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2016-09-30T16:21:16Z', 'uri': 'http://web.archive.org/web/20160930162116/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2016-12-20T22:43:09Z', 'uri': 'http://web.archive.org/web/20161220224309/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2017-07-13T03:30:08Z', 'uri': 'http://web.archive.org/web/20170713033008/https://www.guideline.gov/summaries/summary/48408/Perioperative-protocol-Health-care-protocol'}, {'datetime': '2017-10-02T20:04:24Z', 'uri': 'http://wayback.archive-it.org/all/20171002200424/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2017-10-02T20:04:24Z', 'uri': 'http://web.archive.org/web/20171002200424/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2018-04-13T18:54:39Z', 'uri': 'http://wayback.archive-it.org/all/20180413185439/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2018-04-13T18:54:39Z', 'uri': 'http://web.archive.org/web/20180413185439/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2018-05-18T21:49:07Z', 'uri': 'http://wayback.archive-it.org/all/20180518214907/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2018-05-18T21:49:07Z', 'uri': 'http://web.archive.org/web/20180518214907/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2018-06-09T10:36:34Z', 'uri': 'http://web.archive.org/web/20180609103634/https://www.guideline.gov/summaries/summary/48408/Perioperative-protocol-Health-care-protocol'}, {'datetime': '2018-06-09T11:34:59Z', 'uri': 'http://web.archive.org/web/20180609113459/https://www.guideline.gov/summaries/summary/48408/perioperative-protocol-health-care-protocol'}, {'datetime': '2018-06-11T17:33:08Z', 'uri': 'http://web.archive.org/web/20180611173308/https://www.guideline.gov/summaries/summary/48408/Perioperative-protocol-Health-care-protocol'}, {'datetime': '2018-06-20T17:37:42Z', 'uri': 'http://web.archive.org/web/20180620173742/https://www.guideline.gov/summaries/summary/48408/Perioperative-protocol-Health-care-protocol'}, {'datetime': '2018-06-20T23:59:56Z', 'uri': 'http://web.archive.org/web/20180620235956/https://www.guideline.gov/summaries/summary/48408/Perioperative-protocol-Health-care-protocol'}]
https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930234905/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2016-09-30T23:49:05Z', 'uri': 'http://web.archive.org/web/20160930234905/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2017-10-03T03:44:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003034448/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2017-10-03T03:44:48Z', 'uri': 'http://web.archive.org/web/20171003034448/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2018-04-14T03:09:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414030957/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2018-04-14T03:09:57Z', 'uri': 'http://web.archive.org/web/20180414030957/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2018-05-19T10:04:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519100412/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2018-05-19T10:04:12Z', 'uri': 'http://web.archive.org/web/20180519100412/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}, {'datetime': '2018-06-09T22:25:55Z', 'uri': 'http://web.archive.org/web/20180609222555/https://www.guideline.gov/summaries/summary/48409/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-2-management-and-treatment-of-atopic-dermatitis-with-topical-therapies'}]
https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930234906/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2016-09-30T23:49:06Z', 'uri': 'http://web.archive.org/web/20160930234906/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2017-10-03T03:44:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003034456/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2017-10-03T03:44:56Z', 'uri': 'http://web.archive.org/web/20171003034456/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2018-04-14T03:10:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414031008/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2018-04-14T03:10:08Z', 'uri': 'http://web.archive.org/web/20180414031008/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2018-05-19T10:04:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519100422/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2018-05-19T10:04:22Z', 'uri': 'http://web.archive.org/web/20180519100422/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}, {'datetime': '2018-06-09T20:12:36Z', 'uri': 'http://web.archive.org/web/20180609201236/https://www.guideline.gov/summaries/summary/48410/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-3-management-and-treatment-with-phototherapy-and-systemic-agents'}]
https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:55:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930225507/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2016-09-30T22:55:07Z', 'uri': 'http://web.archive.org/web/20160930225507/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2017-10-03T02:10:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003021009/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2017-10-03T02:10:09Z', 'uri': 'http://web.archive.org/web/20171003021009/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2018-04-14T00:59:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414005932/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2018-04-14T00:59:32Z', 'uri': 'http://web.archive.org/web/20180414005932/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2018-05-19T07:39:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519073932/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2018-05-19T07:39:32Z', 'uri': 'http://web.archive.org/web/20180519073932/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}, {'datetime': '2018-06-09T15:20:24Z', 'uri': 'http://web.archive.org/web/20180609152024/https://www.guideline.gov/summaries/summary/48428/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-second-report-of-a-task-force-of-the-american-society-for-bone-and-mineral-research'}]
https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:50:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930235004/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:50:04Z', 'uri': 'http://web.archive.org/web/20160930235004/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:48:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003034817/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:48:17Z', 'uri': 'http://web.archive.org/web/20171003034817/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:13:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414031343/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:13:43Z', 'uri': 'http://web.archive.org/web/20180414031343/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:07:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519100758/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T10:07:58Z', 'uri': 'http://web.archive.org/web/20180519100758/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:21:44Z', 'uri': 'http://web.archive.org/web/20180609192144/https://www.guideline.gov/summaries/summary/48429/diagnosis-of-obstructive-sleep-apnea-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930234828/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2016-09-30T23:48:28Z', 'uri': 'http://web.archive.org/web/20160930234828/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2017-10-03T03:41:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003034140/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2017-10-03T03:41:40Z', 'uri': 'http://web.archive.org/web/20171003034140/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2018-04-14T03:06:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414030603/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2018-04-14T03:06:03Z', 'uri': 'http://web.archive.org/web/20180414030603/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2018-05-19T10:00:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519100004/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2018-05-19T10:00:04Z', 'uri': 'http://web.archive.org/web/20180519100004/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}, {'datetime': '2018-06-09T19:32:12Z', 'uri': 'http://web.archive.org/web/20180609193212/https://www.guideline.gov/summaries/summary/48456/preventive-male-sexual-and-reproductive-health-care-recommendations-for-clinical-practice'}]
https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930234827/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2016-09-30T23:48:27Z', 'uri': 'http://web.archive.org/web/20160930234827/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2017-10-03T03:41:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003034133/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2017-10-03T03:41:33Z', 'uri': 'http://web.archive.org/web/20171003034133/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2018-04-14T03:05:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414030555/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2018-04-14T03:05:55Z', 'uri': 'http://web.archive.org/web/20180414030555/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2018-05-19T09:59:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519095955/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2018-05-19T09:59:55Z', 'uri': 'http://web.archive.org/web/20180519095955/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}, {'datetime': '2018-06-09T18:42:42Z', 'uri': 'http://web.archive.org/web/20180609184242/https://www.guideline.gov/summaries/summary/48457/international-ersats-guidelines-on-definition-evaluation-and-treatment-of-severe-asthma'}]
https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930234907/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:49:07Z', 'uri': 'http://web.archive.org/web/20160930234907/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:45:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003034505/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:45:05Z', 'uri': 'http://web.archive.org/web/20171003034505/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:10:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414031018/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:10:18Z', 'uri': 'http://web.archive.org/web/20180414031018/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:04:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519100432/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:04:32Z', 'uri': 'http://web.archive.org/web/20180519100432/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T23:05:34Z', 'uri': 'http://web.archive.org/web/20180610230534/https://www.guideline.gov/summaries/summary/48460/screening-for-abdominal-aortic-aneurysm-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930234801/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2016-09-30T23:48:01Z', 'uri': 'http://web.archive.org/web/20160930234801/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2017-10-03T03:39:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003033905/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2017-10-03T03:39:05Z', 'uri': 'http://web.archive.org/web/20171003033905/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2018-04-14T03:03:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414030332/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2018-04-14T03:03:32Z', 'uri': 'http://web.archive.org/web/20180414030332/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2018-05-19T09:57:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519095733/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2018-05-19T09:57:33Z', 'uri': 'http://web.archive.org/web/20180519095733/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}, {'datetime': '2018-06-09T12:02:54Z', 'uri': 'http://web.archive.org/web/20180609120254/https://www.guideline.gov/summaries/summary/48461/vadod-clinical-practice-guideline-for-screening-and-management-of-overweight-and-obesity'}]
https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930234826/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2016-09-30T23:48:26Z', 'uri': 'http://web.archive.org/web/20160930234826/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2017-10-03T03:41:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003034126/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2017-10-03T03:41:26Z', 'uri': 'http://web.archive.org/web/20171003034126/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2018-04-14T03:05:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414030548/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2018-04-14T03:05:48Z', 'uri': 'http://web.archive.org/web/20180414030548/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2018-05-19T09:59:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519095947/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2018-05-19T09:59:47Z', 'uri': 'http://web.archive.org/web/20180519095947/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}, {'datetime': '2018-06-09T20:50:42Z', 'uri': 'http://web.archive.org/web/20180609205042/https://www.guideline.gov/summaries/summary/48472/best-evidence-statement-best-the-use-of-yoga-to-improve-strength-balance-and-coordination'}]
https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:55:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930225520/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2016-09-30T22:55:20Z', 'uri': 'http://web.archive.org/web/20160930225520/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2017-10-03T02:10:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003021023/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2017-10-03T02:10:23Z', 'uri': 'http://web.archive.org/web/20171003021023/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2018-04-14T00:59:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414005949/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2018-04-14T00:59:49Z', 'uri': 'http://web.archive.org/web/20180414005949/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2018-05-19T07:39:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519073949/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2018-05-19T07:39:49Z', 'uri': 'http://web.archive.org/web/20180519073949/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}, {'datetime': '2018-06-09T11:32:00Z', 'uri': 'http://web.archive.org/web/20180609113200/https://www.guideline.gov/summaries/summary/48473/endovascular-repair-of-traumatic-thoracic-aortic-injury-clinical-practice-guidelines-of-the-society-for-vascular-surgery'}]
https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930234825/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2016-09-30T23:48:25Z', 'uri': 'http://web.archive.org/web/20160930234825/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T03:41:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003034117/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T03:41:17Z', 'uri': 'http://web.archive.org/web/20171003034117/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T03:05:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414030538/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T03:05:38Z', 'uri': 'http://web.archive.org/web/20180414030538/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:59:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519095937/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:59:37Z', 'uri': 'http://web.archive.org/web/20180519095937/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T19:10:36Z', 'uri': 'http://web.archive.org/web/20180609191036/https://www.guideline.gov/summaries/summary/48474/pharmacologic-therapy-for-pulmonary-arterial-hypertension-in-adults-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:55:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930225513/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2016-09-30T22:55:13Z', 'uri': 'http://web.archive.org/web/20160930225513/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2017-10-03T02:10:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003021016/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2017-10-03T02:10:16Z', 'uri': 'http://web.archive.org/web/20171003021016/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-04-14T00:59:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414005940/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-04-14T00:59:40Z', 'uri': 'http://web.archive.org/web/20180414005940/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-05-19T07:39:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519073941/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-05-19T07:39:41Z', 'uri': 'http://web.archive.org/web/20180519073941/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-06-10T01:37:40Z', 'uri': 'http://web.archive.org/web/20180610013740/https://www.guideline.gov/summaries/summary/48475/early-thrombus-removal-strategies-for-acute-deep-venous-thrombosis-clinical-practice-guidelines-for-the-society-for-vascular-surgery-and-the-american-venous-forum'}]
https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:55:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930225533/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2016-09-30T22:55:33Z', 'uri': 'http://web.archive.org/web/20160930225533/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2017-10-03T02:10:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003021029/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2017-10-03T02:10:29Z', 'uri': 'http://web.archive.org/web/20171003021029/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2018-04-14T00:59:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414005957/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2018-04-14T00:59:57Z', 'uri': 'http://web.archive.org/web/20180414005957/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2018-05-19T07:39:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519073958/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2018-05-19T07:39:58Z', 'uri': 'http://web.archive.org/web/20180519073958/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}, {'datetime': '2018-06-09T11:44:28Z', 'uri': 'http://web.archive.org/web/20180609114428/https://www.guideline.gov/summaries/summary/48476/updated-society-for-vascular-surgery-guidelines-for-management-of-extracranial-carotid-disease'}]
https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930234829/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:48:29Z', 'uri': 'http://web.archive.org/web/20160930234829/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:41:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003034156/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:41:56Z', 'uri': 'http://web.archive.org/web/20171003034156/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:06:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414030622/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:06:22Z', 'uri': 'http://web.archive.org/web/20180414030622/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:00:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519100026/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:00:26Z', 'uri': 'http://web.archive.org/web/20180519100026/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T21:49:12Z', 'uri': 'http://web.archive.org/web/20180610214912/https://www.guideline.gov/summaries/summary/48483/behavioral-counseling-to-promote-a-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-with-cardiovascular-risk-factors-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930234829/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2016-09-30T23:48:29Z', 'uri': 'http://web.archive.org/web/20160930234829/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2017-10-03T03:41:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003034149/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2017-10-03T03:41:49Z', 'uri': 'http://web.archive.org/web/20171003034149/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:06:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414030615/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-04-14T03:06:15Z', 'uri': 'http://web.archive.org/web/20180414030615/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:00:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519100016/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-05-19T10:00:16Z', 'uri': 'http://web.archive.org/web/20180519100016/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}, {'datetime': '2018-06-11T07:25:23Z', 'uri': 'http://web.archive.org/web/20180611072523/https://www.guideline.gov/summaries/summary/48484/dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis'}]
https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930234822/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2016-09-30T23:48:22Z', 'uri': 'http://web.archive.org/web/20160930234822/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2017-10-03T03:40:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003034055/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2017-10-03T03:40:55Z', 'uri': 'http://web.archive.org/web/20171003034055/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2018-04-14T03:05:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414030522/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2018-04-14T03:05:22Z', 'uri': 'http://web.archive.org/web/20180414030522/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2018-05-19T09:59:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519095922/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2018-05-19T09:59:22Z', 'uri': 'http://web.archive.org/web/20180519095922/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}, {'datetime': '2018-06-09T11:01:09Z', 'uri': 'http://web.archive.org/web/20180609110109/https://www.guideline.gov/summaries/summary/48499/laboratory-testing-for-the-diagnosis-of-hiv-infection-updated-recommendations'}]
https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:49:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930234909/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:49:09Z', 'uri': 'http://web.archive.org/web/20160930234909/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:45:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003034512/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:45:12Z', 'uri': 'http://web.archive.org/web/20171003034512/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:10:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414031029/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T03:10:29Z', 'uri': 'http://web.archive.org/web/20180414031029/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:04:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519100441/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T10:04:41Z', 'uri': 'http://web.archive.org/web/20180519100441/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T21:54:36Z', 'uri': 'http://web.archive.org/web/20180610215436/https://www.guideline.gov/summaries/summary/48500/screening-for-asymptomatic-carotid-artery-stenosis-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930234816/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2016-09-30T23:48:16Z', 'uri': 'http://web.archive.org/web/20160930234816/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2017-10-03T03:40:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003034036/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2017-10-03T03:40:36Z', 'uri': 'http://web.archive.org/web/20171003034036/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2018-04-14T03:04:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414030459/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2018-04-14T03:04:59Z', 'uri': 'http://web.archive.org/web/20180414030459/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2018-05-19T09:58:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519095859/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2018-05-19T09:58:59Z', 'uri': 'http://web.archive.org/web/20180519095859/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}, {'datetime': '2018-06-09T20:01:20Z', 'uri': 'http://web.archive.org/web/20180609200120/https://www.guideline.gov/summaries/summary/48512/occupational-therapy-practice-guidelines-for-adults-with-neurodegenerative-diseases'}]
https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930234817/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2016-09-30T23:48:17Z', 'uri': 'http://web.archive.org/web/20160930234817/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2017-10-03T03:40:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003034043/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2017-10-03T03:40:43Z', 'uri': 'http://web.archive.org/web/20171003034043/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2018-04-14T03:05:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414030508/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2018-04-14T03:05:08Z', 'uri': 'http://web.archive.org/web/20180414030508/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2018-05-19T09:59:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519095909/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2018-05-19T09:59:09Z', 'uri': 'http://web.archive.org/web/20180519095909/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}, {'datetime': '2018-06-09T10:33:50Z', 'uri': 'http://web.archive.org/web/20180609103350/https://www.guideline.gov/summaries/summary/48513/occupational-therapy-practice-guidelines-for-home-modifications'}]
https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930234812/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2016-09-30T23:48:12Z', 'uri': 'http://web.archive.org/web/20160930234812/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2017-10-03T03:40:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003034003/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2017-10-03T03:40:03Z', 'uri': 'http://web.archive.org/web/20171003034003/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2018-04-14T03:04:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414030420/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2018-04-14T03:04:20Z', 'uri': 'http://web.archive.org/web/20180414030420/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2018-05-19T09:58:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519095818/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2018-05-19T09:58:18Z', 'uri': 'http://web.archive.org/web/20180519095818/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}, {'datetime': '2018-06-09T11:08:05Z', 'uri': 'http://web.archive.org/web/20180609110805/https://www.guideline.gov/summaries/summary/48516/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-detection-and-nonoperative-management-of-pediatric-developmental-dysplasia-of-the-hip-in-infants-up-to-six-months-of-age'}]
https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930234813/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2016-09-30T23:48:13Z', 'uri': 'http://web.archive.org/web/20160930234813/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2017-10-03T03:40:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003034010/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2017-10-03T03:40:10Z', 'uri': 'http://web.archive.org/web/20171003034010/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-04-14T03:04:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414030430/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-04-14T03:04:30Z', 'uri': 'http://web.archive.org/web/20180414030430/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-05-19T09:58:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519095828/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-05-19T09:58:28Z', 'uri': 'http://web.archive.org/web/20180519095828/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-06-09T22:11:08Z', 'uri': 'http://web.archive.org/web/20180609221108/https://www.guideline.gov/summaries/summary/48517/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-anterior-cruciate-ligament-injuries'}]
https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930234814/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2016-09-30T23:48:14Z', 'uri': 'http://web.archive.org/web/20160930234814/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2017-10-03T03:40:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003034013/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2017-10-03T03:40:13Z', 'uri': 'http://web.archive.org/web/20171003034013/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2018-04-14T03:04:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414030433/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2018-04-14T03:04:33Z', 'uri': 'http://web.archive.org/web/20180414030433/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2018-05-19T09:58:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519095831/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2018-05-19T09:58:31Z', 'uri': 'http://web.archive.org/web/20180519095831/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}, {'datetime': '2018-06-09T15:30:12Z', 'uri': 'http://web.archive.org/web/20180609153012/https://www.guideline.gov/summaries/summary/48518/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-hip-fractures-in-the-elderly'}]
https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930234803/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2016-09-30T23:48:03Z', 'uri': 'http://web.archive.org/web/20160930234803/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2017-10-03T03:39:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003033923/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2017-10-03T03:39:23Z', 'uri': 'http://web.archive.org/web/20171003033923/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2018-04-14T03:03:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414030352/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2018-04-14T03:03:52Z', 'uri': 'http://web.archive.org/web/20180414030352/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2018-05-19T09:57:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519095752/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2018-05-19T09:57:52Z', 'uri': 'http://web.archive.org/web/20180519095752/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}, {'datetime': '2018-06-10T02:18:25Z', 'uri': 'http://web.archive.org/web/20180610021825/https://www.guideline.gov/summaries/summary/48523/detecting-managing-and-monitoring-haemostasis-viscoelastometric-pointofcare-testing-rotem-teg-and-sonoclot-systems'}]
https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930234855/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2016-09-30T23:48:55Z', 'uri': 'http://web.archive.org/web/20160930234855/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003034404/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:04Z', 'uri': 'http://web.archive.org/web/20171003034404/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414030905/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:05Z', 'uri': 'http://web.archive.org/web/20180414030905/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519100325/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:25Z', 'uri': 'http://web.archive.org/web/20180519100325/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-06-09T21:46:46Z', 'uri': 'http://web.archive.org/web/20180609214646/https://www.guideline.gov/summaries/summary/48524/health-maintenance-for-people-with-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}]
https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930234857/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2016-09-30T23:48:57Z', 'uri': 'http://web.archive.org/web/20160930234857/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003034420/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:20Z', 'uri': 'http://web.archive.org/web/20171003034420/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414030925/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:25Z', 'uri': 'http://web.archive.org/web/20180414030925/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519100344/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:44Z', 'uri': 'http://web.archive.org/web/20180519100344/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-06-09T21:46:54Z', 'uri': 'http://web.archive.org/web/20180609214654/https://www.guideline.gov/summaries/summary/48525/managing-acute-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}]
https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930234858/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2016-09-30T23:48:58Z', 'uri': 'http://web.archive.org/web/20160930234858/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003034429/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:29Z', 'uri': 'http://web.archive.org/web/20171003034429/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414030936/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:36Z', 'uri': 'http://web.archive.org/web/20180414030936/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519100354/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:54Z', 'uri': 'http://web.archive.org/web/20180519100354/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-06-09T21:46:32Z', 'uri': 'http://web.archive.org/web/20180609214632/https://www.guideline.gov/summaries/summary/48526/managing-chronic-complications-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}]
https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930234856/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2016-09-30T23:48:56Z', 'uri': 'http://web.archive.org/web/20160930234856/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003034412/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:44:12Z', 'uri': 'http://web.archive.org/web/20171003034412/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414030916/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:09:16Z', 'uri': 'http://web.archive.org/web/20180414030916/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519100334/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:34Z', 'uri': 'http://web.archive.org/web/20180519100334/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-06-09T20:18:50Z', 'uri': 'http://web.archive.org/web/20180609201850/https://www.guideline.gov/summaries/summary/48527/hydroxyurea-therapy-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}]
https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930234855/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2016-09-30T23:48:55Z', 'uri': 'http://web.archive.org/web/20160930234855/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:43:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003034356/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:43:56Z', 'uri': 'http://web.archive.org/web/20171003034356/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:08:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414030855/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-04-14T03:08:55Z', 'uri': 'http://web.archive.org/web/20180414030855/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519100316/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-05-19T10:03:16Z', 'uri': 'http://web.archive.org/web/20180519100316/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}, {'datetime': '2018-06-09T21:46:42Z', 'uri': 'http://web.archive.org/web/20180609214642/https://www.guideline.gov/summaries/summary/48528/blood-transfusion-in-the-management-of-sickle-cell-disease-in-evidencebased-management-of-sickle-cell-disease'}]
https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930234633/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2016-09-30T23:46:33Z', 'uri': 'http://web.archive.org/web/20160930234633/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2017-10-03T03:35:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003033551/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2017-10-03T03:35:51Z', 'uri': 'http://web.archive.org/web/20171003033551/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2018-04-14T03:00:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414030014/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2018-04-14T03:00:14Z', 'uri': 'http://web.archive.org/web/20180414030014/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2018-05-19T09:53:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519095353/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2018-05-19T09:53:53Z', 'uri': 'http://web.archive.org/web/20180519095353/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}, {'datetime': '2018-06-09T12:02:46Z', 'uri': 'http://web.archive.org/web/20180609120246/https://www.guideline.gov/summaries/summary/48529/vadod-clinical-practice-guideline-for-the-management-of-upper-extremity-amputation-rehabilitation'}]
https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930234639/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2016-09-30T23:46:39Z', 'uri': 'http://web.archive.org/web/20160930234639/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2017-10-03T03:35:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003033558/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2017-10-03T03:35:58Z', 'uri': 'http://web.archive.org/web/20171003033558/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2018-04-14T03:00:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414030023/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2018-04-14T03:00:23Z', 'uri': 'http://web.archive.org/web/20180414030023/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2018-05-19T09:54:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519095403/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2018-05-19T09:54:03Z', 'uri': 'http://web.archive.org/web/20180519095403/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}, {'datetime': '2018-06-09T15:27:56Z', 'uri': 'http://web.archive.org/web/20180609152756/https://www.guideline.gov/summaries/summary/48530/vadod-clinical-practice-guideline-for-the-nonsurgical-management-of-hip-and-knee-osteoarthritis'}]
https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930234754/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2016-09-30T23:47:54Z', 'uri': 'http://web.archive.org/web/20160930234754/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2017-10-03T03:38:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003033851/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2017-10-03T03:38:51Z', 'uri': 'http://web.archive.org/web/20171003033851/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2018-04-14T03:03:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414030315/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2018-04-14T03:03:15Z', 'uri': 'http://web.archive.org/web/20180414030315/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2018-05-19T09:57:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519095714/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2018-05-19T09:57:14Z', 'uri': 'http://web.archive.org/web/20180519095714/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}, {'datetime': '2018-06-09T10:36:28Z', 'uri': 'http://web.archive.org/web/20180609103628/https://www.guideline.gov/summaries/summary/48533/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath'}]
https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:47:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930234749/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2016-09-30T23:47:49Z', 'uri': 'http://web.archive.org/web/20160930234749/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2017-01-06T23:42:16Z', 'uri': 'http://web.archive.org/web/20170106234216/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2017-10-03T03:38:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003033827/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2017-10-03T03:38:27Z', 'uri': 'http://web.archive.org/web/20171003033827/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2018-04-14T03:03:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414030305/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2018-04-14T03:03:05Z', 'uri': 'http://web.archive.org/web/20180414030305/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2018-05-19T09:56:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519095652/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2018-05-19T09:56:52Z', 'uri': 'http://web.archive.org/web/20180519095652/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}, {'datetime': '2018-06-09T19:17:11Z', 'uri': 'http://web.archive.org/web/20180609191711/https://www.guideline.gov/summaries/summary/48534/faecal-calprotectin-diagnostic-tests-for-inflammatory-diseases-of-the-bowel'}]
https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930234739/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2016-09-30T23:47:39Z', 'uri': 'http://web.archive.org/web/20160930234739/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2017-10-03T03:37:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003033758/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2017-10-03T03:37:58Z', 'uri': 'http://web.archive.org/web/20171003033758/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2018-04-14T03:02:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414030235/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2018-04-14T03:02:35Z', 'uri': 'http://web.archive.org/web/20180414030235/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2018-05-19T09:56:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519095624/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2018-05-19T09:56:24Z', 'uri': 'http://web.archive.org/web/20180519095624/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}, {'datetime': '2018-06-10T17:02:32Z', 'uri': 'http://web.archive.org/web/20180610170232/https://www.guideline.gov/summaries/summary/48535/gene-expression-profiling-and-expanded-immunohistochemistry-tests-for-guiding-adjuvant-chemotherapy-decisions-in-early-breast-cancer-management-mammaprint-oncotype-dx-ihc4-and-mammostrat'}]
https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T14:33:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930143349/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2016-09-30T14:33:49Z', 'uri': 'http://web.archive.org/web/20160930143349/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2017-07-14T10:35:18Z', 'uri': 'http://web.archive.org/web/20170714103518/https://guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2017-10-03T03:37:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003033751/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2017-10-03T03:37:51Z', 'uri': 'http://web.archive.org/web/20171003033751/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-04-14T03:02:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414030224/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-04-14T03:02:24Z', 'uri': 'http://web.archive.org/web/20180414030224/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-05-19T09:56:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519095614/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-05-19T09:56:14Z', 'uri': 'http://web.archive.org/web/20180519095614/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}, {'datetime': '2018-06-09T11:40:20Z', 'uri': 'http://web.archive.org/web/20180609114020/https://www.guideline.gov/summaries/summary/48536/egfrtk-mutation-testing-in-adults-with-locally-advanced-or-metastatic-nonsmallcell-lung-cancer'}]
https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930234739/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2016-09-30T23:47:39Z', 'uri': 'http://web.archive.org/web/20160930234739/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2017-10-03T03:38:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003033805/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2017-10-03T03:38:05Z', 'uri': 'http://web.archive.org/web/20171003033805/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2018-04-14T03:02:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414030247/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2018-04-14T03:02:47Z', 'uri': 'http://web.archive.org/web/20180414030247/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2018-05-19T09:56:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519095633/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2018-05-19T09:56:33Z', 'uri': 'http://web.archive.org/web/20180519095633/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}, {'datetime': '2018-06-09T18:41:00Z', 'uri': 'http://web.archive.org/web/20180609184100/https://www.guideline.gov/summaries/summary/48537/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer'}]
https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930234719/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2016-09-30T23:47:19Z', 'uri': 'http://web.archive.org/web/20160930234719/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2017-10-03T03:36:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003033643/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2017-10-03T03:36:43Z', 'uri': 'http://web.archive.org/web/20171003033643/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2018-04-14T03:01:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414030118/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2018-04-14T03:01:18Z', 'uri': 'http://web.archive.org/web/20180414030118/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2018-05-19T09:55:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519095509/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2018-05-19T09:55:09Z', 'uri': 'http://web.archive.org/web/20180519095509/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}, {'datetime': '2018-06-10T12:35:32Z', 'uri': 'http://web.archive.org/web/20180610123532/https://www.guideline.gov/summaries/summary/48538/depth-of-anaesthesia-monitors---bispectral-index-bis-eentropy-and-narcotrendcompact-m'}]
https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930234727/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2016-09-30T23:47:27Z', 'uri': 'http://web.archive.org/web/20160930234727/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2017-10-03T03:36:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003033657/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2017-10-03T03:36:57Z', 'uri': 'http://web.archive.org/web/20171003033657/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2018-04-14T03:01:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414030135/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2018-04-14T03:01:35Z', 'uri': 'http://web.archive.org/web/20180414030135/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2018-05-19T09:55:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519095528/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2018-05-19T09:55:28Z', 'uri': 'http://web.archive.org/web/20180519095528/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}, {'datetime': '2018-06-10T20:02:46Z', 'uri': 'http://web.archive.org/web/20180610200246/https://www.guideline.gov/summaries/summary/48539/sehcat-tauroselcholic-75-selenium-acid-for-the-investigation-of-diarrhoea-due-to-bile-acid-malabsorption-in-people-with-diarrhoeapredominant-irritable-bowel-syndrome-ibsd-or-crohns-disease-without-ileal-resection'}]
https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930234718/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2016-09-30T23:47:18Z', 'uri': 'http://web.archive.org/web/20160930234718/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2017-10-03T03:36:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003033636/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2017-10-03T03:36:36Z', 'uri': 'http://web.archive.org/web/20171003033636/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2018-04-14T03:01:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414030110/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2018-04-14T03:01:10Z', 'uri': 'http://web.archive.org/web/20180414030110/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2018-05-19T09:55:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519095500/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2018-05-19T09:55:00Z', 'uri': 'http://web.archive.org/web/20180519095500/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}, {'datetime': '2018-06-09T21:19:01Z', 'uri': 'http://web.archive.org/web/20180609211901/https://www.guideline.gov/summaries/summary/48540/adjunctive-colposcopy-technologies-for-examination-of-the-uterine-cervix---dysis-and-the-niris-imaging-system'}]
https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930234728/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2016-09-30T23:47:28Z', 'uri': 'http://web.archive.org/web/20160930234728/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2017-10-03T03:37:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003033704/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2017-10-03T03:37:04Z', 'uri': 'http://web.archive.org/web/20171003033704/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2018-04-14T03:01:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414030145/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2018-04-14T03:01:45Z', 'uri': 'http://web.archive.org/web/20180414030145/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2018-05-19T09:55:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519095538/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2018-05-19T09:55:38Z', 'uri': 'http://web.archive.org/web/20180519095538/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}, {'datetime': '2018-06-10T12:35:32Z', 'uri': 'http://web.archive.org/web/20180610123532/https://www.guideline.gov/summaries/summary/48541/sonovue-sulphur-hexafluoride-microbubbles---contrast-agent-for-contrastenhanced-ultrasound-imaging-of-the-liver'}]
https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930234726/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2016-09-30T23:47:26Z', 'uri': 'http://web.archive.org/web/20160930234726/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2017-10-03T03:36:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003033650/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2017-10-03T03:36:50Z', 'uri': 'http://web.archive.org/web/20171003033650/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2018-04-14T03:01:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414030127/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2018-04-14T03:01:27Z', 'uri': 'http://web.archive.org/web/20180414030127/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2018-05-19T09:55:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519095518/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2018-05-19T09:55:18Z', 'uri': 'http://web.archive.org/web/20180519095518/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}, {'datetime': '2018-06-10T20:03:34Z', 'uri': 'http://web.archive.org/web/20180610200334/https://www.guideline.gov/summaries/summary/48542/new-generation-cardiac-ct-scanners-aquilion-one-brilliance-ict-discovery-ct750-hd-and-somatom-definition-flash-for-cardiac-imaging-in-people-with-suspected-or-known-coronary-artery-disease-in-whom-imaging-is-difficult-with-earlier-generation-ct-scanners'}]
https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930234815/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:48:15Z', 'uri': 'http://web.archive.org/web/20160930234815/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:40:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003034028/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:40:28Z', 'uri': 'http://web.archive.org/web/20171003034028/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:04:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414030449/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:04:49Z', 'uri': 'http://web.archive.org/web/20180414030449/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:58:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519095850/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:58:50Z', 'uri': 'http://web.archive.org/web/20180519095850/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T15:27:29Z', 'uri': 'http://web.archive.org/web/20180609152729/https://www.guideline.gov/summaries/summary/48543/nonsurgical-management-of-urinary-incontinence-in-women-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults	ARCHIVED	14 mementos	[{'datetime': '2016-09-30T16:21:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930162124/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2016-09-30T16:21:24Z', 'uri': 'http://web.archive.org/web/20160930162124/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2017-07-13T03:30:57Z', 'uri': 'http://web.archive.org/web/20170713033057/https://www.guideline.gov/summaries/summary/48544/Diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2017-10-02T20:04:35Z', 'uri': 'http://wayback.archive-it.org/all/20171002200435/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2017-10-02T20:04:35Z', 'uri': 'http://web.archive.org/web/20171002200435/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-04-13T18:54:59Z', 'uri': 'http://wayback.archive-it.org/all/20180413185459/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-04-13T18:54:59Z', 'uri': 'http://web.archive.org/web/20180413185459/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-05-18T21:49:22Z', 'uri': 'http://wayback.archive-it.org/all/20180518214922/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-05-18T21:49:22Z', 'uri': 'http://web.archive.org/web/20180518214922/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-06-09T10:35:50Z', 'uri': 'http://web.archive.org/web/20180609103550/https://www.guideline.gov/summaries/summary/48544/Diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-06-09T11:34:49Z', 'uri': 'http://web.archive.org/web/20180609113449/https://www.guideline.gov/summaries/summary/48544/diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-06-11T17:20:13Z', 'uri': 'http://web.archive.org/web/20180611172013/https://www.guideline.gov/summaries/summary/48544/Diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-06-20T17:39:30Z', 'uri': 'http://web.archive.org/web/20180620173930/https://www.guideline.gov/summaries/summary/48544/Diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}, {'datetime': '2018-06-21T00:14:23Z', 'uri': 'http://web.archive.org/web/20180621001423/https://www.guideline.gov/summaries/summary/48544/Diagnosis-and-management-of-type-2-diabetes-mellitus-in-adults'}]
https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930234803/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:48:03Z', 'uri': 'http://web.archive.org/web/20160930234803/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:39:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003033933/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:39:33Z', 'uri': 'http://web.archive.org/web/20171003033933/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:04:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414030402/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:04:02Z', 'uri': 'http://web.archive.org/web/20180414030402/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:58:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519095800/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:58:00Z', 'uri': 'http://web.archive.org/web/20180519095800/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-09T21:53:29Z', 'uri': 'http://web.archive.org/web/20180609215329/https://www.guideline.gov/summaries/summary/48545/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930234823/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2016-09-30T23:48:23Z', 'uri': 'http://web.archive.org/web/20160930234823/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2017-10-03T03:41:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003034101/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2017-10-03T03:41:01Z', 'uri': 'http://web.archive.org/web/20171003034101/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2018-04-14T03:05:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414030531/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2018-04-14T03:05:31Z', 'uri': 'http://web.archive.org/web/20180414030531/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2018-05-19T09:59:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519095930/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2018-05-19T09:59:30Z', 'uri': 'http://web.archive.org/web/20180519095930/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}, {'datetime': '2018-06-09T12:11:13Z', 'uri': 'http://web.archive.org/web/20180609121113/https://www.guideline.gov/summaries/summary/48546/deep-brain-stimulation-for-obsessivecompulsive-disorder-systematic-review-and-evidencebased-guideline-sponsored-by-the-american-society-for-stereotactic-and-functional-neurosurgery-and-the-congress-of-neurological-surgeons-cns-and-endorsed-by-the-cns-and-ameri'}]
https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:48:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930234804/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2016-09-30T23:48:04Z', 'uri': 'http://web.archive.org/web/20160930234804/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2017-01-06T23:45:38Z', 'uri': 'http://web.archive.org/web/20170106234538/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2017-10-03T03:39:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003033940/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2017-10-03T03:39:40Z', 'uri': 'http://web.archive.org/web/20171003033940/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2018-04-14T03:04:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414030411/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2018-04-14T03:04:11Z', 'uri': 'http://web.archive.org/web/20180414030411/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2018-05-19T09:58:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519095809/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2018-05-19T09:58:09Z', 'uri': 'http://web.archive.org/web/20180519095809/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}, {'datetime': '2018-06-10T00:03:57Z', 'uri': 'http://web.archive.org/web/20180610000357/https://www.guideline.gov/summaries/summary/48560/calcium-supplementation-in-pregnant-women'}]
https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930234528/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2016-09-30T23:45:28Z', 'uri': 'http://web.archive.org/web/20160930234528/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2017-10-03T03:34:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003033441/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2017-10-03T03:34:41Z', 'uri': 'http://web.archive.org/web/20171003033441/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2018-04-14T02:58:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414025854/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2018-04-14T02:58:54Z', 'uri': 'http://web.archive.org/web/20180414025854/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2018-05-19T09:52:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519095234/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2018-05-19T09:52:34Z', 'uri': 'http://web.archive.org/web/20180519095234/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}, {'datetime': '2018-06-09T21:19:02Z', 'uri': 'http://web.archive.org/web/20180609211902/https://www.guideline.gov/summaries/summary/48562/atrial-fibrillation-and-heart-valve-disease-selfmonitoring-coagulation-status-using-pointofcare-coagulometers-the-coaguchek-xs-system-and-the-inratio2-ptinr-monitor'}]
https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930234535/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2016-09-30T23:45:35Z', 'uri': 'http://web.archive.org/web/20160930234535/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2017-10-03T03:34:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003033448/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2017-10-03T03:34:48Z', 'uri': 'http://web.archive.org/web/20171003033448/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2018-04-14T02:59:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414025903/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2018-04-14T02:59:03Z', 'uri': 'http://web.archive.org/web/20180414025903/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2018-05-19T09:52:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519095244/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2018-05-19T09:52:44Z', 'uri': 'http://web.archive.org/web/20180519095244/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}, {'datetime': '2018-06-10T11:29:09Z', 'uri': 'http://web.archive.org/web/20180610112909/https://www.guideline.gov/summaries/summary/48563/dyspepsia-and-gastrooesophageal-reflux-disease-investigation-and-management-of-dyspepsia-symptoms-suggestive-of-gastrooesophageal-reflux-disease-or-both'}]
https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930234521/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2016-09-30T23:45:21Z', 'uri': 'http://web.archive.org/web/20160930234521/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2017-10-03T03:34:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003033431/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2017-10-03T03:34:31Z', 'uri': 'http://web.archive.org/web/20171003033431/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2018-04-14T02:58:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414025844/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2018-04-14T02:58:44Z', 'uri': 'http://web.archive.org/web/20180414025844/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2018-05-19T09:52:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519095223/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2018-05-19T09:52:23Z', 'uri': 'http://web.archive.org/web/20180519095223/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}, {'datetime': '2018-06-10T00:22:46Z', 'uri': 'http://web.archive.org/web/20180610002246/https://www.guideline.gov/summaries/summary/48564/drug-allergy-diagnosis-and-management-of-drug-allergy-in-adults-children-and-young-people'}]
https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:44:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930234448/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2016-09-30T23:44:48Z', 'uri': 'http://web.archive.org/web/20160930234448/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2017-07-10T16:08:45Z', 'uri': 'http://web.archive.org/web/20170710160845/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2017-10-03T03:33:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003033311/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2017-10-03T03:33:11Z', 'uri': 'http://web.archive.org/web/20171003033311/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2018-04-14T02:57:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414025739/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2018-04-14T02:57:39Z', 'uri': 'http://web.archive.org/web/20180414025739/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2018-05-19T09:51:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519095108/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2018-05-19T09:51:08Z', 'uri': 'http://web.archive.org/web/20180519095108/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}, {'datetime': '2018-06-09T12:12:53Z', 'uri': 'http://web.archive.org/web/20180609121253/https://www.guideline.gov/summaries/summary/48565/bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care'}]
https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930234755/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2016-09-30T23:47:55Z', 'uri': 'http://web.archive.org/web/20160930234755/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2017-10-03T03:38:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003033858/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2017-10-03T03:38:58Z', 'uri': 'http://web.archive.org/web/20171003033858/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2018-04-14T03:03:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414030324/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2018-04-14T03:03:24Z', 'uri': 'http://web.archive.org/web/20180414030324/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2018-05-19T09:57:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519095724/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2018-05-19T09:57:24Z', 'uri': 'http://web.archive.org/web/20180519095724/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}, {'datetime': '2018-06-10T18:36:14Z', 'uri': 'http://web.archive.org/web/20180610183614/https://www.guideline.gov/summaries/summary/48566/followup-and-surveillance-of-curatively-treated-lung-cancer-patients'}]
https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930234730/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:47:30Z', 'uri': 'http://web.archive.org/web/20160930234730/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:37:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003033711/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:37:11Z', 'uri': 'http://web.archive.org/web/20171003033711/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:01:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414030154/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T03:01:54Z', 'uri': 'http://web.archive.org/web/20180414030154/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:55:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519095547/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:55:47Z', 'uri': 'http://web.archive.org/web/20180519095547/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T23:02:04Z', 'uri': 'http://web.archive.org/web/20180610230204/https://www.guideline.gov/summaries/summary/48623/chemotherapy-and-targeted-therapy-for-women-with-human-epidermal-growth-factor-receptor-2-negative-or-unknown-advanced-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930234731/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2016-09-30T23:47:31Z', 'uri': 'http://web.archive.org/web/20160930234731/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2017-10-03T03:37:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003033718/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2017-10-03T03:37:18Z', 'uri': 'http://web.archive.org/web/20171003033718/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2018-04-14T03:02:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414030203/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2018-04-14T03:02:03Z', 'uri': 'http://web.archive.org/web/20180414030203/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2018-05-19T09:55:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519095556/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2018-05-19T09:55:56Z', 'uri': 'http://web.archive.org/web/20180519095556/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}, {'datetime': '2018-06-09T10:34:04Z', 'uri': 'http://web.archive.org/web/20180609103404/https://www.guideline.gov/summaries/summary/48685/screening-assessment-and-care-of-anxiety-and-depressive-symptoms-in-adults-with-cancer-an-american-society-of-clinical-oncology-guideline-adaptation'}]
https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930234649/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2016-09-30T23:46:49Z', 'uri': 'http://web.archive.org/web/20160930234649/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2017-10-03T03:36:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003033606/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2017-10-03T03:36:06Z', 'uri': 'http://web.archive.org/web/20171003033606/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2018-04-14T03:00:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414030032/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2018-04-14T03:00:32Z', 'uri': 'http://web.archive.org/web/20180414030032/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2018-05-19T09:54:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519095413/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2018-05-19T09:54:13Z', 'uri': 'http://web.archive.org/web/20180519095413/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}, {'datetime': '2018-06-09T20:31:38Z', 'uri': 'http://web.archive.org/web/20180609203138/https://www.guideline.gov/summaries/summary/48690/anaphylaxis-guidelines-from-the-european-academy-of-allergy-and-clinical-immunology'}]
https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930234703/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2016-09-30T23:47:03Z', 'uri': 'http://web.archive.org/web/20160930234703/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2017-10-03T03:36:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003033621/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2017-10-03T03:36:21Z', 'uri': 'http://web.archive.org/web/20171003033621/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2018-04-14T03:00:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414030050/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2018-04-14T03:00:50Z', 'uri': 'http://web.archive.org/web/20180414030050/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2018-05-19T09:54:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519095432/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2018-05-19T09:54:32Z', 'uri': 'http://web.archive.org/web/20180519095432/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}, {'datetime': '2018-06-09T20:12:59Z', 'uri': 'http://web.archive.org/web/20180609201259/https://www.guideline.gov/summaries/summary/48691/eaaci-food-allergy-and-anaphylaxis-guidelines-diagnosis-and-management-of-food-allergy'}]
https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930234657/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2016-09-30T23:46:57Z', 'uri': 'http://web.archive.org/web/20160930234657/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2017-10-03T03:36:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003033614/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2017-10-03T03:36:14Z', 'uri': 'http://web.archive.org/web/20171003033614/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2018-04-14T03:00:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414030042/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2018-04-14T03:00:42Z', 'uri': 'http://web.archive.org/web/20180414030042/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2018-05-19T09:54:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519095423/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2018-05-19T09:54:23Z', 'uri': 'http://web.archive.org/web/20180519095423/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}, {'datetime': '2018-06-09T20:12:55Z', 'uri': 'http://web.archive.org/web/20180609201255/https://www.guideline.gov/summaries/summary/48692/eaaci-food-allergy-and-anaphylaxis-guidelines-primary-prevention-of-food-allergy'}]
https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930234731/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2016-09-30T23:47:31Z', 'uri': 'http://web.archive.org/web/20160930234731/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2017-10-03T03:37:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003033725/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2017-10-03T03:37:25Z', 'uri': 'http://web.archive.org/web/20171003033725/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2018-04-14T03:02:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414030213/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2018-04-14T03:02:13Z', 'uri': 'http://web.archive.org/web/20180414030213/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2018-05-19T09:56:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519095605/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2018-05-19T09:56:05Z', 'uri': 'http://web.archive.org/web/20180519095605/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}, {'datetime': '2018-06-09T21:13:20Z', 'uri': 'http://web.archive.org/web/20180609211320/https://www.guideline.gov/summaries/summary/48745/diagnosis-and-treatment-of-interstitial-cystitisbladder-pain-syndrome'}]
https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:45:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930234520/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2016-09-30T23:45:20Z', 'uri': 'http://web.archive.org/web/20160930234520/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2016-12-16T13:34:03Z', 'uri': 'http://web.archive.org/web/20161216133403/https://guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2017-10-03T03:34:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003033424/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2017-10-03T03:34:24Z', 'uri': 'http://web.archive.org/web/20171003033424/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2018-04-14T02:58:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414025835/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2018-04-14T02:58:35Z', 'uri': 'http://web.archive.org/web/20180414025835/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2018-05-19T09:52:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519095214/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2018-05-19T09:52:14Z', 'uri': 'http://web.archive.org/web/20180519095214/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}, {'datetime': '2018-06-09T21:57:41Z', 'uri': 'http://web.archive.org/web/20180609215741/https://www.guideline.gov/summaries/summary/48746/evidencebased-guideline-summary-diagnosis-and-treatment-of-limbgirdle-and-distal-dystrophies-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuromuscular'}]
https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930234802/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2016-09-30T23:48:02Z', 'uri': 'http://web.archive.org/web/20160930234802/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2017-10-03T03:39:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003033914/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2017-10-03T03:39:14Z', 'uri': 'http://web.archive.org/web/20171003033914/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2018-04-14T03:03:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414030342/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2018-04-14T03:03:42Z', 'uri': 'http://web.archive.org/web/20180414030342/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2018-05-19T09:57:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519095743/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2018-05-19T09:57:43Z', 'uri': 'http://web.archive.org/web/20180519095743/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}, {'datetime': '2018-06-09T19:31:03Z', 'uri': 'http://web.archive.org/web/20180609193103/https://www.guideline.gov/summaries/summary/48747/masccisoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy'}]
https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930234710/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2016-09-30T23:47:10Z', 'uri': 'http://web.archive.org/web/20160930234710/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2017-10-03T03:36:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003033629/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2017-10-03T03:36:29Z', 'uri': 'http://web.archive.org/web/20171003033629/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2018-04-14T03:01:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414030100/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2018-04-14T03:01:00Z', 'uri': 'http://web.archive.org/web/20180414030100/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2018-05-19T09:54:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519095443/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2018-05-19T09:54:43Z', 'uri': 'http://web.archive.org/web/20180519095443/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}, {'datetime': '2018-06-09T21:32:04Z', 'uri': 'http://web.archive.org/web/20180609213204/https://www.guideline.gov/summaries/summary/48751/clinical-practice-guideline-tinnitus'}]
https://www.guideline.gov/summaries/summary/48752/acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:44:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930234433/https://www.guideline.gov/summaries/summary/48752/acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2016-09-30T23:44:33Z', 'uri': 'http://web.archive.org/web/20160930234433/https://www.guideline.gov/summaries/summary/48752/acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2017-10-03T03:33:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003033322/https://www.guideline.gov/summaries/summary/48752/acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2017-10-03T03:33:22Z', 'uri': 'http://web.archive.org/web/20171003033322/https://www.guideline.gov/summaries/summary/48752/acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-04-13T17:01:46Z', 'uri': 'http://wayback.archive-it.org/all/20180413170146/https://www.guideline.gov/summaries/summary/48752/Acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-04-13T17:01:46Z', 'uri': 'http://web.archive.org/web/20180413170146/https://www.guideline.gov/summaries/summary/48752/Acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-05-18T19:26:34Z', 'uri': 'http://wayback.archive-it.org/all/20180518192634/https://www.guideline.gov/summaries/summary/48752/Acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-05-18T19:26:34Z', 'uri': 'http://web.archive.org/web/20180518192634/https://www.guideline.gov/summaries/summary/48752/Acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-06-01T14:50:56Z', 'uri': 'http://web.archive.org/web/20180601145056/https://www.guideline.gov/summaries/summary/48752/Acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-06-09T10:31:57Z', 'uri': 'http://web.archive.org/web/20180609103157/https://www.guideline.gov/summaries/summary/48752/Acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}, {'datetime': '2018-06-10T02:07:12Z', 'uri': 'http://web.archive.org/web/20180610020712/https://www.guideline.gov/summaries/summary/48752/acute-heart-failure-diagnosing-and-managing-acute-heart-failure-in-adults'}]
https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930234441/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2016-09-30T23:44:41Z', 'uri': 'http://web.archive.org/web/20160930234441/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2017-10-03T03:33:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003033331/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2017-10-03T03:33:31Z', 'uri': 'http://web.archive.org/web/20171003033331/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2018-04-14T02:57:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414025755/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2018-04-14T02:57:55Z', 'uri': 'http://web.archive.org/web/20180414025755/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2018-05-19T09:51:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519095122/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2018-05-19T09:51:22Z', 'uri': 'http://web.archive.org/web/20180519095122/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}, {'datetime': '2018-06-09T12:14:02Z', 'uri': 'http://web.archive.org/web/20180609121402/https://www.guideline.gov/summaries/summary/48753/multiple-sclerosis-management-of-multiple-sclerosis-in-primary-and-secondary-care'}]
https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930234427/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2016-09-30T23:44:27Z', 'uri': 'http://web.archive.org/web/20160930234427/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2017-10-03T03:33:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003033302/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2017-10-03T03:33:02Z', 'uri': 'http://web.archive.org/web/20171003033302/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2018-04-14T02:57:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414025726/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2018-04-14T02:57:26Z', 'uri': 'http://web.archive.org/web/20180414025726/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2018-05-19T09:50:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519095058/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2018-05-19T09:50:58Z', 'uri': 'http://web.archive.org/web/20180519095058/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}, {'datetime': '2018-06-09T15:14:23Z', 'uri': 'http://web.archive.org/web/20180609151423/https://www.guideline.gov/summaries/summary/48754/myocardial-infarction-acute-early-rule-out-using-highsensitivity-troponin-tests-elecsys-troponin-t-highsensitive-architect-stat-high-sensitive-troponini-and-accutni-3-assays'}]
https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930234627/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2016-09-30T23:46:27Z', 'uri': 'http://web.archive.org/web/20160930234627/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2017-10-03T03:35:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003033545/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2017-10-03T03:35:45Z', 'uri': 'http://web.archive.org/web/20171003033545/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2018-04-14T03:00:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414030005/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2018-04-14T03:00:05Z', 'uri': 'http://web.archive.org/web/20180414030005/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2018-05-19T09:53:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519095344/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2018-05-19T09:53:44Z', 'uri': 'http://web.archive.org/web/20180519095344/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}, {'datetime': '2018-06-10T23:02:23Z', 'uri': 'http://web.archive.org/web/20180610230223/https://www.guideline.gov/summaries/summary/48755/dabrafenib-for-treating-unresectable-or-metastatic-braf-v600-mutationpositive-melanoma'}]
https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930234549/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:45:49Z', 'uri': 'http://web.archive.org/web/20160930234549/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003033504/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:04Z', 'uri': 'http://web.archive.org/web/20171003033504/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414025914/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:14Z', 'uri': 'http://web.archive.org/web/20180414025914/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:52:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519095255/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:52:55Z', 'uri': 'http://web.archive.org/web/20180519095255/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T12:11:41Z', 'uri': 'http://web.archive.org/web/20180609121141/https://www.guideline.gov/summaries/summary/48761/adult-weight-management-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930234620/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:46:20Z', 'uri': 'http://web.archive.org/web/20160930234620/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003033536/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:36Z', 'uri': 'http://web.archive.org/web/20171003033536/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414025952/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:52Z', 'uri': 'http://web.archive.org/web/20180414025952/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519095334/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:34Z', 'uri': 'http://web.archive.org/web/20180519095334/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T10:37:04Z', 'uri': 'http://web.archive.org/web/20180609103704/https://www.guideline.gov/summaries/summary/48762/prevention-of-type-2-diabetes-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930234559/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:45:59Z', 'uri': 'http://web.archive.org/web/20160930234559/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003033513/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:13Z', 'uri': 'http://web.archive.org/web/20171003033513/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414025924/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:24Z', 'uri': 'http://web.archive.org/web/20180414025924/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519095305/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:05Z', 'uri': 'http://web.archive.org/web/20180519095305/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T20:07:20Z', 'uri': 'http://web.archive.org/web/20180609200720/https://www.guideline.gov/summaries/summary/48763/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-critically-ill-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:46:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930234606/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:46:06Z', 'uri': 'http://web.archive.org/web/20160930234606/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003033520/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:20Z', 'uri': 'http://web.archive.org/web/20171003033520/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414025934/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:34Z', 'uri': 'http://web.archive.org/web/20180414025934/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519095314/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:14Z', 'uri': 'http://web.archive.org/web/20180519095314/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T20:07:04Z', 'uri': 'http://web.archive.org/web/20180609200704/https://www.guideline.gov/summaries/summary/48764/energy-expenditure-measuring-resting-metabolic-rate-rmr-in-the-healthy-and-noncritically-ill-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:46:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930234612/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:46:12Z', 'uri': 'http://web.archive.org/web/20160930234612/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003033528/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T03:35:28Z', 'uri': 'http://web.archive.org/web/20171003033528/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-01-10T12:08:11Z', 'uri': 'http://web.archive.org/web/20180110120811/https://guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414025943/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:59:43Z', 'uri': 'http://web.archive.org/web/20180414025943/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519095324/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T09:53:24Z', 'uri': 'http://web.archive.org/web/20180519095324/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T20:07:04Z', 'uri': 'http://web.archive.org/web/20180609200704/https://www.guideline.gov/summaries/summary/48765/oncology-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:42:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930234243/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2016-09-30T23:42:43Z', 'uri': 'http://web.archive.org/web/20160930234243/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2017-10-03T03:30:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003033044/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2017-10-03T03:30:44Z', 'uri': 'http://web.archive.org/web/20171003033044/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2018-04-14T02:55:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414025520/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2018-04-14T02:55:20Z', 'uri': 'http://web.archive.org/web/20180414025520/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2018-05-19T09:48:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519094842/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2018-05-19T09:48:42Z', 'uri': 'http://web.archive.org/web/20180519094842/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}, {'datetime': '2018-06-09T21:12:51Z', 'uri': 'http://web.archive.org/web/20180609211251/https://www.guideline.gov/summaries/summary/48772/infection-prevention-and-control-guideline-for-cystic-fibrosis-2013-update'}]
https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:42:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930234217/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2016-09-30T23:42:17Z', 'uri': 'http://web.archive.org/web/20160930234217/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2017-10-03T03:30:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003033017/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2017-10-03T03:30:17Z', 'uri': 'http://web.archive.org/web/20171003033017/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2018-04-14T02:54:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414025450/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2018-04-14T02:54:50Z', 'uri': 'http://web.archive.org/web/20180414025450/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2018-05-19T09:48:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519094813/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2018-05-19T09:48:13Z', 'uri': 'http://web.archive.org/web/20180519094813/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}, {'datetime': '2018-06-09T23:37:18Z', 'uri': 'http://web.archive.org/web/20180609233718/https://www.guideline.gov/summaries/summary/48774/quality-improvement-guidelines-for-percutaneous-management-of-acute-lowerextremity-ischemia'}]
https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:42:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930234203/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2016-09-30T23:42:03Z', 'uri': 'http://web.archive.org/web/20160930234203/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2017-10-03T03:30:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003033002/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2017-10-03T03:30:02Z', 'uri': 'http://web.archive.org/web/20171003033002/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2018-04-14T02:54:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414025443/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2018-04-14T02:54:43Z', 'uri': 'http://web.archive.org/web/20180414025443/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2018-05-19T09:48:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519094805/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2018-05-19T09:48:05Z', 'uri': 'http://web.archive.org/web/20180519094805/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}, {'datetime': '2018-06-09T23:37:16Z', 'uri': 'http://web.archive.org/web/20180609233716/https://www.guideline.gov/summaries/summary/48777/society-of-interventional-radiology-position-statement-on-injection-safety-improper-use-of-singledosesingleuse-vials'}]
https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930234105/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2016-09-30T23:41:05Z', 'uri': 'http://web.archive.org/web/20160930234105/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2017-10-03T03:29:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003032909/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2017-10-03T03:29:09Z', 'uri': 'http://web.archive.org/web/20171003032909/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2018-04-14T02:53:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414025334/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2018-04-14T02:53:34Z', 'uri': 'http://web.archive.org/web/20180414025334/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2018-05-19T09:46:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519094651/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2018-05-19T09:46:51Z', 'uri': 'http://web.archive.org/web/20180519094651/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}, {'datetime': '2018-06-09T19:11:24Z', 'uri': 'http://web.archive.org/web/20180609191124/https://www.guideline.gov/summaries/summary/48783/multisociety-consensus-quality-improvement-guidelines-for-intraarterial-catheterdirected-treatment-of-acute-ischemic-stroke-from-the-american-society-of-neuroradiology-canadian-interventional-radiology-association-cardiovascular-and-interventional-radiology-so'}]
https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930234407/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2016-09-30T23:44:07Z', 'uri': 'http://web.archive.org/web/20160930234407/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2017-10-03T03:32:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003033206/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2017-10-03T03:32:06Z', 'uri': 'http://web.archive.org/web/20171003033206/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2018-04-14T02:56:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414025658/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2018-04-14T02:56:58Z', 'uri': 'http://web.archive.org/web/20180414025658/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2018-05-19T09:50:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519095020/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2018-05-19T09:50:20Z', 'uri': 'http://web.archive.org/web/20180519095020/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}, {'datetime': '2018-06-09T20:11:31Z', 'uri': 'http://web.archive.org/web/20180609201131/https://www.guideline.gov/summaries/summary/48784/the-clinical-pharmacogenetics-implementation-consortium-guideline-for-slco1b1-and-simvastatininduced-myopathy-2014-update'}]
https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930234400/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2016-09-30T23:44:00Z', 'uri': 'http://web.archive.org/web/20160930234400/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2017-10-03T03:32:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003033200/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2017-10-03T03:32:00Z', 'uri': 'http://web.archive.org/web/20171003033200/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2018-04-14T02:56:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414025650/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2018-04-14T02:56:50Z', 'uri': 'http://web.archive.org/web/20180414025650/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2018-05-19T09:50:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519095012/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2018-05-19T09:50:12Z', 'uri': 'http://web.archive.org/web/20180519095012/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}, {'datetime': '2018-06-09T19:09:43Z', 'uri': 'http://web.archive.org/web/20180609190943/https://www.guideline.gov/summaries/summary/48785/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-rasburicase-therapy-in-the-context-of-g6pd-deficiency-genotype'}]
https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:42:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930234236/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2016-09-30T23:42:36Z', 'uri': 'http://web.archive.org/web/20160930234236/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2017-10-03T03:30:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003033038/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2017-10-03T03:30:38Z', 'uri': 'http://web.archive.org/web/20171003033038/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2018-04-14T02:55:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414025509/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2018-04-14T02:55:09Z', 'uri': 'http://web.archive.org/web/20180414025509/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2018-05-19T09:48:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519094832/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2018-05-19T09:48:32Z', 'uri': 'http://web.archive.org/web/20180519094832/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}, {'datetime': '2018-06-09T15:26:47Z', 'uri': 'http://web.archive.org/web/20180609152647/https://www.guideline.gov/summaries/summary/48786/recommendations-on-screening-for-prostate-cancer-with-the-prostatespecific-antigen-test'}]
https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:48:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930234814/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:48:14Z', 'uri': 'http://web.archive.org/web/20160930234814/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:40:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003034021/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:40:21Z', 'uri': 'http://web.archive.org/web/20171003034021/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:04:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414030443/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T03:04:43Z', 'uri': 'http://web.archive.org/web/20180414030443/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:58:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519095841/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:58:41Z', 'uri': 'http://web.archive.org/web/20180519095841/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:21Z', 'uri': 'http://web.archive.org/web/20180609192221/https://www.guideline.gov/summaries/summary/48787/dietary-and-pharmacologic-management-to-prevent-recurrent-nephrolithiasis-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930234413/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2016-09-30T23:44:13Z', 'uri': 'http://web.archive.org/web/20160930234413/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2017-10-03T03:32:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003033212/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2017-10-03T03:32:12Z', 'uri': 'http://web.archive.org/web/20171003033212/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-04-14T02:57:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414025707/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-04-14T02:57:07Z', 'uri': 'http://web.archive.org/web/20180414025707/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-05-19T09:50:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519095028/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-05-19T09:50:28Z', 'uri': 'http://web.archive.org/web/20180519095028/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-06-09T18:41:42Z', 'uri': 'http://web.archive.org/web/20180609184142/https://www.guideline.gov/summaries/summary/48789/principles-of-analytic-validation-of-immunohistochemical-assays-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}]
https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930234354/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2016-09-30T23:43:54Z', 'uri': 'http://web.archive.org/web/20160930234354/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2017-10-03T03:31:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003033152/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2017-10-03T03:31:52Z', 'uri': 'http://web.archive.org/web/20171003033152/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2018-04-14T02:56:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414025641/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2018-04-14T02:56:41Z', 'uri': 'http://web.archive.org/web/20180414025641/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2018-05-19T09:50:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519095002/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2018-05-19T09:50:02Z', 'uri': 'http://web.archive.org/web/20180519095002/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}, {'datetime': '2018-06-11T07:05:35Z', 'uri': 'http://web.archive.org/web/20180611070535/https://www.guideline.gov/summaries/summary/48790/palliative-radiotherapy-brain-metastases'}]
https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:47:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930234740/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2016-09-30T23:47:40Z', 'uri': 'http://web.archive.org/web/20160930234740/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2017-10-03T03:38:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003033812/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2017-10-03T03:38:12Z', 'uri': 'http://web.archive.org/web/20171003033812/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2018-04-14T03:02:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414030256/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2018-04-14T03:02:56Z', 'uri': 'http://web.archive.org/web/20180414030256/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2018-05-19T09:56:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519095643/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2018-05-19T09:56:43Z', 'uri': 'http://web.archive.org/web/20180519095643/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}, {'datetime': '2018-06-09T21:29:13Z', 'uri': 'http://web.archive.org/web/20180609212913/https://www.guideline.gov/summaries/summary/48791/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-pediatric-supracondylar-humerus-fractures'}]
https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930234419/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2016-09-30T23:44:19Z', 'uri': 'http://web.archive.org/web/20160930234419/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2017-10-03T03:32:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003033218/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2017-10-03T03:32:18Z', 'uri': 'http://web.archive.org/web/20171003033218/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2018-04-14T02:57:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414025715/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2018-04-14T02:57:15Z', 'uri': 'http://web.archive.org/web/20180414025715/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2018-05-19T09:50:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519095048/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2018-05-19T09:50:48Z', 'uri': 'http://web.archive.org/web/20180519095048/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}, {'datetime': '2018-06-09T22:24:06Z', 'uri': 'http://web.archive.org/web/20180609222406/https://www.guideline.gov/summaries/summary/48858/vadod-clinical-practice-guideline-for-the-diagnosis-and-management-of-hypertension-in-the-primary-care-setting'}]
https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930234334/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2016-09-30T23:43:34Z', 'uri': 'http://web.archive.org/web/20160930234334/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2017-10-03T03:31:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003033137/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2017-10-03T03:31:37Z', 'uri': 'http://web.archive.org/web/20171003033137/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2018-04-14T02:56:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414025622/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2018-04-14T02:56:22Z', 'uri': 'http://web.archive.org/web/20180414025622/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2018-05-19T09:49:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519094940/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2018-05-19T09:49:40Z', 'uri': 'http://web.archive.org/web/20180519094940/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}, {'datetime': '2018-06-09T23:20:17Z', 'uri': 'http://web.archive.org/web/20180609232017/https://www.guideline.gov/summaries/summary/48860/guideline-for-preoperative-patient-skin-antisepsis'}]
https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930234322/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2016-09-30T23:43:22Z', 'uri': 'http://web.archive.org/web/20160930234322/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2017-10-03T03:31:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003033122/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2017-10-03T03:31:22Z', 'uri': 'http://web.archive.org/web/20171003033122/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2018-04-14T02:56:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414025607/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2018-04-14T02:56:07Z', 'uri': 'http://web.archive.org/web/20180414025607/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2018-05-19T09:49:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519094922/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2018-05-19T09:49:22Z', 'uri': 'http://web.archive.org/web/20180519094922/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}, {'datetime': '2018-06-09T23:20:22Z', 'uri': 'http://web.archive.org/web/20180609232022/https://www.guideline.gov/summaries/summary/48861/guideline-for-autologous-tissue-management'}]
https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930234505/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:45:05Z', 'uri': 'http://web.archive.org/web/20160930234505/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:33:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003033349/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:33:49Z', 'uri': 'http://web.archive.org/web/20171003033349/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:58:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414025818/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:58:18Z', 'uri': 'http://web.archive.org/web/20180414025818/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:51:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519095144/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:51:44Z', 'uri': 'http://web.archive.org/web/20180519095144/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T22:50:37Z', 'uri': 'http://web.archive.org/web/20180610225037/https://www.guideline.gov/summaries/summary/48862/lowdose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:28:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930162811/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2016-09-30T16:28:11Z', 'uri': 'http://web.archive.org/web/20160930162811/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:09:08Z', 'uri': 'http://wayback.archive-it.org/all/20171002200908/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:09:08Z', 'uri': 'http://web.archive.org/web/20171002200908/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:45:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414004530/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:45:30Z', 'uri': 'http://web.archive.org/web/20180414004530/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:03:16Z', 'uri': 'http://wayback.archive-it.org/all/20180518220316/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:03:16Z', 'uri': 'http://web.archive.org/web/20180518220316/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-06-09T15:45:59Z', 'uri': 'http://web.archive.org/web/20180609154559/https://www.guideline.gov/summaries/summary/48864/prevention-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:27:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930162743/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2016-09-30T16:27:43Z', 'uri': 'http://web.archive.org/web/20160930162743/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:08:44Z', 'uri': 'http://wayback.archive-it.org/all/20171002200844/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:08:44Z', 'uri': 'http://web.archive.org/web/20171002200844/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:45:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414004502/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:45:02Z', 'uri': 'http://web.archive.org/web/20180414004502/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:02:55Z', 'uri': 'http://wayback.archive-it.org/all/20180518220255/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:02:55Z', 'uri': 'http://web.archive.org/web/20180518220255/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-06-09T10:36:34Z', 'uri': 'http://web.archive.org/web/20180609103634/https://www.guideline.gov/summaries/summary/48865/interventions-for-prevention-and-treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:28:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930162848/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2016-09-30T16:28:48Z', 'uri': 'http://web.archive.org/web/20160930162848/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:09:35Z', 'uri': 'http://wayback.archive-it.org/all/20171002200935/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:09:35Z', 'uri': 'http://web.archive.org/web/20171002200935/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:46:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414004600/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:46:00Z', 'uri': 'http://web.archive.org/web/20180414004600/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:03:46Z', 'uri': 'http://wayback.archive-it.org/all/20180518220346/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:03:46Z', 'uri': 'http://web.archive.org/web/20180518220346/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-06-09T15:30:05Z', 'uri': 'http://web.archive.org/web/20180609153005/https://www.guideline.gov/summaries/summary/48866/treatment-of-pressure-ulcers-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:28:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930162837/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2016-09-30T16:28:37Z', 'uri': 'http://web.archive.org/web/20160930162837/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:09:26Z', 'uri': 'http://wayback.archive-it.org/all/20171002200926/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:09:26Z', 'uri': 'http://web.archive.org/web/20171002200926/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:45:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414004548/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:45:48Z', 'uri': 'http://web.archive.org/web/20180414004548/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:03:34Z', 'uri': 'http://wayback.archive-it.org/all/20180518220334/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-05-18T22:03:34Z', 'uri': 'http://web.archive.org/web/20180518220334/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}, {'datetime': '2018-06-09T15:45:57Z', 'uri': 'http://web.archive.org/web/20180609154557/https://www.guideline.gov/summaries/summary/48867/special-populations-in-prevention-and-treatment-of-pressure-ulcers-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930234341/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2016-09-30T23:43:41Z', 'uri': 'http://web.archive.org/web/20160930234341/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2017-10-03T03:31:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003033143/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2017-10-03T03:31:43Z', 'uri': 'http://web.archive.org/web/20171003033143/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2018-04-14T02:56:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414025629/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2018-04-14T02:56:29Z', 'uri': 'http://web.archive.org/web/20180414025629/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2018-05-19T09:49:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519094949/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2018-05-19T09:49:49Z', 'uri': 'http://web.archive.org/web/20180519094949/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}, {'datetime': '2018-06-09T23:20:26Z', 'uri': 'http://web.archive.org/web/20180609232026/https://www.guideline.gov/summaries/summary/48868/guideline-for-surgical-attire'}]
https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930234150/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2016-09-30T23:41:50Z', 'uri': 'http://web.archive.org/web/20160930234150/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:29:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003032955/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:29:55Z', 'uri': 'http://web.archive.org/web/20171003032955/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:54:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414025430/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:54:30Z', 'uri': 'http://web.archive.org/web/20180414025430/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:47:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519094756/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:47:56Z', 'uri': 'http://web.archive.org/web/20180519094756/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T21:44:20Z', 'uri': 'http://web.archive.org/web/20180609214420/https://www.guideline.gov/summaries/summary/48869/optimal-timing-of-femur-fracture-stabilization-in-polytrauma-patients-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930234145/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2016-09-30T23:41:45Z', 'uri': 'http://web.archive.org/web/20160930234145/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:29:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003032949/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:29:49Z', 'uri': 'http://web.archive.org/web/20171003032949/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:54:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414025422/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:54:22Z', 'uri': 'http://web.archive.org/web/20180414025422/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:47:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519094747/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:47:47Z', 'uri': 'http://web.archive.org/web/20180519094747/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-10T09:03:19Z', 'uri': 'http://web.archive.org/web/20180610090319/https://www.guideline.gov/summaries/summary/48870/timing-and-type-of-surgical-treatment-of-clostridium-difficileassociated-disease-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930234329/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2016-09-30T23:43:29Z', 'uri': 'http://web.archive.org/web/20160930234329/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2017-10-03T03:31:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003033129/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2017-10-03T03:31:29Z', 'uri': 'http://web.archive.org/web/20171003033129/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2018-04-14T02:56:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414025614/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2018-04-14T02:56:14Z', 'uri': 'http://web.archive.org/web/20180414025614/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2018-05-19T09:49:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519094931/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2018-05-19T09:49:31Z', 'uri': 'http://web.archive.org/web/20180519094931/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}, {'datetime': '2018-06-09T11:04:50Z', 'uri': 'http://web.archive.org/web/20180609110450/https://www.guideline.gov/summaries/summary/48871/guideline-for-care-of-the-patient-receiving-local-anesthesia'}]
https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930234346/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2016-09-30T23:43:46Z', 'uri': 'http://web.archive.org/web/20160930234346/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2017-10-03T03:31:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003033149/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2017-10-03T03:31:49Z', 'uri': 'http://web.archive.org/web/20171003033149/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2018-04-14T02:56:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414025637/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2018-04-14T02:56:37Z', 'uri': 'http://web.archive.org/web/20180414025637/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2018-05-19T09:49:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519094958/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2018-05-19T09:49:58Z', 'uri': 'http://web.archive.org/web/20180519094958/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}, {'datetime': '2018-06-10T00:26:49Z', 'uri': 'http://web.archive.org/web/20180610002649/https://www.guideline.gov/summaries/summary/48872/obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults'}]
https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:42:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930234250/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2016-09-30T23:42:50Z', 'uri': 'http://web.archive.org/web/20160930234250/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2017-10-03T03:30:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003033053/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2017-10-03T03:30:53Z', 'uri': 'http://web.archive.org/web/20171003033053/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2018-04-14T02:55:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414025532/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2018-04-14T02:55:32Z', 'uri': 'http://web.archive.org/web/20180414025532/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2018-05-19T09:48:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519094853/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2018-05-19T09:48:53Z', 'uri': 'http://web.archive.org/web/20180519094853/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}, {'datetime': '2018-06-09T12:02:18Z', 'uri': 'http://web.archive.org/web/20180609120218/https://www.guideline.gov/summaries/summary/48873/vadod-clinical-practice-guideline-for-the-management-of-chronic-multisymptom-illness'}]
https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:45:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930234514/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:45:14Z', 'uri': 'http://web.archive.org/web/20160930234514/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:34:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003033416/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:34:16Z', 'uri': 'http://web.archive.org/web/20171003033416/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:58:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414025826/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:58:26Z', 'uri': 'http://web.archive.org/web/20180414025826/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:51:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519095153/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:51:53Z', 'uri': 'http://web.archive.org/web/20180519095153/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T22:17:49Z', 'uri': 'http://web.archive.org/web/20180610221749/https://www.guideline.gov/summaries/summary/48874/screening-for-chlamydia-and-gonorrhea-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:44:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930234458/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:44:58Z', 'uri': 'http://web.archive.org/web/20160930234458/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:33:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003033341/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:33:41Z', 'uri': 'http://web.archive.org/web/20171003033341/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:58:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414025808/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:58:08Z', 'uri': 'http://web.archive.org/web/20180414025808/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:51:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519095134/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:51:34Z', 'uri': 'http://web.archive.org/web/20180519095134/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T08:21:12Z', 'uri': 'http://web.archive.org/web/20180610082112/https://www.guideline.gov/summaries/summary/48875/behavioral-counseling-interventions-to-prevent-sexually-transmitted-infections-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930234046/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2016-09-30T23:40:46Z', 'uri': 'http://web.archive.org/web/20160930234046/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2017-10-03T03:28:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003032854/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2017-10-03T03:28:54Z', 'uri': 'http://web.archive.org/web/20171003032854/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2018-04-14T02:53:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414025312/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2018-04-14T02:53:12Z', 'uri': 'http://web.archive.org/web/20180414025312/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2018-05-19T09:46:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519094632/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2018-05-19T09:46:32Z', 'uri': 'http://web.archive.org/web/20180519094632/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}, {'datetime': '2018-06-11T09:19:56Z', 'uri': 'http://web.archive.org/web/20180611091956/https://www.guideline.gov/summaries/summary/48876/imatinib-for-the-adjuvant-treatment-of-gastrointestinal-stromal-tumours-review-of-nice-technology-appraisal-guidance-196'}]
https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930234033/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2016-09-30T23:40:33Z', 'uri': 'http://web.archive.org/web/20160930234033/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2017-10-03T03:28:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003032841/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2017-10-03T03:28:41Z', 'uri': 'http://web.archive.org/web/20171003032841/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2018-04-14T02:52:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414025254/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2018-04-14T02:52:54Z', 'uri': 'http://web.archive.org/web/20180414025254/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2018-05-19T09:46:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519094613/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2018-05-19T09:46:13Z', 'uri': 'http://web.archive.org/web/20180519094613/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}, {'datetime': '2018-06-10T23:05:33Z', 'uri': 'http://web.archive.org/web/20180610230533/https://www.guideline.gov/summaries/summary/48878/dualchamber-pacemakers-for-symptomatic-bradycardia-due-to-sick-sinus-syndrome-without-atrioventricular-block-part-review-of-technology-appraisal-guidance-88'}]
https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930234039/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2016-09-30T23:40:39Z', 'uri': 'http://web.archive.org/web/20160930234039/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2017-10-03T03:28:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003032847/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2017-10-03T03:28:47Z', 'uri': 'http://web.archive.org/web/20171003032847/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2018-04-14T02:53:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414025302/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2018-04-14T02:53:02Z', 'uri': 'http://web.archive.org/web/20180414025302/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2018-05-19T09:46:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519094623/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2018-05-19T09:46:23Z', 'uri': 'http://web.archive.org/web/20180519094623/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}, {'datetime': '2018-06-10T22:47:01Z', 'uri': 'http://web.archive.org/web/20180610224701/https://www.guideline.gov/summaries/summary/48879/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta-142'}]
https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930234132/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2016-09-30T23:41:32Z', 'uri': 'http://web.archive.org/web/20160930234132/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2017-10-03T03:29:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003032935/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2017-10-03T03:29:35Z', 'uri': 'http://web.archive.org/web/20171003032935/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2018-04-14T02:54:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414025403/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2018-04-14T02:54:03Z', 'uri': 'http://web.archive.org/web/20180414025403/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2018-05-19T09:47:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519094726/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2018-05-19T09:47:26Z', 'uri': 'http://web.archive.org/web/20180519094726/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}, {'datetime': '2018-06-10T00:03:49Z', 'uri': 'http://web.archive.org/web/20180610000349/https://www.guideline.gov/summaries/summary/48893/community-management-of-opioid-overdose'}]
https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930234138/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2016-09-30T23:41:38Z', 'uri': 'http://web.archive.org/web/20160930234138/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2017-10-03T03:29:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003032942/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2017-10-03T03:29:42Z', 'uri': 'http://web.archive.org/web/20171003032942/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2018-04-14T02:54:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414025412/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2018-04-14T02:54:12Z', 'uri': 'http://web.archive.org/web/20180414025412/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2018-05-19T09:47:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519094735/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2018-05-19T09:47:35Z', 'uri': 'http://web.archive.org/web/20180519094735/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}, {'datetime': '2018-06-09T19:31:33Z', 'uri': 'http://web.archive.org/web/20180609193133/https://www.guideline.gov/summaries/summary/48894/guidelines-for-the-identification-and-management-of-substance-use-and-substance-use-disorders-in-pregnancy'}]
https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930234302/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2016-09-30T23:43:02Z', 'uri': 'http://web.archive.org/web/20160930234302/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2017-10-03T03:31:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003033108/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2017-10-03T03:31:08Z', 'uri': 'http://web.archive.org/web/20171003033108/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2018-04-14T02:55:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414025541/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2018-04-14T02:55:41Z', 'uri': 'http://web.archive.org/web/20180414025541/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2018-05-19T09:49:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519094903/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2018-05-19T09:49:03Z', 'uri': 'http://web.archive.org/web/20180519094903/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}, {'datetime': '2018-06-10T22:25:37Z', 'uri': 'http://web.archive.org/web/20180610222537/https://www.guideline.gov/summaries/summary/48902/fluorouracil-chemotherapy-the-my5fu-assay-for-guiding-dose-adjustment'}]
https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930234026/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2016-09-30T23:40:26Z', 'uri': 'http://web.archive.org/web/20160930234026/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2017-10-03T03:28:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003032834/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2017-10-03T03:28:34Z', 'uri': 'http://web.archive.org/web/20171003032834/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2018-04-14T02:52:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414025246/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2018-04-14T02:52:46Z', 'uri': 'http://web.archive.org/web/20180414025246/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2018-05-19T09:46:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519094604/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2018-05-19T09:46:04Z', 'uri': 'http://web.archive.org/web/20180519094604/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}, {'datetime': '2018-06-09T15:14:07Z', 'uri': 'http://web.archive.org/web/20180609151407/https://www.guideline.gov/summaries/summary/48903/dabigatran-etexilate-for-the-treatment-and-secondary-prevention-of-deep-vein-thrombosis-andor-pulmonary-embolism'}]
https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930234051/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:40:51Z', 'uri': 'http://web.archive.org/web/20160930234051/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:29:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003032901/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:29:01Z', 'uri': 'http://web.archive.org/web/20171003032901/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:53:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414025321/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:53:21Z', 'uri': 'http://web.archive.org/web/20180414025321/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:46:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519094642/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:46:42Z', 'uri': 'http://web.archive.org/web/20180519094642/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}, {'datetime': '2018-06-10T00:04:56Z', 'uri': 'http://web.archive.org/web/20180610000456/https://www.guideline.gov/summaries/summary/48930/systemic-therapy-in-men-with-metastatic-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-and-cancer-care-ontario-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930234118/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2016-09-30T23:41:18Z', 'uri': 'http://web.archive.org/web/20160930234118/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2017-10-03T03:29:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003032923/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2017-10-03T03:29:23Z', 'uri': 'http://web.archive.org/web/20171003032923/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2018-04-14T02:53:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414025345/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2018-04-14T02:53:45Z', 'uri': 'http://web.archive.org/web/20180414025345/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2018-05-19T09:47:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519094711/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2018-05-19T09:47:11Z', 'uri': 'http://web.archive.org/web/20180519094711/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}, {'datetime': '2018-06-09T19:17:22Z', 'uri': 'http://web.archive.org/web/20180609191722/https://www.guideline.gov/summaries/summary/48931/colorectal-cancer-the-diagnosis-and-management-of-colorectal-cancer'}]
https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:37:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930233704/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2016-09-30T23:37:04Z', 'uri': 'http://web.archive.org/web/20160930233704/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2017-01-08T03:48:58Z', 'uri': 'http://web.archive.org/web/20170108034858/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2017-10-03T03:25:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003032504/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2017-10-03T03:25:04Z', 'uri': 'http://web.archive.org/web/20171003032504/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2018-04-14T02:48:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414024845/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2018-04-14T02:48:45Z', 'uri': 'http://web.archive.org/web/20180414024845/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2018-05-19T09:41:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519094145/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2018-05-19T09:41:45Z', 'uri': 'http://web.archive.org/web/20180519094145/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}, {'datetime': '2018-06-09T22:28:47Z', 'uri': 'http://web.archive.org/web/20180609222847/https://www.guideline.gov/summaries/summary/48932/intrapartum-care-care-of-healthy-women-and-their-babies-during-childbirth'}]
https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930234316/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2016-09-30T23:43:16Z', 'uri': 'http://web.archive.org/web/20160930234316/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2017-10-03T03:31:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003033115/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2017-10-03T03:31:15Z', 'uri': 'http://web.archive.org/web/20171003033115/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2018-04-14T02:55:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414025559/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2018-04-14T02:55:59Z', 'uri': 'http://web.archive.org/web/20180414025559/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2018-05-19T09:49:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519094913/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2018-05-19T09:49:13Z', 'uri': 'http://web.archive.org/web/20180519094913/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}, {'datetime': '2018-06-09T22:27:42Z', 'uri': 'http://web.archive.org/web/20180609222742/https://www.guideline.gov/summaries/summary/48937/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-with-suspected-acute-nontraumatic-thoracic-aortic-dissection'}]
https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930234013/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2016-09-30T23:40:13Z', 'uri': 'http://web.archive.org/web/20160930234013/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2017-10-03T03:28:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003032819/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2017-10-03T03:28:19Z', 'uri': 'http://web.archive.org/web/20171003032819/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2018-04-14T02:52:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414025226/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2018-04-14T02:52:26Z', 'uri': 'http://web.archive.org/web/20180414025226/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2018-05-19T09:45:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519094545/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2018-05-19T09:45:45Z', 'uri': 'http://web.archive.org/web/20180519094545/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}, {'datetime': '2018-06-09T22:24:08Z', 'uri': 'http://web.archive.org/web/20180609222408/https://www.guideline.gov/summaries/summary/48950/vadod-clinical-practice-guideline-for-the-management-of-dyslipidemia-for-cardiovascular-risk-reduction'}]
https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:59Z', 'uri': 'http://wayback.archive-it.org/all/20160930233959/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2016-09-30T23:39:59Z', 'uri': 'http://web.archive.org/web/20160930233959/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2017-10-03T03:28:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003032802/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2017-10-03T03:28:02Z', 'uri': 'http://web.archive.org/web/20171003032802/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2018-04-14T02:52:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414025202/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2018-04-14T02:52:02Z', 'uri': 'http://web.archive.org/web/20180414025202/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2018-05-19T09:45:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519094522/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2018-05-19T09:45:22Z', 'uri': 'http://web.archive.org/web/20180519094522/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}, {'datetime': '2018-06-09T10:36:29Z', 'uri': 'http://web.archive.org/web/20180609103629/https://www.guideline.gov/summaries/summary/48951/vadod-clinical-practice-guideline-for-the-management-of-chronic-kidney-disease-in-primary-care'}]
https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930234006/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2016-09-30T23:40:06Z', 'uri': 'http://web.archive.org/web/20160930234006/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2017-10-03T03:28:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003032811/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2017-10-03T03:28:11Z', 'uri': 'http://web.archive.org/web/20171003032811/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2018-04-14T02:52:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414025213/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2018-04-14T02:52:13Z', 'uri': 'http://web.archive.org/web/20180414025213/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2018-05-19T09:45:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519094532/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2018-05-19T09:45:32Z', 'uri': 'http://web.archive.org/web/20180519094532/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}, {'datetime': '2018-06-09T22:24:42Z', 'uri': 'http://web.archive.org/web/20180609222442/https://www.guideline.gov/summaries/summary/48952/vadod-clinical-practice-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease'}]
https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:42:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930234230/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:42:30Z', 'uri': 'http://web.archive.org/web/20160930234230/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:30:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003033030/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:30:30Z', 'uri': 'http://web.archive.org/web/20171003033030/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:55:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414025500/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:55:00Z', 'uri': 'http://web.archive.org/web/20180414025500/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:48:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519094823/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:48:23Z', 'uri': 'http://web.archive.org/web/20180519094823/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-11T05:49:50Z', 'uri': 'http://web.archive.org/web/20180611054950/https://www.guideline.gov/summaries/summary/48961/screening-for-vitamin-d-deficiency-in-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:41:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930234125/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2016-09-30T23:41:25Z', 'uri': 'http://web.archive.org/web/20160930234125/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2017-10-03T03:29:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003032926/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2017-10-03T03:29:26Z', 'uri': 'http://web.archive.org/web/20171003032926/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2018-04-14T02:53:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414025349/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2018-04-14T02:53:49Z', 'uri': 'http://web.archive.org/web/20180414025349/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2018-05-19T09:47:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519094715/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2018-05-19T09:47:15Z', 'uri': 'http://web.archive.org/web/20180519094715/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}, {'datetime': '2018-06-09T22:27:50Z', 'uri': 'http://web.archive.org/web/20180609222750/https://www.guideline.gov/summaries/summary/48992/gastrooesophageal-reflux-disease-recognition-diagnosis-and-management-in-children-and-young-people'}]
https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:43:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930234309/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2016-09-30T23:43:09Z', 'uri': 'http://web.archive.org/web/20160930234309/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2017-10-02T20:05:49Z', 'uri': 'http://wayback.archive-it.org/all/20171002200549/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2017-10-02T20:05:49Z', 'uri': 'http://web.archive.org/web/20171002200549/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2018-04-14T02:55:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414025549/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2018-04-14T02:55:49Z', 'uri': 'http://web.archive.org/web/20180414025549/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2018-05-18T19:31:20Z', 'uri': 'http://wayback.archive-it.org/all/20180518193120/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2018-05-18T19:31:20Z', 'uri': 'http://web.archive.org/web/20180518193120/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}, {'datetime': '2018-06-09T10:42:03Z', 'uri': 'http://web.archive.org/web/20180609104203/https://www.guideline.gov/summaries/summary/48994/diagnosis-and-treatment-of-degenerative-lumbar-spondylolisthesis'}]
https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:40:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930234020/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2016-09-30T23:40:20Z', 'uri': 'http://web.archive.org/web/20160930234020/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:28:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003032828/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:28:28Z', 'uri': 'http://web.archive.org/web/20171003032828/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:52:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414025238/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:52:38Z', 'uri': 'http://web.archive.org/web/20180414025238/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:45:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519094555/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:45:55Z', 'uri': 'http://web.archive.org/web/20180519094555/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T20:47:28Z', 'uri': 'http://web.archive.org/web/20180609204728/https://www.guideline.gov/summaries/summary/48995/cervical-spine-collar-clearance-in-the-obtunded-adult-blunt-trauma-patient-a-systematic-review-and-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930233953/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2016-09-30T23:39:53Z', 'uri': 'http://web.archive.org/web/20160930233953/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:27:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003032755/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:27:55Z', 'uri': 'http://web.archive.org/web/20171003032755/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:51:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414025153/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:51:53Z', 'uri': 'http://web.archive.org/web/20180414025153/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:45:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519094513/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:45:13Z', 'uri': 'http://web.archive.org/web/20180519094513/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T21:44:02Z', 'uri': 'http://web.archive.org/web/20180609214402/https://www.guideline.gov/summaries/summary/48996/evaluation-and-management-of-blunt-traumatic-aortic-injury-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930233935/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2016-09-30T23:39:35Z', 'uri': 'http://web.archive.org/web/20160930233935/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2017-10-03T03:27:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003032734/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2017-10-03T03:27:34Z', 'uri': 'http://web.archive.org/web/20171003032734/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2018-04-14T02:51:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414025136/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2018-04-14T02:51:36Z', 'uri': 'http://web.archive.org/web/20180414025136/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2018-05-19T09:44:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519094455/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2018-05-19T09:44:55Z', 'uri': 'http://web.archive.org/web/20180519094455/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}, {'datetime': '2018-06-09T21:44:52Z', 'uri': 'http://web.archive.org/web/20180609214452/https://www.guideline.gov/summaries/summary/49006/american-gastroenterological-association-institute-guideline-on-the-prevention-and-treatment-of-hepatitis-b-virus-reactivation-during-immunosuppressive-drug-therapy'}]
https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930233941/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2016-09-30T23:39:41Z', 'uri': 'http://web.archive.org/web/20160930233941/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2017-10-03T03:27:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003032741/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2017-10-03T03:27:41Z', 'uri': 'http://web.archive.org/web/20171003032741/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2018-04-14T02:51:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414025145/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2018-04-14T02:51:45Z', 'uri': 'http://web.archive.org/web/20180414025145/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2018-05-19T09:45:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519094504/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2018-05-19T09:45:04Z', 'uri': 'http://web.archive.org/web/20180519094504/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}, {'datetime': '2018-06-09T19:34:28Z', 'uri': 'http://web.archive.org/web/20180609193428/https://www.guideline.gov/summaries/summary/49008/guideline-for-primary-antifungal-prophylaxis-for-pediatric-patients-with-cancer-or-hematopoietic-stem-cell-transplant-recipients'}]
https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930233856/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2016-09-30T23:38:56Z', 'uri': 'http://web.archive.org/web/20160930233856/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2017-10-03T03:26:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003032652/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2017-10-03T03:26:52Z', 'uri': 'http://web.archive.org/web/20171003032652/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2018-04-14T02:50:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414025040/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2018-04-14T02:50:40Z', 'uri': 'http://web.archive.org/web/20180414025040/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2018-05-19T09:43:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519094359/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2018-05-19T09:43:59Z', 'uri': 'http://web.archive.org/web/20180519094359/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}, {'datetime': '2018-06-10T01:35:59Z', 'uri': 'http://web.archive.org/web/20180610013559/https://www.guideline.gov/summaries/summary/49009/guideline-for-the-prevention-and-treatment-of-anticipatory-nausea-and-vomiting-due-to-chemotherapy-in-pediatric-cancer-patients'}]
https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930233843/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2016-09-30T23:38:43Z', 'uri': 'http://web.archive.org/web/20160930233843/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2017-10-03T03:26:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003032636/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2017-10-03T03:26:36Z', 'uri': 'http://web.archive.org/web/20171003032636/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2018-04-14T02:50:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414025022/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2018-04-14T02:50:22Z', 'uri': 'http://web.archive.org/web/20180414025022/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2018-05-19T09:43:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519094340/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2018-05-19T09:43:40Z', 'uri': 'http://web.archive.org/web/20180519094340/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}, {'datetime': '2018-06-09T21:31:49Z', 'uri': 'http://web.archive.org/web/20180609213149/https://www.guideline.gov/summaries/summary/49010/clinical-practice-guideline-allergic-rhinitis'}]
https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930233908/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2016-09-30T23:39:08Z', 'uri': 'http://web.archive.org/web/20160930233908/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2017-10-03T03:27:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003032704/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2017-10-03T03:27:04Z', 'uri': 'http://web.archive.org/web/20171003032704/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2018-04-14T02:50:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414025058/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2018-04-14T02:50:58Z', 'uri': 'http://web.archive.org/web/20180414025058/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2018-05-19T09:44:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519094417/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2018-05-19T09:44:17Z', 'uri': 'http://web.archive.org/web/20180519094417/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}, {'datetime': '2018-06-09T20:47:20Z', 'uri': 'http://web.archive.org/web/20180609204720/https://www.guideline.gov/summaries/summary/49013/recommendations-for-prevention-of-weight-gain-and-use-of-behavioural-and-pharmacological-interventions-to-manage-overweight-and-obesity-in-adults-in-primary-care'}]
https://www.guideline.gov/summaries/summary/49014/gallstone-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930233850/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2016-09-30T23:38:50Z', 'uri': 'http://web.archive.org/web/20160930233850/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2017-10-03T03:26:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003032644/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2017-10-03T03:26:44Z', 'uri': 'http://web.archive.org/web/20171003032644/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2018-04-14T02:50:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414025031/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2018-04-14T02:50:31Z', 'uri': 'http://web.archive.org/web/20180414025031/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2018-05-19T09:43:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519094350/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2018-05-19T09:43:50Z', 'uri': 'http://web.archive.org/web/20180519094350/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}, {'datetime': '2018-06-09T20:47:03Z', 'uri': 'http://web.archive.org/web/20180609204703/https://www.guideline.gov/summaries/summary/49014/gallstone-disease'}]
https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930233902/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2016-09-30T23:39:02Z', 'uri': 'http://web.archive.org/web/20160930233902/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2017-10-03T03:26:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003032658/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2017-10-03T03:26:58Z', 'uri': 'http://web.archive.org/web/20171003032658/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2018-04-14T02:50:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414025050/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2018-04-14T02:50:50Z', 'uri': 'http://web.archive.org/web/20180414025050/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2018-05-19T09:44:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519094409/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2018-05-19T09:44:09Z', 'uri': 'http://web.archive.org/web/20180519094409/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}, {'datetime': '2018-06-09T21:16:07Z', 'uri': 'http://web.archive.org/web/20180609211607/https://www.guideline.gov/summaries/summary/49015/the-utility-of-positron-emission-tomography-in-epilepsy'}]
https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930233916/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2016-09-30T23:39:16Z', 'uri': 'http://web.archive.org/web/20160930233916/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2017-10-03T03:27:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003032712/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2017-10-03T03:27:12Z', 'uri': 'http://web.archive.org/web/20171003032712/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2018-04-14T02:51:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414025107/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2018-04-14T02:51:07Z', 'uri': 'http://web.archive.org/web/20180414025107/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2018-05-19T09:44:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519094428/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2018-05-19T09:44:28Z', 'uri': 'http://web.archive.org/web/20180519094428/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}, {'datetime': '2018-06-10T00:04:09Z', 'uri': 'http://web.archive.org/web/20180610000409/https://www.guideline.gov/summaries/summary/49016/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy'}]
https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930233922/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2016-09-30T23:39:22Z', 'uri': 'http://web.archive.org/web/20160930233922/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2017-10-03T03:27:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003032719/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2017-10-03T03:27:19Z', 'uri': 'http://web.archive.org/web/20171003032719/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2018-04-14T02:51:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414025115/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2018-04-14T02:51:15Z', 'uri': 'http://web.archive.org/web/20180414025115/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2018-05-19T09:44:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519094436/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2018-05-19T09:44:36Z', 'uri': 'http://web.archive.org/web/20180519094436/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}, {'datetime': '2018-06-09T11:01:18Z', 'uri': 'http://web.archive.org/web/20180609110118/https://www.guideline.gov/summaries/summary/49017/guideline-updates-on-the-management-of-severe-acute-malnutrition-in-infants-and-children'}]
https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930233836/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2016-09-30T23:38:36Z', 'uri': 'http://web.archive.org/web/20160930233836/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2017-10-03T03:26:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003032629/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2017-10-03T03:26:29Z', 'uri': 'http://web.archive.org/web/20171003032629/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2018-04-14T02:50:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414025012/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2018-04-14T02:50:12Z', 'uri': 'http://web.archive.org/web/20180414025012/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2018-05-19T09:43:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519094331/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2018-05-19T09:43:31Z', 'uri': 'http://web.archive.org/web/20180519094331/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}, {'datetime': '2018-06-09T22:06:10Z', 'uri': 'http://web.archive.org/web/20180609220610/https://www.guideline.gov/summaries/summary/49018/guidelines-for-diagnosing-and-managing-pediatric-concussion'}]
https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:37:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930233714/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2016-09-30T23:37:14Z', 'uri': 'http://web.archive.org/web/20160930233714/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2017-10-03T03:25:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003032535/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2017-10-03T03:25:35Z', 'uri': 'http://web.archive.org/web/20171003032535/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2018-04-14T02:49:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414024901/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2018-04-14T02:49:01Z', 'uri': 'http://web.archive.org/web/20180414024901/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2018-05-19T09:42:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519094217/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2018-05-19T09:42:17Z', 'uri': 'http://web.archive.org/web/20180519094217/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}, {'datetime': '2018-06-09T11:54:27Z', 'uri': 'http://web.archive.org/web/20180609115427/https://www.guideline.gov/summaries/summary/49019/cervical-spine-injury-medical-treatment-guidelines'}]
https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:37:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930233723/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2016-09-30T23:37:23Z', 'uri': 'http://web.archive.org/web/20160930233723/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2017-10-03T03:25:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003032546/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2017-10-03T03:25:46Z', 'uri': 'http://web.archive.org/web/20171003032546/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2018-04-14T02:49:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414024915/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2018-04-14T02:49:15Z', 'uri': 'http://web.archive.org/web/20180414024915/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2018-05-19T09:42:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519094232/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2018-05-19T09:42:32Z', 'uri': 'http://web.archive.org/web/20180519094232/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}, {'datetime': '2018-06-09T11:54:30Z', 'uri': 'http://web.archive.org/web/20180609115430/https://www.guideline.gov/summaries/summary/49020/low-back-pain-medical-treatment-guidelines'}]
https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:39:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930233929/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2016-09-30T23:39:29Z', 'uri': 'http://web.archive.org/web/20160930233929/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2017-10-03T03:27:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003032727/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2017-10-03T03:27:27Z', 'uri': 'http://web.archive.org/web/20171003032727/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2018-04-14T02:51:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414025127/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2018-04-14T02:51:27Z', 'uri': 'http://web.archive.org/web/20180414025127/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2018-05-19T09:44:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519094445/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2018-05-19T09:44:45Z', 'uri': 'http://web.archive.org/web/20180519094445/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}, {'datetime': '2018-06-10T00:04:22Z', 'uri': 'http://web.archive.org/web/20180610000422/https://www.guideline.gov/summaries/summary/49024/systematic-screening-for-active-tuberculosis-principles-and-recommendations'}]
https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930233657/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2016-09-30T23:36:57Z', 'uri': 'http://web.archive.org/web/20160930233657/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2017-10-03T03:24:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003032456/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2017-10-03T03:24:56Z', 'uri': 'http://web.archive.org/web/20171003032456/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2018-04-14T02:48:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414024836/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2018-04-14T02:48:36Z', 'uri': 'http://web.archive.org/web/20180414024836/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2018-05-19T09:41:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519094134/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2018-05-19T09:41:34Z', 'uri': 'http://web.archive.org/web/20180519094134/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}, {'datetime': '2018-06-09T20:19:12Z', 'uri': 'http://web.archive.org/web/20180609201912/https://www.guideline.gov/summaries/summary/49049/irritable-bowel-syndrome-in-adults-diagnosis-and-management-of-irritable-bowel-syndrome-in-primary-care'}]
https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:28:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930162822/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T16:28:22Z', 'uri': 'http://web.archive.org/web/20160930162822/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-02T20:09:16Z', 'uri': 'http://wayback.archive-it.org/all/20171002200916/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-02T20:09:16Z', 'uri': 'http://web.archive.org/web/20171002200916/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T00:45:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414004540/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T00:45:40Z', 'uri': 'http://web.archive.org/web/20180414004540/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-18T22:03:27Z', 'uri': 'http://wayback.archive-it.org/all/20180518220327/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-18T22:03:27Z', 'uri': 'http://web.archive.org/web/20180518220327/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T16:28:56Z', 'uri': 'http://web.archive.org/web/20180609162856/https://www.guideline.gov/summaries/summary/49050/risk-assessment-and-prevention-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930233830/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:38:30Z', 'uri': 'http://web.archive.org/web/20160930233830/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:26:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003032622/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T03:26:22Z', 'uri': 'http://web.archive.org/web/20171003032622/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T02:50:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414025004/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T02:50:04Z', 'uri': 'http://web.archive.org/web/20180414025004/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:43:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519094322/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:43:22Z', 'uri': 'http://web.archive.org/web/20180519094322/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T10:36:55Z', 'uri': 'http://web.archive.org/web/20180609103655/https://www.guideline.gov/summaries/summary/49051/treatment-of-pressure-ulcers-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930233651/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2016-09-30T23:36:51Z', 'uri': 'http://web.archive.org/web/20160930233651/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:24:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003032449/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2017-10-03T03:24:49Z', 'uri': 'http://web.archive.org/web/20171003032449/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2018-04-14T02:48:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414024826/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2018-04-14T02:48:26Z', 'uri': 'http://web.archive.org/web/20180414024826/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2018-05-19T09:41:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519094121/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2018-05-19T09:41:21Z', 'uri': 'http://web.archive.org/web/20180519094121/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}, {'datetime': '2018-06-09T21:29:19Z', 'uri': 'http://web.archive.org/web/20180609212919/https://www.guideline.gov/summaries/summary/49069/an-official-american-thoracic-society-clinical-practice-guideline-diagnosis-risk-stratification-and-management-of-pulmonary-hypertension-of-sickle-cell-disease'}]
https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930233817/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2016-09-30T23:38:17Z', 'uri': 'http://web.archive.org/web/20160930233817/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2017-10-03T03:26:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003032614/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2017-10-03T03:26:14Z', 'uri': 'http://web.archive.org/web/20171003032614/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2018-04-14T02:49:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414024952/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2018-04-14T02:49:52Z', 'uri': 'http://web.archive.org/web/20180414024952/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2018-05-19T09:43:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519094310/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2018-05-19T09:43:10Z', 'uri': 'http://web.archive.org/web/20180519094310/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}, {'datetime': '2018-06-23T14:06:20Z', 'uri': 'http://web.archive.org/web/20180623140620/https://www.guideline.gov/summaries/summary/49070/acr-appropriateness-criteria--evaluation-of-the-symptomatic-male-breast'}]
https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:37:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930233739/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2016-09-30T23:37:39Z', 'uri': 'http://web.archive.org/web/20160930233739/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2017-10-03T03:26:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003032604/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2017-10-03T03:26:04Z', 'uri': 'http://web.archive.org/web/20171003032604/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2018-04-14T02:49:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414024939/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2018-04-14T02:49:39Z', 'uri': 'http://web.archive.org/web/20180414024939/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2018-05-19T09:42:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519094257/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2018-05-19T09:42:57Z', 'uri': 'http://web.archive.org/web/20180519094257/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}, {'datetime': '2018-06-10T23:17:46Z', 'uri': 'http://web.archive.org/web/20180610231746/https://www.guideline.gov/summaries/summary/49071/acr-appropriateness-criteria--crohn-disease'}]
https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:38:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930233824/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2016-09-30T23:38:24Z', 'uri': 'http://web.archive.org/web/20160930233824/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2017-10-03T03:26:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003032616/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2017-10-03T03:26:16Z', 'uri': 'http://web.archive.org/web/20171003032616/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2018-04-14T02:49:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414024956/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2018-04-14T02:49:56Z', 'uri': 'http://web.archive.org/web/20180414024956/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2018-05-19T09:43:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519094313/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2018-05-19T09:43:13Z', 'uri': 'http://web.archive.org/web/20180519094313/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}, {'datetime': '2018-06-10T19:50:35Z', 'uri': 'http://web.archive.org/web/20180610195035/https://www.guideline.gov/summaries/summary/49072/acr-appropriateness-criteria--palpable-abdominal-mass'}]
https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930233636/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2016-09-30T23:36:36Z', 'uri': 'http://web.archive.org/web/20160930233636/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2017-10-03T03:24:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003032433/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2017-10-03T03:24:33Z', 'uri': 'http://web.archive.org/web/20171003032433/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2018-04-14T02:48:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414024809/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2018-04-14T02:48:09Z', 'uri': 'http://web.archive.org/web/20180414024809/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2018-05-19T09:41:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519094102/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2018-05-19T09:41:02Z', 'uri': 'http://web.archive.org/web/20180519094102/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}, {'datetime': '2018-06-10T08:34:54Z', 'uri': 'http://web.archive.org/web/20180610083454/https://www.guideline.gov/summaries/summary/49073/acr-appropriateness-criteria--radiologic-management-of-infected-fluid-collections'}]
https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930233643/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2016-09-30T23:36:43Z', 'uri': 'http://web.archive.org/web/20160930233643/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2017-10-03T03:24:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003032441/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2017-10-03T03:24:41Z', 'uri': 'http://web.archive.org/web/20171003032441/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2018-04-14T02:48:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414024817/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2018-04-14T02:48:17Z', 'uri': 'http://web.archive.org/web/20180414024817/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2018-05-19T09:41:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519094112/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2018-05-19T09:41:12Z', 'uri': 'http://web.archive.org/web/20180519094112/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}, {'datetime': '2018-06-09T11:21:33Z', 'uri': 'http://web.archive.org/web/20180609112133/https://www.guideline.gov/summaries/summary/49074/acr-appropriateness-criteria--radiologic-management-of-lower-gastrointestinal-tract-bleeding'}]
https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:36:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930233629/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2016-09-30T23:36:29Z', 'uri': 'http://web.archive.org/web/20160930233629/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2017-02-03T16:26:55Z', 'uri': 'http://web.archive.org/web/20170203162655/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2017-10-03T03:24:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003032424/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2017-10-03T03:24:24Z', 'uri': 'http://web.archive.org/web/20171003032424/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2018-04-14T02:47:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414024758/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2018-04-14T02:47:58Z', 'uri': 'http://web.archive.org/web/20180414024758/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2018-05-19T09:40:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519094052/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2018-05-19T09:40:52Z', 'uri': 'http://web.archive.org/web/20180519094052/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}, {'datetime': '2018-06-09T21:46:00Z', 'uri': 'http://web.archive.org/web/20180609214600/https://www.guideline.gov/summaries/summary/49075/acr-appropriateness-criteria--acute-trauma-to-the-foot'}]
https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930233532/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2016-09-30T23:35:32Z', 'uri': 'http://web.archive.org/web/20160930233532/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2017-10-03T03:23:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003032316/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2017-10-03T03:23:16Z', 'uri': 'http://web.archive.org/web/20171003032316/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2018-04-14T02:46:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414024640/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2018-04-14T02:46:40Z', 'uri': 'http://web.archive.org/web/20180414024640/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2018-05-19T09:39:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519093929/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2018-05-19T09:39:29Z', 'uri': 'http://web.archive.org/web/20180519093929/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}, {'datetime': '2018-06-10T22:06:48Z', 'uri': 'http://web.archive.org/web/20180610220648/https://www.guideline.gov/summaries/summary/49076/acr-appropriateness-criteria--acute-trauma-to-the-knee'}]
https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930233554/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2016-09-30T23:35:54Z', 'uri': 'http://web.archive.org/web/20160930233554/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2017-10-03T03:23:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003032341/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2017-10-03T03:23:41Z', 'uri': 'http://web.archive.org/web/20171003032341/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2018-04-14T02:47:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414024709/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2018-04-14T02:47:09Z', 'uri': 'http://web.archive.org/web/20180414024709/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2018-05-19T09:40:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519094002/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2018-05-19T09:40:02Z', 'uri': 'http://web.archive.org/web/20180519094002/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}, {'datetime': '2018-06-09T11:23:24Z', 'uri': 'http://web.archive.org/web/20180609112324/https://www.guideline.gov/summaries/summary/49077/acr-appropriateness-criteria--vomiting-in-infants-up-to-3-months-of-age'}]
https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930233525/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2016-09-30T23:35:25Z', 'uri': 'http://web.archive.org/web/20160930233525/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2017-10-03T03:23:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003032308/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2017-10-03T03:23:08Z', 'uri': 'http://web.archive.org/web/20171003032308/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2018-04-14T02:46:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414024631/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2018-04-14T02:46:31Z', 'uri': 'http://web.archive.org/web/20180414024631/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2018-05-19T09:39:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519093920/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2018-05-19T09:39:20Z', 'uri': 'http://web.archive.org/web/20180519093920/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}, {'datetime': '2018-06-09T20:12:30Z', 'uri': 'http://web.archive.org/web/20180609201230/https://www.guideline.gov/summaries/summary/49078/acr-appropriateness-criteria--acute-respiratory-illness-in-immunocompromised-patients'}]
https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930233540/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2016-09-30T23:35:40Z', 'uri': 'http://web.archive.org/web/20160930233540/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2017-10-03T03:23:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003032325/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2017-10-03T03:23:25Z', 'uri': 'http://web.archive.org/web/20171003032325/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2018-04-14T02:46:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414024651/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2018-04-14T02:46:51Z', 'uri': 'http://web.archive.org/web/20180414024651/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2018-05-19T09:39:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519093943/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2018-05-19T09:39:43Z', 'uri': 'http://web.archive.org/web/20180519093943/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}, {'datetime': '2018-06-10T22:28:08Z', 'uri': 'http://web.archive.org/web/20180610222808/https://www.guideline.gov/summaries/summary/49079/acr-appropriateness-criteria--intensive-care-unit-patients'}]
https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:35:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930233547/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2016-09-30T23:35:47Z', 'uri': 'http://web.archive.org/web/20160930233547/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2017-10-03T03:23:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003032334/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2017-10-03T03:23:34Z', 'uri': 'http://web.archive.org/web/20171003032334/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2018-01-10T13:16:35Z', 'uri': 'http://web.archive.org/web/20180110131635/https://guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2018-04-14T02:47:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414024700/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2018-04-14T02:47:00Z', 'uri': 'http://web.archive.org/web/20180414024700/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2018-05-19T09:39:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519093952/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2018-05-19T09:39:52Z', 'uri': 'http://web.archive.org/web/20180519093952/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}, {'datetime': '2018-06-10T02:14:48Z', 'uri': 'http://web.archive.org/web/20180610021448/https://www.guideline.gov/summaries/summary/49080/acr-appropriateness-criteria--occupational-lung-diseases'}]
https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930233518/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2016-09-30T23:35:18Z', 'uri': 'http://web.archive.org/web/20160930233518/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2017-10-03T03:23:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003032301/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2017-10-03T03:23:01Z', 'uri': 'http://web.archive.org/web/20171003032301/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2018-04-14T02:46:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414024622/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2018-04-14T02:46:22Z', 'uri': 'http://web.archive.org/web/20180414024622/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2018-05-19T09:39:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519093910/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2018-05-19T09:39:10Z', 'uri': 'http://web.archive.org/web/20180519093910/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}, {'datetime': '2018-06-10T16:21:51Z', 'uri': 'http://web.archive.org/web/20180610162151/https://www.guideline.gov/summaries/summary/49081/acr-appropriateness-criteria--acute-onset-of-scrotal-pain---without-trauma-without-antecedent-mass'}]
https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930233422/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2016-09-30T23:34:22Z', 'uri': 'http://web.archive.org/web/20160930233422/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2017-10-03T03:22:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003032212/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2017-10-03T03:22:12Z', 'uri': 'http://web.archive.org/web/20171003032212/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2018-04-14T02:45:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414024522/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2018-04-14T02:45:22Z', 'uri': 'http://web.archive.org/web/20180414024522/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2018-05-19T09:38:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519093809/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2018-05-19T09:38:09Z', 'uri': 'http://web.archive.org/web/20180519093809/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}, {'datetime': '2018-06-11T05:59:05Z', 'uri': 'http://web.archive.org/web/20180611055905/https://www.guideline.gov/summaries/summary/49082/acr-appropriateness-criteria--hematuria'}]
https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930233436/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2016-09-30T23:34:36Z', 'uri': 'http://web.archive.org/web/20160930233436/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2017-10-03T03:22:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003032227/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2017-10-03T03:22:27Z', 'uri': 'http://web.archive.org/web/20171003032227/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2018-04-14T02:45:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414024541/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2018-04-14T02:45:41Z', 'uri': 'http://web.archive.org/web/20180414024541/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2018-05-19T09:38:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519093827/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2018-05-19T09:38:27Z', 'uri': 'http://web.archive.org/web/20180519093827/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}, {'datetime': '2018-06-10T16:22:23Z', 'uri': 'http://web.archive.org/web/20180610162223/https://www.guideline.gov/summaries/summary/49083/acr-appropriateness-criteria--recurrent-lower-urinary-tract-infections-in-women'}]
https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930233415/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2016-09-30T23:34:15Z', 'uri': 'http://web.archive.org/web/20160930233415/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2017-10-03T03:22:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003032205/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2017-10-03T03:22:05Z', 'uri': 'http://web.archive.org/web/20171003032205/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2018-04-14T02:45:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414024513/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2018-04-14T02:45:13Z', 'uri': 'http://web.archive.org/web/20180414024513/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2018-05-19T09:38:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519093800/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2018-05-19T09:38:00Z', 'uri': 'http://web.archive.org/web/20180519093800/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}, {'datetime': '2018-06-10T11:49:11Z', 'uri': 'http://web.archive.org/web/20180610114911/https://www.guideline.gov/summaries/summary/49084/acr-appropriateness-criteria--blunt-chest-trauma---suspected-aortic-injury'}]
https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930233443/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2016-09-30T23:34:43Z', 'uri': 'http://web.archive.org/web/20160930233443/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2017-10-03T03:22:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003032235/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2017-10-03T03:22:35Z', 'uri': 'http://web.archive.org/web/20171003032235/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2018-04-14T02:45:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414024550/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2018-04-14T02:45:50Z', 'uri': 'http://web.archive.org/web/20180414024550/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2018-05-19T09:38:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519093837/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2018-05-19T09:38:37Z', 'uri': 'http://web.archive.org/web/20180519093837/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}, {'datetime': '2018-06-11T01:02:48Z', 'uri': 'http://web.archive.org/web/20180611010248/https://www.guideline.gov/summaries/summary/49085/acr-appropriateness-criteria--upper-extremity-swelling'}]
https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930233408/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2016-09-30T23:34:08Z', 'uri': 'http://web.archive.org/web/20160930233408/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2017-10-03T03:21:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003032158/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2017-10-03T03:21:58Z', 'uri': 'http://web.archive.org/web/20171003032158/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2018-04-14T02:45:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414024505/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2018-04-14T02:45:05Z', 'uri': 'http://web.archive.org/web/20180414024505/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2018-05-19T09:37:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519093750/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2018-05-19T09:37:50Z', 'uri': 'http://web.archive.org/web/20180519093750/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}, {'datetime': '2018-06-10T23:37:20Z', 'uri': 'http://web.archive.org/web/20180610233720/https://www.guideline.gov/summaries/summary/49086/acr-appropriateness-criteria--assessment-of-gravid-cervix'}]
https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930233429/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2016-09-30T23:34:29Z', 'uri': 'http://web.archive.org/web/20160930233429/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2017-10-03T03:22:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003032220/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2017-10-03T03:22:20Z', 'uri': 'http://web.archive.org/web/20171003032220/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2018-04-14T02:45:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414024531/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2018-04-14T02:45:31Z', 'uri': 'http://web.archive.org/web/20180414024531/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2018-05-19T09:38:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519093818/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2018-05-19T09:38:18Z', 'uri': 'http://web.archive.org/web/20180519093818/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}, {'datetime': '2018-06-10T23:37:19Z', 'uri': 'http://web.archive.org/web/20180610233719/https://www.guideline.gov/summaries/summary/49087/acr-appropriateness-criteria--infertility'}]
https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:33:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930233306/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2016-09-30T23:33:06Z', 'uri': 'http://web.archive.org/web/20160930233306/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2017-10-03T03:21:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003032103/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2017-10-03T03:21:03Z', 'uri': 'http://web.archive.org/web/20171003032103/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2018-04-14T02:43:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414024357/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2018-04-14T02:43:57Z', 'uri': 'http://web.archive.org/web/20180414024357/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2018-05-19T09:36:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519093624/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2018-05-19T09:36:24Z', 'uri': 'http://web.archive.org/web/20180519093624/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}, {'datetime': '2018-06-09T20:18:47Z', 'uri': 'http://web.archive.org/web/20180609201847/https://www.guideline.gov/summaries/summary/49088/acr-appropriateness-criteria--metastatic-epidural-spinal-cord-compression-and-recurrent-spinal-metastasis'}]
https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:33:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930233314/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2016-09-30T23:33:14Z', 'uri': 'http://web.archive.org/web/20160930233314/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2017-10-03T03:21:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003032112/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2017-10-03T03:21:12Z', 'uri': 'http://web.archive.org/web/20171003032112/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2018-04-14T02:44:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414024412/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2018-04-14T02:44:12Z', 'uri': 'http://web.archive.org/web/20180414024412/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2018-05-19T09:36:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519093636/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2018-05-19T09:36:36Z', 'uri': 'http://web.archive.org/web/20180519093636/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}, {'datetime': '2018-06-10T14:55:36Z', 'uri': 'http://web.archive.org/web/20180610145536/https://www.guideline.gov/summaries/summary/49089/acr-appropriateness-criteria--nonspine-bone-metastases'}]
https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:33:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930233300/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2016-09-30T23:33:00Z', 'uri': 'http://web.archive.org/web/20160930233300/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2017-10-03T03:20:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003032054/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2017-10-03T03:20:54Z', 'uri': 'http://web.archive.org/web/20171003032054/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2018-04-14T02:43:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414024348/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2018-04-14T02:43:48Z', 'uri': 'http://web.archive.org/web/20180414024348/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2018-05-19T09:36:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519093615/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2018-05-19T09:36:15Z', 'uri': 'http://web.archive.org/web/20180519093615/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}, {'datetime': '2018-06-10T23:02:37Z', 'uri': 'http://web.archive.org/web/20180610230237/https://www.guideline.gov/summaries/summary/49090/acr-appropriateness-criteria--followup-and-retreatment-of-brain-metastases'}]
https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:32:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930233252/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2016-09-30T23:32:52Z', 'uri': 'http://web.archive.org/web/20160930233252/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2017-10-03T03:20:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003032045/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2017-10-03T03:20:45Z', 'uri': 'http://web.archive.org/web/20171003032045/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2018-04-14T02:43:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414024337/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2018-04-14T02:43:37Z', 'uri': 'http://web.archive.org/web/20180414024337/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2018-05-19T09:36:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519093603/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2018-05-19T09:36:03Z', 'uri': 'http://web.archive.org/web/20180519093603/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2018-06-10T12:44:05Z', 'uri': 'http://web.archive.org/web/20180610124405/https://www.guideline.gov/summaries/summary/49091/acr-appropriateness-criteria--ductal-carcinoma-in-situ'}, {'datetime': '2018-06-11T14:49:52Z', 'uri': 'http://web.archive.org/web/20180611144952/https://www.guideline.gov/summaries/summary/49091/ACR-Appropriateness-Criteria--ductal-carcinoma-in-situ'}]
https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:33:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930233321/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2016-09-30T23:33:21Z', 'uri': 'http://web.archive.org/web/20160930233321/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2017-10-03T03:21:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003032120/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2017-10-03T03:21:20Z', 'uri': 'http://web.archive.org/web/20171003032120/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2018-04-14T02:44:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414024421/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2018-04-14T02:44:21Z', 'uri': 'http://web.archive.org/web/20180414024421/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2018-05-19T09:36:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519093647/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2018-05-19T09:36:47Z', 'uri': 'http://web.archive.org/web/20180519093647/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}, {'datetime': '2018-06-09T19:16:43Z', 'uri': 'http://web.archive.org/web/20180609191643/https://www.guideline.gov/summaries/summary/49092/acr-appropriateness-criteria--recurrent-rectal-cancer'}]
https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:32:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930233246/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2016-09-30T23:32:46Z', 'uri': 'http://web.archive.org/web/20160930233246/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2017-10-03T03:20:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003032037/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2017-10-03T03:20:37Z', 'uri': 'http://web.archive.org/web/20171003032037/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2018-04-14T02:43:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414024327/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2018-04-14T02:43:27Z', 'uri': 'http://web.archive.org/web/20180414024327/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2018-05-19T09:35:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519093551/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2018-05-19T09:35:51Z', 'uri': 'http://web.archive.org/web/20180519093551/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}, {'datetime': '2018-06-10T13:45:01Z', 'uri': 'http://web.archive.org/web/20180610134501/https://www.guideline.gov/summaries/summary/49093/acr-appropriateness-criteria--aggressive-nonmelanomatous-skin-cancer-of-the-head-and-neck'}]
https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:33:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930233328/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2016-09-30T23:33:28Z', 'uri': 'http://web.archive.org/web/20160930233328/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2017-07-14T10:54:06Z', 'uri': 'http://web.archive.org/web/20170714105406/https://guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2017-10-03T03:21:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003032127/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2017-10-03T03:21:27Z', 'uri': 'http://web.archive.org/web/20171003032127/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2018-04-14T02:44:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414024431/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2018-04-14T02:44:31Z', 'uri': 'http://web.archive.org/web/20180414024431/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2018-05-19T09:37:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519093714/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2018-05-19T09:37:14Z', 'uri': 'http://web.archive.org/web/20180519093714/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}, {'datetime': '2018-06-09T11:20:52Z', 'uri': 'http://web.archive.org/web/20180609112052/https://www.guideline.gov/summaries/summary/49094/care-of-the-pediatric-patient-with-a-brain-tumor'}]
https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930233609/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2016-09-30T23:36:09Z', 'uri': 'http://web.archive.org/web/20160930233609/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2017-10-03T03:23:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003032358/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2017-10-03T03:23:58Z', 'uri': 'http://web.archive.org/web/20171003032358/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2018-04-14T02:47:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414024730/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2018-04-14T02:47:30Z', 'uri': 'http://web.archive.org/web/20180414024730/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2018-05-19T09:40:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519094023/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2018-05-19T09:40:23Z', 'uri': 'http://web.archive.org/web/20180519094023/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}, {'datetime': '2018-06-10T23:17:00Z', 'uri': 'http://web.archive.org/web/20180610231700/https://www.guideline.gov/summaries/summary/49095/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262'}]
https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930233400/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2016-09-30T23:34:00Z', 'uri': 'http://web.archive.org/web/20160930233400/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2017-10-03T03:21:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003032149/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2017-10-03T03:21:49Z', 'uri': 'http://web.archive.org/web/20171003032149/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2018-04-14T02:44:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414024456/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2018-04-14T02:44:56Z', 'uri': 'http://web.archive.org/web/20180414024456/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2018-05-19T09:37:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519093741/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2018-05-19T09:37:41Z', 'uri': 'http://web.archive.org/web/20180519093741/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}, {'datetime': '2018-06-10T11:26:00Z', 'uri': 'http://web.archive.org/web/20180610112600/https://www.guideline.gov/summaries/summary/49112/acr-appropriateness-criteria--resectable-stomach-cancer'}]
https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:33:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930233341/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2016-09-30T23:33:41Z', 'uri': 'http://web.archive.org/web/20160930233341/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2017-10-03T03:21:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003032140/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2017-10-03T03:21:40Z', 'uri': 'http://web.archive.org/web/20171003032140/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2018-04-14T02:44:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414024446/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2018-04-14T02:44:46Z', 'uri': 'http://web.archive.org/web/20180414024446/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2018-05-19T09:37:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519093731/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2018-05-19T09:37:31Z', 'uri': 'http://web.archive.org/web/20180519093731/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}, {'datetime': '2018-06-09T15:22:18Z', 'uri': 'http://web.archive.org/web/20180609152218/https://www.guideline.gov/summaries/summary/49113/acr-appropriateness-criteria--diffuse-large-bcell-lymphoma'}]
https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930233616/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2016-09-30T23:36:16Z', 'uri': 'http://web.archive.org/web/20160930233616/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2017-10-03T03:24:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003032405/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2017-10-03T03:24:05Z', 'uri': 'http://web.archive.org/web/20171003032405/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2018-04-14T02:47:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414024739/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2018-04-14T02:47:39Z', 'uri': 'http://web.archive.org/web/20180414024739/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2018-05-19T09:40:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519094033/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2018-05-19T09:40:33Z', 'uri': 'http://web.archive.org/web/20180519094033/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}, {'datetime': '2018-06-09T18:58:03Z', 'uri': 'http://web.archive.org/web/20180609185803/https://www.guideline.gov/summaries/summary/49114/evaluation-and-treatment-of-functional-constipation-in-infants-and-children-evidencebased-recommendations-from-espghan-and-naspghan'}]
https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:32:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930233218/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2016-09-30T23:32:18Z', 'uri': 'http://web.archive.org/web/20160930233218/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2017-10-03T03:20:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003032010/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2017-10-03T03:20:10Z', 'uri': 'http://web.archive.org/web/20171003032010/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2018-04-14T02:42:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414024253/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2018-04-14T02:42:53Z', 'uri': 'http://web.archive.org/web/20180414024253/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2018-05-19T09:35:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519093515/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2018-05-19T09:35:15Z', 'uri': 'http://web.archive.org/web/20180519093515/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}, {'datetime': '2018-06-09T19:47:56Z', 'uri': 'http://web.archive.org/web/20180609194756/https://www.guideline.gov/summaries/summary/49115/clinical-practice-guideline-planning-for-labor-and-vaginal-birth-after-cesarean'}]
https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930233503/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2016-09-30T23:35:03Z', 'uri': 'http://web.archive.org/web/20160930233503/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2017-10-03T03:22:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003032252/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2017-10-03T03:22:52Z', 'uri': 'http://web.archive.org/web/20171003032252/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2018-04-14T02:46:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414024610/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2018-04-14T02:46:10Z', 'uri': 'http://web.archive.org/web/20180414024610/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2018-05-19T09:38:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519093858/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2018-05-19T09:38:58Z', 'uri': 'http://web.archive.org/web/20180519093858/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}, {'datetime': '2018-06-09T16:25:07Z', 'uri': 'http://web.archive.org/web/20180609162507/https://www.guideline.gov/summaries/summary/49116/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes'}]
https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930233456/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2016-09-30T23:34:56Z', 'uri': 'http://web.archive.org/web/20160930233456/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2017-10-03T03:22:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003032249/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2017-10-03T03:22:49Z', 'uri': 'http://web.archive.org/web/20171003032249/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2018-04-14T02:46:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414024607/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2018-04-14T02:46:07Z', 'uri': 'http://web.archive.org/web/20180414024607/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2018-05-19T09:38:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519093855/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2018-05-19T09:38:55Z', 'uri': 'http://web.archive.org/web/20180519093855/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}, {'datetime': '2018-06-09T11:08:25Z', 'uri': 'http://web.archive.org/web/20180609110825/https://www.guideline.gov/summaries/summary/49117/maintaining-a-healthy-weight-and-preventing-excess-weight-gain-among-adults-and-children'}]
https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930233601/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2016-09-30T23:36:01Z', 'uri': 'http://web.archive.org/web/20160930233601/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2017-10-03T03:23:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003032349/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2017-10-03T03:23:49Z', 'uri': 'http://web.archive.org/web/20171003032349/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2018-04-14T02:47:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414024718/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2018-04-14T02:47:18Z', 'uri': 'http://web.archive.org/web/20180414024718/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2018-05-19T09:40:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519094011/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2018-05-19T09:40:11Z', 'uri': 'http://web.archive.org/web/20180519094011/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}, {'datetime': '2018-06-09T11:59:07Z', 'uri': 'http://web.archive.org/web/20180609115907/https://www.guideline.gov/summaries/summary/49118/depression-in-children-and-young-people-identification-and-management-in-primary-community-and-secondary-care'}]
https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930233021/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2016-09-30T23:30:21Z', 'uri': 'http://web.archive.org/web/20160930233021/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2017-10-03T03:17:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003031737/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2017-10-03T03:17:37Z', 'uri': 'http://web.archive.org/web/20171003031737/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2018-04-14T02:40:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414024048/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2018-04-14T02:40:48Z', 'uri': 'http://web.archive.org/web/20180414024048/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2018-05-19T09:32:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519093256/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2018-05-19T09:32:56Z', 'uri': 'http://web.archive.org/web/20180519093256/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}, {'datetime': '2018-06-10T11:23:15Z', 'uri': 'http://web.archive.org/web/20180610112315/https://www.guideline.gov/summaries/summary/49119/bladder-cancer-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:30:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930233029/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2016-09-30T23:30:29Z', 'uri': 'http://web.archive.org/web/20160930233029/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2017-10-03T03:17:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003031746/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2017-10-03T03:17:46Z', 'uri': 'http://web.archive.org/web/20171003031746/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-04-14T02:40:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414024059/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-04-14T02:40:59Z', 'uri': 'http://web.archive.org/web/20180414024059/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-05-19T09:33:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519093309/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-05-19T09:33:09Z', 'uri': 'http://web.archive.org/web/20180519093309/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-06-09T11:19:50Z', 'uri': 'http://web.archive.org/web/20180609111950/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-07-12T22:12:59Z', 'uri': 'http://web.archive.org/web/20180712221259/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}, {'datetime': '2018-07-12T22:12:59Z', 'uri': 'http://web.archive.org/web/20180712221259/https://www.guideline.gov/summaries/summary/49120/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period'}]
https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:36:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930233622/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:36:22Z', 'uri': 'http://web.archive.org/web/20160930233622/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:24:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003032412/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:24:12Z', 'uri': 'http://web.archive.org/web/20171003032412/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:47:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414024749/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:47:49Z', 'uri': 'http://web.archive.org/web/20180414024749/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:40:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519094042/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:40:42Z', 'uri': 'http://web.archive.org/web/20180519094042/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:44Z', 'uri': 'http://web.archive.org/web/20180610010644/https://www.guideline.gov/summaries/summary/49121/acromegaly-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:32:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930233231/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2016-09-30T23:32:31Z', 'uri': 'http://web.archive.org/web/20160930233231/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2017-10-03T03:20:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003032024/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2017-10-03T03:20:24Z', 'uri': 'http://web.archive.org/web/20171003032024/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2018-04-14T02:43:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414024309/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2018-04-14T02:43:09Z', 'uri': 'http://web.archive.org/web/20180414024309/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2018-05-19T09:35:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519093533/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2018-05-19T09:35:33Z', 'uri': 'http://web.archive.org/web/20180519093533/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}, {'datetime': '2018-06-09T21:44:57Z', 'uri': 'http://web.archive.org/web/20180609214457/https://www.guideline.gov/summaries/summary/49122/american-gastroenterological-association-institute-guideline-on-pharmacological-management-of-irritable-bowel-syndrome'}]
https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:35:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930233511/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2016-09-30T23:35:11Z', 'uri': 'http://web.archive.org/web/20160930233511/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2017-10-03T03:22:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003032255/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2017-10-03T03:22:55Z', 'uri': 'http://web.archive.org/web/20171003032255/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2018-04-14T02:46:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414024614/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2018-04-14T02:46:14Z', 'uri': 'http://web.archive.org/web/20180414024614/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2018-05-19T09:39:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519093902/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2018-05-19T09:39:02Z', 'uri': 'http://web.archive.org/web/20180519093902/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}, {'datetime': '2018-06-10T17:20:01Z', 'uri': 'http://web.archive.org/web/20180610172001/https://www.guideline.gov/summaries/summary/49123/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome'}]
https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:34:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930233450/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2016-09-30T23:34:50Z', 'uri': 'http://web.archive.org/web/20160930233450/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2017-10-03T03:22:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003032243/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2017-10-03T03:22:43Z', 'uri': 'http://web.archive.org/web/20171003032243/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2018-04-14T02:45:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414024559/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2018-04-14T02:45:59Z', 'uri': 'http://web.archive.org/web/20180414024559/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2018-05-19T09:38:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519093846/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2018-05-19T09:38:46Z', 'uri': 'http://web.archive.org/web/20180519093846/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}, {'datetime': '2018-06-11T00:05:07Z', 'uri': 'http://web.archive.org/web/20180611000507/https://www.guideline.gov/summaries/summary/49124/empagliflozin-in-combination-therapy-for-treating-type-2-diabetes'}]
https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930233050/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2016-09-30T23:30:50Z', 'uri': 'http://web.archive.org/web/20160930233050/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2017-10-03T03:18:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003031811/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2017-10-03T03:18:11Z', 'uri': 'http://web.archive.org/web/20171003031811/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2018-04-14T02:41:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414024130/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2018-04-14T02:41:30Z', 'uri': 'http://web.archive.org/web/20180414024130/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2018-05-19T09:33:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519093343/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2018-05-19T09:33:43Z', 'uri': 'http://web.archive.org/web/20180519093343/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}, {'datetime': '2018-06-09T20:18:46Z', 'uri': 'http://web.archive.org/web/20180609201846/https://www.guideline.gov/summaries/summary/49131/recommendations-for-growth-monitoring-and-prevention-and-management-of-overweight-and-obesity-in-children-and-youth-in-primary-care'}]
https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:37:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930233732/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2016-09-30T23:37:32Z', 'uri': 'http://web.archive.org/web/20160930233732/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2017-10-03T03:25:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003032558/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2017-10-03T03:25:58Z', 'uri': 'http://web.archive.org/web/20171003032558/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2018-04-14T02:49:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414024930/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2018-04-14T02:49:30Z', 'uri': 'http://web.archive.org/web/20180414024930/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2018-05-19T09:42:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519094248/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2018-05-19T09:42:48Z', 'uri': 'http://web.archive.org/web/20180519094248/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}, {'datetime': '2018-06-09T23:35:08Z', 'uri': 'http://web.archive.org/web/20180609233508/https://www.guideline.gov/summaries/summary/49132/primary-prevention-of-childhood-obesity-second-edition'}]
https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:32:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930233224/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2016-09-30T23:32:24Z', 'uri': 'http://web.archive.org/web/20160930233224/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2017-10-03T03:20:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003032016/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2017-10-03T03:20:16Z', 'uri': 'http://web.archive.org/web/20171003032016/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2018-04-14T02:43:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414024300/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2018-04-14T02:43:00Z', 'uri': 'http://web.archive.org/web/20180414024300/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2018-05-19T09:35:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519093524/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2018-05-19T09:35:24Z', 'uri': 'http://web.archive.org/web/20180519093524/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}, {'datetime': '2018-06-09T20:51:29Z', 'uri': 'http://web.archive.org/web/20180609205129/https://www.guideline.gov/summaries/summary/49133/prevention-of-acute-exacerbations-of-copd-american-college-of-chest-physicians-and-canadian-thoracic-society-guideline'}]
https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:31:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930233110/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2016-09-30T23:31:10Z', 'uri': 'http://web.archive.org/web/20160930233110/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2017-10-03T03:18:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003031833/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2017-10-03T03:18:33Z', 'uri': 'http://web.archive.org/web/20171003031833/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2018-04-14T02:41:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414024157/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2018-04-14T02:41:57Z', 'uri': 'http://web.archive.org/web/20180414024157/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2018-05-19T09:34:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519093413/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2018-05-19T09:34:13Z', 'uri': 'http://web.archive.org/web/20180519093413/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}, {'datetime': '2018-06-09T11:03:50Z', 'uri': 'http://web.archive.org/web/20180609110350/https://www.guideline.gov/summaries/summary/49134/locoregional-therapy-of-locally-advanced-breast-cancer-labc'}]
https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:31:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930233116/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2016-09-30T23:31:16Z', 'uri': 'http://web.archive.org/web/20160930233116/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2017-10-03T03:18:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003031840/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2017-10-03T03:18:40Z', 'uri': 'http://web.archive.org/web/20171003031840/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2018-04-14T02:42:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414024206/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2018-04-14T02:42:06Z', 'uri': 'http://web.archive.org/web/20180414024206/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2018-05-19T09:34:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519093422/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2018-05-19T09:34:22Z', 'uri': 'http://web.archive.org/web/20180519093422/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2018-06-09T21:16:21Z', 'uri': 'http://web.archive.org/web/20180609211621/https://www.guideline.gov/summaries/summary/49135/optimal-systemic-therapy-for-early-female-breast-cancer'}, {'datetime': '2018-06-11T15:28:18Z', 'uri': 'http://web.archive.org/web/20180611152818/https://www.guideline.gov/summaries/summary/49135/Optimal-systemic-therapy-for-early-female-breast-cancer'}]
https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:31:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930233129/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2016-09-30T23:31:29Z', 'uri': 'http://web.archive.org/web/20160930233129/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2017-10-03T03:19:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003031913/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2017-10-03T03:19:13Z', 'uri': 'http://web.archive.org/web/20171003031913/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2018-04-14T02:42:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414024218/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2018-04-14T02:42:18Z', 'uri': 'http://web.archive.org/web/20180414024218/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2018-05-19T09:34:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519093436/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2018-05-19T09:34:36Z', 'uri': 'http://web.archive.org/web/20180519093436/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}, {'datetime': '2018-06-09T20:11:07Z', 'uri': 'http://web.archive.org/web/20180609201107/https://www.guideline.gov/summaries/summary/49136/clinical-pharmacogenetics-implementation-consortium-guidelines-for-cyp2c9-and-hlab-genotypes-and-phenytoin-dosing'}]
https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930233043/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2016-09-30T23:30:43Z', 'uri': 'http://web.archive.org/web/20160930233043/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2017-10-03T03:18:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003031803/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2017-10-03T03:18:03Z', 'uri': 'http://web.archive.org/web/20171003031803/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2018-04-14T02:41:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414024120/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2018-04-14T02:41:20Z', 'uri': 'http://web.archive.org/web/20180414024120/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2018-05-19T09:33:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519093332/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2018-05-19T09:33:32Z', 'uri': 'http://web.archive.org/web/20180519093332/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}, {'datetime': '2018-06-09T21:46:13Z', 'uri': 'http://web.archive.org/web/20180609214613/https://www.guideline.gov/summaries/summary/49162/guideline-for-management-of-wounds-in-patients-with-lowerextremity-arterial-disease'}]
https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930232949/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2016-09-30T23:29:49Z', 'uri': 'http://web.archive.org/web/20160930232949/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2017-10-03T03:17:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003031701/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2017-10-03T03:17:01Z', 'uri': 'http://web.archive.org/web/20171003031701/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2018-04-14T02:40:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414024003/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2018-04-14T02:40:03Z', 'uri': 'http://web.archive.org/web/20180414024003/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2018-05-19T09:31:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519093145/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2018-05-19T09:31:45Z', 'uri': 'http://web.archive.org/web/20180519093145/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}, {'datetime': '2018-06-10T21:55:33Z', 'uri': 'http://web.archive.org/web/20180610215533/https://www.guideline.gov/summaries/summary/49208/safe-midwifery-staffing-for-maternity-settings'}]
https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:32:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930233239/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2016-09-30T23:32:39Z', 'uri': 'http://web.archive.org/web/20160930233239/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2017-10-03T03:20:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003032031/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2017-10-03T03:20:31Z', 'uri': 'http://web.archive.org/web/20171003032031/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2018-04-14T02:43:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414024318/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2018-04-14T02:43:18Z', 'uri': 'http://web.archive.org/web/20180414024318/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2018-05-19T09:35:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519093543/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2018-05-19T09:35:43Z', 'uri': 'http://web.archive.org/web/20180519093543/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}, {'datetime': '2018-06-10T00:04:22Z', 'uri': 'http://web.archive.org/web/20180610000422/https://www.guideline.gov/summaries/summary/49209/who-position-paper-on-mammography-screening'}]
https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:31:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930233123/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2016-09-30T23:31:23Z', 'uri': 'http://web.archive.org/web/20160930233123/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2017-02-03T16:25:23Z', 'uri': 'http://web.archive.org/web/20170203162523/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2017-10-03T03:18:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003031848/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2017-10-03T03:18:48Z', 'uri': 'http://web.archive.org/web/20171003031848/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-04-14T02:42:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414024208/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-04-14T02:42:08Z', 'uri': 'http://web.archive.org/web/20180414024208/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-05-19T09:34:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519093427/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-05-19T09:34:27Z', 'uri': 'http://web.archive.org/web/20180519093427/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-06-09T22:01:06Z', 'uri': 'http://web.archive.org/web/20180609220106/https://www.guideline.gov/summaries/summary/49218/evidencebased-guideline-management-of-an-unprovoked-first-seizure-in-adults-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}]
https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930232721/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2016-09-30T23:27:21Z', 'uri': 'http://web.archive.org/web/20160930232721/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2017-10-03T03:14:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003031433/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2017-10-03T03:14:33Z', 'uri': 'http://web.archive.org/web/20171003031433/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2018-04-14T02:36:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414023658/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2018-04-14T02:36:58Z', 'uri': 'http://web.archive.org/web/20180414023658/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2018-05-19T09:28:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519092830/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2018-05-19T09:28:30Z', 'uri': 'http://web.archive.org/web/20180519092830/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}, {'datetime': '2018-06-09T11:57:58Z', 'uri': 'http://web.archive.org/web/20180609115758/https://www.guideline.gov/summaries/summary/49219/australian-guidelines-for-the-treatment-of-acute-stress-disorder---posttraumatic-stress-disorder'}]
https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:31:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930233141/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:31:41Z', 'uri': 'http://web.archive.org/web/20160930233141/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:19:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003031927/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:19:27Z', 'uri': 'http://web.archive.org/web/20171003031927/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:42:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414024234/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:42:34Z', 'uri': 'http://web.archive.org/web/20180414024234/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:34:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519093454/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:34:54Z', 'uri': 'http://web.archive.org/web/20180519093454/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-11T05:50:08Z', 'uri': 'http://web.archive.org/web/20180611055008/https://www.guideline.gov/summaries/summary/49227/screening-for-thyroid-dysfunction-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:31:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930233135/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2016-09-30T23:31:35Z', 'uri': 'http://web.archive.org/web/20160930233135/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2017-10-03T03:19:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003031921/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2017-10-03T03:19:21Z', 'uri': 'http://web.archive.org/web/20171003031921/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2018-04-14T02:42:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414024226/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2018-04-14T02:42:26Z', 'uri': 'http://web.archive.org/web/20180414024226/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2018-05-19T09:34:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519093445/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2018-05-19T09:34:45Z', 'uri': 'http://web.archive.org/web/20180519093445/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}, {'datetime': '2018-06-09T18:42:47Z', 'uri': 'http://web.archive.org/web/20180609184247/https://www.guideline.gov/summaries/summary/49232/an-international-ishltatsers-clinical-practice-guideline-diagnosis-and-management-of-bronchiolitis-obliterans-syndrome'}]
https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:31:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930233103/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2016-09-30T23:31:03Z', 'uri': 'http://web.archive.org/web/20160930233103/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2017-10-03T03:18:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003031826/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2017-10-03T03:18:26Z', 'uri': 'http://web.archive.org/web/20171003031826/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2018-04-14T02:41:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414024148/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2018-04-14T02:41:48Z', 'uri': 'http://web.archive.org/web/20180414024148/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2018-05-19T09:34:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519093403/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2018-05-19T09:34:03Z', 'uri': 'http://web.archive.org/web/20180519093403/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}, {'datetime': '2018-06-09T18:37:47Z', 'uri': 'http://web.archive.org/web/20180609183747/https://www.guideline.gov/summaries/summary/49236/consensus-summary-statement-of-the-international-multidisciplinary-consensus-conference-on-multimodality-monitoring-in-neurocritical-care-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-the-european-society-of-intensive-care-me'}]
https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930233037/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2016-09-30T23:30:37Z', 'uri': 'http://web.archive.org/web/20160930233037/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2017-10-03T03:17:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003031756/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2017-10-03T03:17:56Z', 'uri': 'http://web.archive.org/web/20171003031756/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2018-04-14T02:41:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414024112/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2018-04-14T02:41:12Z', 'uri': 'http://web.archive.org/web/20180414024112/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2018-05-19T09:33:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519093323/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2018-05-19T09:33:23Z', 'uri': 'http://web.archive.org/web/20180519093323/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}, {'datetime': '2018-06-09T21:15:50Z', 'uri': 'http://web.archive.org/web/20180609211550/https://www.guideline.gov/summaries/summary/49244/rituximab-in-lymphoma-and-chronic-lymphocytic-leukemia-a-clinical-practice-guideline-version-3'}]
https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930233015/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2016-09-30T23:30:15Z', 'uri': 'http://web.archive.org/web/20160930233015/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2017-10-03T03:17:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003031728/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2017-10-03T03:17:28Z', 'uri': 'http://web.archive.org/web/20171003031728/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2018-04-14T02:40:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414024040/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2018-04-14T02:40:40Z', 'uri': 'http://web.archive.org/web/20180414024040/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2018-05-19T09:32:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519093247/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2018-05-19T09:32:47Z', 'uri': 'http://web.archive.org/web/20180519093247/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}, {'datetime': '2018-06-09T21:52:39Z', 'uri': 'http://web.archive.org/web/20180609215239/https://www.guideline.gov/summaries/summary/49245/methadone-safety-a-clinical-practice-guideline-from-the-american-pain-society-and-college-on-problems-of-drug-dependence-in-collaboration-with-the-heart-rhythm-society'}]
https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T14:35:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930143534/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2016-09-30T14:35:34Z', 'uri': 'http://web.archive.org/web/20160930143534/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2017-10-03T03:12:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003031216/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2017-10-03T03:12:16Z', 'uri': 'http://web.archive.org/web/20171003031216/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2017-11-17T10:05:17Z', 'uri': 'http://web.archive.org/web/20171117100517/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2018-04-14T02:33:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414023348/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2018-04-14T02:33:48Z', 'uri': 'http://web.archive.org/web/20180414023348/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2018-05-19T09:25:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519092503/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2018-05-19T09:25:03Z', 'uri': 'http://web.archive.org/web/20180519092503/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}, {'datetime': '2018-06-09T11:03:08Z', 'uri': 'http://web.archive.org/web/20180609110308/https://www.guideline.gov/summaries/summary/49246/the-use-of-prophylactic-antibiotics-prior-to-dental-procedures-in-patients-with-prosthetic-joints-evidencebased-clinical-practice-guideline-for-dental-practitioners-a-report-of-the-american-dental-association-council-on-scientific-affairs'}]
https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930232910/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2016-09-30T23:29:10Z', 'uri': 'http://web.archive.org/web/20160930232910/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2017-10-03T03:16:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003031625/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2017-10-03T03:16:25Z', 'uri': 'http://web.archive.org/web/20171003031625/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2018-04-14T02:39:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414023917/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2018-04-14T02:39:17Z', 'uri': 'http://web.archive.org/web/20180414023917/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2018-05-19T09:30:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519093055/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2018-05-19T09:30:55Z', 'uri': 'http://web.archive.org/web/20180519093055/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}, {'datetime': '2018-06-09T19:39:28Z', 'uri': 'http://web.archive.org/web/20180609193928/https://www.guideline.gov/summaries/summary/49247/platelet-transfusion-a-clinical-practice-guideline-from-the-aabb'}]
https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930232956/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:29:56Z', 'uri': 'http://web.archive.org/web/20160930232956/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:17:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003031708/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:17:08Z', 'uri': 'http://web.archive.org/web/20171003031708/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:40:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414024012/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:40:12Z', 'uri': 'http://web.archive.org/web/20180414024012/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:32:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519093215/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:32:15Z', 'uri': 'http://web.archive.org/web/20180519093215/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:23Z', 'uri': 'http://web.archive.org/web/20180610010623/https://www.guideline.gov/summaries/summary/49253/androgen-therapy-in-women-a-reappraisal-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930233009/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:30:09Z', 'uri': 'http://web.archive.org/web/20160930233009/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:17:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003031722/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:17:22Z', 'uri': 'http://web.archive.org/web/20171003031722/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:40:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414024031/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:40:31Z', 'uri': 'http://web.archive.org/web/20180414024031/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:32:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519093234/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:32:34Z', 'uri': 'http://web.archive.org/web/20180519093234/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:32Z', 'uri': 'http://web.archive.org/web/20180610010632/https://www.guideline.gov/summaries/summary/49254/pharmacological-management-of-obesity-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930232943/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2016-09-30T23:29:43Z', 'uri': 'http://web.archive.org/web/20160930232943/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2017-10-03T03:16:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003031654/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2017-10-03T03:16:54Z', 'uri': 'http://web.archive.org/web/20171003031654/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2018-04-14T02:39:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414023953/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2018-04-14T02:39:53Z', 'uri': 'http://web.archive.org/web/20180414023953/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2018-05-19T09:31:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519093135/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2018-05-19T09:31:35Z', 'uri': 'http://web.archive.org/web/20180519093135/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}, {'datetime': '2018-06-09T21:45:12Z', 'uri': 'http://web.archive.org/web/20180609214512/https://www.guideline.gov/summaries/summary/49255/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-asymptomatic-neoplastic-pancreatic-cysts'}]
https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930232815/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2016-09-30T23:28:15Z', 'uri': 'http://web.archive.org/web/20160930232815/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2017-10-03T03:15:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003031534/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2017-10-03T03:15:34Z', 'uri': 'http://web.archive.org/web/20171003031534/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2018-04-14T02:38:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414023812/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2018-04-14T02:38:12Z', 'uri': 'http://web.archive.org/web/20180414023812/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2018-05-19T09:29:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519092945/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2018-05-19T09:29:45Z', 'uri': 'http://web.archive.org/web/20180519092945/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}, {'datetime': '2018-06-10T22:25:36Z', 'uri': 'http://web.archive.org/web/20180610222536/https://www.guideline.gov/summaries/summary/49256/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index'}]
https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930232557/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2016-09-30T23:25:57Z', 'uri': 'http://web.archive.org/web/20160930232557/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2017-10-03T03:13:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003031302/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2017-10-03T03:13:02Z', 'uri': 'http://web.archive.org/web/20171003031302/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2018-04-14T02:34:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414023458/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2018-04-14T02:34:58Z', 'uri': 'http://web.archive.org/web/20180414023458/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2018-05-19T09:26:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519092610/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2018-05-19T09:26:10Z', 'uri': 'http://web.archive.org/web/20180519092610/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}, {'datetime': '2018-06-09T22:25:54Z', 'uri': 'http://web.archive.org/web/20180609222554/https://www.guideline.gov/summaries/summary/49257/guidelines-of-care-for-the-management-of-atopic-dermatitis-section-4-prevention-of-disease-flares-and-use-of-adjunctive-therapies-and-approaches'}]
https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930232922/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2016-09-30T23:29:22Z', 'uri': 'http://web.archive.org/web/20160930232922/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2017-10-03T03:16:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003031631/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2017-10-03T03:16:31Z', 'uri': 'http://web.archive.org/web/20171003031631/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2018-04-14T02:39:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414023924/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2018-04-14T02:39:24Z', 'uri': 'http://web.archive.org/web/20180414023924/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2018-05-19T09:31:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519093104/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2018-05-19T09:31:04Z', 'uri': 'http://web.archive.org/web/20180519093104/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}, {'datetime': '2018-06-09T22:00:06Z', 'uri': 'http://web.archive.org/web/20180609220006/https://www.guideline.gov/summaries/summary/49258/clinical-practice-guideline-on-the-management-of-invasive-meningococcal-disease'}]
https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930232857/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2016-09-30T23:28:57Z', 'uri': 'http://web.archive.org/web/20160930232857/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2017-10-03T03:15:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003031555/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2017-10-03T03:15:55Z', 'uri': 'http://web.archive.org/web/20171003031555/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2018-04-14T02:38:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414023840/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2018-04-14T02:38:40Z', 'uri': 'http://web.archive.org/web/20180414023840/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2018-05-19T09:30:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519093013/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2018-05-19T09:30:13Z', 'uri': 'http://web.archive.org/web/20180519093013/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}, {'datetime': '2018-06-10T02:37:15Z', 'uri': 'http://web.archive.org/web/20180610023715/https://www.guideline.gov/summaries/summary/49259/bronchiolitis-in-children'}]
https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930232834/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2016-09-30T23:28:34Z', 'uri': 'http://web.archive.org/web/20160930232834/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2017-10-03T03:16:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003031616/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2017-10-03T03:16:16Z', 'uri': 'http://web.archive.org/web/20171003031616/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2018-04-14T02:39:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414023906/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2018-04-14T02:39:06Z', 'uri': 'http://web.archive.org/web/20180414023906/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2018-05-19T09:30:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519093041/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2018-05-19T09:30:41Z', 'uri': 'http://web.archive.org/web/20180519093041/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}, {'datetime': '2018-06-09T10:35:55Z', 'uri': 'http://web.archive.org/web/20180609103555/https://www.guideline.gov/summaries/summary/49260/anaemia-management-in-people-with-chronic-kidney-disease'}]
https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:30:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930233002/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:30:02Z', 'uri': 'http://web.archive.org/web/20160930233002/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:17:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003031715/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:17:15Z', 'uri': 'http://web.archive.org/web/20171003031715/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:40:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414024021/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:40:21Z', 'uri': 'http://web.archive.org/web/20180414024021/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:32:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519093225/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:32:25Z', 'uri': 'http://web.archive.org/web/20180519093225/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:20Z', 'uri': 'http://web.archive.org/web/20180610010620/https://www.guideline.gov/summaries/summary/49261/pagets-disease-of-bone-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930232841/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2016-09-30T23:28:41Z', 'uri': 'http://web.archive.org/web/20160930232841/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2017-10-03T03:16:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003031602/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2017-10-03T03:16:02Z', 'uri': 'http://web.archive.org/web/20171003031602/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2018-04-14T02:38:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414023849/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2018-04-14T02:38:49Z', 'uri': 'http://web.archive.org/web/20180414023849/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2018-05-19T09:30:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519093023/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2018-05-19T09:30:23Z', 'uri': 'http://web.archive.org/web/20180519093023/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}, {'datetime': '2018-06-09T12:51:06Z', 'uri': 'http://web.archive.org/web/20180609125106/https://www.guideline.gov/summaries/summary/49268/challenging-behaviour-and-learning-disabilities-prevention-and-interventions-for-people-with-learning-disabilities-whose-behaviour-challenges'}]
https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930232808/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2016-09-30T23:28:08Z', 'uri': 'http://web.archive.org/web/20160930232808/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2017-10-03T03:15:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003031525/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2017-10-03T03:15:25Z', 'uri': 'http://web.archive.org/web/20171003031525/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2018-04-14T02:38:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414023804/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2018-04-14T02:38:04Z', 'uri': 'http://web.archive.org/web/20180414023804/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2018-05-19T09:29:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519092936/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2018-05-19T09:29:36Z', 'uri': 'http://web.archive.org/web/20180519092936/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}, {'datetime': '2018-06-09T22:23:57Z', 'uri': 'http://web.archive.org/web/20180609222357/https://www.guideline.gov/summaries/summary/49269/peyronies-disease-aua-guideline'}]
https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930232802/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2016-09-30T23:28:02Z', 'uri': 'http://web.archive.org/web/20160930232802/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2017-10-03T03:15:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003031518/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2017-10-03T03:15:18Z', 'uri': 'http://web.archive.org/web/20171003031518/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2018-04-14T02:37:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414023754/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2018-04-14T02:37:54Z', 'uri': 'http://web.archive.org/web/20180414023754/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2018-05-19T09:29:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519092926/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2018-05-19T09:29:26Z', 'uri': 'http://web.archive.org/web/20180519092926/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}, {'datetime': '2018-06-09T22:23:50Z', 'uri': 'http://web.archive.org/web/20180609222350/https://www.guideline.gov/summaries/summary/49270/castrationresistant-prostate-cancer-aua-guideline'}]
https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930232728/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2016-09-30T23:27:28Z', 'uri': 'http://web.archive.org/web/20160930232728/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2017-10-03T03:14:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003031443/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2017-10-03T03:14:43Z', 'uri': 'http://web.archive.org/web/20171003031443/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2018-04-14T02:37:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414023710/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2018-04-14T02:37:10Z', 'uri': 'http://web.archive.org/web/20180414023710/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2018-05-19T09:28:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519092842/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2018-05-19T09:28:42Z', 'uri': 'http://web.archive.org/web/20180519092842/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}, {'datetime': '2018-06-09T15:15:42Z', 'uri': 'http://web.archive.org/web/20180609151542/https://www.guideline.gov/summaries/summary/49273/lower-urinary-tract-symptoms-in-men-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease	ARCHIVED	12 mementos	[{'datetime': '2016-09-30T23:30:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930233057/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2016-09-30T23:30:57Z', 'uri': 'http://web.archive.org/web/20160930233057/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2017-10-03T03:18:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003031819/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2017-10-03T03:18:19Z', 'uri': 'http://web.archive.org/web/20171003031819/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-03-10T21:39:42Z', 'uri': 'http://web.archive.org/web/20180310213942/https://guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-04-14T02:41:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414024140/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-04-14T02:41:40Z', 'uri': 'http://web.archive.org/web/20180414024140/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-05-19T09:33:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519093354/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-05-19T09:33:54Z', 'uri': 'http://web.archive.org/web/20180519093354/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-06-02T20:42:41Z', 'uri': 'http://web.archive.org/web/20180602204241/https://www.guideline.gov/summaries/summary/49320/Evidence-assessments-and-guideline-recommendations-in-Lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-06-09T10:32:29Z', 'uri': 'http://web.archive.org/web/20180609103229/https://www.guideline.gov/summaries/summary/49320/Evidence-assessments-and-guideline-recommendations-in-Lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}, {'datetime': '2018-06-09T21:56:48Z', 'uri': 'http://web.archive.org/web/20180609215648/https://www.guideline.gov/summaries/summary/49320/evidence-assessments-and-guideline-recommendations-in-lyme-disease-the-clinical-management-of-known-tick-bites-erythema-migrans-rashes-and-persistent-disease'}]
https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930232848/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2016-09-30T23:28:48Z', 'uri': 'http://web.archive.org/web/20160930232848/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2017-10-03T03:16:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003031606/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2017-10-03T03:16:06Z', 'uri': 'http://web.archive.org/web/20171003031606/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2018-04-14T02:38:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414023853/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2018-04-14T02:38:53Z', 'uri': 'http://web.archive.org/web/20180414023853/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2018-05-19T09:30:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519093028/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2018-05-19T09:30:28Z', 'uri': 'http://web.archive.org/web/20180519093028/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}, {'datetime': '2018-06-09T11:57:46Z', 'uri': 'http://web.archive.org/web/20180609115746/https://www.guideline.gov/summaries/summary/49322/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings'}]
https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930232930/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2016-09-30T23:29:30Z', 'uri': 'http://web.archive.org/web/20160930232930/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2017-10-03T03:16:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003031641/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2017-10-03T03:16:41Z', 'uri': 'http://web.archive.org/web/20171003031641/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-04-14T02:39:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414023935/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-04-14T02:39:35Z', 'uri': 'http://web.archive.org/web/20180414023935/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-05-19T09:31:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519093116/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-05-19T09:31:16Z', 'uri': 'http://web.archive.org/web/20180519093116/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-06-10T23:04:38Z', 'uri': 'http://web.archive.org/web/20180610230438/https://www.guideline.gov/summaries/summary/49333/obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia'}]
https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930232936/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2016-09-30T23:29:36Z', 'uri': 'http://web.archive.org/web/20160930232936/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2017-10-03T03:16:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003031647/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2017-10-03T03:16:47Z', 'uri': 'http://web.archive.org/web/20171003031647/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-04-14T02:39:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414023944/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-04-14T02:39:44Z', 'uri': 'http://web.archive.org/web/20180414023944/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-05-19T09:31:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519093125/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-05-19T09:31:25Z', 'uri': 'http://web.archive.org/web/20180519093125/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}, {'datetime': '2018-06-11T08:42:43Z', 'uri': 'http://web.archive.org/web/20180611084243/https://www.guideline.gov/summaries/summary/49334/ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia'}]
https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:29:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930232904/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2016-09-30T23:29:04Z', 'uri': 'http://web.archive.org/web/20160930232904/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2017-10-03T03:16:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003031619/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2017-10-03T03:16:19Z', 'uri': 'http://web.archive.org/web/20171003031619/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2018-04-14T02:39:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414023910/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2018-04-14T02:39:10Z', 'uri': 'http://web.archive.org/web/20180414023910/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2018-05-19T09:30:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519093046/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2018-05-19T09:30:46Z', 'uri': 'http://web.archive.org/web/20180519093046/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}, {'datetime': '2018-06-09T20:36:03Z', 'uri': 'http://web.archive.org/web/20180609203603/https://www.guideline.gov/summaries/summary/49353/a-clinical-practice-guideline-for-the-use-of-hyperbaric-oxygen-therapy-in-the-treatment-of-diabetic-foot-ulcers'}]
https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930232650/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2016-09-30T23:26:50Z', 'uri': 'http://web.archive.org/web/20160930232650/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2017-10-03T03:13:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003031359/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2017-10-03T03:13:59Z', 'uri': 'http://web.archive.org/web/20171003031359/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2018-04-14T02:36:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414023615/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2018-04-14T02:36:15Z', 'uri': 'http://web.archive.org/web/20180414023615/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2018-05-19T09:27:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519092742/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2018-05-19T09:27:42Z', 'uri': 'http://web.archive.org/web/20180519092742/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}, {'datetime': '2018-06-10T23:03:29Z', 'uri': 'http://web.archive.org/web/20180610230329/https://www.guideline.gov/summaries/summary/49354/systemic-therapy-for-well-and-moderately-differentiated-unresectable-pancreatic-neuroendocrine-tumours'}]
https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930232643/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2016-09-30T23:26:43Z', 'uri': 'http://web.archive.org/web/20160930232643/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2017-10-03T03:13:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003031353/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2017-10-03T03:13:53Z', 'uri': 'http://web.archive.org/web/20171003031353/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2018-04-14T02:36:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414023606/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2018-04-14T02:36:06Z', 'uri': 'http://web.archive.org/web/20180414023606/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2018-05-19T09:27:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519092733/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2018-05-19T09:27:33Z', 'uri': 'http://web.archive.org/web/20180519092733/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}, {'datetime': '2018-06-09T20:55:34Z', 'uri': 'http://web.archive.org/web/20180609205534/https://www.guideline.gov/summaries/summary/49355/management-of-malignant-pleural-effusion'}]
https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930232821/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2016-09-30T23:28:21Z', 'uri': 'http://web.archive.org/web/20160930232821/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2017-10-03T03:15:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003031542/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2017-10-03T03:15:42Z', 'uri': 'http://web.archive.org/web/20171003031542/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2018-04-14T02:38:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414023821/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2018-04-14T02:38:21Z', 'uri': 'http://web.archive.org/web/20180414023821/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2018-05-19T09:29:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519092954/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2018-05-19T09:29:54Z', 'uri': 'http://web.archive.org/web/20180519092954/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}, {'datetime': '2018-06-09T11:58:33Z', 'uri': 'http://web.archive.org/web/20180609115833/https://www.guideline.gov/summaries/summary/49419/engaging-clients-who-use-substances'}]
https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:28:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930232827/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:28:27Z', 'uri': 'http://web.archive.org/web/20160930232827/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:15:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003031548/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:15:48Z', 'uri': 'http://web.archive.org/web/20171003031548/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2018-04-14T02:38:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414023830/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2018-04-14T02:38:30Z', 'uri': 'http://web.archive.org/web/20180414023830/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2018-05-19T09:30:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519093003/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2018-05-19T09:30:03Z', 'uri': 'http://web.archive.org/web/20180519093003/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}, {'datetime': '2018-06-09T19:20:28Z', 'uri': 'http://web.archive.org/web/20180609192028/https://www.guideline.gov/summaries/summary/49421/management-of-primary-cutaneous-squamous-cell-carcinoma-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:27:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930232736/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2016-09-30T23:27:36Z', 'uri': 'http://web.archive.org/web/20160930232736/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2017-10-03T03:14:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003031453/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2017-10-03T03:14:53Z', 'uri': 'http://web.archive.org/web/20171003031453/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2017-11-17T06:36:56Z', 'uri': 'http://web.archive.org/web/20171117063656/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2018-04-14T02:37:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414023723/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2018-04-14T02:37:23Z', 'uri': 'http://web.archive.org/web/20180414023723/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2018-05-19T09:28:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519092854/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2018-05-19T09:28:54Z', 'uri': 'http://web.archive.org/web/20180519092854/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}, {'datetime': '2018-06-10T00:23:14Z', 'uri': 'http://web.archive.org/web/20180610002314/https://www.guideline.gov/summaries/summary/49436/suspected-cancer-recognition-and-referral'}]
https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:32:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930163227/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2016-09-30T16:32:27Z', 'uri': 'http://web.archive.org/web/20160930163227/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2017-10-02T20:11:45Z', 'uri': 'http://wayback.archive-it.org/all/20171002201145/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2017-10-02T20:11:45Z', 'uri': 'http://web.archive.org/web/20171002201145/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2018-04-14T00:47:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414004744/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2018-04-14T00:47:44Z', 'uri': 'http://web.archive.org/web/20180414004744/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2018-05-18T22:05:06Z', 'uri': 'http://wayback.archive-it.org/all/20180518220506/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2018-05-18T22:05:06Z', 'uri': 'http://web.archive.org/web/20180518220506/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}, {'datetime': '2018-06-09T23:20:53Z', 'uri': 'http://web.archive.org/web/20180609232053/https://www.guideline.gov/summaries/summary/49437/venous-thromboembolism-in-adults-admitted-to-hospital-reducing-the-risk'}]
https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930232539/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2016-09-30T23:25:39Z', 'uri': 'http://web.archive.org/web/20160930232539/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2017-10-03T03:12:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003031243/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2017-10-03T03:12:43Z', 'uri': 'http://web.archive.org/web/20171003031243/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-04-14T02:34:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414023432/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-04-14T02:34:32Z', 'uri': 'http://web.archive.org/web/20180414023432/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-05-19T09:25:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519092542/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-05-19T09:25:42Z', 'uri': 'http://web.archive.org/web/20180519092542/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}, {'datetime': '2018-06-10T01:40:19Z', 'uri': 'http://web.archive.org/web/20180610014019/https://www.guideline.gov/summaries/summary/49453/intravesical-instillation-with-mitomycin-c-or-bacillus-calmettegu-rin-in-nonmuscle-invasive-bladder-cancer'}]
https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930232743/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:27:43Z', 'uri': 'http://web.archive.org/web/20160930232743/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:14:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003031456/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:14:56Z', 'uri': 'http://web.archive.org/web/20171003031456/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:37:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414023726/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:37:26Z', 'uri': 'http://web.archive.org/web/20180414023726/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:28:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519092857/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:28:57Z', 'uri': 'http://web.archive.org/web/20180519092857/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T15:22:26Z', 'uri': 'http://web.archive.org/web/20180610152226/https://www.guideline.gov/summaries/summary/49454/screening-for-speech-and-language-delay-and-disorders-in-children-aged-5-years-or-younger-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930232702/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:27:02Z', 'uri': 'http://web.archive.org/web/20160930232702/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:14:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003031413/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:14:13Z', 'uri': 'http://web.archive.org/web/20171003031413/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:36:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414023634/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:36:34Z', 'uri': 'http://web.archive.org/web/20180414023634/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:28:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519092802/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:28:02Z', 'uri': 'http://web.archive.org/web/20180519092802/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:09:01Z', 'uri': 'http://web.archive.org/web/20180609220901/https://www.guideline.gov/summaries/summary/49455/definitive-and-adjuvant-radiotherapy-in-locally-advanced-nonsmall-cell-lung-cancer-an-american-society-for-radiation-oncology-astro-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930232637/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2016-09-30T23:26:37Z', 'uri': 'http://web.archive.org/web/20160930232637/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T03:13:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003031346/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T03:13:46Z', 'uri': 'http://web.archive.org/web/20171003031346/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:35:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414023557/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:35:57Z', 'uri': 'http://web.archive.org/web/20180414023557/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:27:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519092724/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:27:24Z', 'uri': 'http://web.archive.org/web/20180519092724/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T20:51:12Z', 'uri': 'http://web.archive.org/web/20180609205112/https://www.guideline.gov/summaries/summary/49457/tools-for-assessing-outcomes-in-studies-of-chronic-cough-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930232631/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2016-09-30T23:26:31Z', 'uri': 'http://web.archive.org/web/20160930232631/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T03:13:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003031340/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T03:13:40Z', 'uri': 'http://web.archive.org/web/20171003031340/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:35:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414023547/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:35:47Z', 'uri': 'http://web.archive.org/web/20180414023547/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:27:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519092715/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:27:15Z', 'uri': 'http://web.archive.org/web/20180519092715/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T11:55:39Z', 'uri': 'http://web.archive.org/web/20180609115539/https://www.guideline.gov/summaries/summary/49458/somatic-cough-syndrome-previously-referred-to-as-psychogenic-cough-and-tic-cough-previously-referred-to-as-habit-cough-in-adults-and-children-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930232427/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2016-09-30T23:24:27Z', 'uri': 'http://web.archive.org/web/20160930232427/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2017-10-03T03:11:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003031112/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2017-10-03T03:11:12Z', 'uri': 'http://web.archive.org/web/20171003031112/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2018-04-14T02:32:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414023247/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2018-04-14T02:32:47Z', 'uri': 'http://web.archive.org/web/20180414023247/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2018-05-19T09:23:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519092356/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2018-05-19T09:23:56Z', 'uri': 'http://web.archive.org/web/20180519092356/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}, {'datetime': '2018-06-10T00:47:42Z', 'uri': 'http://web.archive.org/web/20180610004742/https://www.guideline.gov/summaries/summary/49464/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-2-management-of-posthemorrhagic-hydrocephalus-in-premature-infants'}]
https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930232433/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2016-09-30T23:24:33Z', 'uri': 'http://web.archive.org/web/20160930232433/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2017-10-03T03:11:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003031119/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2017-10-03T03:11:19Z', 'uri': 'http://web.archive.org/web/20171003031119/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2018-04-14T02:32:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414023255/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2018-04-14T02:32:55Z', 'uri': 'http://web.archive.org/web/20180414023255/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2018-05-19T09:24:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519092405/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2018-05-19T09:24:05Z', 'uri': 'http://web.archive.org/web/20180519092405/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}, {'datetime': '2018-06-10T23:17:19Z', 'uri': 'http://web.archive.org/web/20180610231719/https://www.guideline.gov/summaries/summary/49465/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-3-endoscopic-computerassisted-electromagnetic-navigation-and-ultrasonography-as-technical-adjuvants-for-shunt-placement'}]
https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930232440/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2016-09-30T23:24:40Z', 'uri': 'http://web.archive.org/web/20160930232440/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2017-10-03T03:11:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003031126/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2017-10-03T03:11:26Z', 'uri': 'http://web.archive.org/web/20171003031126/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2018-04-14T02:33:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414023302/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2018-04-14T02:33:02Z', 'uri': 'http://web.archive.org/web/20180414023302/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2018-05-19T09:24:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519092416/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2018-05-19T09:24:16Z', 'uri': 'http://web.archive.org/web/20180519092416/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}, {'datetime': '2018-06-10T23:25:40Z', 'uri': 'http://web.archive.org/web/20180610232540/https://www.guideline.gov/summaries/summary/49466/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-4-cerebrospinal-fluid-shunt-or-endoscopic-third-ventriculostomy-for-the-treatment-of-hydrocephalus-in-children'}]
https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930232446/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2016-09-30T23:24:46Z', 'uri': 'http://web.archive.org/web/20160930232446/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2017-10-03T03:11:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003031133/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2017-10-03T03:11:33Z', 'uri': 'http://web.archive.org/web/20171003031133/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2018-04-14T02:33:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414023310/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2018-04-14T02:33:10Z', 'uri': 'http://web.archive.org/web/20180414023310/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2018-05-19T09:24:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519092425/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2018-05-19T09:24:25Z', 'uri': 'http://web.archive.org/web/20180519092425/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}, {'datetime': '2018-06-09T19:48:15Z', 'uri': 'http://web.archive.org/web/20180609194815/https://www.guideline.gov/summaries/summary/49467/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-5-effect-of-valve-type-on-cerebrospinal-fluid-shunt-efficacy'}]
https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930232452/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2016-09-30T23:24:52Z', 'uri': 'http://web.archive.org/web/20160930232452/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T03:11:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003031139/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T03:11:39Z', 'uri': 'http://web.archive.org/web/20171003031139/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T02:33:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414023321/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T02:33:21Z', 'uri': 'http://web.archive.org/web/20180414023321/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T09:24:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519092434/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T09:24:34Z', 'uri': 'http://web.archive.org/web/20180519092434/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-06-10T23:17:19Z', 'uri': 'http://web.archive.org/web/20180610231719/https://www.guideline.gov/summaries/summary/49468/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-6-preoperative-antibiotics-for-shunt-surgery-in-children-with-hydrocephalus-a-systematic-review-and-metaanalysis'}]
https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930232407/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2016-09-30T23:24:07Z', 'uri': 'http://web.archive.org/web/20160930232407/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2017-10-03T03:10:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003031058/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2017-10-03T03:10:58Z', 'uri': 'http://web.archive.org/web/20171003031058/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2018-04-14T02:32:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414023230/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2018-04-14T02:32:30Z', 'uri': 'http://web.archive.org/web/20180414023230/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2018-05-19T09:23:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519092337/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2018-05-19T09:23:37Z', 'uri': 'http://web.archive.org/web/20180519092337/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}, {'datetime': '2018-06-09T19:21:41Z', 'uri': 'http://web.archive.org/web/20180609192141/https://www.guideline.gov/summaries/summary/49469/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-8-management-of-cerebrospinal-fluid-shunt-infection'}]
https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930232401/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2016-09-30T23:24:01Z', 'uri': 'http://web.archive.org/web/20160930232401/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T03:10:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003031052/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T03:10:52Z', 'uri': 'http://web.archive.org/web/20171003031052/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T02:32:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414023221/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T02:32:21Z', 'uri': 'http://web.archive.org/web/20180414023221/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T09:23:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519092328/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T09:23:28Z', 'uri': 'http://web.archive.org/web/20180519092328/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}, {'datetime': '2018-06-09T19:48:23Z', 'uri': 'http://web.archive.org/web/20180609194823/https://www.guideline.gov/summaries/summary/49470/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-7-antibioticimpregnated-shunt-systems-versus-conventional-shunts-in-children-a-systematic-review-and-metaanalysis'}]
https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930232413/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2016-09-30T23:24:13Z', 'uri': 'http://web.archive.org/web/20160930232413/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2017-10-03T03:11:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003031105/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2017-10-03T03:11:05Z', 'uri': 'http://web.archive.org/web/20171003031105/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2018-04-14T02:32:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414023240/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2018-04-14T02:32:40Z', 'uri': 'http://web.archive.org/web/20180414023240/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2018-05-19T09:23:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519092346/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2018-05-19T09:23:46Z', 'uri': 'http://web.archive.org/web/20180519092346/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}, {'datetime': '2018-06-10T22:45:17Z', 'uri': 'http://web.archive.org/web/20180610224517/https://www.guideline.gov/summaries/summary/49471/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-9-effect-of-ventricular-catheter-entry-point-and-position'}]
https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:23:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930232354/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2016-09-30T23:23:54Z', 'uri': 'http://web.archive.org/web/20160930232354/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2017-10-02T20:07:32Z', 'uri': 'http://wayback.archive-it.org/all/20171002200732/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2017-10-02T20:07:32Z', 'uri': 'http://web.archive.org/web/20171002200732/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2018-04-14T02:32:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414023212/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2018-04-14T02:32:12Z', 'uri': 'http://web.archive.org/web/20180414023212/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2018-05-18T19:33:36Z', 'uri': 'http://wayback.archive-it.org/all/20180518193336/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2018-05-18T19:33:36Z', 'uri': 'http://web.archive.org/web/20180518193336/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}, {'datetime': '2018-06-09T10:40:57Z', 'uri': 'http://web.archive.org/web/20180609104057/https://www.guideline.gov/summaries/summary/49472/pediatric-hydrocephalus-systematic-literature-review-and-evidencebased-guidelines-part-10-change-in-ventricle-size-as-a-measurement-of-effective-treatment-of-hydrocephalus'}]
https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930232655/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2016-09-30T23:26:55Z', 'uri': 'http://web.archive.org/web/20160930232655/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2017-10-03T03:14:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003031405/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2017-10-03T03:14:05Z', 'uri': 'http://web.archive.org/web/20171003031405/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2018-04-14T02:36:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414023624/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2018-04-14T02:36:24Z', 'uri': 'http://web.archive.org/web/20180414023624/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2018-05-19T09:27:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519092751/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2018-05-19T09:27:51Z', 'uri': 'http://web.archive.org/web/20180519092751/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}, {'datetime': '2018-06-09T12:51:08Z', 'uri': 'http://web.archive.org/web/20180609125108/https://www.guideline.gov/summaries/summary/49474/clinical-practice-guideline-on-the-management-of-depression-in-adults'}]
https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:25:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930232505/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2016-09-30T23:25:05Z', 'uri': 'http://web.archive.org/web/20160930232505/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2017-10-03T03:12:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003031210/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2017-10-03T03:12:10Z', 'uri': 'http://web.archive.org/web/20171003031210/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2017-11-17T07:17:48Z', 'uri': 'http://web.archive.org/web/20171117071748/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2018-04-14T02:33:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414023339/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2018-04-14T02:33:39Z', 'uri': 'http://web.archive.org/web/20180414023339/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2018-05-19T09:24:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519092454/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2018-05-19T09:24:54Z', 'uri': 'http://web.archive.org/web/20180519092454/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}, {'datetime': '2018-06-09T20:54:59Z', 'uri': 'http://web.archive.org/web/20180609205459/https://www.guideline.gov/summaries/summary/49475/evidencebased-clinical-practice-guideline-on-the-nonsurgical-treatment-of-chronic-periodontitis-by-means-of-scaling-and-root-planing-with-or-without-adjuncts'}]
https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930232519/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2016-09-30T23:25:19Z', 'uri': 'http://web.archive.org/web/20160930232519/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2017-10-03T03:12:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003031222/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2017-10-03T03:12:22Z', 'uri': 'http://web.archive.org/web/20171003031222/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2018-04-14T02:34:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414023405/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2018-04-14T02:34:05Z', 'uri': 'http://web.archive.org/web/20180414023405/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2018-05-19T09:25:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519092512/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2018-05-19T09:25:12Z', 'uri': 'http://web.archive.org/web/20180519092512/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}, {'datetime': '2018-06-09T15:26:13Z', 'uri': 'http://web.archive.org/web/20180609152613/https://www.guideline.gov/summaries/summary/49476/preventing-and-addressing-abuse-and-neglect-of-older-adults-personcentred-collaborative-systemwide-approaches'}]
https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930232140/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2016-09-30T23:21:40Z', 'uri': 'http://web.archive.org/web/20160930232140/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2017-10-03T03:10:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003031007/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2017-10-03T03:10:07Z', 'uri': 'http://web.archive.org/web/20171003031007/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2018-04-14T02:31:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414023125/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2018-04-14T02:31:25Z', 'uri': 'http://web.archive.org/web/20180414023125/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2018-05-19T09:22:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519092232/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2018-05-19T09:22:32Z', 'uri': 'http://web.archive.org/web/20180519092232/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}, {'datetime': '2018-06-10T01:37:41Z', 'uri': 'http://web.archive.org/web/20180610013741/https://www.guideline.gov/summaries/summary/49477/society-for-vascular-surgery-practice-guidelines-for-atherosclerotic-occlusive-disease-of-the-lower-extremities-management-of-asymptomatic-disease-and-claudication'}]
https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930232133/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2016-09-30T23:21:33Z', 'uri': 'http://web.archive.org/web/20160930232133/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2017-10-03T03:09:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003030959/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2017-10-03T03:09:59Z', 'uri': 'http://web.archive.org/web/20171003030959/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-04-14T02:31:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414023116/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-04-14T02:31:16Z', 'uri': 'http://web.archive.org/web/20180414023116/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-05-19T09:22:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519092221/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-05-19T09:22:21Z', 'uri': 'http://web.archive.org/web/20180519092221/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}, {'datetime': '2018-06-09T21:39:59Z', 'uri': 'http://web.archive.org/web/20180609213959/https://www.guideline.gov/summaries/summary/49478/management-of-venous-leg-ulcers-clinical-practice-guidelines-of-the-society-for-vascular-surgery-and-the-american-venous-forum'}]
https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930232617/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2016-09-30T23:26:17Z', 'uri': 'http://web.archive.org/web/20160930232617/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T03:13:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003031326/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T03:13:26Z', 'uri': 'http://web.archive.org/web/20171003031326/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T02:35:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414023528/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T02:35:28Z', 'uri': 'http://web.archive.org/web/20180414023528/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T09:26:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519092641/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T09:26:41Z', 'uri': 'http://web.archive.org/web/20180519092641/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T23:04:11Z', 'uri': 'http://web.archive.org/web/20180610230411/https://www.guideline.gov/summaries/summary/49479/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930232715/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2016-09-30T23:27:15Z', 'uri': 'http://web.archive.org/web/20160930232715/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2017-10-03T03:14:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003031427/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2017-10-03T03:14:27Z', 'uri': 'http://web.archive.org/web/20171003031427/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2018-04-14T02:36:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414023650/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2018-04-14T02:36:50Z', 'uri': 'http://web.archive.org/web/20180414023650/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2018-05-19T09:28:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519092821/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2018-05-19T09:28:21Z', 'uri': 'http://web.archive.org/web/20180519092821/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}, {'datetime': '2018-06-10T00:05:17Z', 'uri': 'http://web.archive.org/web/20180610000517/https://www.guideline.gov/summaries/summary/49480/naloxegol-for-treating-opioidinduced-constipation'}]
https://www.guideline.gov/summaries/summary/49491/care-transitions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930232552/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2016-09-30T23:25:52Z', 'uri': 'http://web.archive.org/web/20160930232552/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2017-10-03T03:12:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003031257/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2017-10-03T03:12:57Z', 'uri': 'http://web.archive.org/web/20171003031257/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2018-04-14T02:34:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414023450/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2018-04-14T02:34:50Z', 'uri': 'http://web.archive.org/web/20180414023450/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2018-05-19T09:26:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519092600/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2018-05-19T09:26:00Z', 'uri': 'http://web.archive.org/web/20180519092600/https://www.guideline.gov/summaries/summary/49491/care-transitions'}, {'datetime': '2018-06-10T01:22:11Z', 'uri': 'http://web.archive.org/web/20180610012211/https://www.guideline.gov/summaries/summary/49491/care-transitions'}]
https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:21:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930232116/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2016-09-30T23:21:16Z', 'uri': 'http://web.archive.org/web/20160930232116/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2017-10-03T03:09:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003030940/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2017-10-03T03:09:40Z', 'uri': 'http://web.archive.org/web/20171003030940/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2018-04-14T02:30:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414023055/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2018-04-14T02:30:55Z', 'uri': 'http://web.archive.org/web/20180414023055/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2018-05-19T09:21:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519092146/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2018-05-19T09:21:46Z', 'uri': 'http://web.archive.org/web/20180519092146/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2018-06-09T19:11:10Z', 'uri': 'http://web.archive.org/web/20180609191110/https://www.guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}, {'datetime': '2018-06-15T12:55:35Z', 'uri': 'http://web.archive.org/web/20180615125535/https://guideline.gov/summaries/summary/49492/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp3a5-genotype-and-tacrolimus-dosing'}]
https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:53:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930225315/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2016-09-30T22:53:15Z', 'uri': 'http://web.archive.org/web/20160930225315/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2017-10-03T02:08:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003020809/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2017-10-03T02:08:09Z', 'uri': 'http://web.archive.org/web/20171003020809/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-04-14T00:57:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414005719/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-04-14T00:57:19Z', 'uri': 'http://web.archive.org/web/20180414005719/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-05-19T07:36:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519073644/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-05-19T07:36:44Z', 'uri': 'http://web.archive.org/web/20180519073644/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}, {'datetime': '2018-06-09T15:28:26Z', 'uri': 'http://web.archive.org/web/20180609152826/https://www.guideline.gov/summaries/summary/49493/aarc-clinical-practice-guideline-effectiveness-of-pharmacologic-airway-clearance-therapies-in-hospitalized-patients'}]
https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930232708/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2016-09-30T23:27:08Z', 'uri': 'http://web.archive.org/web/20160930232708/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2017-10-03T03:14:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003031420/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2017-10-03T03:14:20Z', 'uri': 'http://web.archive.org/web/20171003031420/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-04-14T02:36:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414023642/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-04-14T02:36:42Z', 'uri': 'http://web.archive.org/web/20180414023642/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-05-19T09:28:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519092811/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-05-19T09:28:11Z', 'uri': 'http://web.archive.org/web/20180519092811/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-06-11T07:03:24Z', 'uri': 'http://web.archive.org/web/20180611070324/https://www.guideline.gov/summaries/summary/49494/aflibercept-for-treating-diabetic-macular-oedema'}]
https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930232512/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2016-09-30T23:25:12Z', 'uri': 'http://web.archive.org/web/20160930232512/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2017-10-02T20:05:41Z', 'uri': 'http://wayback.archive-it.org/all/20171002200541/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2017-10-02T20:05:41Z', 'uri': 'http://web.archive.org/web/20171002200541/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2018-04-14T02:33:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414023357/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2018-04-14T02:33:57Z', 'uri': 'http://web.archive.org/web/20180414023357/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2018-05-18T19:31:13Z', 'uri': 'http://wayback.archive-it.org/all/20180518193113/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2018-05-18T19:31:13Z', 'uri': 'http://web.archive.org/web/20180518193113/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}, {'datetime': '2018-06-09T10:39:19Z', 'uri': 'http://web.archive.org/web/20180609103919/https://www.guideline.gov/summaries/summary/49495/clinical-practice-guideline-on-management-of-patients-with-diabetes-and-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin'}]
https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930232755/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2016-09-30T23:27:55Z', 'uri': 'http://web.archive.org/web/20160930232755/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2017-10-03T03:15:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003031510/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2017-10-03T03:15:10Z', 'uri': 'http://web.archive.org/web/20171003031510/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2018-04-14T02:37:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414023745/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2018-04-14T02:37:45Z', 'uri': 'http://web.archive.org/web/20180414023745/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2018-05-19T09:29:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519092916/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2018-05-19T09:29:16Z', 'uri': 'http://web.archive.org/web/20180519092916/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}, {'datetime': '2018-06-09T22:05:34Z', 'uri': 'http://web.archive.org/web/20180609220534/https://www.guideline.gov/summaries/summary/49520/who-guidelines-for-treatment-of-cervical-intraepithelial-neoplasia-23-and-adenocarcinoma-in-situ-cryotherapy-large-loop-excision-of-the-transformation-zone-and-cold-knife-conization'}]
https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:27:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930232749/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2016-09-30T23:27:49Z', 'uri': 'http://web.archive.org/web/20160930232749/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2017-10-03T03:15:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003031504/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2017-10-03T03:15:04Z', 'uri': 'http://web.archive.org/web/20171003031504/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2018-04-14T02:37:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414023735/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2018-04-14T02:37:35Z', 'uri': 'http://web.archive.org/web/20180414023735/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2018-05-19T09:29:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519092907/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2018-05-19T09:29:07Z', 'uri': 'http://web.archive.org/web/20180519092907/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}, {'datetime': '2018-06-09T21:00:35Z', 'uri': 'http://web.archive.org/web/20180609210035/https://www.guideline.gov/summaries/summary/49521/who-guidelines-for-screening-and-treatment-of-precancerous-lesions-for-cervical-cancer-prevention'}]
https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:24:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930232458/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2016-09-30T23:24:58Z', 'uri': 'http://web.archive.org/web/20160930232458/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2017-10-03T03:11:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003031146/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2017-10-03T03:11:46Z', 'uri': 'http://web.archive.org/web/20171003031146/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2018-04-14T02:33:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414023330/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2018-04-14T02:33:30Z', 'uri': 'http://web.archive.org/web/20180414023330/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2018-05-19T09:24:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519092443/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2018-05-19T09:24:43Z', 'uri': 'http://web.archive.org/web/20180519092443/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}, {'datetime': '2018-06-10T01:15:55Z', 'uri': 'http://web.archive.org/web/20180610011555/https://www.guideline.gov/summaries/summary/49522/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-the-treatment-of-pediatric-diaphyseal-femur-fractures'}]
https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930232043/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2016-09-30T23:20:43Z', 'uri': 'http://web.archive.org/web/20160930232043/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2017-10-03T03:09:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003030904/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2017-10-03T03:09:04Z', 'uri': 'http://web.archive.org/web/20171003030904/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2018-04-14T02:30:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414023010/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2018-04-14T02:30:10Z', 'uri': 'http://web.archive.org/web/20180414023010/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2018-05-19T09:20:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519092057/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2018-05-19T09:20:57Z', 'uri': 'http://web.archive.org/web/20180519092057/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}, {'datetime': '2018-06-09T21:57:16Z', 'uri': 'http://web.archive.org/web/20180609215716/https://www.guideline.gov/summaries/summary/49524/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-facioscapulohumeral-muscular-dystrophy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-'}]
https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:53:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930225333/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2016-09-30T22:53:33Z', 'uri': 'http://web.archive.org/web/20160930225333/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2017-10-03T02:08:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003020829/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2017-10-03T02:08:29Z', 'uri': 'http://web.archive.org/web/20171003020829/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2018-04-14T00:57:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414005739/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2018-04-14T00:57:39Z', 'uri': 'http://web.archive.org/web/20180414005739/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2018-05-19T07:37:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519073718/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2018-05-19T07:37:18Z', 'uri': 'http://web.archive.org/web/20180519073718/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}, {'datetime': '2018-06-10T12:09:59Z', 'uri': 'http://web.archive.org/web/20180610120959/https://www.guideline.gov/summaries/summary/49525/everolimus-for-preventing-organ-rejection-in-liver-transplantation'}]
https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:53:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930225327/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2016-09-30T22:53:27Z', 'uri': 'http://web.archive.org/web/20160930225327/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2017-10-03T02:08:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003020822/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2017-10-03T02:08:22Z', 'uri': 'http://web.archive.org/web/20171003020822/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-04-14T00:57:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414005732/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-04-14T00:57:32Z', 'uri': 'http://web.archive.org/web/20180414005732/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-05-19T07:37:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519073709/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-05-19T07:37:09Z', 'uri': 'http://web.archive.org/web/20180519073709/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}, {'datetime': '2018-06-09T15:45:25Z', 'uri': 'http://web.archive.org/web/20180609154525/https://www.guideline.gov/summaries/summary/49526/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema'}]
https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930232533/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2016-09-30T23:25:33Z', 'uri': 'http://web.archive.org/web/20160930232533/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2017-10-03T03:12:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003031235/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2017-10-03T03:12:35Z', 'uri': 'http://web.archive.org/web/20171003031235/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2018-04-14T02:34:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414023423/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2018-04-14T02:34:23Z', 'uri': 'http://web.archive.org/web/20180414023423/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2018-05-19T09:25:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519092532/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2018-05-19T09:25:32Z', 'uri': 'http://web.archive.org/web/20180519092532/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}, {'datetime': '2018-06-09T12:09:59Z', 'uri': 'http://web.archive.org/web/20180609120959/https://www.guideline.gov/summaries/summary/49527/practice-guidelines-for-the-psychiatric-evaluation-of-adults-third-edition'}]
https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930232624/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:26:24Z', 'uri': 'http://web.archive.org/web/20160930232624/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:13:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003031333/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:13:33Z', 'uri': 'http://web.archive.org/web/20171003031333/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:35:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414023538/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:35:38Z', 'uri': 'http://web.archive.org/web/20180414023538/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:26:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519092651/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:26:51Z', 'uri': 'http://web.archive.org/web/20180519092651/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T22:46:40Z', 'uri': 'http://web.archive.org/web/20180610224640/https://www.guideline.gov/summaries/summary/49528/use-of-biomarkers-to-guide-decisions-on-systemic-therapy-for-women-with-metastatic-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930232147/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2016-09-30T23:21:47Z', 'uri': 'http://web.archive.org/web/20160930232147/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2017-10-03T03:10:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003031033/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2017-10-03T03:10:33Z', 'uri': 'http://web.archive.org/web/20171003031033/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2018-04-14T02:31:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414023148/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2018-04-14T02:31:48Z', 'uri': 'http://web.archive.org/web/20180414023148/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2018-05-19T09:22:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519092257/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2018-05-19T09:22:57Z', 'uri': 'http://web.archive.org/web/20180519092257/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}, {'datetime': '2018-06-09T22:42:46Z', 'uri': 'http://web.archive.org/web/20180609224246/https://www.guideline.gov/summaries/summary/49529/type-1-diabetes-in-adults-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:22:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930232202/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2016-09-30T23:22:02Z', 'uri': 'http://web.archive.org/web/20160930232202/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2017-01-01T08:05:36Z', 'uri': 'http://web.archive.org/web/20170101080536/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2017-10-03T03:10:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003031016/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2017-10-03T03:10:16Z', 'uri': 'http://web.archive.org/web/20171003031016/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2018-04-14T02:31:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414023135/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2018-04-14T02:31:35Z', 'uri': 'http://web.archive.org/web/20180414023135/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2018-05-19T09:22:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519092241/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2018-05-19T09:22:41Z', 'uri': 'http://web.archive.org/web/20180519092241/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}, {'datetime': '2018-06-09T20:20:32Z', 'uri': 'http://web.archive.org/web/20180609202032/https://www.guideline.gov/summaries/summary/49530/diabetes-type-1-and-type-2-in-children-and-young-people-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930232155/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2016-09-30T23:21:55Z', 'uri': 'http://web.archive.org/web/20160930232155/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2017-10-03T03:10:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003031026/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2017-10-03T03:10:26Z', 'uri': 'http://web.archive.org/web/20171003031026/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2018-04-14T02:31:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414023139/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2018-04-14T02:31:39Z', 'uri': 'http://web.archive.org/web/20180414023139/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2018-05-19T09:22:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519092246/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2018-05-19T09:22:46Z', 'uri': 'http://web.archive.org/web/20180519092246/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}, {'datetime': '2018-06-10T18:38:40Z', 'uri': 'http://web.archive.org/web/20180610183840/https://www.guideline.gov/summaries/summary/49531/melanoma-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930232604/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2016-09-30T23:26:04Z', 'uri': 'http://web.archive.org/web/20160930232604/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2017-10-03T03:13:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003031311/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2017-10-03T03:13:11Z', 'uri': 'http://web.archive.org/web/20171003031311/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2018-04-14T02:35:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414023510/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2018-04-14T02:35:10Z', 'uri': 'http://web.archive.org/web/20180414023510/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2018-05-19T09:26:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519092623/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2018-05-19T09:26:23Z', 'uri': 'http://web.archive.org/web/20180519092623/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}, {'datetime': '2018-06-09T10:36:33Z', 'uri': 'http://web.archive.org/web/20180609103633/https://www.guideline.gov/summaries/summary/49532/occupational-therapy-practice-guidelines-for-adults-with-stroke'}]
https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:26:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930232611/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2016-09-30T23:26:11Z', 'uri': 'http://web.archive.org/web/20160930232611/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2017-10-03T03:13:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003031318/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2017-10-03T03:13:18Z', 'uri': 'http://web.archive.org/web/20171003031318/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2018-04-14T02:35:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414023519/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2018-04-14T02:35:19Z', 'uri': 'http://web.archive.org/web/20180414023519/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2018-05-19T09:26:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519092632/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2018-05-19T09:26:32Z', 'uri': 'http://web.archive.org/web/20180519092632/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}, {'datetime': '2018-06-09T12:01:02Z', 'uri': 'http://web.archive.org/web/20180609120102/https://www.guideline.gov/summaries/summary/49533/occupational-therapy-practice-guidelines-for-driving-and-community-mobility-for-older-adults'}]
https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930232526/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2016-09-30T23:25:26Z', 'uri': 'http://web.archive.org/web/20160930232526/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2017-10-03T03:12:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003031228/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2017-10-03T03:12:28Z', 'uri': 'http://web.archive.org/web/20171003031228/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2018-04-14T02:34:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414023414/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2018-04-14T02:34:14Z', 'uri': 'http://web.archive.org/web/20180414023414/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2018-05-19T09:25:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519092521/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2018-05-19T09:25:21Z', 'uri': 'http://web.archive.org/web/20180519092521/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}, {'datetime': '2018-06-09T21:39:44Z', 'uri': 'http://web.archive.org/web/20180609213944/https://www.guideline.gov/summaries/summary/49534/clinical-practice-guideline-the-diagnosis-management-and-prevention-of-bronchiolitis'}]
https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930232056/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2016-09-30T23:20:56Z', 'uri': 'http://web.archive.org/web/20160930232056/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2017-10-03T03:09:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003030918/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2017-10-03T03:09:18Z', 'uri': 'http://web.archive.org/web/20171003030918/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2018-04-14T02:30:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414023027/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2018-04-14T02:30:27Z', 'uri': 'http://web.archive.org/web/20180414023027/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2018-05-19T09:21:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519092116/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2018-05-19T09:21:16Z', 'uri': 'http://web.archive.org/web/20180519092116/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}, {'datetime': '2018-06-09T19:38:30Z', 'uri': 'http://web.archive.org/web/20180609193830/https://www.guideline.gov/summaries/summary/49536/clinical-practice-guideline-on-diagnosis-and-treatment-of-hyponatraemia'}]
https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:53:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930225338/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2016-09-30T22:53:38Z', 'uri': 'http://web.archive.org/web/20160930225338/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2017-10-03T02:08:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003020835/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2017-10-03T02:08:35Z', 'uri': 'http://web.archive.org/web/20171003020835/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2018-04-14T00:57:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414005747/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2018-04-14T00:57:47Z', 'uri': 'http://web.archive.org/web/20180414005747/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2018-05-19T07:37:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519073727/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2018-05-19T07:37:27Z', 'uri': 'http://web.archive.org/web/20180519073727/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}, {'datetime': '2018-06-10T01:04:17Z', 'uri': 'http://web.archive.org/web/20180610010417/https://www.guideline.gov/summaries/summary/49537/diagnosis-and-treatment-of-adult-isthmic-spondylolisthesis'}]
https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T22:53:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930225320/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2016-09-30T22:53:20Z', 'uri': 'http://web.archive.org/web/20160930225320/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2017-10-03T02:08:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003020815/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2017-10-03T02:08:15Z', 'uri': 'http://web.archive.org/web/20171003020815/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2018-04-14T00:57:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414005725/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2018-04-14T00:57:25Z', 'uri': 'http://web.archive.org/web/20180414005725/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2018-05-19T07:36:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519073652/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2018-05-19T07:36:52Z', 'uri': 'http://web.archive.org/web/20180519073652/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}, {'datetime': '2018-06-09T22:27:33Z', 'uri': 'http://web.archive.org/web/20180609222733/https://www.guideline.gov/summaries/summary/49538/clinical-policy-use-of-intravenous-tissue-plasminogen-activator-for-the-management-of-acute-ischemic-stroke-in-the-emergency-department'}]
https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:22:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930232217/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2016-09-30T23:22:17Z', 'uri': 'http://web.archive.org/web/20160930232217/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2017-10-03T03:10:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003031044/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2017-10-03T03:10:44Z', 'uri': 'http://web.archive.org/web/20171003031044/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2018-04-14T02:32:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414023202/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2018-04-14T02:32:02Z', 'uri': 'http://web.archive.org/web/20180414023202/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2018-05-19T09:23:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519092317/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2018-05-19T09:23:17Z', 'uri': 'http://web.archive.org/web/20180519092317/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}, {'datetime': '2018-06-09T21:46:29Z', 'uri': 'http://web.archive.org/web/20180609214629/https://www.guideline.gov/summaries/summary/49566/diabetic-foot-problems-prevention-and-management'}]
https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:25:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930232545/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2016-09-30T23:25:45Z', 'uri': 'http://web.archive.org/web/20160930232545/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2017-10-03T03:12:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003031250/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2017-10-03T03:12:50Z', 'uri': 'http://web.archive.org/web/20171003031250/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2018-04-14T02:34:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414023442/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2018-04-14T02:34:42Z', 'uri': 'http://web.archive.org/web/20180414023442/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2018-05-19T09:25:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519092551/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2018-05-19T09:25:51Z', 'uri': 'http://web.archive.org/web/20180519092551/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}, {'datetime': '2018-06-09T15:15:18Z', 'uri': 'http://web.archive.org/web/20180609151518/https://www.guideline.gov/summaries/summary/49567/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism'}]
https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930231949/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2016-09-30T23:19:49Z', 'uri': 'http://web.archive.org/web/20160930231949/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2017-10-03T03:08:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003030802/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2017-10-03T03:08:02Z', 'uri': 'http://web.archive.org/web/20171003030802/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2018-04-14T02:29:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414022906/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2018-04-14T02:29:06Z', 'uri': 'http://web.archive.org/web/20180414022906/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2018-05-19T09:19:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519091943/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2018-05-19T09:19:43Z', 'uri': 'http://web.archive.org/web/20180519091943/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}, {'datetime': '2018-06-10T01:32:34Z', 'uri': 'http://web.archive.org/web/20180610013234/https://www.guideline.gov/summaries/summary/49568/british-thoracic-society-guidelines-for-home-oxygen-use-in-adults'}]
https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930231956/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2016-09-30T23:19:56Z', 'uri': 'http://web.archive.org/web/20160930231956/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2017-10-03T03:08:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003030809/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2017-10-03T03:08:09Z', 'uri': 'http://web.archive.org/web/20171003030809/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2018-04-14T02:29:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414022915/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2018-04-14T02:29:15Z', 'uri': 'http://web.archive.org/web/20180414022915/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2018-05-19T09:19:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519091952/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2018-05-19T09:19:52Z', 'uri': 'http://web.archive.org/web/20180519091952/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}, {'datetime': '2018-06-10T01:32:14Z', 'uri': 'http://web.archive.org/web/20180610013214/https://www.guideline.gov/summaries/summary/49569/british-thoracic-society-guidelines-for-the-investigation-and-management-of-pulmonary-nodules'}]
https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930232122/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2016-09-30T23:21:22Z', 'uri': 'http://web.archive.org/web/20160930232122/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:09:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003030947/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T03:09:47Z', 'uri': 'http://web.archive.org/web/20171003030947/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:31:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414023101/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T02:31:01Z', 'uri': 'http://web.archive.org/web/20180414023101/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:22:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519092200/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T09:22:00Z', 'uri': 'http://web.archive.org/web/20180519092200/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-10T21:58:45Z', 'uri': 'http://web.archive.org/web/20180610215845/https://www.guideline.gov/summaries/summary/49589/an-evidencebased-approach-to-patient-selection-for-emergency-department-thoracotomy-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930232049/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:20:49Z', 'uri': 'http://web.archive.org/web/20160930232049/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:09:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003030911/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:09:11Z', 'uri': 'http://web.archive.org/web/20171003030911/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:30:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414023020/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:30:20Z', 'uri': 'http://web.archive.org/web/20180414023020/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:21:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519092106/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:21:06Z', 'uri': 'http://web.archive.org/web/20180519092106/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}, {'datetime': '2018-06-09T18:42:53Z', 'uri': 'http://web.archive.org/web/20180609184253/https://www.guideline.gov/summaries/summary/49590/an-official-atsersjrsalat-clinical-practice-guideline-treatment-of-idiopathic-pulmonary-fibrosis-an-update-of-the-2011-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930231758/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:17:58Z', 'uri': 'http://web.archive.org/web/20160930231758/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:06:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003030605/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:06:05Z', 'uri': 'http://web.archive.org/web/20171003030605/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:26:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414022641/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:26:41Z', 'uri': 'http://web.archive.org/web/20180414022641/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:16:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519091651/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:16:51Z', 'uri': 'http://web.archive.org/web/20180519091651/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T22:02:03Z', 'uri': 'http://web.archive.org/web/20180609220203/https://www.guideline.gov/summaries/summary/49591/combined-diet-and-physical-activity-promotion-programs-for-prevention-of-diabetes-community-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:22:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930232210/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2016-09-30T23:22:10Z', 'uri': 'http://web.archive.org/web/20160930232210/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2017-10-03T03:10:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003031037/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2017-10-03T03:10:37Z', 'uri': 'http://web.archive.org/web/20171003031037/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2018-04-14T02:31:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414023153/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2018-04-14T02:31:53Z', 'uri': 'http://web.archive.org/web/20180414023153/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2018-05-19T09:23:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519092306/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2018-05-19T09:23:06Z', 'uri': 'http://web.archive.org/web/20180519092306/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}, {'datetime': '2018-06-09T19:21:43Z', 'uri': 'http://web.archive.org/web/20180609192143/https://www.guideline.gov/summaries/summary/49592/coeliac-disease-recognition-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930232109/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2016-09-30T23:21:09Z', 'uri': 'http://web.archive.org/web/20160930232109/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2017-10-03T03:09:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003030933/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2017-10-03T03:09:33Z', 'uri': 'http://web.archive.org/web/20171003030933/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2018-04-14T02:30:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414023045/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2018-04-14T02:30:45Z', 'uri': 'http://web.archive.org/web/20180414023045/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2018-05-19T09:21:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519092137/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2018-05-19T09:21:37Z', 'uri': 'http://web.archive.org/web/20180519092137/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}, {'datetime': '2018-06-09T19:03:43Z', 'uri': 'http://web.archive.org/web/20180609190343/https://www.guideline.gov/summaries/summary/49613/screening-for-iron-deficiency-anemia-in-young-children-uspstf-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930231806/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2016-09-30T23:18:06Z', 'uri': 'http://web.archive.org/web/20160930231806/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2017-10-03T03:06:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003030612/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2017-10-03T03:06:12Z', 'uri': 'http://web.archive.org/web/20171003030612/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2018-04-14T02:26:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414022649/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2018-04-14T02:26:49Z', 'uri': 'http://web.archive.org/web/20180414022649/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2018-05-19T09:17:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519091721/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2018-05-19T09:17:21Z', 'uri': 'http://web.archive.org/web/20180519091721/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}, {'datetime': '2018-06-09T22:02:08Z', 'uri': 'http://web.archive.org/web/20180609220208/https://www.guideline.gov/summaries/summary/49614/teambased-care-to-improve-blood-pressure-control-recommendation-of-the-community-preventive-services-task-force'}]
https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:21:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930232127/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2016-09-30T23:21:27Z', 'uri': 'http://web.archive.org/web/20160930232127/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2017-10-03T03:09:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003030953/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2017-10-03T03:09:53Z', 'uri': 'http://web.archive.org/web/20171003030953/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2018-04-14T02:31:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414023109/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2018-04-14T02:31:09Z', 'uri': 'http://web.archive.org/web/20180414023109/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2018-05-19T09:22:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519092210/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2018-05-19T09:22:10Z', 'uri': 'http://web.archive.org/web/20180519092210/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}, {'datetime': '2018-06-09T10:37:07Z', 'uri': 'http://web.archive.org/web/20180609103707/https://www.guideline.gov/summaries/summary/49615/motor-vehicle-collisionrelated-injuries-in-the-elderly-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review-of-risk-factors-and-prevention'}]
https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930232004/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2016-09-30T23:20:04Z', 'uri': 'http://web.archive.org/web/20160930232004/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2017-10-03T03:08:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003030818/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2017-10-03T03:08:18Z', 'uri': 'http://web.archive.org/web/20171003030818/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2018-04-14T02:29:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414022924/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2018-04-14T02:29:24Z', 'uri': 'http://web.archive.org/web/20180414022924/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2018-05-19T09:20:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519092002/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2018-05-19T09:20:02Z', 'uri': 'http://web.archive.org/web/20180519092002/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}, {'datetime': '2018-06-11T00:47:31Z', 'uri': 'http://web.archive.org/web/20180611004731/https://www.guideline.gov/summaries/summary/49629/occipital-nerve-stimulation-for-the-treatment-of-patients-with-medically-refractory-occipital-neuralgia-congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline'}]
https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:21:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930232103/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:21:03Z', 'uri': 'http://web.archive.org/web/20160930232103/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-01-07T13:17:01Z', 'uri': 'http://web.archive.org/web/20170107131701/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:09:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003030925/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:09:25Z', 'uri': 'http://web.archive.org/web/20171003030925/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:30:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414023036/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:30:36Z', 'uri': 'http://web.archive.org/web/20180414023036/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:21:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519092128/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:21:28Z', 'uri': 'http://web.archive.org/web/20180519092128/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T19:04:20Z', 'uri': 'http://web.archive.org/web/20180609190420/https://www.guideline.gov/summaries/summary/49630/screening-for-iron-deficiency-anemia-and-iron-supplementation-in-pregnant-women-to-improve-maternal-health-and-birth-outcomes-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930232029/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:20:29Z', 'uri': 'http://web.archive.org/web/20160930232029/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:08:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003030849/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:08:49Z', 'uri': 'http://web.archive.org/web/20171003030849/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-04-14T02:29:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414022951/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-04-14T02:29:51Z', 'uri': 'http://web.archive.org/web/20180414022951/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-05-19T09:20:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519092036/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-05-19T09:20:36Z', 'uri': 'http://web.archive.org/web/20180519092036/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}, {'datetime': '2018-06-09T21:17:15Z', 'uri': 'http://web.archive.org/web/20180609211715/https://www.guideline.gov/summaries/summary/49633/diagnosis-and-management-of-epilepsy-in-adults-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930232036/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2016-09-30T23:20:36Z', 'uri': 'http://web.archive.org/web/20160930232036/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:08:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003030858/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2017-10-03T03:08:58Z', 'uri': 'http://web.archive.org/web/20171003030858/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2018-04-14T02:30:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414023001/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2018-04-14T02:30:01Z', 'uri': 'http://web.archive.org/web/20180414023001/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2018-05-19T09:20:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519092047/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2018-05-19T09:20:47Z', 'uri': 'http://web.archive.org/web/20180519092047/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}, {'datetime': '2018-06-09T16:05:44Z', 'uri': 'http://web.archive.org/web/20180609160544/https://www.guideline.gov/summaries/summary/49634/glaucoma-referral-and-safe-discharge-a-national-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930232017/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2016-09-30T23:20:17Z', 'uri': 'http://web.archive.org/web/20160930232017/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2017-10-03T03:08:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003030833/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2017-10-03T03:08:33Z', 'uri': 'http://web.archive.org/web/20171003030833/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2018-04-14T02:29:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414022936/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2018-04-14T02:29:36Z', 'uri': 'http://web.archive.org/web/20180414022936/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2018-05-19T09:20:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519092017/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2018-05-19T09:20:17Z', 'uri': 'http://web.archive.org/web/20180519092017/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}, {'datetime': '2018-06-10T08:38:21Z', 'uri': 'http://web.archive.org/web/20180610083821/https://www.guideline.gov/summaries/summary/49657/prophylaxis-against-infective-endocarditis-antimicrobial-prophylaxis-against-infective-endocarditis-in-adults-and-children-undergoing-interventional-procedures'}]
https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930231819/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:18:19Z', 'uri': 'http://web.archive.org/web/20160930231819/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:07:03Z', 'uri': 'http://wayback.archive-it.org/all/20171002200703/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-02T20:07:03Z', 'uri': 'http://web.archive.org/web/20171002200703/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:27:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414022705/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:27:05Z', 'uri': 'http://web.archive.org/web/20180414022705/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-18T19:31:45Z', 'uri': 'http://wayback.archive-it.org/all/20180518193145/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-18T19:31:45Z', 'uri': 'http://web.archive.org/web/20180518193145/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-09T10:38:44Z', 'uri': 'http://web.archive.org/web/20180609103844/https://www.guideline.gov/summaries/summary/49658/treatment-of-cushings-syndrome-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:20:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930232023/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2016-09-30T23:20:23Z', 'uri': 'http://web.archive.org/web/20160930232023/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2017-10-03T03:08:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003030842/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2017-10-03T03:08:42Z', 'uri': 'http://web.archive.org/web/20171003030842/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2018-04-14T02:29:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414022945/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2018-04-14T02:29:45Z', 'uri': 'http://web.archive.org/web/20180414022945/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2018-05-19T09:20:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519092026/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2018-05-19T09:20:26Z', 'uri': 'http://web.archive.org/web/20180519092026/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}, {'datetime': '2018-06-10T01:21:39Z', 'uri': 'http://web.archive.org/web/20180610012139/https://www.guideline.gov/summaries/summary/49683/person-and-familycentred-care'}]
https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930231825/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:18:25Z', 'uri': 'http://web.archive.org/web/20160930231825/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:06:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003030624/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:06:24Z', 'uri': 'http://web.archive.org/web/20171003030624/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:27:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414022713/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:27:13Z', 'uri': 'http://web.archive.org/web/20180414022713/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:17:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519091739/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:17:39Z', 'uri': 'http://web.archive.org/web/20180519091739/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T21:28:10Z', 'uri': 'http://web.archive.org/web/20180610212810/https://www.guideline.gov/summaries/summary/49684/behavioral-and-pharmacotherapy-interventions-for-tobacco-smoking-cessation-in-adults-including-pregnant-women-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:12:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930231240/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2016-09-30T23:12:40Z', 'uri': 'http://web.archive.org/web/20160930231240/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2017-10-03T03:00:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003030006/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2017-10-03T03:00:06Z', 'uri': 'http://web.archive.org/web/20171003030006/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2018-04-14T02:20:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414022024/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2018-04-14T02:20:24Z', 'uri': 'http://web.archive.org/web/20180414022024/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2018-05-19T09:09:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519090928/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2018-05-19T09:09:28Z', 'uri': 'http://web.archive.org/web/20180519090928/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}, {'datetime': '2018-06-09T20:18:31Z', 'uri': 'http://web.archive.org/web/20180609201831/https://www.guideline.gov/summaries/summary/49831/patient-blood-management-guidelines-module-5--obstetrics-and-maternity'}]
https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930231902/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2016-09-30T23:19:02Z', 'uri': 'http://web.archive.org/web/20160930231902/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2017-10-03T03:07:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003030708/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2017-10-03T03:07:08Z', 'uri': 'http://web.archive.org/web/20171003030708/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2018-04-14T02:28:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414022805/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2018-04-14T02:28:05Z', 'uri': 'http://web.archive.org/web/20180414022805/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2018-05-19T09:18:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519091834/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2018-05-19T09:18:34Z', 'uri': 'http://web.archive.org/web/20180519091834/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}, {'datetime': '2018-06-09T15:20:03Z', 'uri': 'http://web.archive.org/web/20180609152003/https://www.guideline.gov/summaries/summary/49862/efnsensean-guideline-on-concomitant-use-of-cholinesterase-inhibitors-and-memantine-in-moderate-to-severe-alzheimers-disease'}]
https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930231922/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2016-09-30T23:19:22Z', 'uri': 'http://web.archive.org/web/20160930231922/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2017-10-03T03:07:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003030731/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2017-10-03T03:07:31Z', 'uri': 'http://web.archive.org/web/20171003030731/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2018-04-14T02:28:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414022831/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2018-04-14T02:28:31Z', 'uri': 'http://web.archive.org/web/20180414022831/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2018-05-19T09:19:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519091906/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2018-05-19T09:19:06Z', 'uri': 'http://web.archive.org/web/20180519091906/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}, {'datetime': '2018-06-10T08:22:08Z', 'uri': 'http://web.archive.org/web/20180610082208/https://www.guideline.gov/summaries/summary/49863/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-assay'}]
https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930231812/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2016-09-30T23:18:12Z', 'uri': 'http://web.archive.org/web/20160930231812/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2017-10-03T03:06:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003030618/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2017-10-03T03:06:18Z', 'uri': 'http://web.archive.org/web/20171003030618/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2018-04-14T02:26:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414022657/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2018-04-14T02:26:57Z', 'uri': 'http://web.archive.org/web/20180414022657/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2018-05-19T09:17:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519091730/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2018-05-19T09:17:30Z', 'uri': 'http://web.archive.org/web/20180519091730/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}, {'datetime': '2018-06-09T21:35:10Z', 'uri': 'http://web.archive.org/web/20180609213510/https://www.guideline.gov/summaries/summary/49871/pembrolizumab-for-treating-advanced-melanoma-after-disease-progression-with-ipilimumab'}]
https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930231543/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2016-09-30T23:15:43Z', 'uri': 'http://web.archive.org/web/20160930231543/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2017-10-03T03:03:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003030314/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2017-10-03T03:03:14Z', 'uri': 'http://web.archive.org/web/20171003030314/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2018-04-14T02:24:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414022405/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2018-04-14T02:24:05Z', 'uri': 'http://web.archive.org/web/20180414022405/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2018-05-19T09:13:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519091350/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2018-05-19T09:13:50Z', 'uri': 'http://web.archive.org/web/20180519091350/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}, {'datetime': '2018-06-09T10:34:53Z', 'uri': 'http://web.archive.org/web/20180609103453/https://www.guideline.gov/summaries/summary/49873/clinical-practice-guideline-for-the-treatment-of-intrinsic-circadian-rhythm-sleepwake-disorders-advanced-sleepwake-phase-disorder-aswpd-delayed-sleepwake-phase-disorder-dswpd-non24hour-sleepwake-rhythm-disorder-n24swd-and-irregular-sleepwake-rhythm-disorder-is'}]
https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:15:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930231551/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2016-09-30T23:15:51Z', 'uri': 'http://web.archive.org/web/20160930231551/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2017-10-03T03:03:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003030321/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2017-10-03T03:03:21Z', 'uri': 'http://web.archive.org/web/20171003030321/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2017-11-17T10:33:52Z', 'uri': 'http://web.archive.org/web/20171117103352/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2018-04-14T02:24:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414022414/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2018-04-14T02:24:14Z', 'uri': 'http://web.archive.org/web/20180414022414/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2018-05-19T09:14:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519091402/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2018-05-19T09:14:02Z', 'uri': 'http://web.archive.org/web/20180519091402/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}, {'datetime': '2018-06-09T20:26:02Z', 'uri': 'http://web.archive.org/web/20180609202602/https://www.guideline.gov/summaries/summary/49874/clinical-practice-guideline-for-the-treatment-of-obstructive-sleep-apnea-and-snoring-with-oral-appliance-therapy-an-update-for-2015'}]
https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930231943/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2016-09-30T23:19:43Z', 'uri': 'http://web.archive.org/web/20160930231943/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2017-10-03T03:07:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003030754/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2017-10-03T03:07:54Z', 'uri': 'http://web.archive.org/web/20171003030754/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2018-04-14T02:28:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414022859/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2018-04-14T02:28:59Z', 'uri': 'http://web.archive.org/web/20180414022859/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2018-05-19T09:19:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519091934/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2018-05-19T09:19:34Z', 'uri': 'http://web.archive.org/web/20180519091934/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}, {'datetime': '2018-06-10T01:53:11Z', 'uri': 'http://web.archive.org/web/20180610015311/https://www.guideline.gov/summaries/summary/49875/practice-guidelines-for-perioperative-blood-management-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-perioperative-blood-management'}]
https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930231936/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2016-09-30T23:19:36Z', 'uri': 'http://web.archive.org/web/20160930231936/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2017-10-03T03:07:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003030745/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2017-10-03T03:07:45Z', 'uri': 'http://web.archive.org/web/20171003030745/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2018-04-14T02:28:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414022849/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2018-04-14T02:28:49Z', 'uri': 'http://web.archive.org/web/20180414022849/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2018-05-19T09:19:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519091924/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2018-05-19T09:19:24Z', 'uri': 'http://web.archive.org/web/20180519091924/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}, {'datetime': '2018-06-10T01:53:06Z', 'uri': 'http://web.archive.org/web/20180610015306/https://www.guideline.gov/summaries/summary/49876/practice-advisory-on-anesthetic-care-for-magnetic-resonance-imaging-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-anesthetic-care-for-magnetic-resonance-imaging'}]
https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930231715/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:17:15Z', 'uri': 'http://web.archive.org/web/20160930231715/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:05:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003030509/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:05:09Z', 'uri': 'http://web.archive.org/web/20171003030509/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:25:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414022559/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:25:59Z', 'uri': 'http://web.archive.org/web/20180414022559/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:16:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519091603/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:16:03Z', 'uri': 'http://web.archive.org/web/20180519091603/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-11T06:15:13Z', 'uri': 'http://web.archive.org/web/20180611061513/https://www.guideline.gov/summaries/summary/49877/screening-for-high-blood-pressure-in-adults-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930231646/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2016-09-30T23:16:46Z', 'uri': 'http://web.archive.org/web/20160930231646/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2017-10-03T03:04:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003030438/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2017-10-03T03:04:38Z', 'uri': 'http://web.archive.org/web/20171003030438/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2018-04-14T02:25:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414022524/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2018-04-14T02:25:24Z', 'uri': 'http://web.archive.org/web/20180414022524/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2018-05-19T09:15:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519091525/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2018-05-19T09:15:25Z', 'uri': 'http://web.archive.org/web/20180519091525/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}, {'datetime': '2018-06-09T23:05:05Z', 'uri': 'http://web.archive.org/web/20180609230505/https://www.guideline.gov/summaries/summary/49878/breast-cancer-screening-for-women-at-average-risk-2015-guideline-update-from-the-american-cancer-society'}]
https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:17:00Z', 'uri': 'http://wayback.archive-it.org/all/20160930231700/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2016-09-30T23:17:00Z', 'uri': 'http://web.archive.org/web/20160930231700/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2017-02-12T02:52:05Z', 'uri': 'http://web.archive.org/web/20170212025205/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2017-10-03T03:04:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003030456/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2017-10-03T03:04:56Z', 'uri': 'http://web.archive.org/web/20171003030456/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2018-04-14T02:25:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414022543/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2018-04-14T02:25:43Z', 'uri': 'http://web.archive.org/web/20180414022543/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2018-05-19T09:15:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519091545/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2018-05-19T09:15:45Z', 'uri': 'http://web.archive.org/web/20180519091545/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}, {'datetime': '2018-06-09T21:15:57Z', 'uri': 'http://web.archive.org/web/20180609211557/https://www.guideline.gov/summaries/summary/49879/plerixafor-for-autologous-hematopoietic-stem-cell-mobilization-and-transplantation-for-patients-in-ontario'}]
https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930231536/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2016-09-30T23:15:36Z', 'uri': 'http://web.archive.org/web/20160930231536/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2017-10-03T03:03:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003030306/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2017-10-03T03:03:06Z', 'uri': 'http://web.archive.org/web/20171003030306/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2018-04-14T02:23:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414022355/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2018-04-14T02:23:55Z', 'uri': 'http://web.archive.org/web/20180414022355/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2018-05-19T09:13:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519091340/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2018-05-19T09:13:40Z', 'uri': 'http://web.archive.org/web/20180519091340/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}, {'datetime': '2018-06-09T21:57:20Z', 'uri': 'http://web.archive.org/web/20180609215720/https://www.guideline.gov/summaries/summary/49881/evidencebased-guideline-summary-evaluation-diagnosis-and-management-of-congenital-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology-and-the-practice-issues-review-panel-of-the-american-association-of-neuro'}]
https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930231603/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2016-09-30T23:16:03Z', 'uri': 'http://web.archive.org/web/20160930231603/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2017-10-03T03:03:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003030334/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2017-10-03T03:03:34Z', 'uri': 'http://web.archive.org/web/20171003030334/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2018-04-14T02:24:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414022429/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2018-04-14T02:24:29Z', 'uri': 'http://web.archive.org/web/20180414022429/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2018-05-19T09:14:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519091419/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2018-05-19T09:14:19Z', 'uri': 'http://web.archive.org/web/20180519091419/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}, {'datetime': '2018-06-09T21:45:04Z', 'uri': 'http://web.archive.org/web/20180609214504/https://www.guideline.gov/summaries/summary/49888/american-gastroenterological-association-institute-guideline-on-the-role-of-upper-gastrointestinal-biopsy-to-evaluate-dyspepsia-in-the-adult-patient-in-the-absence-of-visible-mucosal-lesions'}]
https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930231557/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2016-09-30T23:15:57Z', 'uri': 'http://web.archive.org/web/20160930231557/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2017-10-03T03:03:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003030327/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2017-10-03T03:03:27Z', 'uri': 'http://web.archive.org/web/20171003030327/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2018-04-14T02:24:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414022421/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2018-04-14T02:24:21Z', 'uri': 'http://web.archive.org/web/20180414022421/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2018-05-19T09:14:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519091411/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2018-05-19T09:14:11Z', 'uri': 'http://web.archive.org/web/20180519091411/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}, {'datetime': '2018-06-09T21:44:53Z', 'uri': 'http://web.archive.org/web/20180609214453/https://www.guideline.gov/summaries/summary/49889/american-gastroenterological-association-institute-guideline-on-the-diagnosis-and-management-of-lynch-syndrome'}]
https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930231930/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2016-09-30T23:19:30Z', 'uri': 'http://web.archive.org/web/20160930231930/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2017-10-03T03:07:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003030738/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2017-10-03T03:07:38Z', 'uri': 'http://web.archive.org/web/20171003030738/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2018-04-14T02:28:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414022840/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2018-04-14T02:28:40Z', 'uri': 'http://web.archive.org/web/20180414022840/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2018-05-19T09:19:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519091915/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2018-05-19T09:19:15Z', 'uri': 'http://web.archive.org/web/20180519091915/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}, {'datetime': '2018-06-10T23:02:22Z', 'uri': 'http://web.archive.org/web/20180610230222/https://www.guideline.gov/summaries/summary/49903/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions'}]
https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:16:53Z', 'uri': 'http://wayback.archive-it.org/all/20160930231653/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2016-09-30T23:16:53Z', 'uri': 'http://web.archive.org/web/20160930231653/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2017-10-03T03:04:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003030446/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2017-10-03T03:04:46Z', 'uri': 'http://web.archive.org/web/20171003030446/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-04-14T02:25:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414022534/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-04-14T02:25:34Z', 'uri': 'http://web.archive.org/web/20180414022534/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-05-19T09:15:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519091535/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-05-19T09:15:35Z', 'uri': 'http://web.archive.org/web/20180519091535/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-06-09T11:54:15Z', 'uri': 'http://web.archive.org/web/20180609115415/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-07-12T21:43:45Z', 'uri': 'http://web.archive.org/web/20180712214345/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}, {'datetime': '2018-07-12T21:43:45Z', 'uri': 'http://web.archive.org/web/20180712214345/https://www.guideline.gov/summaries/summary/49904/menopause-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/49905/blood-transfusion	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930231908/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2016-09-30T23:19:08Z', 'uri': 'http://web.archive.org/web/20160930231908/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2017-10-03T03:07:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003030723/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2017-10-03T03:07:23Z', 'uri': 'http://web.archive.org/web/20171003030723/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2018-04-14T02:28:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414022821/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2018-04-14T02:28:21Z', 'uri': 'http://web.archive.org/web/20180414022821/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2018-05-19T09:18:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519091855/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2018-05-19T09:18:55Z', 'uri': 'http://web.archive.org/web/20180519091855/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}, {'datetime': '2018-06-10T01:05:14Z', 'uri': 'http://web.archive.org/web/20180610010514/https://www.guideline.gov/summaries/summary/49905/blood-transfusion'}]
https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:19:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930231915/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2016-09-30T23:19:15Z', 'uri': 'http://web.archive.org/web/20160930231915/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2017-10-03T03:07:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003030714/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2017-10-03T03:07:14Z', 'uri': 'http://web.archive.org/web/20171003030714/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2018-04-14T02:28:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414022811/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2018-04-14T02:28:11Z', 'uri': 'http://web.archive.org/web/20180414022811/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2018-05-19T09:18:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519091843/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2018-05-19T09:18:43Z', 'uri': 'http://web.archive.org/web/20180519091843/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}, {'datetime': '2018-06-10T21:49:09Z', 'uri': 'http://web.archive.org/web/20180610214909/https://www.guideline.gov/summaries/summary/49906/preterm-labour-and-birth'}]
https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930231833/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2016-09-30T23:18:33Z', 'uri': 'http://web.archive.org/web/20160930231833/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2017-10-03T03:06:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003030632/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2017-10-03T03:06:32Z', 'uri': 'http://web.archive.org/web/20171003030632/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2018-04-14T02:27:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414022723/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2018-04-14T02:27:23Z', 'uri': 'http://web.archive.org/web/20180414022723/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2018-05-19T09:17:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519091749/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2018-05-19T09:17:49Z', 'uri': 'http://web.archive.org/web/20180519091749/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}, {'datetime': '2018-06-09T11:21:25Z', 'uri': 'http://web.archive.org/web/20180609112125/https://www.guideline.gov/summaries/summary/49907/acr-appropriateness-criteria--acute-nonspecific-chest-pain---low-probability-of-coronary-artery-disease'}]
https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:47Z', 'uri': 'http://wayback.archive-it.org/all/20160930231847/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2016-09-30T23:18:47Z', 'uri': 'http://web.archive.org/web/20160930231847/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2017-10-03T03:06:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003030657/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2017-10-03T03:06:57Z', 'uri': 'http://web.archive.org/web/20171003030657/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2018-04-14T02:27:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414022751/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2018-04-14T02:27:51Z', 'uri': 'http://web.archive.org/web/20180414022751/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2018-05-19T09:18:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519091821/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2018-05-19T09:18:21Z', 'uri': 'http://web.archive.org/web/20180519091821/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}, {'datetime': '2018-06-10T11:54:28Z', 'uri': 'http://web.archive.org/web/20180610115428/https://www.guideline.gov/summaries/summary/49908/acr-appropriateness-criteria--radiologic-management-of-hepatic-malignancy'}]
https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930231854/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2016-09-30T23:18:54Z', 'uri': 'http://web.archive.org/web/20160930231854/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2017-10-03T03:06:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003030659/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2017-10-03T03:06:59Z', 'uri': 'http://web.archive.org/web/20171003030659/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2018-04-14T02:27:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414022754/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2018-04-14T02:27:54Z', 'uri': 'http://web.archive.org/web/20180414022754/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2018-05-19T09:18:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519091824/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2018-05-19T09:18:24Z', 'uri': 'http://web.archive.org/web/20180519091824/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}, {'datetime': '2018-06-10T23:00:53Z', 'uri': 'http://web.archive.org/web/20180610230053/https://www.guideline.gov/summaries/summary/49909/acr-appropriateness-criteria--radiologic-management-of-thoracic-nodules-and-masses'}]
https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:34:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930143421/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2016-09-30T14:34:21Z', 'uri': 'http://web.archive.org/web/20160930143421/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2017-10-03T03:06:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003030639/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2017-10-03T03:06:39Z', 'uri': 'http://web.archive.org/web/20171003030639/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2018-04-14T02:27:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414022732/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2018-04-14T02:27:32Z', 'uri': 'http://web.archive.org/web/20180414022732/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2018-05-19T09:17:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519091759/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2018-05-19T09:17:59Z', 'uri': 'http://web.archive.org/web/20180519091759/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}, {'datetime': '2018-06-09T18:47:47Z', 'uri': 'http://web.archive.org/web/20180609184747/https://www.guideline.gov/summaries/summary/49910/acr-appropriateness-criteria--chronic-elbow-pain'}]
https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:18:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930231840/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2016-09-30T23:18:40Z', 'uri': 'http://web.archive.org/web/20160930231840/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2017-10-03T03:06:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003030648/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2017-10-03T03:06:48Z', 'uri': 'http://web.archive.org/web/20171003030648/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2018-04-14T02:27:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414022742/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2018-04-14T02:27:42Z', 'uri': 'http://web.archive.org/web/20180414022742/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2018-05-19T09:18:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519091810/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2018-05-19T09:18:10Z', 'uri': 'http://web.archive.org/web/20180519091810/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}, {'datetime': '2018-06-10T23:00:51Z', 'uri': 'http://web.archive.org/web/20180610230051/https://www.guideline.gov/summaries/summary/49911/acr-appropriateness-criteria--followup-of-malignant-or-aggressive-musculoskeletal-tumors'}]
https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930231731/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2016-09-30T23:17:31Z', 'uri': 'http://web.archive.org/web/20160930231731/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2017-10-03T03:05:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003030527/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2017-10-03T03:05:27Z', 'uri': 'http://web.archive.org/web/20171003030527/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2018-04-14T02:26:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414022620/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2018-04-14T02:26:20Z', 'uri': 'http://web.archive.org/web/20180414022620/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2018-05-19T09:16:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519091625/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2018-05-19T09:16:25Z', 'uri': 'http://web.archive.org/web/20180519091625/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}, {'datetime': '2018-06-09T15:22:14Z', 'uri': 'http://web.archive.org/web/20180609152214/https://www.guideline.gov/summaries/summary/49912/acr-appropriateness-criteria--imaging-after-total-hip-arthroplasty'}]
https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:51Z', 'uri': 'http://wayback.archive-it.org/all/20160930231751/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2016-09-30T23:17:51Z', 'uri': 'http://web.archive.org/web/20160930231751/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2017-10-03T03:06:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003030602/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2017-10-03T03:06:02Z', 'uri': 'http://web.archive.org/web/20171003030602/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2018-04-14T02:26:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414022638/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2018-04-14T02:26:38Z', 'uri': 'http://web.archive.org/web/20180414022638/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2018-05-19T09:16:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519091647/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2018-05-19T09:16:47Z', 'uri': 'http://web.archive.org/web/20180519091647/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}, {'datetime': '2018-06-09T15:22:52Z', 'uri': 'http://web.archive.org/web/20180609152252/https://www.guideline.gov/summaries/summary/49913/acr-appropriateness-criteria--osteonecrosis-of-the-hip'}]
https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:22Z', 'uri': 'http://wayback.archive-it.org/all/20160930231722/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2016-09-30T23:17:22Z', 'uri': 'http://web.archive.org/web/20160930231722/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2017-10-03T03:05:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003030517/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2017-10-03T03:05:17Z', 'uri': 'http://web.archive.org/web/20171003030517/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2018-04-14T02:26:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414022609/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2018-04-14T02:26:09Z', 'uri': 'http://web.archive.org/web/20180414022609/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2018-05-19T09:16:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519091614/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2018-05-19T09:16:14Z', 'uri': 'http://web.archive.org/web/20180519091614/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}, {'datetime': '2018-06-10T21:58:59Z', 'uri': 'http://web.archive.org/web/20180610215859/https://www.guideline.gov/summaries/summary/49914/acr-appropriateness-criteria--head-trauma'}]
https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930231738/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2016-09-30T23:17:38Z', 'uri': 'http://web.archive.org/web/20160930231738/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2017-10-02T21:17:20Z', 'uri': 'http://wayback.archive-it.org/all/20171002211720/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2017-10-02T21:17:20Z', 'uri': 'http://web.archive.org/web/20171002211720/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2018-04-13T20:15:19Z', 'uri': 'http://wayback.archive-it.org/all/20180413201519/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2018-04-13T20:15:19Z', 'uri': 'http://web.archive.org/web/20180413201519/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2018-05-19T00:38:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519003827/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2018-05-19T00:38:27Z', 'uri': 'http://web.archive.org/web/20180519003827/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}, {'datetime': '2018-06-10T06:48:19Z', 'uri': 'http://web.archive.org/web/20180610064819/https://www.guideline.gov/summaries/summary/49915/acr-appropriateness-criteria--low-back-pain'}]
https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:45Z', 'uri': 'http://wayback.archive-it.org/all/20160930231745/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2016-09-30T23:17:45Z', 'uri': 'http://web.archive.org/web/20160930231745/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2017-10-03T03:05:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003030537/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2017-10-03T03:05:37Z', 'uri': 'http://web.archive.org/web/20171003030537/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2018-04-14T02:26:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414022630/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2018-04-14T02:26:30Z', 'uri': 'http://web.archive.org/web/20180414022630/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2018-05-19T09:16:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519091636/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2018-05-19T09:16:36Z', 'uri': 'http://web.archive.org/web/20180519091636/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}, {'datetime': '2018-06-10T22:08:14Z', 'uri': 'http://web.archive.org/web/20180610220814/https://www.guideline.gov/summaries/summary/49916/acr-appropriateness-criteria--myelopathy'}]
https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930231624/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2016-09-30T23:16:24Z', 'uri': 'http://web.archive.org/web/20160930231624/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2017-10-03T03:03:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003030355/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2017-10-03T03:03:55Z', 'uri': 'http://web.archive.org/web/20171003030355/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2018-04-14T02:24:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414022455/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2018-04-14T02:24:55Z', 'uri': 'http://web.archive.org/web/20180414022455/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2018-05-19T09:14:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519091448/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2018-05-19T09:14:48Z', 'uri': 'http://web.archive.org/web/20180519091448/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}, {'datetime': '2018-06-10T08:26:12Z', 'uri': 'http://web.archive.org/web/20180610082612/https://www.guideline.gov/summaries/summary/49917/acr-appropriateness-criteria--fever-without-source-or-unknown-origin---child'}]
https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930231638/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2016-09-30T23:16:38Z', 'uri': 'http://web.archive.org/web/20160930231638/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2017-10-03T03:04:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003030411/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2017-10-03T03:04:11Z', 'uri': 'http://web.archive.org/web/20171003030411/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2018-04-14T02:25:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414022514/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2018-04-14T02:25:14Z', 'uri': 'http://web.archive.org/web/20180414022514/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2018-05-19T09:15:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519091514/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2018-05-19T09:15:14Z', 'uri': 'http://web.archive.org/web/20180519091514/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}, {'datetime': '2018-06-09T15:44:15Z', 'uri': 'http://web.archive.org/web/20180609154415/https://www.guideline.gov/summaries/summary/49918/acr-appropriateness-criteria--routine-chest-radiography'}]
https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930231608/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2016-09-30T23:16:08Z', 'uri': 'http://web.archive.org/web/20160930231608/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2017-10-03T03:03:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003030340/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2017-10-03T03:03:40Z', 'uri': 'http://web.archive.org/web/20171003030340/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2018-04-14T02:24:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414022437/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2018-04-14T02:24:37Z', 'uri': 'http://web.archive.org/web/20180414022437/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2018-05-19T09:14:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519091429/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2018-05-19T09:14:29Z', 'uri': 'http://web.archive.org/web/20180519091429/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}, {'datetime': '2018-06-10T16:22:25Z', 'uri': 'http://web.archive.org/web/20180610162225/https://www.guideline.gov/summaries/summary/49919/acr-appropriateness-criteria--acute-onset-flank-pain---suspicion-of-stone-disease-urolithiasis'}]
https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930231631/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2016-09-30T23:16:31Z', 'uri': 'http://web.archive.org/web/20160930231631/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2017-10-03T03:04:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003030404/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2017-10-03T03:04:04Z', 'uri': 'http://web.archive.org/web/20171003030404/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2018-04-14T02:25:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414022505/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2018-04-14T02:25:05Z', 'uri': 'http://web.archive.org/web/20180414022505/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2018-05-19T09:14:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519091458/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2018-05-19T09:14:58Z', 'uri': 'http://web.archive.org/web/20180519091458/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}, {'datetime': '2018-06-10T22:55:40Z', 'uri': 'http://web.archive.org/web/20180610225540/https://www.guideline.gov/summaries/summary/49920/acr-appropriateness-criteria--renal-cell-carcinoma-staging'}]
https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:16:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930231616/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2016-09-30T23:16:16Z', 'uri': 'http://web.archive.org/web/20160930231616/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2017-10-03T03:03:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003030348/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2017-10-03T03:03:48Z', 'uri': 'http://web.archive.org/web/20171003030348/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2018-04-14T02:24:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414022446/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2018-04-14T02:24:46Z', 'uri': 'http://web.archive.org/web/20180414022446/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2018-05-19T09:14:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519091439/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2018-05-19T09:14:39Z', 'uri': 'http://web.archive.org/web/20180519091439/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}, {'datetime': '2018-06-10T23:06:37Z', 'uri': 'http://web.archive.org/web/20180610230637/https://www.guideline.gov/summaries/summary/49921/acr-appropriateness-criteria--clinically-suspected-pulmonary-arteriovenous-malformation-pavm'}]
https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930231458/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2016-09-30T23:14:58Z', 'uri': 'http://web.archive.org/web/20160930231458/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2017-10-03T03:02:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003030225/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2017-10-03T03:02:25Z', 'uri': 'http://web.archive.org/web/20171003030225/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2018-04-14T02:23:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414022304/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2018-04-14T02:23:04Z', 'uri': 'http://web.archive.org/web/20180414022304/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2018-05-19T09:12:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519091247/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2018-05-19T09:12:47Z', 'uri': 'http://web.archive.org/web/20180519091247/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}, {'datetime': '2018-06-10T00:15:41Z', 'uri': 'http://web.archive.org/web/20180610001541/https://www.guideline.gov/summaries/summary/49922/acr-appropriateness-criteria--acute-pelvic-pain-in-the-reproductive-age-group'}]
https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:28Z', 'uri': 'http://wayback.archive-it.org/all/20160930231528/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2016-09-30T23:15:28Z', 'uri': 'http://web.archive.org/web/20160930231528/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2017-10-03T03:02:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003030258/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2017-10-03T03:02:58Z', 'uri': 'http://web.archive.org/web/20171003030258/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2018-04-14T02:23:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414022344/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2018-04-14T02:23:44Z', 'uri': 'http://web.archive.org/web/20180414022344/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2018-05-19T09:13:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519091330/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2018-05-19T09:13:30Z', 'uri': 'http://web.archive.org/web/20180519091330/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}, {'datetime': '2018-06-10T23:00:54Z', 'uri': 'http://web.archive.org/web/20180610230054/https://www.guideline.gov/summaries/summary/49923/acr-appropriateness-criteria--pretreatment-planning-of-invasive-cancer-of-the-cervix'}]
https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930231512/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2016-09-30T23:15:12Z', 'uri': 'http://web.archive.org/web/20160930231512/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2017-10-03T03:02:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003030242/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2017-10-03T03:02:42Z', 'uri': 'http://web.archive.org/web/20171003030242/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2018-04-14T02:23:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414022324/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2018-04-14T02:23:24Z', 'uri': 'http://web.archive.org/web/20180414022324/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2018-05-19T09:13:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519091308/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2018-05-19T09:13:08Z', 'uri': 'http://web.archive.org/web/20180519091308/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}, {'datetime': '2018-06-10T19:09:18Z', 'uri': 'http://web.archive.org/web/20180610190918/https://www.guideline.gov/summaries/summary/49924/acr-appropriateness-criteria--localregional-therapy-for-resectable-oropharyngeal-squamous-cell-carcinomas'}]
https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930231521/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2016-09-30T23:15:21Z', 'uri': 'http://web.archive.org/web/20160930231521/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2017-10-03T03:02:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003030250/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2017-10-03T03:02:50Z', 'uri': 'http://web.archive.org/web/20171003030250/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2018-04-14T02:23:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414022335/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2018-04-14T02:23:35Z', 'uri': 'http://web.archive.org/web/20180414022335/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2018-05-19T09:13:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519091320/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2018-05-19T09:13:20Z', 'uri': 'http://web.archive.org/web/20180519091320/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}, {'datetime': '2018-06-09T22:43:31Z', 'uri': 'http://web.archive.org/web/20180609224331/https://www.guideline.gov/summaries/summary/49925/acr-appropriateness-criteria--nasopharyngeal-carcinoma'}]
https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:15:05Z', 'uri': 'http://wayback.archive-it.org/all/20160930231505/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2016-09-30T23:15:05Z', 'uri': 'http://web.archive.org/web/20160930231505/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2017-10-03T03:02:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003030232/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2017-10-03T03:02:32Z', 'uri': 'http://web.archive.org/web/20171003030232/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2018-04-14T02:23:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414022314/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2018-04-14T02:23:14Z', 'uri': 'http://web.archive.org/web/20180414022314/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2018-05-19T09:12:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519091257/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2018-05-19T09:12:57Z', 'uri': 'http://web.archive.org/web/20180519091257/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}, {'datetime': '2018-06-10T23:00:53Z', 'uri': 'http://web.archive.org/web/20180610230053/https://www.guideline.gov/summaries/summary/49926/acr-appropriateness-criteria--hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii'}]
https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930231427/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2016-09-30T23:14:27Z', 'uri': 'http://web.archive.org/web/20160930231427/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2017-10-03T03:01:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003030158/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2017-10-03T03:01:58Z', 'uri': 'http://web.archive.org/web/20171003030158/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2018-04-14T02:22:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414022232/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2018-04-14T02:22:32Z', 'uri': 'http://web.archive.org/web/20180414022232/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2018-05-19T09:12:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519091210/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2018-05-19T09:12:10Z', 'uri': 'http://web.archive.org/web/20180519091210/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}, {'datetime': '2018-06-09T18:41:17Z', 'uri': 'http://web.archive.org/web/20180609184117/https://www.guideline.gov/summaries/summary/49927/uniform-labeling-of-blocks-and-slides-in-surgical-pathology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-national-society-for-histotechnology'}]
https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:17:06Z', 'uri': 'http://wayback.archive-it.org/all/20160930231706/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:17:06Z', 'uri': 'http://web.archive.org/web/20160930231706/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:05:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003030501/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T03:05:01Z', 'uri': 'http://web.archive.org/web/20171003030501/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:25:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414022550/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:25:50Z', 'uri': 'http://web.archive.org/web/20180414022550/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:15:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519091554/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:15:54Z', 'uri': 'http://web.archive.org/web/20180519091554/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-10T22:17:50Z', 'uri': 'http://web.archive.org/web/20180610221750/https://www.guideline.gov/summaries/summary/49928/screening-for-abnormal-blood-glucose-and-type-2-diabetes-mellitus-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:14:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930231443/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2016-09-30T23:14:43Z', 'uri': 'http://web.archive.org/web/20160930231443/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2017-10-03T03:02:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003030214/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2017-10-03T03:02:14Z', 'uri': 'http://web.archive.org/web/20171003030214/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2018-04-14T02:22:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414022250/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2018-04-14T02:22:50Z', 'uri': 'http://web.archive.org/web/20180414022250/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2018-05-19T09:12:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519091232/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2018-05-19T09:12:32Z', 'uri': 'http://web.archive.org/web/20180519091232/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2018-06-09T15:21:48Z', 'uri': 'http://web.archive.org/web/20180609152148/https://www.guideline.gov/summaries/summary/49929/older-people-with-social-care-needs-and-multiple-longterm-conditions'}, {'datetime': '2018-06-11T14:49:54Z', 'uri': 'http://web.archive.org/web/20180611144954/https://www.guideline.gov/summaries/summary/49929/Older-people-with-social-care-needs-and-multiple-longterm-conditions'}]
https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930231434/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2016-09-30T23:14:34Z', 'uri': 'http://web.archive.org/web/20160930231434/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2017-10-03T03:02:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003030205/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2017-10-03T03:02:05Z', 'uri': 'http://web.archive.org/web/20171003030205/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2018-04-14T02:22:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414022241/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2018-04-14T02:22:41Z', 'uri': 'http://web.archive.org/web/20180414022241/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2018-05-19T09:12:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519091220/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2018-05-19T09:12:20Z', 'uri': 'http://web.archive.org/web/20180519091220/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}, {'datetime': '2018-06-09T10:34:55Z', 'uri': 'http://web.archive.org/web/20180609103455/https://www.guideline.gov/summaries/summary/49930/childrens-attachment-attachment-in-children-and-young-people-who-are-adopted-from-care-in-care-or-at-high-risk-of-going-into-care'}]
https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930231450/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2016-09-30T23:14:50Z', 'uri': 'http://web.archive.org/web/20160930231450/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2017-10-03T03:02:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003030222/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2017-10-03T03:02:22Z', 'uri': 'http://web.archive.org/web/20171003030222/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2018-04-14T02:23:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414022300/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2018-04-14T02:23:00Z', 'uri': 'http://web.archive.org/web/20180414022300/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2018-05-19T09:12:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519091243/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2018-05-19T09:12:43Z', 'uri': 'http://web.archive.org/web/20180519091243/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}, {'datetime': '2018-06-09T15:20:58Z', 'uri': 'http://web.archive.org/web/20180609152058/https://www.guideline.gov/summaries/summary/49931/type-2-diabetes-in-adults-management'}]
https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:11:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930231146/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2016-09-30T23:11:46Z', 'uri': 'http://web.archive.org/web/20160930231146/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2017-10-03T02:59:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003025925/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2017-10-03T02:59:25Z', 'uri': 'http://web.archive.org/web/20171003025925/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2018-04-14T02:20:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414022012/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2018-04-14T02:20:12Z', 'uri': 'http://web.archive.org/web/20180414022012/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2018-05-19T09:09:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519090914/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2018-05-19T09:09:14Z', 'uri': 'http://web.archive.org/web/20180519090914/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}, {'datetime': '2018-06-09T12:14:47Z', 'uri': 'http://web.archive.org/web/20180609121447/https://www.guideline.gov/summaries/summary/49932/american-geriatrics-society-abstracted-clinical-practice-guideline-for-postoperative-delirium-in-older-adults'}]
https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults	ARCHIVED	16 mementos	[{'datetime': '2016-09-30T23:11:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930231139/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2016-09-30T23:11:39Z', 'uri': 'http://web.archive.org/web/20160930231139/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2016-11-09T21:18:45Z', 'uri': 'http://web.archive.org/web/20161109211845/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2017-07-02T09:03:25Z', 'uri': 'http://web.archive.org/web/20170702090325/https://guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2017-07-09T03:09:56Z', 'uri': 'http://web.archive.org/web/20170709030956/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2017-07-13T02:42:55Z', 'uri': 'http://web.archive.org/web/20170713024255/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2017-10-03T02:59:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003025916/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2017-10-03T02:59:16Z', 'uri': 'http://web.archive.org/web/20171003025916/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2017-12-11T13:23:24Z', 'uri': 'http://web.archive.org/web/20171211132324/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-04-13T17:01:38Z', 'uri': 'http://wayback.archive-it.org/all/20180413170138/https://www.guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-04-13T17:01:38Z', 'uri': 'http://web.archive.org/web/20180413170138/https://www.guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-05-18T19:25:53Z', 'uri': 'http://wayback.archive-it.org/all/20180518192553/https://www.guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-05-18T19:25:53Z', 'uri': 'http://web.archive.org/web/20180518192553/https://www.guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-06-01T14:51:09Z', 'uri': 'http://web.archive.org/web/20180601145109/https://www.guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-06-09T10:32:06Z', 'uri': 'http://web.archive.org/web/20180609103206/https://www.guideline.gov/summaries/summary/49933/American-Geriatrics-Society-2015-updated-Beers-Criteria-for-potentially-inappropriate-medication-use-in-older-adults'}, {'datetime': '2018-06-09T15:28:32Z', 'uri': 'http://web.archive.org/web/20180609152832/https://www.guideline.gov/summaries/summary/49933/american-geriatrics-society-2015-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults'}]
https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:11:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930231131/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2016-09-30T23:11:31Z', 'uri': 'http://web.archive.org/web/20160930231131/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2017-10-03T02:59:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003025907/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2017-10-03T02:59:07Z', 'uri': 'http://web.archive.org/web/20171003025907/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-04-14T02:20:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414022001/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-04-14T02:20:01Z', 'uri': 'http://web.archive.org/web/20180414022001/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-05-19T09:09:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519090903/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-05-19T09:09:03Z', 'uri': 'http://web.archive.org/web/20180519090903/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}, {'datetime': '2018-06-09T15:29:12Z', 'uri': 'http://web.archive.org/web/20180609152912/https://www.guideline.gov/summaries/summary/49934/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-surgical-management-of-osteoarthritis-of-the-knee'}]
https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930231408/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2016-09-30T23:14:08Z', 'uri': 'http://web.archive.org/web/20160930231408/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2017-10-03T03:01:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003030143/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2017-10-03T03:01:43Z', 'uri': 'http://web.archive.org/web/20171003030143/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2018-04-14T02:22:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414022215/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2018-04-14T02:22:15Z', 'uri': 'http://web.archive.org/web/20180414022215/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2018-05-19T09:11:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519091138/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2018-05-19T09:11:38Z', 'uri': 'http://web.archive.org/web/20180519091138/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}, {'datetime': '2018-06-10T23:02:23Z', 'uri': 'http://web.archive.org/web/20180610230223/https://www.guideline.gov/summaries/summary/49935/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab'}]
https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930231402/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2016-09-30T23:14:02Z', 'uri': 'http://web.archive.org/web/20160930231402/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2017-10-03T03:01:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003030136/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2017-10-03T03:01:36Z', 'uri': 'http://web.archive.org/web/20171003030136/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2018-04-14T02:22:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414022207/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2018-04-14T02:22:07Z', 'uri': 'http://web.archive.org/web/20180414022207/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2018-05-19T09:11:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519091128/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2018-05-19T09:11:28Z', 'uri': 'http://web.archive.org/web/20180519091128/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}, {'datetime': '2018-06-09T19:26:33Z', 'uri': 'http://web.archive.org/web/20180609192633/https://www.guideline.gov/summaries/summary/49936/apremilast-for-treating-moderate-to-severe-plaque-psoriasis'}]
https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930231420/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2016-09-30T23:14:20Z', 'uri': 'http://web.archive.org/web/20160930231420/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2017-10-03T03:01:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003030152/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2017-10-03T03:01:52Z', 'uri': 'http://web.archive.org/web/20171003030152/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2018-04-14T02:22:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414022225/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2018-04-14T02:22:25Z', 'uri': 'http://web.archive.org/web/20180414022225/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2018-05-19T09:11:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519091150/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2018-05-19T09:11:50Z', 'uri': 'http://web.archive.org/web/20180519091150/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}, {'datetime': '2018-06-09T20:13:21Z', 'uri': 'http://web.archive.org/web/20180609201321/https://www.guideline.gov/summaries/summary/49937/official-american-thoracic-society-technical-standards-spirometry-in-the-occupational-setting'}]
https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930231355/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:13:55Z', 'uri': 'http://web.archive.org/web/20160930231355/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:01:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003030129/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2017-10-03T03:01:29Z', 'uri': 'http://web.archive.org/web/20171003030129/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:21:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414022157/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:21:57Z', 'uri': 'http://web.archive.org/web/20180414022157/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:11:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519091119/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:11:19Z', 'uri': 'http://web.archive.org/web/20180519091119/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:22:56Z', 'uri': 'http://web.archive.org/web/20180609222256/https://www.guideline.gov/summaries/summary/49938/reducing-pain-during-vaccine-injections-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:13Z', 'uri': 'http://wayback.archive-it.org/all/20160930231313/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2016-09-30T23:13:13Z', 'uri': 'http://web.archive.org/web/20160930231313/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2017-10-03T03:00:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003030044/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2017-10-03T03:00:44Z', 'uri': 'http://web.archive.org/web/20171003030044/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2018-04-14T02:21:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414022102/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2018-04-14T02:21:02Z', 'uri': 'http://web.archive.org/web/20180414022102/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2018-05-19T09:10:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519091017/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2018-05-19T09:10:17Z', 'uri': 'http://web.archive.org/web/20180519091017/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}, {'datetime': '2018-06-09T23:20:24Z', 'uri': 'http://web.archive.org/web/20180609232024/https://www.guideline.gov/summaries/summary/49946/guideline-for-radiation-safety'}]
https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930231301/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2016-09-30T23:13:01Z', 'uri': 'http://web.archive.org/web/20160930231301/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2017-10-03T03:00:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003030028/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2017-10-03T03:00:28Z', 'uri': 'http://web.archive.org/web/20171003030028/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2018-04-14T02:20:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414022048/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2018-04-14T02:20:48Z', 'uri': 'http://web.archive.org/web/20180414022048/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2018-05-19T09:09:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519090958/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2018-05-19T09:09:58Z', 'uri': 'http://web.archive.org/web/20180519090958/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}, {'datetime': '2018-06-09T23:20:20Z', 'uri': 'http://web.archive.org/web/20180609232020/https://www.guideline.gov/summaries/summary/49947/guideline-for-prevention-of-unplanned-patient-hypothermia'}]
https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:12:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930231255/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2016-09-30T23:12:55Z', 'uri': 'http://web.archive.org/web/20160930231255/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2017-10-03T03:00:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003030022/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2017-10-03T03:00:22Z', 'uri': 'http://web.archive.org/web/20171003030022/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2018-04-14T02:20:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414022041/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2018-04-14T02:20:41Z', 'uri': 'http://web.archive.org/web/20180414022041/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2018-05-19T09:09:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519090949/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2018-05-19T09:09:49Z', 'uri': 'http://web.archive.org/web/20180519090949/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}, {'datetime': '2018-06-09T23:20:30Z', 'uri': 'http://web.archive.org/web/20180609232030/https://www.guideline.gov/summaries/summary/49948/guideline-for-prevention-of-retained-surgical-items'}]
https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:12:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930231248/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2016-09-30T23:12:48Z', 'uri': 'http://web.archive.org/web/20160930231248/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2017-10-03T03:00:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003030015/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2017-10-03T03:00:15Z', 'uri': 'http://web.archive.org/web/20171003030015/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2018-04-14T02:20:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414022034/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2018-04-14T02:20:34Z', 'uri': 'http://web.archive.org/web/20180414022034/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2018-05-19T09:09:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519090940/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2018-05-19T09:09:40Z', 'uri': 'http://web.archive.org/web/20180519090940/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}, {'datetime': '2018-06-09T23:20:17Z', 'uri': 'http://web.archive.org/web/20180609232017/https://www.guideline.gov/summaries/summary/49949/guideline-for-care-of-the-patient-receiving-moderate-sedationanalgesia'}]
https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:07Z', 'uri': 'http://wayback.archive-it.org/all/20160930231307/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2016-09-30T23:13:07Z', 'uri': 'http://web.archive.org/web/20160930231307/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2017-10-03T03:00:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003030034/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2017-10-03T03:00:34Z', 'uri': 'http://web.archive.org/web/20171003030034/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2018-04-14T02:20:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414022054/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2018-04-14T02:20:54Z', 'uri': 'http://web.archive.org/web/20180414022054/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2018-05-19T09:10:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519091008/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2018-05-19T09:10:08Z', 'uri': 'http://web.archive.org/web/20180519091008/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}, {'datetime': '2018-06-09T11:03:55Z', 'uri': 'http://web.archive.org/web/20180609110355/https://www.guideline.gov/summaries/summary/49950/guideline-for-processing-flexible-endoscopes'}]
https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930231349/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2016-09-30T23:13:49Z', 'uri': 'http://web.archive.org/web/20160930231349/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2017-10-03T03:01:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003030122/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2017-10-03T03:01:22Z', 'uri': 'http://web.archive.org/web/20171003030122/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2018-04-14T02:21:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414022149/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2018-04-14T02:21:49Z', 'uri': 'http://web.archive.org/web/20180414022149/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2018-05-19T09:11:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519091110/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2018-05-19T09:11:10Z', 'uri': 'http://web.archive.org/web/20180519091110/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}, {'datetime': '2018-06-09T12:00:57Z', 'uri': 'http://web.archive.org/web/20180609120057/https://www.guideline.gov/summaries/summary/49951/recommendations-on-screening-for-cognitive-impairment-in-older-adults'}]
https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930231058/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2016-09-30T23:10:58Z', 'uri': 'http://web.archive.org/web/20160930231058/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2017-10-03T02:58:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003025833/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2017-10-03T02:58:33Z', 'uri': 'http://web.archive.org/web/20171003025833/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-04-14T02:19:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414021928/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-04-14T02:19:28Z', 'uri': 'http://web.archive.org/web/20180414021928/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-05-19T09:08:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519090825/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-05-19T09:08:25Z', 'uri': 'http://web.archive.org/web/20180519090825/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}, {'datetime': '2018-06-09T20:51:40Z', 'uri': 'http://web.archive.org/web/20180609205140/https://www.guideline.gov/summaries/summary/49952/interpretive-diagnostic-error-reduction-in-surgical-pathology-and-cytology-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center-and-the-association-of-directors-of-anatomic-and-surgical-pathology'}]
https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:14:14Z', 'uri': 'http://wayback.archive-it.org/all/20160930231414/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2016-09-30T23:14:14Z', 'uri': 'http://web.archive.org/web/20160930231414/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2017-10-03T03:01:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003030149/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2017-10-03T03:01:49Z', 'uri': 'http://web.archive.org/web/20171003030149/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2018-04-14T02:22:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414022222/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2018-04-14T02:22:22Z', 'uri': 'http://web.archive.org/web/20180414022222/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2018-05-19T09:11:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519091147/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2018-05-19T09:11:47Z', 'uri': 'http://web.archive.org/web/20180519091147/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}, {'datetime': '2018-06-09T15:25:53Z', 'uri': 'http://web.archive.org/web/20180609152553/https://www.guideline.gov/summaries/summary/49954/transition-between-inpatient-hospital-settings-and-community-or-care-home-settings-for-adults-with-social-care-needs'}]
https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:12:03Z', 'uri': 'http://wayback.archive-it.org/all/20160930231203/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2016-09-30T23:12:03Z', 'uri': 'http://web.archive.org/web/20160930231203/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2017-10-03T02:59:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003025955/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2017-10-03T02:59:55Z', 'uri': 'http://web.archive.org/web/20171003025955/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2018-04-14T02:20:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414022021/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2018-04-14T02:20:21Z', 'uri': 'http://web.archive.org/web/20180414022021/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2018-05-19T09:09:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519090924/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2018-05-19T09:09:24Z', 'uri': 'http://web.archive.org/web/20180519090924/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}, {'datetime': '2018-06-10T21:49:28Z', 'uri': 'http://web.archive.org/web/20180610214928/https://www.guideline.gov/summaries/summary/49955/intravenous-fluid-therapy-in-children-and-young-people-in-hospital'}]
https://www.guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T23:11:54Z', 'uri': 'http://wayback.archive-it.org/all/20160930231154/https://www.guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2016-09-30T23:11:54Z', 'uri': 'http://web.archive.org/web/20160930231154/https://www.guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2017-10-03T02:59:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003025952/https://www.guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2017-10-03T02:59:52Z', 'uri': 'http://web.archive.org/web/20171003025952/https://www.guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-01-10T13:15:30Z', 'uri': 'http://web.archive.org/web/20180110131530/https://guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-04-13T17:02:43Z', 'uri': 'http://wayback.archive-it.org/all/20180413170243/https://www.guideline.gov/summaries/summary/49956/Care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-04-13T17:02:43Z', 'uri': 'http://web.archive.org/web/20180413170243/https://www.guideline.gov/summaries/summary/49956/Care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-05-18T19:29:18Z', 'uri': 'http://wayback.archive-it.org/all/20180518192918/https://www.guideline.gov/summaries/summary/49956/Care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-05-18T19:29:18Z', 'uri': 'http://web.archive.org/web/20180518192918/https://www.guideline.gov/summaries/summary/49956/Care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-06-01T14:50:54Z', 'uri': 'http://web.archive.org/web/20180601145054/https://www.guideline.gov/summaries/summary/49956/Care-of-dying-adults-in-the-last-days-of-life'}, {'datetime': '2018-06-09T15:25:39Z', 'uri': 'http://web.archive.org/web/20180609152539/https://www.guideline.gov/summaries/summary/49956/care-of-dying-adults-in-the-last-days-of-life'}]
https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930230924/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:09:24Z', 'uri': 'http://web.archive.org/web/20160930230924/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:57:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003025708/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:57:08Z', 'uri': 'http://web.archive.org/web/20171003025708/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:17:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414021730/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:17:30Z', 'uri': 'http://web.archive.org/web/20180414021730/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T09:06:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519090618/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T09:06:18Z', 'uri': 'http://web.archive.org/web/20180519090618/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-11T06:08:26Z', 'uri': 'http://web.archive.org/web/20180611060826/https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930230950/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2016-09-30T23:09:50Z', 'uri': 'http://web.archive.org/web/20160930230950/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2017-10-03T02:57:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003025728/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2017-10-03T02:57:28Z', 'uri': 'http://web.archive.org/web/20171003025728/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2018-04-14T02:18:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414021806/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2018-04-14T02:18:06Z', 'uri': 'http://web.archive.org/web/20180414021806/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2018-05-19T09:06:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519090651/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2018-05-19T09:06:51Z', 'uri': 'http://web.archive.org/web/20180519090651/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}, {'datetime': '2018-06-09T21:12:49Z', 'uri': 'http://web.archive.org/web/20180609211249/https://www.guideline.gov/summaries/summary/49958/cystic-fibrosis-foundation-pulmonary-guideline-pharmacologic-approaches-to-prevention-and-eradication-of-initial-pseudomonas-aeruginosa-infection'}]
https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:34Z', 'uri': 'http://wayback.archive-it.org/all/20160930231334/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2016-09-30T23:13:34Z', 'uri': 'http://web.archive.org/web/20160930231334/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2017-10-03T03:01:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003030108/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2017-10-03T03:01:08Z', 'uri': 'http://web.archive.org/web/20171003030108/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2018-04-14T02:21:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414022132/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2018-04-14T02:21:32Z', 'uri': 'http://web.archive.org/web/20180414022132/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2018-05-19T09:10:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519091051/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2018-05-19T09:10:51Z', 'uri': 'http://web.archive.org/web/20180519091051/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}, {'datetime': '2018-06-10T01:07:28Z', 'uri': 'http://web.archive.org/web/20180610010728/https://www.guideline.gov/summaries/summary/49960/ciclosporin-for-treating-dry-eye-disease-that-has-not-improved-despite-treatment-with-artificial-tears'}]
https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930231319/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2016-09-30T23:13:19Z', 'uri': 'http://web.archive.org/web/20160930231319/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2017-10-03T03:00:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003030054/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2017-10-03T03:00:54Z', 'uri': 'http://web.archive.org/web/20171003030054/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2018-04-14T02:21:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414022116/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2018-04-14T02:21:16Z', 'uri': 'http://web.archive.org/web/20180414022116/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2018-05-19T09:10:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519091032/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2018-05-19T09:10:32Z', 'uri': 'http://web.archive.org/web/20180519091032/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}, {'datetime': '2018-06-10T22:41:51Z', 'uri': 'http://web.archive.org/web/20180610224151/https://www.guideline.gov/summaries/summary/49961/abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis'}]
https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:11:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930231125/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2016-09-30T23:11:25Z', 'uri': 'http://web.archive.org/web/20160930231125/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2017-10-03T02:59:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003025901/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2017-10-03T02:59:01Z', 'uri': 'http://web.archive.org/web/20171003025901/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2018-04-14T02:19:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414021953/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2018-04-14T02:19:53Z', 'uri': 'http://web.archive.org/web/20180414021953/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2018-05-19T09:08:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519090854/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2018-05-19T09:08:54Z', 'uri': 'http://web.archive.org/web/20180519090854/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}, {'datetime': '2018-06-09T21:16:13Z', 'uri': 'http://web.archive.org/web/20180609211613/https://www.guideline.gov/summaries/summary/49962/management-of-earlystage-hodgkin-lymphoma'}]
https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:13:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930231342/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2016-09-30T23:13:42Z', 'uri': 'http://web.archive.org/web/20160930231342/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2017-10-03T03:01:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003030115/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2017-10-03T03:01:15Z', 'uri': 'http://web.archive.org/web/20171003030115/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2018-04-14T02:21:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414022140/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2018-04-14T02:21:40Z', 'uri': 'http://web.archive.org/web/20180414022140/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2018-05-19T09:11:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519091101/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2018-05-19T09:11:01Z', 'uri': 'http://web.archive.org/web/20180519091101/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2018-06-11T09:19:14Z', 'uri': 'http://web.archive.org/web/20180611091914/https://www.guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}, {'datetime': '2018-06-15T12:55:30Z', 'uri': 'http://web.archive.org/web/20180615125530/https://guideline.gov/summaries/summary/49963/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy'}]
https://www.guideline.gov/summaries/summary/49964/tuberculosis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930231042/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2016-09-30T23:10:42Z', 'uri': 'http://web.archive.org/web/20160930231042/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2017-10-03T02:58:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003025820/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2017-10-03T02:58:20Z', 'uri': 'http://web.archive.org/web/20171003025820/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2018-04-14T02:19:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414021913/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2018-04-14T02:19:13Z', 'uri': 'http://web.archive.org/web/20180414021913/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2018-05-19T09:08:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519090810/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2018-05-19T09:08:10Z', 'uri': 'http://web.archive.org/web/20180519090810/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}, {'datetime': '2018-06-10T08:41:38Z', 'uri': 'http://web.archive.org/web/20180610084138/https://www.guideline.gov/summaries/summary/49964/tuberculosis'}]
https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930231023/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2016-09-30T23:10:23Z', 'uri': 'http://web.archive.org/web/20160930231023/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2017-10-03T02:58:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003025808/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2017-10-03T02:58:08Z', 'uri': 'http://web.archive.org/web/20171003025808/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2018-04-14T02:18:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414021850/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2018-04-14T02:18:50Z', 'uri': 'http://web.archive.org/web/20180414021850/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2018-05-19T09:07:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519090750/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2018-05-19T09:07:50Z', 'uri': 'http://web.archive.org/web/20180519090750/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}, {'datetime': '2018-06-09T20:55:21Z', 'uri': 'http://web.archive.org/web/20180609205521/https://www.guideline.gov/summaries/summary/49965/merkel-cell-carcinoma'}]
https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930231036/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2016-09-30T23:10:36Z', 'uri': 'http://web.archive.org/web/20160930231036/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2017-10-03T02:58:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003025814/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2017-10-03T02:58:14Z', 'uri': 'http://web.archive.org/web/20171003025814/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2018-04-14T02:19:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414021906/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2018-04-14T02:19:06Z', 'uri': 'http://web.archive.org/web/20180414021906/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2018-05-19T09:08:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519090800/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2018-05-19T09:08:00Z', 'uri': 'http://web.archive.org/web/20180519090800/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}, {'datetime': '2018-06-10T22:46:41Z', 'uri': 'http://web.archive.org/web/20180610224641/https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma'}]
https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:10:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930231030/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2016-09-30T23:10:30Z', 'uri': 'http://web.archive.org/web/20160930231030/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2017-07-14T11:31:56Z', 'uri': 'http://web.archive.org/web/20170714113156/https://guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2017-10-02T20:06:23Z', 'uri': 'http://wayback.archive-it.org/all/20171002200623/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2017-10-02T20:06:23Z', 'uri': 'http://web.archive.org/web/20171002200623/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2018-04-14T02:18:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414021859/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2018-04-14T02:18:59Z', 'uri': 'http://web.archive.org/web/20180414021859/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2018-05-18T19:31:59Z', 'uri': 'http://wayback.archive-it.org/all/20180518193159/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2018-05-18T19:31:59Z', 'uri': 'http://web.archive.org/web/20180518193159/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}, {'datetime': '2018-06-09T10:43:17Z', 'uri': 'http://web.archive.org/web/20180609104317/https://www.guideline.gov/summaries/summary/49967/somatostatin-analogues-for-the-management-of-neuroendocrine-tumours'}]
https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930230701/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2016-09-30T23:07:01Z', 'uri': 'http://web.archive.org/web/20160930230701/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2017-10-03T02:54:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003025432/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2017-10-03T02:54:32Z', 'uri': 'http://web.archive.org/web/20171003025432/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2018-04-14T02:14:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414021431/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2018-04-14T02:14:31Z', 'uri': 'http://web.archive.org/web/20180414021431/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2018-05-19T09:02:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519090257/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2018-05-19T09:02:57Z', 'uri': 'http://web.archive.org/web/20180519090257/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}, {'datetime': '2018-06-09T11:58:23Z', 'uri': 'http://web.archive.org/web/20180609115823/https://www.guideline.gov/summaries/summary/49968/vadod-clinical-practice-guideline-for-the-management-of-substance-use-disorders'}]
https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:11:12Z', 'uri': 'http://wayback.archive-it.org/all/20160930231112/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2016-09-30T23:11:12Z', 'uri': 'http://web.archive.org/web/20160930231112/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2017-10-03T02:58:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003025848/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2017-10-03T02:58:48Z', 'uri': 'http://web.archive.org/web/20171003025848/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2018-04-14T02:19:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414021936/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2018-04-14T02:19:36Z', 'uri': 'http://web.archive.org/web/20180414021936/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2018-05-19T09:08:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519090835/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2018-05-19T09:08:35Z', 'uri': 'http://web.archive.org/web/20180519090835/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}, {'datetime': '2018-06-10T19:13:10Z', 'uri': 'http://web.archive.org/web/20180610191310/https://www.guideline.gov/summaries/summary/49969/approach-to-fever-assessment-in-ambulatory-cancer-patients-receiving-chemotherapy'}]
https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:11:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930231119/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2016-09-30T23:11:19Z', 'uri': 'http://web.archive.org/web/20160930231119/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2017-10-03T02:58:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003025854/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2017-10-03T02:58:54Z', 'uri': 'http://web.archive.org/web/20171003025854/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2018-04-14T02:19:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414021944/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2018-04-14T02:19:44Z', 'uri': 'http://web.archive.org/web/20180414021944/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2018-05-19T09:08:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519090845/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2018-05-19T09:08:45Z', 'uri': 'http://web.archive.org/web/20180519090845/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}, {'datetime': '2018-06-09T21:16:15Z', 'uri': 'http://web.archive.org/web/20180609211615/https://www.guideline.gov/summaries/summary/49970/followup-of-patients-who-are-clinically-diseasefree-after-primary-treatment-for-fallopian-tube-primary-peritoneal-and-epithelial-ovarian-cancer'}]
https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930230743/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2016-09-30T23:07:43Z', 'uri': 'http://web.archive.org/web/20160930230743/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2017-10-03T02:55:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003025508/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2017-10-03T02:55:08Z', 'uri': 'http://web.archive.org/web/20171003025508/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2018-04-14T02:15:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414021513/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2018-04-14T02:15:13Z', 'uri': 'http://web.archive.org/web/20180414021513/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2018-05-19T09:03:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519090344/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2018-05-19T09:03:44Z', 'uri': 'http://web.archive.org/web/20180519090344/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}, {'datetime': '2018-06-09T21:29:39Z', 'uri': 'http://web.archive.org/web/20180609212939/https://www.guideline.gov/summaries/summary/49977/an-official-american-thoracic-society-clinical-practice-guideline-the-diagnosis-of-intensive-care-unitacquired-weakness-in-adults'}]
https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:57:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003025743/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}, {'datetime': '2017-10-03T02:57:43Z', 'uri': 'http://web.archive.org/web/20171003025743/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}, {'datetime': '2018-04-14T02:18:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414021823/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}, {'datetime': '2018-04-14T02:18:23Z', 'uri': 'http://web.archive.org/web/20180414021823/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}, {'datetime': '2018-05-19T09:07:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519090720/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}, {'datetime': '2018-05-19T09:07:20Z', 'uri': 'http://web.archive.org/web/20180519090720/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}, {'datetime': '2018-06-09T12:15:39Z', 'uri': 'http://web.archive.org/web/20180609121539/https://www.guideline.gov/summaries/summary/49978/final-recommendation-statement-depression-in-adults-screening'}]
https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:13:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930231326/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2016-09-30T23:13:26Z', 'uri': 'http://web.archive.org/web/20160930231326/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2017-10-03T03:01:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003030100/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2017-10-03T03:01:00Z', 'uri': 'http://web.archive.org/web/20171003030100/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2018-04-14T02:21:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414022123/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2018-04-14T02:21:23Z', 'uri': 'http://web.archive.org/web/20180414022123/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2018-05-19T09:10:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519091041/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2018-05-19T09:10:41Z', 'uri': 'http://web.archive.org/web/20180519091041/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}, {'datetime': '2018-06-10T22:41:52Z', 'uri': 'http://web.archive.org/web/20180610224152/https://www.guideline.gov/summaries/summary/49981/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed'}]
https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930231052/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2016-09-30T23:10:52Z', 'uri': 'http://web.archive.org/web/20160930231052/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:58:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003025825/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:58:25Z', 'uri': 'http://web.archive.org/web/20171003025825/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:19:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414021918/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:19:18Z', 'uri': 'http://web.archive.org/web/20180414021918/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:08:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519090815/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T09:08:15Z', 'uri': 'http://web.archive.org/web/20180519090815/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:31Z', 'uri': 'http://web.archive.org/web/20180610010631/https://www.guideline.gov/summaries/summary/49985/treatment-of-symptoms-of-the-menopause-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:10Z', 'uri': 'http://wayback.archive-it.org/all/20160930230910/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2016-09-30T23:09:10Z', 'uri': 'http://web.archive.org/web/20160930230910/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2017-10-03T02:56:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003025654/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2017-10-03T02:56:54Z', 'uri': 'http://web.archive.org/web/20171003025654/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2018-04-14T02:17:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414021714/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2018-04-14T02:17:14Z', 'uri': 'http://web.archive.org/web/20180414021714/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2018-05-19T09:06:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519090600/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2018-05-19T09:06:00Z', 'uri': 'http://web.archive.org/web/20180519090600/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}, {'datetime': '2018-06-10T23:01:58Z', 'uri': 'http://web.archive.org/web/20180610230158/https://www.guideline.gov/summaries/summary/49999/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases'}]
https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930230852/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2016-09-30T23:08:52Z', 'uri': 'http://web.archive.org/web/20160930230852/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2017-10-03T02:56:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003025633/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2017-10-03T02:56:33Z', 'uri': 'http://web.archive.org/web/20171003025633/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-04-14T02:16:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414021648/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-04-14T02:16:48Z', 'uri': 'http://web.archive.org/web/20180414021648/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-05-19T09:05:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519090532/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-05-19T09:05:32Z', 'uri': 'http://web.archive.org/web/20180519090532/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-06-10T23:03:15Z', 'uri': 'http://web.archive.org/web/20180610230315/https://www.guideline.gov/summaries/summary/50000/enzalutamide-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}]
https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930230904/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2016-09-30T23:09:04Z', 'uri': 'http://web.archive.org/web/20160930230904/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2017-10-03T02:56:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003025647/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2017-10-03T02:56:47Z', 'uri': 'http://web.archive.org/web/20171003025647/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2018-04-14T02:17:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414021705/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2018-04-14T02:17:05Z', 'uri': 'http://web.archive.org/web/20180414021705/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2018-05-19T09:05:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519090551/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2018-05-19T09:05:51Z', 'uri': 'http://web.archive.org/web/20180519090551/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}, {'datetime': '2018-06-10T23:04:14Z', 'uri': 'http://web.archive.org/web/20180610230414/https://www.guideline.gov/summaries/summary/50001/panobinostat-for-treating-multiple-myeloma-after-at-least-2-previous-treatments'}]
https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:58Z', 'uri': 'http://wayback.archive-it.org/all/20160930230858/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2016-09-30T23:08:58Z', 'uri': 'http://web.archive.org/web/20160930230858/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2017-10-03T02:56:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003025640/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2017-10-03T02:56:40Z', 'uri': 'http://web.archive.org/web/20171003025640/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2018-04-14T02:16:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414021656/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2018-04-14T02:16:56Z', 'uri': 'http://web.archive.org/web/20180414021656/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2018-05-19T09:05:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519090542/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2018-05-19T09:05:42Z', 'uri': 'http://web.archive.org/web/20180519090542/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}, {'datetime': '2018-06-09T22:07:37Z', 'uri': 'http://web.archive.org/web/20180609220737/https://www.guideline.gov/summaries/summary/50002/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemotherapy'}]
https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:40Z', 'uri': 'http://wayback.archive-it.org/all/20160930230840/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2016-09-30T23:08:40Z', 'uri': 'http://web.archive.org/web/20160930230840/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2017-10-03T02:56:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003025619/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2017-10-03T02:56:19Z', 'uri': 'http://web.archive.org/web/20171003025619/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2018-04-14T02:16:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414021634/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2018-04-14T02:16:34Z', 'uri': 'http://web.archive.org/web/20180414021634/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2018-05-19T09:05:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519090514/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2018-05-19T09:05:14Z', 'uri': 'http://web.archive.org/web/20180519090514/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}, {'datetime': '2018-06-09T20:55:57Z', 'uri': 'http://web.archive.org/web/20180609205557/https://www.guideline.gov/summaries/summary/50006/kdoqi-clinical-practice-guideline-for-hemodialysis-adequacy-2015-update'}]
https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930230629/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2016-09-30T23:06:29Z', 'uri': 'http://web.archive.org/web/20160930230629/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2017-10-03T02:53:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003025357/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2017-10-03T02:53:57Z', 'uri': 'http://web.archive.org/web/20171003025357/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2018-04-14T02:13:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414021350/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2018-04-14T02:13:50Z', 'uri': 'http://web.archive.org/web/20180414021350/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2018-05-19T09:02:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519090210/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2018-05-19T09:02:10Z', 'uri': 'http://web.archive.org/web/20180519090210/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}, {'datetime': '2018-06-09T12:39:39Z', 'uri': 'http://web.archive.org/web/20180609123939/https://www.guideline.gov/summaries/summary/50007/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-selective-serotonin-reuptake-inhibitors'}]
https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930230918/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:09:18Z', 'uri': 'http://web.archive.org/web/20160930230918/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:57:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003025701/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:57:01Z', 'uri': 'http://web.archive.org/web/20171003025701/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:17:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414021722/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:17:22Z', 'uri': 'http://web.archive.org/web/20180414021722/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T09:06:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519090610/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T09:06:10Z', 'uri': 'http://web.archive.org/web/20180519090610/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T22:00:47Z', 'uri': 'http://web.archive.org/web/20180609220047/https://www.guideline.gov/summaries/summary/50008/practice-guideline-update-summary-corticosteroid-treatment-of-duchenne-muscular-dystrophy-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/50009/pneumonia-in-adults-diagnosis-and-management	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:11:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930231104/https://www.guideline.gov/summaries/summary/50009/pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2016-09-30T23:11:04Z', 'uri': 'http://web.archive.org/web/20160930231104/https://www.guideline.gov/summaries/summary/50009/pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2017-10-03T02:58:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003025839/https://www.guideline.gov/summaries/summary/50009/pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2017-10-03T02:58:39Z', 'uri': 'http://web.archive.org/web/20171003025839/https://www.guideline.gov/summaries/summary/50009/pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2018-04-13T17:01:56Z', 'uri': 'http://wayback.archive-it.org/all/20180413170156/https://www.guideline.gov/summaries/summary/50009/Pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2018-04-13T17:01:56Z', 'uri': 'http://web.archive.org/web/20180413170156/https://www.guideline.gov/summaries/summary/50009/Pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2018-05-18T19:29:26Z', 'uri': 'http://wayback.archive-it.org/all/20180518192926/https://www.guideline.gov/summaries/summary/50009/Pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2018-05-18T19:29:26Z', 'uri': 'http://web.archive.org/web/20180518192926/https://www.guideline.gov/summaries/summary/50009/Pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2018-06-01T14:51:00Z', 'uri': 'http://web.archive.org/web/20180601145100/https://www.guideline.gov/summaries/summary/50009/Pneumonia-in-adults-diagnosis-and-management'}, {'datetime': '2018-06-10T08:41:02Z', 'uri': 'http://web.archive.org/web/20180610084102/https://www.guideline.gov/summaries/summary/50009/pneumonia-in-adults-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T14:35:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930143550/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2016-09-30T14:35:50Z', 'uri': 'http://web.archive.org/web/20160930143550/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2017-07-14T11:20:32Z', 'uri': 'http://web.archive.org/web/20170714112032/https://guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2017-10-03T02:56:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003025610/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2017-10-03T02:56:10Z', 'uri': 'http://web.archive.org/web/20171003025610/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2018-04-14T02:16:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414021623/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2018-04-14T02:16:23Z', 'uri': 'http://web.archive.org/web/20180414021623/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2018-05-19T09:05:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519090501/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2018-05-19T09:05:01Z', 'uri': 'http://web.archive.org/web/20180519090501/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}, {'datetime': '2018-06-09T11:42:00Z', 'uri': 'http://web.archive.org/web/20180609114200/https://www.guideline.gov/summaries/summary/50010/myeloma-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930230832/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2016-09-30T23:08:32Z', 'uri': 'http://web.archive.org/web/20160930230832/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2017-10-03T02:55:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003025558/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2017-10-03T02:55:58Z', 'uri': 'http://web.archive.org/web/20171003025558/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2018-04-14T02:16:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414021613/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2018-04-14T02:16:13Z', 'uri': 'http://web.archive.org/web/20180414021613/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2018-05-19T09:04:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519090451/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2018-05-19T09:04:51Z', 'uri': 'http://web.archive.org/web/20180519090451/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}, {'datetime': '2018-06-09T21:23:49Z', 'uri': 'http://web.archive.org/web/20180609212349/https://www.guideline.gov/summaries/summary/50011/cancer-of-the-upper-aerodigestive-tract-assessment-and-management-in-people-aged-16-and-over'}]
https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:56Z', 'uri': 'http://wayback.archive-it.org/all/20160930230756/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2016-09-30T23:07:56Z', 'uri': 'http://web.archive.org/web/20160930230756/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2017-10-03T02:55:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003025521/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2017-10-03T02:55:21Z', 'uri': 'http://web.archive.org/web/20171003025521/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2018-04-14T02:15:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414021529/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2018-04-14T02:15:29Z', 'uri': 'http://web.archive.org/web/20180414021529/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2018-05-19T09:04:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519090401/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2018-05-19T09:04:01Z', 'uri': 'http://web.archive.org/web/20180519090401/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}, {'datetime': '2018-06-10T08:22:12Z', 'uri': 'http://web.archive.org/web/20180610082212/https://www.guideline.gov/summaries/summary/50012/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay'}]
https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b	ARCHIVED	13 mementos	[{'datetime': '2016-09-30T23:09:29Z', 'uri': 'http://wayback.archive-it.org/all/20160930230929/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2016-09-30T23:09:29Z', 'uri': 'http://web.archive.org/web/20160930230929/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2017-10-02T20:07:10Z', 'uri': 'http://wayback.archive-it.org/all/20171002200710/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2017-10-02T20:07:10Z', 'uri': 'http://web.archive.org/web/20171002200710/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-04-14T02:17:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414021738/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-04-14T02:17:38Z', 'uri': 'http://web.archive.org/web/20180414021738/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-05-18T19:32:42Z', 'uri': 'http://wayback.archive-it.org/all/20180518193242/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-05-18T19:32:42Z', 'uri': 'http://web.archive.org/web/20180518193242/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-06-09T10:38:50Z', 'uri': 'http://web.archive.org/web/20180609103850/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-07-12T21:38:23Z', 'uri': 'http://web.archive.org/web/20180712213823/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-07-12T21:38:23Z', 'uri': 'http://web.archive.org/web/20180712213823/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-07-12T21:38:27Z', 'uri': 'http://web.archive.org/web/20180712213827/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}, {'datetime': '2018-07-12T21:38:27Z', 'uri': 'http://web.archive.org/web/20180712213827/https://www.guideline.gov/summaries/summary/50013/aasld-guidelines-for-treatment-of-chronic-hepatitis-b'}]
https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930231002/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:10:02Z', 'uri': 'http://web.archive.org/web/20160930231002/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T02:57:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003025751/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T02:57:51Z', 'uri': 'http://web.archive.org/web/20171003025751/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:18:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414021833/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:18:33Z', 'uri': 'http://web.archive.org/web/20180414021833/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:07:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519090730/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:07:30Z', 'uri': 'http://web.archive.org/web/20180519090730/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T11:20:17Z', 'uri': 'http://web.archive.org/web/20180609112017/https://www.guideline.gov/summaries/summary/50033/screening-for-breast-cancer-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:57:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003025735/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}, {'datetime': '2017-10-03T02:57:35Z', 'uri': 'http://web.archive.org/web/20171003025735/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}, {'datetime': '2018-04-14T02:18:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414021814/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}, {'datetime': '2018-04-14T02:18:14Z', 'uri': 'http://web.archive.org/web/20180414021814/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}, {'datetime': '2018-05-19T09:07:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519090710/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}, {'datetime': '2018-05-19T09:07:10Z', 'uri': 'http://web.archive.org/web/20180519090710/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}, {'datetime': '2018-06-09T19:03:51Z', 'uri': 'http://web.archive.org/web/20180609190351/https://www.guideline.gov/summaries/summary/50034/final-recommendation-statement-autism-spectrum-disorder-in-young-children-screening'}]
https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:43Z', 'uri': 'http://wayback.archive-it.org/all/20160930230943/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2016-09-30T23:09:43Z', 'uri': 'http://web.archive.org/web/20160930230943/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2017-10-03T02:57:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003025720/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2017-10-03T02:57:20Z', 'uri': 'http://web.archive.org/web/20171003025720/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2018-04-14T02:17:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414021755/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2018-04-14T02:17:55Z', 'uri': 'http://web.archive.org/web/20180414021755/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2018-05-19T09:06:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519090641/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2018-05-19T09:06:41Z', 'uri': 'http://web.archive.org/web/20180519090641/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}, {'datetime': '2018-06-09T11:57:16Z', 'uri': 'http://web.archive.org/web/20180609115716/https://www.guideline.gov/summaries/summary/50062/responding-to-intimate-partner-violence-and-sexual-violence-against-women-who-clinical-and-policy-guidelines'}]
https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:09:38Z', 'uri': 'http://wayback.archive-it.org/all/20160930230938/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2016-09-30T23:09:38Z', 'uri': 'http://web.archive.org/web/20160930230938/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2017-10-03T02:57:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003025714/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2017-10-03T02:57:14Z', 'uri': 'http://web.archive.org/web/20171003025714/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2018-04-14T02:17:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414021748/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2018-04-14T02:17:48Z', 'uri': 'http://web.archive.org/web/20180414021748/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2018-05-19T09:06:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519090633/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2018-05-19T09:06:33Z', 'uri': 'http://web.archive.org/web/20180519090633/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}, {'datetime': '2018-06-09T20:01:49Z', 'uri': 'http://web.archive.org/web/20180609200149/https://www.guideline.gov/summaries/summary/50066/the-society-of-thoracic-surgeons-the-society-of-cardiovascular-anesthesiologists-and-the-american-society-of-extracorporeal-technology-clinical-practice-guidelines-for-cardiopulmonary-bypass-temperature-management-during-cardiopulmonary-bypass'}]
https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930230817/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2016-09-30T23:08:17Z', 'uri': 'http://web.archive.org/web/20160930230817/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2017-10-03T02:55:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003025544/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2017-10-03T02:55:44Z', 'uri': 'http://web.archive.org/web/20171003025544/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2018-04-14T02:15:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414021555/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2018-04-14T02:15:55Z', 'uri': 'http://web.archive.org/web/20180414021555/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2018-05-19T09:04:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519090430/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2018-05-19T09:04:30Z', 'uri': 'http://web.archive.org/web/20180519090430/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}, {'datetime': '2018-06-10T00:14:47Z', 'uri': 'http://web.archive.org/web/20180610001447/https://www.guideline.gov/summaries/summary/50070/practice-guidelines-for-obstetric-anesthesia-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-obstetric-anesthesia-and-the-society-for-obstetric-anesthesia-and-perinatology'}]
https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:26Z', 'uri': 'http://wayback.archive-it.org/all/20160930230826/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2016-09-30T23:08:26Z', 'uri': 'http://web.archive.org/web/20160930230826/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2017-10-03T02:55:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003025551/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2017-10-03T02:55:51Z', 'uri': 'http://web.archive.org/web/20171003025551/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2018-04-14T02:16:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414021605/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2018-04-14T02:16:05Z', 'uri': 'http://web.archive.org/web/20180414021605/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2018-05-19T09:04:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519090440/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2018-05-19T09:04:40Z', 'uri': 'http://web.archive.org/web/20180519090440/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}, {'datetime': '2018-06-09T11:30:11Z', 'uri': 'http://web.archive.org/web/20180609113011/https://www.guideline.gov/summaries/summary/50071/practice-guidelines-for-the-prevention-detection-and-management-of-respiratory-depression-associated-with-neuraxial-opioid-administration-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-neuraxial-opioids-and-the-american-society-of'}]
https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930230809/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2016-09-30T23:08:09Z', 'uri': 'http://web.archive.org/web/20160930230809/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2017-10-03T02:55:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003025536/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2017-10-03T02:55:36Z', 'uri': 'http://web.archive.org/web/20171003025536/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2018-04-14T02:15:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414021546/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2018-04-14T02:15:46Z', 'uri': 'http://web.archive.org/web/20180414021546/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2018-05-19T09:04:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519090420/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2018-05-19T09:04:20Z', 'uri': 'http://web.archive.org/web/20180519090420/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}, {'datetime': '2018-06-10T00:04:23Z', 'uri': 'http://web.archive.org/web/20180610000423/https://www.guideline.gov/summaries/summary/50072/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection'}]
https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:10:16Z', 'uri': 'http://wayback.archive-it.org/all/20160930231016/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2016-09-30T23:10:16Z', 'uri': 'http://web.archive.org/web/20160930231016/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T02:58:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003025800/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T02:58:00Z', 'uri': 'http://web.archive.org/web/20171003025800/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:18:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414021842/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:18:42Z', 'uri': 'http://web.archive.org/web/20180414021842/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:07:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519090741/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T09:07:41Z', 'uri': 'http://web.archive.org/web/20180519090741/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T10:33:15Z', 'uri': 'http://web.archive.org/web/20180609103315/https://www.guideline.gov/summaries/summary/50073/screening-for-depression-in-children-and-adolescents-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930230649/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2016-09-30T23:06:49Z', 'uri': 'http://web.archive.org/web/20160930230649/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2017-10-03T02:54:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003025418/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2017-10-03T02:54:18Z', 'uri': 'http://web.archive.org/web/20171003025418/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2018-04-14T02:14:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414021416/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2018-04-14T02:14:16Z', 'uri': 'http://web.archive.org/web/20180414021416/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2018-05-19T09:02:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519090237/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2018-05-19T09:02:37Z', 'uri': 'http://web.archive.org/web/20180519090237/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}, {'datetime': '2018-06-09T21:18:31Z', 'uri': 'http://web.archive.org/web/20180609211831/https://www.guideline.gov/summaries/summary/50074/subclinical-hypothyroidism-in-the-infertile-female-population-a-guideline'}]
https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930230846/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2016-09-30T23:08:46Z', 'uri': 'http://web.archive.org/web/20160930230846/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:56:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003025627/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:56:27Z', 'uri': 'http://web.archive.org/web/20171003025627/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T02:16:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414021641/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T02:16:41Z', 'uri': 'http://web.archive.org/web/20180414021641/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:05:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519090523/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T09:05:23Z', 'uri': 'http://web.archive.org/web/20180519090523/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T12:21:25Z', 'uri': 'http://web.archive.org/web/20180609122125/https://www.guideline.gov/summaries/summary/50075/nonpharmacologic-versus-pharmacologic-treatment-of-adult-patients-with-major-depressive-disorder-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:52Z', 'uri': 'http://wayback.archive-it.org/all/20160930230452/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2016-09-30T23:04:52Z', 'uri': 'http://web.archive.org/web/20160930230452/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2017-10-03T02:51:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003025146/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2017-10-03T02:51:46Z', 'uri': 'http://web.archive.org/web/20171003025146/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2018-04-14T02:11:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414021152/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2018-04-14T02:11:52Z', 'uri': 'http://web.archive.org/web/20180414021152/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2018-05-19T08:59:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519085949/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2018-05-19T08:59:49Z', 'uri': 'http://web.archive.org/web/20180519085949/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}, {'datetime': '2018-06-09T11:23:19Z', 'uri': 'http://web.archive.org/web/20180609112319/https://www.guideline.gov/summaries/summary/50076/fractures-complex-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:05:01Z', 'uri': 'http://wayback.archive-it.org/all/20160930230501/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2016-09-30T23:05:01Z', 'uri': 'http://web.archive.org/web/20160930230501/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2017-01-06T23:46:58Z', 'uri': 'http://web.archive.org/web/20170106234658/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2017-10-03T02:52:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003025213/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2017-10-03T02:52:13Z', 'uri': 'http://web.archive.org/web/20171003025213/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2018-04-14T02:12:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414021202/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2018-04-14T02:12:02Z', 'uri': 'http://web.archive.org/web/20180414021202/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2018-05-19T09:00:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519090001/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2018-05-19T09:00:01Z', 'uri': 'http://web.archive.org/web/20180519090001/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}, {'datetime': '2018-06-09T23:36:01Z', 'uri': 'http://web.archive.org/web/20180609233601/https://www.guideline.gov/summaries/summary/50077/fractures-noncomplex-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930230432/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2016-09-30T23:04:32Z', 'uri': 'http://web.archive.org/web/20160930230432/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2017-10-03T02:51:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003025113/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2017-10-03T02:51:13Z', 'uri': 'http://web.archive.org/web/20171003025113/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2018-04-14T02:11:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414021116/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2018-04-14T02:11:16Z', 'uri': 'http://web.archive.org/web/20180414021116/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2018-05-19T08:59:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519085909/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2018-05-19T08:59:09Z', 'uri': 'http://web.archive.org/web/20180519085909/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}, {'datetime': '2018-06-10T21:49:27Z', 'uri': 'http://web.archive.org/web/20180610214927/https://www.guideline.gov/summaries/summary/50078/major-trauma-assessment-and-initial-management'}]
https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:34:32Z', 'uri': 'http://wayback.archive-it.org/all/20160930143432/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2016-09-30T14:34:32Z', 'uri': 'http://web.archive.org/web/20160930143432/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2017-10-03T02:51:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003025125/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2017-10-03T02:51:25Z', 'uri': 'http://web.archive.org/web/20171003025125/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2018-04-14T02:11:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414021127/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2018-04-14T02:11:27Z', 'uri': 'http://web.archive.org/web/20180414021127/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2018-05-19T08:59:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519085921/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2018-05-19T08:59:21Z', 'uri': 'http://web.archive.org/web/20180519085921/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}, {'datetime': '2018-06-09T20:57:32Z', 'uri': 'http://web.archive.org/web/20180609205732/https://www.guideline.gov/summaries/summary/50079/major-trauma-service-delivery'}]
https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930230508/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2016-09-30T23:05:08Z', 'uri': 'http://web.archive.org/web/20160930230508/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2017-10-03T02:52:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003025222/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2017-10-03T02:52:22Z', 'uri': 'http://web.archive.org/web/20171003025222/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2018-04-14T02:12:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414021213/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2018-04-14T02:12:13Z', 'uri': 'http://web.archive.org/web/20180414021213/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2018-05-19T09:00:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519090013/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2018-05-19T09:00:13Z', 'uri': 'http://web.archive.org/web/20180519090013/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}, {'datetime': '2018-06-10T10:59:07Z', 'uri': 'http://web.archive.org/web/20180610105907/https://www.guideline.gov/summaries/summary/50080/spinal-injury-assessment-and-initial-management'}]
https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:09Z', 'uri': 'http://wayback.archive-it.org/all/20160930230709/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2016-09-30T23:07:09Z', 'uri': 'http://web.archive.org/web/20160930230709/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2017-10-03T02:54:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003025435/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2017-10-03T02:54:35Z', 'uri': 'http://web.archive.org/web/20171003025435/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2018-04-14T02:14:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414021434/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2018-04-14T02:14:34Z', 'uri': 'http://web.archive.org/web/20180414021434/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2018-05-19T09:03:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519090301/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2018-05-19T09:03:01Z', 'uri': 'http://web.archive.org/web/20180519090301/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}, {'datetime': '2018-06-10T15:23:12Z', 'uri': 'http://web.archive.org/web/20180610152312/https://www.guideline.gov/summaries/summary/50081/motor-neurone-disease-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:54:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003025411/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}, {'datetime': '2017-10-03T02:54:11Z', 'uri': 'http://web.archive.org/web/20171003025411/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}, {'datetime': '2018-04-14T02:14:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414021406/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}, {'datetime': '2018-04-14T02:14:06Z', 'uri': 'http://web.archive.org/web/20180414021406/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}, {'datetime': '2018-05-19T09:02:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519090228/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}, {'datetime': '2018-05-19T09:02:28Z', 'uri': 'http://web.archive.org/web/20180519090228/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}, {'datetime': '2018-06-09T15:45:27Z', 'uri': 'http://web.archive.org/web/20180609154527/https://www.guideline.gov/summaries/summary/50084/final-recommendation-statement-impaired-visual-acuity-in-older-adults-screening'}]
https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:49Z', 'uri': 'http://wayback.archive-it.org/all/20160930230749/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2016-09-30T23:07:49Z', 'uri': 'http://web.archive.org/web/20160930230749/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2017-10-03T02:55:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003025514/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2017-10-03T02:55:14Z', 'uri': 'http://web.archive.org/web/20171003025514/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2018-04-14T02:15:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414021521/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2018-04-14T02:15:21Z', 'uri': 'http://web.archive.org/web/20180414021521/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2018-05-19T09:03:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519090351/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2018-05-19T09:03:51Z', 'uri': 'http://web.archive.org/web/20180519090351/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}, {'datetime': '2018-06-09T21:19:05Z', 'uri': 'http://web.archive.org/web/20180609211905/https://www.guideline.gov/summaries/summary/50085/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system'}]
https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:08:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930230802/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2016-09-30T23:08:02Z', 'uri': 'http://web.archive.org/web/20160930230802/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2017-10-03T02:55:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003025529/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2017-10-03T02:55:29Z', 'uri': 'http://web.archive.org/web/20171003025529/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2018-04-14T02:15:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414021538/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2018-04-14T02:15:38Z', 'uri': 'http://web.archive.org/web/20180414021538/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2018-05-19T09:04:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519090411/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2018-05-19T09:04:11Z', 'uri': 'http://web.archive.org/web/20180519090411/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}, {'datetime': '2018-06-09T18:41:34Z', 'uri': 'http://web.archive.org/web/20180609184134/https://www.guideline.gov/summaries/summary/50086/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits'}]
https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:31Z', 'uri': 'http://wayback.archive-it.org/all/20160930230731/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2016-09-30T23:07:31Z', 'uri': 'http://web.archive.org/web/20160930230731/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2017-10-03T02:54:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003025456/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2017-10-03T02:54:56Z', 'uri': 'http://web.archive.org/web/20171003025456/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2018-04-14T02:14:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414021459/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2018-04-14T02:14:59Z', 'uri': 'http://web.archive.org/web/20180414021459/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2018-05-19T09:03:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519090326/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2018-05-19T09:03:26Z', 'uri': 'http://web.archive.org/web/20180519090326/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}, {'datetime': '2018-06-10T23:05:25Z', 'uri': 'http://web.archive.org/web/20180610230525/https://www.guideline.gov/summaries/summary/50087/stem-cell-transplantation-in-the-treatment-of-acute-lymphoblastic-leukemia'}]
https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:37Z', 'uri': 'http://wayback.archive-it.org/all/20160930230737/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2016-09-30T23:07:37Z', 'uri': 'http://web.archive.org/web/20160930230737/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2017-10-03T02:55:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003025502/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2017-10-03T02:55:02Z', 'uri': 'http://web.archive.org/web/20171003025502/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2018-04-14T02:15:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414021505/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2018-04-14T02:15:05Z', 'uri': 'http://web.archive.org/web/20180414021505/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2018-05-19T09:03:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519090334/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2018-05-19T09:03:34Z', 'uri': 'http://web.archive.org/web/20180519090334/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}, {'datetime': '2018-06-09T21:16:04Z', 'uri': 'http://web.archive.org/web/20180609211604/https://www.guideline.gov/summaries/summary/50088/systemic-treatment-of-acute-myeloid-leukemia-aml'}]
https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:24Z', 'uri': 'http://wayback.archive-it.org/all/20160930230724/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2016-09-30T23:07:24Z', 'uri': 'http://web.archive.org/web/20160930230724/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2017-10-03T02:54:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003025453/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2017-10-03T02:54:53Z', 'uri': 'http://web.archive.org/web/20171003025453/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-04-14T02:14:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414021456/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-04-14T02:14:56Z', 'uri': 'http://web.archive.org/web/20180414021456/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-05-19T09:03:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519090323/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-05-19T09:03:23Z', 'uri': 'http://web.archive.org/web/20180519090323/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-06-11T00:48:52Z', 'uri': 'http://web.archive.org/web/20180611004852/https://www.guideline.gov/summaries/summary/50089/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}]
https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:07:17Z', 'uri': 'http://wayback.archive-it.org/all/20160930230717/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2016-09-30T23:07:17Z', 'uri': 'http://web.archive.org/web/20160930230717/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2017-10-03T02:54:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003025446/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2017-10-03T02:54:46Z', 'uri': 'http://web.archive.org/web/20171003025446/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2018-04-14T02:14:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414021447/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2018-04-14T02:14:47Z', 'uri': 'http://web.archive.org/web/20180414021447/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2018-05-19T09:03:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519090314/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2018-05-19T09:03:14Z', 'uri': 'http://web.archive.org/web/20180519090314/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}, {'datetime': '2018-06-10T23:05:33Z', 'uri': 'http://web.archive.org/web/20180610230533/https://www.guideline.gov/summaries/summary/50090/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia'}]
https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:02Z', 'uri': 'http://wayback.archive-it.org/all/20160930230602/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2016-09-30T23:06:02Z', 'uri': 'http://web.archive.org/web/20160930230602/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T02:53:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003025324/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T02:53:24Z', 'uri': 'http://web.archive.org/web/20171003025324/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:13:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414021317/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:13:17Z', 'uri': 'http://web.archive.org/web/20180414021317/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:01:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519090124/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T09:01:24Z', 'uri': 'http://web.archive.org/web/20180519090124/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T20:51:14Z', 'uri': 'http://web.archive.org/web/20180609205114/https://www.guideline.gov/summaries/summary/50091/treatment-of-unexplained-chronic-cough-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930230555/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2016-09-30T23:05:55Z', 'uri': 'http://web.archive.org/web/20160930230555/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2017-10-03T02:53:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003025315/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2017-10-03T02:53:15Z', 'uri': 'http://web.archive.org/web/20171003025315/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T02:13:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414021308/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T02:13:08Z', 'uri': 'http://web.archive.org/web/20180414021308/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T09:01:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519090114/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T09:01:14Z', 'uri': 'http://web.archive.org/web/20180519090114/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-06-10T01:16:24Z', 'uri': 'http://web.archive.org/web/20180610011624/https://www.guideline.gov/summaries/summary/50092/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-carpal-tunnel-syndrome'}]
https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:33Z', 'uri': 'http://wayback.archive-it.org/all/20160930230533/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2016-09-30T23:05:33Z', 'uri': 'http://web.archive.org/web/20160930230533/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2017-10-03T02:52:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003025249/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2017-10-03T02:52:49Z', 'uri': 'http://web.archive.org/web/20171003025249/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2018-04-14T02:12:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414021241/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2018-04-14T02:12:41Z', 'uri': 'http://web.archive.org/web/20180414021241/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2018-05-19T09:00:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519090045/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2018-05-19T09:00:45Z', 'uri': 'http://web.archive.org/web/20180519090045/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}, {'datetime': '2018-06-09T21:23:25Z', 'uri': 'http://web.archive.org/web/20180609212325/https://www.guideline.gov/summaries/summary/50109/clinical-practice-guideline-otitis-media-with-effusion-update'}]
https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:39Z', 'uri': 'http://wayback.archive-it.org/all/20160930230439/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2016-09-30T23:04:39Z', 'uri': 'http://web.archive.org/web/20160930230439/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2017-10-03T02:51:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003025133/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2017-10-03T02:51:33Z', 'uri': 'http://web.archive.org/web/20171003025133/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2018-04-14T02:11:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414021136/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2018-04-14T02:11:36Z', 'uri': 'http://web.archive.org/web/20180414021136/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2018-05-19T08:59:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519085931/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2018-05-19T08:59:31Z', 'uri': 'http://web.archive.org/web/20180519085931/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}, {'datetime': '2018-06-09T21:05:37Z', 'uri': 'http://web.archive.org/web/20180609210537/https://www.guideline.gov/summaries/summary/50110/guidelines-for-the-appropriate-use-of-bedside-general-and-cardiac-ultrasonography-in-the-evaluation-of-critically-ill-patientspart-i-general-ultrasonography'}]
https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:08Z', 'uri': 'http://wayback.archive-it.org/all/20160930230608/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2016-09-30T23:06:08Z', 'uri': 'http://web.archive.org/web/20160930230608/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2017-10-03T02:53:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003025334/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2017-10-03T02:53:34Z', 'uri': 'http://web.archive.org/web/20171003025334/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2018-04-14T02:13:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414021325/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2018-04-14T02:13:25Z', 'uri': 'http://web.archive.org/web/20180414021325/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2018-05-19T09:01:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519090133/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2018-05-19T09:01:33Z', 'uri': 'http://web.archive.org/web/20180519090133/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}, {'datetime': '2018-06-09T21:45:06Z', 'uri': 'http://web.archive.org/web/20180609214506/https://www.guideline.gov/summaries/summary/50113/american-gastroenterological-association-institute-guideline-on-the-management-of-acute-diverticulitis'}]
https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930230615/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2016-09-30T23:06:15Z', 'uri': 'http://web.archive.org/web/20160930230615/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2017-10-03T02:53:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003025340/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2017-10-03T02:53:40Z', 'uri': 'http://web.archive.org/web/20171003025340/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2018-04-14T02:13:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414021332/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2018-04-14T02:13:32Z', 'uri': 'http://web.archive.org/web/20180414021332/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2018-05-19T09:01:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519090143/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2018-05-19T09:01:43Z', 'uri': 'http://web.archive.org/web/20180519090143/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}, {'datetime': '2018-06-09T21:44:50Z', 'uri': 'http://web.archive.org/web/20180609214450/https://www.guideline.gov/summaries/summary/50114/american-gastroenterological-association-institute-guideline-on-the-medical-management-of-microscopic-colitis'}]
https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003024840/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:40Z', 'uri': 'http://web.archive.org/web/20171003024840/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414020815/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:15Z', 'uri': 'http://web.archive.org/web/20180414020815/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519085541/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:41Z', 'uri': 'http://web.archive.org/web/20180519085541/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T23:02:45Z', 'uri': 'http://web.archive.org/web/20180610230245/https://www.guideline.gov/summaries/summary/50115/the-role-of-imaging-in-the-management-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003024834/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:34Z', 'uri': 'http://web.archive.org/web/20171003024834/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414020808/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:08Z', 'uri': 'http://web.archive.org/web/20180414020808/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519085533/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:33Z', 'uri': 'http://web.archive.org/web/20180519085533/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-09T11:40:29Z', 'uri': 'http://web.archive.org/web/20180609114029/https://www.guideline.gov/summaries/summary/50116/the-role-of-biopsy-in-the-management-of-patients-with-presumed-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003024854/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:54Z', 'uri': 'http://web.archive.org/web/20171003024854/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414020830/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:30Z', 'uri': 'http://web.archive.org/web/20180414020830/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:56:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519085600/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:56:00Z', 'uri': 'http://web.archive.org/web/20180519085600/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T22:42:28Z', 'uri': 'http://web.archive.org/web/20180610224228/https://www.guideline.gov/summaries/summary/50117/the-role-of-surgery-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003024847/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:47Z', 'uri': 'http://web.archive.org/web/20171003024847/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414020823/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:23Z', 'uri': 'http://web.archive.org/web/20180414020823/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519085550/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:50Z', 'uri': 'http://web.archive.org/web/20180519085550/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T23:02:46Z', 'uri': 'http://web.archive.org/web/20180610230246/https://www.guideline.gov/summaries/summary/50118/the-role-of-neuropathology-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003024827/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:27Z', 'uri': 'http://web.archive.org/web/20171003024827/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414020800/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:08:00Z', 'uri': 'http://web.archive.org/web/20180414020800/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519085525/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:25Z', 'uri': 'http://web.archive.org/web/20180519085525/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-09T19:48:23Z', 'uri': 'http://web.archive.org/web/20180609194823/https://www.guideline.gov/summaries/summary/50119/the-role-of-radiotherapy-in-the-management-of-patients-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003024820/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:20Z', 'uri': 'http://web.archive.org/web/20171003024820/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:07:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414020752/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:07:52Z', 'uri': 'http://web.archive.org/web/20180414020752/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519085517/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:55:17Z', 'uri': 'http://web.archive.org/web/20180519085517/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T00:47:32Z', 'uri': 'http://web.archive.org/web/20180610004732/https://www.guideline.gov/summaries/summary/50120/the-role-of-initial-chemotherapy-for-the-treatment-of-adults-with-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003024808/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:48:08Z', 'uri': 'http://web.archive.org/web/20171003024808/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:07:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414020737/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:07:37Z', 'uri': 'http://web.archive.org/web/20180414020737/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:54:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519085459/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:54:59Z', 'uri': 'http://web.archive.org/web/20180519085459/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T23:02:39Z', 'uri': 'http://web.archive.org/web/20180610230239/https://www.guideline.gov/summaries/summary/50121/management-of-patients-with-recurrence-of-diffuse-low-grade-glioma-a-systematic-review-and-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003024814/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}, {'datetime': '2017-10-03T02:48:14Z', 'uri': 'http://web.archive.org/web/20171003024814/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}, {'datetime': '2018-04-14T02:07:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414020745/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}, {'datetime': '2018-04-14T02:07:45Z', 'uri': 'http://web.archive.org/web/20180414020745/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}, {'datetime': '2018-05-19T08:55:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519085509/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}, {'datetime': '2018-05-19T08:55:09Z', 'uri': 'http://web.archive.org/web/20180519085509/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}, {'datetime': '2018-06-09T19:48:26Z', 'uri': 'http://web.archive.org/web/20180609194826/https://www.guideline.gov/summaries/summary/50122/the-role-of-emerging-therapy-in-the-management-of-patients-with-diffuse-low-grade-glioma'}]
https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930230541/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2016-09-30T23:05:41Z', 'uri': 'http://web.archive.org/web/20160930230541/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2017-10-03T02:52:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003025259/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2017-10-03T02:52:59Z', 'uri': 'http://web.archive.org/web/20171003025259/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2018-04-14T02:12:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414021250/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2018-04-14T02:12:50Z', 'uri': 'http://web.archive.org/web/20180414021250/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2018-05-19T09:00:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519090055/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2018-05-19T09:00:55Z', 'uri': 'http://web.archive.org/web/20180519090055/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}, {'datetime': '2018-06-09T19:16:17Z', 'uri': 'http://web.archive.org/web/20180609191617/https://www.guideline.gov/summaries/summary/50123/recommendations-on-screening-for-colorectal-cancer-in-primary-care'}]
https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:46Z', 'uri': 'http://wayback.archive-it.org/all/20160930230446/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2016-09-30T23:04:46Z', 'uri': 'http://web.archive.org/web/20160930230446/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2017-10-03T02:51:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003025139/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2017-10-03T02:51:39Z', 'uri': 'http://web.archive.org/web/20171003025139/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2018-04-14T02:11:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414021144/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2018-04-14T02:11:44Z', 'uri': 'http://web.archive.org/web/20180414021144/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2018-05-19T08:59:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519085940/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2018-05-19T08:59:40Z', 'uri': 'http://web.archive.org/web/20180519085940/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}, {'datetime': '2018-06-09T22:06:01Z', 'uri': 'http://web.archive.org/web/20180609220601/https://www.guideline.gov/summaries/summary/50124/who-guideline-daily-iron-supplementation-in-infants-and-children'}]
https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:03:36Z', 'uri': 'http://wayback.archive-it.org/all/20160930230336/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2016-09-30T23:03:36Z', 'uri': 'http://web.archive.org/web/20160930230336/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2017-10-03T02:50:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003025020/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2017-10-03T02:50:20Z', 'uri': 'http://web.archive.org/web/20171003025020/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2018-04-14T02:10:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414021007/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2018-04-14T02:10:07Z', 'uri': 'http://web.archive.org/web/20180414021007/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2018-05-19T08:58:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519085805/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2018-05-19T08:58:05Z', 'uri': 'http://web.archive.org/web/20180519085805/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}, {'datetime': '2018-06-09T11:21:41Z', 'uri': 'http://web.archive.org/web/20180609112141/https://www.guideline.gov/summaries/summary/50133/guideline-for-reversal-of-antithrombotics-in-intracranial-hemorrhage-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society-and-society-of-critical-care-medicine'}]
https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930230527/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2016-09-30T23:05:27Z', 'uri': 'http://web.archive.org/web/20160930230527/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2017-10-03T02:52:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003025241/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2017-10-03T02:52:41Z', 'uri': 'http://web.archive.org/web/20171003025241/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-04-14T02:12:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414021234/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-04-14T02:12:34Z', 'uri': 'http://web.archive.org/web/20180414021234/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-05-19T09:00:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519090034/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-05-19T09:00:34Z', 'uri': 'http://web.archive.org/web/20180519090034/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-06-09T15:20:28Z', 'uri': 'http://web.archive.org/web/20180609152028/https://www.guideline.gov/summaries/summary/50134/therapeutic-drug-monitoring-of-vancomycin-a-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}]
https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:25Z', 'uri': 'http://wayback.archive-it.org/all/20160930230425/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:04:25Z', 'uri': 'http://web.archive.org/web/20160930230425/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-02T20:06:56Z', 'uri': 'http://wayback.archive-it.org/all/20171002200656/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-02T20:06:56Z', 'uri': 'http://web.archive.org/web/20171002200656/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:11:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414021106/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:11:06Z', 'uri': 'http://web.archive.org/web/20180414021106/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-18T19:32:35Z', 'uri': 'http://wayback.archive-it.org/all/20180518193235/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-18T19:32:35Z', 'uri': 'http://web.archive.org/web/20180518193235/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T10:42:56Z', 'uri': 'http://web.archive.org/web/20180609104256/https://www.guideline.gov/summaries/summary/50136/pediatric-weight-management-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:18Z', 'uri': 'http://wayback.archive-it.org/all/20160930230418/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:04:18Z', 'uri': 'http://web.archive.org/web/20160930230418/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T02:51:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003025104/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T02:51:04Z', 'uri': 'http://web.archive.org/web/20171003025104/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:10:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414021057/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:10:57Z', 'uri': 'http://web.archive.org/web/20180414021057/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T08:58:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519085859/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T08:58:59Z', 'uri': 'http://web.archive.org/web/20180519085859/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T20:06:57Z', 'uri': 'http://web.archive.org/web/20180609200657/https://www.guideline.gov/summaries/summary/50137/hypertension-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:04:11Z', 'uri': 'http://wayback.archive-it.org/all/20160930230411/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2016-09-30T23:04:11Z', 'uri': 'http://web.archive.org/web/20160930230411/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T02:50:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003025055/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2017-10-03T02:50:55Z', 'uri': 'http://web.archive.org/web/20171003025055/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:10:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414021047/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T02:10:47Z', 'uri': 'http://web.archive.org/web/20180414021047/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T08:58:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519085848/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T08:58:48Z', 'uri': 'http://web.archive.org/web/20180519085848/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T20:07:12Z', 'uri': 'http://web.archive.org/web/20180609200712/https://www.guideline.gov/summaries/summary/50138/diabetes-type-1-and-type-2-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:54:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003025404/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2017-10-03T02:54:04Z', 'uri': 'http://web.archive.org/web/20171003025404/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2018-04-14T02:13:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414021358/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2018-04-14T02:13:58Z', 'uri': 'http://web.archive.org/web/20180414021358/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2018-05-19T09:02:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519090219/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2018-05-19T09:02:19Z', 'uri': 'http://web.archive.org/web/20180519090219/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2018-06-09T19:03:50Z', 'uri': 'http://web.archive.org/web/20180609190350/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}, {'datetime': '2018-06-15T00:24:24Z', 'uri': 'http://web.archive.org/web/20180615002424/https://www.guideline.gov/summaries/summary/50139/final-recommendation-statement-chronic-obstructive-pulmonary-disease-screening'}]
https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:03:23Z', 'uri': 'http://wayback.archive-it.org/all/20160930230323/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2016-09-30T23:03:23Z', 'uri': 'http://web.archive.org/web/20160930230323/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2017-10-03T02:50:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003025006/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2017-10-03T02:50:06Z', 'uri': 'http://web.archive.org/web/20171003025006/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2018-04-14T02:09:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414020949/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2018-04-14T02:09:49Z', 'uri': 'http://web.archive.org/web/20180414020949/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2018-05-19T08:57:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519085745/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2018-05-19T08:57:45Z', 'uri': 'http://web.archive.org/web/20180519085745/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}, {'datetime': '2018-06-09T12:02:22Z', 'uri': 'http://web.archive.org/web/20180609120222/https://www.guideline.gov/summaries/summary/50140/vadod-clinical-practice-guideline-for-the-management-of-concussionmild-traumatic-brain-injury'}]
https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:05:21Z', 'uri': 'http://wayback.archive-it.org/all/20160930230521/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2016-09-30T23:05:21Z', 'uri': 'http://web.archive.org/web/20160930230521/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2017-10-03T02:52:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003025234/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2017-10-03T02:52:34Z', 'uri': 'http://web.archive.org/web/20171003025234/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2018-04-14T02:12:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414021226/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2018-04-14T02:12:26Z', 'uri': 'http://web.archive.org/web/20180414021226/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2018-05-19T09:00:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519090025/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2018-05-19T09:00:25Z', 'uri': 'http://web.archive.org/web/20180519090025/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2018-06-10T00:27:16Z', 'uri': 'http://web.archive.org/web/20180610002716/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}, {'datetime': '2018-06-15T00:07:09Z', 'uri': 'http://web.archive.org/web/20180615000709/https://www.guideline.gov/summaries/summary/50141/recommendations-on-screening-for-lung-cancer'}]
https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:03:42Z', 'uri': 'http://wayback.archive-it.org/all/20160930230342/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2016-09-30T23:03:42Z', 'uri': 'http://web.archive.org/web/20160930230342/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T02:50:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003025027/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T02:50:27Z', 'uri': 'http://web.archive.org/web/20171003025027/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:10:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414021015/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T02:10:15Z', 'uri': 'http://web.archive.org/web/20180414021015/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:58:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519085814/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:58:14Z', 'uri': 'http://web.archive.org/web/20180519085814/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T11:31:34Z', 'uri': 'http://web.archive.org/web/20180609113134/https://www.guideline.gov/summaries/summary/50142/antithrombotic-therapy-for-vte-disease-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:03:50Z', 'uri': 'http://wayback.archive-it.org/all/20160930230350/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2016-09-30T23:03:50Z', 'uri': 'http://web.archive.org/web/20160930230350/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2017-10-03T02:50:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003025036/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2017-10-03T02:50:36Z', 'uri': 'http://web.archive.org/web/20171003025036/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2018-04-14T02:10:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414021025/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2018-04-14T02:10:25Z', 'uri': 'http://web.archive.org/web/20180414021025/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2018-05-19T08:58:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519085825/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2018-05-19T08:58:25Z', 'uri': 'http://web.archive.org/web/20180519085825/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}, {'datetime': '2018-06-09T19:47:28Z', 'uri': 'http://web.archive.org/web/20180609194728/https://www.guideline.gov/summaries/summary/50143/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-adult-critically-ill-patient-society-of-critical-care-medicine-sccm-and-american-society-for-parenteral-and-enteral-nutrition-aspen'}]
https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:55Z', 'uri': 'http://wayback.archive-it.org/all/20160930230655/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2016-09-30T23:06:55Z', 'uri': 'http://web.archive.org/web/20160930230655/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2017-10-03T02:54:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003025424/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2017-10-03T02:54:24Z', 'uri': 'http://web.archive.org/web/20171003025424/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2018-04-14T02:14:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414021422/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2018-04-14T02:14:22Z', 'uri': 'http://web.archive.org/web/20180414021422/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2018-05-19T09:02:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519090245/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2018-05-19T09:02:45Z', 'uri': 'http://web.archive.org/web/20180519090245/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}, {'datetime': '2018-06-09T11:59:14Z', 'uri': 'http://web.archive.org/web/20180609115914/https://www.guideline.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pain---united-states-2016'}]
https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T14:36:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930143627/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2016-09-30T14:36:27Z', 'uri': 'http://web.archive.org/web/20160930143627/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2017-10-03T02:49:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003024907/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2017-10-03T02:49:07Z', 'uri': 'http://web.archive.org/web/20171003024907/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2018-04-14T02:08:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414020845/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2018-04-14T02:08:45Z', 'uri': 'http://web.archive.org/web/20180414020845/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2018-05-19T08:56:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519085617/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2018-05-19T08:56:17Z', 'uri': 'http://web.archive.org/web/20180519085617/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2018-06-09T11:22:53Z', 'uri': 'http://web.archive.org/web/20180609112253/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}, {'datetime': '2018-06-15T00:24:26Z', 'uri': 'http://web.archive.org/web/20180615002426/https://www.guideline.gov/summaries/summary/50176/btsics-guideline-for-the-ventilatory-management-of-acute-hypercapnic-respiratory-failure-in-adults'}]
https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:03:57Z', 'uri': 'http://wayback.archive-it.org/all/20160930230357/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2016-09-30T23:03:57Z', 'uri': 'http://web.archive.org/web/20160930230357/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2017-10-03T02:50:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003025044/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2017-10-03T02:50:44Z', 'uri': 'http://web.archive.org/web/20171003025044/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2018-04-14T02:10:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414021034/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2018-04-14T02:10:34Z', 'uri': 'http://web.archive.org/web/20180414021034/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2018-05-19T08:58:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519085834/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2018-05-19T08:58:34Z', 'uri': 'http://web.archive.org/web/20180519085834/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2018-06-09T22:55:58Z', 'uri': 'http://web.archive.org/web/20180609225558/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}, {'datetime': '2018-06-15T00:07:04Z', 'uri': 'http://web.archive.org/web/20180615000704/https://www.guideline.gov/summaries/summary/50177/routine-preoperative-tests-for-elective-surgery'}]
https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:04:04Z', 'uri': 'http://wayback.archive-it.org/all/20160930230404/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2016-09-30T23:04:04Z', 'uri': 'http://web.archive.org/web/20160930230404/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2017-10-03T02:50:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003025052/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2017-10-03T02:50:52Z', 'uri': 'http://web.archive.org/web/20171003025052/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2018-04-14T02:10:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414021043/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2018-04-14T02:10:43Z', 'uri': 'http://web.archive.org/web/20180414021043/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2018-05-19T08:58:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519085845/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2018-05-19T08:58:45Z', 'uri': 'http://web.archive.org/web/20180519085845/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2018-06-10T19:21:47Z', 'uri': 'http://web.archive.org/web/20180610192147/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}, {'datetime': '2018-06-15T00:07:02Z', 'uri': 'http://web.archive.org/web/20180615000702/https://www.guideline.gov/summaries/summary/50178/controlled-drugs-safe-use-and-management'}]
https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930230548/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2016-09-30T23:05:48Z', 'uri': 'http://web.archive.org/web/20160930230548/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2017-10-03T02:53:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003025307/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2017-10-03T02:53:07Z', 'uri': 'http://web.archive.org/web/20171003025307/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2018-04-14T02:12:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414021259/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2018-04-14T02:12:59Z', 'uri': 'http://web.archive.org/web/20180414021259/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2018-05-19T09:01:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519090104/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2018-05-19T09:01:04Z', 'uri': 'http://web.archive.org/web/20180519090104/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}, {'datetime': '2018-06-09T21:20:25Z', 'uri': 'http://web.archive.org/web/20180609212025/https://www.guideline.gov/summaries/summary/50181/the-management-of-diabetic-foot-a-clinical-practice-guideline-by-the-society-for-vascular-surgery-in-collaboration-with-the-american-podiatric-medical-association-and-the-society-for-vascular-medicine'}]
https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:47:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003024720/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:47:20Z', 'uri': 'http://web.archive.org/web/20171003024720/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:06:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414020639/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:06:39Z', 'uri': 'http://web.archive.org/web/20180414020639/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:54:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519085400/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:54:00Z', 'uri': 'http://web.archive.org/web/20180519085400/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:34Z', 'uri': 'http://web.archive.org/web/20180610010634/https://www.guideline.gov/summaries/summary/50197/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:46:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003024659/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}, {'datetime': '2017-10-03T02:46:59Z', 'uri': 'http://web.archive.org/web/20171003024659/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}, {'datetime': '2018-04-14T02:06:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414020615/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}, {'datetime': '2018-04-14T02:06:15Z', 'uri': 'http://web.archive.org/web/20180414020615/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}, {'datetime': '2018-05-19T08:53:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519085334/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}, {'datetime': '2018-05-19T08:53:34Z', 'uri': 'http://web.archive.org/web/20180519085334/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}, {'datetime': '2018-06-09T22:27:38Z', 'uri': 'http://web.archive.org/web/20180609222738/https://www.guideline.gov/summaries/summary/50207/clinical-policy-for-wellappearing-infants-and-children-younger-than-2-years-of-age-presenting-to-the-emergency-department-with-fever'}]
https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T23:03:30Z', 'uri': 'http://wayback.archive-it.org/all/20160930230330/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2016-09-30T23:03:30Z', 'uri': 'http://web.archive.org/web/20160930230330/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2017-10-03T02:50:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003025014/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2017-10-03T02:50:14Z', 'uri': 'http://web.archive.org/web/20171003025014/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-04-14T02:09:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414020959/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-04-14T02:09:59Z', 'uri': 'http://web.archive.org/web/20180414020959/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-05-19T08:57:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519085756/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-05-19T08:57:56Z', 'uri': 'http://web.archive.org/web/20180519085756/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-06-10T22:17:25Z', 'uri': 'http://web.archive.org/web/20180610221725/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}, {'datetime': '2018-06-15T00:06:59Z', 'uri': 'http://web.archive.org/web/20180615000659/https://www.guideline.gov/summaries/summary/50208/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated'}]
https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:26:48Z', 'uri': 'http://wayback.archive-it.org/all/20160930162648/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2016-09-30T16:26:48Z', 'uri': 'http://web.archive.org/web/20160930162648/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2017-10-03T02:49:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003024952/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2017-10-03T02:49:52Z', 'uri': 'http://web.archive.org/web/20171003024952/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2018-04-14T02:09:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414020935/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2018-04-14T02:09:35Z', 'uri': 'http://web.archive.org/web/20180414020935/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2018-05-19T08:57:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519085730/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2018-05-19T08:57:30Z', 'uri': 'http://web.archive.org/web/20180519085730/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}, {'datetime': '2018-06-10T00:04:10Z', 'uri': 'http://web.archive.org/web/20180610000410/https://www.guideline.gov/summaries/summary/50209/who-guideline-daily-iron-supplementation-in-adult-women-and-adolescent-girls'}]
https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:05:15Z', 'uri': 'http://wayback.archive-it.org/all/20160930230515/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2016-09-30T23:05:15Z', 'uri': 'http://web.archive.org/web/20160930230515/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:52:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003025225/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:52:25Z', 'uri': 'http://web.archive.org/web/20171003025225/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:12:17Z', 'uri': 'http://wayback.archive-it.org/all/20180414021217/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:12:17Z', 'uri': 'http://web.archive.org/web/20180414021217/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T09:00:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519090016/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T09:00:16Z', 'uri': 'http://web.archive.org/web/20180519090016/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T22:01:07Z', 'uri': 'http://web.archive.org/web/20180609220107/https://www.guideline.gov/summaries/summary/50220/practice-guideline-update-summary-botulinum-neurotoxin-for-the-treatment-of-blepharospasm-cervical-dystonia-adult-spasticity-and-headache-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis	ARCHIVED	11 mementos	[{'datetime': '2016-09-30T16:26:27Z', 'uri': 'http://wayback.archive-it.org/all/20160930162627/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2016-09-30T16:26:27Z', 'uri': 'http://web.archive.org/web/20160930162627/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2017-07-10T16:04:48Z', 'uri': 'http://web.archive.org/web/20170710160448/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2017-10-03T02:49:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003024931/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2017-10-03T02:49:31Z', 'uri': 'http://web.archive.org/web/20171003024931/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2018-04-14T02:09:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414020911/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2018-04-14T02:09:11Z', 'uri': 'http://web.archive.org/web/20180414020911/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2018-05-19T08:56:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519085645/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2018-05-19T08:56:45Z', 'uri': 'http://web.archive.org/web/20180519085645/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2018-06-09T21:12:47Z', 'uri': 'http://web.archive.org/web/20180609211247/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}, {'datetime': '2018-06-15T00:29:03Z', 'uri': 'http://web.archive.org/web/20180615002903/https://www.guideline.gov/summaries/summary/50221/clinical-practice-guidelines-from-the-cystic-fibrosis-foundation-for-preschoolers-with-cystic-fibrosis'}]
https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T16:26:41Z', 'uri': 'http://wayback.archive-it.org/all/20160930162641/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2016-09-30T16:26:41Z', 'uri': 'http://web.archive.org/web/20160930162641/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2017-10-03T02:49:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003024945/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2017-10-03T02:49:45Z', 'uri': 'http://web.archive.org/web/20171003024945/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2018-04-14T02:09:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414020926/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2018-04-14T02:09:26Z', 'uri': 'http://web.archive.org/web/20180414020926/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2018-05-19T08:57:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519085721/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2018-05-19T08:57:21Z', 'uri': 'http://web.archive.org/web/20180519085721/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}, {'datetime': '2018-06-09T13:10:59Z', 'uri': 'http://web.archive.org/web/20180609131059/https://www.guideline.gov/summaries/summary/50227/the-management-of-depression-in-patients-with-cancer'}]
https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:46:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003024631/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}, {'datetime': '2017-10-03T02:46:31Z', 'uri': 'http://web.archive.org/web/20171003024631/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}, {'datetime': '2018-04-14T02:05:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414020547/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}, {'datetime': '2018-04-14T02:05:47Z', 'uri': 'http://web.archive.org/web/20180414020547/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}, {'datetime': '2018-05-19T08:53:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519085303/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}, {'datetime': '2018-05-19T08:53:03Z', 'uri': 'http://web.archive.org/web/20180519085303/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}, {'datetime': '2018-06-09T11:54:32Z', 'uri': 'http://web.archive.org/web/20180609115432/https://www.guideline.gov/summaries/summary/50266/shoulder-injury-medical-treatment-guidelines'}]
https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T23:06:20Z', 'uri': 'http://wayback.archive-it.org/all/20160930230620/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2016-09-30T23:06:20Z', 'uri': 'http://web.archive.org/web/20160930230620/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2017-10-03T02:53:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003025347/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2017-10-03T02:53:47Z', 'uri': 'http://web.archive.org/web/20171003025347/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2018-04-14T02:13:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414021341/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2018-04-14T02:13:41Z', 'uri': 'http://web.archive.org/web/20180414021341/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2018-05-19T09:01:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519090152/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2018-05-19T09:01:52Z', 'uri': 'http://web.archive.org/web/20180519090152/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}, {'datetime': '2018-06-09T21:39:53Z', 'uri': 'http://web.archive.org/web/20180609213953/https://www.guideline.gov/summaries/summary/50267/brief-resolved-unexplained-events-formerly-apparent-lifethreatening-events-and-evaluation-of-lowerrisk-infants'}]
https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:36:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930143635/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2016-09-30T14:36:35Z', 'uri': 'http://web.archive.org/web/20160930143635/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2017-10-03T02:49:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003024916/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2017-10-03T02:49:16Z', 'uri': 'http://web.archive.org/web/20171003024916/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2018-04-14T02:08:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414020854/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2018-04-14T02:08:54Z', 'uri': 'http://web.archive.org/web/20180414020854/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2018-05-19T08:56:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519085626/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2018-05-19T08:56:26Z', 'uri': 'http://web.archive.org/web/20180519085626/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}, {'datetime': '2018-06-10T00:27:24Z', 'uri': 'http://web.archive.org/web/20180610002724/https://www.guideline.gov/summaries/summary/50268/recommendations-on-screening-for-developmental-delay'}]
https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer	ARCHIVED	10 mementos	[{'datetime': '2016-09-30T16:26:35Z', 'uri': 'http://wayback.archive-it.org/all/20160930162635/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2016-09-30T16:26:35Z', 'uri': 'http://web.archive.org/web/20160930162635/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2017-10-03T02:49:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003024939/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2017-10-03T02:49:39Z', 'uri': 'http://web.archive.org/web/20171003024939/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2018-04-14T02:09:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414020919/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2018-04-14T02:09:19Z', 'uri': 'http://web.archive.org/web/20180414020919/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2018-05-19T08:57:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519085712/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2018-05-19T08:57:12Z', 'uri': 'http://web.archive.org/web/20180519085712/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2018-06-10T23:03:43Z', 'uri': 'http://web.archive.org/web/20180610230343/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}, {'datetime': '2018-06-15T00:04:42Z', 'uri': 'http://web.archive.org/web/20180615000442/https://www.guideline.gov/summaries/summary/50292/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-nonsmall-cell-lung-cancer'}]
https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease	ARCHIVED	9 mementos	[{'datetime': '2016-09-30T14:36:19Z', 'uri': 'http://wayback.archive-it.org/all/20160930143619/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2016-09-30T14:36:19Z', 'uri': 'http://web.archive.org/web/20160930143619/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2017-10-03T02:49:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003024901/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2017-10-03T02:49:01Z', 'uri': 'http://web.archive.org/web/20171003024901/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2018-04-14T02:08:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414020837/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2018-04-14T02:08:37Z', 'uri': 'http://web.archive.org/web/20180414020837/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2018-05-19T08:56:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519085609/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2018-05-19T08:56:09Z', 'uri': 'http://web.archive.org/web/20180519085609/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}, {'datetime': '2018-06-09T18:37:59Z', 'uri': 'http://web.archive.org/web/20180609183759/https://www.guideline.gov/summaries/summary/50299/scenic-international-consensus-statement-on-surveillance-and-management-of-dysplasia-in-inflammatory-bowel-disease'}]
https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society	ARCHIVED	11 mementos	[{'datetime': '2017-07-13T02:53:02Z', 'uri': 'http://web.archive.org/web/20170713025302/https://www.guideline.gov/summaries/summary/50300/1-American-Society-of-Clinical-Oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-Adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-American-Society'}, {'datetime': '2017-10-03T02:46:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003024622/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2017-10-03T02:46:22Z', 'uri': 'http://web.archive.org/web/20171003024622/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2018-04-14T02:05:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414020537/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2018-04-14T02:05:37Z', 'uri': 'http://web.archive.org/web/20180414020537/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2018-05-19T08:52:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519085252/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2018-05-19T08:52:52Z', 'uri': 'http://web.archive.org/web/20180519085252/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2018-06-09T10:35:48Z', 'uri': 'http://web.archive.org/web/20180609103548/https://www.guideline.gov/summaries/summary/50300/1-American-Society-of-Clinical-Oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-Adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-American-Society'}, {'datetime': '2018-06-10T00:21:20Z', 'uri': 'http://web.archive.org/web/20180610002120/https://www.guideline.gov/summaries/summary/50300/1-american-society-of-clinical-oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-american-society'}, {'datetime': '2018-06-20T17:39:53Z', 'uri': 'http://web.archive.org/web/20180620173953/https://www.guideline.gov/summaries/summary/50300/1-American-Society-of-Clinical-Oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-Adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-American-Society'}, {'datetime': '2018-06-21T00:11:30Z', 'uri': 'http://web.archive.org/web/20180621001130/https://www.guideline.gov/summaries/summary/50300/1-American-Society-of-Clinical-Oncology-clinical-practice-guideline-update-on-adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-2-Adjuvant-endocrine-therapy-for-women-with-hormone-receptor-positive-breast-cancer-American-Society'}]
https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:46:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003024644/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2017-10-03T02:46:44Z', 'uri': 'http://web.archive.org/web/20171003024644/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2018-04-14T02:05:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414020558/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2018-04-14T02:05:58Z', 'uri': 'http://web.archive.org/web/20180414020558/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2018-05-19T08:53:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519085315/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2018-05-19T08:53:15Z', 'uri': 'http://web.archive.org/web/20180519085315/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2018-06-09T10:32:48Z', 'uri': 'http://web.archive.org/web/20180609103248/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}, {'datetime': '2018-06-15T00:24:22Z', 'uri': 'http://web.archive.org/web/20180615002422/https://www.guideline.gov/summaries/summary/50325/vadod-clinical-practice-guideline-for-the-management-of-major-depressive-disorder'}]
https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:46:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003024653/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}, {'datetime': '2017-10-03T02:46:53Z', 'uri': 'http://web.archive.org/web/20171003024653/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}, {'datetime': '2018-04-14T02:06:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414020608/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}, {'datetime': '2018-04-14T02:06:08Z', 'uri': 'http://web.archive.org/web/20180414020608/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}, {'datetime': '2018-05-19T08:53:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519085326/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}, {'datetime': '2018-05-19T08:53:26Z', 'uri': 'http://web.archive.org/web/20180519085326/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}, {'datetime': '2018-06-09T19:16:41Z', 'uri': 'http://web.archive.org/web/20180609191641/https://www.guideline.gov/summaries/summary/50326/colonoscopy-surveillance-after-colorectal-cancer-resection-recommendations-of-the-us-multisociety-task-force-on-colorectal-cancer'}]
https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:45:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003024552/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}, {'datetime': '2017-10-03T02:45:52Z', 'uri': 'http://web.archive.org/web/20171003024552/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}, {'datetime': '2018-04-14T02:05:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414020502/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}, {'datetime': '2018-04-14T02:05:02Z', 'uri': 'http://web.archive.org/web/20180414020502/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}, {'datetime': '2018-05-19T08:52:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519085213/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}, {'datetime': '2018-05-19T08:52:13Z', 'uri': 'http://web.archive.org/web/20180519085213/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}, {'datetime': '2018-06-09T22:25:46Z', 'uri': 'http://web.archive.org/web/20180609222546/https://www.guideline.gov/summaries/summary/50327/guidelines-for-the-use-of-local-anesthesia-in-officebased-dermatologic-surgery'}]
https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:45:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003024502/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}, {'datetime': '2017-10-03T02:45:02Z', 'uri': 'http://web.archive.org/web/20171003024502/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}, {'datetime': '2018-04-14T02:04:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414020406/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}, {'datetime': '2018-04-14T02:04:06Z', 'uri': 'http://web.archive.org/web/20180414020406/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}, {'datetime': '2018-05-19T08:51:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519085101/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}, {'datetime': '2018-05-19T08:51:01Z', 'uri': 'http://web.archive.org/web/20180519085101/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}, {'datetime': '2018-06-09T10:34:55Z', 'uri': 'http://web.archive.org/web/20180609103455/https://www.guideline.gov/summaries/summary/50334/the-american-psychiatric-association-practice-guideline-on-the-use-of-antipsychotics-to-treat-agitation-or-psychosis-in-patients-with-dementia'}]
https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:43:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003024338/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}, {'datetime': '2017-10-03T02:43:38Z', 'uri': 'http://web.archive.org/web/20171003024338/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}, {'datetime': '2018-04-14T02:02:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414020236/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}, {'datetime': '2018-04-14T02:02:36Z', 'uri': 'http://web.archive.org/web/20180414020236/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}, {'datetime': '2018-05-19T08:49:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519084926/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}, {'datetime': '2018-05-19T08:49:26Z', 'uri': 'http://web.archive.org/web/20180519084926/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}, {'datetime': '2018-06-09T15:27:15Z', 'uri': 'http://web.archive.org/web/20180609152715/https://www.guideline.gov/summaries/summary/50335/male-external-catheters-in-adults-urinary-catheter-management'}]
https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:46:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003024602/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}, {'datetime': '2017-10-03T02:46:02Z', 'uri': 'http://web.archive.org/web/20171003024602/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}, {'datetime': '2018-04-14T02:05:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414020512/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}, {'datetime': '2018-04-14T02:05:12Z', 'uri': 'http://web.archive.org/web/20180414020512/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}, {'datetime': '2018-05-19T08:52:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519085224/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}, {'datetime': '2018-05-19T08:52:24Z', 'uri': 'http://web.archive.org/web/20180519085224/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}, {'datetime': '2018-06-09T21:36:45Z', 'uri': 'http://web.archive.org/web/20180609213645/https://www.guideline.gov/summaries/summary/50336/1-the-treatment-of-central-sleep-apnea-syndromes-in-adults-practice-parameters-with-an-evidencebased-literature-review-and-metaanalyses-2-updated-adaptive-servoventilation-recommendations-for-the-2012-aasm-guideline-the-treatment-of-central-sleep-apnea-syndrom'}]
https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:49:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003024923/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2017-10-03T02:49:23Z', 'uri': 'http://web.archive.org/web/20171003024923/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2018-04-14T02:09:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414020902/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2018-04-14T02:09:02Z', 'uri': 'http://web.archive.org/web/20180414020902/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2018-05-19T08:56:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519085636/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2018-05-19T08:56:36Z', 'uri': 'http://web.archive.org/web/20180519085636/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2018-06-09T11:02:28Z', 'uri': 'http://web.archive.org/web/20180609110228/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}, {'datetime': '2018-06-15T00:01:55Z', 'uri': 'http://web.archive.org/web/20180615000155/https://www.guideline.gov/summaries/summary/50337/final-recommendation-statement-syphilis-infection-in-nonpregnant-adults-and-adolescents-screening'}]
https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:47:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003024712/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2017-10-03T02:47:12Z', 'uri': 'http://web.archive.org/web/20171003024712/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2018-04-14T02:06:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414020630/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2018-04-14T02:06:30Z', 'uri': 'http://web.archive.org/web/20180414020630/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2018-05-19T08:53:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519085351/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2018-05-19T08:53:51Z', 'uri': 'http://web.archive.org/web/20180519085351/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2018-06-10T22:45:36Z', 'uri': 'http://web.archive.org/web/20180610224536/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}, {'datetime': '2018-06-15T00:06:59Z', 'uri': 'http://web.archive.org/web/20180615000659/https://www.guideline.gov/summaries/summary/50338/topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-treating-recurrent-ovarian-cancer'}]
https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:47:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003024705/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}, {'datetime': '2017-10-03T02:47:05Z', 'uri': 'http://web.archive.org/web/20171003024705/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}, {'datetime': '2018-04-14T02:06:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414020623/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}, {'datetime': '2018-04-14T02:06:23Z', 'uri': 'http://web.archive.org/web/20180414020623/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}, {'datetime': '2018-05-19T08:53:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519085343/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}, {'datetime': '2018-05-19T08:53:43Z', 'uri': 'http://web.archive.org/web/20180519085343/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}, {'datetime': '2018-06-10T17:15:04Z', 'uri': 'http://web.archive.org/web/20180610171504/https://www.guideline.gov/summaries/summary/50340/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes'}]
https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:43:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003024332/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2017-10-03T02:43:32Z', 'uri': 'http://web.archive.org/web/20171003024332/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-04-14T02:02:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414020228/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-04-14T02:02:28Z', 'uri': 'http://web.archive.org/web/20180414020228/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-05-19T08:49:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519084911/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-05-19T08:49:11Z', 'uri': 'http://web.archive.org/web/20180519084911/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-06-09T11:02:01Z', 'uri': 'http://web.archive.org/web/20180609110201/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-06-15T00:24:22Z', 'uri': 'http://web.archive.org/web/20180615002422/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}, {'datetime': '2018-06-15T00:27:40Z', 'uri': 'http://web.archive.org/web/20180615002740/https://www.guideline.gov/summaries/summary/50342/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-ugt1a1-and-atazanavir-prescribing'}]
https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement	ARCHIVED	9 mementos	[{'datetime': '2017-07-14T12:00:21Z', 'uri': 'http://web.archive.org/web/20170714120021/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T02:42:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003024240/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2017-10-03T02:42:40Z', 'uri': 'http://web.archive.org/web/20171003024240/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:01:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414020128/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-04-14T02:01:28Z', 'uri': 'http://web.archive.org/web/20180414020128/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T08:47:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519084750/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-05-19T08:47:50Z', 'uri': 'http://web.archive.org/web/20180519084750/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-09T19:03:56Z', 'uri': 'http://web.archive.org/web/20180609190356/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}, {'datetime': '2018-06-15T00:01:30Z', 'uri': 'http://web.archive.org/web/20180615000130/https://www.guideline.gov/summaries/summary/50360/aspirin-use-for-the-primary-prevention-of-cardiovascular-disease-and-colorectal-cancer-us-preventive-services-task-force-recommendation-statement'}]
https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:43:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003024320/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:43:20Z', 'uri': 'http://web.archive.org/web/20171003024320/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:02:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414020214/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T02:02:14Z', 'uri': 'http://web.archive.org/web/20180414020214/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:48:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519084853/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:48:53Z', 'uri': 'http://web.archive.org/web/20180519084853/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-11T00:48:51Z', 'uri': 'http://web.archive.org/web/20180611004851/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-15T00:01:46Z', 'uri': 'http://web.archive.org/web/20180615000146/https://www.guideline.gov/summaries/summary/50370/practice-advisory-etanercept-for-poststroke-disability-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis	ARCHIVED	8 mementos	[{'datetime': '2017-05-07T03:54:18Z', 'uri': 'http://web.archive.org/web/20170507035418/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2017-10-03T02:46:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003024616/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2017-10-03T02:46:16Z', 'uri': 'http://web.archive.org/web/20171003024616/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2018-04-14T02:05:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414020528/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2018-04-14T02:05:28Z', 'uri': 'http://web.archive.org/web/20180414020528/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2018-05-19T08:52:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519085243/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2018-05-19T08:52:43Z', 'uri': 'http://web.archive.org/web/20180519085243/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}, {'datetime': '2018-06-09T19:26:49Z', 'uri': 'http://web.archive.org/web/20180609192649/https://www.guideline.gov/summaries/summary/50371/clinical-practice-guideline-for-the-treatment-of-patients-with-axial-spondyloarthritis-and-psoriatic-arthritis'}]
https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:45:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003024508/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}, {'datetime': '2017-10-03T02:45:08Z', 'uri': 'http://web.archive.org/web/20171003024508/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}, {'datetime': '2018-04-14T02:04:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414020416/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}, {'datetime': '2018-04-14T02:04:16Z', 'uri': 'http://web.archive.org/web/20180414020416/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}, {'datetime': '2018-05-19T08:51:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519085109/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}, {'datetime': '2018-05-19T08:51:09Z', 'uri': 'http://web.archive.org/web/20180519085109/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}, {'datetime': '2018-06-09T18:42:00Z', 'uri': 'http://web.archive.org/web/20180609184200/https://www.guideline.gov/summaries/summary/50372/nhfmcmaster-guideline-on-care-models-for-haemophilia-management'}]
https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:42:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003024249/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}, {'datetime': '2017-10-03T02:42:49Z', 'uri': 'http://web.archive.org/web/20171003024249/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}, {'datetime': '2018-04-14T02:01:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414020137/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}, {'datetime': '2018-04-14T02:01:37Z', 'uri': 'http://web.archive.org/web/20180414020137/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}, {'datetime': '2018-05-19T08:47:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519084759/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}, {'datetime': '2018-05-19T08:47:59Z', 'uri': 'http://web.archive.org/web/20180519084759/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}, {'datetime': '2018-06-09T15:45:27Z', 'uri': 'http://web.archive.org/web/20180609154527/https://www.guideline.gov/summaries/summary/50373/final-recommendation-statement-colorectal-cancer-screening'}]
https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:43:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003024326/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:43:26Z', 'uri': 'http://web.archive.org/web/20171003024326/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T02:02:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414020221/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T02:02:21Z', 'uri': 'http://web.archive.org/web/20180414020221/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:49:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519084901/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:49:01Z', 'uri': 'http://web.archive.org/web/20180519084901/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:07Z', 'uri': 'http://web.archive.org/web/20180609192207/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-14T23:57:34Z', 'uri': 'http://web.archive.org/web/20180614235734/https://www.guideline.gov/summaries/summary/50399/management-of-chronic-insomnia-disorder-in-adults-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:44:56Z', 'uri': 'http://wayback.archive-it.org/all/20171003024456/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}, {'datetime': '2017-10-03T02:44:56Z', 'uri': 'http://web.archive.org/web/20171003024456/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}, {'datetime': '2018-04-14T02:03:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414020358/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}, {'datetime': '2018-04-14T02:03:58Z', 'uri': 'http://web.archive.org/web/20180414020358/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}, {'datetime': '2018-05-19T08:50:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519085052/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}, {'datetime': '2018-05-19T08:50:52Z', 'uri': 'http://web.archive.org/web/20180519085052/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}, {'datetime': '2018-06-09T12:07:15Z', 'uri': 'http://web.archive.org/web/20180609120715/https://www.guideline.gov/summaries/summary/50400/occupational-therapy-practice-guidelines-for-individuals-with-autism-spectrum-disorder'}]
https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:44:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003024448/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}, {'datetime': '2017-10-03T02:44:48Z', 'uri': 'http://web.archive.org/web/20171003024448/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}, {'datetime': '2018-04-14T02:03:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414020350/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}, {'datetime': '2018-04-14T02:03:50Z', 'uri': 'http://web.archive.org/web/20180414020350/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}, {'datetime': '2018-05-19T08:50:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519085042/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}, {'datetime': '2018-05-19T08:50:42Z', 'uri': 'http://web.archive.org/web/20180519085042/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}, {'datetime': '2018-06-09T12:10:54Z', 'uri': 'http://web.archive.org/web/20180609121054/https://www.guideline.gov/summaries/summary/50401/occupational-therapy-practice-guidelines-for-adults-with-traumatic-brain-injury'}]
https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:44:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003024406/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2017-10-03T02:44:06Z', 'uri': 'http://web.archive.org/web/20171003024406/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2018-04-14T02:03:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414020302/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2018-04-14T02:03:02Z', 'uri': 'http://web.archive.org/web/20180414020302/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2018-05-19T08:49:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519084953/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2018-05-19T08:49:53Z', 'uri': 'http://web.archive.org/web/20180519084953/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2018-06-10T22:50:43Z', 'uri': 'http://web.archive.org/web/20180610225043/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}, {'datetime': '2018-06-14T23:56:46Z', 'uri': 'http://web.archive.org/web/20180614235646/https://www.guideline.gov/summaries/summary/50402/selection-of-optimal-adjuvant-chemotherapy-regimens-for-human-epidermal-growth-factor-receptor-2-her2negative-and-adjuvant-targeted-therapy-for-her2positive-breast-cancers-an-american-society-of-clinical-oncology-guideline-adaptation-of-the-cancer-care-ontario'}]
https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:41:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003024105/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2017-10-03T02:41:05Z', 'uri': 'http://web.archive.org/web/20171003024105/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2018-04-14T02:01:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414020102/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2018-04-14T02:01:02Z', 'uri': 'http://web.archive.org/web/20180414020102/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2018-05-19T08:47:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519084723/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2018-05-19T08:47:23Z', 'uri': 'http://web.archive.org/web/20180519084723/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2018-06-09T22:23:55Z', 'uri': 'http://web.archive.org/web/20180609222355/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}, {'datetime': '2018-06-15T00:27:01Z', 'uri': 'http://web.archive.org/web/20180615002701/https://www.guideline.gov/summaries/summary/50404/male-urethral-stricture-aua-guideline'}]
https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles	ARCHIVED	8 mementos	[{'datetime': '2017-01-30T13:18:52Z', 'uri': 'http://web.archive.org/web/20170130131852/https://guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2017-10-03T02:40:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003024008/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2017-10-03T02:40:08Z', 'uri': 'http://web.archive.org/web/20171003024008/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2018-04-14T02:00:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414020014/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2018-04-14T02:00:14Z', 'uri': 'http://web.archive.org/web/20180414020014/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2018-05-19T08:46:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519084625/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2018-05-19T08:46:25Z', 'uri': 'http://web.archive.org/web/20180519084625/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}, {'datetime': '2018-06-09T10:34:59Z', 'uri': 'http://web.archive.org/web/20180609103459/https://www.guideline.gov/summaries/summary/50405/healthy-lifestyles'}]
https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care	ARCHIVED	13 mementos	[{'datetime': '2017-01-30T13:18:46Z', 'uri': 'http://web.archive.org/web/20170130131846/https://guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2017-07-13T03:33:41Z', 'uri': 'http://web.archive.org/web/20170713033341/https://www.guideline.gov/summaries/summary/50406/Adult-depression-in-primary-care'}, {'datetime': '2017-10-02T20:04:45Z', 'uri': 'http://wayback.archive-it.org/all/20171002200445/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2017-10-02T20:04:45Z', 'uri': 'http://web.archive.org/web/20171002200445/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2018-04-13T18:55:14Z', 'uri': 'http://wayback.archive-it.org/all/20180413185514/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2018-04-13T18:55:14Z', 'uri': 'http://web.archive.org/web/20180413185514/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2018-05-18T21:49:36Z', 'uri': 'http://wayback.archive-it.org/all/20180518214936/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2018-05-18T21:49:36Z', 'uri': 'http://web.archive.org/web/20180518214936/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2018-06-09T10:36:37Z', 'uri': 'http://web.archive.org/web/20180609103637/https://www.guideline.gov/summaries/summary/50406/Adult-depression-in-primary-care'}, {'datetime': '2018-06-09T11:35:16Z', 'uri': 'http://web.archive.org/web/20180609113516/https://www.guideline.gov/summaries/summary/50406/adult-depression-in-primary-care'}, {'datetime': '2018-06-11T16:37:40Z', 'uri': 'http://web.archive.org/web/20180611163740/https://www.guideline.gov/summaries/summary/50406/Adult-depression-in-primary-care'}, {'datetime': '2018-06-20T17:39:06Z', 'uri': 'http://web.archive.org/web/20180620173906/https://www.guideline.gov/summaries/summary/50406/Adult-depression-in-primary-care'}, {'datetime': '2018-06-20T19:59:55Z', 'uri': 'http://web.archive.org/web/20180620195955/https://www.guideline.gov/summaries/summary/50406/Adult-depression-in-primary-care'}]
https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:40:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003024058/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}, {'datetime': '2017-10-03T02:40:58Z', 'uri': 'http://web.archive.org/web/20171003024058/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}, {'datetime': '2018-04-14T02:00:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414020053/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}, {'datetime': '2018-04-14T02:00:53Z', 'uri': 'http://web.archive.org/web/20180414020053/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}, {'datetime': '2018-05-19T08:47:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519084713/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}, {'datetime': '2018-05-19T08:47:13Z', 'uri': 'http://web.archive.org/web/20180519084713/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}, {'datetime': '2018-06-09T22:23:27Z', 'uri': 'http://web.archive.org/web/20180609222327/https://www.guideline.gov/summaries/summary/50407/diagnosis-and-treatment-of-nonmuscle-invasive-bladder-cancer-auasuo-guideline'}]
https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline	ARCHIVED	10 mementos	[{'datetime': '2017-10-03T02:41:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003024112/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2017-10-03T02:41:12Z', 'uri': 'http://web.archive.org/web/20171003024112/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-04-14T02:01:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414020110/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-04-14T02:01:10Z', 'uri': 'http://web.archive.org/web/20180414020110/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-05-19T08:47:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519084731/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-05-19T08:47:31Z', 'uri': 'http://web.archive.org/web/20180519084731/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-06-09T11:04:57Z', 'uri': 'http://web.archive.org/web/20180609110457/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-06-15T00:21:53Z', 'uri': 'http://web.archive.org/web/20180615002153/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-07-12T21:47:30Z', 'uri': 'http://web.archive.org/web/20180712214730/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}, {'datetime': '2018-07-12T21:47:30Z', 'uri': 'http://web.archive.org/web/20180712214730/https://www.guideline.gov/summaries/summary/50408/surgical-management-of-stones-american-urological-associationendourological-society-guideline'}]
https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:43:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003024345/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:43:45Z', 'uri': 'http://web.archive.org/web/20171003024345/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:02:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414020244/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:02:44Z', 'uri': 'http://web.archive.org/web/20180414020244/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:49:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519084935/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:49:35Z', 'uri': 'http://web.archive.org/web/20180519084935/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T02:41:42Z', 'uri': 'http://web.archive.org/web/20180610024142/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:51:36Z', 'uri': 'http://web.archive.org/web/20180614235136/https://www.guideline.gov/summaries/summary/50409/locally-advanced-unresectable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:40:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003024016/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2017-10-03T02:40:16Z', 'uri': 'http://web.archive.org/web/20171003024016/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2018-04-14T02:00:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414020023/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2018-04-14T02:00:23Z', 'uri': 'http://web.archive.org/web/20180414020023/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2018-05-19T08:46:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519084635/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2018-05-19T08:46:35Z', 'uri': 'http://web.archive.org/web/20180519084635/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2018-06-09T21:53:17Z', 'uri': 'http://web.archive.org/web/20180609215317/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}, {'datetime': '2018-06-14T23:57:42Z', 'uri': 'http://web.archive.org/web/20180614235742/https://www.guideline.gov/summaries/summary/50411/nonhodgkins-lymphoma-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:40:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003024031/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2017-10-03T02:40:31Z', 'uri': 'http://web.archive.org/web/20171003024031/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-01-10T13:22:18Z', 'uri': 'http://web.archive.org/web/20180110132218/https://guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-04-14T02:00:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414020040/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-04-14T02:00:40Z', 'uri': 'http://web.archive.org/web/20180414020040/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-05-19T08:46:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519084652/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-05-19T08:46:52Z', 'uri': 'http://web.archive.org/web/20180519084652/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-06-09T15:29:56Z', 'uri': 'http://web.archive.org/web/20180609152956/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}, {'datetime': '2018-06-14T23:57:24Z', 'uri': 'http://web.archive.org/web/20180614235724/https://www.guideline.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management'}]
https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:40:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003024025/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2017-10-03T02:40:25Z', 'uri': 'http://web.archive.org/web/20171003024025/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2018-04-14T02:00:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414020034/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2018-04-14T02:00:34Z', 'uri': 'http://web.archive.org/web/20180414020034/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2018-05-19T08:46:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519084645/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2018-05-19T08:46:45Z', 'uri': 'http://web.archive.org/web/20180519084645/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2018-06-11T02:13:35Z', 'uri': 'http://web.archive.org/web/20180611021335/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}, {'datetime': '2018-06-14T23:56:27Z', 'uri': 'http://web.archive.org/web/20180614235627/https://www.guideline.gov/summaries/summary/50413/cirrhosis-in-over-16s-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:40:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003024028/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2017-10-03T02:40:28Z', 'uri': 'http://web.archive.org/web/20171003024028/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2018-04-14T02:00:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414020037/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2018-04-14T02:00:37Z', 'uri': 'http://web.archive.org/web/20180414020037/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2018-05-19T08:46:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519084648/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2018-05-19T08:46:48Z', 'uri': 'http://web.archive.org/web/20180519084648/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2018-06-10T01:21:05Z', 'uri': 'http://web.archive.org/web/20180610012105/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}, {'datetime': '2018-06-14T23:56:33Z', 'uri': 'http://web.archive.org/web/20180614235633/https://www.guideline.gov/summaries/summary/50414/nonalcoholic-fatty-liver-disease-nafld-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:05:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003020557/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:05:57Z', 'uri': 'http://web.archive.org/web/20171003020557/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:55:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414005519/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T00:55:19Z', 'uri': 'http://web.archive.org/web/20180414005519/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T07:34:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519073411/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T07:34:11Z', 'uri': 'http://web.archive.org/web/20180519073411/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-09T15:29:13Z', 'uri': 'http://web.archive.org/web/20180609152913/https://www.guideline.gov/summaries/summary/50415/radiation-therapy-for-glioblastoma-an-astro-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:43:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003024312/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}, {'datetime': '2017-10-03T02:43:12Z', 'uri': 'http://web.archive.org/web/20171003024312/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}, {'datetime': '2018-04-14T02:02:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414020205/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}, {'datetime': '2018-04-14T02:02:05Z', 'uri': 'http://web.archive.org/web/20180414020205/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}, {'datetime': '2018-05-19T08:48:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519084843/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}, {'datetime': '2018-05-19T08:48:43Z', 'uri': 'http://web.archive.org/web/20180519084843/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}, {'datetime': '2018-06-10T18:39:38Z', 'uri': 'http://web.archive.org/web/20180610183938/https://www.guideline.gov/summaries/summary/50416/final-recommendation-statement-skin-cancer-screening'}]
https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:41:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003024120/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}, {'datetime': '2017-10-03T02:41:20Z', 'uri': 'http://web.archive.org/web/20171003024120/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}, {'datetime': '2018-04-14T02:01:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414020120/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}, {'datetime': '2018-04-14T02:01:20Z', 'uri': 'http://web.archive.org/web/20180414020120/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}, {'datetime': '2018-05-19T08:47:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519084741/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}, {'datetime': '2018-05-19T08:47:41Z', 'uri': 'http://web.archive.org/web/20180519084741/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}, {'datetime': '2018-06-09T22:22:24Z', 'uri': 'http://web.archive.org/web/20180609222224/https://www.guideline.gov/summaries/summary/50417/the-insertion-and-management-of-external-ventricular-drains-an-evidencebased-consensus-statement-a-statement-for-healthcare-professionals-from-the-neurocritical-care-society'}]
https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:38:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003023816/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:38:16Z', 'uri': 'http://web.archive.org/web/20171003023816/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:57:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414015755/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:57:55Z', 'uri': 'http://web.archive.org/web/20180414015755/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:43:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519084354/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:43:54Z', 'uri': 'http://web.archive.org/web/20180519084354/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:04:30Z', 'uri': 'http://web.archive.org/web/20180610010430/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-15T00:28:47Z', 'uri': 'http://web.archive.org/web/20180615002847/https://www.guideline.gov/summaries/summary/50418/vestibular-rehabilitation-for-peripheral-vestibular-hypofunction-an-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries	ARCHIVED	8 mementos	[{'datetime': '2017-01-30T13:19:08Z', 'uri': 'http://web.archive.org/web/20170130131908/https://guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2017-10-03T02:40:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003024001/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2017-10-03T02:40:01Z', 'uri': 'http://web.archive.org/web/20171003024001/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-04-14T02:00:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414020006/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-04-14T02:00:06Z', 'uri': 'http://web.archive.org/web/20180414020006/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-05-19T08:46:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519084615/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-05-19T08:46:15Z', 'uri': 'http://web.archive.org/web/20180519084615/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}, {'datetime': '2018-06-10T01:16:07Z', 'uri': 'http://web.archive.org/web/20180610011607/https://www.guideline.gov/summaries/summary/50419/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-treatment-of-anterior-cruciate-ligament-injuries'}]
https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle	ARCHIVED	8 mementos	[{'datetime': '2017-01-30T13:18:50Z', 'uri': 'http://web.archive.org/web/20170130131850/https://guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2017-10-03T02:39:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003023955/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2017-10-03T02:39:55Z', 'uri': 'http://web.archive.org/web/20171003023955/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2018-04-14T01:59:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414015959/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2018-04-14T01:59:59Z', 'uri': 'http://web.archive.org/web/20180414015959/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2018-05-19T08:46:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519084606/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2018-05-19T08:46:06Z', 'uri': 'http://web.archive.org/web/20180519084606/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}, {'datetime': '2018-06-09T22:10:54Z', 'uri': 'http://web.archive.org/web/20180609221054/https://www.guideline.gov/summaries/summary/50420/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-management-of-osteochondritis-dissecans-of-the-femoral-condyle'}]
https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:47:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003024744/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}, {'datetime': '2017-10-03T02:47:44Z', 'uri': 'http://web.archive.org/web/20171003024744/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}, {'datetime': '2018-04-14T02:07:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414020706/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}, {'datetime': '2018-04-14T02:07:06Z', 'uri': 'http://web.archive.org/web/20180414020706/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}, {'datetime': '2018-05-19T08:54:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519085429/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}, {'datetime': '2018-05-19T08:54:29Z', 'uri': 'http://web.archive.org/web/20180519085429/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}, {'datetime': '2018-06-10T23:43:05Z', 'uri': 'http://web.archive.org/web/20180610234305/https://www.guideline.gov/summaries/summary/50422/acr-appropriateness-criteria--breast-pain'}]
https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:48:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003024800/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}, {'datetime': '2017-10-03T02:48:00Z', 'uri': 'http://web.archive.org/web/20171003024800/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}, {'datetime': '2018-04-14T02:07:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414020725/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}, {'datetime': '2018-04-14T02:07:25Z', 'uri': 'http://web.archive.org/web/20180414020725/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}, {'datetime': '2018-05-19T08:54:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519085449/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}, {'datetime': '2018-05-19T08:54:49Z', 'uri': 'http://web.archive.org/web/20180519085449/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}, {'datetime': '2018-06-10T01:23:20Z', 'uri': 'http://web.archive.org/web/20180610012320/https://www.guideline.gov/summaries/summary/50423/acr-appropriateness-criteria--stage-i-breast-cancer-initial-workup-and-surveillance-for-local-recurrence-and-distant-metastases-in-asymptomatic-women'}]
https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:47:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003024728/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}, {'datetime': '2017-10-03T02:47:28Z', 'uri': 'http://web.archive.org/web/20171003024728/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}, {'datetime': '2018-04-14T02:06:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414020647/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}, {'datetime': '2018-04-14T02:06:47Z', 'uri': 'http://web.archive.org/web/20180414020647/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}, {'datetime': '2018-05-19T08:54:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519085409/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}, {'datetime': '2018-05-19T08:54:09Z', 'uri': 'http://web.archive.org/web/20180519085409/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}, {'datetime': '2018-06-10T22:00:13Z', 'uri': 'http://web.archive.org/web/20180610220013/https://www.guideline.gov/summaries/summary/50424/acr-appropriateness-criteria--acute-chest-pain---suspected-pulmonary-embolism'}]
https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:47:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003024752/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}, {'datetime': '2017-10-03T02:47:52Z', 'uri': 'http://web.archive.org/web/20171003024752/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}, {'datetime': '2018-04-14T02:07:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414020715/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}, {'datetime': '2018-04-14T02:07:15Z', 'uri': 'http://web.archive.org/web/20180414020715/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}, {'datetime': '2018-05-19T08:54:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519085438/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}, {'datetime': '2018-05-19T08:54:38Z', 'uri': 'http://web.archive.org/web/20180519085438/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}, {'datetime': '2018-06-09T19:17:21Z', 'uri': 'http://web.archive.org/web/20180609191721/https://www.guideline.gov/summaries/summary/50425/acr-appropriateness-criteria--pretreatment-staging-of-colorectal-cancer'}]
https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:45:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003024520/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}, {'datetime': '2017-10-03T02:45:20Z', 'uri': 'http://web.archive.org/web/20171003024520/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}, {'datetime': '2018-04-14T02:04:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414020426/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}, {'datetime': '2018-04-14T02:04:26Z', 'uri': 'http://web.archive.org/web/20180414020426/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}, {'datetime': '2018-05-19T08:51:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519085121/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}, {'datetime': '2018-05-19T08:51:21Z', 'uri': 'http://web.archive.org/web/20180519085121/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}, {'datetime': '2018-06-10T11:04:00Z', 'uri': 'http://web.archive.org/web/20180610110400/https://www.guideline.gov/summaries/summary/50426/acr-appropriateness-criteria--radiologic-management-of-mesenteric-ischemia'}]
https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy	ARCHIVED	8 mementos	[{'datetime': '2016-12-16T13:38:18Z', 'uri': 'http://web.archive.org/web/20161216133818/https://guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2017-10-03T02:45:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003024517/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2017-10-03T02:45:17Z', 'uri': 'http://web.archive.org/web/20171003024517/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2018-04-14T02:04:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414020423/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2018-04-14T02:04:23Z', 'uri': 'http://web.archive.org/web/20180414020423/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2018-05-19T08:51:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519085117/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2018-05-19T08:51:17Z', 'uri': 'http://web.archive.org/web/20180519085117/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}, {'datetime': '2018-06-11T05:58:46Z', 'uri': 'http://web.archive.org/web/20180611055846/https://www.guideline.gov/summaries/summary/50427/acr-appropriateness-criteria--chronic-back-pain-suspected-sacroiliitisspondyloarthropathy'}]
https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot	ARCHIVED	8 mementos	[{'datetime': '2016-12-16T18:53:35Z', 'uri': 'http://web.archive.org/web/20161216185335/https://guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2017-10-03T02:45:43Z', 'uri': 'http://wayback.archive-it.org/all/20171003024543/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2017-10-03T02:45:43Z', 'uri': 'http://web.archive.org/web/20171003024543/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2018-04-14T02:04:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414020451/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2018-04-14T02:04:51Z', 'uri': 'http://web.archive.org/web/20180414020451/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2018-05-19T08:51:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519085152/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2018-05-19T08:51:52Z', 'uri': 'http://web.archive.org/web/20180519085152/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}, {'datetime': '2018-06-09T11:01:04Z', 'uri': 'http://web.archive.org/web/20180609110104/https://www.guideline.gov/summaries/summary/50428/acr-appropriateness-criteria--suspected-osteomyelitis-septic-arthritis-or-soft-tissue-infection-excluding-spine-and-diabetic-foot'}]
https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy	ARCHIVED	8 mementos	[{'datetime': '2016-12-16T13:39:42Z', 'uri': 'http://web.archive.org/web/20161216133942/https://guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2017-10-03T02:45:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003024527/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2017-10-03T02:45:27Z', 'uri': 'http://web.archive.org/web/20171003024527/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2018-04-14T02:04:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414020435/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2018-04-14T02:04:35Z', 'uri': 'http://web.archive.org/web/20180414020435/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2018-05-19T08:51:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519085134/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2018-05-19T08:51:34Z', 'uri': 'http://web.archive.org/web/20180519085134/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}, {'datetime': '2018-06-10T16:21:15Z', 'uri': 'http://web.archive.org/web/20180610162115/https://www.guideline.gov/summaries/summary/50429/acr-appropriateness-criteria--staging-of-testicular-malignancy'}]
https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg	ARCHIVED	8 mementos	[{'datetime': '2016-12-16T18:52:58Z', 'uri': 'http://web.archive.org/web/20161216185258/https://guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2017-10-03T02:45:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003024536/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2017-10-03T02:45:36Z', 'uri': 'http://web.archive.org/web/20171003024536/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2018-04-14T02:04:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414020443/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2018-04-14T02:04:43Z', 'uri': 'http://web.archive.org/web/20180414020443/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2018-05-19T08:51:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519085143/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2018-05-19T08:51:43Z', 'uri': 'http://web.archive.org/web/20180519085143/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}, {'datetime': '2018-06-10T22:00:15Z', 'uri': 'http://web.archive.org/web/20180610220015/https://www.guideline.gov/summaries/summary/50430/acr-appropriateness-criteria--sudden-onset-of-cold-painful-leg'}]
https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:38:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003023811/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T02:38:11Z', 'uri': 'http://web.archive.org/web/20171003023811/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:57:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414015748/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:57:48Z', 'uri': 'http://web.archive.org/web/20180414015748/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:43:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519084345/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:43:45Z', 'uri': 'http://web.archive.org/web/20180519084345/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T11:21:21Z', 'uri': 'http://web.archive.org/web/20180609112121/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-15T00:24:29Z', 'uri': 'http://web.archive.org/web/20180615002429/https://www.guideline.gov/summaries/summary/50431/surgery-or-stenting-for-colonic-obstruction-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:38:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003023804/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2017-10-03T02:38:04Z', 'uri': 'http://web.archive.org/web/20171003023804/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T01:57:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414015713/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-04-14T01:57:13Z', 'uri': 'http://web.archive.org/web/20180414015713/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T08:43:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519084335/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-05-19T08:43:35Z', 'uri': 'http://web.archive.org/web/20180519084335/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}, {'datetime': '2018-06-09T19:16:23Z', 'uri': 'http://web.archive.org/web/20180609191623/https://www.guideline.gov/summaries/summary/50432/management-of-penetrating-extraperitoneal-rectal-injuries-an-eastern-association-for-the-surgery-of-trauma-practice-management-guideline'}]
https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly	ARCHIVED	7 mementos	[{'datetime': '2017-10-02T20:10:05Z', 'uri': 'http://wayback.archive-it.org/all/20171002201005/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}, {'datetime': '2017-10-02T20:10:05Z', 'uri': 'http://web.archive.org/web/20171002201005/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}, {'datetime': '2018-04-14T00:46:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414004624/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}, {'datetime': '2018-04-14T00:46:24Z', 'uri': 'http://web.archive.org/web/20180414004624/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}, {'datetime': '2018-05-18T22:04:11Z', 'uri': 'http://wayback.archive-it.org/all/20180518220411/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}, {'datetime': '2018-05-18T22:04:11Z', 'uri': 'http://web.archive.org/web/20180518220411/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}, {'datetime': '2018-06-09T15:35:57Z', 'uri': 'http://web.archive.org/web/20180609153557/https://www.guideline.gov/summaries/summary/50433/prevention-of-fallrelated-injuries-in-the-elderly'}]
https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:39:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003023938/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}, {'datetime': '2017-10-03T02:39:38Z', 'uri': 'http://web.archive.org/web/20171003023938/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}, {'datetime': '2018-04-14T01:59:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414015937/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}, {'datetime': '2018-04-14T01:59:37Z', 'uri': 'http://web.archive.org/web/20180414015937/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}, {'datetime': '2018-05-19T08:45:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519084545/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}, {'datetime': '2018-05-19T08:45:45Z', 'uri': 'http://web.archive.org/web/20180519084545/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}, {'datetime': '2018-06-09T20:18:25Z', 'uri': 'http://web.archive.org/web/20180609201825/https://www.guideline.gov/summaries/summary/50444/patient-blood-management-guidelines-module-6--neonatal-and-paediatrics'}]
https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:06:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003020607/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}, {'datetime': '2017-10-03T02:06:07Z', 'uri': 'http://web.archive.org/web/20171003020607/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}, {'datetime': '2018-04-14T00:55:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414005529/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}, {'datetime': '2018-04-14T00:55:29Z', 'uri': 'http://web.archive.org/web/20180414005529/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}, {'datetime': '2018-05-19T07:34:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519073424/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}, {'datetime': '2018-05-19T07:34:24Z', 'uri': 'http://web.archive.org/web/20180519073424/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}, {'datetime': '2018-06-09T10:36:17Z', 'uri': 'http://web.archive.org/web/20180609103617/https://www.guideline.gov/summaries/summary/50445/assessment-and-management-of-pressure-injuries-for-the-interprofessional-team-third-edition'}]
https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:43:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003024304/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2017-10-03T02:43:04Z', 'uri': 'http://web.archive.org/web/20171003024304/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2018-04-14T02:01:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414020156/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2018-04-14T02:01:56Z', 'uri': 'http://web.archive.org/web/20180414020156/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2018-05-19T08:48:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519084834/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2018-05-19T08:48:34Z', 'uri': 'http://web.archive.org/web/20180519084834/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2018-06-09T19:03:45Z', 'uri': 'http://web.archive.org/web/20180609190345/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}, {'datetime': '2018-06-14T23:51:31Z', 'uri': 'http://web.archive.org/web/20180614235131/https://www.guideline.gov/summaries/summary/50446/final-recommendation-statement-lipid-disorders-in-children-and-adolescents-screening'}]
https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:37:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003023723/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2017-10-03T02:37:23Z', 'uri': 'http://web.archive.org/web/20171003023723/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2017-11-17T10:07:49Z', 'uri': 'http://web.archive.org/web/20171117100749/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2018-04-14T01:56:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414015623/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2018-04-14T01:56:23Z', 'uri': 'http://web.archive.org/web/20180414015623/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2018-05-19T08:41:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519084137/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2018-05-19T08:41:37Z', 'uri': 'http://web.archive.org/web/20180519084137/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2018-06-09T20:54:49Z', 'uri': 'http://web.archive.org/web/20180609205449/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}, {'datetime': '2018-06-14T23:58:01Z', 'uri': 'http://web.archive.org/web/20180614235801/https://www.guideline.gov/summaries/summary/50447/evidencebased-clinical-practice-guideline-for-the-use-of-pitandfissure-sealants-a-report-of-the-american-dental-association-and-the-american-academy-of-pediatric-dentistry'}]
https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:43:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003024355/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:43:55Z', 'uri': 'http://web.archive.org/web/20171003024355/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:02:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414020253/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T02:02:53Z', 'uri': 'http://web.archive.org/web/20180414020253/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:49:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519084944/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:49:44Z', 'uri': 'http://web.archive.org/web/20180519084944/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:44:55Z', 'uri': 'http://web.archive.org/web/20180609224455/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:51:22Z', 'uri': 'http://web.archive.org/web/20180614235122/https://www.guideline.gov/summaries/summary/50448/metastatic-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:39:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003023928/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2017-10-03T02:39:28Z', 'uri': 'http://web.archive.org/web/20171003023928/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2018-04-14T01:59:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414015925/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2018-04-14T01:59:25Z', 'uri': 'http://web.archive.org/web/20180414015925/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2018-05-19T08:45:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519084531/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2018-05-19T08:45:31Z', 'uri': 'http://web.archive.org/web/20180519084531/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2018-06-09T21:36:04Z', 'uri': 'http://web.archive.org/web/20180609213604/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}, {'datetime': '2018-06-15T00:06:29Z', 'uri': 'http://web.archive.org/web/20180615000629/https://www.guideline.gov/summaries/summary/50449/guidelines-of-care-for-the-management-of-acne-vulgaris'}]
https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:39:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003023947/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2017-10-03T02:39:47Z', 'uri': 'http://web.archive.org/web/20171003023947/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2018-04-14T01:59:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414015948/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2018-04-14T01:59:48Z', 'uri': 'http://web.archive.org/web/20180414015948/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2018-05-19T08:45:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519084557/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2018-05-19T08:45:57Z', 'uri': 'http://web.archive.org/web/20180519084557/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2018-06-09T15:17:39Z', 'uri': 'http://web.archive.org/web/20180609151739/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}, {'datetime': '2018-06-14T23:56:20Z', 'uri': 'http://web.archive.org/web/20180614235620/https://www.guideline.gov/summaries/summary/50450/oral-health-for-adults-in-care-homes'}]
https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:46:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003024609/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2017-10-03T02:46:09Z', 'uri': 'http://web.archive.org/web/20171003024609/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2018-04-14T02:05:21Z', 'uri': 'http://wayback.archive-it.org/all/20180414020521/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2018-04-14T02:05:21Z', 'uri': 'http://web.archive.org/web/20180414020521/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2018-05-19T08:52:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519085234/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2018-05-19T08:52:34Z', 'uri': 'http://web.archive.org/web/20180519085234/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2018-06-09T11:49:03Z', 'uri': 'http://web.archive.org/web/20180609114903/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}, {'datetime': '2018-06-14T23:51:25Z', 'uri': 'http://web.archive.org/web/20180614235125/https://www.guideline.gov/summaries/summary/50451/american-osteopathic-association-guidelines-for-osteopathic-manipulative-treatment-omt-for-patients-with-low-back-pain'}]
https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:37:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003023729/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}, {'datetime': '2017-10-03T02:37:29Z', 'uri': 'http://web.archive.org/web/20171003023729/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}, {'datetime': '2018-04-14T01:56:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414015631/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}, {'datetime': '2018-04-14T01:56:31Z', 'uri': 'http://web.archive.org/web/20180414015631/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}, {'datetime': '2018-05-19T08:41:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519084147/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}, {'datetime': '2018-05-19T08:41:47Z', 'uri': 'http://web.archive.org/web/20180519084147/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}, {'datetime': '2018-06-09T11:54:56Z', 'uri': 'http://web.archive.org/web/20180609115456/https://www.guideline.gov/summaries/summary/50453/lower-extremity-injury-medical-treatment-guidelines'}]
https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-02-07T00:11:38Z', 'uri': 'http://web.archive.org/web/20170207001138/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2017-10-03T02:39:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003023901/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2017-10-03T02:39:01Z', 'uri': 'http://web.archive.org/web/20171003023901/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2018-04-14T01:58:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414015849/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2018-04-14T01:58:49Z', 'uri': 'http://web.archive.org/web/20180414015849/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2018-05-19T08:44:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519084457/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2018-05-19T08:44:57Z', 'uri': 'http://web.archive.org/web/20180519084457/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}, {'datetime': '2018-06-09T19:16:34Z', 'uri': 'http://web.archive.org/web/20180609191634/https://www.guideline.gov/summaries/summary/50454/selfexpandable-metal-stents-for-obstructing-colonic-and-extracolonic-cancer-european-society-of-gastrointestinal-endoscopy-esge-clinical-guideline'}]
https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes	ARCHIVED	8 mementos	[{'datetime': '2017-02-04T06:17:00Z', 'uri': 'http://web.archive.org/web/20170204061700/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2017-10-03T02:39:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003023923/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2017-10-03T02:39:23Z', 'uri': 'http://web.archive.org/web/20171003023923/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2018-04-14T01:59:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414015919/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2018-04-14T01:59:19Z', 'uri': 'http://web.archive.org/web/20180414015919/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2018-05-19T08:45:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519084524/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2018-05-19T08:45:24Z', 'uri': 'http://web.archive.org/web/20180519084524/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}, {'datetime': '2018-06-09T21:45:47Z', 'uri': 'http://web.archive.org/web/20180609214547/https://www.guideline.gov/summaries/summary/50455/iwgdf-guidance-on-the-prevention-of-foot-ulcers-in-atrisk-patients-with-diabetes'}]
https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes	ARCHIVED	8 mementos	[{'datetime': '2017-02-04T05:00:11Z', 'uri': 'http://web.archive.org/web/20170204050011/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2017-10-03T02:39:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003023915/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2017-10-03T02:39:15Z', 'uri': 'http://web.archive.org/web/20171003023915/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2018-04-14T01:59:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414015909/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2018-04-14T01:59:09Z', 'uri': 'http://web.archive.org/web/20180414015909/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2018-05-19T08:45:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519084515/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2018-05-19T08:45:15Z', 'uri': 'http://web.archive.org/web/20180519084515/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}, {'datetime': '2018-06-09T21:46:25Z', 'uri': 'http://web.archive.org/web/20180609214625/https://www.guideline.gov/summaries/summary/50456/iwgdf-guidance-on-footwear-and-offloading-interventions-to-prevent-and-heal-foot-ulcers-in-patients-with-diabetes'}]
https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes	ARCHIVED	8 mementos	[{'datetime': '2017-02-04T06:50:01Z', 'uri': 'http://web.archive.org/web/20170204065001/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2017-10-03T02:39:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003023921/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2017-10-03T02:39:21Z', 'uri': 'http://web.archive.org/web/20171003023921/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2018-04-14T01:59:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414015915/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2018-04-14T01:59:15Z', 'uri': 'http://web.archive.org/web/20180414015915/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2018-05-19T08:45:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519084521/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2018-05-19T08:45:21Z', 'uri': 'http://web.archive.org/web/20180519084521/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}, {'datetime': '2018-06-09T21:46:23Z', 'uri': 'http://web.archive.org/web/20180609214623/https://www.guideline.gov/summaries/summary/50457/iwgdf-guidance-on-the-diagnosis-prognosis-and-management-of-peripheral-artery-disease-in-patients-with-foot-ulcers-in-diabetes'}]
https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes	ARCHIVED	8 mementos	[{'datetime': '2017-02-04T04:36:48Z', 'uri': 'http://web.archive.org/web/20170204043648/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2017-10-03T02:39:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003023917/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2017-10-03T02:39:17Z', 'uri': 'http://web.archive.org/web/20171003023917/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2018-04-14T01:59:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414015912/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2018-04-14T01:59:12Z', 'uri': 'http://web.archive.org/web/20180414015912/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2018-05-19T08:45:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519084518/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2018-05-19T08:45:18Z', 'uri': 'http://web.archive.org/web/20180519084518/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}, {'datetime': '2018-06-09T21:45:26Z', 'uri': 'http://web.archive.org/web/20180609214526/https://www.guideline.gov/summaries/summary/50458/iwgdf-guidance-on-the-diagnosis-and-management-of-foot-infections-in-persons-with-diabetes'}]
https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes	ARCHIVED	8 mementos	[{'datetime': '2017-02-04T05:39:07Z', 'uri': 'http://web.archive.org/web/20170204053907/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2017-10-03T02:39:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003023925/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2017-10-03T02:39:25Z', 'uri': 'http://web.archive.org/web/20171003023925/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2018-04-14T01:59:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414015922/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2018-04-14T01:59:22Z', 'uri': 'http://web.archive.org/web/20180414015922/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2018-05-19T08:45:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519084528/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2018-05-19T08:45:28Z', 'uri': 'http://web.archive.org/web/20180519084528/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}, {'datetime': '2018-06-09T21:46:09Z', 'uri': 'http://web.archive.org/web/20180609214609/https://www.guideline.gov/summaries/summary/50459/iwgdf-guidance-on-use-of-interventions-to-enhance-the-healing-of-chronic-ulcers-of-the-foot-in-diabetes'}]
https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:44:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003024435/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2017-10-03T02:44:35Z', 'uri': 'http://web.archive.org/web/20171003024435/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2018-04-14T02:03:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414020336/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2018-04-14T02:03:36Z', 'uri': 'http://web.archive.org/web/20180414020336/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2018-05-19T08:50:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519085028/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2018-05-19T08:50:28Z', 'uri': 'http://web.archive.org/web/20180519085028/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2018-06-09T22:11:32Z', 'uri': 'http://web.archive.org/web/20180609221132/https://www.guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}, {'datetime': '2018-06-15T12:55:14Z', 'uri': 'http://web.archive.org/web/20180615125514/https://guideline.gov/summaries/summary/50460/acr-appropriateness-criteria--imaging-after-shoulder-arthroplasty'}]
https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:44:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003024445/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}, {'datetime': '2017-10-03T02:44:45Z', 'uri': 'http://web.archive.org/web/20171003024445/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}, {'datetime': '2018-04-14T02:03:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414020346/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}, {'datetime': '2018-04-14T02:03:46Z', 'uri': 'http://web.archive.org/web/20180414020346/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}, {'datetime': '2018-05-19T08:50:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519085039/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}, {'datetime': '2018-05-19T08:50:39Z', 'uri': 'http://web.archive.org/web/20180519085039/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}, {'datetime': '2018-06-09T15:22:54Z', 'uri': 'http://web.archive.org/web/20180609152254/https://www.guideline.gov/summaries/summary/50461/acr-appropriateness-criteria--osteoporosis-and-bone-mineral-density'}]
https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:44:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003024423/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}, {'datetime': '2017-10-03T02:44:23Z', 'uri': 'http://web.archive.org/web/20171003024423/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}, {'datetime': '2018-04-14T02:03:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414020320/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}, {'datetime': '2018-04-14T02:03:20Z', 'uri': 'http://web.archive.org/web/20180414020320/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}, {'datetime': '2018-05-19T08:50:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519085013/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}, {'datetime': '2018-05-19T08:50:13Z', 'uri': 'http://web.archive.org/web/20180519085013/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}, {'datetime': '2018-06-10T00:05:15Z', 'uri': 'http://web.archive.org/web/20180610000515/https://www.guideline.gov/summaries/summary/50462/acr-appropriateness-criteria--cerebrovascular-disease'}]
https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:44:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003024414/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}, {'datetime': '2017-10-03T02:44:14Z', 'uri': 'http://web.archive.org/web/20171003024414/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}, {'datetime': '2018-04-14T02:03:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414020311/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}, {'datetime': '2018-04-14T02:03:11Z', 'uri': 'http://web.archive.org/web/20180414020311/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}, {'datetime': '2018-05-19T08:50:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519085003/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}, {'datetime': '2018-05-19T08:50:03Z', 'uri': 'http://web.archive.org/web/20180519085003/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}, {'datetime': '2018-06-10T22:46:39Z', 'uri': 'http://web.archive.org/web/20180610224639/https://www.guideline.gov/summaries/summary/50463/acr-appropriateness-criteria--assessment-of-fetal-wellbeing'}]
https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:38:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003023824/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2017-10-03T02:38:24Z', 'uri': 'http://web.archive.org/web/20171003023824/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2018-04-14T01:58:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414015803/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2018-04-14T01:58:03Z', 'uri': 'http://web.archive.org/web/20180414015803/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2018-05-19T08:44:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519084408/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2018-05-19T08:44:08Z', 'uri': 'http://web.archive.org/web/20180519084408/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2018-06-10T22:46:40Z', 'uri': 'http://web.archive.org/web/20180610224640/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}, {'datetime': '2018-06-14T23:26:04Z', 'uri': 'http://web.archive.org/web/20180614232604/https://www.guideline.gov/summaries/summary/50469/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer-american-society-of-clinical-oncology-guideline'}]
https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer	ARCHIVED	8 mementos	[{'datetime': '2017-04-16T18:49:59Z', 'uri': 'http://web.archive.org/web/20170416184959/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2017-10-03T02:36:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003023651/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2017-10-03T02:36:51Z', 'uri': 'http://web.archive.org/web/20171003023651/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2018-04-14T01:55:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414015533/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2018-04-14T01:55:33Z', 'uri': 'http://web.archive.org/web/20180414015533/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2018-05-19T08:40:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519084057/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2018-05-19T08:40:57Z', 'uri': 'http://web.archive.org/web/20180519084057/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}, {'datetime': '2018-06-10T01:35:56Z', 'uri': 'http://web.archive.org/web/20180610013556/https://www.guideline.gov/summaries/summary/50470/guideline-for-the-treatment-of-breakthrough-and-the-prevention-of-refractory-chemotherapyinduced-nausea-and-vomiting-in-children-with-cancer'}]
https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation	ARCHIVED	10 mementos	[{'datetime': '2017-04-16T20:02:16Z', 'uri': 'http://web.archive.org/web/20170416200216/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2017-07-14T11:35:10Z', 'uri': 'http://web.archive.org/web/20170714113510/https://guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2017-10-03T02:36:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003023644/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2017-10-03T02:36:44Z', 'uri': 'http://web.archive.org/web/20171003023644/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2017-11-17T06:13:59Z', 'uri': 'http://web.archive.org/web/20171117061359/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-04-14T01:55:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414015524/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-04-14T01:55:24Z', 'uri': 'http://web.archive.org/web/20180414015524/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-05-19T08:40:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519084049/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-05-19T08:40:49Z', 'uri': 'http://web.archive.org/web/20180519084049/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}, {'datetime': '2018-06-09T11:40:23Z', 'uri': 'http://web.archive.org/web/20180609114023/https://www.guideline.gov/summaries/summary/50471/guideline-for-the-prevention-of-oral-and-oropharyngeal-mucositis-in-children-receiving-treatment-for-cancer-or-undergoing-haematopoietic-stem-cell-transplantation'}]
https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer	ARCHIVED	8 mementos	[{'datetime': '2017-02-07T00:11:14Z', 'uri': 'http://web.archive.org/web/20170207001114/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2017-10-03T02:39:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003023908/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2017-10-03T02:39:08Z', 'uri': 'http://web.archive.org/web/20171003023908/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2018-04-14T01:59:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414015902/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2018-04-14T01:59:02Z', 'uri': 'http://web.archive.org/web/20180414015902/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2018-05-19T08:45:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519084506/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2018-05-19T08:45:06Z', 'uri': 'http://web.archive.org/web/20180519084506/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}, {'datetime': '2018-06-09T21:15:48Z', 'uri': 'http://web.archive.org/web/20180609211548/https://www.guideline.gov/summaries/summary/50472/clinical-utility-of-multigene-profiling-assays-in-invasive-earlystage-breast-cancer'}]
https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries	ARCHIVED	7 mementos	[{'datetime': '2017-10-02T20:08:36Z', 'uri': 'http://wayback.archive-it.org/all/20171002200836/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}, {'datetime': '2017-10-02T20:08:36Z', 'uri': 'http://web.archive.org/web/20171002200836/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}, {'datetime': '2018-04-14T00:44:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414004453/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}, {'datetime': '2018-04-14T00:44:53Z', 'uri': 'http://web.archive.org/web/20180414004453/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}, {'datetime': '2018-05-18T22:02:46Z', 'uri': 'http://wayback.archive-it.org/all/20180518220246/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}, {'datetime': '2018-05-18T22:02:46Z', 'uri': 'http://web.archive.org/web/20180518220246/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}, {'datetime': '2018-06-09T16:48:46Z', 'uri': 'http://web.archive.org/web/20180609164846/https://www.guideline.gov/summaries/summary/50473/guideline-for-prevention-and-management-of-pressure-ulcers-injuries'}]
https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department	ARCHIVED	10 mementos	[{'datetime': '2017-02-07T00:10:57Z', 'uri': 'http://web.archive.org/web/20170207001057/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2017-10-03T02:38:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003023846/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2017-10-03T02:38:46Z', 'uri': 'http://web.archive.org/web/20171003023846/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-01-10T13:02:00Z', 'uri': 'http://web.archive.org/web/20180110130200/https://guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-04-14T01:58:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414015832/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-04-14T01:58:32Z', 'uri': 'http://web.archive.org/web/20180414015832/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-05-19T08:44:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519084436/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-05-19T08:44:36Z', 'uri': 'http://web.archive.org/web/20180519084436/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-06-09T22:27:27Z', 'uri': 'http://web.archive.org/web/20180609222727/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}, {'datetime': '2018-06-14T23:25:57Z', 'uri': 'http://web.archive.org/web/20180614232557/https://www.guideline.gov/summaries/summary/50474/clinical-policy-critical-issues-in-the-evaluation-of-adult-patients-with-suspected-transient-ischemic-attack-in-the-emergency-department'}]
https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:42:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003024257/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2017-10-03T02:42:57Z', 'uri': 'http://web.archive.org/web/20171003024257/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2018-04-14T02:01:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414020147/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2018-04-14T02:01:47Z', 'uri': 'http://web.archive.org/web/20180414020147/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2018-05-19T08:48:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519084810/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2018-05-19T08:48:10Z', 'uri': 'http://web.archive.org/web/20180519084810/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2018-06-10T08:16:22Z', 'uri': 'http://web.archive.org/web/20180610081622/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}, {'datetime': '2018-06-14T23:25:59Z', 'uri': 'http://web.archive.org/web/20180614232559/https://www.guideline.gov/summaries/summary/50475/final-recommendation-statement-latent-tuberculosis-infection-screening'}]
https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:37:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003023715/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2017-10-03T02:37:15Z', 'uri': 'http://web.archive.org/web/20171003023715/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2018-04-14T01:56:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414015613/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2018-04-14T01:56:13Z', 'uri': 'http://web.archive.org/web/20180414015613/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2018-05-19T08:41:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519084127/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2018-05-19T08:41:27Z', 'uri': 'http://web.archive.org/web/20180519084127/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2018-06-09T12:37:22Z', 'uri': 'http://web.archive.org/web/20180609123722/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}, {'datetime': '2018-06-14T23:51:15Z', 'uri': 'http://web.archive.org/web/20180614235115/https://www.guideline.gov/summaries/summary/50476/transition-between-inpatient-mental-health-settings-and-community-or-care-home-settings'}]
https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:06:14Z', 'uri': 'http://wayback.archive-it.org/all/20171003020614/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}, {'datetime': '2017-10-03T02:06:14Z', 'uri': 'http://web.archive.org/web/20171003020614/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}, {'datetime': '2018-04-14T00:55:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414005538/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}, {'datetime': '2018-04-14T00:55:38Z', 'uri': 'http://web.archive.org/web/20180414005538/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}, {'datetime': '2018-05-19T07:34:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519073434/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}, {'datetime': '2018-05-19T07:34:34Z', 'uri': 'http://web.archive.org/web/20180519073434/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}, {'datetime': '2018-06-09T10:33:21Z', 'uri': 'http://web.archive.org/web/20180609103321/https://www.guideline.gov/summaries/summary/50477/delirium-dementia-and-depression-in-older-adults-assessment-and-care'}]
https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:38:31Z', 'uri': 'http://wayback.archive-it.org/all/20171003023831/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:38:31Z', 'uri': 'http://web.archive.org/web/20171003023831/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:58:12Z', 'uri': 'http://wayback.archive-it.org/all/20180414015812/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:58:12Z', 'uri': 'http://web.archive.org/web/20180414015812/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:44:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519084417/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:44:17Z', 'uri': 'http://web.archive.org/web/20180519084417/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T15:52:43Z', 'uri': 'http://web.archive.org/web/20180610155243/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:25:49Z', 'uri': 'http://web.archive.org/web/20180614232549/https://www.guideline.gov/summaries/summary/50478/management-of-chronic-pain-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:36:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003023657/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}, {'datetime': '2017-10-03T02:36:57Z', 'uri': 'http://web.archive.org/web/20171003023657/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}, {'datetime': '2018-04-14T01:55:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414015542/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}, {'datetime': '2018-04-14T01:55:42Z', 'uri': 'http://web.archive.org/web/20180414015542/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}, {'datetime': '2018-05-19T08:41:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519084106/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}, {'datetime': '2018-05-19T08:41:06Z', 'uri': 'http://web.archive.org/web/20180519084106/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}, {'datetime': '2018-06-09T21:17:28Z', 'uri': 'http://web.archive.org/web/20180609211728/https://www.guideline.gov/summaries/summary/50483/comprehensive-adult-eye-and-vision-examination'}]
https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:38:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003023838/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:38:38Z', 'uri': 'http://web.archive.org/web/20171003023838/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:58:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414015822/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:58:22Z', 'uri': 'http://web.archive.org/web/20180414015822/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:44:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519084426/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:44:26Z', 'uri': 'http://web.archive.org/web/20180519084426/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:57:25Z', 'uri': 'http://web.archive.org/web/20180609225725/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-11T14:49:53Z', 'uri': 'http://web.archive.org/web/20180611144953/https://www.guideline.gov/summaries/summary/50485/Neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-Society-of-Gynecologic-Oncology-and-American-Society-of-Clinical-Oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:25:40Z', 'uri': 'http://web.archive.org/web/20180614232540/https://www.guideline.gov/summaries/summary/50485/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-gynecologic-oncology-and-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis	ARCHIVED	8 mementos	[{'datetime': '2017-04-16T18:31:54Z', 'uri': 'http://web.archive.org/web/20170416183154/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T02:36:11Z', 'uri': 'http://wayback.archive-it.org/all/20171003023611/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T02:36:11Z', 'uri': 'http://web.archive.org/web/20171003023611/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T01:55:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414015508/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T01:55:08Z', 'uri': 'http://web.archive.org/web/20180414015508/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T08:40:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519084028/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T08:40:28Z', 'uri': 'http://web.archive.org/web/20180519084028/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-06-09T18:41:37Z', 'uri': 'http://web.archive.org/web/20180609184137/https://www.guideline.gov/summaries/summary/50486/effectiveness-of-practices-to-increase-timeliness-of-providing-targeted-therapy-for-inpatients-with-bloodstream-infections-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}]
https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis	ARCHIVED	8 mementos	[{'datetime': '2017-04-16T19:46:12Z', 'uri': 'http://web.archive.org/web/20170416194612/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T02:36:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003023620/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2017-10-03T02:36:20Z', 'uri': 'http://web.archive.org/web/20171003023620/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T01:55:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414015515/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-04-14T01:55:15Z', 'uri': 'http://web.archive.org/web/20180414015515/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T08:40:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519084038/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-05-19T08:40:38Z', 'uri': 'http://web.archive.org/web/20180519084038/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}, {'datetime': '2018-06-09T19:21:36Z', 'uri': 'http://web.archive.org/web/20180609192136/https://www.guideline.gov/summaries/summary/50487/effectiveness-of-preanalytic-practices-on-contamination-and-diagnostic-accuracy-of-urine-cultures-a-laboratory-medicine-best-practices-systematic-review-and-metaanalysis'}]
https://www.guideline.gov/summaries/summary/50488/updated-webbased-nutrition-management-guideline-for-pku-an-evidence-and-consensus-based-approach	ARCHIVED	3 mementos	[{'datetime': '2017-10-03T02:35:37Z', 'uri': 'http://wayback.archive-it.org/all/20171003023537/https://www.guideline.gov/summaries/summary/50488/updated-webbased-nutrition-management-guideline-for-pku-an-evidence-and-consensus-based-approach'}, {'datetime': '2018-04-14T01:54:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414015427/https://www.guideline.gov/summaries/summary/50488/updated-webbased-nutrition-management-guideline-for-pku-an-evidence-and-consensus-based-approach'}, {'datetime': '2018-05-19T08:39:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519083948/https://www.guideline.gov/summaries/summary/50488/updated-webbased-nutrition-management-guideline-for-pku-an-evidence-and-consensus-based-approach'}]
https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-02T20:06:47Z', 'uri': 'http://wayback.archive-it.org/all/20171002200647/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2017-10-02T20:06:47Z', 'uri': 'http://web.archive.org/web/20171002200647/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2018-04-14T01:55:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414015551/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2018-04-14T01:55:51Z', 'uri': 'http://web.archive.org/web/20180414015551/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2018-05-18T19:32:19Z', 'uri': 'http://wayback.archive-it.org/all/20180518193219/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2018-05-18T19:32:19Z', 'uri': 'http://web.archive.org/web/20180518193219/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2018-06-09T10:34:38Z', 'uri': 'http://web.archive.org/web/20180609103438/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}, {'datetime': '2018-06-14T23:25:50Z', 'uri': 'http://web.archive.org/web/20180614232550/https://www.guideline.gov/summaries/summary/50491/mental-health-problems-in-people-with-learning-disabilities-prevention-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:37:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003023706/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2017-10-03T02:37:06Z', 'uri': 'http://web.archive.org/web/20171003023706/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2018-04-14T01:56:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414015603/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2018-04-14T01:56:03Z', 'uri': 'http://web.archive.org/web/20180414015603/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2018-05-19T08:41:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519084116/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2018-05-19T08:41:16Z', 'uri': 'http://web.archive.org/web/20180519084116/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2018-06-09T15:29:18Z', 'uri': 'http://web.archive.org/web/20180609152918/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}, {'datetime': '2018-06-14T23:25:46Z', 'uri': 'http://web.archive.org/web/20180614232546/https://www.guideline.gov/summaries/summary/50492/multimorbidity-clinical-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:35:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003023513/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}, {'datetime': '2017-10-03T02:35:13Z', 'uri': 'http://web.archive.org/web/20171003023513/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}, {'datetime': '2018-04-14T01:53:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414015358/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}, {'datetime': '2018-04-14T01:53:58Z', 'uri': 'http://web.archive.org/web/20180414015358/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}, {'datetime': '2018-05-19T08:39:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519083918/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}, {'datetime': '2018-05-19T08:39:18Z', 'uri': 'http://web.archive.org/web/20180519083918/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}, {'datetime': '2018-06-10T19:10:29Z', 'uri': 'http://web.archive.org/web/20180610191029/https://www.guideline.gov/summaries/summary/50493/acr-appropriateness-criteria--back-pain-child'}]
https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:35:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003023522/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}, {'datetime': '2017-10-03T02:35:22Z', 'uri': 'http://web.archive.org/web/20171003023522/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}, {'datetime': '2018-04-14T01:54:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414015409/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}, {'datetime': '2018-04-14T01:54:09Z', 'uri': 'http://web.archive.org/web/20180414015409/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}, {'datetime': '2018-05-19T08:39:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519083929/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}, {'datetime': '2018-05-19T08:39:29Z', 'uri': 'http://web.archive.org/web/20180519083929/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}, {'datetime': '2018-06-09T19:26:42Z', 'uri': 'http://web.archive.org/web/20180609192642/https://www.guideline.gov/summaries/summary/50494/acr-appropriateness-criteria--chronic-extremity-joint-pain-suspected-inflammatory-arthritis'}]
https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:35:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003023544/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}, {'datetime': '2017-10-03T02:35:44Z', 'uri': 'http://web.archive.org/web/20171003023544/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}, {'datetime': '2018-04-14T01:54:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414015436/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}, {'datetime': '2018-04-14T01:54:36Z', 'uri': 'http://web.archive.org/web/20180414015436/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}, {'datetime': '2018-05-19T08:39:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519083956/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}, {'datetime': '2018-05-19T08:39:56Z', 'uri': 'http://web.archive.org/web/20180519083956/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}, {'datetime': '2018-06-10T16:21:50Z', 'uri': 'http://web.archive.org/web/20180610162150/https://www.guideline.gov/summaries/summary/50495/acr-appropriateness-criteria--hematospermia'}]
https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:35:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003023530/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}, {'datetime': '2017-10-03T02:35:30Z', 'uri': 'http://web.archive.org/web/20171003023530/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}, {'datetime': '2018-04-14T01:54:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414015418/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}, {'datetime': '2018-04-14T01:54:18Z', 'uri': 'http://web.archive.org/web/20180414015418/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}, {'datetime': '2018-05-19T08:39:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519083938/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}, {'datetime': '2018-05-19T08:39:38Z', 'uri': 'http://web.archive.org/web/20180519083938/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}, {'datetime': '2018-06-10T08:35:00Z', 'uri': 'http://web.archive.org/web/20180610083500/https://www.guideline.gov/summaries/summary/50496/acr-appropriateness-criteria--imaging-of-possible-tuberculosis'}]
https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:35:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003023551/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}, {'datetime': '2017-10-03T02:35:51Z', 'uri': 'http://web.archive.org/web/20171003023551/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}, {'datetime': '2018-04-14T01:54:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414015444/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}, {'datetime': '2018-04-14T01:54:44Z', 'uri': 'http://web.archive.org/web/20180414015444/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}, {'datetime': '2018-05-19T08:40:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519084004/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}, {'datetime': '2018-05-19T08:40:04Z', 'uri': 'http://web.archive.org/web/20180519084004/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}, {'datetime': '2018-06-10T11:22:36Z', 'uri': 'http://web.archive.org/web/20180610112236/https://www.guideline.gov/summaries/summary/50497/acr-appropriateness-criteria--renal-transplant-dysfunction'}]
https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:36:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003023600/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}, {'datetime': '2017-10-03T02:36:00Z', 'uri': 'http://web.archive.org/web/20171003023600/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}, {'datetime': '2018-04-14T01:54:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414015454/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}, {'datetime': '2018-04-14T01:54:54Z', 'uri': 'http://web.archive.org/web/20180414015454/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}, {'datetime': '2018-05-19T08:40:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519084015/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}, {'datetime': '2018-05-19T08:40:15Z', 'uri': 'http://web.archive.org/web/20180519084015/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}, {'datetime': '2018-06-09T22:11:34Z', 'uri': 'http://web.archive.org/web/20180609221134/https://www.guideline.gov/summaries/summary/50498/acr-appropriateness-criteria--stress-fatigueinsufficiency-fracture-including-sacrum-excluding-other-vertebrae'}]
https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:36:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003023602/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}, {'datetime': '2017-10-03T02:36:02Z', 'uri': 'http://web.archive.org/web/20171003023602/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}, {'datetime': '2018-04-14T01:54:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414015458/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}, {'datetime': '2018-04-14T01:54:58Z', 'uri': 'http://web.archive.org/web/20180414015458/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}, {'datetime': '2018-05-19T08:40:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519084019/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}, {'datetime': '2018-05-19T08:40:19Z', 'uri': 'http://web.archive.org/web/20180519084019/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}, {'datetime': '2018-06-10T08:25:01Z', 'uri': 'http://web.archive.org/web/20180610082501/https://www.guideline.gov/summaries/summary/50499/acr-appropriateness-criteria--urinary-tract-infection-child'}]
https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:35:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003023500/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}, {'datetime': '2017-10-03T02:35:00Z', 'uri': 'http://web.archive.org/web/20171003023500/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}, {'datetime': '2018-04-14T01:53:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414015337/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}, {'datetime': '2018-04-14T01:53:37Z', 'uri': 'http://web.archive.org/web/20180414015337/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}, {'datetime': '2018-05-19T08:38:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519083858/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}, {'datetime': '2018-05-19T08:38:58Z', 'uri': 'http://web.archive.org/web/20180519083858/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}, {'datetime': '2018-06-09T19:32:12Z', 'uri': 'http://web.archive.org/web/20180609193212/https://www.guideline.gov/summaries/summary/50500/iapac-guidelines-for-optimizing-the-hiv-care-continuum-for-adults-and-adolescents'}]
https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:34:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003023453/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2017-10-03T02:34:53Z', 'uri': 'http://web.archive.org/web/20171003023453/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-04-14T01:53:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414015329/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-04-14T01:53:29Z', 'uri': 'http://web.archive.org/web/20180414015329/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-05-19T08:38:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519083850/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-05-19T08:38:50Z', 'uri': 'http://web.archive.org/web/20180519083850/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-06-09T21:08:50Z', 'uri': 'http://web.archive.org/web/20180609210850/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-06-14T23:26:06Z', 'uri': 'http://web.archive.org/web/20180614232606/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}, {'datetime': '2018-06-14T23:26:26Z', 'uri': 'http://web.archive.org/web/20180614232626/https://www.guideline.gov/summaries/summary/50501/bone-marrow-synoptic-reporting-for-hematologic-neoplasms-guideline-from-the-college-of-american-pathologists-pathology-and-laboratory-quality-center'}]
https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:35:07Z', 'uri': 'http://wayback.archive-it.org/all/20171003023507/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2017-10-03T02:35:07Z', 'uri': 'http://web.archive.org/web/20171003023507/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2018-04-14T01:53:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414015346/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2018-04-14T01:53:46Z', 'uri': 'http://web.archive.org/web/20180414015346/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2018-05-19T08:39:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519083908/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2018-05-19T08:39:08Z', 'uri': 'http://web.archive.org/web/20180519083908/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2018-06-09T23:31:10Z', 'uri': 'http://web.archive.org/web/20180609233110/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}, {'datetime': '2018-06-14T23:51:11Z', 'uri': 'http://web.archive.org/web/20180614235111/https://www.guideline.gov/summaries/summary/50502/lipoprotein-biomarkers-and-risk-of-cardiovascular-disease-a-laboratory-medicine-best-practices-lmbp-systematic-review'}]
https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update	ARCHIVED	9 mementos	[{'datetime': '2017-02-07T00:10:37Z', 'uri': 'http://web.archive.org/web/20170207001037/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2017-10-03T02:38:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003023852/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2017-10-03T02:38:52Z', 'uri': 'http://web.archive.org/web/20171003023852/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2018-04-14T01:58:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414015839/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2018-04-14T01:58:39Z', 'uri': 'http://web.archive.org/web/20180414015839/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2018-05-19T08:44:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519084445/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2018-05-19T08:44:45Z', 'uri': 'http://web.archive.org/web/20180519084445/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2018-06-09T15:13:34Z', 'uri': 'http://web.archive.org/web/20180609151334/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}, {'datetime': '2018-06-14T23:51:34Z', 'uri': 'http://web.archive.org/web/20180614235134/https://www.guideline.gov/summaries/summary/50503/british-hiv-association-guidelines-for-the-treatment-of-hiv1positive-adults-with-antiretroviral-therapy-2015-2016-interim-update'}]
https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:34:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003023441/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2017-10-03T02:34:41Z', 'uri': 'http://web.archive.org/web/20171003023441/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2018-04-14T01:53:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414015313/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2018-04-14T01:53:13Z', 'uri': 'http://web.archive.org/web/20180414015313/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2018-05-19T08:38:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519083833/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2018-05-19T08:38:33Z', 'uri': 'http://web.archive.org/web/20180519083833/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2018-06-09T21:57:40Z', 'uri': 'http://web.archive.org/web/20180609215740/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}, {'datetime': '2018-06-15T00:03:38Z', 'uri': 'http://web.archive.org/web/20180615000338/https://www.guideline.gov/summaries/summary/50522/consensus-statement-using-laryngeal-electromyography-for-the-diagnosis-and-treatment-of-vocal-cord-paralysis'}]
https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:37:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003023741/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}, {'datetime': '2017-10-03T02:37:41Z', 'uri': 'http://web.archive.org/web/20171003023741/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}, {'datetime': '2018-04-14T01:56:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414015645/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}, {'datetime': '2018-04-14T01:56:45Z', 'uri': 'http://web.archive.org/web/20180414015645/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}, {'datetime': '2018-05-19T08:43:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519084306/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}, {'datetime': '2018-05-19T08:43:06Z', 'uri': 'http://web.archive.org/web/20180519084306/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}, {'datetime': '2018-06-09T22:05:55Z', 'uri': 'http://web.archive.org/web/20180609220555/https://www.guideline.gov/summaries/summary/50523/guideline-updates-on-hiv-and-infant-feeding-the-duration-of-breastfeeding-and-support-from-health-services-to-improve-feeding-practices-among-mothers-living-with-hiv'}]
https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:37:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003023749/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2017-10-03T02:37:49Z', 'uri': 'http://web.archive.org/web/20171003023749/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2018-04-14T01:56:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414015655/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2018-04-14T01:56:55Z', 'uri': 'http://web.archive.org/web/20180414015655/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2018-05-19T08:43:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519084316/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2018-05-19T08:43:16Z', 'uri': 'http://web.archive.org/web/20180519084316/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2018-06-09T21:28:08Z', 'uri': 'http://web.archive.org/web/20180609212808/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}, {'datetime': '2018-06-14T23:57:55Z', 'uri': 'http://web.archive.org/web/20180614235755/https://www.guideline.gov/summaries/summary/50524/us-medical-eligibility-criteria-for-contraceptive-use-2016'}]
https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:31:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003023103/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}, {'datetime': '2017-10-03T02:31:03Z', 'uri': 'http://web.archive.org/web/20171003023103/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}, {'datetime': '2018-04-14T01:49:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414014910/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}, {'datetime': '2018-04-14T01:49:10Z', 'uri': 'http://web.archive.org/web/20180414014910/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}, {'datetime': '2018-05-19T08:34:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519083404/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}, {'datetime': '2018-05-19T08:34:04Z', 'uri': 'http://web.archive.org/web/20180519083404/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}, {'datetime': '2018-06-09T18:37:16Z', 'uri': 'http://web.archive.org/web/20180609183716/https://www.guideline.gov/summaries/summary/50525/evidencebased-guidelines-for-the-management-of-large-hemispheric-infarction-a-statement-for-health-care-professionals-from-the-neurocritical-care-society-and-the-german-society-for-neurointensive-care-and-emergency-medicine'}]
https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:34:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003023447/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}, {'datetime': '2017-10-03T02:34:47Z', 'uri': 'http://web.archive.org/web/20171003023447/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}, {'datetime': '2018-04-14T01:53:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414015320/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}, {'datetime': '2018-04-14T01:53:20Z', 'uri': 'http://web.archive.org/web/20180414015320/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}, {'datetime': '2018-05-19T08:38:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519083841/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}, {'datetime': '2018-05-19T08:38:41Z', 'uri': 'http://web.archive.org/web/20180519083841/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}, {'datetime': '2018-06-09T11:24:30Z', 'uri': 'http://web.archive.org/web/20180609112430/https://www.guideline.gov/summaries/summary/50526/heel-pain-plantar-fasciitis-revision-2014'}]
https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:33:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003023348/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}, {'datetime': '2017-10-03T02:33:48Z', 'uri': 'http://web.archive.org/web/20171003023348/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}, {'datetime': '2018-04-14T01:52:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414015207/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}, {'datetime': '2018-04-14T01:52:07Z', 'uri': 'http://web.archive.org/web/20180414015207/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}, {'datetime': '2018-05-19T08:37:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519083720/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}, {'datetime': '2018-05-19T08:37:20Z', 'uri': 'http://web.archive.org/web/20180519083720/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}, {'datetime': '2018-06-10T21:54:35Z', 'uri': 'http://web.archive.org/web/20180610215435/https://www.guideline.gov/summaries/summary/50527/final-recommendation-statement-breastfeeding-primary-care-interventions'}]
https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:34:17Z', 'uri': 'http://wayback.archive-it.org/all/20171003023417/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2017-10-03T02:34:17Z', 'uri': 'http://web.archive.org/web/20171003023417/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2018-04-14T01:52:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414015243/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2018-04-14T01:52:43Z', 'uri': 'http://web.archive.org/web/20180414015243/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2018-05-19T08:37:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519083758/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2018-05-19T08:37:58Z', 'uri': 'http://web.archive.org/web/20180519083758/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2018-06-10T23:20:06Z', 'uri': 'http://web.archive.org/web/20180610232006/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}, {'datetime': '2018-06-14T23:23:17Z', 'uri': 'http://web.archive.org/web/20180614232317/https://www.guideline.gov/summaries/summary/50528/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-diagnosis-of-patients-with-positional-plagiocephaly-the-role-of-imaging'}]
https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:34:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003023430/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2017-10-03T02:34:30Z', 'uri': 'http://web.archive.org/web/20171003023430/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2018-04-14T01:52:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414015259/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2018-04-14T01:52:59Z', 'uri': 'http://web.archive.org/web/20180414015259/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2018-05-19T08:38:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519083816/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2018-05-19T08:38:16Z', 'uri': 'http://web.archive.org/web/20180519083816/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2018-06-10T23:18:57Z', 'uri': 'http://web.archive.org/web/20180610231857/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}, {'datetime': '2018-06-14T23:20:59Z', 'uri': 'http://web.archive.org/web/20180614232059/https://www.guideline.gov/summaries/summary/50529/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-management-of-patients-with-positional-plagiocephaly-the-role-of-repositioning'}]
https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:34:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003023423/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2017-10-03T02:34:23Z', 'uri': 'http://web.archive.org/web/20171003023423/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2018-04-14T01:52:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414015252/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2018-04-14T01:52:52Z', 'uri': 'http://web.archive.org/web/20180414015252/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2018-05-19T08:38:07Z', 'uri': 'http://wayback.archive-it.org/all/20180519083807/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2018-05-19T08:38:07Z', 'uri': 'http://web.archive.org/web/20180519083807/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2018-06-10T23:18:58Z', 'uri': 'http://web.archive.org/web/20180610231858/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}, {'datetime': '2018-06-14T23:23:12Z', 'uri': 'http://web.archive.org/web/20180614232312/https://www.guideline.gov/summaries/summary/50530/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-positional-plagiocephaly-the-role-of-physical-therapy'}]
https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:34:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003023436/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2017-10-03T02:34:36Z', 'uri': 'http://web.archive.org/web/20171003023436/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2018-04-14T01:53:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414015306/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2018-04-14T01:53:06Z', 'uri': 'http://web.archive.org/web/20180414015306/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2018-05-19T08:38:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519083825/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2018-05-19T08:38:25Z', 'uri': 'http://web.archive.org/web/20180519083825/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2018-06-09T11:48:30Z', 'uri': 'http://web.archive.org/web/20180609114830/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}, {'datetime': '2018-06-14T23:20:46Z', 'uri': 'http://web.archive.org/web/20180614232046/https://www.guideline.gov/summaries/summary/50531/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-the-role-of-cranial-molding-orthosis-helmet-therapy-for-patients-with-positional-plagiocephaly'}]
https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:33:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003023335/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2017-10-03T02:33:35Z', 'uri': 'http://web.archive.org/web/20171003023335/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2018-04-14T01:51:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414015150/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2018-04-14T01:51:50Z', 'uri': 'http://web.archive.org/web/20180414015150/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2018-05-19T08:36:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519083652/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2018-05-19T08:36:52Z', 'uri': 'http://web.archive.org/web/20180519083652/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2018-06-09T15:21:37Z', 'uri': 'http://web.archive.org/web/20180609152137/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}, {'datetime': '2018-06-14T23:25:47Z', 'uri': 'http://web.archive.org/web/20180614232547/https://www.guideline.gov/summaries/summary/50532/bone-health-and-bonetargeted-therapies-for-prostate-cancer'}]
https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:37:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003023757/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2017-10-03T02:37:57Z', 'uri': 'http://web.archive.org/web/20171003023757/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2018-04-14T01:57:04Z', 'uri': 'http://wayback.archive-it.org/all/20180414015704/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2018-04-14T01:57:04Z', 'uri': 'http://web.archive.org/web/20180414015704/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2018-05-19T08:43:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519084326/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2018-05-19T08:43:26Z', 'uri': 'http://web.archive.org/web/20180519084326/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2018-06-09T22:06:06Z', 'uri': 'http://web.archive.org/web/20180609220606/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}, {'datetime': '2018-06-14T23:57:49Z', 'uri': 'http://web.archive.org/web/20180614235749/https://www.guideline.gov/summaries/summary/50533/us-selected-practice-recommendations-for-contraceptive-use-2016'}]
https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:33:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003023341/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2017-10-03T02:33:41Z', 'uri': 'http://web.archive.org/web/20171003023341/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2018-04-14T01:51:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414015158/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2018-04-14T01:51:58Z', 'uri': 'http://web.archive.org/web/20180414015158/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2018-05-19T08:37:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519083712/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2018-05-19T08:37:12Z', 'uri': 'http://web.archive.org/web/20180519083712/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2018-06-09T21:16:16Z', 'uri': 'http://web.archive.org/web/20180609211616/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}, {'datetime': '2018-06-14T23:51:20Z', 'uri': 'http://web.archive.org/web/20180614235120/https://www.guideline.gov/summaries/summary/50534/systemic-therapy-in-the-curative-treatment-of-head-and-neck-squamous-cell-cancer'}]
https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:34:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003023410/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}, {'datetime': '2017-10-03T02:34:10Z', 'uri': 'http://web.archive.org/web/20171003023410/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}, {'datetime': '2018-04-14T01:52:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414015234/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}, {'datetime': '2018-04-14T01:52:34Z', 'uri': 'http://web.archive.org/web/20180414015234/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}, {'datetime': '2018-05-19T08:37:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519083749/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}, {'datetime': '2018-05-19T08:37:49Z', 'uri': 'http://web.archive.org/web/20180519083749/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}, {'datetime': '2018-06-09T20:54:51Z', 'uri': 'http://web.archive.org/web/20180609205451/https://www.guideline.gov/summaries/summary/50553/clinical-practice-guidelines-for-recall-and-maintenance-of-patients-with-toothborne-and-implantborne-dental-restorations'}]
https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:34:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003023402/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2017-10-03T02:34:02Z', 'uri': 'http://web.archive.org/web/20171003023402/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2018-04-14T01:52:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414015224/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2018-04-14T01:52:24Z', 'uri': 'http://web.archive.org/web/20180414015224/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2018-05-19T08:37:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519083739/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2018-05-19T08:37:39Z', 'uri': 'http://web.archive.org/web/20180519083739/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2018-06-09T11:42:59Z', 'uri': 'http://web.archive.org/web/20180609114259/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}, {'datetime': '2018-06-14T23:20:48Z', 'uri': 'http://web.archive.org/web/20180614232048/https://www.guideline.gov/summaries/summary/50554/final-recommendation-statement-statin-use-for-the-primary-prevention-of-cardiovascular-disease-in-adults-preventive-medication'}]
https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003023245/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:32:45Z', 'uri': 'http://web.archive.org/web/20171003023245/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414015108/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:08Z', 'uri': 'http://web.archive.org/web/20180414015108/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519083603/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:03Z', 'uri': 'http://web.archive.org/web/20180519083603/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-09T19:48:09Z', 'uri': 'http://web.archive.org/web/20180609194809/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:23:19Z', 'uri': 'http://web.archive.org/web/20180614232319/https://www.guideline.gov/summaries/summary/50555/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-preoperative-imaging-assessment-of-patients-with-suspected-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:23Z', 'uri': 'http://wayback.archive-it.org/all/20171003023223/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:32:23Z', 'uri': 'http://web.archive.org/web/20171003023223/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:50:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414015042/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:50:42Z', 'uri': 'http://web.archive.org/web/20180414015042/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:35:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519083538/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:35:38Z', 'uri': 'http://web.archive.org/web/20180519083538/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-10T22:39:28Z', 'uri': 'http://web.archive.org/web/20180610223928/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:25:38Z', 'uri': 'http://web.archive.org/web/20180614232538/https://www.guideline.gov/summaries/summary/50556/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-pretreatment-endocrine-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:52Z', 'uri': 'http://wayback.archive-it.org/all/20171003023252/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:32:52Z', 'uri': 'http://web.archive.org/web/20171003023252/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414015116/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:16Z', 'uri': 'http://web.archive.org/web/20180414015116/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:16Z', 'uri': 'http://wayback.archive-it.org/all/20180519083616/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:16Z', 'uri': 'http://web.archive.org/web/20180519083616/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-09T19:48:39Z', 'uri': 'http://web.archive.org/web/20180609194839/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:23:20Z', 'uri': 'http://web.archive.org/web/20180614232320/https://www.guideline.gov/summaries/summary/50557/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-pretreatment-ophthalmology-evaluation-in-patients-with-suspected-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003023258/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:32:58Z', 'uri': 'http://web.archive.org/web/20171003023258/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414015125/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:25Z', 'uri': 'http://web.archive.org/web/20180414015125/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519083625/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:25Z', 'uri': 'http://web.archive.org/web/20180519083625/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-10T01:07:12Z', 'uri': 'http://web.archive.org/web/20180610010712/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:23:27Z', 'uri': 'http://web.archive.org/web/20180614232327/https://www.guideline.gov/summaries/summary/50558/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-primary-management-of-patients-with-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:33:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003023304/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:33:04Z', 'uri': 'http://web.archive.org/web/20171003023304/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414015132/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:51:32Z', 'uri': 'http://web.archive.org/web/20180414015132/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519083634/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:36:34Z', 'uri': 'http://web.archive.org/web/20180519083634/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-09T15:20:47Z', 'uri': 'http://web.archive.org/web/20180609152047/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:25:39Z', 'uri': 'http://web.archive.org/web/20180614232539/https://www.guideline.gov/summaries/summary/50559/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-surgical-techniques-and-technologies-for-the-management-of-patients-with-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003023230/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:32:30Z', 'uri': 'http://web.archive.org/web/20171003023230/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:50:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414015050/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:50:50Z', 'uri': 'http://web.archive.org/web/20180414015050/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:35:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519083547/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:35:47Z', 'uri': 'http://web.archive.org/web/20180519083547/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-10T23:02:37Z', 'uri': 'http://web.archive.org/web/20180610230237/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:23:22Z', 'uri': 'http://web.archive.org/web/20180614232322/https://www.guideline.gov/summaries/summary/50560/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-for-the-management-of-patients-with-residual-or-recurrent-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003023236/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2017-10-03T02:32:36Z', 'uri': 'http://web.archive.org/web/20171003023236/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:50:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414015058/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-04-14T01:50:58Z', 'uri': 'http://web.archive.org/web/20180414015058/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:35:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519083555/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-05-19T08:35:55Z', 'uri': 'http://web.archive.org/web/20180519083555/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-10T01:06:58Z', 'uri': 'http://web.archive.org/web/20180610010658/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}, {'datetime': '2018-06-14T23:23:29Z', 'uri': 'http://web.archive.org/web/20180614232329/https://www.guideline.gov/summaries/summary/50561/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guideline-on-posttreatment-followup-evaluation-of-patients-with-nonfunctioning-pituitary-adenomas'}]
https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:31:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003023154/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2017-10-03T02:31:54Z', 'uri': 'http://web.archive.org/web/20171003023154/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2018-04-14T01:50:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414015006/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2018-04-14T01:50:06Z', 'uri': 'http://web.archive.org/web/20180414015006/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2018-05-19T08:35:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519083503/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2018-05-19T08:35:03Z', 'uri': 'http://web.archive.org/web/20180519083503/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2018-06-09T20:57:31Z', 'uri': 'http://web.archive.org/web/20180609205731/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}, {'datetime': '2018-06-14T23:20:54Z', 'uri': 'http://web.archive.org/web/20180614232054/https://www.guideline.gov/summaries/summary/50563/pain-management-for-blunt-thoracic-trauma-a-joint-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-trauma-anesthesiology-society'}]
https://www.guideline.gov/summaries/summary/50564/prevention-of-firearmrelated-injuries-with-restrictive-licensing-and-concealed-carry-laws-an-eastern-association-for-the-surgery-of-trauma-systematic-review	ARCHIVED	2 mementos	[{'datetime': '2018-06-09T21:44:36Z', 'uri': 'http://web.archive.org/web/20180609214436/https://www.guideline.gov/summaries/summary/50564/prevention-of-firearmrelated-injuries-with-restrictive-licensing-and-concealed-carry-laws-an-eastern-association-for-the-surgery-of-trauma-systematic-review'}, {'datetime': '2018-06-14T23:22:58Z', 'uri': 'http://web.archive.org/web/20180614232258/https://www.guideline.gov/summaries/summary/50564/prevention-of-firearmrelated-injuries-with-restrictive-licensing-and-concealed-carry-laws-an-eastern-association-for-the-surgery-of-trauma-systematic-review'}]
https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003023220/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2017-10-03T02:32:20Z', 'uri': 'http://web.archive.org/web/20171003023220/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2018-04-14T01:50:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414015038/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2018-04-14T01:50:38Z', 'uri': 'http://web.archive.org/web/20180414015038/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2018-05-19T08:35:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519083534/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2018-05-19T08:35:34Z', 'uri': 'http://web.archive.org/web/20180519083534/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2018-06-10T21:29:45Z', 'uri': 'http://web.archive.org/web/20180610212945/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}, {'datetime': '2018-06-14T23:20:41Z', 'uri': 'http://web.archive.org/web/20180614232041/https://www.guideline.gov/summaries/summary/50565/physical-health-of-people-in-prison'}]
https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:31:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003023140/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2017-10-03T02:31:40Z', 'uri': 'http://web.archive.org/web/20171003023140/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2018-04-14T01:49:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414014950/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2018-04-14T01:49:50Z', 'uri': 'http://web.archive.org/web/20180414014950/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2018-05-19T08:34:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519083445/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2018-05-19T08:34:45Z', 'uri': 'http://web.archive.org/web/20180519083445/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2018-06-09T15:17:06Z', 'uri': 'http://web.archive.org/web/20180609151706/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}, {'datetime': '2018-06-14T23:20:51Z', 'uri': 'http://web.archive.org/web/20180614232051/https://www.guideline.gov/summaries/summary/50566/clinical-practice-guideline-on-management-of-older-patients-with-chronic-kidney-disease-stage-3b-or-higher-egfr--45-mlmin173-m2'}]
https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:30:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003023050/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2017-10-03T02:30:50Z', 'uri': 'http://web.archive.org/web/20171003023050/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-04-14T01:48:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414014851/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-04-14T01:48:51Z', 'uri': 'http://web.archive.org/web/20180414014851/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-05-19T08:33:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519083345/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-05-19T08:33:45Z', 'uri': 'http://web.archive.org/web/20180519083345/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}, {'datetime': '2018-06-09T22:56:54Z', 'uri': 'http://web.archive.org/web/20180609225654/https://www.guideline.gov/summaries/summary/50567/american-college-of-rheumatologyspondylitis-association-of-americaspondyloarthritis-research-and-treatment-network-2015-recommendations-for-the-treatment-of-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis'}]
https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:30:19Z', 'uri': 'http://wayback.archive-it.org/all/20171003023019/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}, {'datetime': '2017-10-03T02:30:19Z', 'uri': 'http://web.archive.org/web/20171003023019/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}, {'datetime': '2018-04-14T01:48:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414014811/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}, {'datetime': '2018-04-14T01:48:11Z', 'uri': 'http://web.archive.org/web/20180414014811/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}, {'datetime': '2018-05-19T08:33:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519083302/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}, {'datetime': '2018-05-19T08:33:02Z', 'uri': 'http://web.archive.org/web/20180519083302/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}, {'datetime': '2018-06-09T11:58:58Z', 'uri': 'http://web.archive.org/web/20180609115858/https://www.guideline.gov/summaries/summary/50568/pain-assessment-nonopioid-treatment-approaches-and-opioid-management'}]
https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003023210/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2017-10-03T02:32:10Z', 'uri': 'http://web.archive.org/web/20171003023210/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2018-04-14T01:50:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414015028/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2018-04-14T01:50:28Z', 'uri': 'http://web.archive.org/web/20180414015028/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2018-05-19T08:35:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519083524/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2018-05-19T08:35:24Z', 'uri': 'http://web.archive.org/web/20180519083524/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2018-06-09T11:24:55Z', 'uri': 'http://web.archive.org/web/20180609112455/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}, {'datetime': '2018-06-14T23:19:03Z', 'uri': 'http://web.archive.org/web/20180614231903/https://www.guideline.gov/summaries/summary/50569/low-back-pain-and-sciatica-in-over-16s-assessment-and-management'}]
https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:30:44Z', 'uri': 'http://wayback.archive-it.org/all/20171003023044/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}, {'datetime': '2017-10-03T02:30:44Z', 'uri': 'http://web.archive.org/web/20171003023044/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}, {'datetime': '2018-04-14T01:48:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414014843/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}, {'datetime': '2018-04-14T01:48:43Z', 'uri': 'http://web.archive.org/web/20180414014843/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}, {'datetime': '2018-05-19T08:33:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519083336/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}, {'datetime': '2018-05-19T08:33:36Z', 'uri': 'http://web.archive.org/web/20180519083336/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}, {'datetime': '2018-06-09T21:12:35Z', 'uri': 'http://web.archive.org/web/20180609211235/https://www.guideline.gov/summaries/summary/50570/2015-recommendations-for-the-management-of-polymyalgia-rheumatica-a-european-league-against-rheumatismamerican-college-of-rheumatology-collaborative-initiative'}]
https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:31:34Z', 'uri': 'http://wayback.archive-it.org/all/20171003023134/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2017-10-03T02:31:34Z', 'uri': 'http://web.archive.org/web/20171003023134/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2018-04-14T01:49:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414014941/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2018-04-14T01:49:41Z', 'uri': 'http://web.archive.org/web/20180414014941/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2018-05-19T08:34:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519083436/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2018-05-19T08:34:36Z', 'uri': 'http://web.archive.org/web/20180519083436/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2018-06-09T22:57:11Z', 'uri': 'http://web.archive.org/web/20180609225711/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}, {'datetime': '2018-06-14T23:20:41Z', 'uri': 'http://web.archive.org/web/20180614232041/https://www.guideline.gov/summaries/summary/50579/society-of-surgical-oncology-american-society-for-radiation-oncology-american-society-of-clinical-oncology-consensus-guideline-on-margins-for-breastconserving-surgery-with-wholebreast-irradiation-in-ductal-carcinoma-in-situ'}]
https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:31:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003023120/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2017-10-03T02:31:20Z', 'uri': 'http://web.archive.org/web/20171003023120/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2018-04-14T01:49:29Z', 'uri': 'http://wayback.archive-it.org/all/20180414014929/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2018-04-14T01:49:29Z', 'uri': 'http://web.archive.org/web/20180414014929/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2018-05-19T08:34:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519083424/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2018-05-19T08:34:24Z', 'uri': 'http://web.archive.org/web/20180519083424/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2018-06-09T11:22:51Z', 'uri': 'http://web.archive.org/web/20180609112251/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}, {'datetime': '2018-06-14T22:48:29Z', 'uri': 'http://web.archive.org/web/20180614224829/https://www.guideline.gov/summaries/summary/50594/clinical-policy-critical-issues-in-the-evaluation-and-management-of-adult-patients-presenting-to-the-emergency-department-with-acute-carbon-monoxide-poisoning'}]
https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:33:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003023355/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2017-10-03T02:33:55Z', 'uri': 'http://web.archive.org/web/20171003023355/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2018-04-14T01:52:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414015216/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2018-04-14T01:52:16Z', 'uri': 'http://web.archive.org/web/20180414015216/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2018-05-19T08:37:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519083730/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2018-05-19T08:37:30Z', 'uri': 'http://web.archive.org/web/20180519083730/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2018-06-10T16:21:25Z', 'uri': 'http://web.archive.org/web/20180610162125/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}, {'datetime': '2018-06-14T23:18:57Z', 'uri': 'http://web.archive.org/web/20180614231857/https://www.guideline.gov/summaries/summary/50595/final-recommendation-statement-genital-herpes-infection-serologic-screening'}]
https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:32:00Z', 'uri': 'http://wayback.archive-it.org/all/20171003023200/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2017-10-03T02:32:00Z', 'uri': 'http://web.archive.org/web/20171003023200/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2018-04-14T01:50:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414015016/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2018-04-14T01:50:16Z', 'uri': 'http://web.archive.org/web/20180414015016/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2018-05-19T08:35:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519083512/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2018-05-19T08:35:12Z', 'uri': 'http://web.archive.org/web/20180519083512/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2018-06-10T21:49:40Z', 'uri': 'http://web.archive.org/web/20180610214940/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}, {'datetime': '2018-06-14T23:18:34Z', 'uri': 'http://web.archive.org/web/20180614231834/https://www.guideline.gov/summaries/summary/50596/end-of-life-care-for-infants-children-and-young-people-with-lifelimiting-conditions-planning-and-management'}]
https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:30:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003023057/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2017-10-03T02:30:57Z', 'uri': 'http://web.archive.org/web/20171003023057/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2018-04-14T01:49:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414014900/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2018-04-14T01:49:00Z', 'uri': 'http://web.archive.org/web/20180414014900/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2018-05-19T08:33:54Z', 'uri': 'http://wayback.archive-it.org/all/20180519083354/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2018-05-19T08:33:54Z', 'uri': 'http://web.archive.org/web/20180519083354/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2018-06-09T11:01:07Z', 'uri': 'http://web.archive.org/web/20180609110107/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}, {'datetime': '2018-06-14T23:18:46Z', 'uri': 'http://web.archive.org/web/20180614231846/https://www.guideline.gov/summaries/summary/50597/hiv-testing-increasing-uptake-among-people-who-may-have-undiagnosed-hiv-joint-nice-and-public-health-england-guideline'}]
https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:31:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003023113/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T02:31:13Z', 'uri': 'http://web.archive.org/web/20171003023113/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T01:49:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414014920/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T01:49:20Z', 'uri': 'http://web.archive.org/web/20180414014920/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:34:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519083415/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:34:15Z', 'uri': 'http://web.archive.org/web/20180519083415/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T20:51:02Z', 'uri': 'http://web.archive.org/web/20180609205102/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-14T23:18:49Z', 'uri': 'http://web.archive.org/web/20180614231849/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-14T23:19:24Z', 'uri': 'http://web.archive.org/web/20180614231924/https://www.guideline.gov/summaries/summary/50598/chronic-cough-due-to-gastroesophageal-reflux-in-adults-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:30:35Z', 'uri': 'http://wayback.archive-it.org/all/20171003023035/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:30:35Z', 'uri': 'http://web.archive.org/web/20171003023035/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:48:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414014832/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:48:32Z', 'uri': 'http://web.archive.org/web/20180414014832/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:33:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519083323/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:33:23Z', 'uri': 'http://web.archive.org/web/20180519083323/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:21Z', 'uri': 'http://web.archive.org/web/20180609192221/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-14T22:48:46Z', 'uri': 'http://web.archive.org/web/20180614224846/https://www.guideline.gov/summaries/summary/50607/diagnosis-of-acute-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:30:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003023041/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:30:41Z', 'uri': 'http://web.archive.org/web/20171003023041/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:48:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414014840/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:48:40Z', 'uri': 'http://web.archive.org/web/20180414014840/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:33:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519083333/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:33:33Z', 'uri': 'http://web.archive.org/web/20180519083333/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:03Z', 'uri': 'http://web.archive.org/web/20180609192203/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-14T22:48:40Z', 'uri': 'http://web.archive.org/web/20180614224840/https://www.guideline.gov/summaries/summary/50608/management-of-acute-and-recurrent-gout-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:31:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003023126/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T02:31:26Z', 'uri': 'http://web.archive.org/web/20171003023126/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:49:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414014937/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:49:37Z', 'uri': 'http://web.archive.org/web/20180414014937/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:34:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519083433/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:34:33Z', 'uri': 'http://web.archive.org/web/20180519083433/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T00:21:02Z', 'uri': 'http://web.archive.org/web/20180610002102/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-14T22:52:13Z', 'uri': 'http://web.archive.org/web/20180614225213/https://www.guideline.gov/summaries/summary/50609/integration-of-palliative-care-into-standard-oncology-care-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:27:28Z', 'uri': 'http://wayback.archive-it.org/all/20171003022728/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2017-10-03T02:27:28Z', 'uri': 'http://web.archive.org/web/20171003022728/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2018-04-14T01:44:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414014440/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2018-04-14T01:44:40Z', 'uri': 'http://web.archive.org/web/20180414014440/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2018-05-19T08:29:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519082927/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2018-05-19T08:29:27Z', 'uri': 'http://web.archive.org/web/20180519082927/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2018-06-09T21:18:17Z', 'uri': 'http://web.archive.org/web/20180609211817/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}, {'datetime': '2018-06-14T23:51:11Z', 'uri': 'http://web.archive.org/web/20180614235111/https://www.guideline.gov/summaries/summary/50610/uterine-septum-a-guideline'}]
https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:26:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003022651/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}, {'datetime': '2017-10-03T02:26:51Z', 'uri': 'http://web.archive.org/web/20171003022651/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}, {'datetime': '2018-04-14T01:43:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414014352/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}, {'datetime': '2018-04-14T01:43:52Z', 'uri': 'http://web.archive.org/web/20180414014352/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}, {'datetime': '2018-05-19T08:28:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519082834/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}, {'datetime': '2018-05-19T08:28:34Z', 'uri': 'http://web.archive.org/web/20180519082834/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}, {'datetime': '2018-06-09T23:20:30Z', 'uri': 'http://web.archive.org/web/20180609232030/https://www.guideline.gov/summaries/summary/50611/guideline-for-safe-use-of-energygenerating-devices'}]
https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:26:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003022645/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}, {'datetime': '2017-10-03T02:26:45Z', 'uri': 'http://web.archive.org/web/20171003022645/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}, {'datetime': '2018-04-14T01:43:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414014343/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}, {'datetime': '2018-04-14T01:43:43Z', 'uri': 'http://web.archive.org/web/20180414014343/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}, {'datetime': '2018-05-19T08:28:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519082825/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}, {'datetime': '2018-05-19T08:28:25Z', 'uri': 'http://web.archive.org/web/20180519082825/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}, {'datetime': '2018-06-09T23:20:23Z', 'uri': 'http://web.archive.org/web/20180609232023/https://www.guideline.gov/summaries/summary/50612/guideline-for-patient-information-management'}]
https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:26:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003022633/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2017-10-03T02:26:33Z', 'uri': 'http://web.archive.org/web/20171003022633/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2018-04-14T01:43:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414014327/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2018-04-14T01:43:27Z', 'uri': 'http://web.archive.org/web/20180414014327/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2018-05-19T08:28:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519082806/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2018-05-19T08:28:06Z', 'uri': 'http://web.archive.org/web/20180519082806/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2018-06-09T23:20:22Z', 'uri': 'http://web.archive.org/web/20180609232022/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}, {'datetime': '2018-06-14T23:34:54Z', 'uri': 'http://web.archive.org/web/20180614233454/https://www.guideline.gov/summaries/summary/50613/guideline-for-hand-hygiene'}]
https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:26:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003022657/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2017-10-03T02:26:57Z', 'uri': 'http://web.archive.org/web/20171003022657/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2018-04-14T01:44:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414014401/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2018-04-14T01:44:01Z', 'uri': 'http://web.archive.org/web/20180414014401/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2018-05-19T08:28:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519082843/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2018-05-19T08:28:43Z', 'uri': 'http://web.archive.org/web/20180519082843/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2018-06-09T11:03:31Z', 'uri': 'http://web.archive.org/web/20180609110331/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}, {'datetime': '2018-06-14T23:18:43Z', 'uri': 'http://web.archive.org/web/20180614231843/https://www.guideline.gov/summaries/summary/50614/guideline-for-surgical-smoke-safety'}]
https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:30:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003023012/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T02:30:12Z', 'uri': 'http://web.archive.org/web/20171003023012/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:48:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414014801/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:48:01Z', 'uri': 'http://web.archive.org/web/20180414014801/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:32:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519083253/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:32:53Z', 'uri': 'http://web.archive.org/web/20180519083253/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T21:44:32Z', 'uri': 'http://web.archive.org/web/20180609214432/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-14T22:51:42Z', 'uri': 'http://web.archive.org/web/20180614225142/https://www.guideline.gov/summaries/summary/50615/management-of-adult-pancreatic-injuries-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:31:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003023148/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}, {'datetime': '2017-10-03T02:31:48Z', 'uri': 'http://web.archive.org/web/20171003023148/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}, {'datetime': '2018-04-14T01:49:59Z', 'uri': 'http://wayback.archive-it.org/all/20180414014959/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}, {'datetime': '2018-04-14T01:49:59Z', 'uri': 'http://web.archive.org/web/20180414014959/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}, {'datetime': '2018-05-19T08:34:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519083455/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}, {'datetime': '2018-05-19T08:34:55Z', 'uri': 'http://web.archive.org/web/20180519083455/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}, {'datetime': '2018-06-09T21:44:37Z', 'uri': 'http://web.archive.org/web/20180609214437/https://www.guideline.gov/summaries/summary/50616/hospitalbased-violence-intervention-programs-targeting-adult-populations-an-eastern-association-for-the-surgery-of-trauma-evidencebased-review'}]
https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:29:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003022957/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2017-10-03T02:29:57Z', 'uri': 'http://web.archive.org/web/20171003022957/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2018-04-14T01:47:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414014743/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2018-04-14T01:47:43Z', 'uri': 'http://web.archive.org/web/20180414014743/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2018-05-19T08:32:35Z', 'uri': 'http://wayback.archive-it.org/all/20180519083235/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2018-05-19T08:32:35Z', 'uri': 'http://web.archive.org/web/20180519083235/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2018-06-09T19:16:39Z', 'uri': 'http://web.archive.org/web/20180609191639/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}, {'datetime': '2018-06-14T22:48:09Z', 'uri': 'http://web.archive.org/web/20180614224809/https://www.guideline.gov/summaries/summary/50617/american-gastroenterological-association-institute-guideline-on-the-management-of-crohns-disease-after-surgical-resection'}]
https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:26:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003022639/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2017-10-03T02:26:39Z', 'uri': 'http://web.archive.org/web/20171003022639/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2018-04-14T01:43:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414014335/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2018-04-14T01:43:35Z', 'uri': 'http://web.archive.org/web/20180414014335/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2018-05-19T08:28:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519082815/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2018-05-19T08:28:15Z', 'uri': 'http://web.archive.org/web/20180519082815/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2018-06-09T23:20:29Z', 'uri': 'http://web.archive.org/web/20180609232029/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}, {'datetime': '2018-06-14T23:18:48Z', 'uri': 'http://web.archive.org/web/20180614231848/https://www.guideline.gov/summaries/summary/50618/guideline-for-minimally-invasive-surgery'}]
https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:27:59Z', 'uri': 'http://wayback.archive-it.org/all/20171003022759/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2017-10-03T02:27:59Z', 'uri': 'http://web.archive.org/web/20171003022759/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2018-04-14T01:45:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414014516/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2018-04-14T01:45:16Z', 'uri': 'http://web.archive.org/web/20180414014516/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2018-05-19T08:30:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519083005/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2018-05-19T08:30:05Z', 'uri': 'http://web.archive.org/web/20180519083005/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2018-06-10T21:28:11Z', 'uri': 'http://web.archive.org/web/20180610212811/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}, {'datetime': '2018-06-14T23:15:31Z', 'uri': 'http://web.archive.org/web/20180614231531/https://www.guideline.gov/summaries/summary/50619/final-recommendation-statement-folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication'}]
https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:30:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003023004/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2017-10-03T02:30:04Z', 'uri': 'http://web.archive.org/web/20171003023004/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2018-04-14T01:47:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414014751/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2018-04-14T01:47:51Z', 'uri': 'http://web.archive.org/web/20180414014751/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2018-05-19T08:32:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519083244/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2018-05-19T08:32:44Z', 'uri': 'http://web.archive.org/web/20180519083244/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2018-06-09T11:31:08Z', 'uri': 'http://web.archive.org/web/20180609113108/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}, {'datetime': '2018-06-14T23:25:53Z', 'uri': 'http://web.archive.org/web/20180614232553/https://www.guideline.gov/summaries/summary/50620/guidelines-for-the-management-of-severe-traumatic-brain-injury-4th-edition'}]
https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:27:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003022733/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}, {'datetime': '2017-10-03T02:27:33Z', 'uri': 'http://web.archive.org/web/20171003022733/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}, {'datetime': '2018-04-14T01:44:48Z', 'uri': 'http://wayback.archive-it.org/all/20180414014448/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}, {'datetime': '2018-04-14T01:44:48Z', 'uri': 'http://web.archive.org/web/20180414014448/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}, {'datetime': '2018-05-19T08:29:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519082936/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}, {'datetime': '2018-05-19T08:29:36Z', 'uri': 'http://web.archive.org/web/20180519082936/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}, {'datetime': '2018-06-09T12:12:06Z', 'uri': 'http://web.archive.org/web/20180609121206/https://www.guideline.gov/summaries/summary/50622/clinical-practice-guideline-for-the-management-of-patients-with-parkinsons-disease'}]
https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:25:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003022549/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:25:49Z', 'uri': 'http://web.archive.org/web/20171003022549/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T01:42:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414014224/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T01:42:24Z', 'uri': 'http://web.archive.org/web/20180414014224/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:27:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519082712/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:27:12Z', 'uri': 'http://web.archive.org/web/20180519082712/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T22:00:49Z', 'uri': 'http://web.archive.org/web/20180609220049/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-14T23:20:38Z', 'uri': 'http://web.archive.org/web/20180614232038/https://www.guideline.gov/summaries/summary/50623/practice-advisory-the-utility-of-eeg-thetabeta-power-ratio-in-adhd-diagnosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline	ARCHIVED	12 mementos	[{'datetime': '2017-07-13T03:00:55Z', 'uri': 'http://web.archive.org/web/20170713030055/https://www.guideline.gov/summaries/summary/50624/Palliative-radiation-therapy-for-bone-metastases-update-of-an-ASTRO-evidencebased-guideline'}, {'datetime': '2017-10-03T02:26:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003022626/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2017-10-03T02:26:26Z', 'uri': 'http://web.archive.org/web/20171003022626/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-04-14T01:43:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414014320/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-04-14T01:43:20Z', 'uri': 'http://web.archive.org/web/20180414014320/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-05-19T08:27:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519082758/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-05-19T08:27:58Z', 'uri': 'http://web.archive.org/web/20180519082758/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-09T10:35:49Z', 'uri': 'http://web.archive.org/web/20180609103549/https://www.guideline.gov/summaries/summary/50624/Palliative-radiation-therapy-for-bone-metastases-update-of-an-ASTRO-evidencebased-guideline'}, {'datetime': '2018-06-10T01:14:44Z', 'uri': 'http://web.archive.org/web/20180610011444/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-14T23:51:28Z', 'uri': 'http://web.archive.org/web/20180614235128/https://www.guideline.gov/summaries/summary/50624/palliative-radiation-therapy-for-bone-metastases-update-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-20T17:39:37Z', 'uri': 'http://web.archive.org/web/20180620173937/https://www.guideline.gov/summaries/summary/50624/Palliative-radiation-therapy-for-bone-metastases-update-of-an-ASTRO-evidencebased-guideline'}, {'datetime': '2018-06-21T00:15:31Z', 'uri': 'http://web.archive.org/web/20180621001531/https://www.guideline.gov/summaries/summary/50624/Palliative-radiation-therapy-for-bone-metastases-update-of-an-ASTRO-evidencebased-guideline'}]
https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:27:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003022709/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2017-10-03T02:27:09Z', 'uri': 'http://web.archive.org/web/20171003022709/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2017-11-11T09:10:34Z', 'uri': 'http://web.archive.org/web/20171111091034/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2018-04-14T01:44:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414014416/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2018-04-14T01:44:16Z', 'uri': 'http://web.archive.org/web/20180414014416/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2018-05-19T08:29:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519082900/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2018-05-19T08:29:00Z', 'uri': 'http://web.archive.org/web/20180519082900/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2018-06-09T21:18:18Z', 'uri': 'http://web.archive.org/web/20180609211818/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}, {'datetime': '2018-06-14T23:19:04Z', 'uri': 'http://web.archive.org/web/20180614231904/https://www.guideline.gov/summaries/summary/50625/fertility-drugs-and-cancer-a-guideline'}]
https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:27:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003022715/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2017-10-03T02:27:15Z', 'uri': 'http://web.archive.org/web/20171003022715/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2017-11-11T09:03:57Z', 'uri': 'http://web.archive.org/web/20171111090357/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2018-04-14T01:44:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414014423/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2018-04-14T01:44:23Z', 'uri': 'http://web.archive.org/web/20180414014423/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2018-05-19T08:29:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519082909/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2018-05-19T08:29:09Z', 'uri': 'http://web.archive.org/web/20180519082909/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2018-06-09T21:18:19Z', 'uri': 'http://web.archive.org/web/20180609211819/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}, {'datetime': '2018-06-14T23:18:51Z', 'uri': 'http://web.archive.org/web/20180614231851/https://www.guideline.gov/summaries/summary/50626/prevention-and-treatment-of-moderate-and-severe-ovarian-hyperstimulation-syndrome-a-guideline'}]
https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:27:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003022703/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2017-10-03T02:27:03Z', 'uri': 'http://web.archive.org/web/20171003022703/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2017-11-11T09:02:13Z', 'uri': 'http://web.archive.org/web/20171111090213/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2018-04-14T01:44:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414014408/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2018-04-14T01:44:08Z', 'uri': 'http://web.archive.org/web/20180414014408/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2018-05-19T08:28:52Z', 'uri': 'http://wayback.archive-it.org/all/20180519082852/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2018-05-19T08:28:52Z', 'uri': 'http://web.archive.org/web/20180519082852/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2018-06-09T21:18:21Z', 'uri': 'http://web.archive.org/web/20180609211821/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}, {'datetime': '2018-06-14T22:51:27Z', 'uri': 'http://web.archive.org/web/20180614225127/https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline'}]
https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:29:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003022910/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}, {'datetime': '2017-10-03T02:29:10Z', 'uri': 'http://web.archive.org/web/20171003022910/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}, {'datetime': '2018-04-14T01:46:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414014646/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}, {'datetime': '2018-04-14T01:46:46Z', 'uri': 'http://web.archive.org/web/20180414014646/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}, {'datetime': '2018-05-19T08:31:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519083131/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}, {'datetime': '2018-05-19T08:31:31Z', 'uri': 'http://web.archive.org/web/20180519083131/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}, {'datetime': '2018-06-10T02:16:27Z', 'uri': 'http://web.archive.org/web/20180610021627/https://www.guideline.gov/summaries/summary/50636/acr-appropriateness-criteria--chronic-chest-pain-high-probability-of-coronary-artery-disease'}]
https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain	ARCHIVED	8 mementos	[{'datetime': '2017-07-14T10:11:51Z', 'uri': 'http://web.archive.org/web/20170714101151/https://guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2017-10-03T02:29:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003022920/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2017-10-03T02:29:20Z', 'uri': 'http://web.archive.org/web/20171003022920/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2018-04-14T01:46:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414014656/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2018-04-14T01:46:56Z', 'uri': 'http://web.archive.org/web/20180414014656/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2018-05-19T08:31:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519083140/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2018-05-19T08:31:40Z', 'uri': 'http://web.archive.org/web/20180519083140/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}, {'datetime': '2018-06-09T11:08:59Z', 'uri': 'http://web.archive.org/web/20180609110859/https://www.guideline.gov/summaries/summary/50637/acr-appropriateness-criteria--chronic-hip-pain'}]
https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:29:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003022938/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}, {'datetime': '2017-10-03T02:29:38Z', 'uri': 'http://web.archive.org/web/20171003022938/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}, {'datetime': '2018-04-14T01:47:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414014718/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}, {'datetime': '2018-04-14T01:47:18Z', 'uri': 'http://web.archive.org/web/20180414014718/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}, {'datetime': '2018-05-19T08:32:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519083210/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}, {'datetime': '2018-05-19T08:32:10Z', 'uri': 'http://web.archive.org/web/20180519083210/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}, {'datetime': '2018-06-10T21:00:42Z', 'uri': 'http://web.archive.org/web/20180610210042/https://www.guideline.gov/summaries/summary/50639/acr-appropriateness-criteria--chylothorax-treatment-planning'}]
https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:29:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003022945/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}, {'datetime': '2017-10-03T02:29:45Z', 'uri': 'http://web.archive.org/web/20171003022945/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}, {'datetime': '2018-04-14T01:47:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414014727/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}, {'datetime': '2018-04-14T01:47:27Z', 'uri': 'http://web.archive.org/web/20180414014727/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}, {'datetime': '2018-05-19T08:32:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519083220/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}, {'datetime': '2018-05-19T08:32:20Z', 'uri': 'http://web.archive.org/web/20180519083220/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}, {'datetime': '2018-06-09T11:23:02Z', 'uri': 'http://web.archive.org/web/20180609112302/https://www.guideline.gov/summaries/summary/50640/acr-appropriateness-criteria--dyspnea-suspected-cardiac-origin'}]
https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:29:48Z', 'uri': 'http://wayback.archive-it.org/all/20171003022948/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}, {'datetime': '2017-10-03T02:29:48Z', 'uri': 'http://web.archive.org/web/20171003022948/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}, {'datetime': '2018-04-14T01:47:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414014731/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}, {'datetime': '2018-04-14T01:47:31Z', 'uri': 'http://web.archive.org/web/20180414014731/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}, {'datetime': '2018-05-19T08:32:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519083224/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}, {'datetime': '2018-05-19T08:32:24Z', 'uri': 'http://web.archive.org/web/20180519083224/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}, {'datetime': '2018-06-10T11:22:15Z', 'uri': 'http://web.archive.org/web/20180610112215/https://www.guideline.gov/summaries/summary/50641/acr-appropriateness-criteria--evaluation-of-nipple-discharge'}]
https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:28:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003022821/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}, {'datetime': '2017-10-03T02:28:21Z', 'uri': 'http://web.archive.org/web/20171003022821/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}, {'datetime': '2018-04-14T01:45:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414014545/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}, {'datetime': '2018-04-14T01:45:45Z', 'uri': 'http://web.archive.org/web/20180414014545/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}, {'datetime': '2018-05-19T08:30:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519083033/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}, {'datetime': '2018-05-19T08:30:33Z', 'uri': 'http://web.archive.org/web/20180519083033/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}, {'datetime': '2018-06-10T23:00:54Z', 'uri': 'http://web.archive.org/web/20180610230054/https://www.guideline.gov/summaries/summary/50642/acr-appropriateness-criteria--plexopathy'}]
https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging	ARCHIVED	8 mementos	[{'datetime': '2017-07-14T02:44:43Z', 'uri': 'http://web.archive.org/web/20170714024443/https://guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2017-10-03T02:28:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003022829/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2017-10-03T02:28:29Z', 'uri': 'http://web.archive.org/web/20171003022829/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2018-04-14T01:45:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414014556/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2018-04-14T01:45:56Z', 'uri': 'http://web.archive.org/web/20180414014556/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2018-05-19T08:30:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519083043/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2018-05-19T08:30:43Z', 'uri': 'http://web.archive.org/web/20180519083043/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}, {'datetime': '2018-06-09T23:41:37Z', 'uri': 'http://web.archive.org/web/20180609234137/https://www.guideline.gov/summaries/summary/50643/acr-appropriateness-criteria--prostate-cancer-pretreatment-detection-surveillance-and-staging'}]
https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm	ARCHIVED	8 mementos	[{'datetime': '2017-07-14T02:35:29Z', 'uri': 'http://web.archive.org/web/20170714023529/https://guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2017-10-03T02:28:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003022838/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2017-10-03T02:28:38Z', 'uri': 'http://web.archive.org/web/20171003022838/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2018-04-14T01:46:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414014607/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2018-04-14T01:46:07Z', 'uri': 'http://web.archive.org/web/20180414014607/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2018-05-19T08:30:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519083053/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2018-05-19T08:30:53Z', 'uri': 'http://web.archive.org/web/20180519083053/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}, {'datetime': '2018-06-10T23:06:37Z', 'uri': 'http://web.archive.org/web/20180610230637/https://www.guideline.gov/summaries/summary/50644/acr-appropriateness-criteria--pulsatile-abdominal-mass-suspected-abdominal-aortic-aneurysm'}]
https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases	ARCHIVED	8 mementos	[{'datetime': '2017-07-14T03:23:49Z', 'uri': 'http://web.archive.org/web/20170714032349/https://guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2017-10-03T02:28:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003022845/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2017-10-03T02:28:45Z', 'uri': 'http://web.archive.org/web/20171003022845/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2018-04-14T01:46:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414014616/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2018-04-14T01:46:16Z', 'uri': 'http://web.archive.org/web/20180414014616/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2018-05-19T08:31:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519083102/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2018-05-19T08:31:02Z', 'uri': 'http://web.archive.org/web/20180519083102/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}, {'datetime': '2018-06-10T11:22:24Z', 'uri': 'http://web.archive.org/web/20180610112224/https://www.guideline.gov/summaries/summary/50645/acr-appropriateness-criteria--suspected-liver-metastases'}]
https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child	ARCHIVED	8 mementos	[{'datetime': '2017-07-14T02:16:17Z', 'uri': 'http://web.archive.org/web/20170714021617/https://guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2017-10-03T02:28:53Z', 'uri': 'http://wayback.archive-it.org/all/20171003022853/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2017-10-03T02:28:53Z', 'uri': 'http://web.archive.org/web/20171003022853/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2018-04-14T01:46:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414014627/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2018-04-14T01:46:27Z', 'uri': 'http://web.archive.org/web/20180414014627/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2018-05-19T08:31:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519083111/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2018-05-19T08:31:11Z', 'uri': 'http://web.archive.org/web/20180519083111/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}, {'datetime': '2018-06-10T15:50:55Z', 'uri': 'http://web.archive.org/web/20180610155055/https://www.guideline.gov/summaries/summary/50646/acr-appropriateness-criteria--suspected-physical-abuse-child'}]
https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension	ARCHIVED	8 mementos	[{'datetime': '2017-07-14T00:53:36Z', 'uri': 'http://web.archive.org/web/20170714005336/https://guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2017-10-03T02:29:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003022902/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2017-10-03T02:29:02Z', 'uri': 'http://web.archive.org/web/20171003022902/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2018-04-14T01:46:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414014637/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2018-04-14T01:46:37Z', 'uri': 'http://web.archive.org/web/20180414014637/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2018-05-19T08:31:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519083121/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2018-05-19T08:31:21Z', 'uri': 'http://web.archive.org/web/20180519083121/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}, {'datetime': '2018-06-10T02:39:14Z', 'uri': 'http://web.archive.org/web/20180610023914/https://www.guideline.gov/summaries/summary/50647/acr-appropriateness-criteria--suspected-pulmonary-hypertension'}]
https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:27:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003022751/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:27:51Z', 'uri': 'http://web.archive.org/web/20171003022751/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:45:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414014507/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:45:07Z', 'uri': 'http://web.archive.org/web/20180414014507/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:29:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519082955/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:29:55Z', 'uri': 'http://web.archive.org/web/20180519082955/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-06-09T21:15:19Z', 'uri': 'http://web.archive.org/web/20180609211519/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:25:05Z', 'uri': 'http://web.archive.org/web/20180614232505/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:25:29Z', 'uri': 'http://web.archive.org/web/20180614232529/https://www.guideline.gov/summaries/summary/50653/the-treatment-of-neck-painassociated-disorders-and-whiplashassociated-disorders-a-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy	ARCHIVED	10 mementos	[{'datetime': '2017-10-02T20:07:26Z', 'uri': 'http://wayback.archive-it.org/all/20171002200726/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2017-10-02T20:07:26Z', 'uri': 'http://web.archive.org/web/20171002200726/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-04-14T01:43:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414014301/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-04-14T01:43:01Z', 'uri': 'http://web.archive.org/web/20180414014301/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-05-18T19:33:14Z', 'uri': 'http://wayback.archive-it.org/all/20180518193314/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-05-18T19:33:14Z', 'uri': 'http://web.archive.org/web/20180518193314/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-06-09T10:42:38Z', 'uri': 'http://web.archive.org/web/20180609104238/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-06-14T22:46:41Z', 'uri': 'http://web.archive.org/web/20180614224641/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-07-12T21:38:53Z', 'uri': 'http://web.archive.org/web/20180712213853/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}, {'datetime': '2018-07-12T21:38:53Z', 'uri': 'http://web.archive.org/web/20180712213853/https://www.guideline.gov/summaries/summary/50654/clinical-policy-critical-issues-in-the-initial-evaluation-and-management-of-patients-presenting-to-the-emergency-department-in-early-pregnancy'}]
https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:26:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003022602/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:26:02Z', 'uri': 'http://web.archive.org/web/20171003022602/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T01:42:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414014242/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T01:42:42Z', 'uri': 'http://web.archive.org/web/20180414014242/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:27:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519082730/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:27:30Z', 'uri': 'http://web.archive.org/web/20180519082730/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T22:01:43Z', 'uri': 'http://web.archive.org/web/20180609220143/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-14T22:48:55Z', 'uri': 'http://web.archive.org/web/20180614224855/https://www.guideline.gov/summaries/summary/50655/practice-guideline-summary-use-of-fmri-in-the-presurgical-evaluation-of-patients-with-epilepsy-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:30:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003023029/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2017-10-03T02:30:29Z', 'uri': 'http://web.archive.org/web/20171003023029/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2018-04-14T01:48:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414014823/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2018-04-14T01:48:23Z', 'uri': 'http://web.archive.org/web/20180414014823/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2018-05-19T08:33:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519083315/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2018-05-19T08:33:15Z', 'uri': 'http://web.archive.org/web/20180519083315/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2018-06-10T23:05:00Z', 'uri': 'http://web.archive.org/web/20180610230500/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}, {'datetime': '2018-06-14T23:18:28Z', 'uri': 'http://web.archive.org/web/20180614231828/https://www.guideline.gov/summaries/summary/50656/systemic-therapy-of-incurable-gastroenteropancreatic-neuroendocrine-tumours'}]
https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:28:13Z', 'uri': 'http://wayback.archive-it.org/all/20171003022813/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2017-10-03T02:28:13Z', 'uri': 'http://web.archive.org/web/20171003022813/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2018-04-14T01:45:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414014536/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2018-04-14T01:45:36Z', 'uri': 'http://web.archive.org/web/20180414014536/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2018-05-19T08:30:24Z', 'uri': 'http://wayback.archive-it.org/all/20180519083024/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2018-05-19T08:30:24Z', 'uri': 'http://web.archive.org/web/20180519083024/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2018-06-09T11:20:13Z', 'uri': 'http://web.archive.org/web/20180609112013/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}, {'datetime': '2018-06-14T22:48:23Z', 'uri': 'http://web.archive.org/web/20180614224823/https://www.guideline.gov/summaries/summary/50657/final-recommendation-statement-obstructive-sleep-apnea-in-adults-screening'}]
https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:24:46Z', 'uri': 'http://wayback.archive-it.org/all/20171003022446/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2017-10-03T02:24:46Z', 'uri': 'http://web.archive.org/web/20171003022446/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2018-04-14T01:41:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414014118/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2018-04-14T01:41:18Z', 'uri': 'http://web.archive.org/web/20180414014118/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2018-05-19T08:26:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519082600/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2018-05-19T08:26:00Z', 'uri': 'http://web.archive.org/web/20180519082600/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2018-06-09T21:29:46Z', 'uri': 'http://web.archive.org/web/20180609212946/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}, {'datetime': '2018-06-14T23:22:56Z', 'uri': 'http://web.archive.org/web/20180614232256/https://www.guideline.gov/summaries/summary/50658/cardiac-rehabilitation-delivery-model-for-lowresource-settings-an-international-council-of-cardiovascular-prevention-and-rehabilitation-consensus-statement'}]
https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-07-13T05:16:37Z', 'uri': 'http://web.archive.org/web/20170713051637/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:25:15Z', 'uri': 'http://wayback.archive-it.org/all/20171003022515/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:25:15Z', 'uri': 'http://web.archive.org/web/20171003022515/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:41:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414014156/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:41:56Z', 'uri': 'http://web.archive.org/web/20180414014156/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:26:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519082638/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:26:38Z', 'uri': 'http://web.archive.org/web/20180519082638/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T22:17:10Z', 'uri': 'http://web.archive.org/web/20180610221710/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:46:50Z', 'uri': 'http://web.archive.org/web/20180614224650/https://www.guideline.gov/summaries/summary/50659/management-of-small-renal-masses-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:24:24Z', 'uri': 'http://wayback.archive-it.org/all/20171003022424/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:24:24Z', 'uri': 'http://web.archive.org/web/20171003022424/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:40:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414014052/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:40:52Z', 'uri': 'http://web.archive.org/web/20180414014052/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:25:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519082532/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:25:32Z', 'uri': 'http://web.archive.org/web/20180519082532/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-06-09T10:38:05Z', 'uri': 'http://web.archive.org/web/20180609103805/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:46:46Z', 'uri': 'http://web.archive.org/web/20180614224646/https://www.guideline.gov/summaries/summary/50660/clinical-practice-guideline-for-the-pharmacologic-treatment-of-chronic-insomnia-in-adults-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:24:39Z', 'uri': 'http://wayback.archive-it.org/all/20171003022439/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2017-10-03T02:24:39Z', 'uri': 'http://web.archive.org/web/20171003022439/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-04-14T01:41:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414014110/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-04-14T01:41:10Z', 'uri': 'http://web.archive.org/web/20180414014110/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-05-19T08:25:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519082551/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-05-19T08:25:51Z', 'uri': 'http://web.archive.org/web/20180519082551/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-06-09T18:42:42Z', 'uri': 'http://web.archive.org/web/20180609184242/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-06-11T14:49:53Z', 'uri': 'http://web.archive.org/web/20180611144953/https://www.guideline.gov/summaries/summary/50661/European-Respiratory-Society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}, {'datetime': '2018-06-14T22:48:51Z', 'uri': 'http://web.archive.org/web/20180614224851/https://www.guideline.gov/summaries/summary/50661/european-respiratory-society-guidelines-for-the-diagnosis-of-primary-ciliary-dyskinesia'}]
https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:27:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003022742/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2017-10-03T02:27:42Z', 'uri': 'http://web.archive.org/web/20171003022742/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2018-04-14T01:44:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414014458/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2018-04-14T01:44:58Z', 'uri': 'http://web.archive.org/web/20180414014458/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2018-05-19T08:29:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519082946/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2018-05-19T08:29:46Z', 'uri': 'http://web.archive.org/web/20180519082946/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2018-06-09T22:57:16Z', 'uri': 'http://web.archive.org/web/20180609225716/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}, {'datetime': '2018-06-14T23:14:17Z', 'uri': 'http://web.archive.org/web/20180614231417/https://www.guideline.gov/summaries/summary/50668/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update'}]
https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2017-07-13T05:15:19Z', 'uri': 'http://web.archive.org/web/20170713051519/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:25:09Z', 'uri': 'http://wayback.archive-it.org/all/20171003022509/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:25:09Z', 'uri': 'http://web.archive.org/web/20171003022509/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:41:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414014147/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:41:47Z', 'uri': 'http://web.archive.org/web/20180414014147/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:26:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519082628/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:26:28Z', 'uri': 'http://web.archive.org/web/20180519082628/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:22:16Z', 'uri': 'http://web.archive.org/web/20180609192216/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}, {'datetime': '2018-06-14T22:46:55Z', 'uri': 'http://web.archive.org/web/20180614224655/https://www.guideline.gov/summaries/summary/50669/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:24:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003022432/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2017-10-03T02:24:32Z', 'uri': 'http://web.archive.org/web/20171003022432/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2018-04-14T01:41:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414014102/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2018-04-14T01:41:02Z', 'uri': 'http://web.archive.org/web/20180414014102/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2018-05-19T08:25:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519082541/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2018-05-19T08:25:41Z', 'uri': 'http://web.archive.org/web/20180519082541/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2018-06-09T19:20:17Z', 'uri': 'http://web.archive.org/web/20180609192017/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}, {'datetime': '2018-06-14T22:45:43Z', 'uri': 'http://web.archive.org/web/20180614224543/https://www.guideline.gov/summaries/summary/50670/breast-reconstruction-following-prophylactic-or-therapeutic-mastectomy-for-breast-cancer'}]
https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:24:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003022454/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2017-10-03T02:24:54Z', 'uri': 'http://web.archive.org/web/20171003022454/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2018-04-14T01:41:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414014128/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2018-04-14T01:41:28Z', 'uri': 'http://web.archive.org/web/20180414014128/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2018-05-19T08:26:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519082610/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2018-05-19T08:26:10Z', 'uri': 'http://web.archive.org/web/20180519082610/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2018-06-09T21:34:18Z', 'uri': 'http://web.archive.org/web/20180609213418/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}, {'datetime': '2018-06-15T00:06:34Z', 'uri': 'http://web.archive.org/web/20180615000634/https://www.guideline.gov/summaries/summary/50686/care-of-the-hospitalized-patient-with-acute-exacerbation-of-copd'}]
https://www.guideline.gov/summaries/summary/50687/low-back-disorders	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:23:30Z', 'uri': 'http://wayback.archive-it.org/all/20171003022330/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}, {'datetime': '2017-10-03T02:23:30Z', 'uri': 'http://web.archive.org/web/20171003022330/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}, {'datetime': '2018-04-14T01:39:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414013941/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}, {'datetime': '2018-04-14T01:39:41Z', 'uri': 'http://web.archive.org/web/20180414013941/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}, {'datetime': '2018-05-19T08:24:15Z', 'uri': 'http://wayback.archive-it.org/all/20180519082415/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}, {'datetime': '2018-05-19T08:24:15Z', 'uri': 'http://web.archive.org/web/20180519082415/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}, {'datetime': '2018-06-09T21:15:07Z', 'uri': 'http://web.archive.org/web/20180609211507/https://www.guideline.gov/summaries/summary/50687/low-back-disorders'}]
https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:21Z', 'uri': 'http://wayback.archive-it.org/all/20171003022321/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2017-10-03T02:23:21Z', 'uri': 'http://web.archive.org/web/20171003022321/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2018-04-14T01:39:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414013930/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2018-04-14T01:39:30Z', 'uri': 'http://web.archive.org/web/20180414013930/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2018-05-19T08:24:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519082403/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2018-05-19T08:24:03Z', 'uri': 'http://web.archive.org/web/20180519082403/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2018-06-09T20:18:53Z', 'uri': 'http://web.archive.org/web/20180609201853/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}, {'datetime': '2018-06-15T00:03:55Z', 'uri': 'http://web.archive.org/web/20180615000355/https://www.guideline.gov/summaries/summary/50688/cervical-and-thoracic-spine-disorders'}]
https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:25:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003022555/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2017-10-03T02:25:55Z', 'uri': 'http://web.archive.org/web/20171003022555/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T01:42:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414014233/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-04-14T01:42:33Z', 'uri': 'http://web.archive.org/web/20180414014233/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:27:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519082721/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-05-19T08:27:21Z', 'uri': 'http://web.archive.org/web/20180519082721/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T12:18:42Z', 'uri': 'http://web.archive.org/web/20180609121842/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-14T23:14:04Z', 'uri': 'http://web.archive.org/web/20180614231404/https://www.guideline.gov/summaries/summary/50689/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003022345/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2017-10-03T02:23:45Z', 'uri': 'http://web.archive.org/web/20171003022345/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2018-04-14T01:40:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414014000/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2018-04-14T01:40:00Z', 'uri': 'http://web.archive.org/web/20180414014000/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2018-05-19T08:24:36Z', 'uri': 'http://wayback.archive-it.org/all/20180519082436/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2018-05-19T08:24:36Z', 'uri': 'http://web.archive.org/web/20180519082436/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2018-06-09T23:51:26Z', 'uri': 'http://web.archive.org/web/20180609235126/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}, {'datetime': '2018-06-14T22:46:21Z', 'uri': 'http://web.archive.org/web/20180614224621/https://www.guideline.gov/summaries/summary/50690/canadian-cardiovascular-society-and-canadian-pediatric-cardiology-association-position-statement-on-the-approach-to-syncope-in-the-pediatric-patient'}]
https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:24:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003022418/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2017-10-03T02:24:18Z', 'uri': 'http://web.archive.org/web/20171003022418/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2018-04-14T01:40:45Z', 'uri': 'http://wayback.archive-it.org/all/20180414014045/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2018-04-14T01:40:45Z', 'uri': 'http://web.archive.org/web/20180414014045/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2018-05-19T08:25:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519082523/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2018-05-19T08:25:23Z', 'uri': 'http://web.archive.org/web/20180519082523/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2018-06-09T23:21:11Z', 'uri': 'http://web.archive.org/web/20180609232111/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}, {'datetime': '2018-06-14T22:51:04Z', 'uri': 'http://web.archive.org/web/20180614225104/https://www.guideline.gov/summaries/summary/50696/the-society-of-thoracic-surgeons-2017-clinical-practice-guidelines-for-the-surgical-treatment-of-atrial-fibrillation'}]
https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:27:22Z', 'uri': 'http://wayback.archive-it.org/all/20171003022722/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}, {'datetime': '2017-10-03T02:27:22Z', 'uri': 'http://web.archive.org/web/20171003022722/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}, {'datetime': '2018-04-14T01:44:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414014431/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}, {'datetime': '2018-04-14T01:44:31Z', 'uri': 'http://web.archive.org/web/20180414014431/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}, {'datetime': '2018-05-19T08:29:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519082918/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}, {'datetime': '2018-05-19T08:29:18Z', 'uri': 'http://web.archive.org/web/20180519082918/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}, {'datetime': '2018-06-09T20:11:55Z', 'uri': 'http://web.archive.org/web/20180609201155/https://www.guideline.gov/summaries/summary/50697/role-of-assisted-hatching-in-in-vitro-fertilization-a-guideline'}]
https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:28:06Z', 'uri': 'http://wayback.archive-it.org/all/20171003022806/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2017-10-03T02:28:06Z', 'uri': 'http://web.archive.org/web/20171003022806/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2018-04-14T01:45:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414014527/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2018-04-14T01:45:27Z', 'uri': 'http://web.archive.org/web/20180414014527/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2018-05-19T08:30:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519083014/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2018-05-19T08:30:14Z', 'uri': 'http://web.archive.org/web/20180519083014/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2018-06-10T22:17:50Z', 'uri': 'http://web.archive.org/web/20180610221750/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}, {'datetime': '2018-06-14T22:39:43Z', 'uri': 'http://web.archive.org/web/20180614223943/https://www.guideline.gov/summaries/summary/50698/final-recommendation-statement-gynecological-conditions-periodic-screening-with-the-pelvic-examination'}]
https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:01:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003020133/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2017-10-03T02:01:33Z', 'uri': 'http://web.archive.org/web/20171003020133/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2018-04-14T00:48:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414004846/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2018-04-14T00:48:46Z', 'uri': 'http://web.archive.org/web/20180414004846/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2018-05-19T07:26:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519072649/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2018-05-19T07:26:49Z', 'uri': 'http://web.archive.org/web/20180519072649/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2018-06-09T11:58:25Z', 'uri': 'http://web.archive.org/web/20180609115825/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}, {'datetime': '2018-06-14T22:52:02Z', 'uri': 'http://web.archive.org/web/20180614225202/https://www.guideline.gov/summaries/summary/50703/vadod-clinical-practice-guideline-for-opioid-therapy-for-chronic-pain'}]
https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	9 mementos	[{'datetime': '2017-07-13T05:16:11Z', 'uri': 'http://web.archive.org/web/20170713051611/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:25:32Z', 'uri': 'http://wayback.archive-it.org/all/20171003022532/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:25:32Z', 'uri': 'http://web.archive.org/web/20171003022532/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:42:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414014205/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:42:05Z', 'uri': 'http://web.archive.org/web/20180414014205/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:26:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519082647/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:26:47Z', 'uri': 'http://web.archive.org/web/20180519082647/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-10T00:21:06Z', 'uri': 'http://web.archive.org/web/20180610002106/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:40:31Z', 'uri': 'http://web.archive.org/web/20180614224031/https://www.guideline.gov/summaries/summary/50704/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	9 mementos	[{'datetime': '2017-07-13T05:16:02Z', 'uri': 'http://web.archive.org/web/20170713051602/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T02:25:41Z', 'uri': 'http://wayback.archive-it.org/all/20171003022541/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2017-10-03T02:25:41Z', 'uri': 'http://web.archive.org/web/20171003022541/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:42:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414014214/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:42:14Z', 'uri': 'http://web.archive.org/web/20180414014214/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:27:03Z', 'uri': 'http://wayback.archive-it.org/all/20180519082703/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:27:03Z', 'uri': 'http://web.archive.org/web/20180519082703/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T11:13:10Z', 'uri': 'http://web.archive.org/web/20180610111310/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-14T23:18:23Z', 'uri': 'http://web.archive.org/web/20180614231823/https://www.guideline.gov/summaries/summary/50705/sentinel-lymph-node-biopsy-for-patients-with-earlystage-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection	ARCHIVED	7 mementos	[{'datetime': '2017-10-02T20:11:21Z', 'uri': 'http://wayback.archive-it.org/all/20171002201121/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}, {'datetime': '2017-10-02T20:11:21Z', 'uri': 'http://web.archive.org/web/20171002201121/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}, {'datetime': '2018-04-14T00:47:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414004731/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}, {'datetime': '2018-04-14T00:47:31Z', 'uri': 'http://web.archive.org/web/20180414004731/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}, {'datetime': '2018-05-18T22:04:56Z', 'uri': 'http://wayback.archive-it.org/all/20180518220456/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}, {'datetime': '2018-05-18T22:04:56Z', 'uri': 'http://web.archive.org/web/20180518220456/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}, {'datetime': '2018-06-10T00:03:42Z', 'uri': 'http://web.archive.org/web/20180610000342/https://www.guideline.gov/summaries/summary/50706/global-guidelines-for-the-prevention-of-surgical-site-infection'}]
https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:50Z', 'uri': 'http://wayback.archive-it.org/all/20171003022350/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2017-10-03T02:23:50Z', 'uri': 'http://web.archive.org/web/20171003022350/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2018-04-14T01:40:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414014008/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2018-04-14T01:40:08Z', 'uri': 'http://web.archive.org/web/20180414014008/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2018-05-19T08:24:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519082445/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2018-05-19T08:24:45Z', 'uri': 'http://web.archive.org/web/20180519082445/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2018-06-10T00:27:03Z', 'uri': 'http://web.archive.org/web/20180610002703/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}, {'datetime': '2018-06-14T22:41:46Z', 'uri': 'http://web.archive.org/web/20180614224146/https://www.guideline.gov/summaries/summary/50707/recommendations-on-behavioural-interventions-for-the-prevention-and-treatment-of-cigarette-smoking-among-schoolaged-children-and-youth'}]
https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:57Z', 'uri': 'http://wayback.archive-it.org/all/20171003022357/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T02:23:57Z', 'uri': 'http://web.archive.org/web/20171003022357/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:40:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414014018/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:40:18Z', 'uri': 'http://web.archive.org/web/20180414014018/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:24:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519082455/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:24:55Z', 'uri': 'http://web.archive.org/web/20180519082455/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-10T12:44:05Z', 'uri': 'http://web.archive.org/web/20180610124405/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-14T22:42:03Z', 'uri': 'http://web.archive.org/web/20180614224203/https://www.guideline.gov/summaries/summary/50708/damage-control-resuscitation-in-patients-with-severe-traumatic-hemorrhage-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:24:04Z', 'uri': 'http://wayback.archive-it.org/all/20171003022404/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2017-10-03T02:24:04Z', 'uri': 'http://web.archive.org/web/20171003022404/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:40:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414014027/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:40:27Z', 'uri': 'http://web.archive.org/web/20180414014027/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:25:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519082504/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:25:04Z', 'uri': 'http://web.archive.org/web/20180519082504/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T21:44:27Z', 'uri': 'http://web.archive.org/web/20180609214427/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-14T22:42:36Z', 'uri': 'http://web.archive.org/web/20180614224236/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-14T22:42:44Z', 'uri': 'http://web.archive.org/web/20180614224244/https://www.guideline.gov/summaries/summary/50709/operative-fixation-of-rib-fractures-after-blunt-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:24:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003022410/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2017-10-03T02:24:10Z', 'uri': 'http://web.archive.org/web/20171003022410/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2018-04-14T01:40:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414014035/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2018-04-14T01:40:35Z', 'uri': 'http://web.archive.org/web/20180414014035/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2018-05-19T08:25:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519082513/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2018-05-19T08:25:13Z', 'uri': 'http://web.archive.org/web/20180519082513/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2018-06-09T21:44:12Z', 'uri': 'http://web.archive.org/web/20180609214412/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}, {'datetime': '2018-06-14T22:42:11Z', 'uri': 'http://web.archive.org/web/20180614224211/https://www.guideline.gov/summaries/summary/50710/prophylaxis-against-venous-thromboembolism-in-pediatric-trauma-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma-and-the-pediatric-trauma-society'}]
https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:33:29Z', 'uri': 'http://wayback.archive-it.org/all/20171003023329/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2017-10-03T02:33:29Z', 'uri': 'http://web.archive.org/web/20171003023329/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2018-04-14T01:51:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414015142/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2018-04-14T01:51:42Z', 'uri': 'http://web.archive.org/web/20180414015142/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2018-05-19T08:36:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519083643/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2018-05-19T08:36:43Z', 'uri': 'http://web.archive.org/web/20180519083643/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2018-06-09T15:28:30Z', 'uri': 'http://web.archive.org/web/20180609152830/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}, {'datetime': '2018-06-14T22:37:05Z', 'uri': 'http://web.archive.org/web/20180614223705/https://www.guideline.gov/summaries/summary/50733/pharmacologic-treatment-of-hypertension-in-adults-aged-60-years-or-older-to-higher-versus-lower-blood-pressure-targets-a-clinical-practice-guideline-from-the-american-college-of-physicians-and-the-american-academy-of-family-physicians'}]
https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:38Z', 'uri': 'http://wayback.archive-it.org/all/20171003022338/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2017-10-03T02:23:38Z', 'uri': 'http://web.archive.org/web/20171003022338/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2018-04-14T01:39:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414013951/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2018-04-14T01:39:51Z', 'uri': 'http://web.archive.org/web/20180414013951/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2018-05-19T08:24:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519082427/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2018-05-19T08:24:27Z', 'uri': 'http://web.archive.org/web/20180519082427/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2018-06-09T19:39:45Z', 'uri': 'http://web.archive.org/web/20180609193945/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}, {'datetime': '2018-06-14T22:48:59Z', 'uri': 'http://web.archive.org/web/20180614224859/https://www.guideline.gov/summaries/summary/50734/british-association-of-dermatologists-guidelines-for-the-management-of-contact-dermatitis-2017'}]
https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003022312/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2017-10-03T02:23:12Z', 'uri': 'http://web.archive.org/web/20171003022312/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2018-04-14T01:39:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414013918/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2018-04-14T01:39:18Z', 'uri': 'http://web.archive.org/web/20180414013918/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2018-05-19T08:23:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519082351/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2018-05-19T08:23:51Z', 'uri': 'http://web.archive.org/web/20180519082351/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2018-06-09T21:36:18Z', 'uri': 'http://web.archive.org/web/20180609213618/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}, {'datetime': '2018-06-14T22:41:53Z', 'uri': 'http://web.archive.org/web/20180614224153/https://www.guideline.gov/summaries/summary/50735/spondyloarthritis-in-over-16s-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis	ARCHIVED	7 mementos	[{'datetime': '2017-10-03T02:22:55Z', 'uri': 'http://wayback.archive-it.org/all/20171003022255/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}, {'datetime': '2017-10-03T02:22:55Z', 'uri': 'http://web.archive.org/web/20171003022255/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}, {'datetime': '2018-04-14T01:38:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414013856/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}, {'datetime': '2018-04-14T01:38:56Z', 'uri': 'http://web.archive.org/web/20180414013856/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}, {'datetime': '2018-05-19T08:23:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519082328/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}, {'datetime': '2018-05-19T08:23:28Z', 'uri': 'http://web.archive.org/web/20180519082328/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}, {'datetime': '2018-06-10T01:44:50Z', 'uri': 'http://web.archive.org/web/20180610014450/https://www.guideline.gov/summaries/summary/50736/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis'}]
https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:22:47Z', 'uri': 'http://wayback.archive-it.org/all/20171003022247/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2017-10-03T02:22:47Z', 'uri': 'http://web.archive.org/web/20171003022247/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2018-04-14T01:38:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414013846/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2018-04-14T01:38:46Z', 'uri': 'http://web.archive.org/web/20180414013846/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2018-05-19T08:23:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519082318/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2018-05-19T08:23:18Z', 'uri': 'http://web.archive.org/web/20180519082318/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2018-06-09T10:36:03Z', 'uri': 'http://web.archive.org/web/20180609103603/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}, {'datetime': '2018-06-14T22:40:35Z', 'uri': 'http://web.archive.org/web/20180614224035/https://www.guideline.gov/summaries/summary/50737/american-academy-of-orthopaedic-surgeons-clinical-practice-guideline-on-management-of-osteoarthritis-of-the-hip'}]
https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:22:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003022233/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2017-10-03T02:22:33Z', 'uri': 'http://web.archive.org/web/20171003022233/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2018-04-14T01:38:26Z', 'uri': 'http://wayback.archive-it.org/all/20180414013826/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2018-04-14T01:38:26Z', 'uri': 'http://web.archive.org/web/20180414013826/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2018-05-19T08:22:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519082258/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2018-05-19T08:22:58Z', 'uri': 'http://web.archive.org/web/20180519082258/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2018-06-09T19:03:40Z', 'uri': 'http://web.archive.org/web/20180609190340/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}, {'datetime': '2018-06-14T22:39:52Z', 'uri': 'http://web.archive.org/web/20180614223952/https://www.guideline.gov/summaries/summary/50738/final-recommendation-statement-celiac-disease-screening'}]
https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:22:20Z', 'uri': 'http://wayback.archive-it.org/all/20171003022220/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2017-10-03T02:22:20Z', 'uri': 'http://web.archive.org/web/20171003022220/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T01:38:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414013810/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T01:38:10Z', 'uri': 'http://web.archive.org/web/20180414013810/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:22:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519082240/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:22:40Z', 'uri': 'http://web.archive.org/web/20180519082240/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-10T17:50:53Z', 'uri': 'http://web.archive.org/web/20180610175053/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-14T22:45:36Z', 'uri': 'http://web.archive.org/web/20180614224536/https://www.guideline.gov/summaries/summary/50739/cough-in-the-athlete-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:26:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003022610/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2017-10-03T02:26:10Z', 'uri': 'http://web.archive.org/web/20171003022610/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2018-04-14T01:42:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414014252/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2018-04-14T01:42:52Z', 'uri': 'http://web.archive.org/web/20180414014252/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2018-05-19T08:27:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519082740/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2018-05-19T08:27:40Z', 'uri': 'http://web.archive.org/web/20180519082740/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2018-06-09T12:00:56Z', 'uri': 'http://web.archive.org/web/20180609120056/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}, {'datetime': '2018-06-14T22:38:23Z', 'uri': 'http://web.archive.org/web/20180614223823/https://www.guideline.gov/summaries/summary/50744/clinical-policy-critical-issues-in-the-diagnosis-and-management-of-the-adult-psychiatric-patient-in-the-emergency-department'}]
https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:23:03Z', 'uri': 'http://wayback.archive-it.org/all/20171003022303/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2017-10-03T02:23:03Z', 'uri': 'http://web.archive.org/web/20171003022303/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2018-04-14T01:39:07Z', 'uri': 'http://wayback.archive-it.org/all/20180414013907/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2018-04-14T01:39:07Z', 'uri': 'http://web.archive.org/web/20180414013907/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2018-05-19T08:23:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519082339/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2018-05-19T08:23:39Z', 'uri': 'http://web.archive.org/web/20180519082339/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2018-06-09T11:59:17Z', 'uri': 'http://web.archive.org/web/20180609115917/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}, {'datetime': '2018-06-14T22:40:48Z', 'uri': 'http://web.archive.org/web/20180614224048/https://www.guideline.gov/summaries/summary/50745/mental-health-of-adults-in-contact-with-the-criminal-justice-system'}]
https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:22:26Z', 'uri': 'http://wayback.archive-it.org/all/20171003022226/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2017-10-03T02:22:26Z', 'uri': 'http://web.archive.org/web/20171003022226/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-04-14T01:38:18Z', 'uri': 'http://wayback.archive-it.org/all/20180414013818/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-04-14T01:38:18Z', 'uri': 'http://web.archive.org/web/20180414013818/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-05-19T08:22:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519082249/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-05-19T08:22:49Z', 'uri': 'http://web.archive.org/web/20180519082249/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-06-09T11:01:35Z', 'uri': 'http://web.archive.org/web/20180609110135/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-06-14T22:47:46Z', 'uri': 'http://web.archive.org/web/20180614224746/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}, {'datetime': '2018-06-14T22:47:52Z', 'uri': 'http://web.archive.org/web/20180614224752/https://www.guideline.gov/summaries/summary/50746/individualized-medication-of-voriconazole-a-practice-guideline-of-the-division-of-therapeutic-drug-monitoring-chinese-pharmacological-society'}]
https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians	ARCHIVED	9 mementos	[{'datetime': '2017-07-13T05:15:31Z', 'uri': 'http://web.archive.org/web/20170713051531/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:25:02Z', 'uri': 'http://wayback.archive-it.org/all/20171003022502/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2017-10-03T02:25:02Z', 'uri': 'http://web.archive.org/web/20171003022502/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:41:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414014138/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-04-14T01:41:38Z', 'uri': 'http://web.archive.org/web/20180414014138/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:26:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519082619/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-05-19T08:26:19Z', 'uri': 'http://web.archive.org/web/20180519082619/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-09T19:21:56Z', 'uri': 'http://web.archive.org/web/20180609192156/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}, {'datetime': '2018-06-14T22:33:15Z', 'uri': 'http://web.archive.org/web/20180614223315/https://www.guideline.gov/summaries/summary/50781/noninvasive-treatments-for-acute-subacute-and-chronic-low-back-pain-a-clinical-practice-guideline-from-the-american-college-of-physicians'}]
https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:58Z', 'uri': 'http://wayback.archive-it.org/all/20171003022158/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2017-10-03T02:21:58Z', 'uri': 'http://web.archive.org/web/20171003022158/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2018-04-14T01:37:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414013742/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2018-04-14T01:37:42Z', 'uri': 'http://web.archive.org/web/20180414013742/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2018-05-19T08:22:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519082210/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2018-05-19T08:22:10Z', 'uri': 'http://web.archive.org/web/20180519082210/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2018-06-09T11:41:59Z', 'uri': 'http://web.archive.org/web/20180609114159/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}, {'datetime': '2018-06-14T22:46:33Z', 'uri': 'http://web.archive.org/web/20180614224633/https://www.guideline.gov/summaries/summary/50783/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology'}]
https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:26:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003022618/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:26:18Z', 'uri': 'http://web.archive.org/web/20171003022618/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:43:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414014310/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:43:10Z', 'uri': 'http://web.archive.org/web/20180414014310/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:27:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519082749/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:27:49Z', 'uri': 'http://web.archive.org/web/20180519082749/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-06-09T21:36:52Z', 'uri': 'http://web.archive.org/web/20180609213652/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:40:44Z', 'uri': 'http://web.archive.org/web/20180614224044/https://www.guideline.gov/summaries/summary/50887/clinical-practice-guideline-for-diagnostic-testing-for-adult-obstructive-sleep-apnea-an-american-academy-of-sleep-medicine-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:20:49Z', 'uri': 'http://wayback.archive-it.org/all/20171003022049/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2017-10-03T02:20:49Z', 'uri': 'http://web.archive.org/web/20171003022049/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2018-04-14T00:47:08Z', 'uri': 'http://wayback.archive-it.org/all/20180414004708/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2018-04-14T00:47:08Z', 'uri': 'http://web.archive.org/web/20180414004708/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2018-05-18T22:04:37Z', 'uri': 'http://wayback.archive-it.org/all/20180518220437/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2018-05-18T22:04:37Z', 'uri': 'http://web.archive.org/web/20180518220437/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2018-06-09T21:34:30Z', 'uri': 'http://web.archive.org/web/20180609213430/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}, {'datetime': '2018-06-14T23:19:00Z', 'uri': 'http://web.archive.org/web/20180614231900/https://www.guideline.gov/summaries/summary/50982/inpatient-diagnosis-and-treatment-of-central-vascular-catheter-cvc-infections'}]
https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:51Z', 'uri': 'http://wayback.archive-it.org/all/20171003022151/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2017-10-03T02:21:51Z', 'uri': 'http://web.archive.org/web/20171003022151/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2018-04-14T01:37:32Z', 'uri': 'http://wayback.archive-it.org/all/20180414013732/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2018-04-14T01:37:32Z', 'uri': 'http://web.archive.org/web/20180414013732/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2018-05-19T08:21:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519082151/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2018-05-19T08:21:51Z', 'uri': 'http://web.archive.org/web/20180519082151/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2018-06-10T01:14:51Z', 'uri': 'http://web.archive.org/web/20180610011451/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}, {'datetime': '2018-06-14T22:42:20Z', 'uri': 'http://web.archive.org/web/20180614224220/https://www.guideline.gov/summaries/summary/51002/accelerated-partial-breast-irradiation-executive-summary-for-the-update-of-an-astro-evidencebased-consensus-statement'}]
https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:22:40Z', 'uri': 'http://wayback.archive-it.org/all/20171003022240/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2017-10-03T02:22:40Z', 'uri': 'http://web.archive.org/web/20171003022240/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2018-04-14T01:38:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414013836/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2018-04-14T01:38:36Z', 'uri': 'http://web.archive.org/web/20180414013836/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2018-05-19T08:23:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519082309/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2018-05-19T08:23:09Z', 'uri': 'http://web.archive.org/web/20180519082309/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2018-06-09T20:18:50Z', 'uri': 'http://web.archive.org/web/20180609201850/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}, {'datetime': '2018-06-14T22:37:15Z', 'uri': 'http://web.archive.org/web/20180614223715/https://www.guideline.gov/summaries/summary/51003/final-recommendation-statement-preeclampsia-screening'}]
https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:20:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003022025/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2017-10-03T02:20:25Z', 'uri': 'http://web.archive.org/web/20171003022025/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2018-04-14T01:35:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414013550/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2018-04-14T01:35:50Z', 'uri': 'http://web.archive.org/web/20180414013550/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2018-05-19T08:20:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519082019/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2018-05-19T08:20:19Z', 'uri': 'http://web.archive.org/web/20180519082019/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2018-06-10T00:27:27Z', 'uri': 'http://web.archive.org/web/20180610002727/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}, {'datetime': '2018-06-14T22:33:25Z', 'uri': 'http://web.archive.org/web/20180614223325/https://www.guideline.gov/summaries/summary/51004/recommendations-on-hepatitis-c-screening-for-adults'}]
https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:27Z', 'uri': 'http://wayback.archive-it.org/all/20171003022127/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2017-10-03T02:21:27Z', 'uri': 'http://web.archive.org/web/20171003022127/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2018-04-14T01:37:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414013701/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2018-04-14T01:37:01Z', 'uri': 'http://web.archive.org/web/20180414013701/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2018-05-19T08:21:20Z', 'uri': 'http://wayback.archive-it.org/all/20180519082120/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2018-05-19T08:21:20Z', 'uri': 'http://web.archive.org/web/20180519082120/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2018-06-10T15:51:01Z', 'uri': 'http://web.archive.org/web/20180610155101/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}, {'datetime': '2018-06-14T23:15:35Z', 'uri': 'http://web.archive.org/web/20180614231535/https://www.guideline.gov/summaries/summary/51005/acr-appropriateness-criteria--cranial-neuropathy'}]
https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer	ARCHIVED	9 mementos	[{'datetime': '2017-10-03T02:21:36Z', 'uri': 'http://wayback.archive-it.org/all/20171003022136/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2017-10-03T02:21:36Z', 'uri': 'http://web.archive.org/web/20171003022136/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-04-14T01:37:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414013713/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-04-14T01:37:13Z', 'uri': 'http://web.archive.org/web/20180414013713/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-05-19T08:21:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519082131/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-05-19T08:21:31Z', 'uri': 'http://web.archive.org/web/20180519082131/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-06-10T23:04:12Z', 'uri': 'http://web.archive.org/web/20180610230412/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-06-11T14:49:54Z', 'uri': 'http://web.archive.org/web/20180611144954/https://www.guideline.gov/summaries/summary/51006/ACR-Appropriateness-Criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}, {'datetime': '2018-06-14T23:14:56Z', 'uri': 'http://web.archive.org/web/20180614231456/https://www.guideline.gov/summaries/summary/51006/acr-appropriateness-criteria--monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer'}]
https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:45Z', 'uri': 'http://wayback.archive-it.org/all/20171003022145/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2017-10-03T02:21:45Z', 'uri': 'http://web.archive.org/web/20171003022145/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2018-04-14T01:37:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414013724/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2018-04-14T01:37:24Z', 'uri': 'http://web.archive.org/web/20180414013724/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2018-05-19T08:21:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519082142/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2018-05-19T08:21:42Z', 'uri': 'http://web.archive.org/web/20180519082142/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2018-06-09T22:44:10Z', 'uri': 'http://web.archive.org/web/20180609224410/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}, {'datetime': '2018-06-14T22:52:17Z', 'uri': 'http://web.archive.org/web/20180614225217/https://www.guideline.gov/summaries/summary/51007/acr-appropriateness-criteria--penetrating-neck-injury'}]
https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:01Z', 'uri': 'http://wayback.archive-it.org/all/20171003022101/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2017-10-03T02:21:01Z', 'uri': 'http://web.archive.org/web/20171003022101/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2018-04-14T01:36:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414013630/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2018-04-14T01:36:30Z', 'uri': 'http://web.archive.org/web/20180414013630/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2018-05-19T08:20:58Z', 'uri': 'http://wayback.archive-it.org/all/20180519082058/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2018-05-19T08:20:58Z', 'uri': 'http://web.archive.org/web/20180519082058/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2018-06-10T11:54:39Z', 'uri': 'http://web.archive.org/web/20180610115439/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}, {'datetime': '2018-06-14T23:15:40Z', 'uri': 'http://web.archive.org/web/20180614231540/https://www.guideline.gov/summaries/summary/51008/acr-appropriateness-criteria--radiologic-management-of-iliac-artery-occlusive-disease'}]
https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:10Z', 'uri': 'http://wayback.archive-it.org/all/20171003022110/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2017-10-03T02:21:10Z', 'uri': 'http://web.archive.org/web/20171003022110/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2018-04-14T01:36:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414013640/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2018-04-14T01:36:40Z', 'uri': 'http://web.archive.org/web/20180414013640/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2018-05-18T19:32:28Z', 'uri': 'http://wayback.archive-it.org/all/20180518193228/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2018-05-18T19:32:28Z', 'uri': 'http://web.archive.org/web/20180518193228/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2018-06-09T10:39:13Z', 'uri': 'http://web.archive.org/web/20180609103913/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}, {'datetime': '2018-06-14T22:48:36Z', 'uri': 'http://web.archive.org/web/20180614224836/https://www.guideline.gov/summaries/summary/51009/acr-appropriateness-criteria--renovascular-hypertension'}]
https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:21:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003022118/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2017-10-03T02:21:18Z', 'uri': 'http://web.archive.org/web/20171003022118/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2018-04-14T01:36:49Z', 'uri': 'http://wayback.archive-it.org/all/20180414013649/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2018-04-14T01:36:49Z', 'uri': 'http://web.archive.org/web/20180414013649/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2018-05-19T08:21:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519082109/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2018-05-19T08:21:09Z', 'uri': 'http://web.archive.org/web/20180519082109/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2018-06-09T15:20:06Z', 'uri': 'http://web.archive.org/web/20180609152006/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}, {'datetime': '2018-06-14T22:51:49Z', 'uri': 'http://web.archive.org/web/20180614225149/https://www.guideline.gov/summaries/summary/51010/acr-appropriateness-criteria--thoracic-aorta-interventional-planning-and-followup'}]
https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:20:18Z', 'uri': 'http://wayback.archive-it.org/all/20171003022018/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2017-10-03T02:20:18Z', 'uri': 'http://web.archive.org/web/20171003022018/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-04-14T01:35:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414013540/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-04-14T01:35:40Z', 'uri': 'http://web.archive.org/web/20180414013540/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-05-19T08:20:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519082010/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-05-19T08:20:10Z', 'uri': 'http://web.archive.org/web/20180519082010/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-06-10T00:38:49Z', 'uri': 'http://web.archive.org/web/20180610003849/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}, {'datetime': '2018-06-14T22:34:56Z', 'uri': 'http://web.archive.org/web/20180614223456/https://www.guideline.gov/summaries/summary/51011/practice-guideline-summary-sudden-unexpected-death-in-epilepsy-incidence-rates-and-risk-factors-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology-and-the-american-epilepsy-society'}]
https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:22:12Z', 'uri': 'http://wayback.archive-it.org/all/20171003022212/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2017-10-03T02:22:12Z', 'uri': 'http://web.archive.org/web/20171003022212/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2018-04-14T01:38:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414013800/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2018-04-14T01:38:00Z', 'uri': 'http://web.archive.org/web/20180414013800/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2018-05-19T08:22:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519082230/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2018-05-19T08:22:30Z', 'uri': 'http://web.archive.org/web/20180519082230/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2018-06-09T18:41:17Z', 'uri': 'http://web.archive.org/web/20180609184117/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}, {'datetime': '2018-06-14T22:35:30Z', 'uri': 'http://web.archive.org/web/20180614223530/https://www.guideline.gov/summaries/summary/51012/molecular-biomarkers-for-the-evaluation-of-colorectal-cancer-guideline-from-the-american-society-for-clinical-pathology-college-of-american-pathologists-association-for-molecular-pathology-and-the-american-society-of-clinical-oncology'}]
https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:20:54Z', 'uri': 'http://wayback.archive-it.org/all/20171003022054/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2017-10-03T02:20:54Z', 'uri': 'http://web.archive.org/web/20171003022054/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2018-04-14T01:36:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414013620/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2018-04-14T01:36:20Z', 'uri': 'http://web.archive.org/web/20180414013620/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2018-05-19T08:20:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519082048/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2018-05-19T08:20:48Z', 'uri': 'http://web.archive.org/web/20180519082048/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2018-06-09T22:06:24Z', 'uri': 'http://web.archive.org/web/20180609220624/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}, {'datetime': '2018-06-14T22:52:08Z', 'uri': 'http://web.archive.org/web/20180614225208/https://www.guideline.gov/summaries/summary/51013/hormonal-contraceptive-eligibility-for-women-at-high-risk-of-hiv-guidance-statement'}]
https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:01:25Z', 'uri': 'http://wayback.archive-it.org/all/20171003020125/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2017-10-03T02:01:25Z', 'uri': 'http://web.archive.org/web/20171003020125/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2018-04-14T01:35:31Z', 'uri': 'http://wayback.archive-it.org/all/20180414013531/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2018-04-14T01:35:31Z', 'uri': 'http://web.archive.org/web/20180414013531/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2018-05-19T08:20:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519082001/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2018-05-19T08:20:01Z', 'uri': 'http://web.archive.org/web/20180519082001/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2018-06-10T23:01:38Z', 'uri': 'http://web.archive.org/web/20180610230138/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}, {'datetime': '2018-06-14T22:35:17Z', 'uri': 'http://web.archive.org/web/20180614223517/https://www.guideline.gov/summaries/summary/51016/final-recommendation-statement-thyroid-cancer-screening'}]
https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:20:33Z', 'uri': 'http://wayback.archive-it.org/all/20171003022033/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2017-10-03T02:20:33Z', 'uri': 'http://web.archive.org/web/20171003022033/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2018-04-14T01:36:00Z', 'uri': 'http://wayback.archive-it.org/all/20180414013600/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2018-04-14T01:36:00Z', 'uri': 'http://web.archive.org/web/20180414013600/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2018-05-19T08:20:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519082029/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2018-05-19T08:20:29Z', 'uri': 'http://web.archive.org/web/20180519082029/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2018-06-09T21:46:24Z', 'uri': 'http://web.archive.org/web/20180609214624/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}, {'datetime': '2018-06-14T22:37:54Z', 'uri': 'http://web.archive.org/web/20180614223754/https://www.guideline.gov/summaries/summary/51017/vadod-clinical-practice-guideline-for-the-management-of-type-2-diabetes-mellitus-in-primary-care'}]
https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:20:42Z', 'uri': 'http://wayback.archive-it.org/all/20171003022042/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2017-10-03T02:20:42Z', 'uri': 'http://web.archive.org/web/20171003022042/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:36:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414013611/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:36:11Z', 'uri': 'http://web.archive.org/web/20180414013611/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:20:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519082040/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:20:40Z', 'uri': 'http://web.archive.org/web/20180519082040/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-09T20:57:59Z', 'uri': 'http://web.archive.org/web/20180609205759/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:21:00Z', 'uri': 'http://web.archive.org/web/20180614232100/https://www.guideline.gov/summaries/summary/51018/diabetes-technology-continuous-subcutaneous-insulin-infusion-therapy-and-continuous-glucose-monitoring-in-adults-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:01:16Z', 'uri': 'http://wayback.archive-it.org/all/20171003020116/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2017-10-03T02:01:16Z', 'uri': 'http://web.archive.org/web/20171003020116/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2018-04-14T01:35:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414013522/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2018-04-14T01:35:22Z', 'uri': 'http://web.archive.org/web/20180414013522/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2018-05-19T08:19:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519081951/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2018-05-19T08:19:51Z', 'uri': 'http://web.archive.org/web/20180519081951/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2018-06-09T19:20:41Z', 'uri': 'http://web.archive.org/web/20180609192041/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}, {'datetime': '2018-06-14T22:46:25Z', 'uri': 'http://web.archive.org/web/20180614224625/https://www.guideline.gov/summaries/summary/51019/clinical-practice-guideline-improving-nasal-form-and-function-after-rhinoplasty'}]
https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:01:08Z', 'uri': 'http://wayback.archive-it.org/all/20171003020108/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2017-10-03T02:01:08Z', 'uri': 'http://web.archive.org/web/20171003020108/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2018-04-14T01:35:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414013511/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2018-04-14T01:35:11Z', 'uri': 'http://web.archive.org/web/20180414013511/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2018-05-19T08:19:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519081940/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2018-05-19T08:19:40Z', 'uri': 'http://web.archive.org/web/20180519081940/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2018-06-09T15:41:15Z', 'uri': 'http://web.archive.org/web/20180609154115/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}, {'datetime': '2018-06-14T22:41:58Z', 'uri': 'http://web.archive.org/web/20180614224158/https://www.guideline.gov/summaries/summary/51020/clinical-practice-guideline-benign-paroxysmal-positional-vertigo-update'}]
https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline	ARCHIVED	8 mementos	[{'datetime': '2017-10-02T19:56:13Z', 'uri': 'http://wayback.archive-it.org/all/20171002195613/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2017-10-02T19:56:13Z', 'uri': 'http://web.archive.org/web/20171002195613/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2018-04-14T01:34:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414013441/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2018-04-14T01:34:41Z', 'uri': 'http://web.archive.org/web/20180414013441/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2018-05-19T08:19:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519081909/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2018-05-19T08:19:09Z', 'uri': 'http://web.archive.org/web/20180519081909/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2018-06-09T12:01:45Z', 'uri': 'http://web.archive.org/web/20180609120145/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}, {'datetime': '2018-06-15T00:06:41Z', 'uri': 'http://web.archive.org/web/20180615000641/https://www.guideline.gov/summaries/summary/51021/american-cancer-society-head-and-neck-cancer-survivorship-care-guideline'}]
https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu	ARCHIVED	8 mementos	[{'datetime': '2017-10-02T19:56:05Z', 'uri': 'http://wayback.archive-it.org/all/20171002195605/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2017-10-02T19:56:05Z', 'uri': 'http://web.archive.org/web/20171002195605/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2018-04-14T01:35:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414013501/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2018-04-14T01:35:01Z', 'uri': 'http://web.archive.org/web/20180414013501/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2018-05-19T08:19:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519081930/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2018-05-19T08:19:30Z', 'uri': 'http://web.archive.org/web/20180519081930/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2018-06-09T12:11:36Z', 'uri': 'http://web.archive.org/web/20180609121136/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}, {'datetime': '2018-06-14T23:14:33Z', 'uri': 'http://web.archive.org/web/20180614231433/https://www.guideline.gov/summaries/summary/51023/guidelines-for-familycentered-care-in-the-neonatal-pediatric-and-adult-icu'}]
https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:32:52Z', 'uri': 'http://wayback.archive-it.org/all/20180414013252/https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline'}, {'datetime': '2018-04-14T01:32:52Z', 'uri': 'http://web.archive.org/web/20180414013252/https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline'}, {'datetime': '2018-05-19T08:16:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519081640/https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline'}, {'datetime': '2018-05-19T08:16:40Z', 'uri': 'http://web.archive.org/web/20180519081640/https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline'}, {'datetime': '2018-06-09T20:48:50Z', 'uri': 'http://web.archive.org/web/20180609204850/https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline'}, {'datetime': '2018-06-14T22:40:15Z', 'uri': 'http://web.archive.org/web/20180614224015/https://www.guideline.gov/summaries/summary/51024/surgical-treatment-of-female-stress-urinary-incontinence-auasufu-guideline'}]
https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:32:42Z', 'uri': 'http://wayback.archive-it.org/all/20180414013242/https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline'}, {'datetime': '2018-04-14T01:32:42Z', 'uri': 'http://web.archive.org/web/20180414013242/https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline'}, {'datetime': '2018-05-19T08:16:29Z', 'uri': 'http://wayback.archive-it.org/all/20180519081629/https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline'}, {'datetime': '2018-05-19T08:16:29Z', 'uri': 'http://web.archive.org/web/20180519081629/https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline'}, {'datetime': '2018-06-09T22:23:37Z', 'uri': 'http://web.archive.org/web/20180609222337/https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline'}, {'datetime': '2018-06-14T22:38:07Z', 'uri': 'http://web.archive.org/web/20180614223807/https://www.guideline.gov/summaries/summary/51025/clinically-localized-prostate-cancer-auaastrosuo-guideline'}]
https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:34:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414013413/https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient'}, {'datetime': '2018-04-14T01:34:13Z', 'uri': 'http://web.archive.org/web/20180414013413/https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient'}, {'datetime': '2018-05-19T08:18:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519081818/https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient'}, {'datetime': '2018-05-19T08:18:18Z', 'uri': 'http://web.archive.org/web/20180519081818/https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient'}, {'datetime': '2018-06-09T23:20:14Z', 'uri': 'http://web.archive.org/web/20180609232014/https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient'}, {'datetime': '2018-06-14T22:35:13Z', 'uri': 'http://web.archive.org/web/20180614223513/https://www.guideline.gov/summaries/summary/51026/guideline-for-positioning-the-patient'}]
https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update	ARCHIVED	8 mementos	[{'datetime': '2017-10-03T02:22:05Z', 'uri': 'http://wayback.archive-it.org/all/20171003022205/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2017-10-03T02:22:05Z', 'uri': 'http://web.archive.org/web/20171003022205/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2018-04-14T01:37:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414013751/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2018-04-14T01:37:51Z', 'uri': 'http://web.archive.org/web/20180414013751/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2018-05-19T08:22:22Z', 'uri': 'http://wayback.archive-it.org/all/20180519082222/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2018-05-19T08:22:22Z', 'uri': 'http://web.archive.org/web/20180519082222/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2018-06-10T00:04:54Z', 'uri': 'http://web.archive.org/web/20180610000454/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}, {'datetime': '2018-06-14T22:35:43Z', 'uri': 'http://web.archive.org/web/20180614223543/https://www.guideline.gov/summaries/summary/51027/brachytherapy-for-patients-with-prostate-cancer-american-society-of-clinical-oncologycancer-care-ontario-joint-guideline-update'}]
https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:33:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414013302/https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment'}, {'datetime': '2018-04-14T01:33:02Z', 'uri': 'http://web.archive.org/web/20180414013302/https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment'}, {'datetime': '2018-05-19T08:16:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519081650/https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment'}, {'datetime': '2018-05-19T08:16:50Z', 'uri': 'http://web.archive.org/web/20180519081650/https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment'}, {'datetime': '2018-06-09T11:57:55Z', 'uri': 'http://web.archive.org/web/20180609115755/https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment'}, {'datetime': '2018-06-14T22:32:04Z', 'uri': 'http://web.archive.org/web/20180614223204/https://www.guideline.gov/summaries/summary/51028/eating-disorders-recognition-and-treatment'}]
https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination	ARCHIVED	8 mementos	[{'datetime': '2017-10-02T19:56:21Z', 'uri': 'http://wayback.archive-it.org/all/20171002195621/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2017-10-02T19:56:21Z', 'uri': 'http://web.archive.org/web/20171002195621/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2018-04-14T01:34:50Z', 'uri': 'http://wayback.archive-it.org/all/20180414013450/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2018-04-14T01:34:50Z', 'uri': 'http://web.archive.org/web/20180414013450/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2018-05-19T08:19:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519081919/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2018-05-19T08:19:19Z', 'uri': 'http://web.archive.org/web/20180519081919/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2018-06-09T21:17:27Z', 'uri': 'http://web.archive.org/web/20180609211727/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}, {'datetime': '2018-06-14T22:51:56Z', 'uri': 'http://web.archive.org/web/20180614225156/https://www.guideline.gov/summaries/summary/51030/comprehensive-pediatric-eye-and-vision-examination'}]
https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:34:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414013430/https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:34:30Z', 'uri': 'http://web.archive.org/web/20180414013430/https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:18:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519081855/https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:18:55Z', 'uri': 'http://web.archive.org/web/20180519081855/https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-10T01:06:24Z', 'uri': 'http://web.archive.org/web/20180610010624/https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline'}, {'datetime': '2018-06-14T23:23:11Z', 'uri': 'http://web.archive.org/web/20180614232311/https://www.guideline.gov/summaries/summary/51031/hormonal-replacement-in-hypopituitarism-in-adults-an-endocrine-society-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:34:22Z', 'uri': 'http://wayback.archive-it.org/all/20180414013422/https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017'}, {'datetime': '2018-04-14T01:34:22Z', 'uri': 'http://web.archive.org/web/20180414013422/https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017'}, {'datetime': '2018-05-19T08:18:45Z', 'uri': 'http://wayback.archive-it.org/all/20180519081845/https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017'}, {'datetime': '2018-05-19T08:18:45Z', 'uri': 'http://web.archive.org/web/20180519081845/https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017'}, {'datetime': '2018-06-09T11:39:50Z', 'uri': 'http://web.archive.org/web/20180609113950/https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017'}, {'datetime': '2018-06-14T22:35:36Z', 'uri': 'http://web.archive.org/web/20180614223536/https://www.guideline.gov/summaries/summary/51032/the-use-of-targeted-therapies-in-patients-with-inoperable-locally-advanced-or-metastatic-renal-cell-cancer-updated-guideline-2017'}]
https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:33:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414013346/https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis'}, {'datetime': '2018-04-14T01:33:46Z', 'uri': 'http://web.archive.org/web/20180414013346/https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis'}, {'datetime': '2018-05-19T08:17:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519081750/https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis'}, {'datetime': '2018-05-19T08:17:50Z', 'uri': 'http://web.archive.org/web/20180519081750/https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis'}, {'datetime': '2018-06-09T21:44:50Z', 'uri': 'http://web.archive.org/web/20180609214450/https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis'}, {'datetime': '2018-06-14T22:35:22Z', 'uri': 'http://web.archive.org/web/20180614223522/https://www.guideline.gov/summaries/summary/51033/american-gastroenterological-association-institute-guideline-on-the-role-of-elastography-in-the-evaluation-of-liver-fibrosis'}]
https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:34:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414013403/https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion'}, {'datetime': '2018-04-14T01:34:03Z', 'uri': 'http://web.archive.org/web/20180414013403/https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion'}, {'datetime': '2018-05-19T08:18:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519081808/https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion'}, {'datetime': '2018-05-19T08:18:08Z', 'uri': 'http://web.archive.org/web/20180519081808/https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion'}, {'datetime': '2018-06-10T23:03:35Z', 'uri': 'http://web.archive.org/web/20180610230335/https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion'}, {'datetime': '2018-06-14T22:28:51Z', 'uri': 'http://web.archive.org/web/20180614222851/https://www.guideline.gov/summaries/summary/51034/secondline-hormonal-therapy-for-men-with-chemotherapyna-ve-castrationresistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion'}]
https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:33:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414013325/https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction'}, {'datetime': '2018-04-14T01:33:25Z', 'uri': 'http://web.archive.org/web/20180414013325/https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction'}, {'datetime': '2018-05-19T08:17:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519081728/https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction'}, {'datetime': '2018-05-19T08:17:28Z', 'uri': 'http://web.archive.org/web/20180519081728/https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction'}, {'datetime': '2018-06-09T10:35:53Z', 'uri': 'http://web.archive.org/web/20180609103553/https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction'}, {'datetime': '2018-06-14T22:48:14Z', 'uri': 'http://web.archive.org/web/20180614224814/https://www.guideline.gov/summaries/summary/51035/clinical-practice-guideline-update-earwax-cerumen-impaction'}]
https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:33:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414013355/https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure'}, {'datetime': '2018-04-14T01:33:55Z', 'uri': 'http://web.archive.org/web/20180414013355/https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure'}, {'datetime': '2018-05-19T08:17:59Z', 'uri': 'http://wayback.archive-it.org/all/20180519081759/https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure'}, {'datetime': '2018-05-19T08:17:59Z', 'uri': 'http://web.archive.org/web/20180519081759/https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure'}, {'datetime': '2018-06-09T21:45:11Z', 'uri': 'http://web.archive.org/web/20180609214511/https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure'}, {'datetime': '2018-06-14T22:46:29Z', 'uri': 'http://web.archive.org/web/20180614224629/https://www.guideline.gov/summaries/summary/51036/american-gastroenterological-association-institute-guidelines-for-the-diagnosis-and-management-of-acute-liver-failure'}]
https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:33:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414013316/https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-04-14T01:33:16Z', 'uri': 'http://web.archive.org/web/20180414013316/https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T08:17:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519081719/https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-05-19T08:17:19Z', 'uri': 'http://web.archive.org/web/20180519081719/https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-06-10T01:15:52Z', 'uri': 'http://web.archive.org/web/20180610011552/https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome'}, {'datetime': '2018-06-14T23:18:31Z', 'uri': 'http://web.archive.org/web/20180614231831/https://www.guideline.gov/summaries/summary/51037/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-carpal-tunnel-syndrome'}]
https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:33:36Z', 'uri': 'http://wayback.archive-it.org/all/20180414013336/https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:33:36Z', 'uri': 'http://web.archive.org/web/20180414013336/https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:17:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519081739/https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:17:39Z', 'uri': 'http://web.archive.org/web/20180519081739/https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:07:31Z', 'uri': 'http://web.archive.org/web/20180609220731/https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:27:07Z', 'uri': 'http://web.archive.org/web/20180614222707/https://www.guideline.gov/summaries/summary/51038/use-of-adjuvant-bisphosphonates-and-other-bonemodifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:32:13Z', 'uri': 'http://wayback.archive-it.org/all/20180414013213/https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd'}, {'datetime': '2018-04-14T01:32:13Z', 'uri': 'http://web.archive.org/web/20180414013213/https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd'}, {'datetime': '2018-05-19T08:16:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519081601/https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd'}, {'datetime': '2018-05-19T08:16:01Z', 'uri': 'http://web.archive.org/web/20180519081601/https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd'}, {'datetime': '2018-06-09T18:42:10Z', 'uri': 'http://web.archive.org/web/20180609184210/https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd'}, {'datetime': '2018-06-14T22:26:18Z', 'uri': 'http://web.archive.org/web/20180614222618/https://www.guideline.gov/summaries/summary/51041/kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckdmbd'}]
https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:32:33Z', 'uri': 'http://wayback.archive-it.org/all/20180414013233/https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient'}, {'datetime': '2018-04-14T01:32:33Z', 'uri': 'http://web.archive.org/web/20180414013233/https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient'}, {'datetime': '2018-05-19T08:16:19Z', 'uri': 'http://wayback.archive-it.org/all/20180519081619/https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient'}, {'datetime': '2018-05-19T08:16:19Z', 'uri': 'http://web.archive.org/web/20180519081619/https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient'}, {'datetime': '2018-06-09T21:05:42Z', 'uri': 'http://web.archive.org/web/20180609210542/https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient'}, {'datetime': '2018-06-14T23:23:05Z', 'uri': 'http://web.archive.org/web/20180614232305/https://www.guideline.gov/summaries/summary/51042/clinical-practice-guidelines-for-sustained-neuromuscular-blockade-in-the-adult-critically-ill-patient'}]
https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:32:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414013224/https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition'}, {'datetime': '2018-04-14T01:32:24Z', 'uri': 'http://web.archive.org/web/20180414013224/https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition'}, {'datetime': '2018-05-19T08:16:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519081610/https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition'}, {'datetime': '2018-05-19T08:16:10Z', 'uri': 'http://web.archive.org/web/20180519081610/https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition'}, {'datetime': '2018-06-10T01:21:49Z', 'uri': 'http://web.archive.org/web/20180610012149/https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition'}, {'datetime': '2018-06-14T22:35:03Z', 'uri': 'http://web.archive.org/web/20180614223503/https://www.guideline.gov/summaries/summary/51043/adult-asthma-care-promoting-control-of-asthma-second-edition'}]
https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline	ARCHIVED	7 mementos	[{'datetime': '2018-04-14T01:31:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414013153/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-04-14T01:31:53Z', 'uri': 'http://web.archive.org/web/20180414013153/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:15:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519081540/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-05-19T08:15:40Z', 'uri': 'http://web.archive.org/web/20180519081540/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-09T22:44:49Z', 'uri': 'http://web.archive.org/web/20180609224449/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:25:06Z', 'uri': 'http://web.archive.org/web/20180614222506/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}, {'datetime': '2018-06-14T22:25:17Z', 'uri': 'http://web.archive.org/web/20180614222517/https://www.guideline.gov/summaries/summary/51044/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidencebased-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:31:43Z', 'uri': 'http://wayback.archive-it.org/all/20180414013143/https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation'}, {'datetime': '2018-04-14T01:31:43Z', 'uri': 'http://web.archive.org/web/20180414013143/https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation'}, {'datetime': '2018-05-19T08:15:31Z', 'uri': 'http://wayback.archive-it.org/all/20180519081531/https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation'}, {'datetime': '2018-05-19T08:15:31Z', 'uri': 'http://web.archive.org/web/20180519081531/https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation'}, {'datetime': '2018-06-09T15:28:59Z', 'uri': 'http://web.archive.org/web/20180609152859/https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation'}, {'datetime': '2018-06-14T22:37:59Z', 'uri': 'http://web.archive.org/web/20180614223759/https://www.guideline.gov/summaries/summary/51045/pharmacologic-management-of-newly-detected-atrial-fibrillation'}]
https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:32:02Z', 'uri': 'http://wayback.archive-it.org/all/20180414013202/https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder'}, {'datetime': '2018-04-14T01:32:02Z', 'uri': 'http://web.archive.org/web/20180414013202/https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder'}, {'datetime': '2018-05-19T08:15:50Z', 'uri': 'http://wayback.archive-it.org/all/20180519081550/https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder'}, {'datetime': '2018-05-19T08:15:50Z', 'uri': 'http://web.archive.org/web/20180519081550/https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder'}, {'datetime': '2018-06-09T11:58:51Z', 'uri': 'http://web.archive.org/web/20180609115851/https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder'}, {'datetime': '2018-06-14T23:14:42Z', 'uri': 'http://web.archive.org/web/20180614231442/https://www.guideline.gov/summaries/summary/51046/vadod-clinical-practice-guideline-for-the-management-of-posttraumatic-stress-disorder-and-acute-stress-disorder'}]
https://www.guideline.gov/summaries/summary/51047/final-recommendation-statement-obesity-in-children-and-adolescents-screening	ARCHIVED	2 mementos	[{'datetime': '2018-04-14T01:31:34Z', 'uri': 'http://wayback.archive-it.org/all/20180414013134/https://www.guideline.gov/summaries/summary/51047/final-recommendation-statement-obesity-in-children-and-adolescents-screening'}, {'datetime': '2018-05-19T08:15:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519081521/https://www.guideline.gov/summaries/summary/51047/final-recommendation-statement-obesity-in-children-and-adolescents-screening'}]
https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:31:15Z', 'uri': 'http://wayback.archive-it.org/all/20180414013115/https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding'}, {'datetime': '2018-04-14T01:31:15Z', 'uri': 'http://web.archive.org/web/20180414013115/https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding'}, {'datetime': '2018-05-19T08:15:02Z', 'uri': 'http://wayback.archive-it.org/all/20180519081502/https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding'}, {'datetime': '2018-05-19T08:15:02Z', 'uri': 'http://web.archive.org/web/20180519081502/https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding'}, {'datetime': '2018-06-09T18:53:26Z', 'uri': 'http://web.archive.org/web/20180609185326/https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding'}, {'datetime': '2018-06-15T00:28:55Z', 'uri': 'http://web.archive.org/web/20180615002855/https://www.guideline.gov/summaries/summary/51048/acg-clinical-guideline-management-of-patients-with-acute-lower-gastrointestinal-bleeding'}]
https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:31:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414013124/https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling'}, {'datetime': '2018-04-14T01:31:24Z', 'uri': 'http://web.archive.org/web/20180414013124/https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling'}, {'datetime': '2018-05-19T08:15:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519081510/https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling'}, {'datetime': '2018-05-19T08:15:10Z', 'uri': 'http://web.archive.org/web/20180519081510/https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling'}, {'datetime': '2018-06-09T19:03:54Z', 'uri': 'http://web.archive.org/web/20180609190354/https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling'}, {'datetime': '2018-06-14T22:26:11Z', 'uri': 'http://web.archive.org/web/20180614222611/https://www.guideline.gov/summaries/summary/51050/final-recommendation-statement-healthful-diet-and-physical-activity-for-cardiovascular-disease-prevention-in-adults-without-known-risk-factors-behavioral-counseling'}]
https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:30:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414013056/https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:30:56Z', 'uri': 'http://web.archive.org/web/20180414013056/https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:14:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519081441/https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:14:41Z', 'uri': 'http://web.archive.org/web/20180519081441/https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-09T15:13:12Z', 'uri': 'http://web.archive.org/web/20180609151312/https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-14T22:24:48Z', 'uri': 'http://web.archive.org/web/20180614222448/https://www.guideline.gov/summaries/summary/51051/1-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/51052/gestational-diabetes-mellitus-evidencebased-nutrition-practice-guideline	ARCHIVED	5 mementos	[{'datetime': '2018-04-14T01:30:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414013046/https://www.guideline.gov/summaries/summary/51052/gestational-diabetes-mellitus-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-04-14T01:30:46Z', 'uri': 'http://web.archive.org/web/20180414013046/https://www.guideline.gov/summaries/summary/51052/gestational-diabetes-mellitus-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T08:14:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519081430/https://www.guideline.gov/summaries/summary/51052/gestational-diabetes-mellitus-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-05-19T08:14:30Z', 'uri': 'http://web.archive.org/web/20180519081430/https://www.guideline.gov/summaries/summary/51052/gestational-diabetes-mellitus-evidencebased-nutrition-practice-guideline'}, {'datetime': '2018-06-09T20:07:13Z', 'uri': 'http://web.archive.org/web/20180609200713/https://www.guideline.gov/summaries/summary/51052/gestational-diabetes-mellitus-evidencebased-nutrition-practice-guideline'}]
https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:31:05Z', 'uri': 'http://wayback.archive-it.org/all/20180414013105/https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults'}, {'datetime': '2018-04-14T01:31:05Z', 'uri': 'http://web.archive.org/web/20180414013105/https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults'}, {'datetime': '2018-05-19T08:14:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519081451/https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults'}, {'datetime': '2018-05-19T08:14:51Z', 'uri': 'http://web.archive.org/web/20180519081451/https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults'}, {'datetime': '2018-06-09T12:09:56Z', 'uri': 'http://web.archive.org/web/20180609120956/https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults'}, {'datetime': '2018-06-14T22:24:28Z', 'uri': 'http://web.archive.org/web/20180614222428/https://www.guideline.gov/summaries/summary/51053/parkinsons-disease-in-adults'}]
https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:30:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414013038/https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children'}, {'datetime': '2018-04-14T01:30:38Z', 'uri': 'http://web.archive.org/web/20180414013038/https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children'}, {'datetime': '2018-05-19T08:14:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519081421/https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children'}, {'datetime': '2018-05-19T08:14:21Z', 'uri': 'http://web.archive.org/web/20180519081421/https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children'}, {'datetime': '2018-06-09T21:35:03Z', 'uri': 'http://web.archive.org/web/20180609213503/https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children'}, {'datetime': '2018-06-14T23:18:58Z', 'uri': 'http://web.archive.org/web/20180614231858/https://www.guideline.gov/summaries/summary/51054/clostridium-difficile-infection-in-adults-and-children'}]
https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer	ARCHIVED	8 mementos	[{'datetime': '2018-04-14T01:30:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414013030/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-04-14T01:30:30Z', 'uri': 'http://web.archive.org/web/20180414013030/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-05-19T08:14:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519081412/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-05-19T08:14:12Z', 'uri': 'http://web.archive.org/web/20180519081412/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-06-09T11:52:18Z', 'uri': 'http://web.archive.org/web/20180609115218/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-06-14T22:24:40Z', 'uri': 'http://web.archive.org/web/20180614222440/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-07-12T22:00:52Z', 'uri': 'http://web.archive.org/web/20180712220052/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}, {'datetime': '2018-07-12T22:00:52Z', 'uri': 'http://web.archive.org/web/20180712220052/https://www.guideline.gov/summaries/summary/51055/systemic-therapy-for-recurrent-epithelial-ovarian-cancer'}]
https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:28:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414012825/https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice'}, {'datetime': '2018-04-14T01:28:25Z', 'uri': 'http://web.archive.org/web/20180414012825/https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice'}, {'datetime': '2018-05-19T08:12:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519081206/https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice'}, {'datetime': '2018-05-19T08:12:06Z', 'uri': 'http://web.archive.org/web/20180519081206/https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice'}, {'datetime': '2018-06-09T23:34:37Z', 'uri': 'http://web.archive.org/web/20180609233437/https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice'}, {'datetime': '2018-06-14T22:31:31Z', 'uri': 'http://web.archive.org/web/20180614223131/https://www.guideline.gov/summaries/summary/51056/integrating-tobacco-interventions-into-daily-practice'}]
https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:30:20Z', 'uri': 'http://wayback.archive-it.org/all/20180414013020/https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm'}, {'datetime': '2018-04-14T01:30:20Z', 'uri': 'http://web.archive.org/web/20180414013020/https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm'}, {'datetime': '2018-05-19T08:14:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519081400/https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm'}, {'datetime': '2018-05-19T08:14:00Z', 'uri': 'http://web.archive.org/web/20180519081400/https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm'}, {'datetime': '2018-06-08T18:43:29Z', 'uri': 'http://web.archive.org/web/20180608184329/https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm'}, {'datetime': '2018-06-09T12:12:25Z', 'uri': 'http://web.archive.org/web/20180609121225/https://www.guideline.gov/summaries/summary/51057/developmental-followup-of-children-and-young-people-born-preterm'}]
https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:28:53Z', 'uri': 'http://wayback.archive-it.org/all/20180414012853/https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update'}, {'datetime': '2018-04-14T01:28:53Z', 'uri': 'http://web.archive.org/web/20180414012853/https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update'}, {'datetime': '2018-05-19T08:12:34Z', 'uri': 'http://wayback.archive-it.org/all/20180519081234/https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update'}, {'datetime': '2018-05-19T08:12:34Z', 'uri': 'http://web.archive.org/web/20180519081234/https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update'}, {'datetime': '2018-06-09T12:18:57Z', 'uri': 'http://web.archive.org/web/20180609121857/https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update'}, {'datetime': '2018-06-14T22:26:27Z', 'uri': 'http://web.archive.org/web/20180614222627/https://www.guideline.gov/summaries/summary/51058/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-and-cyp2c19-genotypes-and-dosing-of-tricyclic-antidepressants-2016-update'}]
https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:29:23Z', 'uri': 'http://wayback.archive-it.org/all/20180414012923/https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron'}, {'datetime': '2018-04-14T01:29:23Z', 'uri': 'http://web.archive.org/web/20180414012923/https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron'}, {'datetime': '2018-05-19T08:13:04Z', 'uri': 'http://wayback.archive-it.org/all/20180519081304/https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron'}, {'datetime': '2018-05-19T08:13:04Z', 'uri': 'http://web.archive.org/web/20180519081304/https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron'}, {'datetime': '2018-06-08T18:43:48Z', 'uri': 'http://web.archive.org/web/20180608184348/https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron'}, {'datetime': '2018-06-09T20:11:03Z', 'uri': 'http://web.archive.org/web/20180609201103/https://www.guideline.gov/summaries/summary/51059/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-cyp2d6-genotype-and-use-of-ondansetron-and-tropisetron'}]
https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:29:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414012951/https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy'}, {'datetime': '2018-04-14T01:29:51Z', 'uri': 'http://web.archive.org/web/20180414012951/https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy'}, {'datetime': '2018-05-19T08:13:32Z', 'uri': 'http://wayback.archive-it.org/all/20180519081332/https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy'}, {'datetime': '2018-05-19T08:13:32Z', 'uri': 'http://web.archive.org/web/20180519081332/https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy'}, {'datetime': '2018-06-09T20:11:23Z', 'uri': 'http://web.archive.org/web/20180609201123/https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy'}, {'datetime': '2018-06-14T22:26:46Z', 'uri': 'http://web.archive.org/web/20180614222646/https://www.guideline.gov/summaries/summary/51060/clinical-pharmacogenetics-implementation-consortium-cpic-guidelines-for-cyp2c19-and-voriconazole-therapy'}]
https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T00:52:44Z', 'uri': 'http://wayback.archive-it.org/all/20180414005244/https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings'}, {'datetime': '2018-04-14T00:52:44Z', 'uri': 'http://web.archive.org/web/20180414005244/https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings'}, {'datetime': '2018-05-19T07:31:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519073111/https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings'}, {'datetime': '2018-05-19T07:31:11Z', 'uri': 'http://web.archive.org/web/20180519073111/https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings'}, {'datetime': '2018-06-09T11:31:23Z', 'uri': 'http://web.archive.org/web/20180609113123/https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings'}, {'datetime': '2018-06-14T22:28:57Z', 'uri': 'http://web.archive.org/web/20180614222857/https://www.guideline.gov/summaries/summary/51061/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings'}]
https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T00:53:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414005316/https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update'}, {'datetime': '2018-04-14T00:53:16Z', 'uri': 'http://web.archive.org/web/20180414005316/https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update'}, {'datetime': '2018-05-19T07:31:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519073143/https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update'}, {'datetime': '2018-05-19T07:31:43Z', 'uri': 'http://web.archive.org/web/20180519073143/https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update'}, {'datetime': '2018-06-10T00:53:01Z', 'uri': 'http://web.archive.org/web/20180610005301/https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update'}, {'datetime': '2018-06-14T22:28:28Z', 'uri': 'http://web.archive.org/web/20180614222828/https://www.guideline.gov/summaries/summary/51062/guideline-for-the-management-of-fever-and-neutropenia-in-children-with-cancer-and-hematopoietic-stemcell-transplantation-recipients-2017-update'}]
https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:27:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414012728/https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T01:27:28Z', 'uri': 'http://web.archive.org/web/20180414012728/https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:11:11Z', 'uri': 'http://wayback.archive-it.org/all/20180519081111/https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:11:11Z', 'uri': 'http://web.archive.org/web/20180519081111/https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-10T22:17:37Z', 'uri': 'http://web.archive.org/web/20180610221737/https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-14T22:37:34Z', 'uri': 'http://web.archive.org/web/20180614223734/https://www.guideline.gov/summaries/summary/51063/management-of-children-with-chronic-wet-cough-and-protracted-bacterial-bronchitis-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:27:57Z', 'uri': 'http://wayback.archive-it.org/all/20180414012757/https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-04-14T01:27:57Z', 'uri': 'http://web.archive.org/web/20180414012757/https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:11:38Z', 'uri': 'http://wayback.archive-it.org/all/20180519081138/https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T08:11:38Z', 'uri': 'http://web.archive.org/web/20180519081138/https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T20:12:22Z', 'uri': 'http://web.archive.org/web/20180609201222/https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-14T22:38:33Z', 'uri': 'http://web.archive.org/web/20180614223833/https://www.guideline.gov/summaries/summary/51064/use-of-management-pathways-or-algorithms-in-children-with-chronic-cough-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T00:52:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414005216/https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons'}, {'datetime': '2018-04-14T00:52:16Z', 'uri': 'http://web.archive.org/web/20180414005216/https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons'}, {'datetime': '2018-05-19T07:30:44Z', 'uri': 'http://wayback.archive-it.org/all/20180519073044/https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons'}, {'datetime': '2018-05-19T07:30:44Z', 'uri': 'http://web.archive.org/web/20180519073044/https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons'}, {'datetime': '2018-06-09T19:16:21Z', 'uri': 'http://web.archive.org/web/20180609191621/https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons'}, {'datetime': '2018-06-14T22:24:09Z', 'uri': 'http://web.archive.org/web/20180614222409/https://www.guideline.gov/summaries/summary/51065/clinical-practice-guidelines-for-enhanced-recovery-after-colon-and-rectal-surgery-from-the-american-society-of-colon-and-rectal-surgeons-and-society-of-american-gastrointestinal-and-endoscopic-surgeons'}]
https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:23:27Z', 'uri': 'http://wayback.archive-it.org/all/20180414012327/https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update'}, {'datetime': '2018-04-14T01:23:27Z', 'uri': 'http://web.archive.org/web/20180414012327/https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update'}, {'datetime': '2018-05-19T08:07:46Z', 'uri': 'http://wayback.archive-it.org/all/20180519080746/https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update'}, {'datetime': '2018-05-19T08:07:46Z', 'uri': 'http://web.archive.org/web/20180519080746/https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update'}, {'datetime': '2018-06-08T18:35:58Z', 'uri': 'http://web.archive.org/web/20180608183558/https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update'}, {'datetime': '2018-06-09T20:18:43Z', 'uri': 'http://web.archive.org/web/20180609201843/https://www.guideline.gov/summaries/summary/51066/guideline-for-the-prevention-of-acute-chemotherapyinduced-nausea-and-vomiting-in-pediatric-cancer-patients-a-focused-update'}]
https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:22:58Z', 'uri': 'http://wayback.archive-it.org/all/20180414012258/https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women'}, {'datetime': '2018-04-14T01:22:58Z', 'uri': 'http://web.archive.org/web/20180414012258/https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women'}, {'datetime': '2018-05-19T08:07:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519080717/https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women'}, {'datetime': '2018-05-19T08:07:17Z', 'uri': 'http://web.archive.org/web/20180519080717/https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women'}, {'datetime': '2018-06-08T18:43:13Z', 'uri': 'http://web.archive.org/web/20180608184313/https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women'}, {'datetime': '2018-06-09T23:59:01Z', 'uri': 'http://web.archive.org/web/20180609235901/https://www.guideline.gov/summaries/summary/51067/1-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-earlystage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-2-use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women'}]
https://www.guideline.gov/summaries/summary/51068/cumulative-trauma-conditions-medical-treatment-guidelines	ARCHIVED	1 mementos	[{'datetime': '2018-05-19T07:50:17Z', 'uri': 'http://wayback.archive-it.org/all/20180519075017/https://www.guideline.gov/summaries/summary/51068/cumulative-trauma-conditions-medical-treatment-guidelines'}]
https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline	ARCHIVED	7 mementos	[{'datetime': '2018-04-14T01:22:30Z', 'uri': 'http://wayback.archive-it.org/all/20180414012230/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-04-14T01:22:30Z', 'uri': 'http://web.archive.org/web/20180414012230/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-05-19T08:06:43Z', 'uri': 'http://wayback.archive-it.org/all/20180519080643/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-05-19T08:06:43Z', 'uri': 'http://web.archive.org/web/20180519080643/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-08T18:43:00Z', 'uri': 'http://web.archive.org/web/20180608184300/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-08T18:43:04Z', 'uri': 'http://web.archive.org/web/20180608184304/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}, {'datetime': '2018-06-10T01:14:49Z', 'uri': 'http://web.archive.org/web/20180610011449/https://www.guideline.gov/summaries/summary/51069/stereotactic-body-radiation-therapy-for-earlystage-nonsmall-cell-lung-cancer-executive-summary-of-an-astro-evidencebased-guideline'}]
https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:21:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414012110/https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care'}, {'datetime': '2018-04-14T01:21:10Z', 'uri': 'http://web.archive.org/web/20180414012110/https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care'}, {'datetime': '2018-05-19T08:05:23Z', 'uri': 'http://wayback.archive-it.org/all/20180519080523/https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care'}, {'datetime': '2018-05-19T08:05:23Z', 'uri': 'http://web.archive.org/web/20180519080523/https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care'}, {'datetime': '2018-06-08T18:36:16Z', 'uri': 'http://web.archive.org/web/20180608183616/https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care'}, {'datetime': '2018-06-10T00:27:30Z', 'uri': 'http://web.archive.org/web/20180610002730/https://www.guideline.gov/summaries/summary/51081/recommendations-on-screening-for-abdominal-aortic-aneurysm-in-primary-care'}]
https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:21:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414012137/https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-04-14T01:21:37Z', 'uri': 'http://web.archive.org/web/20180414012137/https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:05:51Z', 'uri': 'http://wayback.archive-it.org/all/20180519080551/https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-05-19T08:05:51Z', 'uri': 'http://web.archive.org/web/20180519080551/https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-08T18:43:56Z', 'uri': 'http://web.archive.org/web/20180608184356/https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T21:44:31Z', 'uri': 'http://web.archive.org/web/20180609214431/https://www.guideline.gov/summaries/summary/51082/surgical-management-of-pancreatic-necrosis-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:22:01Z', 'uri': 'http://wayback.archive-it.org/all/20180414012201/https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management'}, {'datetime': '2018-04-14T01:22:01Z', 'uri': 'http://web.archive.org/web/20180414012201/https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management'}, {'datetime': '2018-05-19T08:06:14Z', 'uri': 'http://wayback.archive-it.org/all/20180519080614/https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management'}, {'datetime': '2018-05-19T08:06:14Z', 'uri': 'http://web.archive.org/web/20180519080614/https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management'}, {'datetime': '2018-06-08T18:36:26Z', 'uri': 'http://web.archive.org/web/20180608183626/https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management'}, {'datetime': '2018-06-10T19:09:17Z', 'uri': 'http://web.archive.org/web/20180610190917/https://www.guideline.gov/summaries/summary/51083/endometriosis-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:19:46Z', 'uri': 'http://wayback.archive-it.org/all/20180414011946/https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017'}, {'datetime': '2018-04-14T01:19:46Z', 'uri': 'http://web.archive.org/web/20180414011946/https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017'}, {'datetime': '2018-05-19T08:04:00Z', 'uri': 'http://wayback.archive-it.org/all/20180519080400/https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017'}, {'datetime': '2018-05-19T08:04:00Z', 'uri': 'http://web.archive.org/web/20180519080400/https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017'}, {'datetime': '2018-06-09T11:50:38Z', 'uri': 'http://web.archive.org/web/20180609115038/https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017'}, {'datetime': '2018-06-14T22:24:56Z', 'uri': 'http://web.archive.org/web/20180614222456/https://www.guideline.gov/summaries/summary/51084/neck-pain-revision-2017'}]
https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:18:47Z', 'uri': 'http://wayback.archive-it.org/all/20180414011847/https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline'}, {'datetime': '2018-04-14T01:18:47Z', 'uri': 'http://web.archive.org/web/20180414011847/https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline'}, {'datetime': '2018-05-19T08:03:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519080301/https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline'}, {'datetime': '2018-05-19T08:03:01Z', 'uri': 'http://web.archive.org/web/20180519080301/https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline'}, {'datetime': '2018-06-09T22:23:50Z', 'uri': 'http://web.archive.org/web/20180609222350/https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline'}, {'datetime': '2018-06-14T22:38:11Z', 'uri': 'http://web.archive.org/web/20180614223811/https://www.guideline.gov/summaries/summary/51085/renal-mass-and-localized-renal-cancer-aua-guideline'}]
https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:16:56Z', 'uri': 'http://wayback.archive-it.org/all/20180414011656/https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline'}, {'datetime': '2018-04-14T01:16:56Z', 'uri': 'http://web.archive.org/web/20180414011656/https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline'}, {'datetime': '2018-05-19T08:01:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519080110/https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline'}, {'datetime': '2018-05-19T08:01:10Z', 'uri': 'http://web.archive.org/web/20180519080110/https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline'}, {'datetime': '2018-06-09T21:18:38Z', 'uri': 'http://web.archive.org/web/20180609211838/https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline'}, {'datetime': '2018-06-14T22:37:47Z', 'uri': 'http://web.archive.org/web/20180614223747/https://www.guideline.gov/summaries/summary/51086/performing-the-embryo-transfer-a-guideline'}]
https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:17:24Z', 'uri': 'http://wayback.archive-it.org/all/20180414011724/https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline'}, {'datetime': '2018-04-14T01:17:24Z', 'uri': 'http://web.archive.org/web/20180414011724/https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline'}, {'datetime': '2018-05-19T08:01:37Z', 'uri': 'http://wayback.archive-it.org/all/20180519080137/https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline'}, {'datetime': '2018-05-19T08:01:37Z', 'uri': 'http://web.archive.org/web/20180519080137/https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline'}, {'datetime': '2018-06-08T18:37:51Z', 'uri': 'http://web.archive.org/web/20180608183751/https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline'}, {'datetime': '2018-06-09T21:18:30Z', 'uri': 'http://web.archive.org/web/20180609211830/https://www.guideline.gov/summaries/summary/51087/removal-of-myomas-in-asymptomatic-patients-to-improve-fertility-andor-reduce-miscarriage-rate-a-guideline'}]
https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:17:51Z', 'uri': 'http://wayback.archive-it.org/all/20180414011751/https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline'}, {'datetime': '2018-04-14T01:17:51Z', 'uri': 'http://web.archive.org/web/20180414011751/https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline'}, {'datetime': '2018-05-19T08:02:06Z', 'uri': 'http://wayback.archive-it.org/all/20180519080206/https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline'}, {'datetime': '2018-05-19T08:02:06Z', 'uri': 'http://web.archive.org/web/20180519080206/https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline'}, {'datetime': '2018-06-08T18:42:43Z', 'uri': 'http://web.archive.org/web/20180608184243/https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline'}, {'datetime': '2018-06-09T21:18:25Z', 'uri': 'http://web.archive.org/web/20180609211825/https://www.guideline.gov/summaries/summary/51088/role-of-metformin-for-ovulation-induction-in-infertile-patients-with-polycystic-ovary-syndrome-pcos-a-guideline'}]
https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:20:41Z', 'uri': 'http://wayback.archive-it.org/all/20180414012041/https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception'}, {'datetime': '2018-04-14T01:20:41Z', 'uri': 'http://web.archive.org/web/20180414012041/https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception'}, {'datetime': '2018-05-19T08:04:55Z', 'uri': 'http://wayback.archive-it.org/all/20180519080455/https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception'}, {'datetime': '2018-05-19T08:04:55Z', 'uri': 'http://web.archive.org/web/20180519080455/https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception'}, {'datetime': '2018-06-09T20:25:43Z', 'uri': 'http://web.archive.org/web/20180609202543/https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception'}, {'datetime': '2018-06-14T22:37:23Z', 'uri': 'http://web.archive.org/web/20180614223723/https://www.guideline.gov/summaries/summary/51089/quick-starting-contraception'}]
https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:18:19Z', 'uri': 'http://wayback.archive-it.org/all/20180414011819/https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:18:19Z', 'uri': 'http://web.archive.org/web/20180414011819/https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:02:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519080233/https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T08:02:33Z', 'uri': 'http://web.archive.org/web/20180519080233/https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update'}, {'datetime': '2018-06-08T18:38:14Z', 'uri': 'http://web.archive.org/web/20180608183814/https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T00:05:04Z', 'uri': 'http://web.archive.org/web/20180610000504/https://www.guideline.gov/summaries/summary/51116/adjuvant-systemic-therapy-and-adjuvant-radiation-therapy-for-stage-i-to-iiia-completely-resected-non-smallcell-lung-cancers-american-society-of-clinical-oncologycancer-care-ontario-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:19:16Z', 'uri': 'http://wayback.archive-it.org/all/20180414011916/https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017'}, {'datetime': '2018-04-14T01:19:16Z', 'uri': 'http://web.archive.org/web/20180414011916/https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017'}, {'datetime': '2018-05-19T08:03:30Z', 'uri': 'http://wayback.archive-it.org/all/20180519080330/https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017'}, {'datetime': '2018-05-19T08:03:30Z', 'uri': 'http://web.archive.org/web/20180519080330/https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017'}, {'datetime': '2018-06-08T18:42:52Z', 'uri': 'http://web.archive.org/web/20180608184252/https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017'}, {'datetime': '2018-06-09T19:39:51Z', 'uri': 'http://web.archive.org/web/20180609193951/https://www.guideline.gov/summaries/summary/51117/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017'}]
https://www.guideline.gov/summaries/summary/51118/emergency-contraception	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:20:14Z', 'uri': 'http://wayback.archive-it.org/all/20180414012014/https://www.guideline.gov/summaries/summary/51118/emergency-contraception'}, {'datetime': '2018-04-14T01:20:14Z', 'uri': 'http://web.archive.org/web/20180414012014/https://www.guideline.gov/summaries/summary/51118/emergency-contraception'}, {'datetime': '2018-05-19T08:04:28Z', 'uri': 'http://wayback.archive-it.org/all/20180519080428/https://www.guideline.gov/summaries/summary/51118/emergency-contraception'}, {'datetime': '2018-05-19T08:04:28Z', 'uri': 'http://web.archive.org/web/20180519080428/https://www.guideline.gov/summaries/summary/51118/emergency-contraception'}, {'datetime': '2018-06-08T16:21:31Z', 'uri': 'http://web.archive.org/web/20180608162131/https://www.guideline.gov/summaries/summary/51118/emergency-contraception'}, {'datetime': '2018-06-09T11:53:05Z', 'uri': 'http://web.archive.org/web/20180609115305/https://www.guideline.gov/summaries/summary/51118/emergency-contraception'}]
https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:11:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414011110/https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults'}, {'datetime': '2018-04-14T01:11:10Z', 'uri': 'http://web.archive.org/web/20180414011110/https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults'}, {'datetime': '2018-05-19T07:56:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519075626/https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults'}, {'datetime': '2018-05-19T07:56:26Z', 'uri': 'http://web.archive.org/web/20180519075626/https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults'}, {'datetime': '2018-06-08T18:40:02Z', 'uri': 'http://web.archive.org/web/20180608184002/https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults'}, {'datetime': '2018-06-09T21:31:32Z', 'uri': 'http://web.archive.org/web/20180609213132/https://www.guideline.gov/summaries/summary/51119/clinical-practice-guideline-evaluation-of-the-neck-mass-in-adults'}]
https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:12:09Z', 'uri': 'http://wayback.archive-it.org/all/20180414011209/https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease'}, {'datetime': '2018-04-14T01:12:09Z', 'uri': 'http://web.archive.org/web/20180414011209/https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease'}, {'datetime': '2018-05-19T07:57:26Z', 'uri': 'http://wayback.archive-it.org/all/20180519075726/https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease'}, {'datetime': '2018-05-19T07:57:26Z', 'uri': 'http://web.archive.org/web/20180519075726/https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease'}, {'datetime': '2018-06-08T18:40:58Z', 'uri': 'http://web.archive.org/web/20180608184058/https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease'}, {'datetime': '2018-06-09T21:44:48Z', 'uri': 'http://web.archive.org/web/20180609214448/https://www.guideline.gov/summaries/summary/51120/american-gastroenterological-association-institute-guideline-on-therapeutic-drug-monitoring-in-inflammatory-bowel-disease'}]
https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:11:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414011139/https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline'}, {'datetime': '2018-04-14T01:11:39Z', 'uri': 'http://web.archive.org/web/20180414011139/https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline'}, {'datetime': '2018-05-19T07:56:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519075656/https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline'}, {'datetime': '2018-05-19T07:56:56Z', 'uri': 'http://web.archive.org/web/20180519075656/https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline'}, {'datetime': '2018-06-09T22:23:44Z', 'uri': 'http://web.archive.org/web/20180609222344/https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline'}, {'datetime': '2018-06-14T22:42:49Z', 'uri': 'http://web.archive.org/web/20180614224249/https://www.guideline.gov/summaries/summary/51121/treatment-of-nonmetastatic-muscleinvasive-bladder-cancer-auaascoastrosuo-guideline'}]
https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:16:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414011625/https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children'}, {'datetime': '2018-04-14T01:16:25Z', 'uri': 'http://web.archive.org/web/20180414011625/https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children'}, {'datetime': '2018-05-19T08:00:40Z', 'uri': 'http://wayback.archive-it.org/all/20180519080040/https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children'}, {'datetime': '2018-05-19T08:00:40Z', 'uri': 'http://web.archive.org/web/20180519080040/https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children'}, {'datetime': '2018-06-08T18:36:06Z', 'uri': 'http://web.archive.org/web/20180608183606/https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children'}, {'datetime': '2018-06-09T22:28:32Z', 'uri': 'http://web.archive.org/web/20180609222832/https://www.guideline.gov/summaries/summary/51122/faltering-growth-recognition-and-management-of-faltering-growth-in-children'}]
https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:08:38Z', 'uri': 'http://wayback.archive-it.org/all/20180414010838/https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice'}, {'datetime': '2018-04-14T01:08:38Z', 'uri': 'http://web.archive.org/web/20180414010838/https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice'}, {'datetime': '2018-05-19T07:54:05Z', 'uri': 'http://wayback.archive-it.org/all/20180519075405/https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice'}, {'datetime': '2018-05-19T07:54:05Z', 'uri': 'http://web.archive.org/web/20180519075405/https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice'}, {'datetime': '2018-06-10T01:39:11Z', 'uri': 'http://web.archive.org/web/20180610013911/https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice'}, {'datetime': '2018-06-14T22:29:14Z', 'uri': 'http://web.archive.org/web/20180614222914/https://www.guideline.gov/summaries/summary/51124/cancerrelated-acute-pain-a-systematic-review-of-evidencebased-interventions-for-putting-evidence-into-practice'}]
https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:09:10Z', 'uri': 'http://wayback.archive-it.org/all/20180414010910/https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology'}, {'datetime': '2018-04-14T01:09:10Z', 'uri': 'http://web.archive.org/web/20180414010910/https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology'}, {'datetime': '2018-05-19T07:54:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519075433/https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology'}, {'datetime': '2018-05-19T07:54:33Z', 'uri': 'http://web.archive.org/web/20180519075433/https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology'}, {'datetime': '2018-06-10T02:07:07Z', 'uri': 'http://web.archive.org/web/20180610020707/https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology'}, {'datetime': '2018-06-14T22:31:42Z', 'uri': 'http://web.archive.org/web/20180614223142/https://www.guideline.gov/summaries/summary/51125/chronic-and-refractory-pain-a-systematic-review-of-pharmacologic-management-in-oncology'}]
https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:08:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414010811/https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management'}, {'datetime': '2018-04-14T01:08:11Z', 'uri': 'http://web.archive.org/web/20180414010811/https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management'}, {'datetime': '2018-05-19T07:53:39Z', 'uri': 'http://wayback.archive-it.org/all/20180519075339/https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management'}, {'datetime': '2018-05-19T07:53:39Z', 'uri': 'http://web.archive.org/web/20180519075339/https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management'}, {'datetime': '2018-06-10T02:07:01Z', 'uri': 'http://web.archive.org/web/20180610020701/https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management'}, {'datetime': '2018-06-14T22:31:52Z', 'uri': 'http://web.archive.org/web/20180614223152/https://www.guideline.gov/summaries/summary/51126/breakthrough-cancer-pain-a-systematic-review-of-pharmacologic-management'}]
https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:09:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414010939/https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain'}, {'datetime': '2018-04-14T01:09:39Z', 'uri': 'http://web.archive.org/web/20180414010939/https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain'}, {'datetime': '2018-05-19T07:55:01Z', 'uri': 'http://wayback.archive-it.org/all/20180519075501/https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain'}, {'datetime': '2018-05-19T07:55:01Z', 'uri': 'http://web.archive.org/web/20180519075501/https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain'}, {'datetime': '2018-06-09T22:06:13Z', 'uri': 'http://web.archive.org/web/20180609220613/https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain'}, {'datetime': '2018-06-14T22:30:20Z', 'uri': 'http://web.archive.org/web/20180614223020/https://www.guideline.gov/summaries/summary/51127/nonpharmacologic-pain-interventions-a-review-of-evidencebased-practices-for-reducing-chronic-cancer-pain'}]
https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:15:25Z', 'uri': 'http://wayback.archive-it.org/all/20180414011525/https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update'}, {'datetime': '2018-04-14T01:15:25Z', 'uri': 'http://web.archive.org/web/20180414011525/https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update'}, {'datetime': '2018-05-19T07:59:42Z', 'uri': 'http://wayback.archive-it.org/all/20180519075942/https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update'}, {'datetime': '2018-05-19T07:59:42Z', 'uri': 'http://web.archive.org/web/20180519075942/https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update'}, {'datetime': '2018-06-08T18:40:16Z', 'uri': 'http://web.archive.org/web/20180608184016/https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update'}, {'datetime': '2018-06-09T20:11:14Z', 'uri': 'http://web.archive.org/web/20180609201114/https://www.guideline.gov/summaries/summary/51128/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-pharmacogeneticsguided-warfarin-dosing-2017-update'}]
https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:14:55Z', 'uri': 'http://wayback.archive-it.org/all/20180414011455/https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:14:55Z', 'uri': 'http://web.archive.org/web/20180414011455/https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T07:59:12Z', 'uri': 'http://wayback.archive-it.org/all/20180519075912/https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T07:59:12Z', 'uri': 'http://web.archive.org/web/20180519075912/https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-08T18:35:48Z', 'uri': 'http://web.archive.org/web/20180608183548/https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-10T23:03:34Z', 'uri': 'http://web.archive.org/web/20180610230334/https://www.guideline.gov/summaries/summary/51129/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:13:35Z', 'uri': 'http://wayback.archive-it.org/all/20180414011335/https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years'}, {'datetime': '2018-04-14T01:13:35Z', 'uri': 'http://web.archive.org/web/20180414011335/https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years'}, {'datetime': '2018-05-19T07:58:21Z', 'uri': 'http://wayback.archive-it.org/all/20180519075821/https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years'}, {'datetime': '2018-05-19T07:58:21Z', 'uri': 'http://web.archive.org/web/20180519075821/https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years'}, {'datetime': '2018-06-08T18:43:39Z', 'uri': 'http://web.archive.org/web/20180608184339/https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years'}, {'datetime': '2018-06-09T20:25:56Z', 'uri': 'http://web.archive.org/web/20180609202556/https://www.guideline.gov/summaries/summary/51130/contraception-for-women-aged-over-40-years'}]
https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:13:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414011306/https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology'}, {'datetime': '2018-04-14T01:13:06Z', 'uri': 'http://web.archive.org/web/20180414011306/https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology'}, {'datetime': '2018-05-19T07:57:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519075753/https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology'}, {'datetime': '2018-05-19T07:57:53Z', 'uri': 'http://web.archive.org/web/20180519075753/https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology'}, {'datetime': '2018-06-08T18:35:39Z', 'uri': 'http://web.archive.org/web/20180608183539/https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology'}, {'datetime': '2018-06-09T21:08:45Z', 'uri': 'http://web.archive.org/web/20180609210845/https://www.guideline.gov/summaries/summary/51131/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology'}]
https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:14:03Z', 'uri': 'http://wayback.archive-it.org/all/20180414011403/https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn'}, {'datetime': '2018-04-14T01:14:03Z', 'uri': 'http://web.archive.org/web/20180414011403/https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn'}, {'datetime': '2018-05-18T19:32:50Z', 'uri': 'http://wayback.archive-it.org/all/20180518193250/https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn'}, {'datetime': '2018-05-18T19:32:50Z', 'uri': 'http://web.archive.org/web/20180518193250/https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn'}, {'datetime': '2018-06-09T10:39:52Z', 'uri': 'http://web.archive.org/web/20180609103952/https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn'}, {'datetime': '2018-06-14T22:38:41Z', 'uri': 'http://web.archive.org/web/20180614223841/https://www.guideline.gov/summaries/summary/51132/practice-advisory-for-the-prevention-diagnosis-and-management-of-infectious-complications-associated-with-neuraxial-techniques-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-infectious-complications-associated-with-neuraxial-techn'}]
https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force	ARCHIVED	7 mementos	[{'datetime': '2018-04-14T01:14:28Z', 'uri': 'http://wayback.archive-it.org/all/20180414011428/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}, {'datetime': '2018-04-14T01:14:28Z', 'uri': 'http://web.archive.org/web/20180414011428/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}, {'datetime': '2018-05-19T07:58:48Z', 'uri': 'http://wayback.archive-it.org/all/20180519075848/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}, {'datetime': '2018-05-19T07:58:48Z', 'uri': 'http://web.archive.org/web/20180519075848/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}, {'datetime': '2018-06-09T20:56:50Z', 'uri': 'http://web.archive.org/web/20180609205650/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}, {'datetime': '2018-06-14T22:40:01Z', 'uri': 'http://web.archive.org/web/20180614224001/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}, {'datetime': '2018-06-14T22:40:08Z', 'uri': 'http://web.archive.org/web/20180614224008/https://www.guideline.gov/summaries/summary/51133/practice-guidelines-for-preoperative-fasting-and-the-use-of-pharmacologic-agents-to-reduce-the-risk-of-pulmonary-aspiration-application-to-healthy-patients-undergoing-elective-procedures-an-updated-report-by-the-american-society-of-anesthesiologists-task-force'}]
https://www.guideline.gov/summaries/summary/51134/vadod-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain	ARCHIVED	7 mementos	[{'datetime': '2018-04-13T17:02:06Z', 'uri': 'http://wayback.archive-it.org/all/20180413170206/https://www.guideline.gov/summaries/summary/51134/VADoD-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}, {'datetime': '2018-04-13T17:02:06Z', 'uri': 'http://web.archive.org/web/20180413170206/https://www.guideline.gov/summaries/summary/51134/VADoD-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}, {'datetime': '2018-05-18T19:26:01Z', 'uri': 'http://wayback.archive-it.org/all/20180518192601/https://www.guideline.gov/summaries/summary/51134/VADoD-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}, {'datetime': '2018-05-18T19:26:01Z', 'uri': 'http://web.archive.org/web/20180518192601/https://www.guideline.gov/summaries/summary/51134/VADoD-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}, {'datetime': '2018-06-01T14:51:19Z', 'uri': 'http://web.archive.org/web/20180601145119/https://www.guideline.gov/summaries/summary/51134/VADoD-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}, {'datetime': '2018-06-08T18:41:17Z', 'uri': 'http://web.archive.org/web/20180608184117/https://www.guideline.gov/summaries/summary/51134/vadod-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}, {'datetime': '2018-06-09T21:15:30Z', 'uri': 'http://web.archive.org/web/20180609211530/https://www.guideline.gov/summaries/summary/51134/vadod-clinical-practice-guideline-for-diagnosis-and-treatment-of-low-back-pain'}]
https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:07:11Z', 'uri': 'http://wayback.archive-it.org/all/20180414010711/https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation'}, {'datetime': '2018-04-14T01:07:11Z', 'uri': 'http://web.archive.org/web/20180414010711/https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation'}, {'datetime': '2018-05-19T07:53:10Z', 'uri': 'http://wayback.archive-it.org/all/20180519075310/https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation'}, {'datetime': '2018-05-19T07:53:10Z', 'uri': 'http://web.archive.org/web/20180519075310/https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation'}, {'datetime': '2018-06-08T18:37:43Z', 'uri': 'http://web.archive.org/web/20180608183743/https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation'}, {'datetime': '2018-06-09T11:25:10Z', 'uri': 'http://web.archive.org/web/20180609112510/https://www.guideline.gov/summaries/summary/51135/vadod-clinical-practice-guideline-for-rehabilitation-of-individuals-with-lower-limb-amputation'}]
https://www.guideline.gov/summaries/summary/51141/conscious-sedation-in-dentistry	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T22:00:04Z', 'uri': 'http://wayback.archive-it.org/all/20180518220004/https://www.guideline.gov/summaries/summary/51141/conscious-sedation-in-dentistry'}, {'datetime': '2018-05-18T22:00:04Z', 'uri': 'http://web.archive.org/web/20180518220004/https://www.guideline.gov/summaries/summary/51141/conscious-sedation-in-dentistry'}, {'datetime': '2018-06-09T20:56:18Z', 'uri': 'http://web.archive.org/web/20180609205618/https://www.guideline.gov/summaries/summary/51141/conscious-sedation-in-dentistry'}, {'datetime': '2018-06-14T22:29:24Z', 'uri': 'http://web.archive.org/web/20180614222924/https://www.guideline.gov/summaries/summary/51141/conscious-sedation-in-dentistry'}]
https://www.guideline.gov/summaries/summary/51142/oral-health-management-of-patients-at-risk-of-medicationrelated-osteonecrosis-of-the-jaw	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T22:00:32Z', 'uri': 'http://wayback.archive-it.org/all/20180518220032/https://www.guideline.gov/summaries/summary/51142/oral-health-management-of-patients-at-risk-of-medicationrelated-osteonecrosis-of-the-jaw'}, {'datetime': '2018-05-18T22:00:32Z', 'uri': 'http://web.archive.org/web/20180518220032/https://www.guideline.gov/summaries/summary/51142/oral-health-management-of-patients-at-risk-of-medicationrelated-osteonecrosis-of-the-jaw'}, {'datetime': '2018-06-09T21:22:51Z', 'uri': 'http://web.archive.org/web/20180609212251/https://www.guideline.gov/summaries/summary/51142/oral-health-management-of-patients-at-risk-of-medicationrelated-osteonecrosis-of-the-jaw'}, {'datetime': '2018-06-14T22:42:27Z', 'uri': 'http://web.archive.org/web/20180614224227/https://www.guideline.gov/summaries/summary/51142/oral-health-management-of-patients-at-risk-of-medicationrelated-osteonecrosis-of-the-jaw'}]
https://www.guideline.gov/summaries/summary/51172/diagnosis-and-treatment-of-osteoporosis	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:07:40Z', 'uri': 'http://wayback.archive-it.org/all/20180414010740/https://www.guideline.gov/summaries/summary/51172/diagnosis-and-treatment-of-osteoporosis'}, {'datetime': '2018-04-14T01:07:40Z', 'uri': 'http://web.archive.org/web/20180414010740/https://www.guideline.gov/summaries/summary/51172/diagnosis-and-treatment-of-osteoporosis'}, {'datetime': '2018-05-18T19:26:41Z', 'uri': 'http://wayback.archive-it.org/all/20180518192641/https://www.guideline.gov/summaries/summary/51172/Diagnosis-and-treatment-of-osteoporosis'}, {'datetime': '2018-05-18T19:26:41Z', 'uri': 'http://web.archive.org/web/20180518192641/https://www.guideline.gov/summaries/summary/51172/Diagnosis-and-treatment-of-osteoporosis'}, {'datetime': '2018-06-09T15:45:31Z', 'uri': 'http://web.archive.org/web/20180609154531/https://www.guideline.gov/summaries/summary/51172/diagnosis-and-treatment-of-osteoporosis'}, {'datetime': '2018-06-14T22:26:56Z', 'uri': 'http://web.archive.org/web/20180614222656/https://www.guideline.gov/summaries/summary/51172/diagnosis-and-treatment-of-osteoporosis'}]
https://www.guideline.gov/summaries/summary/51173/use-of-silver-diamine-fluoride-for-dental-caries-management-in-children-and-adolescents-including-those-with-special-health-care-needs	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T21:59:10Z', 'uri': 'http://wayback.archive-it.org/all/20180518215910/https://www.guideline.gov/summaries/summary/51173/use-of-silver-diamine-fluoride-for-dental-caries-management-in-children-and-adolescents-including-those-with-special-health-care-needs'}, {'datetime': '2018-05-18T21:59:10Z', 'uri': 'http://web.archive.org/web/20180518215910/https://www.guideline.gov/summaries/summary/51173/use-of-silver-diamine-fluoride-for-dental-caries-management-in-children-and-adolescents-including-those-with-special-health-care-needs'}, {'datetime': '2018-06-08T18:37:59Z', 'uri': 'http://web.archive.org/web/20180608183759/https://www.guideline.gov/summaries/summary/51173/use-of-silver-diamine-fluoride-for-dental-caries-management-in-children-and-adolescents-including-those-with-special-health-care-needs'}, {'datetime': '2018-06-09T21:13:11Z', 'uri': 'http://web.archive.org/web/20180609211311/https://www.guideline.gov/summaries/summary/51173/use-of-silver-diamine-fluoride-for-dental-caries-management-in-children-and-adolescents-including-those-with-special-health-care-needs'}]
https://www.guideline.gov/summaries/summary/51174/use-of-vital-pulp-therapies-in-primary-teeth-with-deep-caries-lesions	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T21:59:37Z', 'uri': 'http://wayback.archive-it.org/all/20180518215937/https://www.guideline.gov/summaries/summary/51174/use-of-vital-pulp-therapies-in-primary-teeth-with-deep-caries-lesions'}, {'datetime': '2018-05-18T21:59:37Z', 'uri': 'http://web.archive.org/web/20180518215937/https://www.guideline.gov/summaries/summary/51174/use-of-vital-pulp-therapies-in-primary-teeth-with-deep-caries-lesions'}, {'datetime': '2018-06-08T18:42:32Z', 'uri': 'http://web.archive.org/web/20180608184232/https://www.guideline.gov/summaries/summary/51174/use-of-vital-pulp-therapies-in-primary-teeth-with-deep-caries-lesions'}, {'datetime': '2018-06-10T00:13:59Z', 'uri': 'http://web.archive.org/web/20180610001359/https://www.guideline.gov/summaries/summary/51174/use-of-vital-pulp-therapies-in-primary-teeth-with-deep-caries-lesions'}]
https://www.guideline.gov/summaries/summary/51175/clinical-policy-emergency-department-management-of-patients-needing-reperfusion-therapy-for-acute-stsegment-elevation-myocardial-infarction	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:49:25Z', 'uri': 'http://wayback.archive-it.org/all/20180519074925/https://www.guideline.gov/summaries/summary/51175/clinical-policy-emergency-department-management-of-patients-needing-reperfusion-therapy-for-acute-stsegment-elevation-myocardial-infarction'}, {'datetime': '2018-05-19T07:49:25Z', 'uri': 'http://web.archive.org/web/20180519074925/https://www.guideline.gov/summaries/summary/51175/clinical-policy-emergency-department-management-of-patients-needing-reperfusion-therapy-for-acute-stsegment-elevation-myocardial-infarction'}, {'datetime': '2018-06-08T18:30:37Z', 'uri': 'http://web.archive.org/web/20180608183037/https://www.guideline.gov/summaries/summary/51175/clinical-policy-emergency-department-management-of-patients-needing-reperfusion-therapy-for-acute-stsegment-elevation-myocardial-infarction'}, {'datetime': '2018-06-09T11:23:19Z', 'uri': 'http://web.archive.org/web/20180609112319/https://www.guideline.gov/summaries/summary/51175/clinical-policy-emergency-department-management-of-patients-needing-reperfusion-therapy-for-acute-stsegment-elevation-myocardial-infarction'}]
https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:15:54Z', 'uri': 'http://wayback.archive-it.org/all/20180414011554/https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management'}, {'datetime': '2018-04-14T01:15:54Z', 'uri': 'http://web.archive.org/web/20180414011554/https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management'}, {'datetime': '2018-05-19T08:00:09Z', 'uri': 'http://wayback.archive-it.org/all/20180519080009/https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management'}, {'datetime': '2018-05-19T08:00:09Z', 'uri': 'http://web.archive.org/web/20180519080009/https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management'}, {'datetime': '2018-06-08T18:34:14Z', 'uri': 'http://web.archive.org/web/20180608183414/https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management'}, {'datetime': '2018-06-09T22:28:13Z', 'uri': 'http://web.archive.org/web/20180609222813/https://www.guideline.gov/summaries/summary/51176/cystic-fibrosis-diagnosis-and-management'}]
https://www.guideline.gov/summaries/summary/51177/clinical-practice-guideline-for-the-treatment-of-posttraumatic-stress-disorder-ptsd-in-adults	ARCHIVED	5 mementos	[{'datetime': '2018-05-18T19:35:43Z', 'uri': 'http://wayback.archive-it.org/all/20180518193543/https://www.guideline.gov/summaries/summary/51177/clinical-practice-guideline-for-the-treatment-of-posttraumatic-stress-disorder-ptsd-in-adults'}, {'datetime': '2018-05-18T19:35:43Z', 'uri': 'http://web.archive.org/web/20180518193543/https://www.guideline.gov/summaries/summary/51177/clinical-practice-guideline-for-the-treatment-of-posttraumatic-stress-disorder-ptsd-in-adults'}, {'datetime': '2018-06-09T12:11:45Z', 'uri': 'http://web.archive.org/web/20180609121145/https://www.guideline.gov/summaries/summary/51177/clinical-practice-guideline-for-the-treatment-of-posttraumatic-stress-disorder-ptsd-in-adults'}, {'datetime': '2018-06-14T22:47:02Z', 'uri': 'http://web.archive.org/web/20180614224702/https://www.guideline.gov/summaries/summary/51177/clinical-practice-guideline-for-the-treatment-of-posttraumatic-stress-disorder-ptsd-in-adults'}, {'datetime': '2018-06-22T18:57:49Z', 'uri': 'http://web.archive.org/web/20180622185749/https://www.guideline.gov/summaries/summary/51177/Clinical-practice-guideline-for-the-treatment-of-posttraumatic-stress-disorder-PTSD-in-adults'}]
https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:12:37Z', 'uri': 'http://wayback.archive-it.org/all/20180414011237/https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management'}, {'datetime': '2018-04-14T01:12:37Z', 'uri': 'http://web.archive.org/web/20180414011237/https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management'}, {'datetime': '2018-05-18T19:30:42Z', 'uri': 'http://wayback.archive-it.org/all/20180518193042/https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management'}, {'datetime': '2018-05-18T19:30:42Z', 'uri': 'http://web.archive.org/web/20180518193042/https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management'}, {'datetime': '2018-06-08T18:34:05Z', 'uri': 'http://web.archive.org/web/20180608183405/https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management'}, {'datetime': '2018-06-09T10:41:31Z', 'uri': 'http://web.archive.org/web/20180609104131/https://www.guideline.gov/summaries/summary/51178/cataracts-in-adults-management'}]
https://www.guideline.gov/summaries/summary/51179/final-recommendation-statement-vision-in-children-ages-6-months-to-5-years-screening	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:51:18Z', 'uri': 'http://wayback.archive-it.org/all/20180519075118/https://www.guideline.gov/summaries/summary/51179/final-recommendation-statement-vision-in-children-ages-6-months-to-5-years-screening'}, {'datetime': '2018-05-19T07:51:18Z', 'uri': 'http://web.archive.org/web/20180519075118/https://www.guideline.gov/summaries/summary/51179/final-recommendation-statement-vision-in-children-ages-6-months-to-5-years-screening'}, {'datetime': '2018-06-08T18:38:23Z', 'uri': 'http://web.archive.org/web/20180608183823/https://www.guideline.gov/summaries/summary/51179/final-recommendation-statement-vision-in-children-ages-6-months-to-5-years-screening'}, {'datetime': '2018-06-09T22:47:22Z', 'uri': 'http://web.archive.org/web/20180609224722/https://www.guideline.gov/summaries/summary/51179/final-recommendation-statement-vision-in-children-ages-6-months-to-5-years-screening'}]
https://www.guideline.gov/summaries/summary/51180/diagnosis-and-treatment-of-respiratory-illness-in-children-and-adults	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T19:36:12Z', 'uri': 'http://wayback.archive-it.org/all/20180518193612/https://www.guideline.gov/summaries/summary/51180/diagnosis-and-treatment-of-respiratory-illness-in-children-and-adults'}, {'datetime': '2018-05-18T19:36:12Z', 'uri': 'http://web.archive.org/web/20180518193612/https://www.guideline.gov/summaries/summary/51180/diagnosis-and-treatment-of-respiratory-illness-in-children-and-adults'}, {'datetime': '2018-06-08T18:41:07Z', 'uri': 'http://web.archive.org/web/20180608184107/https://www.guideline.gov/summaries/summary/51180/diagnosis-and-treatment-of-respiratory-illness-in-children-and-adults'}, {'datetime': '2018-06-09T20:07:53Z', 'uri': 'http://web.archive.org/web/20180609200753/https://www.guideline.gov/summaries/summary/51180/diagnosis-and-treatment-of-respiratory-illness-in-children-and-adults'}]
https://www.guideline.gov/summaries/summary/51181/evidencebased-clinical-practice-guideline-for-the-evaluation-of-potentially-malignant-disorders-in-the-oral-cavity-a-report-of-the-american-dental-association	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T19:34:17Z', 'uri': 'http://wayback.archive-it.org/all/20180518193417/https://www.guideline.gov/summaries/summary/51181/evidencebased-clinical-practice-guideline-for-the-evaluation-of-potentially-malignant-disorders-in-the-oral-cavity-a-report-of-the-american-dental-association'}, {'datetime': '2018-05-18T19:34:17Z', 'uri': 'http://web.archive.org/web/20180518193417/https://www.guideline.gov/summaries/summary/51181/evidencebased-clinical-practice-guideline-for-the-evaluation-of-potentially-malignant-disorders-in-the-oral-cavity-a-report-of-the-american-dental-association'}, {'datetime': '2018-06-08T18:34:32Z', 'uri': 'http://web.archive.org/web/20180608183432/https://www.guideline.gov/summaries/summary/51181/evidencebased-clinical-practice-guideline-for-the-evaluation-of-potentially-malignant-disorders-in-the-oral-cavity-a-report-of-the-american-dental-association'}, {'datetime': '2018-06-09T18:40:56Z', 'uri': 'http://web.archive.org/web/20180609184056/https://www.guideline.gov/summaries/summary/51181/evidencebased-clinical-practice-guideline-for-the-evaluation-of-potentially-malignant-disorders-in-the-oral-cavity-a-report-of-the-american-dental-association'}]
https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:10:06Z', 'uri': 'http://wayback.archive-it.org/all/20180414011006/https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline'}, {'datetime': '2018-04-14T01:10:06Z', 'uri': 'http://web.archive.org/web/20180414011006/https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline'}, {'datetime': '2018-05-19T07:55:27Z', 'uri': 'http://wayback.archive-it.org/all/20180519075527/https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline'}, {'datetime': '2018-05-19T07:55:27Z', 'uri': 'http://web.archive.org/web/20180519075527/https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline'}, {'datetime': '2018-06-08T18:31:36Z', 'uri': 'http://web.archive.org/web/20180608183136/https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline'}, {'datetime': '2018-06-09T19:56:41Z', 'uri': 'http://web.archive.org/web/20180609195641/https://www.guideline.gov/summaries/summary/51182/patientclinician-communication-american-society-of-clinical-oncology-consensus-guideline'}]
https://www.guideline.gov/summaries/summary/51183/health-worker-roles-in-providing-safe-abortion-care-and-postabortion-contraception	ARCHIVED	2 mementos	[{'datetime': '2018-06-10T00:04:14Z', 'uri': 'http://web.archive.org/web/20180610000414/https://www.guideline.gov/summaries/summary/51183/health-worker-roles-in-providing-safe-abortion-care-and-postabortion-contraception'}, {'datetime': '2018-06-15T12:55:59Z', 'uri': 'http://web.archive.org/web/20180615125559/https://guideline.gov/summaries/summary/51183/health-worker-roles-in-providing-safe-abortion-care-and-postabortion-contraception'}]
https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women	ARCHIVED	6 mementos	[{'datetime': '2018-04-13T17:07:28Z', 'uri': 'http://wayback.archive-it.org/all/20180413170728/https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women'}, {'datetime': '2018-04-13T17:07:28Z', 'uri': 'http://web.archive.org/web/20180413170728/https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women'}, {'datetime': '2018-05-19T07:52:13Z', 'uri': 'http://wayback.archive-it.org/all/20180519075213/https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women'}, {'datetime': '2018-05-19T07:52:13Z', 'uri': 'http://web.archive.org/web/20180519075213/https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women'}, {'datetime': '2018-06-09T11:02:43Z', 'uri': 'http://web.archive.org/web/20180609110243/https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women'}, {'datetime': '2018-06-14T22:48:02Z', 'uri': 'http://web.archive.org/web/20180614224802/https://www.guideline.gov/summaries/summary/51184/who-guideline-on-syphilis-screening-and-treatment-for-pregnant-women'}]
https://www.guideline.gov/summaries/summary/51185/who-recommendations-on-antenatal-care-for-a-positive-pregnancy-experience	ARCHIVED	5 mementos	[{'datetime': '2018-04-13T17:08:01Z', 'uri': 'http://wayback.archive-it.org/all/20180413170801/https://www.guideline.gov/summaries/summary/51185/who-recommendations-on-antenatal-care-for-a-positive-pregnancy-experience'}, {'datetime': '2018-04-13T17:08:01Z', 'uri': 'http://web.archive.org/web/20180413170801/https://www.guideline.gov/summaries/summary/51185/who-recommendations-on-antenatal-care-for-a-positive-pregnancy-experience'}, {'datetime': '2018-05-19T07:52:41Z', 'uri': 'http://wayback.archive-it.org/all/20180519075241/https://www.guideline.gov/summaries/summary/51185/who-recommendations-on-antenatal-care-for-a-positive-pregnancy-experience'}, {'datetime': '2018-05-19T07:52:41Z', 'uri': 'http://web.archive.org/web/20180519075241/https://www.guideline.gov/summaries/summary/51185/who-recommendations-on-antenatal-care-for-a-positive-pregnancy-experience'}, {'datetime': '2018-06-10T00:03:41Z', 'uri': 'http://web.archive.org/web/20180610000341/https://www.guideline.gov/summaries/summary/51185/who-recommendations-on-antenatal-care-for-a-positive-pregnancy-experience'}]
https://www.guideline.gov/summaries/summary/51186/evidencebased-clinical-practice-guideline-autologous-breast-reconstruction-with-diep-or-pedicled-tram-abdominal-flaps	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:49:53Z', 'uri': 'http://wayback.archive-it.org/all/20180519074953/https://www.guideline.gov/summaries/summary/51186/evidencebased-clinical-practice-guideline-autologous-breast-reconstruction-with-diep-or-pedicled-tram-abdominal-flaps'}, {'datetime': '2018-05-19T07:49:53Z', 'uri': 'http://web.archive.org/web/20180519074953/https://www.guideline.gov/summaries/summary/51186/evidencebased-clinical-practice-guideline-autologous-breast-reconstruction-with-diep-or-pedicled-tram-abdominal-flaps'}, {'datetime': '2018-06-08T18:32:39Z', 'uri': 'http://web.archive.org/web/20180608183239/https://www.guideline.gov/summaries/summary/51186/evidencebased-clinical-practice-guideline-autologous-breast-reconstruction-with-diep-or-pedicled-tram-abdominal-flaps'}, {'datetime': '2018-06-09T19:20:11Z', 'uri': 'http://web.archive.org/web/20180609192011/https://www.guideline.gov/summaries/summary/51186/evidencebased-clinical-practice-guideline-autologous-breast-reconstruction-with-diep-or-pedicled-tram-abdominal-flaps'}]
https://www.guideline.gov/summaries/summary/51187/hip-pain-and-mobility-deficits-hip-osteoarthritis-revision-2017	ARCHIVED	5 mementos	[{'datetime': '2018-05-18T19:34:47Z', 'uri': 'http://wayback.archive-it.org/all/20180518193447/https://www.guideline.gov/summaries/summary/51187/hip-pain-and-mobility-deficits-hip-osteoarthritis-revision-2017'}, {'datetime': '2018-05-18T19:34:47Z', 'uri': 'http://web.archive.org/web/20180518193447/https://www.guideline.gov/summaries/summary/51187/hip-pain-and-mobility-deficits-hip-osteoarthritis-revision-2017'}, {'datetime': '2018-06-09T15:22:26Z', 'uri': 'http://web.archive.org/web/20180609152226/https://www.guideline.gov/summaries/summary/51187/hip-pain-and-mobility-deficits-hip-osteoarthritis-revision-2017'}, {'datetime': '2018-06-14T22:30:29Z', 'uri': 'http://web.archive.org/web/20180614223029/https://www.guideline.gov/summaries/summary/51187/hip-pain-and-mobility-deficits-hip-osteoarthritis-revision-2017'}, {'datetime': '2018-06-14T22:30:40Z', 'uri': 'http://web.archive.org/web/20180614223040/https://www.guideline.gov/summaries/summary/51187/hip-pain-and-mobility-deficits-hip-osteoarthritis-revision-2017'}]
https://www.guideline.gov/summaries/summary/51188/knee-stability-and-movement-coordination-impairments-knee-ligament-sprain-revision-2017	ARCHIVED	4 mementos	[{'datetime': '2018-05-18T19:35:15Z', 'uri': 'http://wayback.archive-it.org/all/20180518193515/https://www.guideline.gov/summaries/summary/51188/knee-stability-and-movement-coordination-impairments-knee-ligament-sprain-revision-2017'}, {'datetime': '2018-05-18T19:35:15Z', 'uri': 'http://web.archive.org/web/20180518193515/https://www.guideline.gov/summaries/summary/51188/knee-stability-and-movement-coordination-impairments-knee-ligament-sprain-revision-2017'}, {'datetime': '2018-06-08T18:32:31Z', 'uri': 'http://web.archive.org/web/20180608183231/https://www.guideline.gov/summaries/summary/51188/knee-stability-and-movement-coordination-impairments-knee-ligament-sprain-revision-2017'}, {'datetime': '2018-06-09T19:54:23Z', 'uri': 'http://web.archive.org/web/20180609195423/https://www.guideline.gov/summaries/summary/51188/knee-stability-and-movement-coordination-impairments-knee-ligament-sprain-revision-2017'}]
https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services	ARCHIVED	6 mementos	[{'datetime': '2018-04-13T17:06:29Z', 'uri': 'http://wayback.archive-it.org/all/20180413170629/https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services'}, {'datetime': '2018-04-13T17:06:29Z', 'uri': 'http://web.archive.org/web/20180413170629/https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services'}, {'datetime': '2018-05-19T07:51:47Z', 'uri': 'http://wayback.archive-it.org/all/20180519075147/https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services'}, {'datetime': '2018-05-19T07:51:47Z', 'uri': 'http://web.archive.org/web/20180519075147/https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services'}, {'datetime': '2018-06-10T22:45:58Z', 'uri': 'http://web.archive.org/web/20180610224558/https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services'}, {'datetime': '2018-06-14T23:14:25Z', 'uri': 'http://web.archive.org/web/20180614231425/https://www.guideline.gov/summaries/summary/51189/guideline-protecting-promoting-and-supporting-breastfeeding-in-facilities-providing-maternity-and-newborn-services'}]
https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	6 mementos	[{'datetime': '2018-04-14T01:10:39Z', 'uri': 'http://wayback.archive-it.org/all/20180414011039/https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-04-14T01:10:39Z', 'uri': 'http://web.archive.org/web/20180414011039/https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T07:55:56Z', 'uri': 'http://wayback.archive-it.org/all/20180519075556/https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-05-19T07:55:56Z', 'uri': 'http://web.archive.org/web/20180519075556/https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-08T18:34:23Z', 'uri': 'http://web.archive.org/web/20180608183423/https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-09T21:54:03Z', 'uri': 'http://web.archive.org/web/20180609215403/https://www.guideline.gov/summaries/summary/51190/systemic-therapy-for-stage-iv-non-smallcell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/51191/asthma-diagnosis-monitoring-and-chronic-asthma-management	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:30:27Z', 'uri': 'http://web.archive.org/web/20180608183027/https://www.guideline.gov/summaries/summary/51191/asthma-diagnosis-monitoring-and-chronic-asthma-management'}, {'datetime': '2018-06-09T19:52:27Z', 'uri': 'http://web.archive.org/web/20180609195227/https://www.guideline.gov/summaries/summary/51191/asthma-diagnosis-monitoring-and-chronic-asthma-management'}]
https://www.guideline.gov/summaries/summary/51220/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-pediatric-critically-ill-patient-society-of-critical-care-medicine-and-american-society-for-parenteral-and-enteral-nutrition	ARCHIVED	2 mementos	[{'datetime': '2018-06-09T19:47:22Z', 'uri': 'http://web.archive.org/web/20180609194722/https://www.guideline.gov/summaries/summary/51220/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-pediatric-critically-ill-patient-society-of-critical-care-medicine-and-american-society-for-parenteral-and-enteral-nutrition'}, {'datetime': '2018-06-14T22:26:37Z', 'uri': 'http://web.archive.org/web/20180614222637/https://www.guideline.gov/summaries/summary/51220/guidelines-for-the-provision-and-assessment-of-nutrition-support-therapy-in-the-pediatric-critically-ill-patient-society-of-critical-care-medicine-and-american-society-for-parenteral-and-enteral-nutrition'}]
https://www.guideline.gov/summaries/summary/51221/chronic-pain-disorder-medical-treatment-guideline	ARCHIVED	3 mementos	[{'datetime': '2018-06-08T18:30:08Z', 'uri': 'http://web.archive.org/web/20180608183008/https://www.guideline.gov/summaries/summary/51221/chronic-pain-disorder-medical-treatment-guideline'}, {'datetime': '2018-06-09T10:33:44Z', 'uri': 'http://web.archive.org/web/20180609103344/https://www.guideline.gov/summaries/summary/51221/chronic-pain-disorder-medical-treatment-guideline'}, {'datetime': '2018-07-10T00:51:12Z', 'uri': 'http://web.archive.org/web/20180710005112/https://www.guideline.gov/summaries/summary/51221/chronic-pain-disorder-medical-treatment-guideline'}]
https://www.guideline.gov/summaries/summary/51222/complex-regional-pain-syndromereflex-sympathetic-dystrophy-medical-treatment-guideline	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:30:18Z', 'uri': 'http://web.archive.org/web/20180608183018/https://www.guideline.gov/summaries/summary/51222/complex-regional-pain-syndromereflex-sympathetic-dystrophy-medical-treatment-guideline'}, {'datetime': '2018-06-09T11:54:51Z', 'uri': 'http://web.archive.org/web/20180609115451/https://www.guideline.gov/summaries/summary/51222/complex-regional-pain-syndromereflex-sympathetic-dystrophy-medical-treatment-guideline'}]
https://www.guideline.gov/summaries/summary/51223/final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions	ARCHIVED	6 mementos	[{'datetime': '2018-05-18T19:27:09Z', 'uri': 'http://wayback.archive-it.org/all/20180518192709/https://www.guideline.gov/summaries/summary/51223/Final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions'}, {'datetime': '2018-05-18T19:27:09Z', 'uri': 'http://web.archive.org/web/20180518192709/https://www.guideline.gov/summaries/summary/51223/Final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions'}, {'datetime': '2018-06-02T20:42:46Z', 'uri': 'http://web.archive.org/web/20180602204246/https://www.guideline.gov/summaries/summary/51223/Final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions'}, {'datetime': '2018-06-08T18:29:25Z', 'uri': 'http://web.archive.org/web/20180608182925/https://www.guideline.gov/summaries/summary/51223/final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions'}, {'datetime': '2018-06-09T10:32:27Z', 'uri': 'http://web.archive.org/web/20180609103227/https://www.guideline.gov/summaries/summary/51223/Final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions'}, {'datetime': '2018-06-09T19:54:41Z', 'uri': 'http://web.archive.org/web/20180609195441/https://www.guideline.gov/summaries/summary/51223/final-recommendation-statement-hormone-therapy-in-postmenopausal-women-primary-prevention-of-chronic-conditions'}]
https://www.guideline.gov/summaries/summary/51224/role-of-bonemodifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:48:57Z', 'uri': 'http://wayback.archive-it.org/all/20180519074857/https://www.guideline.gov/summaries/summary/51224/role-of-bonemodifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update'}, {'datetime': '2018-05-19T07:48:57Z', 'uri': 'http://web.archive.org/web/20180519074857/https://www.guideline.gov/summaries/summary/51224/role-of-bonemodifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update'}, {'datetime': '2018-06-08T18:25:48Z', 'uri': 'http://web.archive.org/web/20180608182548/https://www.guideline.gov/summaries/summary/51224/role-of-bonemodifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update'}, {'datetime': '2018-06-09T19:56:50Z', 'uri': 'http://web.archive.org/web/20180609195650/https://www.guideline.gov/summaries/summary/51224/role-of-bonemodifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update'}]
https://www.guideline.gov/summaries/summary/51225/chronic-obstructive-pulmonary-disease	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:32:23Z', 'uri': 'http://web.archive.org/web/20180608183223/https://www.guideline.gov/summaries/summary/51225/chronic-obstructive-pulmonary-disease'}, {'datetime': '2018-06-09T19:52:41Z', 'uri': 'http://web.archive.org/web/20180609195241/https://www.guideline.gov/summaries/summary/51225/chronic-obstructive-pulmonary-disease'}]
https://www.guideline.gov/summaries/summary/51226/practice-advisory-for-the-prevention-of-perioperative-peripheral-neuropathies-2018-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-prevention-of-perioperative-peripheral-neuropathies	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:48:33Z', 'uri': 'http://wayback.archive-it.org/all/20180519074833/https://www.guideline.gov/summaries/summary/51226/practice-advisory-for-the-prevention-of-perioperative-peripheral-neuropathies-2018-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-prevention-of-perioperative-peripheral-neuropathies'}, {'datetime': '2018-05-19T07:48:33Z', 'uri': 'http://web.archive.org/web/20180519074833/https://www.guideline.gov/summaries/summary/51226/practice-advisory-for-the-prevention-of-perioperative-peripheral-neuropathies-2018-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-prevention-of-perioperative-peripheral-neuropathies'}, {'datetime': '2018-06-08T18:25:07Z', 'uri': 'http://web.archive.org/web/20180608182507/https://www.guideline.gov/summaries/summary/51226/practice-advisory-for-the-prevention-of-perioperative-peripheral-neuropathies-2018-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-prevention-of-perioperative-peripheral-neuropathies'}, {'datetime': '2018-06-09T19:53:37Z', 'uri': 'http://web.archive.org/web/20180609195337/https://www.guideline.gov/summaries/summary/51226/practice-advisory-for-the-prevention-of-perioperative-peripheral-neuropathies-2018-an-updated-report-by-the-american-society-of-anesthesiologists-task-force-on-prevention-of-perioperative-peripheral-neuropathies'}]
https://www.guideline.gov/summaries/summary/51227/final-recommendation-statement-adolescent-idiopathic-scoliosis-screening	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:50:49Z', 'uri': 'http://wayback.archive-it.org/all/20180519075049/https://www.guideline.gov/summaries/summary/51227/final-recommendation-statement-adolescent-idiopathic-scoliosis-screening'}, {'datetime': '2018-05-19T07:50:49Z', 'uri': 'http://web.archive.org/web/20180519075049/https://www.guideline.gov/summaries/summary/51227/final-recommendation-statement-adolescent-idiopathic-scoliosis-screening'}, {'datetime': '2018-06-08T16:21:06Z', 'uri': 'http://web.archive.org/web/20180608162106/https://www.guideline.gov/summaries/summary/51227/final-recommendation-statement-adolescent-idiopathic-scoliosis-screening'}, {'datetime': '2018-06-09T19:55:21Z', 'uri': 'http://web.archive.org/web/20180609195521/https://www.guideline.gov/summaries/summary/51227/final-recommendation-statement-adolescent-idiopathic-scoliosis-screening'}]
https://www.guideline.gov/summaries/summary/51228/acr-appropriateness-criteria--imaging-of-deep-inferior-epigastric-arteries-for-surgical-planning-breast-reconstruction-surgery	ARCHIVED	2 mementos	[{'datetime': '2018-06-09T19:21:11Z', 'uri': 'http://web.archive.org/web/20180609192111/https://www.guideline.gov/summaries/summary/51228/acr-appropriateness-criteria--imaging-of-deep-inferior-epigastric-arteries-for-surgical-planning-breast-reconstruction-surgery'}, {'datetime': '2018-06-14T22:51:31Z', 'uri': 'http://web.archive.org/web/20180614225131/https://www.guideline.gov/summaries/summary/51228/acr-appropriateness-criteria--imaging-of-deep-inferior-epigastric-arteries-for-surgical-planning-breast-reconstruction-surgery'}]
https://www.guideline.gov/summaries/summary/51229/acr-appropriateness-criteria--staging-of-pancreatic-ductal-adenocarcinoma	ARCHIVED	2 mementos	[{'datetime': '2018-06-10T22:55:37Z', 'uri': 'http://web.archive.org/web/20180610225537/https://www.guideline.gov/summaries/summary/51229/acr-appropriateness-criteria--staging-of-pancreatic-ductal-adenocarcinoma'}, {'datetime': '2018-06-14T23:14:47Z', 'uri': 'http://web.archive.org/web/20180614231447/https://www.guideline.gov/summaries/summary/51229/acr-appropriateness-criteria--staging-of-pancreatic-ductal-adenocarcinoma'}]
https://www.guideline.gov/summaries/summary/51230/acr-appropriateness-criteria--suspected-thoracic-aortic-aneurysm	ARCHIVED	2 mementos	[{'datetime': '2018-06-09T23:42:15Z', 'uri': 'http://web.archive.org/web/20180609234215/https://www.guideline.gov/summaries/summary/51230/acr-appropriateness-criteria--suspected-thoracic-aortic-aneurysm'}, {'datetime': '2018-06-14T22:52:43Z', 'uri': 'http://web.archive.org/web/20180614225243/https://www.guideline.gov/summaries/summary/51230/acr-appropriateness-criteria--suspected-thoracic-aortic-aneurysm'}]
https://www.guideline.gov/summaries/summary/51231/acr-appropriateness-criteria--tinnitus	ARCHIVED	2 mementos	[{'datetime': '2018-06-10T18:02:19Z', 'uri': 'http://web.archive.org/web/20180610180219/https://www.guideline.gov/summaries/summary/51231/acr-appropriateness-criteria--tinnitus'}, {'datetime': '2018-06-14T22:51:14Z', 'uri': 'http://web.archive.org/web/20180614225114/https://www.guideline.gov/summaries/summary/51231/acr-appropriateness-criteria--tinnitus'}]
https://www.guideline.gov/summaries/summary/51232/acr-appropriateness-criteria--radiologic-management-of-central-venous-access	ARCHIVED	2 mementos	[{'datetime': '2018-06-10T08:35:09Z', 'uri': 'http://web.archive.org/web/20180610083509/https://www.guideline.gov/summaries/summary/51232/acr-appropriateness-criteria--radiologic-management-of-central-venous-access'}, {'datetime': '2018-06-14T23:15:16Z', 'uri': 'http://web.archive.org/web/20180614231516/https://www.guideline.gov/summaries/summary/51232/acr-appropriateness-criteria--radiologic-management-of-central-venous-access'}]
https://www.guideline.gov/summaries/summary/51233/acr-appropriateness-criteria--lower-extremity-arterial-revascularization-posttherapy-imaging	ARCHIVED	2 mementos	[{'datetime': '2018-06-10T16:55:18Z', 'uri': 'http://web.archive.org/web/20180610165518/https://www.guideline.gov/summaries/summary/51233/acr-appropriateness-criteria--lower-extremity-arterial-revascularization-posttherapy-imaging'}, {'datetime': '2018-06-14T22:52:21Z', 'uri': 'http://web.archive.org/web/20180614225221/https://www.guideline.gov/summaries/summary/51233/acr-appropriateness-criteria--lower-extremity-arterial-revascularization-posttherapy-imaging'}]
https://www.guideline.gov/summaries/summary/51234/monitoring-modalities-and-assessment-of-fluid-status-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:25:40Z', 'uri': 'http://web.archive.org/web/20180608182540/https://www.guideline.gov/summaries/summary/51234/monitoring-modalities-and-assessment-of-fluid-status-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}, {'datetime': '2018-06-09T19:55:12Z', 'uri': 'http://web.archive.org/web/20180609195512/https://www.guideline.gov/summaries/summary/51234/monitoring-modalities-and-assessment-of-fluid-status-a-practice-management-guideline-from-the-eastern-association-for-the-surgery-of-trauma'}]
https://www.guideline.gov/summaries/summary/51235/acr-appropriateness-criteria--shoulder-pain-traumatic	ARCHIVED	2 mementos	[{'datetime': '2018-06-10T21:58:44Z', 'uri': 'http://web.archive.org/web/20180610215844/https://www.guideline.gov/summaries/summary/51235/acr-appropriateness-criteria--shoulder-pain-traumatic'}, {'datetime': '2018-06-14T23:15:08Z', 'uri': 'http://web.archive.org/web/20180614231508/https://www.guideline.gov/summaries/summary/51235/acr-appropriateness-criteria--shoulder-pain-traumatic'}]
https://www.guideline.gov/summaries/summary/51236/practice-guideline-update-summary-mild-cognitive-impairment-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T16:20:21Z', 'uri': 'http://web.archive.org/web/20180608162021/https://www.guideline.gov/summaries/summary/51236/practice-guideline-update-summary-mild-cognitive-impairment-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}, {'datetime': '2018-06-09T11:51:25Z', 'uri': 'http://web.archive.org/web/20180609115125/https://www.guideline.gov/summaries/summary/51236/practice-guideline-update-summary-mild-cognitive-impairment-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology'}]
https://www.guideline.gov/summaries/summary/51237/classification-of-cough-as-a-symptom-in-adults-and-management-algorithms-chest-guideline-and-expert-panel-report	ARCHIVED	4 mementos	[{'datetime': '2018-05-19T07:48:08Z', 'uri': 'http://wayback.archive-it.org/all/20180519074808/https://www.guideline.gov/summaries/summary/51237/classification-of-cough-as-a-symptom-in-adults-and-management-algorithms-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-05-19T07:48:08Z', 'uri': 'http://web.archive.org/web/20180519074808/https://www.guideline.gov/summaries/summary/51237/classification-of-cough-as-a-symptom-in-adults-and-management-algorithms-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-08T16:21:23Z', 'uri': 'http://web.archive.org/web/20180608162123/https://www.guideline.gov/summaries/summary/51237/classification-of-cough-as-a-symptom-in-adults-and-management-algorithms-chest-guideline-and-expert-panel-report'}, {'datetime': '2018-06-09T19:56:34Z', 'uri': 'http://web.archive.org/web/20180609195634/https://www.guideline.gov/summaries/summary/51237/classification-of-cough-as-a-symptom-in-adults-and-management-algorithms-chest-guideline-and-expert-panel-report'}]
https://www.guideline.gov/summaries/summary/51252/acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T21:50:57Z', 'uri': 'http://web.archive.org/web/20180612215057/https://www.guideline.gov/summaries/summary/51252/acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup'}]
https://www.guideline.gov/summaries/summary/51253/acr-appropriateness-criteria--breast-cancer-screening	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T21:50:55Z', 'uri': 'http://web.archive.org/web/20180612215055/https://www.guideline.gov/summaries/summary/51253/acr-appropriateness-criteria--breast-cancer-screening'}]
https://www.guideline.gov/summaries/summary/51254/acr-appropriateness-criteria--chronic-liver-disease	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T21:51:01Z', 'uri': 'http://web.archive.org/web/20180612215101/https://www.guideline.gov/summaries/summary/51254/acr-appropriateness-criteria--chronic-liver-disease'}]
https://www.guideline.gov/summaries/summary/51255/acr-appropriateness-criteria--chronic-wrist-pain	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T21:45:38Z', 'uri': 'http://web.archive.org/web/20180612214538/https://www.guideline.gov/summaries/summary/51255/acr-appropriateness-criteria--chronic-wrist-pain'}]
https://www.guideline.gov/summaries/summary/51256/acr-appropriateness-criteria--imaging-for-transcatheter-aortic-valve-replacement	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T21:50:52Z', 'uri': 'http://web.archive.org/web/20180612215052/https://www.guideline.gov/summaries/summary/51256/acr-appropriateness-criteria--imaging-for-transcatheter-aortic-valve-replacement'}]
https://www.guideline.gov/summaries/summary/51257/acr-appropriateness-criteria--multiple-gestations	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51258/acr-appropriateness-criteria--ovarian-cancer-screening	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51259/acr-appropriateness-criteria--chronic-ankle-pain	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51260/acr-appropriateness-criteria--first-trimester-vaginal-bleeding	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51261/acr-appropriateness-criteria--headache---child	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51262/acr-appropriateness-criteria--orbits-vision-and-visual-loss	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51263/acr-appropriateness-criteria--pretreatment-staging-of-muscleinvasive-bladder-cancer	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51264/acr-appropriateness-criteria--posttreatment-followup-of-prostate-cancer	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51265/acr-appropriateness-criteria--softtissue-masses	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51266/acr-appropriateness-criteria--radiologic-management-of-uterine-leiomyomas	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51267/treatment-of-seasonal-allergic-rhinitis-an-evidencebased-focused-2017-guideline-update	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:29:11Z', 'uri': 'http://web.archive.org/web/20180608182911/https://www.guideline.gov/summaries/summary/51267/treatment-of-seasonal-allergic-rhinitis-an-evidencebased-focused-2017-guideline-update'}, {'datetime': '2018-06-09T11:51:29Z', 'uri': 'http://web.archive.org/web/20180609115129/https://www.guideline.gov/summaries/summary/51267/treatment-of-seasonal-allergic-rhinitis-an-evidencebased-focused-2017-guideline-update'}]
https://www.guideline.gov/summaries/summary/51268/management-of-indirect-neonatal-hyperbilirubinemia	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:35:26Z', 'uri': 'http://web.archive.org/web/20180608183526/https://www.guideline.gov/summaries/summary/51268/management-of-indirect-neonatal-hyperbilirubinemia'}, {'datetime': '2018-06-09T11:51:22Z', 'uri': 'http://web.archive.org/web/20180609115122/https://www.guideline.gov/summaries/summary/51268/management-of-indirect-neonatal-hyperbilirubinemia'}]
https://www.guideline.gov/summaries/summary/51269/occupational-therapy-practice-guidelines-for-adults-with-alzheimers-disease-and-related-major-neurocognitive-disorders	ARCHIVED	2 mementos	[{'datetime': '2018-06-09T11:51:19Z', 'uri': 'http://web.archive.org/web/20180609115119/https://www.guideline.gov/summaries/summary/51269/occupational-therapy-practice-guidelines-for-adults-with-alzheimers-disease-and-related-major-neurocognitive-disorders'}, {'datetime': '2018-06-14T23:15:24Z', 'uri': 'http://web.archive.org/web/20180614231524/https://www.guideline.gov/summaries/summary/51269/occupational-therapy-practice-guidelines-for-adults-with-alzheimers-disease-and-related-major-neurocognitive-disorders'}]
https://www.guideline.gov/summaries/summary/51270/occupational-therapy-practice-guidelines-for-cancer-rehabilitation-with-adults	ARCHIVED	2 mementos	[{'datetime': '2018-06-09T10:34:01Z', 'uri': 'http://web.archive.org/web/20180609103401/https://www.guideline.gov/summaries/summary/51270/occupational-therapy-practice-guidelines-for-cancer-rehabilitation-with-adults'}, {'datetime': '2018-06-14T22:52:32Z', 'uri': 'http://web.archive.org/web/20180614225232/https://www.guideline.gov/summaries/summary/51270/occupational-therapy-practice-guidelines-for-cancer-rehabilitation-with-adults'}]
https://www.guideline.gov/summaries/summary/51271/preventing-falls-and-reducing-injury-from-falls-fourth-edition	ARCHIVED	3 mementos	[{'datetime': '2018-06-08T18:40:49Z', 'uri': 'http://web.archive.org/web/20180608184049/https://www.guideline.gov/summaries/summary/51271/preventing-falls-and-reducing-injury-from-falls-fourth-edition'}, {'datetime': '2018-06-09T10:43:41Z', 'uri': 'http://web.archive.org/web/20180609104341/https://www.guideline.gov/summaries/summary/51271/preventing-falls-and-reducing-injury-from-falls-fourth-edition'}, {'datetime': '2018-06-10T03:39:41Z', 'uri': 'http://web.archive.org/web/20180610033941/https://www.guideline.gov/summaries/summary/51271/Preventing-falls-and-reducing-injury-from-falls-fourth-edition'}]
https://www.guideline.gov/summaries/summary/51272/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update	ARCHIVED	2 mementos	[{'datetime': '2018-06-08T18:24:15Z', 'uri': 'http://web.archive.org/web/20180608182415/https://www.guideline.gov/summaries/summary/51272/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update'}, {'datetime': '2018-06-09T10:44:21Z', 'uri': 'http://web.archive.org/web/20180609104421/https://www.guideline.gov/summaries/summary/51272/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/51273/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-otologic-and-audiologic-screening-for-patients-with-vestibular-schwannomas	ARCHIVED	1 mementos	[{'datetime': '2018-06-21T18:43:47Z', 'uri': 'http://web.archive.org/web/20180621184347/https://www.guideline.gov/summaries/summary/51273/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-otologic-and-audiologic-screening-for-patients-with-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51274/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-hearing-preservation-outcomes-in-patients-with-sporadic-vestibular-schwannomas	ARCHIVED	1 mementos	[{'datetime': '2018-06-21T18:42:41Z', 'uri': 'http://web.archive.org/web/20180621184241/https://www.guideline.gov/summaries/summary/51274/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-hearing-preservation-outcomes-in-patients-with-sporadic-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51275/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-intraoperative-cranial-nerve-monitoring-in-vestibular-schwannoma-surgery	ARCHIVED	1 mementos	[{'datetime': '2018-06-21T18:42:17Z', 'uri': 'http://web.archive.org/web/20180621184217/https://www.guideline.gov/summaries/summary/51275/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-intraoperative-cranial-nerve-monitoring-in-vestibular-schwannoma-surgery'}]
https://www.guideline.gov/summaries/summary/51276/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-the-role-of-imaging-in-the-diagnosis-and-management-of-patients-with-vestibular-schwannomas	ARCHIVED	1 mementos	[{'datetime': '2018-06-21T18:44:56Z', 'uri': 'http://web.archive.org/web/20180621184456/https://www.guideline.gov/summaries/summary/51276/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-the-role-of-imaging-in-the-diagnosis-and-management-of-patients-with-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51277/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-pathological-methods-and-prognostic-factors-in-vestibular-schwannomas	ARCHIVED	1 mementos	[{'datetime': '2018-06-21T18:45:24Z', 'uri': 'http://web.archive.org/web/20180621184524/https://www.guideline.gov/summaries/summary/51277/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-pathological-methods-and-prognostic-factors-in-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51278/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-the-role-of-radiosurgery-and-radiation-therapy-in-the-management-of-patients-with-vestibular-schwannomas	ARCHIVED	2 mementos	[{'datetime': '2018-06-21T03:18:02Z', 'uri': 'http://web.archive.org/web/20180621031802/https://www.guideline.gov/summaries/summary/51278/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-the-role-of-radiosurgery-and-radiation-therapy-in-the-management-of-patients-with-vestibular-schwannomas'}, {'datetime': '2018-06-21T18:41:16Z', 'uri': 'http://web.archive.org/web/20180621184116/https://www.guideline.gov/summaries/summary/51278/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-the-role-of-radiosurgery-and-radiation-therapy-in-the-management-of-patients-with-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51279/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-surgical-resection-for-the-treatment-of-patients-with-vestibular-schwannomas	ARCHIVED	2 mementos	[{'datetime': '2018-06-21T03:19:12Z', 'uri': 'http://web.archive.org/web/20180621031912/https://www.guideline.gov/summaries/summary/51279/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-surgical-resection-for-the-treatment-of-patients-with-vestibular-schwannomas'}, {'datetime': '2018-06-21T18:41:04Z', 'uri': 'http://web.archive.org/web/20180621184104/https://www.guideline.gov/summaries/summary/51279/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-surgical-resection-for-the-treatment-of-patients-with-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51280/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-emerging-therapies-for-the-treatment-of-patients-with-vestibular-schwannomas	ARCHIVED	2 mementos	[{'datetime': '2018-06-21T03:19:02Z', 'uri': 'http://web.archive.org/web/20180621031902/https://www.guideline.gov/summaries/summary/51280/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-emerging-therapies-for-the-treatment-of-patients-with-vestibular-schwannomas'}, {'datetime': '2018-06-21T18:41:12Z', 'uri': 'http://web.archive.org/web/20180621184112/https://www.guideline.gov/summaries/summary/51280/congress-of-neurological-surgeons-systematic-review-and-evidencebased-guidelines-on-emerging-therapies-for-the-treatment-of-patients-with-vestibular-schwannomas'}]
https://www.guideline.gov/summaries/summary/51281/the-american-psychiatric-association-practice-guideline-for-the-pharmacological-treatment-of-patients-with-alcohol-use-disorder	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T22:09:26Z', 'uri': 'http://web.archive.org/web/20180612220926/https://www.guideline.gov/summaries/summary/51281/the-american-psychiatric-association-practice-guideline-for-the-pharmacological-treatment-of-patients-with-alcohol-use-disorder'}]
https://www.guideline.gov/summaries/summary/51282/platelet-transfusion-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update	ARCHIVED	1 mementos	[{'datetime': '2018-06-14T10:52:28Z', 'uri': 'http://web.archive.org/web/20180614105228/https://www.guideline.gov/summaries/summary/51282/platelet-transfusion-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update'}]
https://www.guideline.gov/summaries/summary/51283/practice-guidelines-for-moderate-procedural-sedation-and-analgesia-2018-a-report-by-the-american-society-of-anesthesiologists-task-force-on-moderate-procedural-sedation-and-analgesia-the-american-association-of-oral-and-maxillofacial-surgeons-american-college-	ARCHIVED	1 mementos	[{'datetime': '2018-07-13T12:28:58Z', 'uri': 'http://web.archive.org/web/20180713122858/http://www.guideline.gov/summaries/summary/51283/practice-guidelines-for-moderate-procedural-sedation-and-analgesia-2018-a-report-by-the-american-society-of-anesthesiologists-task-force-on-moderate-procedural-sedation-and-analgesia-the-american-association-of-oral-and-maxillofacial-surgeons-american-college-'}]
https://www.guideline.gov/summaries/summary/51284/final-recommendation-statement-ovarian-cancer-screening	ARCHIVED	2 mementos	[{'datetime': '2018-06-12T22:08:55Z', 'uri': 'http://web.archive.org/web/20180612220855/https://www.guideline.gov/summaries/summary/51284/final-recommendation-statement-ovarian-cancer-screening'}, {'datetime': '2018-07-13T09:02:14Z', 'uri': 'http://web.archive.org/web/20180713090214/http://www.guideline.gov/summaries/summary/51284/final-recommendation-statement-ovarian-cancer-screening'}]
https://www.guideline.gov/summaries/summary/51285/traditional-chinese-medicine-treatment-guideline-for-primary-headache-disorders	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T22:17:25Z', 'uri': 'http://web.archive.org/web/20180612221725/https://www.guideline.gov/summaries/summary/51285/traditional-chinese-medicine-treatment-guideline-for-primary-headache-disorders'}]
https://www.guideline.gov/summaries/summary/51286/occupational-therapy-practice-guidelines-for-adults-with-arthritis-and-other-rheumatic-conditions	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51287/occupational-therapy-practice-guidelines-for-adults-with-musculoskeletal-conditions	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51288/clinical-practice-guideline-on-perinatal-hypoxicischaemic-encephalopathy-on-newborns	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T20:44:13Z', 'uri': 'http://web.archive.org/web/20180612204413/https://www.guideline.gov/summaries/summary/51288/clinical-practice-guideline-on-perinatal-hypoxicischaemic-encephalopathy-on-newborns'}]
https://www.guideline.gov/summaries/summary/51289/clinical-practice-guideline-on-perioperative-care-in-major-abdominal-surgery	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T20:44:16Z', 'uri': 'http://web.archive.org/web/20180612204416/https://www.guideline.gov/summaries/summary/51289/clinical-practice-guideline-on-perioperative-care-in-major-abdominal-surgery'}]
https://www.guideline.gov/summaries/summary/51290/betablockers-and-traumatic-brain-injury-a-systematic-review-metaanalysis-and-eastern-association-for-the-surgery-of-trauma-guideline	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T20:44:19Z', 'uri': 'http://web.archive.org/web/20180612204419/https://www.guideline.gov/summaries/summary/51290/betablockers-and-traumatic-brain-injury-a-systematic-review-metaanalysis-and-eastern-association-for-the-surgery-of-trauma-guideline'}]
https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society	ARCHIVED	2 mementos	[{'datetime': '2018-07-12T20:37:17Z', 'uri': 'http://web.archive.org/web/20180712203717/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society'}, {'datetime': '2018-07-12T20:37:17Z', 'uri': 'http://web.archive.org/web/20180712203717/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society'}]
https://www.guideline.gov/summaries/summary/51293/implementing-supervised-injection-services	ARCHIVED	3 mementos	[{'datetime': '2018-06-08T16:07:32Z', 'uri': 'http://web.archive.org/web/20180608160732/https://www.guideline.gov/summaries/summary/51293/implementing-supervised-injection-services'}, {'datetime': '2018-06-09T10:44:41Z', 'uri': 'http://web.archive.org/web/20180609104441/https://www.guideline.gov/summaries/summary/51293/implementing-supervised-injection-services'}, {'datetime': '2018-06-10T03:39:35Z', 'uri': 'http://web.archive.org/web/20180610033935/https://www.guideline.gov/summaries/summary/51293/Implementing-supervised-injection-services'}]
https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51295/clinical-practice-guideline-hoarseness-dysphonia-update	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T20:44:09Z', 'uri': 'http://web.archive.org/web/20180612204409/https://www.guideline.gov/summaries/summary/51295/clinical-practice-guideline-hoarseness-dysphonia-update'}]
https://www.guideline.gov/summaries/summary/51296/crisis-intervention-for-adults-using-a-traumainformed-approach-initial-four-weeks-of-management-third-edition	ARCHIVED	3 mementos	[{'datetime': '2018-06-08T18:29:00Z', 'uri': 'http://web.archive.org/web/20180608182900/https://www.guideline.gov/summaries/summary/51296/crisis-intervention-for-adults-using-a-traumainformed-approach-initial-four-weeks-of-management-third-edition'}, {'datetime': '2018-06-09T10:44:51Z', 'uri': 'http://web.archive.org/web/20180609104451/https://www.guideline.gov/summaries/summary/51296/crisis-intervention-for-adults-using-a-traumainformed-approach-initial-four-weeks-of-management-third-edition'}, {'datetime': '2018-06-10T03:39:32Z', 'uri': 'http://web.archive.org/web/20180610033932/https://www.guideline.gov/summaries/summary/51296/Crisis-intervention-for-adults-using-a-traumainformed-approach-initial-four-weeks-of-management-third-edition'}]
https://www.guideline.gov/summaries/summary/51297/cystic-fibrosis-foundation-pulmonary-guidelines-use-of-cystic-fibrosis-transmembrane-conductance-regulator-modulator-therapy-in-patients-with-cystic-fibrosis	ARCHIVED	2 mementos	[{'datetime': '2018-06-21T03:18:32Z', 'uri': 'http://web.archive.org/web/20180621031832/https://www.guideline.gov/summaries/summary/51297/cystic-fibrosis-foundation-pulmonary-guidelines-use-of-cystic-fibrosis-transmembrane-conductance-regulator-modulator-therapy-in-patients-with-cystic-fibrosis'}, {'datetime': '2018-06-21T18:40:59Z', 'uri': 'http://web.archive.org/web/20180621184059/https://www.guideline.gov/summaries/summary/51297/cystic-fibrosis-foundation-pulmonary-guidelines-use-of-cystic-fibrosis-transmembrane-conductance-regulator-modulator-therapy-in-patients-with-cystic-fibrosis'}]
https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update	NOT ARCHIVED	 	 
https://www.guideline.gov/summaries/summary/51299/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-osteoarthritis-of-the-hip	ARCHIVED	1 mementos	[{'datetime': '2018-07-13T13:04:29Z', 'uri': 'http://web.archive.org/web/20180713130429/http://www.guideline.gov/summaries/summary/51299/american-academy-of-orthopaedic-surgeons-appropriate-use-criteria-for-the-management-of-osteoarthritis-of-the-hip'}]
https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline	ARCHIVED	1 mementos	[{'datetime': '2018-07-12T15:01:13Z', 'uri': 'http://web.archive.org/web/20180712150113/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline'}]
https://www.guideline.gov/summaries/summary/51301/final-recommendation-statement-skin-cancer-prevention-behavioral-counseling	ARCHIVED	2 mementos	[{'datetime': '2018-06-21T03:18:16Z', 'uri': 'http://web.archive.org/web/20180621031816/https://www.guideline.gov/summaries/summary/51301/final-recommendation-statement-skin-cancer-prevention-behavioral-counseling'}, {'datetime': '2018-06-21T18:40:54Z', 'uri': 'http://web.archive.org/web/20180621184054/https://www.guideline.gov/summaries/summary/51301/final-recommendation-statement-skin-cancer-prevention-behavioral-counseling'}]
https://www.guideline.gov/summaries/summary/51324/lyme-disease	ARCHIVED	1 mementos	[{'datetime': '2018-06-12T20:44:05Z', 'uri': 'http://web.archive.org/web/20180612204405/https://www.guideline.gov/summaries/summary/51324/lyme-disease'}]
https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy	ARCHIVED	1 mementos	[{'datetime': '2018-07-13T11:57:58Z', 'uri': 'http://web.archive.org/web/20180713115758/http://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy'}]
